FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Bilimoria, KY Liu, YM Paruch, JL Zhou, L Kmiecik, TE Ko, CY Cohen, ME AF Bilimoria, Karl Y. Liu, Yaoming Paruch, Jennifer L. Zhou, Lynn Kmiecik, Thomas E. Ko, Clifford Y. Cohen, Mark E. TI Development and Evaluation of the Universal ACS NSQIP Surgical Risk Calculator: A Decision Aid and Informed Consent Tool for Patients and Surgeons SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article; Proceedings Paper CT Annual ACS NSQIP Conference CY JUL, 2013 CL San Diego, CA SP ACS ID QUALITY IMPROVEMENT PROGRAM; AMERICAN-COLLEGE; COMPLICATIONS; ADJUSTMENT; PREDICTION; HOSPITALS; MORTALITY; MODELS AB BACKGROUND: Accurately estimating surgical risks is critical for shared decision making and informed consent. The Centers for Medicare and Medicaid Services may soon put forth a measure requiring surgeons to provide patients with patient-specific, empirically derived estimates of postoperative complications. Our objectives were to develop a universal surgical risk estimation tool, to compare performance of the universal vs previous procedure-specific surgical risk calculators, and to allow surgeons to empirically adjust the estimates of risk. STUDY DESIGN: Using standardized clinical data from 393 ACS NSQIP hospitals, a web-based tool was developed to allow surgeons to easily enter 21 preoperative factors (demographics, comorbidities, procedure). Regression models were developed to predict 8 outcomes based on the preoperative risk factors. The universal model was compared with procedure-specific models. To incorporate surgeon input, a subjective surgeon adjustment score, allowing risk estimates to vary within the estimate's confidence interval, was introduced and tested with 80 surgeons using 10 case scenarios. RESULTS: Based on 1,414,006 patients encompassing 1,557 unique CPT codes, a universal surgical risk calculator model was developed that had excellent performance for mortality (c-statistic = 0.944; Brier score = 0.011 [where scores approaching 0 are better]), morbidity (c-statistic = 0.816, Brier score = 0.069), and 6 additional complications (c-statistics > 0.8). Predictions were similarly robust for the universal calculator vs procedure-specific calculators (eg, colorectal). Surgeons demonstrated considerable agreement on the case scenario scoring (80% to 100% agreement), suggesting reliable score assignment between surgeons. CONCLUSIONS: The ACS NSQIP surgical risk calculator is a decision-support tool based on reliable multi-institutional clinical data, which can be used to estimate the risks of most operations. The ACS NSQIP surgical risk calculator will allow clinicians and patients to make decisions using empirically derived, patient-specific postoperative risks. ((C) 2013 by the American College of Surgeons) C1 [Bilimoria, Karl Y.; Liu, Yaoming; Paruch, Jennifer L.; Zhou, Lynn; Ko, Clifford Y.; Cohen, Mark E.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA. [Bilimoria, Karl Y.; Kmiecik, Thomas E.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Surg Outcomes & Qual Improvement Ctr, Chicago, IL 60611 USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Bilimoria, KY (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,22nd Floor, Chicago, IL 60611 USA. EM kbilimoria@facs.org FU NCATS NIH HHS [L30 TR000300] NR 24 TC 151 Z9 151 U1 1 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD NOV PY 2013 VL 217 IS 5 BP 833 EP + DI 10.1016/j.jamcollsurg.2013.07.385 PG 13 WC Surgery SC Surgery GA 235YO UT WOS:000325759500011 PM 24055383 ER PT J AU Raposo, RAS Abdel-Mohsen, M Bilska, M Montefiori, DC Nixon, DF Pillai, SK AF Raposo, Rui Andre Saraiva Abdel-Mohsen, Mohamed Bilska, Miroslawa Montefiori, David C. Nixon, Douglas F. Pillai, Satish K. TI Effects of Cellular Activation on Anti-HIV-1 Restriction Factor Expression Profile in Primary Cells SO JOURNAL OF VIROLOGY LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 IN-VIVO; ANTIRETROVIRAL FACTOR; TYPE-1 HIV-1; PROTEIN; INFECTION; REPLICATION; INHIBITION; RELEASE; SAMHD1 AB Expression of cell-intrinsic antiviral factors suppresses HIV-1 replication. We hypothesized that cellular activation modulates host restriction and susceptibility to HIV-1 infection. We measured the gene expression of 34 antiviral factors in healthy peripheral blood mononuclear cells (PBMC). Cellular activation induced expression of interferon-stimulated gene 15 (ISG15), tripartite motif 5 alpha (TRIM5 alpha), bone marrow stromal cell antigen 2 (BST-2)/tetherin, and certain apolipoprotein B mRNA editing enzyme 3 (APOBEC3) family members. Expression of RTF1, RNA polymerase II-associated factor 1 (PAF1), TRIM11, TRIM26, and BST-2/tetherin correlated with decreased HIV-1 infectivity. This report demonstrates synchronous effects of activation-induced antiviral genes on HIV-1 infectivity, providing candidates for pharmacological manipulation. C1 [Raposo, Rui Andre Saraiva; Nixon, Douglas F.] Univ Calif San Francisco, Div Expt Med, San Francisco, CA 94143 USA. [Abdel-Mohsen, Mohamed; Pillai, Satish K.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Bilska, Miroslawa; Montefiori, David C.] Duke Univ, Med Ctr, Dept Surg, Lab AIDS Vaccine Res & Dev, Durham, NC 27710 USA. [Pillai, Satish K.] Blood Syst Res Inst, San Francisco, CA USA. [Pillai, Satish K.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. RP Raposo, RAS (reprint author), Univ Calif San Francisco, Div Expt Med, San Francisco, CA 94143 USA. EM Andre.Raposo@ucsf.edu OI Raposo, R. Andre/0000-0001-5435-0290; Nixon, Douglas/0000-0002-2801-1786 FU National Institutes of Health [AI093179, 1K01DA024654]; Peter and Shelagh Godsoe Family Foundation through the AIDS Research Institute at UCSF; UCSF-Gladstone Institute of Virology & Immunology Center for AIDS Research [P30-AI027763]; Academic Senate under the UCSF RAP awards program FX This work was supported by grants from the National Institutes of Health (AI093179 to D.F.N. and 1K01DA024654 to S. K. P.), the Peter and Shelagh Godsoe Family Foundation through the AIDS Research Institute at UCSF (to D.F.N.), and the UCSF-Gladstone Institute of Virology & Immunology Center for AIDS Research (P30-AI027763 to R. A. S. R.) and in part by a grant provided by the Academic Senate under the UCSF RAP awards program (to D.F.N.). NR 45 TC 17 Z9 17 U1 0 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD NOV PY 2013 VL 87 IS 21 BP 11924 EP 11929 DI 10.1128/JVI.02128-13 PG 6 WC Virology SC Virology GA 237IR UT WOS:000325863400055 PM 23966394 ER PT J AU Amstadter, AB Sumner, JA Acierno, R Ruggiero, KJ Koenen, KC Kilpatrick, DG Galea, S Gelernter, J AF Amstadter, A. B. Sumner, J. A. Acierno, R. Ruggiero, K. J. Koenen, K. C. Kilpatrick, D. G. Galea, S. Gelernter, J. TI Support for association of RORA variant and post traumatic stress symptoms in a population-based study of hurricane exposed adults SO MOLECULAR PSYCHIATRY LA English DT Letter ID GENOME-WIDE ASSOCIATION; POSTTRAUMATIC-STRESS; DISORDER; RISK C1 [Amstadter, A. B.] Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Richmond, VA 23284 USA. [Sumner, J. A.; Acierno, R.; Ruggiero, K. J.; Kilpatrick, D. G.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Acierno, R.; Ruggiero, K. J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Koenen, K. C.; Galea, S.] Columbia Univ, Dept Epidemiol, New York, NY USA. [Gelernter, J.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Gelernter, J.] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA. [Gelernter, J.] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT USA. [Gelernter, J.] VA CT Healthcare Ctr, West Haven, CT USA. RP Amstadter, AB (reprint author), Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Richmond, VA 23284 USA. EM abamstadter@vcu.edu FU NIMH NIH HHS [R21 MH074469] NR 10 TC 11 Z9 12 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 EI 1476-5578 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD NOV PY 2013 VL 18 IS 11 BP 1148 EP 1149 DI 10.1038/mp.2012.189 PG 2 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA 240KN UT WOS:000326094800001 PM 23319003 ER PT J AU Lam, TI Bingham, D Chang, TJ Lee, CC Shi, J Wang, DM Massa, S Swanson, RA Liu, JL AF Lam, Tina I. Bingham, Deborah Chang, Ting Ju Lee, Chih Cheng Shi, Jian Wang, Dongmin Massa, Stephen Swanson, Raymond A. Liu, Jialing TI Beneficial Effects of Minocycline and Botulinum Toxin-Induced Constraint Physical Therapy Following Experimental Traumatic Brain Injury SO NEUROREHABILITATION AND NEURAL REPAIR LA English DT Article DE controlled cortical impact; constraint-induced movement therapy (CIMT); botox; rehabilitation; microglia; glial fibrillary acidic protein (GFAP) ID INDUCED MOVEMENT THERAPY; MICROGLIAL ACTIVATION; ANIMAL-MODELS; STROKE; METAANALYSIS; CNS; MECHANISMS; PLASTICITY; DISORDERS; CHILDREN AB Background. Effective recovery from functional impairments caused by traumatic brain injury (TBI) requires appropriate rehabilitation therapy. Multiple pathways are involved in secondary injury and recovery suggesting a role for multimodal approaches. Objective. Here, we examined the efficacy of the anti-inflammatory agent minocycline and botulinum toxin (botox)-induced limb constraint with structured physical therapy, delivered alone or in combination, after a severe TBI produced by a controlled cortical impact in rats. Methods. Minocycline was administered at 25 mg/kg daily for 2 weeks beginning 1 day after TBI or sham surgery. For constraint/physical therapy, botox-type A was injected into the nonaffected forearm muscle 1 day after injury and 2 weeks of physical therapy commenced at 5 days after injury. Functional evaluations were conducted 8 weeks after injury. Results. Minocycline, either as a monotherapy or as combination treatment with botox/physical therapy significantly reduced impairments of spatial learning and memory in the water maze test, whereas botox/physical therapy reduced forelimb motor asymmetry and improved manual dexterity in the cylinder and vermicelli handling tests, A synergistic effect between the 2 treatments was observed when rats performed tasks requiring dexterity. Inflammation was attenuated in the peri-contusion cortex and hippocampus in all TBI groups receiving mono or combination therapies, though there was no significant difference in lesion size among groups. Conclusion. These data provide a rationale for incorporating anti-inflammatory treatment during rehabilitation therapy. C1 [Lam, Tina I.; Bingham, Deborah; Chang, Ting Ju; Lee, Chih Cheng; Shi, Jian; Wang, Dongmin; Massa, Stephen; Swanson, Raymond A.; Liu, Jialing] San Francisco VA Med Ctr, San Francisco, CA USA. [Lam, Tina I.; Shi, Jian; Wang, Dongmin; Massa, Stephen; Swanson, Raymond A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Lam, Tina I.] USDA, Foodborne Contaminants Res Unit, Western Reg Res Ctr, Res Serv, Albany, CA USA. [Bingham, Deborah; Chang, Ting Ju; Lee, Chih Cheng; Liu, Jialing] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA. RP Liu, JL (reprint author), Univ Calif San Francisco, Dept Neurol Surg 112C, 4150 Clement St, San Francisco, CA 94121 USA. EM jialing.liu@ucsf.edu RI Liu, Jialing/A-8627-2012 OI Liu, Jialing/0000-0003-4420-4382; Swanson, Raymond/0000-0002-3664-5359 FU Veterans Affairs Research Enhancement Award; Veterans Affairs merit awards FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by a Veterans Affairs Research Enhancement Award (RAS), and Veterans Affairs merit awards (JL, SM).]. NR 41 TC 14 Z9 14 U1 1 U2 12 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1545-9683 EI 1552-6844 J9 NEUROREHAB NEURAL RE JI Neurorehabil. Neural Repair PD NOV PY 2013 VL 27 IS 9 BP 889 EP 899 DI 10.1177/1545968313491003 PG 11 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 229IL UT WOS:000325256000013 PM 23778701 ER PT J AU Reis, JP Launer, LJ Terry, JG Loria, CM Al Hazzouri, AZ Sidney, S Yaffe, K Jacobs, DR Whitlow, CT Zhu, N Carr, JJ AF Reis, Jared P. Launer, Lenore J. Terry, James G. Loria, Catherine M. Al Hazzouri, Adina Zeki Sidney, Stephen Yaffe, Kristine Jacobs, David R., Jr. Whitlow, Christopher T. Zhu, Na Carr, J. Jeffrey TI Subclinical atherosclerotic calcification and cognitive functioning in middle-aged adults: The CARDIA study SO ATHEROSCLEROSIS LA English DT Article DE Atherosclerosis; Cognition; Subclinical disease; Risk factors ID CORONARY-ARTERY CALCIUM; DIABETES-MELLITUS; BLOOD-PRESSURE; DEMENTIA; ASSOCIATION; IMPAIRMENT; MIDLIFE; HEALTH; RISK AB Objective: Cardiovascular risk factors in middle-age are associated with cognitive impairment and dementia in older age. Less is known about the burden of calcified subclinical atherosclerosis and cognition, especially in midlife. We examined the association of coronary artery and abdominal aortic calcified plaque (CAC and AAC, respectively) with cognitive functioning in middle-aged adults. Methods: This cross-sectional study included 2510 black and white adults (age: 43-55 years) without heart disease or stroke who completed a year 25 follow-up exam (2010-11) as part of the Coronary Artery Risk Development in Young Adults Study. CAC and AAC were measured with non-contrast computed tomography. Cognition was assessed with the Digit Symbol Substitution Test (DSST) (psychomotor speed), Stroop Test (executive function), and Rey Auditory Verbal Learning Test (RAVLT) (verbal memory). Results: A greater amount of CAC and AAC was associated with worse performance on each test of cognitive function after adjustment for age, sex, race, education, and study center. Associations were attenuated, but remained significant for the DSST and RAVLT following additional adjustment for vascular risk factors, including adiposity, smoking, alcohol use, dyslipidemia, hypertension, and diabetes. Compared to participants without CAC or AAC, those with both CAC and AAC, but not CAC or AAC alone was associated with lower DSST scores (p < 0.05). Conclusions: In this community-based sample, greater subclinical atherosclerotic calcification was associated with worse psychomotor speed and memory in midlife. These findings underscore the importance of a life course approach to the study of cognitive impairment with aging. Published by Elsevier Ireland Ltd. C1 [Reis, Jared P.; Loria, Catherine M.] NHLBI, Div Cardiovasc Sci, Bethesda, MD 20892 USA. [Launer, Lenore J.] NIA, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA. [Terry, James G.; Whitlow, Christopher T.; Carr, J. Jeffrey] Wake Forest Univ, Bowman Gray Sch Med, Dept Radiol, Winston Salem, NC USA. [Al Hazzouri, Adina Zeki; Yaffe, Kristine] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Sidney, Stephen] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [Jacobs, David R., Jr.; Zhu, Na] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Jacobs, David R., Jr.] Univ Oslo, Dept Nutr, Oslo, Norway. RP Reis, JP (reprint author), NHLBI, Div Cardiovasc Sci, 6701 Rockledge Dr,Suite 10197, Bethesda, MD 20892 USA. EM reisjp@mail.nih.gov RI Carr, John/A-1938-2012 OI Carr, John/0000-0002-4398-8237 FU National Heart, Lung, and Blood Institute [N01-HC95095, N01-HC48047, N01-HC48050, N01-HC48049, N01-HC48048, R01-HL098445] FX The Coronary Risk Development in Young Adults Study is conducted and supported by the National Heart, Lung, and Blood Institute (N01-HC95095, N01-HC48047, N01-HC48050, N01-HC48049, N01-HC48048, R01-HL098445). NR 29 TC 13 Z9 13 U1 0 U2 10 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 EI 1879-1484 J9 ATHEROSCLEROSIS JI Atherosclerosis PD NOV PY 2013 VL 231 IS 1 BP 72 EP 77 DI 10.1016/j.atherosclerosis.2013.08.038 PG 6 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 235XH UT WOS:000325755300014 PM 24125414 ER PT J AU Millett, F Havens, J Rajagukguk, S Durham, B AF Millett, Francis Havens, Jeffrey Rajagukguk, Sany Durham, Bill TI Design and use of photoactive ruthenium complexes to study electron transfer within cytochrome bc(1) and from cytochrome bc(1) to cytochrome c SO BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS LA English DT Review DE Cytochrome bc(1); Cytochrome c; Electron transfer; Ruthenium ID IRON-SULFUR PROTEIN; FE-S PROTEIN; PHOTOSYNTHETIC REACTION-CENTER; QUINOL OXIDATION SITE; PROTONMOTIVE Q-CYCLE; DOMAIN MOVEMENT; Q(O) SITE; RHODOBACTER-SPHAEROIDES; PARACOCCUS-DENITRIFICANS; BC1 COMPLEX AB The cytochrome bc(1) complex (ubiquinone:cytochrome c oxidoreductase) is the central integral membrane protein in the mitochondrial respiratory chain as well as the electron-transfer chains of many respiratory and photosynthetic prokaryotes. Based on X-ray crystallographic studies of cytochrome bc(1), a mechanism has been proposed in which the extrinsic domain of the iron-sulfur protein first binds to cytochrome b where it accepts an electron from ubiquinol in the Q(o) site, and then rotates by 57 degrees to a position close to cytochrome c(1) where it transfers an electron to cytochrome c(1). This review describes the development of a ruthenium photooxidation technique to measure key electron transfer steps in cytochrome bc(1), including rapid electron transfer from the iron-sulfur protein to cytochrome c(1). It was discovered that this reaction is rate-limited by the rotational dynamics of the iron-sulfur protein rather than true electron transfer. A conformational linkage between the occupant of the Q(o) ubiquinol binding site and the rotational dynamics of the iron-sulfur protein was discovered which could play a role in the bifurcated oxidation of ubiquinol. A ruthenium photoexcitation method is also described for the measurement of electron transfer from cytochrome c(1) to cytochrome c. This article is part of a Special Issue entitled: Respiratory Complex III and related bc complexes. (C) 2012 Elsevier B.V. All rights reserved. C1 [Millett, Francis; Havens, Jeffrey; Durham, Bill] Univ Arkansas, Dept Chem & Biochem, Fayetteville, AR 72701 USA. [Rajagukguk, Sany] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Millett, F (reprint author), Univ Arkansas, Dept Chem & Biochem, Fayetteville, AR 72701 USA. EM millett@uark.edu; jahavens@uark.edu; sany.rajagukguk@gmail.com; bdurham@uark.edu FU NIH [GM20488, 8P30GM103450] FX This work was supported in part by NIH grants GM20488 and 8P30GM103450. NR 112 TC 10 Z9 10 U1 9 U2 50 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0005-2728 EI 0006-3002 J9 BBA-BIOENERGETICS JI Biochim. Biophys. Acta-Bioenerg. PD NOV-DEC PY 2013 VL 1827 IS 11-12 SI SI BP 1309 EP 1319 DI 10.1016/j.bbabio.2012.09.002 PG 11 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 232RA UT WOS:000325510500005 PM 22985600 ER PT J AU Felts, AS Rodriguez, AL Morrison, RD Venable, DF Manka, JT Bates, BS Blobaum, AL Byers, FW Daniels, JS Niswender, CM Jones, CK Conn, PJ Lindsley, CW Emmitte, KA AF Felts, Andrew S. Rodriguez, Alice L. Morrison, Ryan D. Venable, Daryl F. Manka, Jason T. Bates, Brittney S. Blobaum, Anna L. Byers, Frank W. Daniels, J. Scott Niswender, Colleen M. Jones, Carrie K. Conn, P. Jeffrey Lindsley, Craig W. Emmitte, Kyle A. TI Discovery of VU0409106: A negative allosteric modulator of mGlu(5) with activity in a mouse model of anxiety SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS LA English DT Article DE Glutamate; CNS; mGlu(5); Allosteric modulator; Anxiety ID MGLUR5 ANTAGONIST MPEP; METABOTROPIC GLUTAMATE-RECEPTOR-5 ANTAGONIST; ESOPHAGEAL SPHINCTER RELAXATIONS; CUE-INDUCED REINSTATEMENT; RECEPTOR SUBTYPE 5; GLUTAMATE RECEPTORS; GASTROESOPHAGEAL-REFLUX; NUCLEUS-ACCUMBENS; SQUIRREL-MONKEYS; SEEKING BEHAVIOR AB Development of SAR in an aryl ether series of mGlu(5) NAMs leading to the identification of tool compound VU0409106 is described in this Letter. VU0409106 is a potent and selective negative allosteric modulator of mGlu5 that binds at the known allosteric binding site and demonstrates good CNS exposure following intraperitoneal dosing in mice. VU0409106 also proved efficacious in a mouse marble burying model of anxiety, an assay known to be sensitive to mGlu(5) antagonists as well as clinically efficacious anxiolytics. (c) 2013 Elsevier Ltd. All rights reserved. C1 [Felts, Andrew S.; Rodriguez, Alice L.; Morrison, Ryan D.; Venable, Daryl F.; Manka, Jason T.; Bates, Brittney S.; Blobaum, Anna L.; Byers, Frank W.; Daniels, J. Scott; Niswender, Colleen M.; Jones, Carrie K.; Conn, P. Jeffrey; Lindsley, Craig W.; Emmitte, Kyle A.] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Neurosci Drug Discovery, Nashville, TN 37232 USA. [Felts, Andrew S.; Rodriguez, Alice L.; Morrison, Ryan D.; Venable, Daryl F.; Manka, Jason T.; Bates, Brittney S.; Blobaum, Anna L.; Byers, Frank W.; Daniels, J. Scott; Niswender, Colleen M.; Jones, Carrie K.; Conn, P. Jeffrey; Lindsley, Craig W.; Emmitte, Kyle A.] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA. [Lindsley, Craig W.; Emmitte, Kyle A.] Vanderbilt Univ, Dept Chem, Nashville, TN 37232 USA. [Jones, Carrie K.] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA. RP Emmitte, KA (reprint author), Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Neurosci Drug Discovery, Nashville, TN 37232 USA. EM kyle.a.emmitte@Vanderbilt.edu FU NIDA [RO1 DA023947]; Seaside Therapeutics [VUMC33842] FX We thank NIDA (RO1 DA023947) and Seaside Therapeutics (VUMC33842) for their support of our programs in the development of noncompetitive antagonist of mGlu5. We also thank Tammy S. Santomango for technical contributions with the protein binding assays. NR 71 TC 12 Z9 12 U1 0 U2 11 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-894X EI 1464-3405 J9 BIOORG MED CHEM LETT JI Bioorg. Med. Chem. Lett. PD NOV 1 PY 2013 VL 23 IS 21 BP 5779 EP 5785 DI 10.1016/j.bmcl.2013.09.001 PG 7 WC Chemistry, Medicinal; Chemistry, Organic SC Pharmacology & Pharmacy; Chemistry GA 232HH UT WOS:000325483000003 PM 24074843 ER PT J AU Musher, DM Sandvall, BP Rueda, AM AF Musher, Daniel M. Sandvall, Barcleigh P. Rueda, Adriana M. TI Long-term Survival in Community-Acquired Pneumonia Caused by Other Bacteria Than Pneumococci Is Impaired More Than in Pneumococcal Pneumonia: Effect of Underlying Disease? Reply SO CLINICAL INFECTIOUS DISEASES LA English DT Letter C1 [Musher, Daniel M.; Rueda, Adriana M.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Musher, Daniel M.; Sandvall, Barcleigh P.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. RP Musher, DM (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. NR 1 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 1 PY 2013 VL 57 IS 9 BP 1371 EP 1371 DI 10.1093/cid/cit509 PG 1 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 235ZM UT WOS:000325762500035 PM 23929888 ER PT J AU Lu, ZY Li, YC Samuvel, DJ Jin, JF Zhang, XM Lopes-Virella, MF Huang, Y AF Lu, Zhongyang Li, Yanchun Samuvel, Devadoss J. Jin, Junfei Zhang, Xiaoming Lopes-Virella, Maria F. Huang, Yan TI MD-2 is involved in the stimulation of matrix metalloproteinase-1 expression by interferon-gamma and high glucose in mononuclear cells - a potential role of MD-2 in Toll-like receptor 4-independent signalling SO IMMUNOLOGY LA English DT Article DE inflammation; interferon-; MD-2; mononuclear cells; Toll-like receptor ID GRAM-NEGATIVE BACTERIA; NECROSIS-FACTOR-ALPHA; E-DEFICIENT MICE; LIPOPOLYSACCHARIDE-RECOGNITION; TRANSCRIPTION FACTOR; MMP-1 EXPRESSION; IFN-GAMMA; LPS; ACTIVATION; TLR4 AB We reported recently that treatment of diabetic apolipoprotein E-deficient mice with the Toll-like receptor 4 (TLR4) antagonist Rs-LPS, a lipopolysaccharide isolated from Rhodobacter sphaeroides, inhibited atherosclerosis. Since it is known that Rs-LPS antagonizes TLR4 by targeting TLR4 co-receptor MD-2, this finding indicates that MD-2 is a potential target for the treatment of atherosclerosis. In this study, we determined if MD-2 is involved in the gene expression regulated by signalling pathways independent of TLR4. Given that interferon- (IFN) and hyperglycaemia play key roles in atherosclerosis, we determined if MD-2 is involved in IFN- and high-glucose-regulated gene expression in mononuclear cells. Results showed that IFN- and high glucose synergistically stimulated matrix metalloproteinase 1 (MMP-1), a proteinase essential for vascular tissue remodelling and atherosclerosis, in U937 mononuclear cells, but Rs-LPS inhibited the MMP-1 stimulation. To provide more evidence for a role of MD-2 in IFN--stimulated MMP-1, studies using antibodies and small interfering RNA demonstrated that MD-2 blockade or knockdown attenuated the effect of IFN- on MMP-1. Furthermore, studies using PCR arrays showed that MD-2 blockade had a similar effect as IFN- receptor blockade on the inhibition of IFN--stimulated pro-inflammatory molecules. Although these findings indicate the involvement of MD-2 in IFN- signalling, we also observed that MD-2 was up-regulated by IFN- and high glucose. We found that MD-2 up-regulation by IFN- played an essential role in the synergistic effect of IFN- and LPS on MMP-1 expression. Taken together, these findings indicate that MD-2 is involved in IFN- signalling and IFN--augmented MMP-1 up-regulation by LPS. C1 [Lu, Zhongyang; Li, Yanchun; Samuvel, Devadoss J.; Jin, Junfei; Zhang, Xiaoming; Lopes-Virella, Maria F.; Huang, Yan] Med Univ S Carolina, Coll Med, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29403 USA. [Lopes-Virella, Maria F.; Huang, Yan] Ralph H Johnson Vet Affairs Med Ctr, Dept Vet Affairs, Charleston, SC USA. RP Huang, Y (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, 114 Doughty St, Charleston, SC 29403 USA. EM huangyan@musc.edu FU Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs; NIH [DE016353] FX This work was supported by the Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs and by NIH grant DE016353 (to Y.H.). This study was presented as an abstract at the 72nd American Diabetes Association Scientific Sessions, in Philadelphia, PA, 8 12 June 2012. NR 42 TC 3 Z9 3 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0019-2805 EI 1365-2567 J9 IMMUNOLOGY JI Immunology PD NOV PY 2013 VL 140 IS 3 BP 301 EP 313 DI 10.1111/imm.12138 PG 13 WC Immunology SC Immunology GA 229JN UT WOS:000325259200003 PM 23800176 ER PT J AU Teodorescu, M Polomis, DA Gangnon, RE Consens, FB Chervin, RD Teodorescu, MC AF Teodorescu, Mihaela Polomis, David A. Gangnon, Ronald E. Consens, Flavia B. Chervin, Ronald D. Teodorescu, Mihai C. TI Sleep duration, asthma and obesity SO JOURNAL OF ASTHMA LA English DT Article DE Obesity; mechanisms ID WEIGHT-GAIN; PROSPECTIVE COMMUNITY; UNITED-STATES; LEPTIN LEVELS; YOUNG-ADULTS; ASSOCIATION; WOMEN; QUALITY; RISK; CHILDREN AB Background: Obesity is more prevalent in asthmatics. Sleep duration is a novel risk factor for obesity in general populations. Objective: We tested the association of sleep duration and asthma characteristics with obesity. Methods: Adults at tertiary clinics were surveyed on asthma symptoms and habitual sleep duration. Medical records were used to assess asthma severity step (1-4), extract height and weight, current medications and diagnosed comorbid conditions. BMI >= 30 kg/m(2) defined obesity. Habitual sleep was categorized as <6 (very short), 6 to <7 h (short), 7-8 h (normal), >8 to <= 9 h (long) and >9 h (very long). Inhaled corticosteroid doses were categorized as low, moderate and high. Results: Among 611 participants (mean BMI 30 +/- 8), 249 (41%) were obese. After adjustment for covariates, obesity was associated with short and very long sleep: as compared to normal sleepers, the odds of being obese were on an average 66% higher ([95% CI: 1.07-2.57], p = 0.02) among short and 124% higher ([1.08-1.65], p = 0.03) among very long sleepers, and the association with very short sleep approached significance (1.74 [0.96-3.14], p = 0.06). Obesity was also significantly related to highest asthma step (1.87 [1.09-3.21], p = 0.02) and psychopathology (1.64 [1.08-2.48], p = 0.02), and a trend was seen with high-dose inhaled corticosteroids (1.82 [0.93-3.56], p = 0.08). Conclusions: Obesity in asthmatics is associated with shorter and very long sleep duration, worse asthma severity, psychopathology and high-dose inhaled corticosteroids. Although this cross-sectional study cannot prove causality, we speculate that further investigation of sleep may provide new opportunities to reduce the rising prevalence of obesity among asthmatics. C1 [Teodorescu, Mihaela] William S Middleton Mem Vet Adm Med Ctr, Med Serv, James B Skatrud Pulm Sleep Res Lab, Madison, WI USA. [Teodorescu, Mihaela; Polomis, David A.] Univ Wisconsin, Sch Med & Publ Hlth, Div Allergy Pulm & Crit Care Med, Madison, WI 53792 USA. [Teodorescu, Mihaela; Teodorescu, Mihai C.] Univ Wisconsin, Sch Med & Publ Hlth, Ctr Sleep Med & Sleep Res Wisconsin Sleep, Madison, WI 53792 USA. [Gangnon, Ronald E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53792 USA. [Gangnon, Ronald E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53792 USA. [Consens, Flavia B.; Chervin, Ronald D.] Univ Michigan Hlth Syst, Dept Neurol, Ann Arbor, MI USA. [Consens, Flavia B.; Chervin, Ronald D.] Univ Michigan Hlth Syst, Sleep Disorders Ctr, Ann Arbor, MI USA. [Teodorescu, Mihai C.] Univ Wisconsin, Sch Med & Publ Hlth, Div Geriatr & Gerontol, Madison, WI 53792 USA. RP Teodorescu, M (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Div Allergy Pulm & Crit Care Med, K4-910 CSC 9988,600 Highland Ave, Madison, WI 53792 USA. EM mt3@medicine.wisc.edu FU University of Wisconsin School of Medicine and Public Health, Department of Medicine and Medical Education and Research Committee - New Investigator Award; Clinical and Translational Science Award (CTSA) program of the National Center for Research Resources, National Institutes of Health for asthma- sleep apnea research [1UL1RR025011]; National Institutes of Health; Fox Foundation; Philips Respironics, Inc.; Fisher Paykel, Inc. FX MT received funding from the University of Wisconsin School of Medicine and Public Health, Department of Medicine and Medical Education and Research Committee - New Investigator Award, and 1UL1RR025011 from the Clinical and Translational Science Award (CTSA) program of the National Center for Research Resources, National Institutes of Health for asthma- sleep apnea research. DAP, REG, FBC and MCT have no relationships to disclose. RDC has received research support from the National Institutes of Health and Fox Foundation; has served on advisory boards for Pavad Medical, not-for-profit Sweet Dreamzzz, and the NHLBI (Sleep Disorders Research Advisory Board); is a section editor for UpToDate, Inc.; received support for educational purposes from Philips Respironics, Inc. and Fisher Paykel, Inc.; has consulted for Arena Pharmaceuticals, Proctor & Gamble, and Zansors; serves on boards of directors for the American Academy of Sleep Medicine and the International Pediatric Sleep Association and is named in University of Michigan patents for algorithms and devices to facilitate diagnosis and treatment of sleep disorders. No scientific writing assistance was used for this article. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government. NR 50 TC 4 Z9 4 U1 2 U2 8 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 0277-0903 EI 1532-4303 J9 J ASTHMA JI J. Asthma PD NOV PY 2013 VL 50 IS 9 BP 945 EP 953 DI 10.3109/02770903.2013.831871 PG 9 WC Allergy; Respiratory System SC Allergy; Respiratory System GA 236AS UT WOS:000325766500005 PM 23923994 ER PT J AU Chapman, EN Kaatz, A Carnes, M AF Chapman, Elizabeth N. Kaatz, Anna Carnes, Molly TI Physicians and Implicit Bias: How Doctors May Unwittingly Perpetuate Health Care Disparities SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE implicit bias; health care disparities; physicians ID ACUTE MYOCARDIAL-INFARCTION; EMERGENCY-DEPARTMENT; KNEE ARTHROPLASTY; MEDICAL-STUDENTS; ASSOCIATION TEST; BLACK PATIENTS; GENDER BIAS; RACE; ATTITUDES; PAIN AB Although the medical profession strives for equal treatment of all patients, disparities in health care are prevalent. Cultural stereotypes may not be consciously endorsed, but their mere existence influences how information about an individual is processed and leads to unintended biases in decision-making, so called "implicit bias". All of society is susceptible to these biases, including physicians. Research suggests that implicit bias may contribute to health care disparities by shaping physician behavior and producing differences in medical treatment along the lines of race, ethnicity, gender or other characteristics. We review the origins of implicit bias, cite research documenting the existence of implicit bias among physicians, and describe studies that demonstrate implicit bias in clinical decision-making. We then present the bias-reducing strategies of consciously taking patients' perspectives and intentionally focusing on individual patients' information apart from their social group. We conclude that the contribution of implicit bias to health care disparities could decrease if all physicians acknowledged their susceptibility to it, and deliberately practiced perspective-taking and individuation when providing patient care. We further conclude that increasing the number of African American/Black physicians could reduce the impact of implicit bias on health care disparities because they exhibit significantly less implicit race bias. C1 [Chapman, Elizabeth N.; Carnes, Molly] Univ Wisconsin, Dept Med, Madison, WI USA. [Carnes, Molly] Univ Wisconsin, Dept Psychiat, Madison, WI 53706 USA. [Carnes, Molly] Univ Wisconsin, Madison, WI 53706 USA. [Kaatz, Anna; Carnes, Molly] Univ Wisconsin, Ctr Womens Hlth Res, Madison, WI 53706 USA. [Chapman, Elizabeth N.; Carnes, Molly] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA. RP Chapman, EN (reprint author), William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison VA GRECC, 2500 Overlook Terrace, Madison, WI 53705 USA. EM echapman@uwhealth.org FU NIH [R01 GM088477, DP4 GM096822] FX Dr. Chapman is a Geriatric Fellow at the Madison GRECC and Dr. Kaatz is a postdoctoral fellow at the Center for Women's Health Research. This is GRECC Manuscript No. 2013-14. Dr. Carnes's research on implicit bias is supported by NIH grant no. R01 GM088477 and DP4 GM096822. NR 61 TC 52 Z9 52 U1 13 U2 48 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD NOV PY 2013 VL 28 IS 11 BP 1504 EP 1510 DI 10.1007/s11606-013-2441-1 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 236DQ UT WOS:000325774800026 PM 23576243 ER PT J AU Bayrak, OF Gulluoglu, S Aydemir, E Ture, U Acar, H Atalay, B Demir, Z Sevli, S Creighton, CJ Ittmann, M Sahin, F Ozen, M AF Bayrak, Omer Faruk Gulluoglu, Sukru Aydemir, Esra Ture, Ugur Acar, Hasan Atalay, Basar Demir, Zeynel Sevli, Serhat Creighton, Chad J. Ittmann, Michael Sahin, Fikrettin Ozen, Mustafa TI MicroRNA expression profiling reveals the potential function of microRNA-31 in chordomas SO JOURNAL OF NEURO-ONCOLOGY LA English DT Article DE Chordoma; hsa-miR-31; Microarray; miRNA; Nucleus pulposus; Skull base ID MET; PROLIFERATION; CANCER; CELLS; DIFFERENTIATION; MIGRATION; SURVIVAL; RADIXIN; MIR-31; TUMORS AB Chordomas are rare bone tumors arising from remnants of the notochord. Molecular studies to determine the pathways involved in their pathogenesis and develop better treatments are limited. Alterations in microRNAs (miRNAs) play important roles in cancer. miRNAs are small RNA sequences that affect transcriptional and post-transcriptional regulation of gene expression in most eukaryotic organisms. Studies show that miRNA dysregulation is important for tumor initiation and progression. We compared the expression profile of miRNAs in chordomas to that of healthy nucleus pulposus samples to gain insight into the molecular pathogenesis of chordomas. Results of functional studies on one of the altered miRNAs, miR-31, are presented. The comparison between the miRNA profile of chordoma samples and the profile of normal nucleus pulposus samples suggests dysregulation of 53 miRNAs. Thirty miRNAs were upregulated in our tumor samples, while 23 were downregulated. Notably, hsa-miR-140-3p and hsa-miR-148a were upregulated in most chordomas relative to levels in nucleus pulposus cells. Two other miRNAs, hsa-miR-31 and hsa-miR-222, were downregulated in chordomas compared with the control group. Quantification with real-time polymerase chain reaction confirmed up or downregulation of these miRNAs among all samples. Functional analyses showed that hsa-miR-31 has an apoptotic effect on chordoma cells and downregulates the expression of c-MET and radixin. miRNA profiling showed that hsa-miR-31, hsa-miR-222, hsa-miR-140-3p and hsa-miR-148a are differentially expressed in chordomas compared with healthy nucleus pulposus. Our profiling may be the first step toward delineating the differential regulation of cancer-related genes in chordomas, helping to reveal the mechanisms of initiation and progression. C1 [Bayrak, Omer Faruk; Gulluoglu, Sukru; Aydemir, Esra] Yeditepe Univ, Sch Med, Dept Med Genet, Istanbul, Turkey. [Bayrak, Omer Faruk; Gulluoglu, Sukru; Aydemir, Esra] Yeditepe Univ Hosp, Istanbul, Turkey. [Gulluoglu, Sukru; Aydemir, Esra; Sevli, Serhat; Sahin, Fikrettin] Yeditepe Univ, Inst Sci, Dept Biotechnol, Istanbul, Turkey. [Ture, Ugur; Atalay, Basar] Yeditepe Univ Hosp, Dept Neurosurg, Istanbul, Turkey. [Acar, Hasan] Selcuklu Med Sch, Dept Med Genet, Konya, Turkey. [Creighton, Chad J.; Ittmann, Michael; Ozen, Mustafa] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. [Creighton, Chad J.; Ittmann, Michael; Ozen, Mustafa] Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA. [Creighton, Chad J.; Ittmann, Michael; Ozen, Mustafa] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA. [Ittmann, Michael] Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX USA. [Ozen, Mustafa] Istanbul Univ, Cerrahpasa Med Sch, Dept Med Genet, TR-3409 Istanbul, Turkey. RP Ozen, M (reprint author), Istanbul Univ, Cerrahpasa Med Sch, Dept Med Genet, TR-3409 Istanbul, Turkey. EM mozen@bcm.edu OI Bayrak, Omer Faruk/0000-0001-7562-6604 NR 28 TC 14 Z9 15 U1 0 U2 14 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X EI 1573-7373 J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD NOV PY 2013 VL 115 IS 2 BP 143 EP 151 DI 10.1007/s11060-013-1211-6 PG 9 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 236TJ UT WOS:000325821900002 PM 23912551 ER PT J AU Wang, HW Xu, JJ Grindle, G Vazquez, J Salatin, B Kelleher, A Ding, D Collins, DM Cooper, RA AF Wang, Hongwu Xu, Jijie Grindle, Garrett Vazquez, Juan Salatin, Ben Kelleher, Annmarie Ding, Dan Collins, Diane M. Cooper, Rory A. TI Performance evaluation of The Personal Mobility and Manipulation Appliance (PerMMA) SO MEDICAL ENGINEERING & PHYSICS LA English DT Article DE Assistive robot; Powered mobility; Wheelchair mounted robotic arm; Remote operator; Cooperative control; Performance evaluation; Personal assistance ID MOUNTED ROBOTIC ARM; WHEELCHAIR; INTERFACE; DESIGN; MANUS AB The Personal Mobility and Manipulation Appliance (PerMMA) is a recently developed personal assistance robot created to provide people with severe physical disabilities enhanced assistance in both mobility and manipulation. PerMMA aims to improve functional independence when a personal care attendant is not available on site. PerMMA integrates both a smart powered wheelchair and two dexterous robotic arms to assist its users in completing essential mobility and manipulation tasks during basic and instrumental activities of daily living (ADL). Two user interfaces were developed: a local control interface and a remote operator controller. This paper reports on the evaluation of PerMMA with end users completing basic ADL tasks. Participants with both lower and upper extremity impairments (N = 15) were recruited to operate PerMMA and complete up to five ADL tasks in a single session of no more than two hours (to avoid fatigue or frustration of the participants). The performance of PerMMA was evaluated by participants completing ADL tasks with two different control modes: local mode and cooperative control. The users' task completion performance and answers on pre/post-evaluation questionnaires demonstrated not only the ease in learning and usefulness of PerMMA, but also their attitudes toward assistance from advanced technology like PerMMA. As a part of the iterative development process, results of this work will serve as supporting evidence to identify design criteria and other areas for improvement of PerMMA. (C) 2013 IPEM. Published by Elsevier Ltd. All rights reserved. C1 [Wang, Hongwu; Xu, Jijie; Grindle, Garrett; Vazquez, Juan; Salatin, Ben; Kelleher, Annmarie; Ding, Dan; Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [Wang, Hongwu; Xu, Jijie; Grindle, Garrett; Vazquez, Juan; Salatin, Ben; Kelleher, Annmarie; Ding, Dan; Collins, Diane M.; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Kelleher, Annmarie] Univ Pittsburgh, Med Ctr, Ctr Assist Technol, Pittsburgh, PA USA. RP Wang, HW (reprint author), Human Engn Res Labs, 6425 Penn Ave,Suite 400, Pittsburgh, PA 15206 USA. EM how11@pitt.edu FU National Science Foundation [EEC-540865]; Office of Research and Development, Rehabilitation Research & Development Service, Department of Veterans Affairs [B3142C, B6789C]; National Institute for Disability and Rehabilitation Research [H133P09001002] FX This material is based upon work supported in part by the National Science Foundation Grant#EEC-540865, Office of Research and Development, Rehabilitation Research & Development Service, Department of Veterans Affairs, Grant#B3142C and #B6789C, and National Institute for Disability and Rehabilitation Research Grant# H133P09001002. NR 28 TC 5 Z9 5 U1 1 U2 11 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1350-4533 EI 1873-4030 J9 MED ENG PHYS JI Med. Eng. Phys. PD NOV PY 2013 VL 35 IS 11 BP 1613 EP 1619 DI 10.1016/j.medengphy.2013.05.008 PG 7 WC Engineering, Biomedical SC Engineering GA 233SV UT WOS:000325590700009 PM 23769146 ER PT J AU Carrion, I Nedjat-Haiem, F Macip-Billbe, M AF Carrion, Iraida Nedjat-Haiem, Frances Macip-Billbe, Melania TI Coping Strategies Among Latino Men and Women With a Cancer Diagnosis Living in the U.S SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Carrion, Iraida; Macip-Billbe, Melania] Univ S Florida, Tampa, FL USA. [Nedjat-Haiem, Frances] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD NOV PY 2013 VL 22 SU 3 SI SI BP 43 EP 44 PG 2 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA 235AS UT WOS:000325687200065 ER PT J AU Horan, WP Hajcak, G Wynn, JK Green, MF AF Horan, W. P. Hajcak, G. Wynn, J. K. Green, M. F. TI Impaired emotion regulation in schizophrenia: evidence from event-related potentials SO PSYCHOLOGICAL MEDICINE LA English DT Article DE Emotion regulation; event-related potentials (ERPs); late positive potential; schizophrenia ID PSYCHIATRIC RATING-SCALE; QUALITY-ASSURANCE; CONTEXT; REAPPRAISAL; PICTURES; DEFICITS; CONSEQUENCES; INTELLIGENCE; NEUROLEPTICS; DYSFUNCTION AB Background. Although several aspects of emotion seem to be intact in schizophrenia, there is emerging evidence that patients show an impaired ability to adaptively regulate their emotions. This event-related potential (ERP) study examined whether schizophrenia is associated with impaired neural responses to appraisal frames, that is when negative stimuli are presented in a less negative context. Method. Thirty-one schizophrenia out-patients and 27 healthy controls completed a validated picture-viewing task with three conditions: (1) neutral pictures preceded by neutral descriptions ('Neutral'), (2) unpleasant pictures preceded by negative descriptions ('Preappraised negative'), and (3) unpleasant pictures preceded by more neutral descriptions ('Preappraised neutral' Analyses focused on the late positive potential (LPP), an index of facilitated attention to emotional stimuli that is reduced following cognitive emotion regulation strategies, during four time windows from 300 to 2000 ms post-picture onset. Results. Replicating prior studies, controls showed smaller LPP in Preappraised neutral and Neutral versus Preappraised negative conditions throughout the 300-2000-ms time period. By contrast, patients showed (a) larger LPP in Preappraised neutral and Preappraised negative versus Neutral conditions in the initial period (300-600 ms) and (b) an atypical pattern of larger LPP to Preappraised neutral versus Preappraised negative and Neutral conditions in the 600-1500-ms epochs. Conclusions. Modulation of neural responses by a cognitive emotion regulation strategy seems to be impaired in schizophrenia during the first 2 s after exposure to unpleasant stimuli. C1 [Horan, W. P.; Wynn, J. K.; Green, M. F.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Hajcak, G.] SUNY Stony Brook, Stony Brook, NY 11794 USA. RP Horan, WP (reprint author), Univ Calif Los Angeles, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM horan@ucla.edu RI Wynn, Jonathan/H-3749-2014 OI Wynn, Jonathan/0000-0002-1763-8540 FU Veteran Affairs (VA) Career Development Award; National Institute of Mental Health (NIMH) [MH065707, MH43292] FX Support for this study came from a Veteran Affairs (VA) Career Development Award (PI: W. P. Horan) and National Institute of Mental Health (NIMH) Grants MH065707 and MH43292 (PI: M. F. Green). We thank J. Lee, A. Bender, M. Dolinsky, C. Gibson, C. Tripp and K. Weiner for assistance in data collection. NR 62 TC 18 Z9 19 U1 5 U2 31 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0033-2917 EI 1469-8978 J9 PSYCHOL MED JI Psychol. Med. PD NOV PY 2013 VL 43 IS 11 BP 2377 EP 2391 DI 10.1017/S0033291713000019 PG 15 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 234KB UT WOS:000325641200014 PM 23360592 ER PT J AU Han, JH Bilker, WB Nachamkin, I Zaoutis, TE Coffin, SE Linkin, DR Hu, BF Tolomeo, P Fishman, NO Lautenbach, E AF Han, Jennifer H. Bilker, Warren B. Nachamkin, Irving Zaoutis, Theoklis E. Coffin, Susan E. Linkin, Darren R. Hu, Baofeng Tolomeo, Pam Fishman, Neil O. Lautenbach, Ebbing TI The Effect of a Hospital-Wide Urine Culture Screening Intervention on the Incidence of Extended-Spectrum beta-Lactamase-Producing Escherichia coli and Klebsiella Species SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID INFECTION-CONTROL MEASURES; TO-PATIENT TRANSMISSION; ANTIBIOTIC-RESISTANCE; UNITED-STATES; ENTEROBACTERIACEAE; COMMUNITY; IMPACT; ORGANISMS; ACQUISITION; PREVALENCE AB Objective.Optimal strategies for limiting the transmission of extended-spectrum -lactamase-producing Escherichia coli and Klebsiella spp (ESBL-EK) in the hospital setting remain unclear. The objective of this study was to evaluate the impact of a urine culture screening strategy on the incidence of ESBL-EK.Design.Prospective quasi-experimental study.Setting.Two intervention hospitals and one control hospital within a university health system from 2005 to 2009.Patients and Intervention.All clinical urine cultures with E. coli or Klebsiella spp were screened for ESBL-EK. Patients determined to be colonized or infected with ESBL-EK were placed in a private room with contact precautions. The primary outcome of interest was nosocomial ESBL-EK incidence in nonurinary clinical cultures (cases occurring more than 48 hours after admission). Changes in monthly ESBL-EK incidence rates were evaluated with mixed-effects Poisson regression models, with adjustment for institution-level characteristics (eg, total admissions).Results.The overall incidence of ESBL-EK increased from 1.42/10,000 patient-days to 2.16/10,000 patient-days during the study period. The incidence of community-acquired ESBL-EK increased nearly 3-fold, from 0.33/10,000 patient-days to 0.92/10,000 patient-days (P < .001). On multivariable analysis, the intervention was not significantly associated with a reduction in nosocomial ESBL-EK incidence (incidence rate ratio, 1.38 [95% confidence interval, 0.83 2.31]; P = .21).Conclusions.Universal screening of clinical urine cultures for ESBL-EK did not result in a reduction in nosocomial ESBL-EK incidence rates, most likely because of increases in importation of ESBL-EK cases from the community. Further studies are needed on elucidating optimal infection control interventions to limit spread of ESBL-producing organisms in the hospital setting. C1 [Han, Jennifer H.; Linkin, Darren R.; Fishman, Neil O.; Lautenbach, Ebbing] Univ Penn, Sch Med, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA. [Han, Jennifer H.; Bilker, Warren B.; Zaoutis, Theoklis E.; Tolomeo, Pam; Lautenbach, Ebbing] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Han, Jennifer H.; Bilker, Warren B.; Zaoutis, Theoklis E.; Coffin, Susan E.; Linkin, Darren R.; Tolomeo, Pam; Lautenbach, Ebbing] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Nachamkin, Irving; Hu, Baofeng] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Zaoutis, Theoklis E.; Coffin, Susan E.] Childrens Hosp Philadelphia, Div Infect Dis, Philadelphia, PA 19104 USA. [Zaoutis, Theoklis E.; Coffin, Susan E.] Childrens Hosp Philadelphia, Ctr Pediat Clin Effectiveness, Philadelphia, PA 19104 USA. [Linkin, Darren R.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Han, JH (reprint author), Hosp Univ Penn, Dept Med, Div Infect Dis, 811 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM jennifer.han@uphs.upenn.edu FU Centers for Disease Control and Prevention (CDC) [R01-CI000389]; CDC Prevention Epicenters Program [U54-CK000163]; National Institutes of Health [K24 AI080942]; Commonwealth Universal Research Enhancement Program from the Pennsylvania State Department of Health FX This work was supported by the Centers for Disease Control and Prevention (CDC; grant R01-CI000389 to E. L.). This study was also supported, in part, by the CDC Prevention Epicenters Program (grant U54-CK000163 to E. L.), the National Institutes of Health (grant K24 AI080942 to E. L.), and a Commonwealth Universal Research Enhancement Program grant from the Pennsylvania State Department of Health (to E. L.). The funding agencies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. NR 28 TC 4 Z9 7 U1 0 U2 7 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD NOV 1 PY 2013 VL 34 IS 11 BP 1160 EP 1166 DI 10.1086/673453 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 232KB UT WOS:000325491500005 PM 24113599 ER PT J AU Grossbard, JR Hawkins, EJ Lapham, GT Williams, EC Rubinsky, AD Simpson, TL Seal, KH Kivlahan, DR Bradley, KA AF Grossbard, Joel R. Hawkins, Eric J. Lapham, Gwen T. Williams, Emily C. Rubinsky, Anna D. Simpson, Tracy L. Seal, Karen H. Kivlahan, Daniel R. Bradley, Katharine A. TI Follow-up care for alcohol misuse among OEF/OIF veterans with and without alcohol use disorders and posttraumatic stress disorder SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE Alcohol misuse; PTSD; OEF/OIF veterans; Brief alcohol interventions; Referral to treatment ID SUBSTANCE USE DISORDERS; AFFAIRS HEALTH-CARE; IDENTIFICATION TEST AUDIT; MENTAL-HEALTH; AFGHANISTAN VETERANS; BRIEF INTERVENTIONS; RETURNING VETERANS; MILITARY PERSONNEL; SEEKING SAFETY; UNITED-STATES AB Little is known about follow-up care for alcohol misuse in the Veterans Affairs (VA) health care system among Operations Enduring and Iraqi Freedom (OEF/OIF) veterans with and without alcohol use disorders (AUD) and/or posttraumatic stress disorder (PTSD). Using data from 4725 OEF/OIF VA outpatients with alcohol screening (2006-2010), we compared the prevalence of follow-up for alcohol misuse brief intervention (BI) or referral to treatment among patients with and without AUD and/or PTSD. Among 933 (19.7%) patients with alcohol misuse (AUDIT-C >= 5), 77.0% had AUD and/or PTSD. Rates of BI or referral for alcohol misuse were higher among patients with AUD (76.9%) and both AUD and PTSD (70.1%) compared to those with PTSD only (53.1%) and neither AUD nor PTSD (52.3%). Among OEF/OIF VA outpatients with alcohol misuse, those with AUD had higher rates of follow-up for alcohol misuse than those without, but PTSD was not associated with differential follow-up. Published by Elsevier Inc. C1 [Grossbard, Joel R.; Hawkins, Eric J.; Lapham, Gwen T.; Williams, Emily C.; Rubinsky, Anna D.; Kivlahan, Daniel R.; Bradley, Katharine A.] Vet Affairs VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev HSR&D, Seattle, WA 98101 USA. [Hawkins, Eric J.; Simpson, Tracy L.; Kivlahan, Daniel R.; Bradley, Katharine A.] Vet Affairs VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98101 USA. [Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA USA. [Grossbard, Joel R.; Lapham, Gwen T.; Williams, Emily C.; Rubinsky, Anna D.; Bradley, Katharine A.] Univ Washington, Hlth Serv, Seattle, WA 98195 USA. [Hawkins, Eric J.; Simpson, Tracy L.; Kivlahan, Daniel R.] Univ Washington, Seattle, WA 98195 USA. [Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA USA. [Seal, Karen H.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Grossbard, JR (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA 98101 USA. EM Joel.Grossbard@va.gov FU HSRD VA [IK2 HX001161] NR 57 TC 6 Z9 6 U1 2 U2 14 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD NOV-DEC PY 2013 VL 45 IS 5 BP 409 EP 415 DI 10.1016/j.jsat.2013.04.007 PG 7 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 224PK UT WOS:000324900400004 PM 23906670 ER PT J AU Valente, AJ Sakamuri, SSVP Siddesha, JM Yoshida, T Gardner, JD Prabhu, R Siebenlist, U Chandrasekar, B AF Valente, Anthony J. Sakamuri, Siva S. V. P. Siddesha, Jalahalli M. Yoshida, Tadashi Gardner, Jason D. Prabhu, Ramesh Siebenlist, Ulrich Chandrasekar, Bysani TI TRAF3IP2 mediates interleukin-18-induced cardiac fibroblast migration and differentiation SO CELLULAR SIGNALLING LA English DT Article DE RNA interference; Cardiac fibroblasts; Migration; TRAF3IP2; Cardiac fibrosis; Remodeling ID NF-KAPPA-B; GROWTH-FACTOR; TRANSCRIPTION FACTORS; CIKS ACT1; IN-VIVO; EXPRESSION; CELL; PROTEIN; INFLAMMATION; ACTIVATION AB TRAF3IP2 is a cytoplasmic adapter protein and an upstream regulator of IKK/NF-kappa B and JNK/AP-1. Here we demonstrate for the first time that the proinflammatory cytokine interleukin (IL)-18 induces TRAF3IP2 expression in primary cardiac fibroblasts (CF) in a Nox4/hydrogen peroxide-dependent manner. Silencing TRAF3IP2 using a phosphorothioated, 2'-O-methyl modified, cholesterol-tagged TRAF3IP2 siRNA duplex markedly attenuated IL-18-induced NF-kappa B and AP-1 activation and CF migration. Using co-IP/IB and co-localization experiments, we show that Nox4 physically associates with IL-18 receptor proteins, and IL-18 enhances their binding. Further, IL-18 promotes fibroblast to myofibroblast transition, as evidenced by enhanced a-smooth muscle actin expression, types 1 and 3 collagen induction, and soluble collagen secretion, via TRAF3IP2. These results indicate that TRAF3IP2 is a critical intermediate in IL-18-induced CF migration and differentiation in vitro. TRAF3IP2 could serve as a potential therapeutic target in cardiac fibrosis and adverse remodeling in vivo. (C) 2013 Elsevier Inc. All rights reserved. C1 [Valente, Anthony J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Valente, Anthony J.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Sakamuri, Siva S. V. P.; Siddesha, Jalahalli M.; Yoshida, Tadashi; Chandrasekar, Bysani] Tulane Univ, Sch Med, Inst Heart & Vasc, New Orleans, LA 70112 USA. [Gardner, Jason D.] Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA 70112 USA. [Prabhu, Ramesh] Tulane Univ, Sch Med, New Orleans, LA 70112 USA. [Siebenlist, Ulrich] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA. [Chandrasekar, Bysani] Southeast Louisiana Vet Hlth Care Syst, Res Serv, New Orleans, LA 70161 USA. RP Chandrasekar, B (reprint author), Tulane Univ, Sch Med, Inst Heart & Vasc, 1430 Tulane Ave, New Orleans, LA 70112 USA. EM bchandra@tulane.edu OI Yoshida, Tadashi/0000-0002-4544-1497 FU Department of Veterans Affairs Research Career Scientist award; VA Office of Research and Development Biomedical Laboratory Research and Development Service Award [1IO1BX000246]; NIH/NHLBI [HL-86787] FX BC is a recipient of the Department of Veterans Affairs Research Career Scientist award, and is supported by VA Office of Research and Development Biomedical Laboratory Research and Development Service Award 1IO1BX000246 and the NIH/NHLBI grant HL-86787. The contents of this report do not represent the views of the Department of Veterans Affairs or the United States Government NR 30 TC 18 Z9 19 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0898-6568 J9 CELL SIGNAL JI Cell. Signal. PD NOV PY 2013 VL 25 IS 11 BP 2176 EP 2184 DI 10.1016/j.cellsig.2013.07.013 PG 9 WC Cell Biology SC Cell Biology GA 225OI UT WOS:000324971800011 PM 23872479 ER PT J AU Brashers, DE Hogan, TP AF Brashers, Dale E. Hogan, Timothy P. TI The appraisal and management of uncertainty: Implications for information-retrieval systems SO INFORMATION PROCESSING & MANAGEMENT LA English DT Article DE Uncertainty; Information retrieval; Appraisal; Anxiety; Hope ID HUNTINGTONS-DISEASE; BRCA2 MUTATIONS; IR TOOL; SEEKING; BEHAVIOR; COMMUNICATION; NEED; AIDS; HIV; PEOPLE AB Uncertainty is an important idea in information-retrieval (IR) research, but the concept has yet to be fully elaborated and explored. Common assumptions about uncertainty are (a) that it is a negative (anxiety-producing) state and (b) that it will be reduced through information search and retrieval. Research in the domain of uncertainty in illness, however, has demonstrated that uncertainty is a complex phenomenon that shares a complicated relationship with information. Past research on people living with HIV and individuals who have tested positive for genetic risk for different illnesses has revealed that information and the reduction of uncertainty can, in fact, produce anxiety, and that maintaining uncertainty can be associated with optimism and hope. We review the theory of communication and uncertainty management and offer nine principles based on that theoretical work that can be used to influence IR system design. The principles reflect a view of uncertainty as a multi-faceted and dynamic experience, one subject to ongoing appraisal and management efforts that include interaction with and use of information in a variety of forms. Published by Elsevier Ltd. C1 [Brashers, Dale E.] Univ Illinois, Coll Liberal Arts & Sci, Dept Commun, Urbana, IL 61801 USA. [Hogan, Timothy P.] US Dept Vet Affairs, Ctr Hlth Qual Outcomes & Econ Res, eHlth Qual Enhancement Res Initiat, Natl eHlth QUERI Coordinating Ctr,Edith Nourse Ro, Bedford, MA 01730 USA. [Hogan, Timothy P.] Univ Massachusetts, Sch Med, Div Hlth Informat & Implementat Sci, Dept Quantitat Hlth Sci,Albert Sherman Ctr, Worcester, MA 01605 USA. RP Hogan, TP (reprint author), US Dept Vet Affairs, Ctr Hlth Qual Outcomes & Econ Res, eHlth Qual Enhancement Res Initiat, Natl eHlth QUERI Coordinating Ctr,Edith Nourse Ro, 200 Springs Rd Bldg 70 152, Bedford, MA 01730 USA. EM timothy.hogan@va.gov NR 71 TC 6 Z9 6 U1 8 U2 55 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0306-4573 J9 INFORM PROCESS MANAG JI Inf. Process. Manage. PD NOV PY 2013 VL 49 IS 6 BP 1241 EP 1249 DI 10.1016/j.ipm.2013.06.002 PG 9 WC Computer Science, Information Systems; Information Science & Library Science SC Computer Science; Information Science & Library Science GA 217JA UT WOS:000324354600004 ER PT J AU Kubota, T Elalieh, HZ Saless, N Fong, C Wang, YM Babey, M Cheng, ZQ Bikle, DD AF Kubota, Takuo Elalieh, Hashem Z. Saless, Neema Fong, Chak Wang, Yongmei Babey, Muriel Cheng, Zhiqiang Bikle, Daniel D. TI Insulin-like growth factor-1 receptor in mature osteoblasts is required for periosteal bone formation induced by reloading SO ACTA ASTRONAUTICA LA English DT Article; Proceedings Paper CT 18th Humans in Space (HIS) Symposium of the International-Academy-of-Astronautics (IAA) CY APR 11-15, 2011 CL Houston, TX SP Int Acad Astronaut DE Insulin-like growth factor 1 receptor; Osteoblasts; Unloading; Reloading; Periosteal bone formation ID LONG-DURATION SPACEFLIGHT; GENE-EXPRESSION; SPACE-FLIGHT; IGF-I; RECOVERY; HORMONE; PERIOD; MICE AB Skeletal loading and unloading has a pronounced impact on bone remodeling, a process also regulated by insulin-like growth factor-1 (IGF-1) signaling. Skeletal unloading leads to resistance to the anabolic effect of IGF-1, while reloading after unloading restores responsiveness to IGF-1. However, a direct study of the importance of IGF-1 signaling in the skeletal response to mechanical loading remains to be tested. In this study, we assessed the skeletal response of osteoblast-specific Igf-1 receptor deficient (Igf-1r(-/-)) mice to unloading and reloading. The mice were hindlimb unloaded for 14 days and then reloaded for 16 days. Igf-1r(-/-) mice displayed smaller cortical bone and diminished periosteal and endosteal bone formation at baseline. Periosteal and endosteal bone formation decreased with unloading in Igf-1r(+/+) mice. However, the recovery of periosteal bone formation with reloading was completely inhibited in Igf-1r(-/-) mice, although reloading-induced endosteal bone formation was not hampered. These changes in bone formation resulted in the abolishment of the expected increase in total cross-sectional area with reloading in Igf-1r(-/-) mice compared to the control mice. These results suggest that the Igf-1r in mature osteoblasts has a critical role in periosteal bone formation in the skeletal response to mechanical loading. Published by Elsevier Ltd. on behalf of IAA. C1 [Bikle, Daniel D.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA. San Francisco VA Med Ctr, Endocrine Res Unit, San Francisco, CA 94121 USA. RP Bikle, DD (reprint author), Univ Calif San Francisco, Dept Med, 4150 Clement St,111N, San Francisco, CA 94121 USA. EM daniel.bikle@ucsf.edu FU BLRD VA [IP1 BX001599]; NIAMS NIH HHS [R01 AR055924, R01 AR050023]; NIDDK NIH HHS [R01 DK054793] NR 29 TC 8 Z9 8 U1 0 U2 9 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0094-5765 J9 ACTA ASTRONAUT JI Acta Astronaut. PD NOV PY 2013 VL 92 IS 1 SI SI BP 73 EP 78 DI 10.1016/j.actaastro.2012.08.007 PG 6 WC Engineering, Aerospace SC Engineering GA 212VX UT WOS:000324012000011 PM 23976802 ER PT J AU Johnson, MS Mitchell, T Moore, DR Lei, XY Barnes, S Zhang, JH Koizumi, A Ramanadham, S Darley-Usmar, VM AF Johnson, Michelle S. Mitchell, Tanecia Moore, D. Ray Lei, Xiaoyong Barnes, Stephen Zhang, Jianhua Koizumi, Akio Ramanadham, Sasanka Darley-Usmar, Victor M. TI The Voltage-Dependant Anion Channel (VDAC) is S-Glutathionylated in Ins(2Akita) Derived B-Cells SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Meeting Abstract C1 [Johnson, Michelle S.; Mitchell, Tanecia; Darley-Usmar, Victor M.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Johnson, Michelle S.; Mitchell, Tanecia; Barnes, Stephen; Zhang, Jianhua; Darley-Usmar, Victor M.] Univ Alabama Birmingham, Ctr Free Radical Biol, Birmingham, AL USA. [Zhang, Jianhua] Univ Alabama Birmingham, Birmingham VA Med Ctr, Birmingham, AL USA. [Koizumi, Akio] Kyoto Grad Sch Med, Dept Hlth & Environm Sci, Kyoto, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 EI 1873-4596 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD NOV 1 PY 2013 VL 65 SU 2 MA 102 BP S54 EP S55 DI 10.1016/j.freeradbiomed.2013.10.519 PG 2 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA V40JU UT WOS:000209475700121 ER PT J AU Oates, JC Mashmoushi, AK AF Oates, Jim C. Mashmoushi, Ahmad K. TI Nitric Oxide and Not Superoxide Production by Inducible Nitric Oxide Synthase Leads to Podocyte Dysfunction that is Seen in Lupus Nephritis SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Meeting Abstract C1 [Oates, Jim C.; Mashmoushi, Ahmad K.] Med Univ S Carolina, Charleston, SC USA. [Oates, Jim C.] Ralph H Johnson VAMC, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 EI 1873-4596 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD NOV 1 PY 2013 VL 65 SU 2 MA 62 BP S38 EP S38 DI 10.1016/j.freeradbiomed.2013.10.477 PG 1 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA V40JU UT WOS:000209475700081 ER PT J AU Oates, JC Mashmoushi, AK Hofbauer, AF Gilkeson, GS AF Oates, Jim C. Mashmoushi, Ahmad K. Hofbauer, Ann F. Gilkeson, Gary S. TI Nitric Oxide Modulation of Redox-Modulated Cytokines in Lupus Nephritis SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Meeting Abstract C1 [Oates, Jim C.; Mashmoushi, Ahmad K.; Gilkeson, Gary S.] Med Univ S Carolina, Charleston, SC USA. [Oates, Jim C.; Hofbauer, Ann F.; Gilkeson, Gary S.] Ralph H Johnson VAMC, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 EI 1873-4596 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD NOV 1 PY 2013 VL 65 SU 2 MA 61 BP S37 EP S38 DI 10.1016/j.freeradbiomed.2013.10.476 PG 2 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA V40JU UT WOS:000209475700080 ER PT J AU Tsui, I Sarraf, D AF Tsui, Irena Sarraf, David TI Paracentral Acute Middle Maculopathy and Acute Macular Neuroretinopathy SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA LA English DT Article AB Type 1 acute macular neuroretinopathy (AMN), also known as paracentral acute middle maculopathy (PAMM), is a novel form of AMN in which spectral-domain optical coherence tomography (SD-OCT) demonstrates a characteristic hyper-reflective band-like lesion at the level of the inner nuclear layer. This form of AMN has only recently been described in five patients who were predominantly older men with vasculopathy. Herein, we describe a young, healthy female patient with classic features of type 1 AMN or PAMM with SD-OCT. C1 [Tsui, Irena] Univ Calif Los Angeles, Jules Stein Eye Inst, Retina Div, Los Angeles, CA 90024 USA. [Tsui, Irena; Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. [Sarraf, David] Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA 90024 USA. RP Sarraf, D (reprint author), Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, 100 Stein Plaza, Los Angeles, CA 90024 USA. EM dsarraf@ucla.edu NR 6 TC 13 Z9 13 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 2325-8160 EI 2325-8179 J9 OSLI RETINA JI Ophthalmic Surg. Lasers Imag. Retin. PD NOV-DEC PY 2013 VL 44 IS 6 SU S BP S33 EP S35 DI 10.3928/23258160-20131101-06 PG 3 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA V37XT UT WOS:000209309200006 PM 24220881 ER PT J AU Meinzer, M Beeson, PM Cappa, S Crinion, J Kiran, S Saur, D Parrish, T Crosson, B Thompson, CK AF Meinzer, Marcus Beeson, Pelagie M. Cappa, Stefano Crinion, Jenny Kiran, Swathi Saur, Dorothee Parrish, Todd Crosson, Bruce Thompson, Cynthia K. TI Neuroimaging in aphasia treatment research: Consensus and practical guidelines for data analysis (vol 73, pg 215, 2013) SO NEUROIMAGE LA English DT Correction C1 [Meinzer, Marcus] Charite, Dept Neurol, Ctr Stroke Res Berlin, D-13353 Berlin, Germany. [Meinzer, Marcus] Cluster Excellence NeuroCure, D-13353 Berlin, Germany. [Meinzer, Marcus; Crosson, Bruce] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA. [Beeson, Pelagie M.] Univ Arizona, Dept Speech Language & Hearing Sci, Tucson, AZ USA. [Cappa, Stefano] Univ Vita Salute San Raffaele, Dept Clin Neurosci, Milan, Italy. [Crinion, Jenny] UCL, Inst Cognit Neurosci, London, England. [Kiran, Swathi] Boston Univ, Sargent Coll Hlth & Rehabil Sci, Boston, MA 02215 USA. [Saur, Dorothee] Univ Leipzig, Dept Neurol, Language & Aphasia Lab, D-04109 Leipzig, Germany. [Parrish, Todd] Northwestern Univ, Dept Radiol, Chicago, IL 60611 USA. [Crosson, Bruce] US Dept Vet Affairs, Brain Rehabil Res Ctr Excellence, Gainesville, FL USA. [Thompson, Cynthia K.] Northwestern Univ, Dept Commun Sci & Disorders, Evanston, IL USA. [Thompson, Cynthia K.] Northwestern Univ, Dept Neurol, Evanston, IL USA. RP Meinzer, M (reprint author), Charite, Dept Neurol, Ctr Stroke Res Berlin, D-13353 Berlin, Germany. EM marcus.meinzer@charite.de RI Crosson, Bruce/L-3128-2013 NR 1 TC 0 Z9 0 U1 0 U2 9 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 J9 NEUROIMAGE JI Neuroimage PD NOV 1 PY 2013 VL 81 BP 507 EP 507 DI 10.1016/j.neuroimage.2013.05.059 PG 1 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 198PI UT WOS:000322934400052 ER PT J AU McGregor, KM Nocera, JR Sudhyadhom, A Patten, C Manini, TM Kleim, JA Crosson, B Butler, AJ AF McGregor, Keith M. Nocera, Joe R. Sudhyadhom, Atchar Patten, Carolynn Manini, Todd M. Kleim, Jeffrey A. Crosson, Bruce Butler, Andrew J. TI Effects of aerobic fitness on aging-related changes of interhemispheric inhibition and motor performance SO FRONTIERS IN AGING NEUROSCIENCE LA English DT Article DE agingneuroscience; aging; fMRI; TMS; physicalfitness; interhemisphericcommunication; negative BOLD; dexterity ID PRIMARY SOMATOSENSORY CORTEX; AGE-RELATED DIFFERENCES; TRANSCRANIAL MAGNETIC STIMULATION; UNILATERAL HAND MOVEMENTS; BOLD SIGNAL CHANGES; CORPUS-CALLOSUM; MULTIPLE-SCLEROSIS; CARDIOVASCULAR FITNESS; NEURONAL INHIBITION; PHYSICAL-ACTIVITY AB Physical Fitness has been long associated with maintenance and improvement of motor performance as we age. In particular, measures of psychomotor speed and motor dexterity tend to be higher in physically fit aging adults as compared to their sedentary counterparts. Using functional magnetic resonance imaging and transcranial magnetic stimulation, we explored the patterns of neural activity that may, in part, account for differences between individuals of varying physical fitness levels. In this study, we enrolled both sedentary and physically fit middle age (40-60) and younger (18-30) adults and measured upper extremity motor performance during behavioral testing. In a follow-up session, we employed TMS and fMRI to assess levels of interhemispheric communication during unimanual tasks. Results show that increased physical fitness is associated with better upper extremity motor performance on distal dexterity assessments and increased levels of interhemispheric inhibition in middle-age adults. Further, the functional correlates of changes of ipsilateral activity appears to be restricted to the aging process as younger adults of varying fitness levels do not differ in hemispheric patterns of activity or motor performance. We conclude that sedentary aging confers a loss of interhemispheric inhibition that is deleterious to some aspects of motor function, as early as midlife, but these changes can be mediated by chronic engagement in aerobic exercise C1 [McGregor, Keith M.; Nocera, Joe R.; Crosson, Bruce; Butler, Andrew J.] US Dept Vet Affairs, Ctr Visual & Neurocognit Rehabil, Decatur, GA USA. [McGregor, Keith M.; Nocera, Joe R.; Crosson, Bruce] Emory Univ, Dept Neurol, Atlanta, GA USA. [Sudhyadhom, Atchar; Patten, Carolynn] VA Ctr Excellence, Gainesville, FL USA. [Sudhyadhom, Atchar] Univ Florida, Dept Neurosurg, Gainesville, FL USA. [Patten, Carolynn] Univ Florida, Dept Phys Therapy, Gainesville, FL USA. [Manini, Todd M.] Univ Florida, Dept Geriatr, Gainesville, FL USA. [Kleim, Jeffrey A.] Arizona State Univ, Sch Biol & Hlth Syst Engn, Tempe, AZ USA. [Butler, Andrew J.] Georgia State Univ, Dept Phys Therapy, Atlanta, GA 30303 USA. RP McGregor, KM (reprint author), Emory Univ, Dept Neurol, 1518 Clifton Rd NE, Decatur, GA 30033 USA. EM keith.mcgregor@emory.edu RI Patten, Carolynn/B-4804-2009 OI Patten, Carolynn/0000-0002-9948-0045; McGregor, Keith/0000-0003-3654-351X FU NIA NIH HHS [P30 AG028740] NR 92 TC 11 Z9 11 U1 2 U2 19 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1663-4365 J9 FRONT AGING NEUROSCI JI Front. Aging Neurosci. PD OCT 30 PY 2013 VL 5 DI 10.3389/fnagi.2013.00066 PG 14 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 242UA UT WOS:000326266700001 PM 24198784 ER PT J AU Hill, SY Jones, BL Holmes, B Steinhauer, SR Zezza, N Stiffler, S AF Hill, Shirley Y. Jones, Bobby L. Holmes, Brian Steinhauer, Stuart R. Zezza, Nicholas Stiffler, Scott TI Cholinergic receptor gene (CHRM2) variation and familial loading for alcohol dependence predict childhood developmental trajectories of P300 SO PSYCHIATRY RESEARCH LA English DT Article DE P300; CHRM2; High-risk; Alcohol dependence; Offspring; ERP; Childhood ID EVENT-RELATED POTENTIALS; SUBSTANCE USE DISORDERS; LINKAGE-PHYSICAL MAP; HIGH-RISK; EXTERNALIZING PSYCHOPATHOLOGY; AMPLITUDE DEVELOPMENT; DRUG-DEPENDENCE; SAS PROCEDURE; HUMAN GENOME; ASSOCIATION AB P300 amplitude in childhood predicts substance use disorders by young adulthood. Trajectories of visual P300 amplitude show an association between low amplitude P300 and familial risk for alcohol dependence (AD). Variation in the cholinergic muscarinic receptor gene (CHRM2) has previously been associated with P300 amplitude and AD. The present study used group based trajectory modeling of auditory P300 data collected longitudinally from offspring in families with and without familial loading for AD to determine if specific trajectories would be associated with familial risk and CHRM2 variation. Trajectory modeling confirms previous reports of an association between the low visual P300 trajectory with high familial risk in male offspring. This association was detected in offspring in the 8-12 age range, but not in 13-18 or 19-29 year olds or in high-risk female offspring. CHRM2 association analysis with P300 finds 8-12 year olds who are homozygous for the T allele of rs1824024 are 2.6 times more likely to follow a P300 trajectory characterized by lower and slower change regardless of familial loading. Combining the odds for being male and having a TT genotype results in odds of 6.5 that individuals will follow the low P300 trajectory. (C) 2013 Elsevier Ireland Ltd. All rights reserved. C1 [Hill, Shirley Y.; Jones, Bobby L.; Holmes, Brian; Zezza, Nicholas; Stiffler, Scott] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA. [Steinhauer, Stuart R.] VA Pittsburgh Healthcare Syst, Biometr Res, Pittsburgh, PA 15206 USA. RP Hill, SY (reprint author), Univ Pittsburgh, Med Ctr, Dept Psychiat, 3811 OHara, St Pittsburgh, PA 15213 USA. EM syh50@pitt.edu FU NIAAA [AA018289, AA005909, AA 008082, AA015168] FX This research was supported by NIAAA Grants AA018289, AA005909, AA 008082, and AA015168 to SYH. NR 57 TC 6 Z9 7 U1 2 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD OCT 30 PY 2013 VL 209 IS 3 BP 504 EP 511 DI 10.1016/j.psychres.2013.04.027 PG 8 WC Psychiatry SC Psychiatry GA 249GS UT WOS:000326766300039 PM 23747232 ER PT J AU Ganguly, K Poo, MM AF Ganguly, Karunesh Poo, Mu-ming TI Activity-Dependent Neural Plasticity from Bench to Bedside SO NEURON LA English DT Review ID TRANSCRANIAL MAGNETIC STIMULATION; PRIMARY SOMATOSENSORY CORTEX; CA1 PYRAMIDAL NEURONS; OCULAR DOMINANCE PLASTICITY; TERM SYNAPTIC PLASTICITY; INDUCED MOVEMENT THERAPY; DEEP-BRAIN-STIMULATION; PRIMARY VISUAL-CORTEX; PRIMARY MOTOR CORTEX; FOCAL HAND DYSTONIA AB Much progress has been made in understanding how behavioral experience and neural activity can modify the structure and function of neural circuits during development and in the adult brain. Studies of physiological and molecular mechanisms underlying activity-dependent plasticity in animal models have suggested potential therapeutic approaches for a wide range of brain disorders in humans. Physiological and electrical stimulations as well as plasticity-modifying molecular agents may facilitate functional recovery by selectively enhancing existing neural circuits or promoting the formation of new functional circuits. Here, we review the advances in basic studies of neural plasticity mechanisms in developing and adult nervous systems and current clinical treatments that harness neural plasticity, and we offer perspectives on future development of plasticity-based therapy. C1 [Ganguly, Karunesh] San Francisco VA Med Ctr, Dept Neurol & Rehabil, San Francisco, CA 94121 USA. [Ganguly, Karunesh] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94122 USA. [Poo, Mu-ming] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA. [Poo, Mu-ming] Chinese Acad Sci, Inst Neurosci, Shanghai 200031, Peoples R China. RP Ganguly, K (reprint author), San Francisco VA Med Ctr, Dept Neurol & Rehabil, San Francisco, CA 94121 USA. EM karunesh.ganguly@ucsf.edu; mpoo@berkeley.edu FU Department of Veterans Affairs [B6674W]; American Heart Association [0875016N]; Doris Duke Charitable Foundation [2013101]; Burroughs Wellcome Fund [1009855]; NIH [NS36999] FX This work is supported by grants to K.G. from the Department of Veterans Affairs (B6674W), American Heart Association (0875016N), Doris Duke Charitable Foundation (2013101), and Burroughs Wellcome Fund (1009855); and to M.M.P. from the NIH (NS36999). NR 173 TC 35 Z9 37 U1 1 U2 38 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0896-6273 EI 1097-4199 J9 NEURON JI Neuron PD OCT 30 PY 2013 VL 80 IS 3 BP 729 EP 741 DI 10.1016/j.neuron.2013.10.028 PG 13 WC Neurosciences SC Neurosciences & Neurology GA 247IA UT WOS:000326609900017 PM 24183023 ER PT J AU Sun, CR Sun, H Wu, S Lee, CC Akamatsu, Y Wang, RKK Kernie, SG Liu, JL AF Sun, Chongran Sun, Hui Wu, Steven Lee, Chih Cheng Akamatsu, Yosuke Wang, Ruikang K. Kernie, Steven G. Liu, Jialing TI Conditional Ablation of Neuroprogenitor Cells in Adult Mice Impedes Recovery of Poststroke Cognitive Function and Reduces Synaptic Connectivity in the Perforant Pathway SO JOURNAL OF NEUROSCIENCE LA English DT Article ID TRAUMATIC BRAIN-INJURY; FOCAL CEREBRAL-ISCHEMIA; HIPPOCAMPAL NEUROGENESIS; PATTERN SEPARATION; PSEUDORABIES VIRUS; EXPERIMENTAL STROKE; GENERATED NEURONS; PROGENITOR CELLS; GAIT IMPAIRMENT; DENTATE GYRUS AB The causal relationship between neurogenesis and the recovery of poststroke cognitive function has not been properly explored. The current study aimed to determine whether depleting neuroprogenitor cells (NPCs) affects poststroke functional outcome in nestin-delta-HSV-TK-EGFP transgenic mice, in which the expression of a truncated viral thymidine kinase gene and EGFP was restricted to nestin-expressing NPCs. Ganciclovir (GCV; 200 mg/kg/d) or saline was continuously administered via osmotic pumps in mice for 4 weeks before the induction of experimental stroke. Both baseline and stroke-induced type 1 and type 2 NPCs were conditionally ablated. GCV eliminated NPCs in a duration-dependent fashion, but it did not attenuate the genesis of astroglia or oligodendrocytes in the peri-infarct cortex, nor did it affect infarct size or cerebral blood reperfusion after stroke. Transgenic stroke mice given GCV displayed impaired spatial learning and memory in the Barnes maze test compared with saline control or wild-type stroke mice given GCV, suggesting a contributing role of stroke-induced neurogenesis in the recovery of cognitive function. However, there was no significant difference in poststroke motor function between transgenic mice treated with GCV and those treated with vehicle, despite a significant ablation of NPCs in the subventricular zone of the former. Furthermore, nestin-delta-HSV-TK-EGFP mice treated with GCV had fewer retrogradely labeled neurons in the entorhinal cortex (EC) when injected with the polysynaptic viral marker PRV614 in the dentate gyrus (DG), suggesting that there might be reduced synaptic connectivity between the DG and EC following ablation of NPCs, which may contribute to impaired poststroke memory function. C1 [Sun, Chongran; Sun, Hui; Wu, Steven; Lee, Chih Cheng; Akamatsu, Yosuke; Liu, Jialing] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94121 USA. [Sun, Chongran; Sun, Hui; Wu, Steven; Lee, Chih Cheng; Akamatsu, Yosuke; Liu, Jialing] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Sun, Chongran] Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Neurol Surg, Hangzhou 310009, Zhejiang, Peoples R China. [Sun, Hui] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Neurol Surg, Shanghai 201101, Peoples R China. [Akamatsu, Yosuke] Tohoku Univ, Grad Sch Med, Dept Neurol Surg, Aoba Ku, Sendai, Miyagi 9808574, Japan. [Wang, Ruikang K.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA. [Wang, Ruikang K.] Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA. [Kernie, Steven G.] Columbia Univ, Dept Pediat, New York, NY 10032 USA. [Kernie, Steven G.] Columbia Univ, Dept Pathol, New York, NY 10032 USA. [Kernie, Steven G.] Columbia Univ, Dept Cell Biol, New York, NY 10032 USA. RP Liu, JL (reprint author), Univ Calif San Francisco, Dept Neurol Surg 112C, 4150 Clement St, San Francisco, CA 94121 USA. EM jialing.liu@ucsf.edu RI Liu, Jialing/A-8627-2012 OI Liu, Jialing/0000-0003-4420-4382 FU National Institutes of Health [R01 NS071050]; AHA EIA [0940065N] FX This work was supported by National Institutes of Health Grants R01 NS071050 (J.L.) and AHA EIA 0940065N (J.L.). We thank Dr. Lin An for his technical assistance in the analysis of blood perfusion by optical coherence tomography. NR 37 TC 21 Z9 21 U1 3 U2 11 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD OCT 30 PY 2013 VL 33 IS 44 BP 17314 EP 17325 DI 10.1523/JNEUROSCI.2129-13.2013 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 246BB UT WOS:000326509800009 PM 24174664 ER PT J AU Singh, GD Amsterdam, EA Armstrong, EJ Barsness, G Chan, K Chiam, JR Chua, K Hou, KC Low, R Mahmud, E McCabe, JM Nishimura, M Rogers, JH Shunk, K Waldo, S Yap, J Yeo, KK AF Singh, Gagan D. Amsterdam, Ezra A. Armstrong, Ehrin J. Barsness, Gregory Chan, Krystal Chiam, Jenn R. Chua, Kelvin Hou, Koh C. Low, Reginald Mahmud, Ehtisham McCabe, James M. Nishimura, Marin Rogers, Jason H. Shunk, Kendrick Waldo, Stephen Yap, Jonathan Yeo, Khung Keong TI ECG Findings in ST-Elevation Myocardial Infarction from Culprit Left Main Coronary Artery Disease: A Multicenter Registry Study SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 25th Annual Symposium on Transcatheter Cardiovascular Therapeutics (TCT) CY OCT 27-NOV 01, 2013 CL San Francisco, CA C1 [Singh, Gagan D.] UC Davis Med Ctr, Sacramento, CA USA. [Amsterdam, Ezra A.; Chan, Krystal; Nishimura, Marin; Rogers, Jason H.] Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA. [Armstrong, Ehrin J.] Univ Calif Davis, Sacramento, CA USA. [Barsness, Gregory] Mayo, Rochester, MN USA. [Chiam, Jenn R.; Chua, Kelvin; Hou, Koh C.] Natl Heart Ctr, Singapore, Singapore. [Low, Reginald] Univ Calif Davis, Sacramento, CA 95817 USA. [Mahmud, Ehtisham] Univ Calif San Diego, San Diego, CA 92103 USA. [McCabe, James M.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Shunk, Kendrick] San Francisco VA Med Ctr, San Francisco, CA USA. [Waldo, Stephen] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Yap, Jonathan; Yeo, Khung Keong] Natl Heart Ctr Singapore, Singapore, Singapore. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD OCT 29 PY 2013 VL 62 IS 18 SU 1 BP B82 EP B82 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 291RA UT WOS:000329845600248 ER PT J AU Wang, TY Zettler, M Effron, MB McCoy, L Anstrom, K Fonarow, GC Messenger, JC Stone, G Cohen, D Henry, TD Peterson, E AF Wang, Tracy Y. Zettler, Marjorie Effron, Mark B. McCoy, Lisa Anstrom, Kevin Fonarow, Gregg C. Messenger, John C. Stone, Gregg Cohen, David Henry, Timothy D. Peterson, Eric TI Comparative Effectiveness of Prasugrel vs. Clopidogrel Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: 30-Day Outcomes from the TRANSLATE-ACS Observational Study SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 25th Annual Symposium on Transcatheter Cardiovascular Therapeutics (TCT) CY OCT 27-NOV 01, 2013 CL San Francisco, CA C1 [Wang, Tracy Y.] Duke Univ, Durham, NC 27705 USA. [Zettler, Marjorie] Lilly Inc, Indianapolis, IN USA. [Effron, Mark B.] Eli Lilly & Co, Indianapolis, IN 46285 USA. [McCoy, Lisa; Anstrom, Kevin] Duke Clin Res Inst, Durham, NC USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA. [Messenger, John C.] Denver VA Med Ctr, Denver, CO USA. [Stone, Gregg] Columbia Univ, Med Ctr, New York, NY USA. [Stone, Gregg] Cardiovasc Res Fdn, New York, NY USA. [Cohen, David] St Lukes Mid Amer Heart Inst, Kansas City, KS USA. [Henry, Timothy D.] Abbott NW Hosp, Minneapolis Heart Inst Fdn, Minneapolis, MN 55407 USA. [Peterson, Eric] NA, Durham, NC USA. RI Effron, Mark/P-9300-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD OCT 29 PY 2013 VL 62 IS 18 SU 1 BP B1 EP B1 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 291RA UT WOS:000329845600003 ER PT J AU Studenski, S AF Studenski, Stephanie TI Prognosis for Recovery After Injurious Falls Clinical and Policy Implications of Varying Definitions of Recovery SO JAMA INTERNAL MEDICINE LA English DT Editorial Material C1 [Studenski, Stephanie] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr & Gerontol, Pittsburgh, PA 15213 USA. [Studenski, Stephanie] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Studenski, S (reprint author), Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr & Gerontol, 3471 Fifth Ave,Ste 500, Pittsburgh, PA 15213 USA. EM sas33@pitt.edu FU NIA NIH HHS [P30 AG024827, AG024827] NR 6 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD OCT 28 PY 2013 VL 173 IS 19 BP 1786 EP 1787 DI 10.1001/jamainternmed.2013.8252 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 302EO UT WOS:000330584900007 PM 23959545 ER PT J AU Grande, D Mitra, N Shah, A Wan, F Asch, DA AF Grande, David Mitra, Nandita Shah, Anand Wan, Fei Asch, David A. TI Public Preferences About Secondary Uses of Electronic Health Information SO JAMA INTERNAL MEDICINE LA English DT Article ID MEDICAL-RESEARCH; PERSONAL INFORMATION; AFRICAN-AMERICANS; CONJOINT-ANALYSIS; ATTITUDES; PRIVACY; WILLINGNESS; PARTICIPATE; DISTRUST; CONSENT AB IMPORTANCE As health information technology grows, secondary uses of personal health information offer promise in advancing research, public health, and health care. Public perceptions about sharing personal health data are important for establishing and evaluating ethical and regulatory structures to oversee the use of these data. OBJECTIVE To measure patient preferences about sharing their electronic health information for secondary purposes (other than their own health care). DESIGN. SETTING, AND PARTICIPANTS In this conjoint analysis study, we surveyed 3336 adults (568 Hispanic, 500 non-Hispanic African American, and 2268 non-Hispanic white); participants were randomized to 6 of 18 scenarios describing secondary uses of electronic health information, constructed with 3 attributes: uses (research, quality improvement, or commercial marketing), users (university hospitals, commercial enterprises, or public health departments), and data sensitivity (whether it included genetic information about their own cancer risk). This design enabled participants to reveal their preferences for secondary uses of their personal health information. MAIN OUTCOMES AND MEASURES Participants responded to each conjoint scenario by rating their willingness to share their electronic personal health information on a 1 to 10 scale (1 represents low willingness; 10, high willingness). Conjoint analysis yields importance weights reflecting the contribution of a dimension (use, user, or sensitivity) to willingness to share personal health information. RESULTS The use of data was a more important factor in the conjoint analysis (importance weight, 64.3%) than the user (importance weight, 32.6%) and data sensitivity (importance weight, 3.1%). In unadjusted linear regression models, marketing uses (beta = -1.55), quality improvement uses (beta = -0.51), drug company users (beta = -0.80), and public health department users (beta = -0.52) were associated with less willingness to share health information than research uses and university hospital users (all P < .001). Hispanics and African Americans differentiated less than whites between uses. CONCLUSIONS AND RELEVANCE Participants cared most about the specific purpose for using their health information, although differences were smaller among racial and ethnic minorities. The user of the information was of secondary importance, and the sensitivity was not a significant factor. These preferences should be considered in policies governing secondary uses of health information. C1 [Grande, David; Asch, David A.] Univ Penn, Perelman Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19014 USA. [Grande, David; Asch, David A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19014 USA. [Mitra, Nandita; Wan, Fei] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19014 USA. [Shah, Anand] Univ Texas SW Med Ctr Dallas, Div Emergency Med, Dallas, TX 75390 USA. [Asch, David A.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Grande, D (reprint author), Univ Penn, Perelman Sch Med, Dept Med, Div Gen Internal Med, 3641 Locust Walk,Colonial Penn Ctr 407, Philadelphia, PA 19014 USA. EM dgrande@wharton.upenn.edu OI Asch, David/0000-0002-7970-286X FU National Human Genome Research Institute [5R21HG006047-02] FX This research was supported by grant 5R21HG006047-02 from the National Human Genome Research Institute. NR 44 TC 26 Z9 26 U1 3 U2 11 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD OCT 28 PY 2013 VL 173 IS 19 BP 1798 EP 1806 DI 10.1001/jamainternmed.2013.9166 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 302EO UT WOS:000330584900010 PM 23958803 ER PT J AU Brown, RT Kiely, DK Bharel, M Grande, LJ Mitchell, SL AF Brown, Rebecca T. Kiely, Dan K. Bharel, Monica Grande, Laura J. Mitchell, Susan L. TI Use of Acute Care Services Among Older Homeless Adults SO JAMA INTERNAL MEDICINE LA English DT Letter C1 [Brown, Rebecca T.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [Kiely, Dan K.; Mitchell, Susan L.] Hebrew SeniorLife Inst Aging Res, Boston, MA USA. [Bharel, Monica] Boston Hlth Care Homeless Program, Boston, MA USA. [Grande, Laura J.] Vet Affairs Boston Healthcare Syst, Psychol Serv, Boston, MA USA. RP Brown, RT (reprint author), San Francisco VA Med Ctr, 4150 Clement St,181G, San Francisco, CA 94122 USA. EM rebecca.brown@ucsf.edu FU NIA NIH HHS [K24 AG033640, P30 AG044281, T32 AG000212] NR 9 TC 4 Z9 4 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD OCT 28 PY 2013 VL 173 IS 19 BP 1831 EP 1834 DI 10.1001/jamainternmed.2013.6627 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 302EO UT WOS:000330584900017 PM 23752708 ER PT J AU Dubin, RF Li, YM He, J Jaar, BG Kallem, R Lash, JP Makos, G Rosas, SE Soliman, EZ Townsend, RR Yang, W Go, AS Keane, M deFilippi, C Mishra, R Wolf, M Shlipak, MG AF Dubin, Ruth F. Li, Yongmei He, Jiang Jaar, Bernard G. Kallem, Radhakrishna Lash, James P. Makos, Gail Rosas, Sylvia E. Soliman, Elsayed Z. Townsend, Ray R. Yang, Wei Go, Alan S. Keane, Martin deFilippi, Christopher Mishra, Rakesh Wolf, Myles Shlipak, Michael G. CA CRIC Study Investigators TI Predictors of high sensitivity cardiac troponin T in chronic kidney disease patients: a cross-sectional study in the chronic renal insufficiency cohort (CRIC) SO BMC NEPHROLOGY LA English DT Article DE Troponin T; Chronic kidney disease; Cardiovascular disease ID LEFT-VENTRICULAR HYPERTROPHY; GROWTH-FACTOR 23; CYSTATIN-C CONCENTRATION; CORONARY-ARTERY-DISEASE; CARDIOVASCULAR EVENTS; HEART-FAILURE; HEMODIALYSIS-PATIENTS; GENERAL-POPULATION; MORTALITY RISK; ESTIMATED GFR AB Background: Cardiac troponin T is independently associated with cardiovascular events and mortality in patients with chronic kidney disease (CKD). Serum levels of high sensitivity cardiac troponin T (hs-TnT) reflect subclinical myocardial injury in ambulatory patients. We sought to determine the distribution and predictors of hs-TnT in CKD patients without overt cardiovascular disease (CVD). Methods: We studied 2464 participants within the multi-ethnic Chronic Renal Insufficiency Cohort (CRIC) who did not have self-reported CVD. We considered renal and non-renal factors as potential determinants of hs-TnT, including demographics, comorbidities, left ventricular (LV) mass, serologic factors, estimated glomerular filtration rate (eGFR) and albumin to creatinine ratio. Results: Hs-TnT was detectable in 81% of subjects, and the median (IQR) hs-TnT was 9.4 pg/ml (4.3-18.3). Analysis was performed using Tobit regression, adjusting for renal and non-renal factors. After adjustment, lower eGFR was associated with higher expected hs-TnT; participants with eGFR <30 ml/min/1.73m(2) had 3-fold higher expected hs-TnT compared to subjects with eGFR >60. Older age, male gender, black race, LV mass, diabetes and higher blood pressure all had strong, independent associations with higher expected hs-TnT. Conclusions: Knowledge of the determinants of hs-TnT in this cohort may guide further research on the pathology of heart disease in patients with CKD and help to stratify sub-groups of CKD patients at higher cardiovascular risk. C1 [Dubin, Ruth F.; Li, Yongmei; Mishra, Rakesh; Shlipak, Michael G.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [He, Jiang] Tulane Univ, Sch Publ Hlth & Trop Med, New Orleans, LA USA. [Jaar, Bernard G.] Johns Hopkins Univ, Baltimore, MD USA. [Kallem, Radhakrishna; Rosas, Sylvia E.; Townsend, Ray R.; Keane, Martin] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Lash, James P.] Univ Illinois, Chicago, IL USA. [Makos, Gail] St Johns Hlth Syst, Detroit, MI USA. [Soliman, Elsayed Z.] Wake Forest Sch Med, Epidemiol Cardiol Res Ctr EPICARE, Dept Epidemiol, Winston Salem, NC USA. [Soliman, Elsayed Z.] Wake Forest Sch Med, Dept Internal Med, Cardiol Sect, Winston Salem, NC USA. [Yang, Wei] Univ Penn, Sci & Data Coordinating Ctr, Philadelphia, PA 19104 USA. [Go, Alan S.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [deFilippi, Christopher] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA. [Wolf, Myles] Univ Miami, Miller Sch Med, Miami, FL 33136 USA. RP Dubin, RF (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, 4150 Clement St,Box 111A1, San Francisco, CA 94121 USA. EM ruth.dubin@ucsf.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028, U01DK060980, U01DK060963, U01DK060902]; University of Pennsylvania CTRC CTSA [UL1 RR-024134]; Johns Hopkins University [UL1 RR-025005]; University of Maryland GCRC [M01 RR-16500]; Clinical and Translational Science Collaborative of Cleveland; National Center for Advancing Translational Sciences (NCATS) component of the National Institutes of Health [UL1TR000439]; NIH roadmap for Medical Research; Michigan Institute for Clinical and Health Research (MICHR) [UL1RR024986]; University of Illinois at Chicago CTSA [UL1RR029879]; Tulane University Translational Research in Hypertension and Renal Biology [P30GM103337]; Kaiser Permanente Northern California NIH/NCRR UCSF-CTSI [UL1 RR-024131]; [R01 DK066488]; [K23 DK092354] FX Support Funding for the CRIC Study was obtained under a cooperative agreement from National Institute of Diabetes and Digestive and Kidney Diseases (U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028, U01DK060980, U01DK060963, and U01DK060902). This project was supported by M.S.'s R01 DK066488 award (principal investigator M. S.). R. D. is supported by K23 DK092354. In addition, this work was supported in part by: the University of Pennsylvania CTRC CTSA UL1 RR-024134, Johns Hopkins University UL1 RR-025005, University of Maryland GCRC M01 RR-16500, Clinical and Translational Science Collaborative of Cleveland, UL1TR000439 from the National Center for Advancing Translational Sciences (NCATS) component of the National Institutes of Health and NIH roadmap for Medical Research, Michigan Institute for Clinical and Health Research (MICHR) UL1RR024986, University of Illinois at Chicago CTSA UL1RR029879, Tulane University Translational Research in Hypertension and Renal Biology P30GM103337, Kaiser Permanente Northern California NIH/NCRR UCSF-CTSI UL1 RR-024131. NR 37 TC 20 Z9 21 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2369 J9 BMC NEPHROL JI BMC Nephrol. PD OCT 22 PY 2013 VL 14 AR 229 DI 10.1186/1471-2369-14-229 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 258TX UT WOS:000327482700002 PM 24148285 ER PT J AU Pulliam, DA Bhattacharya, A Van Remmen, H AF Pulliam, Daniel A. Bhattacharya, Arunabh Van Remmen, Holly TI Mitochondrial Dysfunction in Aging and Longevity: A Causal or Protective Role? SO ANTIOXIDANTS & REDOX SIGNALING LA English DT Review ID AGE-RELATED-CHANGES; SKELETAL-MUSCLE MITOCHONDRIA; OXYGEN SPECIES PRODUCTION; FREE-RADICAL GENERATION; RAT-LIVER MITOCHONDRIA; LIFE-SPAN; CAENORHABDITIS-ELEGANS; OXIDATIVE DAMAGE; SUPEROXIDE-DISMUTASE; CALORIC RESTRICTION AB Significance: Among the most highly investigated theories of aging is the mitochondrial theory of aging. The basis of this theory includes a central role for altered or compromised mitochondrial function in the pathophysiologic declines associated with aging. In general, studies in various organisms, including nematodes, rodents, and humans, have largely upheld that aging is associated with mitochondrial dysfunction. However, results from a number of studies directly testing the mitochondrial theory of aging by modulating oxidant production or scavenging in vivo in rodents have generally been inconsistent with predictions of the theory. Recent Advances: Interestingly, electron transport chain mutations or deletions in invertebrates and mice that causes mitochondrial dysfunction paradoxically leads to enhanced longevity, further challenging the mitochondrial theory of aging. Critical Issues: How can mitochondrial dysfunction contribute to lifespan extension in the mitochondrial mutants, and what does it mean for the mitochondrial theory of aging? Future Directions: It will be important to determine the potential mechanisms that lead to enhanced longevity in the mammalian mitochondrial mutants. Antioxid. Redox Signal. 19, 1373-1387. C1 [Pulliam, Daniel A.; Bhattacharya, Arunabh; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. [Pulliam, Daniel A.; Bhattacharya, Arunabh] Univ Texas San Antonio, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78284 USA. [Van Remmen, Holly] South Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA. RP Van Remmen, H (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, 15355 Lambda Dr,Mail Code 5577, San Antonio, TX 78245 USA. EM vanremmen@uthscsa.edu FU Ellison Medical Foundation FX This work was supported by a Senior Scholar Award to Dr. Van Remmen by the Ellison Medical Foundation. NR 97 TC 9 Z9 10 U1 1 U2 17 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1523-0864 EI 1557-7716 J9 ANTIOXID REDOX SIGN JI Antioxid. Redox Signal. PD OCT 20 PY 2013 VL 19 IS 12 BP 1373 EP 1387 DI 10.1089/ars.2012.4950 PG 15 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 229LX UT WOS:000325267800006 PM 23025472 ER PT J AU Wang, RY Brewster, LP Gleason, RL AF Wang, Ruoya Brewster, Luke P. Gleason, Rudolph L., Jr. TI In-situ characterization of the uncrimping process of arterial collagen fibers using two-photon confocal microscopy and digital image correlation SO JOURNAL OF BIOMECHANICS LA English DT Article DE Adventitia; Digital image correlation; Two-photon excitation microscopy; Deformation; Arterial mechanics ID CAROTID ARTERIES; WALL MECHANICS; DEVICE AB Uncrimping of collagen fibers in the arterial wall is an integral process in regulating the macro-level mechanical response of arteries. Uncrimping of collagen fibers leads to a gradual, but significant strain-stiffening response of the artery at physiological pressures and prevents overdistention at elevated pressures. In this study, we imaged adventitial collagen fibers from fresh primate arteries using two-photon excitation microscopy while subjecting the arteries to physiological inflation pressures and axial stretches. The imaging focal plane was fixed at a constant radial location in the adventitial wall by adjusting the focal distance as the arteries inflated, allowing for the continuously monitoring of the uncrimping process of a single region of collagen fibers. Digital image correlation was then applied to the sequential images to assess and correlate the local displacements to manual traces of selected reference fibers and their engagements. We found that the collagen fibers of interest became fully engaged at a luminal pressure of 20 mmHg, this was then followed by rotation of these fibers as the bulk artery continued to dilate. This technique helps to further the understanding of the uncrimping process of collagen fibers under physiological loads, which can aid in the development of more accurate microstructural constitutive models. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Wang, Ruoya; Gleason, Rudolph L., Jr.] George W Woodruff Sch Mech Engn, Atlanta, GA USA. [Gleason, Rudolph L., Jr.] Wallace H Coulter Dept Biomed Engn, Atlanta, GA USA. [Brewster, Luke P.; Gleason, Rudolph L., Jr.] Georgia Inst Technol, Parker H Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA. [Wang, Ruoya; Brewster, Luke P.] Emory Univ, Sch Med, Dept Surg, Div Vasc Surg, Atlanta, GA 30322 USA. [Brewster, Luke P.] US Dept Vet Affairs, Atlanta VA Med Ctr, Surg Serv, Atlanta, GA USA. [Brewster, Luke P.] US Dept Vet Affairs, Atlanta VA Med Ctr, Res Serv, Atlanta, GA USA. RP Wang, RY (reprint author), Emory Univ, Sch Med, Dept Vasc Surg, 101 Woodruff Circle,5211 WMB, Atlanta, GA 30322 USA. EM r.wang@gatech.edu FU Yerkes National Primate Center [P51OD11132]; Vascular Surgery Startup Grant; Georgia Tech IBB Microscopy Core Facility FX The authors would like to thank the Yerkes National Primate Center (Grant P51OD11132) for providing the primate tissues, Georgia Tech IBB Microscopy Core Facility and manager Andrew Shaw and the Vascular Surgery Startup Grant for funding. A portion of this study was presented at the Biomedical Engineering Society conference in Atlanta, GA on October 27, 2012. NR 10 TC 7 Z9 7 U1 0 U2 13 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0021-9290 EI 1873-2380 J9 J BIOMECH JI J. Biomech. PD OCT 18 PY 2013 VL 46 IS 15 BP 2726 EP 2729 DI 10.1016/j.jbiomech.2013.08.001 PG 4 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA 249IV UT WOS:000326771800022 PM 24050510 ER PT J AU Wise, RA Anzueto, A Cotton, D Dahl, R Devins, T Disse, B Dusser, D Joseph, E Kattenbeck, S Koenen-Bergmann, M Pledger, G Calverley, P AF Wise, Robert A. Anzueto, Antonio Cotton, Daniel Dahl, Ronald Devins, Theresa Disse, Bernd Dusser, Daniel Joseph, Elizabeth Kattenbeck, Sabine Koenen-Bergmann, Michael Pledger, Gordon Calverley, Peter CA TIOSPIR Investigators TI Tiotropium Respimat Inhaler and the Risk of Death in COPD SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED CONTROLLED-TRIALS; SAFETY; METAANALYSIS; MEDICATIONS; SALMETEROL; EFFICACY AB BackgroundTiotropium delivered at a dose of 5 g with the Respimat inhaler showed efficacy similar to that of 18 g of tiotropium delivered with the HandiHaler inhalation device in placebo-controlled trials involving patients with chronic obstructive pulmonary disease (COPD). Although tiotropium HandiHaler was associated with reduced mortality, as compared with placebo, more deaths were reported with tiotropium Respimat than with placebo. MethodsIn this randomized, double-blind, parallel-group trial involving 17,135 patients with COPD, we evaluated the safety and efficacy of tiotropium Respimat at a once-daily dose of 2.5 g or 5 g, as compared with tiotropium HandiHaler at a once-daily dose of 18 g. Primary end points were the risk of death (noninferiority study, Respimat at a dose of 5 g or 2.5 g vs. HandiHaler) and the risk of the first COPD exacerbation (superiority study, Respimat at a dose of 5 g vs. HandiHaler). We also assessed cardiovascular safety, including safety in patients with stable cardiac disease. ResultsDuring a mean follow-up of 2.3 years, Respimat was noninferior to HandiHaler with respect to the risk of death (Respimat at a dose of 5 g vs. HandiHaler: hazard ratio, 0.96; 95% confidence interval [CI], 0.84 to 1.09; Respimat at a dose of 2.5 g vs. HandiHaler: hazard ratio, 1.00; 95% CI, 0.87 to 1.14) and not superior to HandiHaler with respect to the risk of the first exacerbation (Respimat at a dose of 5 g vs. HandiHaler: hazard ratio, 0.98; 95% CI, 0.93 to 1.03). Causes of death and incidences of major cardiovascular adverse events were similar in the three groups. ConclusionsTiotropium Respimat at a dose of 5 g or 2.5 g had a safety profile and exacerbation efficacy similar to those of tiotropium HandiHaler at a dose of 18 g in patients with COPD. (Funded by Boehringer Ingelheim; TIOSPIR ClinicalTrials.gov number, NCT01126437.) C1 [Wise, Robert A.] Johns Hopkins Univ, Sch Med, Baltimore, MD 21224 USA. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Anzueto, Antonio] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Cotton, Daniel; Devins, Theresa; Joseph, Elizabeth] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA. [Dahl, Ronald] Odense Univ Hosp, DK-5000 Odense, Denmark. [Disse, Bernd; Kattenbeck, Sabine; Koenen-Bergmann, Michael] Boehringer Ingelheim KG, Ingelheim, Germany. [Dusser, Daniel] Univ Paris 05, Hop Cochin, AP HP, Serv Pneumol,Sorbonne Paris Cite, Paris, France. [Calverley, Peter] Univ Liverpool, Inst Ageing & Chron Dis, Liverpool L69 3BX, Merseyside, England. RP Wise, RA (reprint author), Johns Hopkins Univ, Sch Med, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA. EM rwise@jhmi.edu RI Wiemer, Stefan/E-5033-2015; Vrbica, Zarko/Q-2705-2015; Cilli, Aykut/C-7681-2016; Zadionchenko, Vladimir/A-7445-2016; POLATLI, MEHMET/A-3516-2017 OI Zadionchenko, Vladimir/0000-0003-2377-5266; Van de Werf, Frans/0000-0001-9479-7767; Field, Stephen/0000-0002-6682-4155 FU Boehringer Ingelheim FX Funded by Boehringer Ingelheim; TIOSPIR ClinicalTrials.gov number, NCT01126437. NR 26 TC 139 Z9 146 U1 4 U2 34 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD OCT 17 PY 2013 VL 369 IS 16 BP 1491 EP 1501 DI 10.1056/NEJMoa1303342 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 267MJ UT WOS:000328101700006 PM 23992515 ER PT J AU Goswami, ND Pfeiffer, CD Horton, JR Chiswell, K Tasneem, A Tsalik, EL AF Goswami, Neela D. Pfeiffer, Christopher D. Horton, John R. Chiswell, Karen Tasneem, Asba Tsalik, Ephraim L. TI The State of Infectious Diseases Clinical Trials: A Systematic Review of ClinicalTrials.gov SO PLOS ONE LA English DT Article ID PRACTICE GUIDELINES; REGISTRATION; SOCIETY; ISSUES AB Background: There is a paucity of clinical trials informing specific questions faced by infectious diseases (ID) specialists. The ClinicalTrials.gov registry offers an opportunity to evaluate the ID clinical trials portfolio. Methods: We examined 40,970 interventional trials registered with ClinicalTrials.gov from 2007-2010, focusing on study conditions and interventions to identify ID-related trials. Relevance to ID was manually confirmed for each programmatically identified trial, yielding 3570 ID trials and 37,400 non-ID trials for analysis. Results: The number of ID trials was similar to the number of trials identified as belonging to cardiovascular medicine (n = 3437) or mental health (n = 3695) specialties. Slightly over half of ID trials were treatment-oriented trials (53%, vs. 77% for non-ID trials) followed by prevention (38%, vs. 8% in non-ID trials). ID trials tended to be larger than those of other specialties, with a median enrollment of 125 subjects (interquartile range [IQR], 45-400) vs. 60 (IQR, 30-160) for non-ID trials. Most ID studies are randomized (73%) but nonblinded (56%). Industry was the funding source in 51% of ID trials vs. 10% that were primarily NIH-funded. HIV-AIDS trials constitute the largest subset of ID trials (n = 815 [23%]), followed by influenza vaccine (n = 375 [11%]), and hepatitis C (n = 339 [9%]) trials. Relative to U. S. and global mortality rates, HIV-AIDS and hepatitis C virus trials are over-represented, whereas lower respiratory tract infection trials are under-represented in this large sample of ID clinical trials. Conclusions: This work is the first to characterize ID clinical trials registered in ClinicalTrials.gov, providing a framework to discuss prioritization, methodology, and policy. C1 [Goswami, Neela D.; Tsalik, Ephraim L.] Duke Univ, Sch Med, Dept Med, Div Infect Dis & Int Hlth, Durham, NC 27706 USA. [Pfeiffer, Christopher D.] Portland VA Med Ctr, Dept Hosp & Specialty Med, Portland, OR USA. [Pfeiffer, Christopher D.] Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA. [Horton, John R.; Chiswell, Karen; Tasneem, Asba] Duke Clin Res Inst, Durham, NC USA. [Tsalik, Ephraim L.] Durham VA Med Ctr, Emergency Med Serv, Durham, NC USA. RP Tsalik, EL (reprint author), Duke Univ, Sch Med, Dept Med, Div Infect Dis & Int Hlth, Durham, NC 27706 USA. EM e.t@duke.edu FU US Food and Drug Administration [U19FD003800]; Clinical Science Research and Development Service of the Veterans Health Administration Office of Research and Development [1IK2CX000530] FX This work was supported by grant U19FD003800 from the US Food and Drug Administration awarded to Duke University for the Clinical Trials Transformation Initiative. Dr. Tsalik's efforts were also supported by Award Number 1IK2CX000530 from the Clinical Science Research and Development Service of the Veterans Health Administration Office of Research and Development. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 19 TC 4 Z9 4 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 16 PY 2013 VL 8 IS 10 AR e77086 DI 10.1371/journal.pone.0077086 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 239JR UT WOS:000326019400093 PM 24146958 ER PT J AU Abdel-Mohsen, M Raposo, RAS Deng, XT Li, MQ Liegler, T Sinclair, E Salama, MS Ghanem, HEDA Hoh, R Wong, JK David, M Nixon, DF Deeks, SG Pillai, SK AF Abdel-Mohsen, Mohamed Raposo, Rui Andre Saraiva Deng, Xutao Li, Manqing Liegler, Teri Sinclair, Elizabeth Salama, Mohamed S. Ghanem, Hussam El-Din A. Hoh, Rebecca Wong, Joseph K. David, Michael Nixon, Douglas F. Deeks, Steven G. Pillai, Satish K. TI Expression profile of host restriction factors in HIV-1 elite controllers SO RETROVIROLOGY LA English DT Article DE Elite controllers; Intrinsic immunity; Retroviral restriction factors; APOBEC3; BST2/tetherin; TRIM; schlafen 11; p21; T cell activation ID IMMUNODEFICIENCY-VIRUS TYPE-1; CD4(+) T-CELLS; INFECTION; REPLICATION; PROTEIN; ACTIVATION; MACROPHAGES; SUPPRESSORS; INHIBITION; RESPONSES AB Background: Several host-encoded antiviral factors suppress HIV-1 replication in a cell-autonomous fashion in vitro. The relevance of these defenses to the control of HIV-1 in vivo remains to be elucidated. We hypothesized that cellular restriction of HIV-1 replication plays a significant role in the observed suppression of HIV-1 in "elite controllers", individuals who maintain undetectable levels of viremia in the absence of antiretroviral therapy (ART). We comprehensively compared the expression levels of 34 host restriction factors and cellular activation levels in CD4+ T cells and sorted T cell subsets between elite controllers, HIV-1-infected (untreated) non-controllers, ART-suppressed, and uninfected individuals. Results: Expression of schlafen 11, a codon usage-based inhibitor of HIV-1 protein synthesis, was significantly elevated in CD4+ T cells from elite controllers as compared to both non-controllers (p=0.048) and ART-suppressed individuals (p=0.024), with this effect most apparent in central memory CD4+ T cells. Schlafen 11 expression levels were comparable between controllers and uninfected individuals. Cumulative restriction factor expression was positively correlated with CD4+ T cell activation (r(2)=0.597, p<0.0001), viral load (r(2)=0.34, p=0.015), and expression of ISG15 (r(2)=0.73, p<0.0001), a marker of interferon exposure. APOBEC3C, APOBEC3D, CTR9, TRIM26, and TRIM32 were elevated in elite controllers with respect to ART-suppressed individuals, while levels were comparable to uninfected individuals and non-controllers. Conclusions: Host restriction factor expression typically scales with cellular activation levels. However, the elevated mRNA and protein expression of schlafen 11, despite low activation and viral load, violates the global pattern and may be a signature characteristic of HIV-1 elite control. C1 [Abdel-Mohsen, Mohamed; Liegler, Teri; Sinclair, Elizabeth; Hoh, Rebecca; Wong, Joseph K.; Deeks, Steven G.; Pillai, Satish K.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Raposo, Rui Andre Saraiva; Nixon, Douglas F.] Univ Calif San Francisco, Dept Expt Med, San Francisco, CA USA. [Deng, Xutao; Pillai, Satish K.] Blood Syst Res Inst, San Francisco, CA USA. [Li, Manqing; David, Michael] Univ Calif San Diego, Mol Biol Sect, Div Biol Sci, La Jolla, CA 92093 USA. [Abdel-Mohsen, Mohamed; Salama, Mohamed S.; Ghanem, Hussam El-Din A.] Ain Shams Univ, Fac Sci, Cairo, Egypt. [Wong, Joseph K.; Pillai, Satish K.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94118 USA. RP Pillai, SK (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. EM satish.pillai@ucsf.edu RI Salama, Mohamed/P-7169-2016 OI Raposo, R. Andre/0000-0001-5435-0290; Nixon, Douglas/0000-0002-2801-1786 FU National Institutes of Health [1K01DA024654, R01 AI087145, K24 AI069994, R21 AI93179]; University of California, San Francisco-Gladstone Institute of Virology & Immunology Center for AIDS Research [P30 AI027763]; DARE: Delaney AIDS Research Enterprise (DARE) [U19AI096109]; American Foundation for AIDS Research [106710-40-RGRL]; UCSF Clinical and Translational Research Institute Clinical Research Center [UL1 RR024131]; Center for AIDS Prevention Studies [P30 MH62246]; CFAR Network of Integrated Systems [R24 AI067039] FX We thank all UCSF SCOPE Cohort patients who participated in our study, the physicians and study nurses for excellent patient care, Dr. John Guatelli for helpful discussion and suggestions regarding the panel of restriction factors analyzed, and the UCSF CFAR Core Virology Lab and Core Immunology Lab staff for processing and storage of the samples: Alex Carvidi, Christina Gonzaga, David Chung, Khooshbu Shah, Lorrie Epling, Maudi Killian, Montha Pao, Sophie Stephenson, Timothy Ryner, and Timothy Schmidt. This study was supported by grants from the National Institutes of Health (1K01DA024654, R01 AI087145, K24 AI069994, R21 AI93179), the University of California, San Francisco-Gladstone Institute of Virology & Immunology Center for AIDS Research (grant number P30 AI027763), the DARE: Delaney AIDS Research Enterprise (DARE; U19AI096109), the American Foundation for AIDS Research (grant number 106710-40-RGRL), the UCSF Clinical and Translational Research Institute Clinical Research Center (UL1 RR024131), the Center for AIDS Prevention Studies (P30 MH62246), and the CFAR Network of Integrated Systems (R24 AI067039). NR 55 TC 32 Z9 33 U1 0 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-4690 J9 RETROVIROLOGY JI Retrovirology PD OCT 16 PY 2013 VL 10 AR 106 DI 10.1186/1742-4690-10-106 PG 13 WC Virology SC Virology GA 280PH UT WOS:000329042700001 PM 24131498 ER PT J AU Shah, NR Chokshi, DA AF Shah, Nirav R. Chokshi, Dave A. TI Should Health Care Systems Become Insurers? SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID ORGANIZATIONS C1 [Shah, Nirav R.] New York State Dept Hlth, Albany, NY USA. [Chokshi, Dave A.] US Dept Vet Affairs, Washington, DC USA. RP Chokshi, DA (reprint author), Dept Vet Affairs, 810 Vermont Ave NW, Washington, DC 20006 USA. EM dave.chokshi@alumni.duke.edu OI Shah, Nirav/0000-0003-2044-7865; Chokshi, Dave/0000-0001-7467-4591 NR 6 TC 2 Z9 2 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD OCT 16 PY 2013 VL 310 IS 15 BP 1561 EP 1562 DI 10.1001/jama.2013.280015 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 234EP UT WOS:000325624800015 PM 24129460 ER PT J AU Smucny, J Tregellas, J AF Smucny, Jason Tregellas, Jason TI Nicotinic modulation of intrinsic brain networks in Schizophrenia SO BIOCHEMICAL PHARMACOLOGY LA English DT Review DE Schizophrenia; Nicotinic; Salience network; Default network; Small-world network ID ANTERIOR CINGULATE CIRCUITS; RESTING-STATE NETWORKS; DEFAULT MODE NETWORK; SMALL-WORLD NETWORKS; SUBUNIT GENE CHRNA7; ACETYLCHOLINE-RECEPTOR; FUNCTIONAL CONNECTIVITY; ALLOSTERIC MODULATORS; PARTIAL DUPLICATION; CIGARETTE-SMOKING AB The nicotinic receptor is a promising drug target currently being investigated for the treatment of cognitive symptoms in schizophrenia. A key step in this process is the development of noninvasive functional neuroimaging biomarkers that can be used to determine if nicotinic agents are eliciting their targeted biological effect, ideally through modulation of a fundamental aspect of neuronal function. To that end, neuroimaging researchers are beginning to understand how nicotinic modulation affects "intrinsic" brain networks to elicit potentially therapeutic effects. An intrinsic network is a functionally and (often) structurally connected network of brain areas whose activity reflects a fundamental neurobiological organizational principle of the brain. This review summarizes findings of the effects of nicotinic drugs on three topics related to intrinsic brain network activity: (1) the default mode network, a group of brain areas for which activity is maximal at rest and reduced during cognitive tasks, (2) the salience network, which integrates incoming sensory data with prior internal representations to guide future actions and change predictive values, and (3) multi-scale complex network dynamics, which describe these brain's ability to efficiency integrate information while preserving local functional specialization. These early findings can be used to inform future neuroimaging studies that examine the network effects of nicotinic agents. (C) 2013 Elsevier Inc. All rights reserved. C1 [Smucny, Jason; Tregellas, Jason] Univ Colorado, Neurosci Program, Aurora, CO 80045 USA. [Smucny, Jason; Tregellas, Jason] Univ Colorado, Dept Psychiat, Aurora, CO 80045 USA. [Smucny, Jason; Tregellas, Jason] Denver VA Med Ctr, Res Serv, Denver, CO 80220 USA. RP Smucny, J (reprint author), Univ Colorado, Neurosci Program, Anschutz Med Campus, Aurora, CO 80045 USA. EM Jason.smucny@ucdenver.edu; Jason.tregellas@ucdenver.edu RI Tregellas, Jason/J-3637-2015 OI Smucny, Jason/0000-0001-5656-7987 FU NIMH NIH HHS [F31 MH102879] NR 124 TC 7 Z9 7 U1 3 U2 16 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0006-2952 EI 1873-2968 J9 BIOCHEM PHARMACOL JI Biochem. Pharmacol. PD OCT 15 PY 2013 VL 86 IS 8 SI SI BP 1163 EP 1172 DI 10.1016/j.bcp.2013.06.011 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 239FC UT WOS:000326007000015 PM 23796751 ER PT J AU Fetterman, JL Zelickson, BR Johnson, LW Moellering, DR Westbrook, DG Pompilius, M Sammy, MJ Johnson, M Dunham-Snary, KJ Cao, XM Bradley, WE Zhang, JJ Wei, CC Chacko, B Schurr, TG Kesterson, RA Dell'Italia, LJ Darley-Usmar, VM Welch, DR Ballinger, SW AF Fetterman, Jessica L. Zelickson, Blake R. Johnson, Larry W. Moellering, Douglas R. Westbrook, David G. Pompilius, Melissa Sammy, Melissa J. Johnson, Michelle Dunham-Snary, Kimberly J. Cao, Xuemei Bradley, Wayne E. Zhang, Jinju Wei, Chih-Chang Chacko, Balu Schurr, Theodore G. Kesterson, Robert A. Dell'Italia, Louis J. Darley-Usmar, Victor M. Welch, Danny R. Ballinger, Scott W. TI Mitochondrial genetic background modulates bioenergetics and susceptibility to acute cardiac volume overload SO BIOCHEMICAL JOURNAL LA English DT Article DE bioenergetics; disease susceptibility; mitochondria; mtDNA; oxidative stress ID NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE; OXYGEN SPECIES PRODUCTION; CORONARY-HEART-DISEASE; CARDIOVASCULAR-DISEASE; SMOKE EXPOSURE; ATHEROSCLEROSIS SUSCEPTIBILITY; C57BL/6J MICE; MOUSE; DNA; NUCLEAR AB Dysfunctional bioenergetics has emerged as a key feature in many chronic pathologies such as diabetes and cardiovascular disease. This has led to the mitochondrial paradigm in which it has been proposed that mtDNA sequence variation contributes to disease susceptibility. In the present study we show a novel animal model of mtDNA polymorphisms, the MNX (mitochondrial nuclear exchange) mouse, in which the mtDNA from the C3H/HeN mouse has been inserted on to the C57/BL6 nuclear background and vice versa to test this concept. Our data show a major contribution of the C57/BL6 mtDNA to the susceptibility to the pathological stress of cardiac volume overload which is independent of the nuclear background. Mitochondria harbouring the C57/BL6J mtDNA generate more ROS (reactive oxygen species) and have a higher mitochondrial membrane potential relative to those with C3H/HeN mtDNA, independent of nuclear background. We propose this is the primary mechanism associated with increased bioenergetic dysfunction in response to volume overload. In summary, these studies support the 'mitochondrial paradigm' for the development of disease susceptibility, and show that the mtDNA modulates cellular bioenergetics, mitochondrial ROS generation and susceptibility to cardiac stress. C1 [Fetterman, Jessica L.; Zelickson, Blake R.; Westbrook, David G.; Pompilius, Melissa; Sammy, Melissa J.; Johnson, Michelle; Dunham-Snary, Kimberly J.; Chacko, Balu; Darley-Usmar, Victor M.; Ballinger, Scott W.] Univ Alabama Birmingham, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA. [Fetterman, Jessica L.; Zelickson, Blake R.; Moellering, Douglas R.; Sammy, Melissa J.; Dunham-Snary, Kimberly J.; Chacko, Balu; Dell'Italia, Louis J.; Darley-Usmar, Victor M.; Ballinger, Scott W.] Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35294 USA. [Johnson, Larry W.; Zhang, Jinju; Kesterson, Robert A.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA. [Moellering, Douglas R.] Univ Alabama Birmingham, Birmingham, AL 35294 USA. [Cao, Xuemei; Welch, Danny R.] Univ Kansas, Ctr Canc, Dept Canc Biol, Kansas City, KS 66160 USA. [Bradley, Wayne E.; Wei, Chih-Chang; Dell'Italia, Louis J.] Univ Alabama Birmingham, Div Cardiol, Birmingham, AL 35294 USA. [Schurr, Theodore G.] Univ Penn, Dept Anthropol, Philadelphia, PA 19104 USA. [Dell'Italia, Louis J.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. RP Welch, DR (reprint author), Univ Kansas, Ctr Canc, Dept Canc Biol, Kansas City, KS 66160 USA. EM dwelch@kumc.edu; sballing@uab.edu OI Sammy, Melissa/0000-0002-5460-0963 FU National Institutes for Health [RO1 94518, RO1 103859]; National Foundation for Cancer Research; Susan G. Komen for the Cure [SAC111370]; U.S. Army Medical Research & Material Command [W81XWH-07-1-0540d]; University of Alabama at Birmingham Comprehensive Cancer Center [CA013148]; National Institutes of Health [RO1 HL109785, P30 CA13148, P30 AR048311, P30 DK074038, P30 DK05336, P60 DK079626]; a National Institutes of Health predoctoral training programme in cardiovascular pathophysiology [T32 HL007918]; American Heart Association [09PRE2240046, 11PRE7650033]; Diabetes Research Center Bioanalytical Redox Biology Core [P60 DK079626] FX This work was funded by the National Institutes for Health [grant numbers RO1 94518 and RO1 103859 (to S.W.B.)], the National Foundation for Cancer Research (to D.R.W.), Susan G. Komen for the Cure [grant number SAC111370 (to D.R.W.)], U.S. Army Medical Research & Material Command [grant number W81XWH-07-1-0540d (to S.W.B.)] and a pilot grant from the University of Alabama at Birmingham Comprehensive Cancer Center [grant number CA013148 (to D.R.W. and S.W.B.)]. Additional support was received from the National Institutes of Health [grant number RO1 HL109785 (to L.J.D.)), a National Institutes of Health predoctoral training programme in cardiovascular pathophysiology [grant number T32 HL007918 (to J.L.F.)], American Heart Association predoctoral fellowships [numbers 09PRE2240046 (to J.L.F.) and 11PRE7650033 (to K.J.D.)). The University of Alabama at Birmingham Transgenic Mouse Facility (RAK) is supported by the National Institutes of Health [grant numbers P30 CA13148, P30 AR048311, P30 DK074038, P30 DK05336 and P60 DK079626] and by the National Institutes of Health-funded Diabetes Research Center Bioanalytical Redox Biology Core [grant number P60 DK079626) located at the University of Alabama at Birmingham. NR 66 TC 22 Z9 22 U1 2 U2 12 PU PORTLAND PRESS LTD PI LONDON PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND SN 0264-6021 EI 1470-8728 J9 BIOCHEM J JI Biochem. J. PD OCT 15 PY 2013 VL 455 BP 157 EP 167 DI 10.1042/BJ20130029 PN 2 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 243ZV UT WOS:000326357800003 PM 23924350 ER PT J AU McCarthy, AM Bristol, M Fredricks, T Wilkins, L Roelfsema, I Liao, KJ Shea, JA Groeneveld, P Domchek, SM Armstrong, K AF McCarthy, Anne Marie Bristol, Mirar Fredricks, Tracey Wilkins, Lache Roelfsema, Irene Liao, Kaijun Shea, Judy A. Groeneveld, Peter Domchek, Susan M. Armstrong, Katrina TI Are Physician Recommendations for BRCA1/2 Testing in Patients With Breast Cancer Appropriate? A Population-Based Study SO CANCER LA English DT Article DE breast cancer; genetic testing; BRCA1; 2; physician recommendations; cancer registry ID MUTATION CARRIERS; WOMEN; RISK; DECISIONS; KNOWLEDGE; ATTITUDES; FAMILIES; COVERAGE; SURGERY AB BACKGROUNDTo the best of the authors' knowledge, few population-based studies to date have examined the use of BRCA1/2 testing or patterns of physician recommendations for genetic testing among women diagnosed with breast cancer. The objective of the current study was to evaluate the rates and predictors of physician recommendation for BRCA1/2 testing among patients with breast cancer. METHODSWomen aged 18 years to 64 years who were diagnosed with invasive breast cancer in 2007 were identified from the Pennsylvania Cancer Registry and mailed a survey regarding their family history of cancer, physician treatment recommendations, and BRCA1/2 testing. Of the 4009 women who were sent surveys, 2258 responded (56%). Based on age at diagnosis and family history, women were categorized as being at high, moderate, or low risk of BRCA1/2 mutations. RESULTSNearly 25% of the participants were classified as being at high risk of carrying a BRCA1/2 mutation based on their age at the time of breast cancer diagnosis and family history of breast and/or ovarian cancer. Physician recommendations for BRCA1/2 testing were found to be strongly associated with risk of carrying a mutation, with 53% of high-risk women reporting a testing recommendation compared with 9% of low-risk women. In addition, physician recommendations were strongly correlated with the use of testing in all risk groups. Among high-risk women, the lack of a recommendation for BRCA1/2 testing was more common among older, low-income, and employed women. CONCLUSIONSAlthough BRCA1/2 testing recommendations appear to be appropriately correlated with mutation risk, a significant percentage of patients with breast cancer who meet criteria for BRCA1/2 testing may not receive a recommendation for such testing from their health care providers. Cancer 2013;119:3596-3603. (c) 2013 American Cancer Society. C1 [McCarthy, Anne Marie; Bristol, Mirar; Fredricks, Tracey; Wilkins, Lache; Roelfsema, Irene; Liao, Kaijun; Shea, Judy A.; Groeneveld, Peter; Domchek, Susan M.; Armstrong, Katrina] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Groeneveld, Peter] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Domchek, Susan M.; Armstrong, Katrina] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. RP McCarthy, AM (reprint author), Univ Penn, 423 Guardian Dr,Room 1009, Philadelphia, PA 19104 USA. EM annemcc@mail.med.upenn.edu FU National Institutes of Health grant from the National Cancer Institute [5-R01-CA133004-3] FX Supported by a National Institutes of Health grant from the National Cancer Institute (5-R01-CA133004-3). NR 25 TC 8 Z9 8 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD OCT 15 PY 2013 VL 119 IS 20 BP 3596 EP 3603 DI 10.1002/cncr.28268 PG 8 WC Oncology SC Oncology GA 230WJ UT WOS:000325373700039 PM 23861169 ER PT J AU Skolarus, TA Chan, S Shelton, JB Antonio, AL Sales, AE Malin, JL Saigal, CS AF Skolarus, Ted A. Chan, Stephanie Shelton, Jeremy B. Antonio, Anna Liza Sales, Anne E. Malin, Jennifer L. Saigal, Christopher S. TI Quality of Prostate Cancer Care Among Rural Men in the Veterans Health Administration SO CANCER LA English DT Article DE prostate cancer; quality; rural; integrated delivery system; access ID RADIATION-THERAPY; ANDROGEN SUPPRESSION; ACCESS; ADENOCARCINOMA; BARRIERS; TRIAL; RISK; TERM; VA AB BACKGROUNDPatient travel distances, coupled with variation in facility-level resources, create barriers for prostate cancer care in the Veterans Health Administration integrated delivery system. For these reasons, the authors investigated the degree to which these barriers impact the quality of prostate cancer care. METHODSThe Veterans Affairs Central Cancer Registry was used to identify all men who were diagnosed with prostate cancer in 2008. Patient residence was characterized using Rural Urban Commuting Area codes. The authors then examined whether rural residence, compared with urban residence, was associated with less access to cancer-related resources and worse quality of care for 5 prostate cancer quality measures. RESULTSApproximately 25% of the 11,368 patients who were diagnosed with prostate cancer in 2008 lived in either a rural area or a large town. Rural patients tended to be white (62% urban vs 86% rural) and married (47% urban vs 63% rural), and they tended to have slightly higher incomes (all P<.01) but similar tumor grade (P=.23) and stage (P=.12) compared with urban patients. Rural patients were significantly less likely to be treated at facilities with comprehensive cancer resources, although they received a similar or better quality of care for 4 of the 5 prostate cancer quality measures. The time to prostate cancer treatment was similar (rural patients vs urban patients, 96.6 days vs 105.7 days). CONCLUSIONSRural patients with prostate cancer had less access to comprehensive oncology resources, although they received a similar quality of care, compared with their urban counterparts in the Veterans Health Administration integrated delivery system. A better understanding of the degree to which facility factors contribute to the quality of cancer care may assist other organizations involved in rural health care delivery. Cancer 2013;119:3629-3635. (c) 2013 American Cancer Society. C1 [Skolarus, Ted A.; Sales, Anne E.] Vet Affairs Ann Arbor Healthcare Syst, Hlth Serv Res & Dev Serv, Ctr Clin Management Res, Ann Arbor, MI USA. [Skolarus, Ted A.] Univ Michigan, Dow Div Hlth Serv Res, Dept Urol, Ann Arbor, MI 48109 USA. [Chan, Stephanie] Frederick S Pardee RAND Grad Sch, Santa Monica, CA USA. [Shelton, Jeremy B.; Antonio, Anna Liza; Malin, Jennifer L.; Saigal, Christopher S.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Shelton, Jeremy B.; Saigal, Christopher S.] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA. [Sales, Anne E.] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA. [Malin, Jennifer L.] Wellpoint Inc, Med Oncol, Indianapolis, IN USA. RP Skolarus, TA (reprint author), Univ Michigan, Dept Urol, VA Ctr Clin Management Res, VA Ann Arbor Healthcare Syst, Ann Arbor, MI 48109 USA. EM tskolar@med.umich.edu OI Sales, Anne/0000-0001-9360-3334 FU Veterans Health Administration Office of Analytics and Business Intelligence; VA HSR&D Career Development Award - 2 [CDA 12-171] FX This work was supported by the Veterans Health Administration Office of Analytics and Business Intelligence "Supportive Care, End of Life Care, and Crosscutting Quality Indicators for Patients with Cancer Within VA" Project. Dr. Skolarus is supported by a VA HSR&D Career Development Award - 2 (CDA 12-171). NR 33 TC 7 Z9 7 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD OCT 15 PY 2013 VL 119 IS 20 BP 3629 EP 3635 DI 10.1002/cncr.28275 PG 7 WC Oncology SC Oncology GA 230WJ UT WOS:000325373700043 PM 23913676 ER PT J AU Wills, LP Beeson, GC Trager, RE Lindsey, CC Beeson, CC Peterson, YK Schnellmann, RG AF Wills, Lauren P. Beeson, Gyda C. Trager, Richard E. Lindsey, Christopher C. Beeson, Craig C. Peterson, Yuri K. Schnellmann, Rick G. TI High-throughput respirometric assay identifies predictive toxicophore of mitochondrial injury SO TOXICOLOGY AND APPLIED PHARMACOLOGY LA English DT Article DE Mitochondria; Toxicophore; Renal proximal tubule cells; LOPAC; ChemBridge; Seahorse Biosciences Extracellular Flux ID OXYGEN-SENSITIVE PROBES; IN-VITRO; PERMEABILITY TRANSITION; TOXICITY; CELLS; DRUGS; MECHANISMS; APOPTOSIS; CULTURE; TARGETS AB Many environmental chemicals and drugs negatively affect human health through deleterious effects on mitochondrial function. Currently there is no chemical library of mitochondrial toxicants, and no reliable methods for predicting mitochondrial toxicity. We hypothesized that discrete toxicophores defined by distinct chemical entities can identify previously unidentified mitochondrial toxicants. We used a respirometric assay to screen 1760 compounds (5 mu M) from the LOPAC and ChemBridge DIVERSet libraries. Thirty-one of the assayed compounds decreased uncoupled respiration, a stress test for mitochondrial dysfunction, prior to a decrease in cell viability and reduced the oxygen consumption rate in isolated mitochondria. The mitochondrial toxicants were grouped by chemical similarity and two clusters containing four compounds each were identified. Cheminformatic analysis of one of the clusters identified previously uncharacterized mitochondrial toxicants from the ChemBridge DIVERSet This approach will enable the identification of mitochondrial toxicants and advance the prediction of mitochondrial toxicity for both drug discovery and risk assessment. (C) 2013 The Authors. Published by Elsevier Inc. All rights reserved. C1 [Beeson, Gyda C.; Trager, Richard E.; Lindsey, Christopher C.; Peterson, Yuri K.; Schnellmann, Rick G.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. [Schnellmann, Rick G.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. [Wills, Lauren P.; Beeson, Craig C.] MitoHealth Inc, Charleston, SC 29403 USA. RP Schnellmann, RG (reprint author), Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, 280 Calhoun St,MSC140, Charleston, SC 29425 USA. EM schnell@musc.edu FU NCRR NIH HHS [S10 RR027122]; NIEHS NIH HHS [R44 ES019378, R43 ES019378]; NIGMS NIH HHS [R43 GM097770, R01 GM084147] NR 44 TC 5 Z9 5 U1 1 U2 9 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0041-008X EI 1096-0333 J9 TOXICOL APPL PHARM JI Toxicol. Appl. Pharmacol. PD OCT 15 PY 2013 VL 272 IS 2 BP 490 EP 502 DI 10.1016/j.taap.2013.06.014 PG 13 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA 237XS UT WOS:000325905500025 PM 23811330 ER PT J AU Jorgenson, TC Zhong, WX Oberley, TD AF Jorgenson, Tonia C. Zhong, Weixiong Oberley, Terry D. TI Redox Imbalance and Biochemical Changes in Cancer SO CANCER RESEARCH LA English DT Article ID MOLECULAR-MECHANISMS; S-GLUTATHIONYLATION; OXIDATIVE STRESS; THIOREDOXIN; ACTIVATION; CELLS; NRF2; SUMOYLATION; METHYLATION; LEUKEMIA AB For this article, we explore a hypothesis involving the possible role of reduction/oxidation (redox) state in cancer. We hypothesize that many modifications in cellular macromolecules, observed in cancer progression, may be caused by redox imbalance. Recent biochemical data suggest that human prostate cancer cell lines show a redox imbalance (oxidizing) compared with benign primary prostate epithelial cells; the degree of oxidation varied with aggressive behavior of each cell line. Our recent data suggest that human breast cancer tissues show a redox imbalance (reducing) compared with benign adjacent breast tissues. Accumulating data summarized in this article suggest that redox imbalance may regulate gene expression and alter protein stability by posttranslational modifications, in turn modulating existing cellular programs. Despite significant improvements in cancer therapeutics, resistance occurs, and redox imbalance may play a role in this process. Studies show that some cancer therapeutic agents increase generation of reactive oxygen/nitrogen species and antioxidant enzymes, which may alter total antioxidant capacity, cause cellular adaptation, and result in reduced effectiveness of treatment modalities. Approaches involving modulations of intra-and extracellular redox states, in combination with other therapies, may lead to new treatment options, especially for patients who are resistant to standard treatments. Cancer Res; 73(20); 6118-23. (C) 2013 AACR. C1 [Jorgenson, Tonia C.; Zhong, Weixiong; Oberley, Terry D.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Inst Med Res, Dept Pathol & Lab Med, Madison, WI 53705 USA. [Zhong, Weixiong; Oberley, Terry D.] William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Madison, WI 53705 USA. RP Jorgenson, TC (reprint author), Univ Wisconsin, Wisconsin Inst Med Res, 1111 Highland Ave, Madison, WI 53705 USA. EM tjorgenson@wisc.edu FU Department of Pathology and Laboratory Medicine, University of Wisconsin; NCI UW Carbone Comprehensive Cancer Center (NIH) [P30 CA014520]; NIH [RO1CA139844, RO1CA139843, RO1CA073599] FX This work was supported in part by funds from the Department of Pathology and Laboratory Medicine, University of Wisconsin, NCI UW Carbone Comprehensive Cancer Center (NIH grant P30 CA014520), NIH grants RO1CA139844, RO1CA139843, RO1CA073599 (TDO-CoI), and resources and facilities at the William S. Middleton Memorial Veterans Hospital (Madison, WI). Tonia C. Jorgenson is supported in part by PF-13-286-01-TBE from the American Cancer Society. NR 30 TC 27 Z9 28 U1 0 U2 13 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD OCT 15 PY 2013 VL 73 IS 20 BP 6118 EP 6123 DI 10.1158/0008-5472.CAN-13-1117 PG 6 WC Oncology SC Oncology GA 236KV UT WOS:000325796100004 PM 23878188 ER PT J AU Yarchoan, M Louneva, N Xie, SX Swenson, FJ Hu, W Soares, H Trojanowski, JQ Lee, VMY Kling, MA Shaw, LM Chen-Plotkin, A Wolk, DA Arnold, SE AF Yarchoan, Mark Louneva, Natalia Xie, Sharon X. Swenson, Frank J. Hu, William Soares, Holly Trojanowski, John Q. Lee, Virginia M. -Y. Kling, Mitchel A. Shaw, Leslie M. Chen-Plotkin, Alice Wolk, David A. Arnold, Steven E. TI Association of plasma C-reactive protein levels with the diagnosis of Alzheimer's disease SO JOURNAL OF THE NEUROLOGICAL SCIENCES LA English DT Article DE Alzheimer disease; Mild cognitive impairment; C-reactive protein; Inflammation; Biological markers; Apolipoprotein E ID COGNITIVE FUNCTION; INFLAMMATION; RISK; DEMENTIA; MARKER; HEALTH; CRP AB C-reactive protein (CRP) participates in the systemic response to inflammation. Previous studies report inconsistent findings regarding the relationship between plasma CRP and Alzheimer's disease (AD). We measured plasma CRP in 203 subjects with AD, 58 subjects with mild cognitive impairment (MCI) and 117 normal aging subjects and administered annual Mini-Mental State Examinations (MMSE) during a 3-year follow-up period to investigate CRP's relationship with diagnosis and progression of cognitive decline. Adjusted for age, sex, and education, subjects with AD had significantly lower levels of plasma CRP than subjects with MCI and normal aging. However, there was no significant association between plasma CRP at baseline and subsequent cognitive decline as assessed by longitudinal changes in MMSE score. Our results support previous reports of reduced levels of plasma CRP in AD and indicate its potential utility as a biomarker for the diagnosis of AD. (C) 2013 Elsevier B.V. All rights reserved. C1 [Yarchoan, Mark] Univ Penn, Dept Internal Med, Philadelphia, PA 19104 USA. [Louneva, Natalia; Arnold, Steven E.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Xie, Sharon X.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Swenson, Frank J.] Pfizer Diagnost, PharmaTX Precis Med, Groton, CT USA. [Hu, William] Emory Univ, Emory Alzheimers Dis Res Ctr, Atlanta, GA 30322 USA. [Soares, Holly] Pfizer Global Res & Dev, Groton, CT USA. [Trojanowski, John Q.; Lee, Virginia M. -Y.] Univ Penn, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA. [Kling, Mitchel A.] Philadelphia VA Med Ctr, Behav Hlth Serv, Philadelphia, PA USA. [Shaw, Leslie M.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA. [Chen-Plotkin, Alice; Wolk, David A.; Arnold, Steven E.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. RP Arnold, SE (reprint author), 3615 Chestnut St, Philadelphia, PA 19104 USA. EM steven.arnold@uphs.upenn.edu OI Kling, Mitchel/0000-0002-2232-1409 FU National Institutes of Health [AG10124]; Penn-Pfizer Research Alliance at the University of Pennsylvania; Marian S. Ware Alzheimer's Program; Allen H. and Selma W. Berkman Charitable Trust FX This study has been supported by the National Institutes of Health (grant no. AG10124), the Penn-Pfizer Research Alliance at the University of Pennsylvania, the Marian S. Ware Alzheimer's Program, and the Allen H. and Selma W. Berkman Charitable Trust. We thank Xiaoyan Han, M.S., for her help with the statistical programming of the mixed-effects model analysis. NR 16 TC 12 Z9 12 U1 0 U2 8 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0022-510X EI 1878-5883 J9 J NEUROL SCI JI J. Neurol. Sci. PD OCT 15 PY 2013 VL 333 IS 1-2 BP 9 EP 12 DI 10.1016/j.jns.2013.05.028 PG 4 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 235SN UT WOS:000325741100003 PM 23978419 ER PT J AU Yukl, SA Shergill, AK Ho, T Killian, M Girling, V Epling, L Li, PL Wong, LK Crouch, P Deeks, SG Havlir, DV McQuaid, K Sinclair, E Wong, JK AF Yukl, Steven A. Shergill, Amandeep K. Ho, Terence Killian, Maudi Girling, Valerie Epling, Lorrie Li, Peilin Wong, Lisa K. Crouch, Pierre Deeks, Steven G. Havlir, Diane V. McQuaid, Kenneth Sinclair, Elizabeth Wong, Joseph K. TI The Distribution of HIV DNA and RNA in Cell Subsets Differs in Gut and Blood of HIV-Positive Patients on ART: Implications for Viral Persistence SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE HIV; HIV-1; ART; persistence; reservoir; CD4(+) T cell; gut; intestine; ileum; rectum ID ACTIVE ANTIRETROVIRAL THERAPY; CD4(+) T-CELLS; VIRUS TYPE-1 RNA; LYMPHOID-TISSUE; IN-VIVO; PERIPHERAL-BLOOD; CENTRAL MEMORY; INFECTION; PLASMA; RESERVOIR AB Even with optimal antiretroviral therapy, human immunodeficiency virus (HIV) persists in plasma, blood cells, and tissues. To develop new therapies, it is essential to know what cell types harbor residual HIV. We measured levels of HIV DNA, RNA, and RNA/DNA ratios in sorted subsets of CD4(+) T cells (CCR7(+), transitional memory, and effector memory) and non-CD4(+) T leukocytes from blood, ileum, and rectum of 8 ART-suppressed HIV-positive subjects. Levels of HIV DNA/million cells in CCR7(+) and effector memory cells were higher in the ileum than blood. When normalized by cell frequencies, most HIV DNA and RNA in the blood were found in CCR7(+) cells, whereas in both gut sites, most HIV DNA and RNA were found in effector memory cells. HIV DNA and RNA were observed in non-CD4(+) T leukocytes at low levels, particularly in gut tissues. Compared to the blood, the ileum had higher levels of HIV DNA and RNA in both CD4(+) T cells and non-CD4(+) T leukocytes, whereas the rectum had higher HIV DNA levels in both cell types but lower RNA levels in CD4(+) T cells. Future studies should determine whether different mechanisms allow HIV to persist in these distinct reservoirs, and the degree to which different therapies can affect each reservoir. C1 [Yukl, Steven A.; Shergill, Amandeep K.; Li, Peilin; Crouch, Pierre; McQuaid, Kenneth; Wong, Joseph K.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94121 USA. [Yukl, Steven A.; Shergill, Amandeep K.; Ho, Terence; Killian, Maudi; Girling, Valerie; Epling, Lorrie; Li, Peilin; Crouch, Pierre; Deeks, Steven G.; Havlir, Diane V.; McQuaid, Kenneth; Sinclair, Elizabeth; Wong, Joseph K.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Ho, Terence; Killian, Maudi; Girling, Valerie; Epling, Lorrie; Deeks, Steven G.; Havlir, Diane V.; Sinclair, Elizabeth] San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA. [Wong, Lisa K.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. RP Yukl, SA (reprint author), San Francisco VA Med Ctr, 4150 Clement St,111W3, San Francisco, CA 94121 USA. EM steven.yukl@ucsf.edu FU US Department of Veterans Affairs [1 IK2 CX000520-01, I01 BX000192]; UCSF-Gladstone Center for AIDS Research (CFAR) [P30-AI027763]; National Institute of Allergy and Infectious Diseases at the National Institutes of Health [R56AI091573, K24 AI069994, U19AI096109] FX This work was supported by the US Department of Veterans Affairs (1 IK2 CX000520-01 [to S. Y.], I01 BX000192 [to J. W.]); the UCSF-Gladstone Center for AIDS Research (CFAR) (P30-AI027763 [to S. Y.]); and the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (R56AI091573 [J. W., S. Y., A. S., D. H.], K24 AI069994 [to S. D.], U19AI096109 [to S. D., J. W.]). NR 43 TC 42 Z9 42 U1 1 U2 15 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 15 PY 2013 VL 208 IS 8 BP 1212 EP 1220 DI 10.1093/infdis/jit308 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 223TJ UT WOS:000324832800004 PM 23852128 ER PT J AU Caverly, TJ Prochazka, AV Stickrath, C AF Caverly, Tanner J. Prochazka, Allan V. Stickrath, Chad TI Do Physicians Have an Obligation to Disclose the Uncertainty About Harms or Just the Harms? Reply SO JAMA INTERNAL MEDICINE LA English DT Letter ID COMPUTED-TOMOGRAPHY; RADIATION-EXPOSURE; CT SCANS; CHILDHOOD; RISK C1 [Caverly, Tanner J.; Prochazka, Allan V.; Stickrath, Chad] Univ Colorado, Div Gen Internal Med, Dept Med, Aurora, CO 80042 USA. [Caverly, Tanner J.; Prochazka, Allan V.; Stickrath, Chad] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Caverly, TJ (reprint author), Univ Colorado, Univ Phys Inc, Div Gen Internal Med, Dept Med,Sch Med, 13199 E Montview Blvd,3rd Floor,Ste 300, Aurora, CO 80042 USA. EM Tanner.Caverly@gmail.com FU PHS HHS [T32HP1006] NR 6 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD OCT 14 PY 2013 VL 173 IS 18 BP 1752 EP 1752 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 268TO UT WOS:000328193600024 PM 24126773 ER PT J AU Singh, H Sittig, DF AF Singh, Hardeep Sittig, Dean F. TI Toward Electronic Medical Record Alerts That Consume Less Physician Time Reply SO JAMA INTERNAL MEDICINE LA English DT Letter C1 [Singh, Hardeep] Baylor Coll Med, Dept Med, Houston VA Hlth Serv Res & Dev HSR&D, Ctr Excellence,Michael E DeBakey Vet Affairs Med, Houston, TX 77030 USA. [Singh, Hardeep] Sect Hlth Serv Res, Houston, TX USA. [Sittig, Dean F.] Univ Texas Houston, Sch Biomed Informat, Houston, TX USA. [Sittig, Dean F.] Univ Texas Houston, Mem Hermann Ctr Healthcare Qual & Safety, Houston, TX USA. RP Singh, H (reprint author), VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hardeeps@bcm.edu NR 6 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD OCT 14 PY 2013 VL 173 IS 18 BP 1756 EP 1756 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 268TO UT WOS:000328193600031 PM 24126782 ER PT J AU Turner, EH AF Turner, Erick H. TI How to access and process FDA drug approval packages for use in research SO BMJ-BRITISH MEDICAL JOURNAL LA English DT Article ID CLINICAL-TRIALS; PUBLICATION; INFORMATION; DOCUMENTS; REVIEWS C1 [Turner, Erick H.] Portland VA Med Ctr, Behav Hlth & Neurosci Div, Portland, OR USA. [Turner, Erick H.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Turner, Erick H.] Oregon Hlth & Sci Univ, Dept Pharmacol, Portland, OR 97201 USA. [Turner, Erick H.] Oregon Hlth & Sci Univ, Ctr Eth Hlth Care, Portland, OR 97201 USA. RP Turner, EH (reprint author), Portland VA Med Ctr, Behav Hlth & Neurosci Div, Portland, OR USA. EM turnere@ohsu.edu RI Turner, Erick/A-4848-2008 OI Turner, Erick/0000-0002-3522-3357 NR 25 TC 15 Z9 15 U1 1 U2 4 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1756-1833 J9 BMJ-BRIT MED J JI BMJ-British Medical Journal PD OCT 14 PY 2013 VL 347 AR f5992 DI 10.1136/bmj.f5992 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 238VR UT WOS:000325980100001 PM 24126858 ER PT J AU Bekelman, JE Epstein, AJ Emanuel, EJ AF Bekelman, Justin E. Epstein, Andrew J. Emanuel, Ezekiel J. TI Single- vs Multiple-Fraction Radiotherapy for Bone Metastases From Prostate Cancer SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 [Bekelman, Justin E.] Univ Penn, Perelman Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA. [Epstein, Andrew J.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Emanuel, Ezekiel J.] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA. RP Bekelman, JE (reprint author), Univ Penn, Perelman Sch Med, 3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM bekelman@uphs.upenn.edu FU NCI NIH HHS [K07 CA163616, K07-CA163616] NR 6 TC 24 Z9 24 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD OCT 9 PY 2013 VL 310 IS 14 BP 1501 EP 1502 DI 10.1001/jama.2013.277081 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 230PK UT WOS:000325354100027 PM 24104375 ER PT J AU Raitt, MH AF Raitt, Merritt H. TI Inappropriate Implantable Defibrillator Shocks SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Editorial Material DE beta-blockers; carvedilol; defibrillator; heart failure; inappropriate therapy ID CARDIAC-RESYNCHRONIZATION THERAPY; HEART-FAILURE; CARDIOVERTER-DEFIBRILLATORS; BETA-BLOCKERS; CARVEDILOL; METOPROLOL; METAANALYSIS; PREVENTION; OUTCOMES; TRIAL C1 [Raitt, Merritt H.] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Div Cardiol, Portland, OR 97201 USA. [Raitt, Merritt H.] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Portland, OR 97201 USA. RP Raitt, MH (reprint author), Portland VA Med Ctr, P-3 CARD,3710 SW US Vet Rd, Portland, OR 97239 USA. EM merritt.raitt@va.gov NR 14 TC 3 Z9 3 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD OCT 8 PY 2013 VL 62 IS 15 BP 1351 EP 1352 DI 10.1016/j.jacc.2013.05.055 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 225ZY UT WOS:000325005000008 PM 23770170 ER PT J AU Zhang, JH Palevsky, PM Chertow, GM Hartigan, J O'Connor, TZ Guarino, P Zhou, BQ AF Zhang, Jane H. Palevsky, Paul M. Chertow, Glenn M. Hartigan, John O'Connor, Theresa Z. Guarino, Peter Zhou, Bingqing TI Piecewise Analysis of Patient Survival after Onset of AKI SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID ACUTE-RENAL-FAILURE; CRITICALLY-ILL PATIENTS; MORTALITY; EPIDEMIOLOGY; INTENSITY; OUTCOMES; THERAPY; SUPPORT; TRIAL; POINT AB Background and objectivesAKI affects approximately 2%-7% of hospitalized patients and >35% of critically ill patients. Survival after AKI may be described as having an acute phase (including an initial hyperacute component) followed by a convalescent phase, which may itself have early and late components.Design, setting, participants, & measurementsData from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network (ATN) study was used to model mortality risk among patients with dialysis-requiring AKI. This study assumed that the mortality hazard can be described by a piecewise log-linear function with change points. Using an average likelihood method, the authors tested for the number of change points in a piecewise log-linear hazard model. The maximum likelihood approach to locate the change point(s) was then adopted, and associated parameters and standard errors were estimated.ResultsThere were 1124 ATN participants with follow-up to 1 year. The mortality hazard of AKI decreased over time with inflections in the rate of decrease at days 4, 42, and 148, with the sharpest change at day 42. The daily rate of decline in the log of the hazard for death was 0.220 over the first 4 days, 0.046 between day 4 and day 42, 0.017 between day 42 and day 148, and 0.003 between day 148 and day 365.ConclusionsThere appear to be two major phases of mortality risk after AKI: an early phase extending over the first 6 weeks and a late phase from 6 weeks to 1 year. Within the first 42 days, this can be further divided into hyperacute (days 1-4) and acute (days 4-42) phases. After 42 days, there appear to be early (days 42-148) and late (after day 148) convalescent phases. These findings may help to inform the design of AKI clinical trials and assist critical care physicians in prognostic stratification. C1 [Zhang, Jane H.; O'Connor, Theresa Z.; Guarino, Peter; Zhou, Bingqing] Vet Affairs Connecticut Hlth Care Syst, Cooperat Studies Program Coordinating Ctr, West Haven, CT 06516 USA. [Palevsky, Paul M.] Vet Affairs Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Chertow, Glenn M.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. [Hartigan, John] Yale Univ, Dept Stat, New Haven, CT USA. [Zhou, Bingqing] Yale Univ, Sch Publ Hlth, Div Biostat, New Haven, CT USA. RP Zhang, JH (reprint author), Vet Affairs Connecticut Hlth Care Syst, Cooperat Studies Program Coordinating Ctr, 950 Campbell Ave, West Haven, CT 06516 USA. EM Jane.Zhang@va.gov OI Palevsky, Paul/0000-0002-7334-5400 FU Department of Veterans Affairs Office of Research and Development; National Institute of Diabetes and Digestive and Kidney Diseases [Y1-DK-3508-01] FX This study was supported by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development and by the National Institute of Diabetes and Digestive and Kidney Diseases (interagency agreement Y1-DK-3508-01). NR 19 TC 4 Z9 4 U1 0 U2 1 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD OCT 7 PY 2013 VL 8 IS 10 BP 1679 EP 1684 DI 10.2215/CJN.07250712 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 229MA UT WOS:000325268200008 PM 23813558 ER PT J AU Lee, DY Wauquier, F Eid, AA Roman, LJ Ghosh-Choudhury, G Khazim, K Block, K Gorin, Y AF Lee, Doug-Yoon Wauquier, Fabien Eid, Assaad A. Roman, Linda J. Ghosh-Choudhury, Goutam Khazim, Khaled Block, Karen Gorin, Yves TI Nox4 NADPH Oxidase Mediates Peroxynitrite-dependent Uncoupling of Endothelial Nitric-oxide Synthase and Fibronectin Expression in Response to Angiotensin II ROLE OF MITOCHONDRIAL REACTIVE OXYGEN SPECIES SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article DE Angiotensin II; Extracellular Matrix Proteins; Kidney; Nitric-oxide Synthase; Nox; Oxidative Stress ID RAT MESANGIAL CELLS; EXPERIMENTAL DIABETIC-NEPHROPATHY; NAD(P)H OXIDASE; MOLECULAR-MECHANISMS; GLOMERULAR INJURY; RECEPTOR BLOCKADE; VASCULAR-DISEASE; REDOX CONTROL; UP-REGULATION; SUPEROXIDE AB Activation of glomerular mesangial cells (MCs) by angiotensin II (Ang II) leads to extracellular matrix accumulation. Here, we demonstrate that, in MCs, Ang II induces endothelial nitric-oxide synthase (eNOS) uncoupling with enhanced generation of reactive oxygen species (ROS) and decreased production of NO. Ang II promotes a rapid increase in 3-nitrotyrosine formation, and uric acid attenuates Ang II-induced decrease in NO bioavailability, demonstrating that peroxynitrite mediates the effects of Ang II on eNOS dysfunction. Ang II rapidly up-regulates Nox4 protein. Inhibition of Nox4 abolishes the increase in ROS and peroxynitrite generation as well as eNOS uncoupling triggered by Ang II, indicating that Nox4 is upstream of eNOS. This pathway contributes to Ang II-mediated fibronectin accumulation in MCs. Ang II also elicits an increase in mitochondrial abundance of Nox4 protein, and the oxidase contributes to ROS production in mitochondria. Overexpression of mitochondrial manganese superoxide dismutase prevents the stimulatory effects of Ang II on mitochondrial ROS production, loss of NO availability, and MC fibronectin accumulation, whereas manganese superoxide dismutase depletion increases mitochondrial ROS, NO deficiency, and fibronectin synthesis basally and in cells exposed to Ang II. This work provides the first evidence that uncoupled eNOS is responsible for Ang II-induced MC fibronectin accumulation and identifies Nox4 and mitochondrial ROS as mediators of eNOS dysfunction. These data shed light on molecular processes underlying the oxidative signaling cascade engaged by Ang II and identify potential targets for intervention to prevent renal fibrosis. C1 [Lee, Doug-Yoon; Wauquier, Fabien; Eid, Assaad A.; Ghosh-Choudhury, Goutam; Khazim, Khaled; Block, Karen; Gorin, Yves] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Roman, Linda J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Ghosh-Choudhury, Goutam] Vet Adm Res & Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. [Ghosh-Choudhury, Goutam; Block, Karen] South Texas Vet Hlth Care Syst, Audie Leon Murphy Mem Hosp Div, San Antonio, TX 78229 USA. RP Gorin, Y (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol MC 7882, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM gorin@uthscsa.edu FU National Institutes of Health [RO1 DK 079996, RO1 CA 131272, RO1 DK 50190]; Juvenile Diabetes Research Foundation Multiproject Grant; Juvenile Diabetes Research Foundation Advanced Research Fellowship Grant; Veterans Administration Merit Awards; Veterans Administration Senior Research Career Scientist Award FX This work was supported, in whole or in part, by National Institutes of Health Grants RO1 DK 079996 (to Y. G.), RO1 CA 131272 (to K. B.), and RO1 DK 50190 (to G. G. C.). This work was also supported in part by a Juvenile Diabetes Research Foundation Multiproject Grant (to Y. G. and K. B.), a Juvenile Diabetes Research Foundation Advanced Research Fellowship Grant (to A. A. E.), and Veterans Administration Merit Awards (to K. B. and G. G. C.).; Recipient of Veterans Administration Senior Research Career Scientist Award. NR 78 TC 46 Z9 47 U1 2 U2 14 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD OCT 4 PY 2013 VL 288 IS 40 BP 28668 EP 28686 DI 10.1074/jbc.M113.470971 PG 19 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 298BL UT WOS:000330298800022 PM 23940049 ER PT J AU Sano, M Egelko, S Donohue, M Paparello, S Sun, CK Aisen, P Ferris, S Kaye, J Hayes, T Mundt, J AF Sano, Mary Egelko, Susan Donohue, Michael Paparello, Silvia Sun, Chung-Kai Aisen, Paul Ferris, Steven Kaye, Jeffrey Hayes, Tamara Mundt, James TI Satisfaction of elderly research participants with home-based clinical trial participation SO INTERNATIONAL PSYCHOGERIATRICS LA English DT Meeting Abstract C1 [Sano, Mary; Egelko, Susan] Mt Sinai Sch Med, New York, NY USA. [Sano, Mary; Egelko, Susan] James J Peters VAMC, New York, NY USA. [Donohue, Michael; Paparello, Silvia; Sun, Chung-Kai; Aisen, Paul] Univ Calif San Diego, San Diego, CA 92103 USA. [Ferris, Steven] NYU Langone Med Ctr ADC, New York, NY USA. [Kaye, Jeffrey; Hayes, Tamara] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Mundt, James] Ctr Psychol Res Training & Consultat, Little Rock, AR USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1041-6102 EI 1741-203X J9 INT PSYCHOGERIATR JI Int. Psychogeriatr. PD OCT PY 2013 VL 25 SU 1 MA PS01-106 BP S109 EP S110 PG 2 WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry; Psychology SC Psychology; Geriatrics & Gerontology; Psychiatry GA AJ5UB UT WOS:000337753100247 ER PT J AU Havasi, V Clines, GA Stalvey, MS AF Havasi, V Clines, G. A. Stalvey, M. S. TI REDUCED BONE DENSITY IN G551D-CFTR MICE: A NOVEL MODEL TO STUDY EFFECTS OF CFTR ON BONE METABOLISM SO PEDIATRIC PULMONOLOGY LA English DT Meeting Abstract C1 [Havasi, V; Clines, G. A.; Stalvey, M. S.] Univ Alabama Birmingham, Birmingham, AL USA. [Clines, G. A.] Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 8755-6863 EI 1099-0496 J9 PEDIATR PULM JI Pediatr. Pulmonol. PD OCT PY 2013 VL 48 SU 36 BP 419 EP 420 PG 2 WC Pediatrics; Respiratory System SC Pediatrics; Respiratory System GA AF0FB UT WOS:000334387200658 ER PT J AU Roetker, NS Page, CD Yonker, JA Chang, V Roan, CL Herd, P Hauser, TS Hauser, RM Atwood, CS AF Roetker, Nicholas S. Page, C. David Yonker, James A. Chang, Vicky Roan, Carol L. Herd, Pamela Hauser, Taissa S. Hauser, Robert M. Atwood, Craig S. TI Assessment of Genetic and Nongenetic Interactions for the Prediction of Depressive Symptomatology: An Analysis of the Wisconsin Longitudinal Study Using Machine Learning Algorithms SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID NATIONAL COMORBIDITY SURVEY; SEROTONIN TRANSPORTER GENE; GENOME-WIDE ASSOCIATION; STRESSFUL LIFE EVENTS; HORMONE-RECEPTOR GENE; MAJOR DEPRESSION; ADULT DEPRESSION; ENVIRONMENT INTERACTIONS; CHILDHOOD MALTREATMENT; TREATMENT RESPONSE AB Objectives. We examined depression within a multidimensional framework consisting of genetic, environmental, and sociobehavioral factors and, using machine learning algorithms, explored interactions among these factors that might better explain the etiology of depressive symptoms. Methods. We measured current depressive symptoms using the Center for Epidemiologic Studies Depression Scale (n = 6378 participants in the Wisconsin Longitudinal Study). Genetic factors were 78 single nucleotide polymorphisms (SNPs); environmental factors-13 stressful life events (SLEs), plus a composite proportion of SLEs index; and sociobehavioral factors-18 personality, intelligence, and other health or behavioral measures. We performed traditional SNP associations via logistic regression likelihood ratio testing and explored interactions with support vector machines and Bayesian networks. Results. After correction for multiple testing, we found no significant single genotypic associations with depressive symptoms. Machine learning algorithms showed no evidence of interactions. Naive Bayes produced the best models in both subsets and included only environmental and sociobehavioral factors. Conclusions. We found no single or interactive associations with genetic factors and depressive symptoms. Various environmental and sociobehavioral factors were more predictive of depressive symptoms, yet their impacts were independent of one another. A genome-wide analysis of genetic alterations using machine learning methodologies will provide a framework for identifying genetic-environmental-sociobehavioral interactions in depressive symptoms. C1 [Roetker, Nicholas S.; Yonker, James A.; Chang, Vicky; Roan, Carol L.; Herd, Pamela; Hauser, Taissa S.; Hauser, Robert M.] Univ Wisconsin Madison, Dept Sociol, Madison, WI 53715 USA. [Herd, Pamela] Univ Wisconsin Madison, La Follete Sch Publ Affairs, Madison, WI USA. [Page, C. David] Univ Wisconsin Madison, Dept Biostat & Med Informat, Madison, WI USA. [Atwood, Craig S.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Atwood, Craig S.] Univ Wisconsin Madison Sch Med & Publ Hlth, Dept Med, Madison, WI 53705 USA. RP Atwood, CS (reprint author), Univ Wisconsin Madison Sch Med & Publ Hlth, William S Middleton Mem Vet Hosp GRECC 11G, 2500 Overlook Terrace, Madison, WI 53705 USA. EM csa@medicine.wisc.edu RI Yonker, James/J-6561-2014 OI Yonker, James/0000-0002-9483-8511 FU National Institute on Aging [AG-9775, AG-21079, AG-033285]; Vilas Estate Trust; National Science Foundation; Spencer Foundation; Graduate School of the University of Wisconsin-Madison FX This research used data from the Wisconsin Longitudinal Study (WLS) of the University of Wisconsin-Madison. Since 1991, the WLS has been supported principally by the National Institute on Aging (AG-9775, AG-21079, and AG-033285), with additional support from the Vilas Estate Trust, the National Science Foundation, the Spencer Foundation, and the Graduate School of the University of Wisconsin-Madison. A public use file of data from the Wisconsin Longitudinal Study is available from the WLS, University of Wisconsin-Madison, 1180 Observatory Drive, Madison, WI 53706, and at http://www.ssc.wisc.edu/wlsresearch/data. This material is the result of work supported with resources at the William S. Middleton Memorial Veterans Hospital, Madison, WI. NR 82 TC 1 Z9 1 U1 2 U2 9 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD OCT PY 2013 VL 103 SU 1 BP 136 EP 144 DI 10.2105/AJPH.2012.301141 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA4NC UT WOS:000331071600021 ER PT J AU Ioannou, GN Scott, JD Yang, Y Green, P Beste, LA AF Ioannou, George N. Scott, John D. Yang, Yin Green, Pamela Beste, Lauren A. TI Antiviral Treatment for Hepatitis C Virus in HIV/HCV Co-infected Patients SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Ioannou, George N.; Yang, Yin; Green, Pamela; Beste, Lauren A.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Ioannou, George N.; Scott, John D.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 37 BP 225A EP 225A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252201037 ER PT J AU Harwood, NM Golden-Mason, L Rosen, HR Mengshol, JA AF Harwood, Noah M. Golden-Mason, Lucy Rosen, Hugo R. Mengshol, John A. TI Macrophage Immunoregulatory Galectin-9 Production is increased by Contact with Hepatitis C Virus-infected Hepatocytes and Differentiation SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Harwood, Noah M.; Golden-Mason, Lucy; Rosen, Hugo R.; Mengshol, John A.] Univ Colorado SOM, Denver VA Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 235 BP 325A EP 325A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252201235 ER PT J AU Bril, F Lomonaco, R Orsak, B Chang, Z Ortiz-Lopez, C Hecht, J Tio, F Cusi, K AF Bril, Fernando Lomonaco, Romina Orsak, Beverly Chang, Zhi Ortiz-Lopez, Carolina Hecht, Joan Tio, Fermin Cusi, Kenneth TI Role of plasma FGF21 as a biomarker for nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Bril, Fernando; Lomonaco, Romina; Cusi, Kenneth] Univ Florida, Gainesville, FL USA. [Orsak, Beverly; Chang, Zhi; Ortiz-Lopez, Carolina; Hecht, Joan; Tio, Fermin; Cusi, Kenneth] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Hecht, Joan; Tio, Fermin] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. NR 0 TC 0 Z9 0 U1 3 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 585 BP 487A EP 487A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252202189 ER PT J AU Bril, F Lomonaco, R Orsak, B Hecht, J Ortiz-Lopez, C Hardies, J Tio, F Cusi, K AF Bril, Fernando Lomonaco, Romina Orsak, Beverly Hecht, Joan Ortiz-Lopez, Carolina Hardies, Jean Tio, Fermin Cusi, Kenneth TI Predictors of response after extended pioglitazone treatment in patients with prediabetes or T2DM and nonalcoholic steatohepatitis (NASH) SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Bril, Fernando; Lomonaco, Romina; Hardies, Jean; Cusi, Kenneth] Univ Florida, Gainesville, FL USA. [Orsak, Beverly; Hecht, Joan; Ortiz-Lopez, Carolina; Tio, Fermin; Cusi, Kenneth] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Hecht, Joan; Tio, Fermin] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 639 BP 513A EP 514A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252202243 ER PT J AU Bril, F Lomonaco, R Orsak, B Subbarayan, S Kadiyala, S Ortiz-Lopez, C Webb, A Cusi, K AF Bril, Fernando Lomonaco, Romina Orsak, Beverly Subbarayan, Sreevidya Kadiyala, Sushma Ortiz-Lopez, Carolina Webb, Amy Cusi, Kenneth TI Is there a link between hypothyroidism and nonalcoholic fatty liver disease? SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Bril, Fernando; Lomonaco, Romina; Subbarayan, Sreevidya; Kadiyala, Sushma; Cusi, Kenneth] Univ Florida, Gainesville, FL USA. [Orsak, Beverly; Ortiz-Lopez, Carolina; Webb, Amy; Cusi, Kenneth] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Webb, Amy] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 656 BP 521A EP 522A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252202260 ER PT J AU Bril, F Lomonaco, R Orsak, B Ortiz-Lopez, C Biernacki, D Klaczak, A Chang, Z Hardies, J Cusi, K AF Bril, Fernando Lomonaco, Romina Orsak, Beverly Ortiz-Lopez, Carolina Biernacki, Diane Klaczak, Ashley Chang, Zhi Hardies, Jean Cusi, Kenneth TI Vitamin D deficiency and development of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Bril, Fernando; Lomonaco, Romina; Biernacki, Diane; Klaczak, Ashley; Cusi, Kenneth] Univ Florida, Gainesville, FL USA. [Orsak, Beverly; Ortiz-Lopez, Carolina; Chang, Zhi; Hardies, Jean; Cusi, Kenneth] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Biernacki, Diane] Malcom Randall Vet Adm Med Ctr, Gainesville, FL USA. [Hardies, Jean] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. NR 0 TC 0 Z9 0 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 657 BP 522A EP 522A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252202261 ER PT J AU Chang, MF Dominitz, JA Ioannou, GN Forsberg, CW Boyko, EJ Sporleder, JL Smith, NL AF Chang, Michael F. Dominitz, Jason A. Ioannou, George N. Forsberg, Christopher W. Boyko, Edward J. Sporleder, Jennifer L. Smith, Nicholas L. TI Elevated prevalence of hepatitis B chronic infection and exposure in users of United States Veterans Medical Centers SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Chang, Michael F.] OHSU PVAMC, Portland, OR USA. [Chang, Michael F.] Portland VA Med Ctr, Northwest Hepatitis Resource Ctr C, Portland, OR USA. [Dominitz, Jason A.; Ioannou, George N.] VA Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, Seattle, WA USA. [Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Sporleder, Jennifer L.] VA Puget Sound Hlth Care Syst, Northwest Hepatitis Resource Ctr C, Seattle, WA USA. [Forsberg, Christopher W.; Sporleder, Jennifer L.; Smith, Nicholas L.] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA. [Boyko, Edward J.; Smith, Nicholas L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 876 BP 623A EP 624A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252203044 ER PT J AU Basu, P Shah, NJ Rahman, MA Siriki, R Farhat, S AF Basu, Patrick Shah, Niraj J. Rahman, Md A. Siriki, Ravi Farhat, Sakina TI Restless Leg Syndrome (RLS) is associated with Hepatic Encephalopathy (HE) in decompensated cirrhosis. A clinical pilot study SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Basu, Patrick; Farhat, Sakina] Columbia Univ, Sch Phys & Surg, Forest Hills, NY USA. [Basu, Patrick; Rahman, Md A.; Siriki, Ravi] NSLIJHS Hofstra North Shore LIJ Sch Med, New York, NY USA. [Shah, Niraj J.] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 1355 BP 867A EP 867A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252204138 ER PT J AU Tartaglione, E Derleth, M Yu, L Ioannou, GN AF Tartaglione, Erica Derleth, Mark Yu, Lei Ioannou, George N. TI Can computerized brain training games be used to identify early cognitive impairment in cirrhosis? SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Tartaglione, Erica; Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Derleth, Mark; Yu, Lei; Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 1391 BP 884A EP 884A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252204174 ER PT J AU Berry, K Ioannou, GN AF Berry, Kristin Ioannou, George N. TI The association between transjugular intrahepatic portosystemic shunt and survival SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Berry, Kristin; Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 1634 BP 996A EP 996A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252204417 ER PT J AU Tarlow, B Naugler, WE Orloff, SL Haft, A Grompe, M AF Tarlow, Branden Naugler, Willscott E. Orloff, Susan L. Haft, Annelise Grompe, Markus TI Repopulation of mouse liver with human hepatocytes from core biopsies: a new approach to modeling human liver diseases SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Tarlow, Branden; Naugler, Willscott E.; Haft, Annelise; Grompe, Markus] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Orloff, Susan L.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 1664 BP 1010A EP 1010A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252205014 ER PT J AU Basu, P Shah, NJ Siriki, R Rahman, MA Farhat, S AF Basu, Patrick Shah, Niraj J. Siriki, Ravi Rahman, Md A. Farhat, Sakina TI Romiplostim's Effect to Optimize SVR with Telaprevir, Ribavirin, And Peg Interferon-alfa 2a in Thrombocytopenic Cirrhotics with Chronic Hepatitis C. A Placebo Controlled Prospective Clinical Trial: RESTRAINT C Trial SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Basu, Patrick; Farhat, Sakina] Columbia Univ Sch Phys & Surg, New York, NY USA. [Basu, Patrick; Siriki, Ravi; Rahman, Md A.] NSLIJHS Hofstra North Shore LIJ Sch Med, New York, NY USA. [Shah, Niraj J.] Mt Sinai, Icahn Sch Med, James J Peters VA Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 1886 BP 1117A EP 1117A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252205236 ER PT J AU Saxena, V Yee, HS Catalli, L Wayne, EM Chua, J Monto, A Terrault, N AF Saxena, Varun Yee, Helen S. Catalli, Lisa Wayne, Elizabeth M. Chua, Joshua Monto, Alexander Terrault, Norah TI Protease-Inhibitor (PI) Triple Therapy (TT) in Mildly Decompensated Cirrhotics: Predictors of Treatment Discontinuation, Worsening Decompensation and Sustained Virologic Response SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Saxena, Varun; Yee, Helen S.; Catalli, Lisa; Wayne, Elizabeth M.; Monto, Alexander; Terrault, Norah] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Yee, Helen S.; Chua, Joshua; Monto, Alexander] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 1969 BP 1161A EP 1161A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252205319 ER PT J AU Ojiro, K Kikuchi, M Park, JJ Bunchorntavakul, C Jones, LM Valiga, ME Kaplan, DE Nunes, F Reddy, R Chang, KM AF Ojiro, Keisuke Kikuchi, Masahiro Park, Jang-June Bunchorntavakul, Chalermrat Jones, Lisa M. Valiga, Mary E. Kaplan, David E. Nunes, Frederick Reddy, Rajender Chang, Kyong-Mi TI IL28B genotype defines differential immune costimulatory receptor expression in acute hepatitis C SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Ojiro, Keisuke; Kikuchi, Masahiro; Park, Jang-June; Bunchorntavakul, Chalermrat; Jones, Lisa M.; Valiga, Mary E.; Kaplan, David E.; Nunes, Frederick; Reddy, Rajender; Chang, Kyong-Mi] Univ Penn, Philadelphia, PA 19104 USA. [Ojiro, Keisuke; Kikuchi, Masahiro; Park, Jang-June; Valiga, Mary E.; Kaplan, David E.; Chang, Kyong-Mi] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 2024 BP 1187A EP 1187A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252205374 ER PT J AU Beste, LA Ioannou, GN Yang, Y Chang, MF Ross, D Dominitz, JA AF Beste, Lauren A. Ioannou, George N. Yang, Yin Chang, Michael F. Ross, David Dominitz, Jason A. TI Improvement in use of hepatocellular carcinoma surveillance by a primary-care oriented computerized clinical reminder SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Beste, Lauren A.] VA Puget Sound Hlth Care Syst, Primary Care, Seattle, WA USA. [Beste, Lauren A.; Ioannou, George N.; Dominitz, Jason A.] Univ Washington, Seattle, WA 98195 USA. [Ioannou, George N.; Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, Gastroenterol, Seattle, WA USA. [Chang, Michael F.] Portland VA Med Ctr, Hepatol, Portland, OR USA. [Ross, David] VA Cent Off, HIV Hepatitis C & Publ Hlth Pathogens Program, Washington, DC USA. [Chang, Michael F.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Yang, Yin] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 2037 BP 1193A EP 1193A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252205387 ER PT J AU Beste, LA Harp, BK Blais, RK Zickmund, S AF Beste, Lauren A. Harp, Bonnie K. Blais, Rebecca K. Zickmund, Susan TI "They Gotta Want to Live More Than They Want to Die": Primary Care Attitudes and Beliefs about Cirrhosis SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Beste, Lauren A.] VA Puget Sound Hlth Care Syst, Primary Care, Seattle, WA USA. [Harp, Bonnie K.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Blais, Rebecca K.] VA Puget Sound Hlth Care Syst, Mental Hlth, Seattle, WA USA. [Beste, Lauren A.] Univ Washington, Seattle, WA 98195 USA. [Zickmund, Susan] VA Pittsburgh Hlth Care Syst, Hlth Serv Res & Dev, Pittsburgh, PA USA. [Zickmund, Susan] Univ Pittsburgh, Dept Med & Clin & Translat Sci, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 2061 BP 1204A EP 1205A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252206013 ER PT J AU Fox, RK Marcus, S Merchante, N Kikuchi, L Minguez, B Vispo, E Harris, M Badshah, MB Jain, MK Page, EE Kaplan, DE Nelson, M Barrero, P Pineda, JA Brau, N AF Fox, Rena K. Marcus, Sonja Merchante, Nicolas Kikuchi, Luciana Minguez, Beatriz Vispo, Eugenia Harris, Marianne Badshah, Maaz B. Jain, Mamta K. Page, Emma E. Kaplan, David E. Nelson, Mark Barrero, Pablo Pineda, Juan A. Brau, Norbert TI Impact of Screening on Staging and Survival of Hepatocellular Carcinoma (HCC) in HIV/HCV-Coinfected Patients SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Fox, Rena K.] Univ Calif San Francicso, San Francisco, CA USA. [Marcus, Sonja; Badshah, Maaz B.; Brau, Norbert] Bronx VA Med Ctr, Bronx, NY USA. [Merchante, Nicolas; Pineda, Juan A.] Hosp Univ Valme, Seville, Spain. [Kikuchi, Luciana] Univ Sao Paulo, Sao Paulo, Brazil. [Minguez, Beatriz] Hosp Univ Vall dHebron, Barcelona, Spain. [Vispo, Eugenia; Barrero, Pablo] Hosp Carlos III, Madrid, Spain. [Harris, Marianne] St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada. [Harris, Marianne] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Jain, Mamta K.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Page, Emma E.; Nelson, Mark] Chelsea & Westminster Hosp, London, England. [Page, Emma E.; Nelson, Mark] Univ London Imperial Coll Sci Technol & Med, London, England. [Kaplan, David E.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Kaplan, David E.] Univ Penn, Philadelphia, PA 19104 USA. [Brau, Norbert] Mt Sinai Sch Med, New York, NY USA. RI Minguez, Beatriz/N-4456-2014 OI Minguez, Beatriz/0000-0002-7276-9666 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 2125 BP 1236A EP 1236A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252206077 ER PT J AU Marks, KM Page, EE Merchante, N Kikuchi, LO Minguez, B Vispo, E Harris, M Badshah, MB Jain, MK Marcus, S Kaplan, DE Nelson, M Barrero, P Pineda, JA Brau, N AF Marks, Kristen M. Page, Emma E. Merchante, Nicolas Kikuchi, Luciana O. Minguez, Beatriz Vispo, Eugenia Harris, Marianne Badshah, Maaz B. Jain, Mamta K. Marcus, Sonja Kaplan, David E. Nelson, Mark Barrero, Pablo Pineda, Juan A. Brau, Norbert TI Trends of Hepatocellular Carcinoma (HCC) in HIV-Infected Patients over Time, 1995-2013 SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Marks, Kristen M.] Weill Cornell Coll Med, New York, NY USA. [Badshah, Maaz B.; Marcus, Sonja; Brau, Norbert] Bronx VA Med Ctr, Bronx, NY USA. [Merchante, Nicolas; Pineda, Juan A.] Hosp Univ Valme, Seville, Spain. [Harris, Marianne] St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada. [Harris, Marianne] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Kikuchi, Luciana O.] Univ Sao Paulo, Sao Paulo, Brazil. [Minguez, Beatriz] Hosp Univ Vall dHebron, Barcelona, Spain. [Vispo, Eugenia; Barrero, Pablo] Hosp Carlos III, Madrid, Spain. [Jain, Mamta K.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Nelson, Mark] Chelsea & Westminster Hosp, London, England. [Nelson, Mark] Univ London Imperial Coll Sci Technol & Med, London, England. [Kaplan, David E.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Kaplan, David E.] Univ Penn, Philadelphia, PA 19104 USA. [Brau, Norbert] Mt Sinai Sch Med, New York, NY USA. RI Minguez, Beatriz/N-4456-2014 OI Minguez, Beatriz/0000-0002-7276-9666 NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 2151 BP 1249A EP 1249A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252206103 ER PT J AU Ioannou, GN Bryson, C Weiss, NS Boyko, EJ AF Ioannou, George N. Bryson, Christopher Weiss, Noel S. Boyko, Edward J. TI Antiretroviral medications, lipodystrophy and cirrhosis in HIV-infected patients SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Ioannou, George N.; Bryson, Christopher; Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Ioannou, George N.; Bryson, Christopher; Weiss, Noel S.; Boyko, Edward J.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 2216 BP 1279A EP 1280A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252206168 ER PT J AU Yu, L Morishima, C Ioannou, GN AF Yu, Lei Morishima, Chihiro Ioannou, George N. TI Dietary cholesterol intake is associated with death and liver transplantation in chronic hepatitis C virus infection: Analysis of extended follow-up data from the HALT-C trial SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Yu, Lei; Morishima, Chihiro; Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA. [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 2219 BP 1281A EP 1281A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252206171 ER PT J AU Dieperink, E Fuller, B Ho, SB Thuras, P McMaken, K Shira, K Lenox, R Wasil, MM Isenhart, C Morgan, TR Hauser, P AF Dieperink, Eric Fuller, Bret Ho, Samuel B. Thuras, Paul McMaken, Kelly Shira, Kern Lenox, Rebecca Wasil, Michelene M. Isenhart, Carl Morgan, Timothy R. Hauser, Peter TI Association of self-reported change in alcohol use behavior with changes in percent carbohydrate deficient transferring (%CDT), ethyl glucuronide (EtG) and ethyl sulfate (EtS) levels in Veterans with Hepatitis C SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Ho, Samuel B.; Wasil, Michelene M.] VA San Diego Healthcare Syst, San Diego, CA USA. [Fuller, Bret; Lenox, Rebecca] Portland VA Med Ctr, Portland, OR USA. [Dieperink, Eric; Thuras, Paul; McMaken, Kelly; Isenhart, Carl] Minneapolis VA Med Ctr, Minneapolis, MN USA. [Shira, Kern; Morgan, Timothy R.; Hauser, Peter] Long Beach VA Med Ctr, Long Beach, CA USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 2229 BP 1286A EP 1286A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252206181 ER PT J AU Chapman, LW Hsiao, JL Sarantopoulos, P Chiu, MW AF Chapman, Lance W. Hsiao, Jennifer L. Sarantopoulos, Peter Chiu, Melvin W. TI Reddish-Brown Nodules and Papules in an Elderly Man Progressive nodular histiocytosis SO JAMA DERMATOLOGY LA English DT Editorial Material C1 [Chapman, Lance W.; Hsiao, Jennifer L.; Chiu, Melvin W.] Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Los Angeles, CA 90095 USA. [Sarantopoulos, Peter] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Chiu, Melvin W.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Dermatol, Los Angeles, CA USA. RP Chiu, MW (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, 200 UCLA Med Plaza,Ste 450, Los Angeles, CA 90095 USA. EM mchiu@mednet.ucla.edu NR 9 TC 0 Z9 2 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6068 EI 2168-6084 J9 JAMA DERMATOL JI JAMA Dermatol. PD OCT PY 2013 VL 149 IS 10 BP 1229 EP 1230 DI 10.1001/jamadermatol.2013.4040 PG 2 WC Dermatology SC Dermatology GA AA3DT UT WOS:000330973800025 PM 23945611 ER PT J AU Alishahi, Y Kundrotas, L AF Alishahi, Yasmin Kundrotas, Leon TI A Retrospective Review of the Clinical Impact of Hydrogen Breath Testing for Small Bowel Bacterial Overgrowth in South Texas Veterans Health Care System SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 78th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 11-16, 2013 CL San Diego, CA SP Amer Coll Gastroenterol C1 [Alishahi, Yasmin] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Kundrotas, Leon] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2013 VL 108 SU 1 MA 1643 BP S493 EP S493 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 296II UT WOS:000330178101795 ER PT J AU Anderson, J Goel, G Cohen, H Leung, F AF Anderson, Joshua Goel, Gati Cohen, Hartley Leung, Felix TI Water Infusion Distension during Colonoscopy Is a Safe Alternative Technique to Facilitate Polypectomy in a "Difficult Location" SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 78th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 11-16, 2013 CL San Diego, CA SP Amer Coll Gastroenterol C1 [Anderson, Joshua; Goel, Gati; Cohen, Hartley; Leung, Felix] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2013 VL 108 SU 1 MA 1484 BP S440 EP S440 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 296II UT WOS:000330178101636 ER PT J AU Basu, P Shah, N Siriki, R Rahaman, M Farhat, S AF Basu, Patrick Shah, Niraj Siriki, Ravi Rahaman, Md Farhat, S. TI Romiplostim's Effect to Optimize SVR with Telaprevir, Ribavirin, and PEG Interferon-alfa 2a in Thrombocytopenic Cirrhotics with Chronic Hepatitis C: A Placebo-controlled Prospective Clinical Trial: RESTRAINT C Trial SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 78th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 11-16, 2013 CL San Diego, CA SP Amer Coll Gastroenterol C1 [Basu, Patrick; Farhat, S.] Columbia Sch Physicians & Surg, New York, NY USA. [Siriki, Ravi; Rahaman, Md] NSLIJHS Hofstra N Shore LIJ Sch Med, New York, NY USA. [Shah, Niraj] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2013 VL 108 SU 1 MA 506 BP S150 EP S150 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 296II UT WOS:000330178100506 ER PT J AU Basu, P Shah, N Siriki, R Rahaman, M Farhat, S AF Basu, Patrick Shah, Niraj Siriki, Ravi Rahaman, Md Farhat, S. TI Telaprevir with Adjusted Dose of Ribavirin in Naive CHC-G1: Efficacy and Treatment in CHC in Hemodialysis Population TARGET C Trial: A Placebo Randomized Control Clinical Trial SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 78th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 11-16, 2013 CL San Diego, CA SP Amer Coll Gastroenterol C1 [Basu, Patrick; Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA. [Siriki, Ravi; Rahaman, Md] NSLIJHS Hofstra N Shore LIJ Sch Med, New York, NY USA. [Shah, Niraj] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2013 VL 108 SU 1 MA 513 BP S152 EP S152 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 296II UT WOS:000330178100513 ER PT J AU Basu, P Shah, N Siriki, R Rahaman, M Farhat, S AF Basu, Patrick Shah, Niraj Siriki, Ravi Rahaman, Md Farhat, S. TI Curcumin, Antioxidant, and Pioglitazone Therapy with Inclusion of Vitamin E In Non-Alcoholic Fatty Liver Disease: A Randomized, Open-label, Placebo-controlled Clinical Prospective Trial (CAPTIVE) SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 78th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 11-16, 2013 CL San Diego, CA SP Amer Coll Gastroenterol C1 [Basu, Patrick; Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA. [Siriki, Ravi; Rahaman, Md] NSLIJHS Hofstra North Shore LIJ Sch Med, New York, NY USA. [Shah, Niraj] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2013 VL 108 SU 1 MA 505 BP S149 EP S150 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 296II UT WOS:000330178100505 ER PT J AU Basu, P Shah, N Rahaman, M Siriki, R Farhat, S AF Basu, Patrick Shah, Niraj Rahaman, Md Siriki, Ravi Farhat, S. TI Prevalence of Small Bowel Bacterial Overgrowth (SIBO) in Decompensated Cirrhosis with Portal Hypertension: A Clinical Pilot Study SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 78th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 11-16, 2013 CL San Diego, CA SP Amer Coll Gastroenterol C1 [Basu, Patrick; Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA. [Rahaman, Md; Siriki, Ravi] NSLIJHS Hofstra North Shore LIJ Sch Med, New York, NY USA. [Shah, Niraj] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2013 VL 108 SU 1 MA 486 BP S144 EP S145 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 296II UT WOS:000330178100486 ER PT J AU Basu, P Shah, N Farhat, S Siriki, R Rahaman, M AF Basu, Patrick Shah, Niraj Farhat, S. Siriki, Ravi Rahaman, Md TI Restless Leg Syndrome (RLS) is Associated with Hepatic Encephalopathy (HE) in Decompensated Cirrhosis: A Clinical Pilot Study SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 78th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 11-16, 2013 CL San Diego, CA SP Amer Coll Gastroenterol C1 [Basu, Patrick; Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA. [Siriki, Ravi; Rahaman, Md] NSLIJHS Hofstra North Shore LIJ Sch Med, New York, NY USA. [Shah, Niraj] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2013 VL 108 SU 1 MA 485 BP S144 EP S144 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 296II UT WOS:000330178100485 ER PT J AU Basu, P Shah, N Siriki, R Rahaman, M Farhat, S AF Basu, Patrick Shah, Niraj Siriki, Ravi Rahaman, Md Farhat, S. TI Effect of N Acetylcysteine (NAC) in Hypoxia-Induced Liver Injury (HILI): A Randomized Placebo Control Clinical Trial SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 78th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 11-16, 2013 CL San Diego, CA SP Amer Coll Gastroenterol C1 [Basu, Patrick; Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA. [Siriki, Ravi; Rahaman, Md] NSLIJHS Hofstra North Shore LIJ Sch Med, New York, NY USA. [Shah, Niraj] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2013 VL 108 SU 1 MA 484 BP S144 EP S144 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 296II UT WOS:000330178100484 ER PT J AU Basu, P Shah, N Rahaman, MD Siriki, R Farhat, S AF Basu, Patrick Shah, Niraj Rahaman, M. D. Siriki, Ravi Farhat, S. TI Rifabutin, Omeprazole, Alinia, and Doxycycline Therapy for Prior Treatment Failure Helicobacter pylori Population: A Randomized, Open-Label Clinical Pilot Study ROAD Trial SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 78th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 11-16, 2013 CL San Diego, CA SP Amer Coll Gastroenterol C1 [Basu, Patrick; Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA. [Rahaman, M. D.; Siriki, Ravi] NSLIJHS Hofstra North Shore LIJ Sch Med, New York, NY USA. [Shah, Niraj] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2013 VL 108 SU 1 MA 157 BP S49 EP S49 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 296II UT WOS:000330178100158 ER PT J AU Basu, P Shah, N Siriki, R Rahaman, MD Farhat, S AF Basu, Patrick Shah, Niraj Siriki, Ravi Rahaman, M. D. Farhat, S. TI Latent Eosinophilic Esophagitis (LEOE) Is a Unraveled Novel Clinical Entity: A Randomized, Open Clinical Pilot Study SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 78th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 11-16, 2013 CL San Diego, CA SP Amer Coll Gastroenterol C1 [Basu, Patrick; Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA. [Siriki, Ravi; Rahaman, M. D.] NSLIJHS Hofstra North Shore LIJ Sch Med, New York, NY USA. [Shah, Niraj] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2013 VL 108 SU 1 MA 68 BP S23 EP S24 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 296II UT WOS:000330178100069 ER PT J AU Hotte, C Vela, M AF Hotte, Charles Vela, Marcelo TI Body Mass Index (BMI) and Percent Fat Are Not Associated with Increased Reflux in a Veteran Hospital Review SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 78th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 11-16, 2013 CL San Diego, CA SP Amer Coll Gastroenterol C1 [Hotte, Charles] Baylor Coll Med, Houston, TX 77030 USA. [Vela, Marcelo] Michael E Debakey Vet Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2013 VL 108 SU 1 MA 38 BP S14 EP S14 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 296II UT WOS:000330178100039 ER PT J AU Kaung, A Chak, E Cohen, H Ohning, G Leung, F AF Kaung, Aung Chak, Eric Cohen, Hartley Ohning, Gordon Leung, Felix TI Water Exchange Colonoscopy without Air Insufflation May Facilitate Terminal Ileum Intubation SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 78th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 11-16, 2013 CL San Diego, CA SP Amer Coll Gastroenterol C1 [Kaung, Aung; Cohen, Hartley; Ohning, Gordon; Leung, Felix] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. [Chak, Eric] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2013 VL 108 SU 1 MA 1483 BP S439 EP S440 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 296II UT WOS:000330178101635 ER PT J AU Kovacs, T Jensen, D Ohning, G Ghassemi, K Dulai, G Machicado, G Jutabha, R AF Kovacs, Thomas Jensen, Dennis Ohning, Gordon Ghassemi, Kevin Dulai, Gareth Machicado, Gustavo Jutabha, Rome TI A Prospective Study of Patients with Bleeding Mallory Weiss Tears: Does Portal Hypertension Matter? SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 78th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 11-16, 2013 CL San Diego, CA SP Amer Coll Gastroenterol C1 [Ghassemi, Kevin; Jutabha, Rome] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Dulai, Gareth] CURE DDRC GI Hemostasis Res Unit, Los Angeles, CA USA. [Ohning, Gordon] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Kovacs, Thomas; Jensen, Dennis; Machicado, Gustavo] Univ Calif Los Angeles, Div Digest Dis, Los Angeles, CA USA. [Kovacs, Thomas; Jensen, Dennis; Machicado, Gustavo] VA WLA Med Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2013 VL 108 SU 1 MA 2029 BP S615 EP S615 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 296II UT WOS:000330178102357 ER PT J AU McPhaul, C Sonnenberg, A Genta, R AF McPhaul, Christopher Sonnenberg, Amnon Genta, Robert TI Low Prevalence of Colon Polyps in Patients with Diarrhea and Microscopic Colitis SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 78th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 11-16, 2013 CL San Diego, CA SP Amer Coll Gastroenterol C1 [Genta, Robert] Miraca Life Sci Res Inst, GI Pathol, Irving, TX USA. [McPhaul, Christopher] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA. [Sonnenberg, Amnon] OHSU, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2013 VL 108 SU 1 MA 558 BP S164 EP S164 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 296II UT WOS:000330178100558 ER PT J AU Nguyen, K Jacobs, J Cao, WW Chak, E Cohen, H Leung, F AF Nguyen, Ken Jacobs, Jonathan Cao, Weiwei Chak, Eric Cohen, Hartley Leung, Felix TI Water Exchange Colonoscopy for Evaluation of Severe Ulcerative Colitis: A Case Series SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 78th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 11-16, 2013 CL San Diego, CA SP Amer Coll Gastroenterol C1 [Cohen, Hartley; Leung, Felix] VA Greater Los Angeles Healthcare Syst, Div Gastroenterol, Los Angeles, CA USA. [Nguyen, Ken] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA. [Jacobs, Jonathan; Cao, Weiwei; Chak, Eric] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2013 VL 108 SU 1 MA 1405 BP S416 EP S417 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 296II UT WOS:000330178101557 ER PT J AU Raza, MQ Trang, T Qureshi, W AF Raza, Mohammad Qasim Trang, Tony Qureshi, Waqar TI Colo-colonic Intussusception Presenting as Intermittent Testicular Pain SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 78th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 11-16, 2013 CL San Diego, CA SP Amer Coll Gastroenterol C1 [Raza, Mohammad Qasim; Qureshi, Waqar] Baylor Coll Med, Houston, TX 77030 USA. [Trang, Tony] VA Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2013 VL 108 SU 1 MA 1324 BP S394 EP S394 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 296II UT WOS:000330178101476 ER PT J AU Sonnenberg, A Byrd-Clark, D AF Sonnenberg, Amnon Byrd-Clark, Danita TI US Hospitalizations for Colorectal Cancer: 1970-2010 SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 78th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 11-16, 2013 CL San Diego, CA SP Amer Coll Gastroenterol C1 [Sonnenberg, Amnon] Portland VA Med Ctr, GI P3, Portland, OR USA. [Byrd-Clark, Danita] Social & Sci Syst, Silver Spring, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2013 VL 108 SU 1 MA 557 BP S164 EP S164 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 296II UT WOS:000330178100557 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Time Trends of US Hospitalization for Esophageal Disease SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 78th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 11-16, 2013 CL San Diego, CA SP Amer Coll Gastroenterol C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2013 VL 108 SU 1 MA 13 BP S5 EP S5 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 296II UT WOS:000330178100014 ER PT J AU Taydas, E Malik, M Russell, S Latt, N Gurakar, A AF Taydas, Eren Malik, Mohammad Russell, Stuart Latt, Nyan Gurakar, Ahmet TI The Role of Coronary Artery Calcium Score and Age in Early Identification of Occult Coronary Artery Disease among Patients Undergoing Liver Transplant Work-up for End-stage Liver Disease SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 78th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 11-16, 2013 CL San Diego, CA SP Amer Coll Gastroenterol C1 [Taydas, Eren] MedStar Franklin Sq Med Ctr, Baltimore, MD USA. [Malik, Mohammad; Russell, Stuart; Gurakar, Ahmet] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. [Latt, Nyan] W Los Angeles Vet Affairs Med Ctr, Dept Gastroenterol & Hepatol, Los Angeles, CA 90073 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2013 VL 108 SU 1 MA 500 BP S148 EP S148 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 296II UT WOS:000330178100500 ER PT J AU Maust, DT Oslin, DW Thase, ME AF Maust, Donovan T. Oslin, David W. Thase, Michael E. TI Going Beyond Antidepressant Monotherapy for Incomplete Response in Nonpsychotic Late-Life Depression: A Critical Review SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Review DE Antidepressant; augmentation; depression; pharmacotherapy ID TREATMENT-RESISTANT DEPRESSION; RECURRENT MAJOR DEPRESSION; LITHIUM AUGMENTATION; GERIATRIC DEPRESSION; PRIMARY-CARE; REFRACTORY DEPRESSION; UNIPOLAR DEPRESSION; ELDERLY-PATIENTS; CONTROLLED-TRIAL; OLDER PATIENTS AB Many older adults with major depressive disorder (MDD) do not respond to antidepressant monotherapy. Although there are evidence-based treatment options to support treatment beyond monotherapy for adults, the evidence for such strategies, specifically in late-life MDD, is relatively scarce. This review examines the published data describing strategies for antidepressant augmentation or acceleration studied specifically in older adults, including lithium, stimulants, and second-generation antipsychotics. In addition, the authors suggest strategies for future research, such as study of specific agents, refining understanding of the impact of medical or cognitive comorbidity in late-life depression, and comparative effectiveness to examine methods already used in clinical practice. C1 [Maust, Donovan T.; Oslin, David W.; Thase, Michael E.] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Oslin, David W.; Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Oslin, David W.; Thase, Michael E.] VISN 4 Mental Illness Res Educ & Clin Ctr MIREC, Philadelphia, PA USA. [Thase, Michael E.] Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA USA. RP Maust, DT (reprint author), Univ Penn, Sect Geriatr Psychiat, 3615 Chestnut St, Philadelphia, PA 19104 USA. EM Donovan.Maust@uphs.upenn.edu FU NIMH [R25-MH060490] FX Dr. Maust is supported through the NIMH-funded Clinical Research Scholars Program (R25-MH060490) of the Department of Psychiatry, University of Pennsylvania, Perelman School of Medicine. NR 58 TC 10 Z9 10 U1 3 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD OCT PY 2013 VL 21 IS 10 BP 973 EP 986 DI 10.1016/j.jagp.2013.01.030 PG 14 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 298YZ UT WOS:000330362300007 PM 23567381 ER PT J AU Sakurai, D Zhao, J Deng, Y Kelly, JA Brown, EE Harley, JB Bae, SC Alarcon-Riqueime, ME Edberg, JC Kimberly, RP Ramsey-Goldman, R Petri, MA Reveille, JD Vila, LM Alarcon, GS Kaufman, KM Vyse, TJ Jacob, CO Gaffney, PM Sivils, KM James, JA Kamen, DL Gilkeson, GS Niewold, TB Merrill, JT Scofield, RH Criswell, LA Stevens, AM Boackle, SA Kim, JH Choi, J Pons-Estel, BA Freedman, BI Anaya, JM Martin, J Yu, CY Chang, DM Song, YW Langefeld, CD Chen, WL Grossman, JM Cantor, RM Hahn, BH Tsao, BP AF Sakurai, Daisuke Zhao, Jian Deng, Yun Kelly, Jennifer A. Brown, Elizabeth E. Harley, John B. Bae, Sang-Cheol Alarcon-Riqueime, Marta E. Edberg, Jeffrey C. Kimberly, Robert P. Ramsey-Goldman, Rosalind Petri, Michelle A. Reveille, John D. Vila, Luis M. Alarcon, Graciela S. Kaufman, Kenneth M. Vyse, Timothy J. Jacob, Chaim O. Gaffney, Patrick M. Sivils, Kathy Moser James, Judith A. Kamen, Diane L. Gilkeson, Gary S. Niewold, Timothy B. Merrill, Joan T. Scofield, R. Hal Criswell, Lindsey A. Stevens, Anne M. Boackle, Susan A. Kim, Jae-Hoon Choi, Jiyoung Pons-Estel, Bernardo A. Freedman, Barry I. Anaya, Juan-Manuel Martin, Javier Yu, C. Yung Chang, Deh-Ming Song, Yeong Wook Langefeld, Carl D. Chen, Weiling Grossman, Jennifer M. Cantor, Rita M. Hahn, Bevra H. Tsao, Betty P. CA BIOLUPUS & GENLES networks Argentine Collaborative Grp TI Preferential Binding to Elk-1 by SLE-Associated IL10 Risk Allele Upregulates IL10 Expression SO PLOS GENETICS LA English DT Article ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; GENOME-WIDE ASSOCIATION; INFLAMMATORY-BOWEL-DISEASE; HUMAN B-LYMPHOCYTES; CELL-DERIVED IL-10; RHEUMATOID-ARTHRITIS; SUSCEPTIBILITY LOCI; AUTOIMMUNE-DISEASE; INTERLEUKIN-10 PRODUCTION; 1ST-DEGREE RELATIVES AB Immunoregulatory cytokine interleukin-10 (IL-10) is elevated in sera from patients with systemic lupus erythematosus (SLE) correlating with disease activity. The established association of IL10 with SLE and other autoimmune diseases led us to fine map causal variant(s) and to explore underlying mechanisms. We assessed 19 tag SNPs, covering the IL10 gene cluster including IL19, IL20 and IL24, for association with SLE in 15,533 case and control subjects from four ancestries. The previously reported IL10 variant, rs3024505 located at 1 kb downstream of IL10, exhibited the strongest association signal and was confirmed for association with SLE in European American (EA) (P = 2.7x10(-8), OR = 1.30), but not in non-EA ancestries. SNP imputation conducted in EA dataset identified three additional SLE-associated SNPs tagged by rs3024505 (rs3122605, rs3024493 and rs3024495 located at 9.2 kb upstream, intron 3 and 4 of IL10, respectively), and SLE-risk alleles of these SNPs were dose-dependently associated with elevated levels of IL10 mRNA in PBMCs and circulating IL-10 protein in SLE patients and controls. Using nuclear extracts of peripheral blood cells from SLE patients for electrophoretic mobility shift assays, we identified specific binding of transcription factor Elk-1 to oligodeoxynucleotides containing the risk (G) allele of rs3122605, suggesting rs3122605 as the most likely causal variant regulating IL10 expression. Elk-1 is known to be activated by phosphorylation and nuclear localization to induce transcription. Of interest, phosphorylated Elk-1 (p-Elk-1) detected only in nuclear extracts of SLE PBMCs appeared to increase with disease activity. Co-expression levels of p-Elk-1 and IL-10 were elevated in SLE T, B cells and monocytes, associated with increased disease activity in SLE B cells, and were best downregulated by ERK inhibitor. Taken together, our data suggest that preferential binding of activated Elk-1 to the IL10 rs3122605-G allele upregulates IL10 expression and confers increased risk for SLE in European Americans. C1 [Sakurai, Daisuke; Zhao, Jian; Deng, Yun; Chen, Weiling; Grossman, Jennifer M.; Hahn, Bevra H.; Tsao, Betty P.] Univ Calif Los Angeles, David Geffen Sch Med, Div Rheumatol, Los Angeles, CA 90095 USA. [Kelly, Jennifer A.; Alarcon-Riqueime, Marta E.; Gaffney, Patrick M.; Sivils, Kathy Moser; James, Judith A.; Scofield, R. Hal] Oklahoma Med Res Fdn, Arthritis & Clin Immunol Program, Oklahoma City, OK 73104 USA. [Brown, Elizabeth E.; Edberg, Jeffrey C.; Kimberly, Robert P.; Alarcon, Graciela S.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Brown, Elizabeth E.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA. [Harley, John B.; Kaufman, Kenneth M.] Cincinnati Childrens Hosp Med Ctr, Div Rheumatol, Cincinnati, OH 45229 USA. [Harley, John B.; Kaufman, Kenneth M.] Cincinnati Childrens Hosp Med Ctr, Ctr Autoimmune Genom & Etiol, Cincinnati, OH 45229 USA. [Harley, John B.; Kaufman, Kenneth M.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. [Bae, Sang-Cheol; Kim, Jae-Hoon; Choi, Jiyoung] Hanyang Univ, Hosp Rheumat Dis, Dept Rheumatol, Seoul 133791, South Korea. [Alarcon-Riqueime, Marta E.] Univ Granada Junta Andalucia, Pfizer, GENYO, Ctr Genom & Invest Oncol, Granada, Spain. [Ramsey-Goldman, Rosalind] Northwestern Univ, Feinberg Sch Med, Div Rheumatol, Chicago, IL 60611 USA. [Petri, Michelle A.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Reveille, John D.] Univ Texas Houston, Hlth Sci Ctr, Dept Internal Med, Houston, TX 77225 USA. [Vila, Luis M.] Univ Puerto Rico, Dept Med, San Juan, PR 00936 USA. [Vyse, Timothy J.] Kings Coll London, Div Genet, London WC2R 2LS, England. [Vyse, Timothy J.] Kings Coll London, Div Mol Med, London WC2R 2LS, England. [Vyse, Timothy J.] Kings Coll London, Div Immunol, London WC2R 2LS, England. [Jacob, Chaim O.] Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90033 USA. [James, Judith A.; Scofield, R. Hal] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. [Kamen, Diane L.; Gilkeson, Gary S.] Med Univ S Carolina, Dept Med, Div Rheumatol, Charleston, SC 29425 USA. [Niewold, Timothy B.] Mayo Clin, Div Rheumatol, Rochester, MN USA. [Niewold, Timothy B.] Mayo Clin, Dept Immunol, Rochester, MN USA. [Merrill, Joan T.] Oklahoma Med Res Fdn, Clin Pharmacol Program, Oklahoma City, OK 73104 USA. [Scofield, R. Hal] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. [Criswell, Lindsey A.] Univ Calif San Francisco, Rosalind Russell Med Res Ctr Arthritis, Dept Med, San Francisco, CA 94143 USA. [Stevens, Anne M.] Univ Washington, Dept Pediat, Div Rheumatol, Seattle, WA 98195 USA. [Stevens, Anne M.] Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, Seattle, WA USA. [Boackle, Susan A.] Univ Colorado, Sch Med, Div Rheumatol, Aurora, CO USA. [Pons-Estel, Bernardo A.] Sanatorio Parque, Dept Med, Rosario, Argentina. [Freedman, Barry I.] Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC USA. [Anaya, Juan-Manuel] Univ Rosario, Ctr Autoimmune Dis Res, Bogota, Colombia. [Martin, Javier] CSIC, Inst Parasitol & Biomed Lopez Neyra, Granada, Spain. [Yu, C. Yung] Nationwide Childrens Hosp, Ctr Mol & Human Genet, Res Inst, Columbus, OH USA. [Yu, C. Yung] Ohio State Univ, Columbus, OH 43210 USA. [Chang, Deh-Ming] Natl Def Med Ctr, Taipei, Taiwan. [Song, Yeong Wook] Seoul Natl Univ, Div Rheumatol, Seoul, South Korea. [Langefeld, Carl D.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA. [Cantor, Rita M.] Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA USA. RP Sakurai, D (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Rheumatol, Los Angeles, CA 90095 USA. EM btsao@mednet.ucla.edu RI ; Martin, Javier/B-8141-2008; Yu, Chack-Yung/E-4360-2011; Anaya, Juan-Manuel/J-1960-2016 OI Kimberly, Robert/0000-0002-5330-3086; Niewold, Timothy/0000-0003-3532-6660; Anaya, Juan-Manuel/0000-0002-6444-1249; Catoggio, Luis Jose/0000-0002-4047-4863; Universidad del Rosario, Biblioteca/0000-0003-3491-9392; Silva, Berta/0000-0001-6579-5068 FU US National Institutes of Health [R01AR043814, P30AR48311, R01CA141700, RC1AR058621, P01AI083194, P01AR049084, R01AR33062, K24AR002138, P602AR30692, UL1RR025741, R01AR43727, P01AR052915, U01AI090909]; Lupus Research Institute; Alliance for Lupus Research grants; U.S. Department of Defense [PR094002]; US Department of Veterans Affairs; Arthritis National Research Foundation; Charles Barkley Research Award; Ministry for Health and Welfare, Republic of Korea [A120404]; Swedish Research Council of Medicine; Arthritis Research UK; Arthritis Foundation; National Center for Advancing Translational Sciences (NCATS) [UL1RR025014-02, UL1TR000165, UL1RR025005]; National Center for Research Resources (NCRR) component of the National Institutes of Health (NIH); Kirkland Scholar Award; Federico Wilhelm Agricola Foundation; Wake Forest University Health Sciences Center for Public Health Genomics; MKE/KEIT [10035615]; UCLA Clinical and Translational Science Institute (CTSI) [UL1RR033176, UL1TR000124]; US NIH [R01AR057172, R01AI063274, RC2AR058959, R01AR043274, P30AR053483, P30GM103510, U19AI082714, U01AI101934, P60AR049459, UL1RR029882, K08AI083790, L30AI071651, UL1RR024999, P60AR053308, UL1TR000004, R01AR051545-01A2, R21AI070304, 1R01AR054459] FX Support for this work was provided by the US National Institutes of Health grants: R01AR043814 (BPT), P30AR48311 (EEB), R01CA141700 and RC1AR058621 (MEAR), P01AI083194 (JBH KMS RPK LAC TJV MEAR COJ BPT PMG), P01AR049084 (RPK JBH EEB JCE RRG LMV MAP), R01AR33062 (RPK), K24AR002138, P602AR30692 and UL1RR025741 (RRG), R01AR43727 (MAP), P01AR052915 and U01AI090909 (JDR), R01AR057172 (COJ), R01AI063274 and RC2AR058959 (PMG), R01AR043274 (KMS), P30AR053483, P30GM103510, U19AI082714 and U01AI101934 (JAJ), P60AR049459 and UL1RR029882 (GSG DLK), K08AI083790, L30AI071651 and UL1RR024999 (TBN), P60AR053308 and UL1TR000004 (LAC), R01AR051545-01A2 (AMS), R21AI070304 (SAB), and 1R01AR054459 (CYY). Additional support was provided by the Lupus Research Institute grant (BPT); the Alliance for Lupus Research grants (BPT YD KMS TBN LAC COJ); the U.S. Department of Defense PR094002 and the US Department of Veterans Affairs Merit Award (JBH); the Arthritis National Research Foundation Eng Tan Scholar Award (TBN JZ); Charles Barkley Research Award (EEB); the Korea Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea (A120404; SCB); funding from the Swedish Research Council of Medicine (MEAR); the Arthritis Research UK (TJV); the Arthritis Foundation (AMS PMG); Clinical and Translational Science Grant Number UL1RR025014-02 (AMS), UL1TR000165 (JCE) and UL1RR025005 (MAP) from the National Center for Advancing Translational Sciences (NCATS) and National Center for Research Resources (NCRR) component of the National Institutes of Health (NIH); Kirkland Scholar Award (LAC); the Federico Wilhelm Agricola Foundation Research grant (BAPE); Wake Forest University Health Sciences Center for Public Health Genomics (CDL); the Korean Research and Development Program of MKE/KEIT (10035615; YWS); and UCLA Clinical and Translational Science Institute (CTSI) grants: UL1RR033176 and UL1TR000124. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 89 TC 13 Z9 13 U1 322 U2 328 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7404 J9 PLOS GENET JI PLoS Genet. PD OCT PY 2013 VL 9 IS 10 AR e1003870 DI 10.1371/journal.pgen.1003870 PG 12 WC Genetics & Heredity SC Genetics & Heredity GA 299AR UT WOS:000330367200046 PM 24130510 ER PT J AU Hatano, H Yukl, SA Ferre, AL Graf, EH Somsouk, M Sinclair, E Abdel-Mohsen, M Liegler, T Harvill, K Hoh, R Palmer, S Bacchetti, P Hunt, PW Martin, JN McCune, JM Tracy, RP Busch, MP O'Doherty, U Shacklett, BL Wong, JK Deeks, SG AF Hatano, Hiroyu Yukl, Steven A. Ferre, April L. Graf, Erin H. Somsouk, Ma Sinclair, Elizabeth Abdel-Mohsen, Mohamed Liegler, Teri Harvill, Kara Hoh, Rebecca Palmer, Sarah Bacchetti, Peter Hunt, Peter W. Martin, Jeffrey N. McCune, Joseph M. Tracy, Russell P. Busch, Michael P. O'Doherty, Una Shacklett, Barbara L. Wong, Joseph K. Deeks, Steven G. TI Prospective Antiretroviral Treatment of Asymptomatic, HIV-1 Infected Controllers SO PLOS PATHOGENS LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL-ACTIVATION; POLYMERASE-CHAIN-REACTION; HIV-1 ELITE CONTROLLERS; BLOOD MONONUCLEAR-CELLS; LOW-LEVEL VIREMIA; RALTEGRAVIR INTENSIFICATION; IMMUNE ACTIVATION; RECTAL MUCOSA; TYPE-1 RNA AB The study of HIV-infected "controllers'' who are able to maintain low levels of plasma HIV RNA in the absence of antiretroviral therapy (ART) may provide insights for HIV cure and vaccine strategies. Despite maintaining very low levels of plasma viremia, controllers have elevated immune activation and accelerated atherosclerosis. However, the degree to which low-level replication contributes to these phenomena is not known. Sixteen asymptomatic controllers were prospectively treated with ART for 24 weeks. Controllers had a statistically significant decrease in ultrasensitive plasma and rectal HIV RNA levels with ART. Markers of T cell activation/dysfunction in blood and gut mucosa also decreased substantially with ART. Similar reductions were observed in the subset of "elite'' controllers with pre-ART plasma HIV RNA levels below conventional assays (<40 copies/mL). These data confirm that HIV replication persists in controllers and contributes to a chronic inflammatory state. ART should be considered for these individuals (ClinicalTrials.gov NCT01025427). C1 [Hatano, Hiroyu; Yukl, Steven A.; Somsouk, Ma; Sinclair, Elizabeth; Abdel-Mohsen, Mohamed; Liegler, Teri; Harvill, Kara; Hoh, Rebecca; Hunt, Peter W.; McCune, Joseph M.; Wong, Joseph K.; Deeks, Steven G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Yukl, Steven A.; Wong, Joseph K.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Ferre, April L.; Shacklett, Barbara L.] Univ Calif Davis, Sch Med, Dept Med Microbiol & Immunol, Davis, CA 95616 USA. [Graf, Erin H.; O'Doherty, Una] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA. [Palmer, Sarah] Karolinska Inst, Solna, Sweden. [Palmer, Sarah] Swedish Inst Infect Dis Control, Solna, Sweden. [Palmer, Sarah] Westmead Millennium Inst, Ctr Virus Res, Westmead, NSW, Australia. [Palmer, Sarah] Univ Sydney, Westmead, NSW 2145, Australia. [Bacchetti, Peter; Martin, Jeffrey N.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Tracy, Russell P.] Univ Vermont, Dept Pathol, Colchester, VT USA. [Tracy, Russell P.] Univ Vermont, Dept Biochem, Colchester, VT USA. [Busch, Michael P.] Blood Syst Res Inst, San Francisco, CA USA. [Busch, Michael P.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA. RP Hatano, H (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. EM hhatano@php.ucsf.edu RI Shacklett, Barbara/A-7288-2009 OI Shacklett, Barbara/0000-0002-7067-732X FU National Institute of Allergy and Infectious Diseases [R01 AI087145, K23 AI075985, K24 AI069994, R56 AI091573, R01 NS051132, R01 AI057020]; National Cancer Institute [K23 CA157929]; Delaney AIDS Research Enterprise (DARE) [U19 AI0961090]; California HIV/AIDS Research Program [ID08-SF-004]; American Foundation for AIDS Research [106710-40-RGRL, 107170-44-RGRL, 108073-50-RGRL]; UCSF/Gladstone Institute of Virology & Immunology CFAR [P30 AI027763]; UCSF Clinical and Translational Research Institute Clinical Research Center [UL1 RR024131]; Center for AIDS Prevention Studies [P30 MH62246]; CFAR Network of Integrated Systems [R24 AI067039]; U.S. Department of Veterans Affairs [1 IK2 CX000520-01, 5101BX001048] FX This work was supported by grants from the National Institute of Allergy and Infectious Diseases (R01 AI087145, K23 AI075985, K24 AI069994, R56 AI091573, R01 NS051132, R01 AI057020), the National Cancer Institute (K23 CA157929), the Delaney AIDS Research Enterprise (DARE; U19 AI0961090), California HIV/AIDS Research Program (ID08-SF-004), the American Foundation for AIDS Research (106710-40-RGRL, 107170-44-RGRL, and 108073-50-RGRL), the UCSF/Gladstone Institute of Virology & Immunology CFAR (P30 AI027763), the UCSF Clinical and Translational Research Institute Clinical Research Center (UL1 RR024131), the Center for AIDS Prevention Studies (P30 MH62246), the CFAR Network of Integrated Systems (R24 AI067039), and the U.S. Department of Veterans Affairs (1 IK2 CX000520-01, 5101BX001048). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 67 TC 35 Z9 35 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7374 J9 PLOS PATHOG JI PLoS Pathog. PD OCT PY 2013 VL 9 IS 10 AR e1003691 DI 10.1371/journal.ppat.1003691 PG 13 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA 299GJ UT WOS:000330383800060 PM 24130489 ER PT J AU Feldt, B Dion, GR Weitzel, EK McMains, KC AF Feldt, Brent Dion, Gregory R. Weitzel, Erik K. McMains, Kevin C. TI Acute Sinusitis SO SOUTHERN MEDICAL JOURNAL LA English DT Review DE acute sinusitis; bacterial sinusitis; nasal airway obstruction; purulent rhinorrhea; sinusitis ID ACUTE BACTERIAL RHINOSINUSITIS; ANTIMICROBIAL THERAPY; CONTROLLED TRIAL; DOUBLE-BLIND; ADULTS; METAANALYSIS; ANTIBIOTICS; AMOXICILLIN; DIAGNOSIS; RHINITIS AB Sinusitis is a common patient complaint that carries with it a large economic burden. It is one of the most common reasons patients visit their primary care physician. Acute bacterial rhinosinusitis (ABRS) can be distinguished from other forms of rhinosinusitis based on symptom duration of <4 weeks in a patient with purulent rhinorrhea associated with facial pain or pressure. Native upper aerodigestive tract bacteria are the most common etiologic agents. Treatment of ABRS is targeted primarily at symptom improvement. Amoxicillin can be used based on the clinical scenario and patient comorbidities. Computed tomographic scans are reserved for complicated presentations or when there is concern for intracranial extension or other complications. A systematic approach to ABRS will allow for improved patient quality of life and a decreased overall economic burden of this common entity. C1 Wilford Hall Ambulatory Surg Ctr, San Antonio, TX USA. Brooke Army Med Ctr, San Antonio Mil Med Ctr, Ft Sam Houston, TX 78234 USA. Audie L Murphy Mem Vet Adm Med Ctr, South Texas Vet Hlth Care, San Antonio, TX 78284 USA. RP Dion, GR (reprint author), ATTN MCHE SDT Oto, Dept Otolaryngol, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA. EM greg.r.dion@us.army.mil NR 32 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0038-4348 EI 1541-8243 J9 SOUTH MED J JI South.Med.J. PD OCT PY 2013 VL 106 IS 10 BP 577 EP 581 DI 10.1097/SMJ.0000000000000002 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 298UK UT WOS:000330349800007 PM 24096952 ER PT J AU Mrejen, S Sarraf, D Mukkamala, K Freund, KB AF Mrejen, Sarah Sarraf, David Mukkamala, Krishna Freund, K. Bailey TI MULTIMODAL IMAGING OF PIGMENT EPITHELIAL DETACHMENT A Guide to Evaluation SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES LA English DT Review DE retinal pigment epithelial detachment; age-related macular degeneration; drusenoid pigment epithelial detachment; serous pigment epithelial detachment; vascularized pigment epithelial detachment; retinal angiomatous proliferation; polypoidal choroidal vasculopathy; multimodal imaging; central serous chorioretinopathy ID CENTRAL SEROUS CHORIORETINOPATHY; OPTICAL COHERENCE TOMOGRAPHY; RETINAL ANGIOMATOUS PROLIFERATION; POLYPOIDAL CHOROIDAL VASCULOPATHY; INDOCYANINE-GREEN VIDEOANGIOGRAPHY; COMBINED INTRAVITREAL RANIBIZUMAB; SCANNING LASER OPHTHALMOSCOPE; GROWTH-FACTOR THERAPY; TERM-FOLLOW-UP; MACULAR DEGENERATION AB Purpose: To describe the spectrum of pigment epithelial detachments (PEDs) occurring mainly in age-related macular degeneration and central serous chorioretinopathy and also in other inflammatory, neoplastic and iatrogenic, retinal, and systemic disorders. Methods: Pigment epithelial detachments are divided into drusenoid, serous, vascularized, or mixed categories. Results: The clinical presentation, classification, and natural history of PEDs are reviewed as illustrated with multimodal imaging combining traditional and novel imaging techniques, including fluorescein angiography, indocyanine green angiography, fundus autofluorescence, and spectral domain optical coherence tomography. Most PEDs occur because of pathophysiologic mechanisms taking place below the retinal pigment epithelium that are difficult to identify with conventional imaging modalities. Enhanced depth imaging optical coherence tomography and indocyanine green angiography allow a better analysis of the subretinal pigment epithelium compartment. Conclusion: The differentiation between various kinds of PEDs is essential because each PED type is a distinct entity that has a specific pathogenesis, natural history, prognosis, and optimal treatment strategy. C1 [Mrejen, Sarah; Mukkamala, Krishna; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA. [Mrejen, Sarah; Mukkamala, Krishna; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA. [Sarraf, David] Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA 90024 USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. RP Freund, KB (reprint author), Vitreous Retina Macula Consultants New York, 460 Pk Ave,Fifth Floor, New York, NY 10022 USA. EM kbfnyf@aol.com FU Macula Foundation, Inc. FX Supported in part by the Macula Foundation, Inc. NR 151 TC 24 Z9 26 U1 0 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0275-004X EI 1539-2864 J9 RETINA-J RET VIT DIS JI Retin.-J. Retin. Vitr. Dis. PD OCT PY 2013 VL 33 IS 9 BP 1735 EP 1762 PG 28 WC Ophthalmology SC Ophthalmology GA 297DL UT WOS:000330235500002 PM 23873168 ER PT J AU Leonardis, RL Duvvuri, U Mehta, D AF Leonardis, Rachel L. Duvvuri, Umamaheswar Mehta, Deepak TI Transoral Robotic-Assisted Lingual Tonsillectomy in the Pediatric Population SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article ID OBSTRUCTIVE SLEEP-APNEA; SURGERY; HEAD; NECK; OTOLARYNGOLOGY; SAFETY AB IMPORTANCE Since technologic advances allow the use of robotic assistance in various surgical interventions performed to treat pediatric otolaryngology patients, the feasibility and outcomes of potential procedures must be assessed. OBJECTIVE To assess the feasibility and outcomes of robotic-assisted lingual tonsillectomy in the pediatric population. DESIGN, SETTING, AND PARTICIPANTS Retrospective medical record review in a tertiary care children's hospital of 16 pediatric patients who underwent robotic-assisted lingual tonsillectomy from March 1, 2011, through December 31, 2012. INTERVENTION All patients underwent robotic-assisted lingual tonsillectomy using the da Vinci Surgical System (Intuitive Surgical, Inc) at the Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center. MAIN OUTCOMES AND MEASURES Demographic data, comorbidities, robot docking time, operative time, estimated blood loss, and postoperative course, including complications in the immediate and longer-term postoperative period, were collected and analyzed. RESULTS All patients successfully underwent lingual tonsillectomy using the da Vinci Surgical System. Endotracheal intubation was performed in all patients and did not interfere with visualization of the oropharynx. Optimal retraction allowed visualization of pertinent structures and maximized transoral access. A significant learning curve from the first 5 surgical cases to subsequent cases with respect to robot docking time was observed (9 vs 3 minutes, respectively; P < .05). Operative time, estimated blood loss, and postoperative complication profiles are within the expected and acceptable limitations for performing lingual tonsillectomy in the pediatric population. CONCLUSIONS AND RELEVANCE Technologic advances have allowed miniaturization of robotic instrumentation and have expanded the scope of surgical options for the pediatric airway. Robotic-assisted lingual tonsillectomy is well tolerated and can be performed in the pediatric population with excellent success. It should be considered a feasible option for implementation at an institution-based level. C1 [Leonardis, Rachel L.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Duvvuri, Umamaheswar] Univ Pittsburgh, Vet Affairs Pittsburgh Hlth Syst, Med Ctr, Inst Eye & Ear,Dept Otolaryngol, Pittsburgh, PA 15213 USA. [Mehta, Deepak] Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Dept Otolaryngol, Pittsburgh, PA 15213 USA. RP Duvvuri, U (reprint author), Univ Pittsburgh, Vet Affairs Pittsburgh Hlth Syst, Med Ctr, Inst Eye & Ear,Dept Otolaryngol, 203 Lothrop St,Ste 300, Pittsburgh, PA 15213 USA. EM duvvuriu@upmc.edu NR 15 TC 8 Z9 8 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6181 EI 2168-619X J9 JAMA OTOLARYNGOL JI JAMA Otolaryngol-Head Neck Surg. PD OCT PY 2013 VL 139 IS 10 BP 1032 EP 1036 DI 10.1001/jamaoto.2013.4924 PG 5 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 279DU UT WOS:000328941400007 PM 24135744 ER PT J AU West, JS Price, M Gros, KS Ruggiero, KJ AF West, Jenny S. Price, Matthew Gros, Kirstin Stauffacher Ruggiero, Kenneth J. TI Community Support as a Moderator of Postdisaster Mental Health Symptoms in Urban and Nonurban Communities SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS LA English DT Article DE community support; urban nonurban; PTSD; depression ID SOCIAL SUPPORT; NATURAL DISASTER; HURRICANE IKE; PSYCHOLOGICAL DISTRESS; VIOLENT CRIME; STRESS; INTERVENTION; PTSD; ADULTS; CONSERVATION AB Objective We examined the association between disaster exposure, community support, and mental health outcomes in urban and nonurban participants of Galveston and Chambers counties after Hurricane Ike. The moderating effect of community support was evaluated as a protective factor relative to postdisaster mental health. Methods A representative population-based sample of 157 urban and 714 nonurban adults were interviewed 12 to 17 months after the hurricane about their mental health functioning, disaster exposure, and perceptions of community support. Results A series of multiple regressions demonstrated that disaster exposure was associated with mental health outcomes for both groups. The strength of the association varied across population samples.Community support moderated the association between interpersonal effects of the disaster and posttraumatic stress disorder (PTSD) and depression outcomes in nonurban participants and the association between property damage and PTSD in urban participants. Conclusions Community support played a larger role in reducing PTSD and depression symptoms associated with the interpersonal effects of a disaster in the nonurban sample only. Communities may play a more beneficial role in the recovery process in nonurban areas that have elevated levels of injury or death attributed to a disaster. C1 [West, Jenny S.; Price, Matthew; Gros, Kirstin Stauffacher; Ruggiero, Kenneth J.] Med Univ S Carolina, Charleston, SC 29425 USA. [Price, Matthew; Gros, Kirstin Stauffacher; Ruggiero, Kenneth J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [West, Jenny S.] Univ Calif Irvine, Irvine, CA USA. RP Ruggiero, KJ (reprint author), Med Univ S Carolina, Natl Crime Victims Ctr, 67 President St, Charleston, SC 29425 USA. EM prima@musc.edu FU National Institutes of Mental Health [R34MH77149]; [T32MH018869] FX This study is supported by the National Institutes of Mental Health Grant R34MH77149 (Dr Ruggiero). Dr. Price is supported by T32MH018869. NR 34 TC 2 Z9 2 U1 1 U2 6 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1935-7893 EI 1938-744X J9 DISASTER MED PUBLIC JI Dis. Med. Public Health Prep. PD OCT PY 2013 VL 7 IS 5 BP 443 EP 451 DI 10.1017/dmp.2013.74 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 273PC UT WOS:000328546700003 PM 24274123 ER PT J AU Yoo, JW Kim, S Seol, H Kim, SJ Yang, JM Ryu, WS Min, TJ Choi, JB Kwon, M Nakagawa, S AF Yoo, Ji Won Kim, Sulgi Seol, Haesun Kim, Sun Jung Yang, Janet Miyoung Ryu, Woo Sang Min, Too Jae Choi, Jong Bum Kwon, Minkyung Nakagawa, Shunichi TI Effects of an internal medicine floor interdisciplinary team on hospital and clinical outcomes of seniors with acute medical illness SO GERIATRICS & GERONTOLOGY INTERNATIONAL LA English DT Article DE clinical education; geriatric assessment; hospital medicine; interdisciplinary team; quality improvement ID CONFUSION ASSESSMENT METHOD; LENGTH-OF-STAY; PROSPECTIVE-PAYMENT; DELIRIUM; GERIATRICS; RELIABILITY; RESIDENTS; TRENDS; RISK; CARE AB AimTo examine whether an internal medicine interdisciplinary floor team enhances the hospital and clinical outcomes for seniors with acute medical illness. MethodsSeniors admitted to medical floor teaching services of a USA teaching hospital were recruited and allocated to the interdisciplinary (ITD; n=236) and usual care teams (n=248). Compared with the usual care team, the interdisciplinary team physicians carried out daily geriatric assessment and management, and led the interdisciplinary team meeting designed for improving interprofessional collaboration. ResultsAfter controlling for patient and physician characteristics, the mean hospital length of stay in the ITD team (6.1 days; 95% CI 5.2-7.7 days) was 0.7 days shorter than that in the usual care team (6.8 days; 95% CI 5.7-8.3 days; P=0.008). There was no significant difference in delirium and 30-day hospital readmission between care groups. ConclusionsNotwithstanding partly positive associations, the results from the present study suggest that interdisciplinary team-based care is, at best, associated with enhancing the clinical and hospital outcomes for seniors with acute medical illness. Geriatr Gerontol Int 2013; 13: 942-948. C1 [Yoo, Ji Won] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA. [Yoo, Ji Won] Univ Michigan, Sch Med, Inst Gerontol, Ann Arbor, MI 48109 USA. [Yang, Janet Miyoung] St Joseph Mercy, Dept Internal Med, Ann Arbor, MI USA. [Kim, Sulgi] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. [Seol, Haesun] VNA Hlth Ctr, Federally Qualified Hlth Ctr, Bensenville, IL USA. [Nakagawa, Shunichi] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA. [Nakagawa, Shunichi] James J Peters Vet Affairs Med Ctr, GRECC, Bronx, NY USA. [Yoo, Ji Won] Korea Univ, Coll Med, Dept Internal Med, Seoul 136705, South Korea. [Ryu, Woo Sang; Min, Too Jae] Korea Univ, Coll Med, Ctr Clin Educ, Seoul 136705, South Korea. [Kim, Sun Jung] Yonsei Univ, Sch Publ Hlth, Seoul 120749, South Korea. [Choi, Jong Bum; Kwon, Minkyung] Yonsei Univ, Coll Med, Ctr Clin Educ, Seoul, South Korea. RP Yoo, JW (reprint author), Univ Michigan, Sch Med, Dept Internal Med, 300 North Ingalls Bldg,Room 932, Ann Arbor, MI 48109 USA. EM yoojiw@trinity-health.org RI Kwon, Minkyung/H-3787-2012 OI Kwon, Minkyung/0000-0003-2437-7606 FU Junior Researcher Seed Grant (American Geriatrics Society); Excellence for Graduate Medical Education Grant (Ministry of Education, Science and Technology, Republic of Korea) FX This study was funded by a Junior Researcher Seed Grant (American Geriatrics Society) and an Excellence for Graduate Medical Education Grant (Ministry of Education, Science and Technology, Republic of Korea). NR 31 TC 2 Z9 2 U1 2 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1444-1586 EI 1447-0594 J9 GERIATR GERONTOL INT JI Geriatr. Gerontol. Int. PD OCT PY 2013 VL 13 IS 4 BP 942 EP 948 DI 10.1111/ggi.12035 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 271LE UT WOS:000328392600016 PM 23441847 ER PT J AU Wamsley, MA Julian, KA O'Sullivan, P McCance-Katz, EF Batki, SL Satre, DD Satterfield, J AF Wamsley, Maria A. Julian, Katherine A. O'Sullivan, Patricia McCance-Katz, Elinore F. Batki, Steven L. Satre, Derek D. Satterfield, Jason TI Team-Based Learning Exercise Efficiently Teaches Brief Intervention Skills to Medicine Residents SO SUBSTANCE ABUSE LA English DT Article DE Curriculum development and evaluation; graduate medical education; substance use; team-based learning ID PATIENTS ALCOHOL-USE; PRIMARY-CARE; SUBSTANCE-ABUSE; TREATMENT SBIRT; DRUG-USE; IMPACT; CURRICULUM; EDUCATION; PERFORMANCE; SETTINGS AB Background: Evaluations of substance use screening and brief intervention (SBI) curricula typically focus on learner attitudes and knowledge, although effects on clinical skills are of greater interest and utility. Moreover, these curricula often require large amounts of training time and teaching resources. This study examined whether a 3-hour SBI curriculum for internal medicine residents utilizing a team-based learning (TBL) format is effective for SBI skills as measured by a standardized patient (SP) assessment. Methods: A waitlist-controlled design was employed. Results: Twenty-four postgraduate year 2 (PGY-2) and PGY-3 residents participated in a SP assessment prior to the TBL session (waitlist control group) and 32 participated in a SP assessment after the TBL session (intervention group). The intervention residents demonstrated better brief intervention skills than waitlist control residents, but there were no differences between the groups in screening and assessment skills. Residents receiving the TBL curriculum prior to the SP assessment reported increased confidence in all SBI skills. Conclusion: Findings indicate that a brief educational intervention can improve brief intervention skills. However, more intensive education may be needed to improve substance use screening and assessment. C1 [Wamsley, Maria A.; Julian, Katherine A.; O'Sullivan, Patricia; Satterfield, Jason] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA. [McCance-Katz, Elinore F.; Batki, Steven L.; Satre, Derek D.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Batki, Steven L.] San Francisco Vet Adm Med Ctr, San Francisco, CA USA. [Satre, Derek D.] Kaiser Permanente, Div Res, San Francisco, CA USA. RP Wamsley, MA (reprint author), Univ Calif San Francisco, Div Gen Internal Med, 1545 Divisadero St,Room 322,Campus Box 0320, San Francisco, CA 94143 USA. EM maria.wamsley@ucsf.edu RI Herring, Anna/L-7859-2014 FU SAMHSA [U79T1020295] FX This research was funded by SAMHSA grant U79T1020295 awarded to Dr. Satterfield. NR 41 TC 4 Z9 4 U1 1 U2 9 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PD OCT 1 PY 2013 VL 34 IS 4 BP 344 EP 349 DI 10.1080/08897077.2013.787958 PG 6 WC Substance Abuse SC Substance Abuse GA 269LB UT WOS:000328241700003 PM 24159904 ER PT J AU Engineer, DR Burney, BO Hayes, TG Garcia, JM AF Engineer, Diana R. Burney, Basil O. Hayes, Teresa G. Garcia, Jose M. TI Exposure to ACEI/ARB and beta-Blockers Is Associated with Improved Survival and Decreased Tumor Progression and Hospitalizations in Patients with Advanced Colon Cancer SO TRANSLATIONAL ONCOLOGY LA English DT Article ID ENDOTHELIAL GROWTH-FACTOR; HEART-FAILURE; CELLS; ANGIOGENESIS; PROPRANOLOL; INHIBITION; EXPRESSION; RECEPTOR; MODEL; PROLIFERATION AB BACKGROUND: Advanced colon cancer is associated with weight loss and decreased survival. Studies suggest that angiotensin and beta-adrenergic blockade decrease colon cancer progression and ameliorate weight loss. This study aims to determine whether exposure to beta-adrenoceptor blockers (BBs), angiotensin-converting enzyme inhibitors (ACEIs), or angiotensin receptor blockers (ARBs) is associated with decreased mortality, tumor progression, number of hospitalizations, or weight loss in colorectal cancer. METHODS: Retrospective chart review included patients with advanced colorectal cancer. Survival, stage, hospitalization, cancer progression, cancer treatment, and body weight history were collected. RESULTS: Two hundred sixty-two of 425 new stage III to IV colorectal cancer cases reviewed met the study criteria. Those exposed to ACEI/ARB, BB, or both were more likely to have diabetes, hypertension, and stage III colorectal cancer. Adjusting for age, presence of hypertension and diabetes, and stage, ACEI/ARB + BB exposure was associated with decreased mortality compared to unexposed individuals [hazard ratio (HR) = 0.5, confidence interval (CI) = 0.29-0.85; Cox regression, P =.01]. Fewer total and cancer-related hospitalizations and decreased cancer progression in the ACEI/ARB + BB group versus the unexposed group (HR = 0.59, CI = 0.36-0.99, P =.047) were seen. Exposure did not affect weight changes; furthermore, body weight changes from both prediagnosis and at diagnosis to 6, 12, 18, and 24 months postdiagnosis predicted survival. CONCLUSIONS: We have observed an association between exposure to a combination of ACEI/ ARB + BB and increased survival, decreased hospitalizations, and decreased tumor progression in advanced colorectal cancer. Future studies will be needed to replicate these results and generalize them to broader populations. Determination of causality will require a randomized controlled trial. C1 [Engineer, Diana R.; Burney, Basil O.; Garcia, Jose M.] Michael E DeBakey VA Med Ctr, Div Diabet Endocrinol & Metab, Ctr Translat Res Inflammatory Dis, Houston, TX USA. [Engineer, Diana R.; Garcia, Jose M.] Baylor Coll Med, Houston, TX 77030 USA. [Engineer, Diana R.] St Lukes Episcopal Hosp, Houston, TX 77030 USA. [Hayes, Teresa G.] Baylor Coll Med, Div Hematol & Oncol, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Garcia, Jose M.] Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA. RP Garcia, JM (reprint author), Baylor Coll Med, Div Endocrinol Diabet & Metab, Michael E DeBakey Vet Affairs Med Ctr, Rm 210,Bldg 109,2002 Holcombe Blvd, Houston, TX 77030 USA. EM jgarcia1@bcm.edu FU Veterans Affairs Medical Center (Houston, TX); Department of Veterans Affairs (MERIT awards) [BX000507, CX000174]; National Institutes of Health [AG040583] FX This material is based on the work supported by the Michael E. DeBakey Veterans Affairs Medical Center (Houston, TX), Department of Veterans Affairs (MERIT awards BX000507 and CX000174), and the National Institutes of Health (AG040583) to J.M.G. The authors report no conflicts of interest. NR 32 TC 17 Z9 18 U1 0 U2 2 PU NEOPLASIA PRESS PI ANN ARBOR PA 1150 W MEDICAL CENTER DR, MSRB III, RM 9303, ANN ARBOR, MI 48109-0648 USA SN 1944-7124 EI 1936-5233 J9 TRANSL ONCOL JI Transl. Oncol. PD OCT PY 2013 VL 6 IS 5 BP 539 EP 545 DI 10.1593/tlo.13346 PG 7 WC Oncology SC Oncology GA 271AQ UT WOS:000328362800005 PM 24151534 ER PT J AU Vashishta, R Soler, ZM Nguyen, SA Schlosser, RJ AF Vashishta, Rishi Soler, Zachary M. Nguyen, Shaun A. Schlosser, Rodney J. TI A systematic review and meta-analysis of asthma outcomes following endoscopic sinus surgery for chronic rhinosinusitis SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY LA English DT Article DE asthma; chronic rhinosinusitis; endoscopic sinus surgery; ESS; FESS ID ALLERGEN-INDUCED RHINITIS; ASPIRIN TRIAD PATIENTS; NASAL POLYPS; INTRANASAL CORTICOSTEROIDS; BRONCHIAL RESPONSIVENESS; TISSUE EOSINOPHILIA; SURGICAL-TREATMENT; MESSENGER-RNA; MILD ASTHMA; PROVOCATION AB BackgroundPatients suffering from both chronic rhinosinusitis (CRS) and asthma demonstrate improved asthma outcomes when upper airway inflammation is controlled with medications. It is unclear if similar benefits exist when the upper airway is treated surgically. This study presents a systematic review and meta-analysis to assess the effects of endoscopic sinus surgery (ESS) on asthma outcomes. MethodsOvid MEDLINE and the Cochrane databases were searched to identify studies examining asthma outcomes in patients with CRS following ESS. Included studies involved a cohort of at least 5 patients and reported at least 1 postoperative asthma outcome. ResultsTwenty-two studies involving a total of 891 patients were identified. Mean follow-up across all studies was 26.4 months. Patients reported improved overall asthma control in 76.1% (95% confidence interval [CI], 71.9% to 80.3%) of cases. The frequency of asthma attacks decreased in 84.8% (95% CI, 76.6% to 93.0%) of patients and the number of hospitalizations decreased in 64.4% (95% CI, 53.3% to 75.6%). Decreased use of oral corticosteroids was seen in 72.8% (95% CI, 67.5% to 78.1%) of patients; inhaled corticosteroid use decreased in 28.5% (95% CI, 22.6% to 34.5%) and bronchodilator use decreased in 36.3% (95% CI, 28.9% to 43.7%) of patients. Mean improvement in predicted forced expiratory volume at 1 second (FEV1) was 1.62%, but was not statistically significant (p = 0.877). ConclusionESS in patients with concomitant bronchial asthma improves clinical asthma outcome measures, but not lung function testing. Difficulty conducting controlled clinical trials of ESS limits the strength of conclusions which can be reached. C1 [Vashishta, Rishi; Soler, Zachary M.; Nguyen, Shaun A.; Schlosser, Rodney J.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. [Schlosser, Rodney J.] Ralph H Johnson VA Med Ctr, Dept Surg Otolaryngol, Charleston, SC USA. RP Schlosser, RJ (reprint author), Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA. EM schlossr@musc.edu FU Merit Award from the Clinical Sciences Research and Development program of the Department of Veterans Affairs at the Ralph H. Johnson VA Medical Center, Charleston, SC FX Funding sources for the study: Merit Award from the Clinical Sciences Research and Development program of the Department of Veterans Affairs at the Ralph H. Johnson VA Medical Center, Charleston, SC. NR 42 TC 24 Z9 25 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2042-6976 EI 2042-6984 J9 INT FORUM ALLERGY RH JI Int. Forum Allergy Rhinol. PD OCT PY 2013 VL 3 IS 10 BP 788 EP 794 DI 10.1002/alr.21182 PG 7 WC Otorhinolaryngology SC Otorhinolaryngology GA 269EG UT WOS:000328223500003 PM 23818462 ER PT J AU Maia, Q Grandner, MA Findley, J Gurubhagavatula, I AF Maia, Querino Grandner, Michael A. Findley, James Gurubhagavatula, Indira TI Short and long sleep duration and risk of drowsy driving and the role of subjective sleep insufficiency SO ACCIDENT ANALYSIS AND PREVENTION LA English DT Article DE Sleep; Driving; Accidents; Sleep duration; Insufficient sleep; Epidemiology ID MOTOR-VEHICLE CRASH; METAANALYSIS; PERFORMANCE; DEPRIVATION; ADULTS; STATES; APNEA AB Experimental sleep restriction increases sleepiness and impairs driving performance. However, it is unclear whether short sleep duration in the general population is associated with drowsy driving. The goal of the present study was to evaluate whether individuals in the general population who obtained sleep of 6 h or less are more likely to report drowsy driving, and evaluate the role of perceived sleep sufficiency. Data exploring whether subgroups of short sleepers (those who report the most or least unmet sleep need) show different risk profiles for drowsy driving are limited. From the 2009 Behavioral Risk Factor Surveillance System (N = 31,522), we obtained the following self-reported data: (1) sleep duration (<= 5, 6, 7, 8, 9, or >= 10h/night); (2) number of days/week of perceived insufficient sleep; (3) among drivers, yes/no response to: "During the past 30 days, have you ever nodded off or fallen asleep, even just for a brief moment, while driving?" (4) demographics, physical/mental health. Using 7 h/night as reference, logistic regression analyses evaluated whether self-reported sleep duration was associated with drowsy driving. Overall, 3.6% reported drowsy driving. Self-identified short-sleepers reported drowsy driving more often, and long sleepers, less often. Among those who perceived sleep as always insufficient, drowsy driving was reported more often when sleep duration was <= 5 h, 6 h, or >= 10 h. Among those who perceived sleep as always sufficient, drowsy driving was reported more often among <= 5 h and 6 h sleepers. Overall, drowsy driving was common, particularly in self-identified short-sleepers as a whole, as well as subgroups based on sleep insufficiency. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Maia, Querino; Grandner, Michael A.; Findley, James; Gurubhagavatula, Indira] Univ Penn, Ctr Sleep & Circadian Neurobiol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Grandner, Michael A.; Findley, James] Univ Penn, Dept Psychiat, Behav Sleep Med Program, Philadelphia, PA 19104 USA. [Gurubhagavatula, Indira] Philadelphia VA Med Ctr, Pulm Crit Care Sleep Sect, Philadelphia, PA USA. RP Grandner, MA (reprint author), Univ Penn, Ctr Sleep & Circadian Neurobiol, 3624 Market St,Suite 205, Philadelphia, PA 19104 USA. EM grandner@upenn.edu FU NCRR NIH HHS [UL1RR024134, UL1 RR024134]; NHLBI NIH HHS [K23 HL110216, K23HL110216]; NIEHS NIH HHS [R21 ES022931, R21ES022931]; NIOSH CDC HHS [R01 OH009149, R01OH009149] NR 23 TC 16 Z9 16 U1 1 U2 7 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0001-4575 EI 1879-2057 J9 ACCIDENT ANAL PREV JI Accid. Anal. Prev. PD OCT PY 2013 VL 59 BP 618 EP 622 DI 10.1016/j.aap.2013.07.028 PG 5 WC Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation SC Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation GA 261SX UT WOS:000327686000071 PM 23973762 ER PT J AU Sano, M Egelko, S Donohue, M Ferris, S Kaye, J Hayes, TL Mundt, JC Sun, CK Paparello, S Aisen, PS AF Sano, Mary Egelko, Susan Donohue, Michael Ferris, Steven Kaye, Jeffrey Hayes, Tamara L. Mundt, James C. Sun, Chung-Kai Paparello, Silvia Aisen, Paul S. CA Alzheimer Disease Cooperative TI Developing Dementia Prevention Trials Baseline Report of the Home-Based Assessment Study SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS LA English DT Article DE Alzheimer disease; clinical trials; in-home assessment; prevention studies ID INSTRUMENT PROJECT; CLINICAL-TRIALS AB This report describes the baseline experience of the multicenter, Home-Based Assessment study, designed to develop methods for dementia prevention trials using novel technologies for test administration and data collection. Nondemented individuals of 75 years of age or more were recruited and evaluated in-person using established clinical trial outcomes of cognition and function, and randomized to one of 3 assessment methodologies: (1) mail-in questionnaire/live telephone interviews [mail-in/phone (MIP)]; (2) automated telephone with interactive voice recognition; and (3) internet-based computer Kiosk. Brief versions of cognitive and noncognitive outcomes were adapted to each methodology and administered at baseline and repeatedly over a 4-year period. Efficiency measures assessed the time from screening to baseline, and staff time required for each methodology. A total of 713 individuals signed consent and were screened; 640 met eligibility and were randomized to one of 3 assessment arms; and 581 completed baseline. Dropout, time from screening to baseline, and total staff time were highest among those assigned to internet-based computer Kiosk. However, efficiency measures were driven by nonrecurring start-up activities suggesting that differences may be mitigated over a long trial. Performance among Home-Based Assessment instruments collected through different technologies will be compared with established outcomes over this 4-year study. C1 [Sano, Mary; Egelko, Susan] Mt Sinai Sch Med, New York, NY USA. [Ferris, Steven] NYU, Langone Med Ctr, New York, NY USA. [Sano, Mary; Egelko, Susan] James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Donohue, Michael; Sun, Chung-Kai; Paparello, Silvia; Aisen, Paul S.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Kaye, Jeffrey; Hayes, Tamara L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Kaye, Jeffrey] Portland VA Med Ctr, Portland, OR USA. [Mundt, James C.] Ctr Psychol Consultat, Madison, WI USA. [Mundt, James C.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA. RP Sano, M (reprint author), James J Peters VA Med Ctr, 130 Kingsbridge Rd,Code 151 Room 1F01, Bronx, NY 10468 USA. EM mary.sano@mssm.edu OI Ferris, Steven/0000-0001-8641-6223; Kaye, Jeffrey/0000-0002-9971-3478 FU NIA [U01AG10483, P50AG005138, P30AG008051, P30AG024978, P30AG08017]; Intel Corporation FX Supported by the following NIA Grants: U01AG10483, P50AG005138, P30AG008051, and P30AG024978. Development of the Kiosk and MedTracker was supported in part by Grants from NIA (P30AG024978; P30AG08017) and Intel Corporation. NR 18 TC 7 Z9 7 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0893-0341 EI 1546-4156 J9 ALZ DIS ASSOC DIS JI Alzheimer Dis. Assoc. Dis. PD OCT-DEC PY 2013 VL 27 IS 4 BP 356 EP 362 DI 10.1097/WAD.0b013e3182769c05 PG 7 WC Clinical Neurology; Pathology SC Neurosciences & Neurology; Pathology GA 262NR UT WOS:000327742800010 PM 23151596 ER PT J AU White, S Acierno, R Ruggiero, KJ Koenen, KC Kilpatrick, DG Galea, S Gelernter, J Williamson, V McMichael, O Vladimirov, VI Amstadter, AB AF White, Simone Acierno, Ron Ruggiero, Kenneth J. Koenen, Karestan C. Kilpatrick, Dean G. Galea, Sandro Gelernter, Joel Williamson, Vernell McMichael, Omari Vladimirov, Vladimir I. Amstadter, Ananda B. TI Association of CRHR1 variants and posttraumatic stress symptoms in hurricane exposed adults SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE Posttraumatic stress disorder; CRHR1; HPA axis; Disasters; Trauma ID POPULATION GROUP ASSIGNMENT; DISORDER SYMPTOMS; COMBAT VETERANS; TRAUMATIC EVENT; RECEPTOR GENE; GENOTYPE DATA; RISK; TWIN; DEPRESSION; MARKERS AB Posttraumatic stress disorder (PTSD) is a moderately heritable anxiety disorder that may develop after exposure to trauma. However, only few genetic variants that relate to PTSD have been studied. This study examined the relationship between 12 single nucleotide polymorphisms (SNPs) in the corticotropin-releasing hormone receptor 1 gene (CRHR1) and post-disaster PTSD symptoms and diagnosis in adults exposed to 2004 Florida hurricanes. CRHR1 regulates the hypothalamic-pituitary-adrenal (HPA) axis; dysregulation of the HPA axis is characteristic of stress phenotypes. Final analyses were conducted in the European-American (EA) subsample (n = 564) due to population stratification. After correction for multiple testing, rs12938031 and rs4792887 remained associated with post-hurricane PTSD symptoms. Additionally, rs12938031 was associated with post-hurricane diagnosis of PTSD. This study is the first to examine CRHR1 in relation to PTSD in adults, and provides evidence for the importance of CRHR1 variation in the etiology of PTSD. Although results are preliminary and require replication, they justify follow-up efforts to characterize how this gene relates to PTSD. (C) 2013 Elsevier Ltd. All rights reserved. C1 [White, Simone; Williamson, Vernell; McMichael, Omari; Vladimirov, Vladimir I.; Amstadter, Ananda B.] Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Richmond, VA 23298 USA. [Acierno, Ron; Ruggiero, Kenneth J.; Kilpatrick, Dean G.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Acierno, Ron; Ruggiero, Kenneth J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Koenen, Karestan C.; Galea, Sandro] Columbia Univ, Dept Epidemiol, New York, NY USA. [Gelernter, Joel] Yale Univ, Sch Med, Div Human Genet Psychiat, New Haven, CT USA. RP Amstadter, AB (reprint author), Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, 800 E Leigh St,Biotech 1,POB 980126, Richmond, VA 23298 USA. EM slw257@cornell.edu; abamstadter@vcu.edu FU NIAAA NIH HHS [R01 AA020179]; NIGMS NIH HHS [R25 GM089614]; NIMH NIH HHS [R21 MH074469]; PHS HHS [NIGMS 089614, NIMH 05220] NR 47 TC 15 Z9 16 U1 4 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 EI 1873-7897 J9 J ANXIETY DISORD JI J. Anxiety Disord. PD OCT PY 2013 VL 27 IS 7 BP 678 EP 683 DI 10.1016/j.janxdis.2013.08.003 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 261ST UT WOS:000327685600008 PM 24077033 ER PT J AU MacDonald, DE Rapuano, BE Vyas, P Lane, JM Meyers, K Wright, T AF MacDonald, Daniel E. Rapuano, Bruce E. Vyas, Parth Lane, Joseph M. Meyers, Kathleen Wright, Timothy TI Heat and Radiofrequency Plasma Glow Discharge Pretreatment of a Titanium Alloy Promote Bone Formation and Osseointegration SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Article DE DENTAL IMPLANT; FIBRONECTIN; OSTEOBLAST; CELL DIFFERENTIATION; BONE MINERALIZATION; OSSEOINTEGRATION ID OXIDE NET CHARGE; OSTEOBLAST ADHESION; DENTAL IMPLANTS; CELL-ADHESION; SURFACE; FIBRONECTIN; TOPOGRAPHY; SITES; DIFFERENTIATION; INTEGRATION AB Orthopedic and dental implants manifest increased failure rates when inserted into low density bone. We determined whether chemical pretreatments of a titanium alloy implant material stimulated new bone formation to increase osseointegration in vivo in trabecular bone using a rat model. Titanium alloy rods were untreated or pretreated with heat (600 degrees C) or radiofrequency plasma glow discharge (RFGD). The rods were then coated with the extracellular matrix protein fibronectin (1nM) or left uncoated and surgically implanted into the rat femoral medullary cavity. Animals were euthanized 3 or 6 weeks later, and femurs were removed for analysis. The number of trabeculae in contact with the implant surface, surface contact between trabeculae and the implant, and the length and area of bone attached to the implant were measured by histomorphometry. Implant shear strength was measured by a pull-out test. Both pretreatments and fibronectin enhanced the number of trabeculae bonding with the implant and trabeculae-to-implant surface contact, with greater effects of fibronectin observed with pretreated compared to untreated implants. RFGD pretreatment modestly increased implant shear strength, which was highly correlated (r(2)=0.87-0.99) with measures of trabecular bonding for untreated and RFGD-pretreated implants. In contrast, heat pretreatment increased shear strength 3-5-fold for both uncoated and fibronectin-coated implants at 3 and 6 weeks, suggesting a more rapid increase in implant-femur bonding compared to the other groups. In summary, our findings suggest that the heat and RFGD pretreatments can promote the osseointegration of a titanium alloy implant material. J. Cell. Biochem. 114: 2363-2374, 2013. (c) 2013 Wiley Periodicals, Inc. C1 [MacDonald, Daniel E.; Rapuano, Bruce E.; Vyas, Parth; Lane, Joseph M.; Meyers, Kathleen; Wright, Timothy] Cornell Univ, Weill Med Coll, Hosp Special Surg, New York, NY 10021 USA. [MacDonald, Daniel E.] James J Peters VA Med Ctr, Bronx, NY 10468 USA. [MacDonald, Daniel E.] Columbia Univ, Langmuir Ctr Colloids & Interfaces, New York, NY 10027 USA. RP MacDonald, DE (reprint author), Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA. EM dem14@columbia.edu FU National Center for Research Resources, NIH [C06-RR12538-01] FX The sponsor did not have any role in the study design; the collection, analysis and interpretation of data; the writing of the report; or the decision to submit the article for publication. This material also resulted from work supported with resources and the use of facilities at the James J. Peters VA Medical Center, Bronx, New York. This investigation was also conducted at the HSS research facility constructed with support of Grant C06-RR12538-01 from the National Center for Research Resources, NIH. We thank Dr. Hannes Schniepp for the AFM surface analyses, Dr. Stephen Doty, and Tony Labissiere for technical assistance with the SEM analyses, Dr. Adele Boskey and Lyudmila Spevak for assistance with FTIR, and Kyle Hackshaw, Carrie Guan, and Jenny Lee for help with preparation of the alloy implants. NR 50 TC 4 Z9 4 U1 0 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0730-2312 EI 1097-4644 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD OCT PY 2013 VL 114 IS 10 BP 2363 EP 2374 DI 10.1002/jcb.24585 PG 12 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 263NP UT WOS:000327815600017 PM 23649564 ER PT J AU Garrido, MM Idler, EL Leventhal, H Carr, D AF Garrido, Melissa M. Idler, Ellen L. Leventhal, Howard Carr, Deborah TI Pathways From Religion to Advance Care Planning: Beliefs About Control Over Length of Life and End-of-Life Values SO GERONTOLOGIST LA English DT Article DE Advance directive; living wills; durable power of attorney for healthcare ID TREATMENT PREFERENCES; DECISION-MAKING; RACIAL-DIFFERENCES; CANCER-PATIENTS; DIRECTIVES; HEALTH; DEATH; PHYSICIANS; RESIDENTS; ATTITUDES AB Purpose of the Study: To evaluate the extent to which religious affiliation and self-identified religious importance affect advance care planning (ACP) via beliefs about control over life length and end-of-life values. Design and Methods: Three hundred and five adults aged 55 and older from diverse racial and socioeconomic groups seeking outpatient care in New Jersey were surveyed. Measures included discussion of end-of-life preferences; living will (LW) completion; durable power of attorney for healthcare (DPAHC) appointment; religious affiliation; importance of religion; and beliefs about who/what controls life length, end-of-life values, health status, and sociodemographics. Results: Of the sample, 68.9% had an informal discussion and 46.2% both discussed their preferences and did formal ACP (LW and/or DPAHC). Conservative Protestants and those placing great importance on religion/spirituality had a lower likelihood of ACP. These associations were largely accounted for by beliefs about God's controlling life length and values for using all available treatments. Implications: Beliefs and values about control account for relationships between religiosity and ACP. Beliefs and some values differ by religious affiliation. As such, congregations may be one nonclinical setting in which ACP discussions could be held, as individuals with similar attitudes toward the end of life could discuss their treatment preferences with those who share their views. C1 [Garrido, Melissa M.] GRECC, James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Garrido, Melissa M.] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY USA. [Idler, Ellen L.] Emory Univ, Dept Sociol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Idler, Ellen L.] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Leventhal, Howard] Rutgers State Univ, Dept Psychol, New Brunswick, NJ 08903 USA. [Leventhal, Howard] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ 08903 USA. [Carr, Deborah] Rutgers State Univ, Dept Sociol, New Brunswick, NJ 08903 USA. [Carr, Deborah] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ 08903 USA. RP Garrido, MM (reprint author), GRECC, James J Peters VA Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM melissa.garrido@mssm.edu FU NIA NIH HHS [AG023958]; NIMH NIH HHS [T32 MH16242-29] NR 38 TC 11 Z9 11 U1 4 U2 23 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2013 VL 53 IS 5 BP 801 EP 816 DI 10.1093/geront/gns128 PG 16 WC Gerontology SC Geriatrics & Gerontology GA 258DL UT WOS:000327439300010 PM 23161430 ER PT J AU Bradley, KA Chavez, LJ Lapham, GT Williams, EC Achtmeyer, CE Rubinsky, AD Hawkins, EJ Saitz, R Kivlahan, DR AF Bradley, Katharine A. Chavez, Laura J. Lapham, Gwendolyn T. Williams, Emily C. Achtmeyer, Carol E. Rubinsky, Anna D. Hawkins, Eric J. Saitz, Richard Kivlahan, Daniel R. TI When Quality Indicators Undermine Quality: Bias in a Quality Indicator of Follow-Up for Alcohol Misuse SO PSYCHIATRIC SERVICES LA English DT Article ID SERVICES-TASK-FORCE; PRIMARY-CARE; HEALTH-CARE; PREVENTIVE-SERVICES; MENTAL-HEALTH; PERFORMANCE-MEASURES; MEANINGFUL USE; INTERVENTIONS; ACCOUNTABILITY; IMPROVEMENT AB Objective: Valid quality indicators are needed to monitor and encourage identification and management of mental health and substance use conditions (behavioral conditions). Because behavioral conditions are frequently underidentified, quality indicators often evaluate the proportion of patients who screen positive for a condition who also have appropriate follow-up care documented. However, these "positive-screen-based" quality indicators of follow-up for behavioral conditions could be biased by differences in the denominator due to differential screening quality ("denominator bias") and could reward identification of fewer patients with the behavioral conditions of interest. This study evaluated denominator bias in the performance of Veterans Health Administration (VHA) networks on a quality indicator of follow-up for alcohol misuse that used the number of patients with positive alcohol screens as the denominator. Methods: Two quality indicators of follow-up for alcohol misuse-a positive-screen-based quality indicator and a population-based quality indicator-were compared among 21 VHA networks by review of 219,119 medical records. Results: Results for the two quality indicators were inconsistent. For example, two networks performed similarly on the quality indicators (64.7% and 65.4% follow-up) even though one network identified and documented follow-up for almost twice as many patients (5,411 and 2,899 per 100,000 eligible, respectively). Networks that performed better on the positive-screen-based quality indicator identified fewer patients with alcohol misuse than networks that performed better on the population-based quality indicator (mean 4.1% versus 7.4%, respectively). Conclusions: A positive-screen-based quality indicator of follow-up for alcohol misuse preferentially rewarded networks that identified fewer patients with alcohol misuse. C1 [Bradley, Katharine A.; Lapham, Gwendolyn T.] Grp Hlth Res Inst, Seattle, WA 98101 USA. [Chavez, Laura J.; Williams, Emily C.; Achtmeyer, Carol E.; Rubinsky, Anna D.; Kivlahan, Daniel R.] Vet Affairs VA Hlth Serv Res & Dev, Northwest Ctr Excellence, Seattle, WA USA. [Chavez, Laura J.; Williams, Emily C.] Univ Washington, Dept Hlth Serv, Sch Publ Hlth, Seattle, WA 98195 USA. [Hawkins, Eric J.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA. [Saitz, Richard] Boston Univ, Dept Gen Internal Med, Boston, MA 02215 USA. RP Bradley, KA (reprint author), Grp Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA. EM bradley.k@ghc.org FU Substance Use Disorders Quality Enhancement Research Initiative from VA Health Services Research and Development [SUB98-000]; National Institute on Alcohol Abuse and Alcoholism [NIAAA R21 AA020894-01A1]; Group Health Research Institute FX This study was supported by the Substance Use Disorders Quality Enhancement Research Initiative SUB98-000 from VA Health Services Research and Development, by grant NIAAA R21 AA020894-01A1 from the National Institute on Alcohol Abuse and Alcoholism, and by the Group Health Research Institute. Funders had no role in the conduct or reporting of research. Data were provided via a data use agreement with the VA OABI (formerly the VA Office of Quality and Performance), which had no role in design or analyses but reviewed the manuscript before submission to ensure accurate use and reporting of data. NR 51 TC 12 Z9 12 U1 3 U2 6 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD OCT PY 2013 VL 64 IS 10 BP 1018 EP 1025 DI 10.1176/appi.ps.201200449 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 255ZH UT WOS:000327278200022 PM 23852137 ER PT J AU Robinson, TN Wu, DS Pointer, L Dunn, CL Cleveland, JC Moss, M AF Robinson, Thomas N. Wu, Daniel S. Pointer, Lauren Dunn, Christina L. Cleveland, Joseph C., Jr. Moss, Marc TI Simple frailty score predicts postoperative complications across surgical specialties SO AMERICAN JOURNAL OF SURGERY LA English DT Article DE Geriatric surgery; Preoperative risk assessment; Surgical morbidity ID OLDER-ADULTS; NONCARDIAC SURGERY; ELDERLY-PATIENTS; CO-MORBIDITY; CARE; MORTALITY; RISK; POPULATION; VALIDATION; SEVERITY AB BACKGROUND: Our purpose was to determine the relationship between preoperative frailty and the occurrence of postoperative complications after colorectal and cardiac operations. METHODS: Patients 65 years or older undergoing elective colorectal or cardiac surgery were enrolled. Seven baseline frailty traits were measured preoperatively: Katz score less than or equal to 5, Timed Up and Go test greater than or equal to 15 seconds, Charlson Index greater than or equal to 3, anemia less than 35%, Mini-Cog score less than or equal to 3, albumin less than 3.4 g/dL, and 1 or more falls within 6 months. Patients were categorized by the number of positive traits as follows: non-frail: 0 to 1 traits, prefrail: 2 to 3 traits, and frail: 4 or more traits. RESULTS: Two hundred one subjects (age 74 +/- 6 years) were studied. Preoperative frailty was associated with increased postoperative complications after colorectal (nonfrail: 21%, prefrail: 40%, frail: 58%; P = .016) and cardiac operations (nonfrail: 17%, prefrail: 28%, frail: 56%; P < .001). This finding in both groups was independent of advancing age. Frail individuals in both groups had longer hospital stays and higher 30-day readmission rates. Receiver operating characteristic curves examining frailty's ability to forecast complications were colorectal (.702, P = .004) and cardiac (. 711, P < .001). CONCLUSIONS: A simple preoperative frailty score defines older adults at higher risk for postoperative complications across surgical specialties. Published by Elsevier Inc. C1 [Robinson, Thomas N.; Wu, Daniel S.; Dunn, Christina L.; Cleveland, Joseph C., Jr.] Univ Colorado Denver Sch Med, Dept Surg, Aurora, CO 80045 USA. [Moss, Marc] Univ Colorado Denver Sch Med, Dept Med, Aurora, CO 80045 USA. [Robinson, Thomas N.; Wu, Daniel S.; Cleveland, Joseph C., Jr.] Denver Vet Affairs Med Ctr, Dept Surg, Denver, CO USA. [Pointer, Lauren] Denver Vet Affairs Med Ctr, Dept Biostat, Denver, CO USA. RP Robinson, TN (reprint author), Univ Colorado Denver Sch Med, Dept Surg, 12631 East 17th Ave,MS C313, Aurora, CO 80045 USA. EM thomas.robinson@ucdenver.edu FU Paul B. Beeson Award [NIA K23AG034632]; Dennis W. Jahnigen Award; American Geriatrics Society; National Institutes of Health [K24-HL-089223] FX Supported by the Paul B. Beeson Award (NIA K23AG034632 [TNR]), Dennis W. Jahnigen Award, American Geriatrics Society (TNR) and National Institutes of Health (K24-HL-089223 [MM]). NR 26 TC 76 Z9 76 U1 1 U2 12 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9610 EI 1879-1883 J9 AM J SURG JI Am. J. Surg. PD OCT PY 2013 VL 206 IS 4 BP 544 EP 550 DI 10.1016/j.amjsurg.2013.03.012 PG 7 WC Surgery SC Surgery GA 246BF UT WOS:000326510500016 PM 23880071 ER PT J AU An, HM Tan, YL Shi, J Wang, ZR Li, J Wang, YC Kosten, TR Zhou, DF Yang, FD Zhang, XY AF An, Hui-Mei Tan, Yun-Long Shi, Jing Wang, Zhi-Ren Li, Jia Wang, Yue-Chan Kosten, Thomas R. Zhou, Dong Feng Yang, Fu-De Zhang, Xiang-Yang TI Extract of Ginkgo biloba is equivalent to vitamin E in attenuating and preventing vacuous chewing movements in a rat model of tardive dyskinesia SO BEHAVIOURAL PHARMACOLOGY LA English DT Article DE animal model; antioxidant; extract of Ginkgo biloba; free radical; rat; tardive dyskinesia; vacuous chewing movements; vitamin E ID INDUCED OROFACIAL DYSKINESIA; PLACEBO-CONTROLLED TRIAL; LONG-TERM TREATMENT; DOUBLE-BLIND; JAW MOVEMENTS; POSSIBLE INVOLVEMENT; ANIMAL-MODELS; SUPEROXIDE-DISMUTASE; PARKINSONIAN TREMOR; OXIDATIVE STRESS AB Free radical-mediated abnormalities may contribute toward the pathogenesis of tardive dyskinesia (TD). Many studies have reported the protective antioxidant and free radical-scavenging activities of extract of Ginkgo biloba (EGb761) against free radical-induced cell damage and dysfunction. This study aimed to compare the efficacy of EGb761 with that of vitamin E for the prevention and treatment of TD in a rat model. We carried out two studies. First, rats were injected with haloperidol (2 mg/kg intraperitoneally) daily for 5 weeks. EGb761 (50mg/kg/day) or vitamin E (20mg/kg/day) were then administered for another 5 weeks, and their effects on vacuous chewing movements (VCMs) were compared. Second, we compared 10 weeks of haloperidol alone with 10 weeks of haloperidol plus EGb761 or vitamin E. The administration of haloperidol led to a progressive increase in VCMs, which peaked at week 5. In study one, EGb761 and vitamin E, administered by an oral gavage for 5 weeks during withdrawal from chronic haloperidol treatment, decreased VCMs significantly, showing 83.8 and 91.0% reduction, respectively, compared with the haloperidol-alone group. In study two, the concomitant administration of EGb761 and vitamin E led to significantly fewer VCMs, by 64.4 and 73.9%, respectively, compared with the haloperidol-alone group. There was no significant difference in either study between EGb761 and vitamin E treatment. EGb761 shows promise for the prevention and treatment of TD in a rat model with a magnitude that was similar to that of vitamin E. (C) 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins. C1 [An, Hui-Mei; Tan, Yun-Long; Shi, Jing; Wang, Zhi-Ren; Li, Jia; Wang, Yue-Chan; Yang, Fu-De; Zhang, Xiang-Yang] Peking Univ, Beijing Huilongguan Hosp, Psychiat Res Ctr, Beijing 100871, Peoples R China. [Zhou, Dong Feng] Peking Univ, Inst Mental Hlth, Beijing 100871, Peoples R China. [Kosten, Thomas R.; Zhang, Xiang-Yang] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Kosten, Thomas R.; Zhang, Xiang-Yang] Michael E DeBakey VA Med Ctr, Houston, TX USA. RP Zhang, XY (reprint author), VA Med Ctr, Res Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA. EM xyzhang@bcm.edu FU National Natural Science Foundation of China [30770782, 81071086]; Stanley Medical Research Institute [03T-459, 05T-726]; United States National Institute of Health [K05-DA0454, P50-DA18827, U01-MH79639] FX This work was supported by grants from the National Natural Science Foundation of China (30770782, 81071086), the Stanley Medical Research Institute (03T-459 and 05T-726), and the United States National Institute of Health K05-DA0454, P50-DA18827 and U01-MH79639. NR 71 TC 3 Z9 3 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0955-8810 EI 1473-5849 J9 BEHAV PHARMACOL JI Behav. Pharmacol. PD OCT PY 2013 VL 24 IS 7 BP 610 EP 616 DI 10.1097/FBP.0b013e3283656d87 PG 7 WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy GA 251YP UT WOS:000326971200008 PM 23994817 ER PT J AU Johnson, GJ Leis, LA Slater, BCS Bach, RR AF Johnson, Gerhard J. Leis, Linda A. Slater, Billie C. S. Bach, Ronald R. TI Elevated platelet count, C-reactive protein and thromboxane analog-induced platelet aggregation in patients with Gulf War veterans' illnesses: evidence of a chronic inflammatory state? SO BLOOD COAGULATION & FIBRINOLYSIS LA English DT Article DE C-reactive protein; Gulf War illness; platelet aggregation; platelet secretion; thromboxane A(2) ID CHRONIC-FATIGUE-SYNDROME; THROMBOCYTOSIS; DYSFUNCTION; ACTIVATION; LINK AB A previous study of Gulf War veteran's illnesses (GWVI) observed evidence of platelet activation in a majority of patients with GWVI. To further characterize platelet function, we studied 43 patients (40 men) with GWVI (GWVI+) and 21 veterans who served concurrently in the Gulf War but who lacked criteria for GWVI (GWVI-). All participants were free of infection and known inflammatory diseases. Studies performed included platelet count, immature platelet fraction (IPF), plasma thrombopoietin (TPO), C-reactive protein (CRP), platelet aggregation and ATP secretion in response to six agonists, and spontaneous aggregation. Platelet counts and CRP were significantly elevated in GWVI+ compared to GWVI- patients without elevation in IPF or TPO. Platelet aggregation did not differ between GWVI+ and GWVI- patients except for spontaneous aggregation that was significantly greater in GWVI+ patients. Platelet ATP secretion was similar in the two groups, except the response to 50mol/l thrombin receptor agonist peptide 6 (TRAP 6) was significantly greater in GWVI+ patients. When platelet aggregation was analyzed in relation to CRP, the response to 0.5mol/l U46619 was significantly greater in patients whose CRP was at least 2g/ml. Therefore, GWVI+ patients had elevated platelet counts, spontaneous aggregation, TRAP 6-induced secretion, and CRP, but no impairment of platelet function. The increased platelet counts and U46619-induced aggregation appear to be consequences of an underlying inflammatory state in GWVI. (C) 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins. C1 [Johnson, Gerhard J.; Leis, Linda A.; Slater, Billie C. S.; Bach, Ronald R.] VA Healthcare Syst, Minneapolis, MN 55417 USA. [Johnson, Gerhard J.; Leis, Linda A.; Slater, Billie C. S.; Bach, Ronald R.] Univ Minnesota, Minneapolis, MN USA. [Leis, Linda A.; Slater, Billie C. S.; Bach, Ronald R.] Univ Minnesota, US Dept Vet Affairs, Res Serv, Minneapolis, MN USA. [Johnson, Gerhard J.] Univ Minnesota, Dept Med, Div Hematol Oncol & Transplant, Minneapolis, MN 55455 USA. RP Johnson, GJ (reprint author), VA Healthcare Syst, Hematol Oncol 111E,1 Vet Dr, Minneapolis, MN 55417 USA. EM johns337@umn.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development; US Department of Defense, Gulf War Illness Research Programs FX Source of support for the work: This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, and by the US Department of Defense, Gulf War Illness Research Programs. NR 25 TC 5 Z9 5 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0957-5235 EI 1473-5733 J9 BLOOD COAGUL FIBRIN JI Blood Coagul. Fibrinolysis PD OCT PY 2013 VL 24 IS 7 BP 736 EP 741 DI 10.1097/MBC.0b013e328362627f PG 6 WC Hematology SC Hematology GA 247EM UT WOS:000326598300011 PM 23751609 ER PT J AU Singh, H AF Singh, Hardeep TI Diagnostic errors: moving beyond 'no respect' and getting ready for prime time SO BMJ QUALITY & SAFETY LA English DT Editorial Material DE Accreditation; Adverse events; epidemiology and detection; Ambulatory care ID PRIMARY-CARE; INFORMATION-TECHNOLOGY; MISSED OPPORTUNITIES; MALPRACTICE CLAIMS; CANCER DIAGNOSIS; PATIENT-SAFETY; SETTINGS; MEDICINE; AUTOPSY; RECORDS C1 [Singh, Hardeep] Baylor Coll Med, Houston VA HSR&D Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, VA Med Ctr, Houston, TX 77030 USA. [Singh, Hardeep] Baylor Coll Med, VA Med Ctr, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. RP Singh, H (reprint author), Baylor Coll Med, Houston VA HSR&D Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, VA Med Ctr, 152 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hardeeps@bcm.edu FU AHRQ HHS [R13 HS019252, R13 HS19252-01, R18HS017820, R18 HS017820]; NCI NIH HHS [K23CA125585, K23 CA125585] NR 39 TC 9 Z9 9 U1 0 U2 1 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-5415 EI 2044-5423 J9 BMJ QUAL SAF JI BMJ Qual. Saf. PD OCT PY 2013 VL 22 IS 10 BP 789 EP 792 DI 10.1136/bmjqs-2013-002387 PG 4 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 247XU UT WOS:000326659100001 PM 24048615 ER PT J AU Daniel, S Soleymani, T Garvey, WT AF Daniel, Sunil Soleymani, Taraneh Garvey, W. Timothy TI A complications-based clinical staging of obesity to guide treatment modality and intensity SO CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY LA English DT Review DE cardiometabolic disease; complications; obesity; treatment algorithm; weight loss ID BODY-MASS INDEX; OBSTRUCTIVE SLEEP-APNEA; QUALITY-OF-LIFE; POLYCYSTIC-OVARY-SYNDROME; FATTY LIVER-DISEASE; BINGE-EATING DISORDER; CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE; GASTROESOPHAGEAL-REFLUX DISEASE; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL AB Purpose of reviewThe current medical model for obesity management is BMI-centric because BMI is the predominant measure used to gauge disease severity, as well as indications for various treatment modalities. Recent advancements in therapy and understanding of the relationship between BMI and obesity-related complications call for a re-examination of this approach.Recent findingsAdvancements in treatment, including the recent approval of two new weight loss medications in the USA, have enabled development of new medical models for management of obesity. On the basis of accumulating data demonstrating the benefits of weight loss regarding multiple obesity-related complications (e.g., diabetes prevention, type 2 diabetes mellitus, cardiovascular disease risk, nonalcoholic steatohepatitis, sleep apnea), a complications-centric model is proposed that employs weight loss as a tool to treat and prevent obesity comorbidities. This model assures that the aggressiveness of therapy is commensurate with disease severity, and that therapy is directed at those obese patients who will benefit most from weight loss therapy. The treatment algorithm is comprehensive in addressing complications and quantitative when possible in the staging of risk or disease severity.SummaryA complications-centric approach to obesity management identifies patients who will benefit most from weight loss, and optimizes patient outcomes, benefit/risk ratio, and the cost-effectiveness of interventions. C1 [Daniel, Sunil] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, Birmingham, MA USA. RP Daniel, S (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, Webb 232,1720 2nd Ave South, Birmingham, AL 35294 USA. EM sunild@uab.edu FU Department of Veterans Affairs; National Institutes of Health [DK-038765, DK-083562]; UAB Diabetes Research Center [P60-DK079626]; Merck; Amylin; Weight Watchers FX This work was supported by the Merit Review program of the Department of Veterans Affairs, the National Institutes of Health (DK-038765 and DK-083562), and the UAB Diabetes Research Center (P60-DK079626).; W.T.G. is a speaker for Merck, Amylin, and Liposcience. He is on the advisory boards of Daiichi-Sankyo, Vivus, Alkermes, Eisai, Liposcience, Tethys Bioscience, and Janssen. He receives research support from Merck, Amylin, and Weight Watchers. S. D. is a speaker for Vivus. T. S. is a speaker for Vivus. NR 130 TC 11 Z9 11 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1752-296X EI 1752-2978 J9 CURR OPIN ENDOCRINOL JI Curr. Opin. Endocrinol. Diabetes Obes. PD OCT PY 2013 VL 20 IS 5 BP 377 EP 388 DI 10.1097/01.med.0000433067.01671.f5 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 247BG UT WOS:000326587900003 PM 23974764 ER PT J AU Frankel, HL Kaplan, LJ AF Frankel, Heidi L. Kaplan, Lewis J. TI In brief SO CURRENT PROBLEMS IN SURGERY LA English DT Editorial Material C1 [Frankel, Heidi L.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Kaplan, Lewis J.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Kaplan, Lewis J.] Yale Univ, Sch Med, Sect Trauma Surg Crit Care & Surg Emergencies, New Haven, CT USA. RP Frankel, HL (reprint author), Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0011-3840 EI 1535-6337 J9 CURR PROB SURG JI Curr. Probl. Surg. PD OCT PY 2013 VL 50 IS 10 BP 414 EP 417 DI 10.1067/j.cpsurg.2013.07.002 PG 4 WC Surgery SC Surgery GA 245QQ UT WOS:000326479300002 ER PT J AU Tinti, MS Gracias, VH Kaplan, LJ AF Tinti, Meridith S. Gracias, Vincente H. Kaplan, Lewis J. TI Adjuncts to ventilation part II: Monitoring, fluid management, bundles, and positioning SO CURRENT PROBLEMS IN SURGERY LA English DT Review ID RESPIRATORY-DISTRESS-SYNDROME; RANDOMIZED CONTROLLED-TRIAL; CENTRAL VENOUS CATHETER; ACUTE LUNG INJURY; COMPARTMENT SYNDROME; PULMONARY-ARTERY; FAILURE; PNEUMONIA; THERAPY C1 [Tinti, Meridith S.] UMDNJ Robert Wood Johnson Med Sch, New Brunswick, NJ USA. [Tinti, Meridith S.; Gracias, Vincente H.] Univ Penn, Med Ctr, Philadelphia, PA 19104 USA. [Gracias, Vincente H.] UMDNJ Robert Wood Johnson Med Sch, Div Trauma & Acute Care Surg, New Brunswick, NJ USA. [Gracias, Vincente H.] Univ Illinois, Chicago, IL 60680 USA. [Gracias, Vincente H.] Univ Penn, Surg ICU, Philadelphia, PA 19104 USA. [Kaplan, Lewis J.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Kaplan, Lewis J.] Yale Univ, Sch Med, Sect Trauma Surg Crit Care & Surg Emergencies, New Haven, CT USA. RP Tinti, MS (reprint author), UMDNJ Robert Wood Johnson Med Sch, New Brunswick, NJ USA. NR 22 TC 0 Z9 0 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0011-3840 EI 1535-6337 J9 CURR PROB SURG JI Curr. Probl. Surg. PD OCT PY 2013 VL 50 IS 10 BP 433 EP 437 DI 10.1067/j.cpsurg.2013.08.006 PG 5 WC Surgery SC Surgery GA 245QQ UT WOS:000326479300004 PM 24156840 ER PT J AU Maung, AA Kaplan, LJ AF Maung, Adrian A. Kaplan, Lewis J. TI Waveform analysis during mechanical ventilation SO CURRENT PROBLEMS IN SURGERY LA English DT Review ID RECRUITMENT; PRESSURE C1 [Maung, Adrian A.; Kaplan, Lewis J.] Yale Univ, Sch Med, Sect Trauma Surg Crit Care & Surg Emergencies, New Haven, CT 06520 USA. [Maung, Adrian A.] Univ Maryland, R Adams Cowley Shock Trauma Ctr, College Pk, MD 20742 USA. [Kaplan, Lewis J.] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Maung, AA (reprint author), Yale Univ, Sch Med, Sect Trauma Surg Crit Care & Surg Emergencies, New Haven, CT 06520 USA. NR 10 TC 0 Z9 0 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0011-3840 EI 1535-6337 J9 CURR PROB SURG JI Curr. Probl. Surg. PD OCT PY 2013 VL 50 IS 10 BP 438 EP 446 DI 10.1067/j.cpsurg.2013.08.007 PG 9 WC Surgery SC Surgery GA 245QQ UT WOS:000326479300005 PM 24156841 ER PT J AU Jung, HS Kaplan, LJ Park, PK AF Jung, Hee Soo Kaplan, Lewis J. Park, Pauline K. TI Reviewing the studies of the National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network: Outcomes and clinical findings SO CURRENT PROBLEMS IN SURGERY LA English DT Review ID GAMMA-LINOLENIC ACID; MECHANICALLY VENTILATED PATIENTS; RANDOMIZED CONTROLLED-TRIAL; ACUTE MYOCARDIAL-INFARCTION; PULMONARY-ARTERY CATHETERS; CRITICALLY-ILL PATIENTS; EICOSAPENTAENOIC ACID; CALORIC-INTAKE; SURGICAL PATIENTS; AIRWAY PRESSURE C1 [Jung, Hee Soo] Univ Wisconsin Madison, Madison, WI USA. [Kaplan, Lewis J.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Kaplan, Lewis J.] Yale Univ, Sch Med, Sect Trauma Surg Crit Care & Surg Emergencies, New Haven, CT USA. [Park, Pauline K.] Univ Michigan, Dept Surg, Sect Gen Surg, Ann Arbor, MI 48109 USA. RP Jung, HS (reprint author), Univ Wisconsin Madison, Madison, WI USA. NR 56 TC 0 Z9 0 U1 1 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0011-3840 EI 1535-6337 J9 CURR PROB SURG JI Curr. Probl. Surg. PD OCT PY 2013 VL 50 IS 10 BP 451 EP 462 DI 10.1067/j.cpsurg.2013.08.009 PG 12 WC Surgery SC Surgery GA 245QQ UT WOS:000326479300007 PM 24156843 ER PT J AU Kaplan, LJ Toevs, CC AF Kaplan, Lewis J. Toevs, Christine C. TI Weaning from mechanical ventilation SO CURRENT PROBLEMS IN SURGERY LA English DT Review ID SPONTANEOUS-BREATHING TRIAL; EXTUBATION FAILURE; INDEX; METAANALYSIS; LIBERATION; SEDATION; PROTOCOL; PREDICT; TRAUMA C1 [Kaplan, Lewis J.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Kaplan, Lewis J.] Yale Univ, Sch Med, Sect Trauma Surg Crit Care & Surg Emergencies, New Haven, CT USA. [Toevs, Christine C.] E Carolina Univ, Sch Med, Greenville, NC 27858 USA. RP Kaplan, LJ (reprint author), Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 22 TC 0 Z9 0 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0011-3840 EI 1535-6337 J9 CURR PROB SURG JI Curr. Probl. Surg. PD OCT PY 2013 VL 50 IS 10 BP 489 EP 494 DI 10.1067/j.cpsurg.2013.08.014 PG 6 WC Surgery SC Surgery GA 245QQ UT WOS:000326479300012 PM 24156848 ER PT J AU Loftis, JM Hauser, P AF Loftis, Jennifer M. Hauser, Peter TI Pain and Opioid Use in Chronic Liver Disease: Optimal Treatment Must Address the Mental Health Care Needs of the Patient SO DIGESTIVE DISEASES AND SCIENCES LA English DT Editorial Material ID SUBSTANCE USE DISORDERS; CHRONIC HEPATITIS-C; PSYCHIATRIC-DISORDERS; DEPRESSED-PATIENTS; VETERANS; INFECTION C1 [Loftis, Jennifer M.] Portland VA Med Ctr, Res & Dev Serv, Portland, OR 97239 USA. [Loftis, Jennifer M.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA. [Hauser, Peter] VISN 22 Network Off, Long Beach, CA 90802 USA. RP Hauser, P (reprint author), VISN 22 Network Off, 300 Oceangate,Suite 700, Long Beach, CA 90802 USA. EM Peter.Hauser2@va.gov FU BLRD VA [I01 BX002061]; NIDA NIH HHS [P50 DA018165] NR 21 TC 1 Z9 1 U1 0 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 EI 1573-2568 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD OCT PY 2013 VL 58 IS 10 BP 2753 EP 2755 DI 10.1007/s10620-013-2809-4 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 223BO UT WOS:000324778900044 PM 23959213 ER PT J AU Sonnenberg, A Genta, RM AF Sonnenberg, Amnon Genta, Robert M. TI Lymphocytic and Collagenous Colitis: Epidemiologic Differences and Similarities SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Adenomatous polyps; Collagenous colitis; Geographic distribution; Epidemiology; Lymphocytic colitis; Microscopic colitis ID MICROSCOPIC COLITIS; DISORDERS; DISEASE AB Background It is unknown whether the subtypes of microscopic colitis (MC) represent distinct nosologic entities or related presentations of the same disease. Our aim was to search for epidemiologic differences among its various histopathologic subtypes. Methods In a computerized database of 789,568 colon pathology reports, we compared the characteristics of 8,745 MC patients with those of the remaining population. Results MC was diagnosed as three distinct histopathologic subtypes: lymphocytic colitis (LC) in 51 %, collagenous colitis (CC) in 43 %, and incomplete colitis (IC) in 6 % of patients. Only 0.65 % was simultaneously diagnosed with more than one subtype of MC. The prevalence of all three subtypes showed an age-dependent rise, with the average age (SD) being 63.3 (14.3) years in LC, 66.4 (12.1) years in CC, and 67.3 (12.7) years in IC (p < 0.0001). There was a striking female predominance in all three subtypes, the female fraction being 72 % in LC, 82 % in CC, and 79 % in IC (p < 0.0001). All three subtypes showed similar geographic distributions among different US states. They were similarly associated with diarrhea and weight loss, the odds ratios for all MC being 45.92 (43.35-48.63) and 5.12 (4.68-5.60), respectively, compared to control patients without MC. All three subtypes also harbored significantly less colonic adenomas, the overall odds ratio being 0.11 (0.10-0.12). Conclusion MC comes in three distinct histopathologic entities, which show striking similarities of their general epidemiologic features. The slight differences in their demographic characteristics could point at varying sets of environmental influences that affect the occurrence of subtypes. C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Dept Gastroenterol, Portland, OR 97239 USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Genta, Robert M.] Miraca Life Sci, Irving, TX USA. [Genta, Robert M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Genta, Robert M.] Dallas VA Med Ctr, Dallas, TX USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, Dept Gastroenterol, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu FU Takeda Pharmaceuticals FX Amnon Sonnenberg was supported by a grant from Takeda Pharmaceuticals. No funding was obtained for this study. NR 14 TC 11 Z9 11 U1 1 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 EI 1573-2568 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD OCT PY 2013 VL 58 IS 10 BP 2970 EP 2975 DI 10.1007/s10620-013-2718-6 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 223BO UT WOS:000324778900010 PM 23709158 ER PT J AU Barnett, CM Corless, CL Heinrich, MC AF Barnett, Christine M. Corless, Christopher L. Heinrich, Michael C. TI Gastrointestinal Stromal Tumors Molecular Markers and Genetic Subtypes SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA LA English DT Article DE GIST; KIT; PDGFRA; RTK-wild-type; SDH ID SUCCINATE-DEHYDROGENASE SUBUNIT; RECEPTOR TYROSINE KINASE; OF-FUNCTION MUTATIONS; C-KIT; PDGFRA MUTATIONS; SDHA MUTATIONS; INTERSTITIAL-CELLS; CARNEY-STRATAKIS; STRUCTURAL BASIS; BRAF MUTATIONS AB Mutation-activated signaling from the KIT and PDGFRA kinases has been successfully targeted in gastrointestinal stromal tumors (GISTs), with subtle differences between the mutations serving to refine prognosis and more precisely tailor therapy. There is a growing understanding of the molecular drivers of GISTs lacking mutations in KIT or PDGFRA, so called wild-type GISTs, further aiding in management decisions. This article provides an overview of all the known molecular subtypes of GIST and provides information about clinical correlates, treatment, and prognosis depending on the subtype. C1 [Barnett, Christine M.] Oregon Hlth & Sci Univ, OHSU Knight Canc Inst, Div Hematol Oncol, Portland VA Med Ctr, Portland, OR 97239 USA. [Corless, Christopher L.] Oregon Hlth & Sci Univ, OHSU Knight Canc Inst, Dept Pathol, Portland, OR 97239 USA. [Heinrich, Michael C.] Oregon Hlth & Sci Univ, OHSU Knight Canc Inst, Div Hematol Oncol, Portland VA Med Ctr,Dept Med, Portland, OR 97239 USA. [Heinrich, Michael C.] Oregon Hlth & Sci Univ, OHSU Knight Canc Inst, Div Hematol Oncol, Dept Cell & Dev Biol,Portland VA Med Ctr, Portland, OR 97239 USA. RP Heinrich, MC (reprint author), Oregon Hlth & Sci Univ, OHSU Knight Canc Inst, Div Hematol Oncol, Dept Cell & Dev Biol,Portland VA Med Ctr, R&D-19 3710,US Vet Hosp Rd, Portland, OR 97239 USA. EM heinrich@ohsu.edu FU Novartis; Pfizer; Bayer; Ariad; MolecularMD; AROG; Imclone FX None (C.M. Barnett); honoraria from Novartis; consulting fees from Novartis and Pfizer; research support from Novartis, Pfizer, and Bayer (C.L. Corless); honoraria from Onyx; consulting fees from Novartis, Pfizer, Ariad, MolecularMD; research support from Novartis, Pfizer, AROG, Ariad, Imclone; equity interest: MolecularMD (M.C. Heinrich). NR 78 TC 14 Z9 14 U1 1 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8588 EI 1558-1977 J9 HEMATOL ONCOL CLIN N JI Hematol. Oncol. Clin. North Am. PD OCT PY 2013 VL 27 IS 5 BP 871 EP 888 DI 10.1016/j.hoc.2013.07.003 PG 18 WC Oncology; Hematology SC Oncology; Hematology GA 244CL UT WOS:000326364600002 PM 24093165 ER PT J AU Harb, GC Phelps, AJ Forbes, D Ross, RJ Gehrman, PR Cook, JM AF Harb, Gerlinde C. Phelps, Andrea J. Forbes, David Ross, Richard J. Gehrman, Philip R. Cook, Joan M. TI A Critical Review of the Evidence Base of Imagery Rehearsal for Posttraumatic Nightmares: Pointing the Way for Future Research SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIALS; SEXUAL ASSAULT SURVIVORS; STRESS-DISORDER; CONSORT STATEMENT; CLINICAL-TRIALS; PTSD; VETERANS; INSOMNIA; QUALITY AB In this article, the authors provide information on key characteristics of imagery rehearsal treatment protocols and examine the quality of reporting of randomized controlled and uncontrolled trials of imagery rehearsal for treating posttraumatic nightmares. Using a reliable and valid scale, two independent psychologists rated 16 trials. Most reports provided insufficient information on a range of variables including the definition of treatment delivery (e.g., therapist supervision, treatment fidelity), description of the participant sample, data analysis (e.g., determination of sample size), and treatment assignment (e.g., randomization procedures). Low methodological quality and poor reporting can lead to inflation of estimates of treatment effects and inadequately substantiated conclusions, such as inflated effect sizes in meta-analytic studies. Numerous imagery rehearsal protocols exist, but in some cases are given different names and tested in pilot studies, slowing progression in the field. Randomized controlled trials of imagery rehearsal with credible comparison conditions, examination of predictors of dropout and outcome, as well as dismantling studies of imagery rehearsal treatment components are needed. C1 [Harb, Gerlinde C.; Ross, Richard J.; Gehrman, Philip R.] Philadelphia VA Med Ctr, Behav Hlth Serv, Philadelphia, PA USA. [Phelps, Andrea J.; Forbes, David] Univ Melbourne, Australian Ctr Posttraumat Mental Hlth, Dept Psychiat, Melbourne, Vic, Australia. [Ross, Richard J.; Gehrman, Philip R.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Cook, Joan M.] Yale Univ, Sch Med, Dept Psychiat, West Haven, CT 06516 USA. [Cook, Joan M.] Natl Ctr PTSD, West Haven, CT USA. RP Cook, JM (reprint author), Yale Univ, Sch Med, Dept Psychiat, NEPEC 182,950 Campbell Ave, West Haven, CT 06516 USA. EM Joan.Cook@yale.edu NR 46 TC 7 Z9 7 U1 3 U2 20 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-9867 EI 1573-6598 J9 J TRAUMA STRESS JI J. Trauma Stress PD OCT PY 2013 VL 26 IS 5 BP 570 EP 579 DI 10.1002/jts.21854 PG 10 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 242ZF UT WOS:000326284900008 PM 24114887 ER PT J AU Tucker, RP Judah, MR O'Keefe, VM Mills, AC Lechner, WV Davidson, CL Grant, DM Wingate, LR AF Tucker, Raymond P. Judah, Matt R. O'Keefe, Victoria M. Mills, Adam C. Lechner, William V. Davidson, Collin L. Grant, DeMond M. Wingate, LaRicka R. TI Humor styles impact the relationship between symptoms of social anxiety and depression SO PERSONALITY AND INDIVIDUAL DIFFERENCES LA English DT Article DE Humor styles; Humor; Social anxiety; Depression; Dysphoria ID SUICIDAL IDEATION; PHOBIA; RISK; DISORDER; ADULTS; COMORBIDITY; LONELINESS; VALIDATION; PREDICTORS; MODEL AB Recent research suggests that examining humor styles may contribute to our understanding of clinical problems, such as risk and resiliency. The goal of the current study was to examine whether humor styles moderate the association between social anxiety and depressive symptoms in an unselected sample. Three-hundred and six participants (66% female) at a large Southern US university completed self-report measures of humor styles and symptoms of social anxiety and depression. Regression analyses suggested that affiliative and self-defeating humor styles individually moderated the relationship between social anxiety and depressive symptoms. Clinical implications regarding the monitoring of humor use as a means of understanding the maintenance of depressive symptoms among socially anxious individuals are discussed. (C) 2013 Published by Elsevier Ltd. C1 [Tucker, Raymond P.; Judah, Matt R.; O'Keefe, Victoria M.; Mills, Adam C.; Lechner, William V.; Grant, DeMond M.; Wingate, LaRicka R.] Oklahoma State Univ, Stillwater, OK 74078 USA. [Davidson, Collin L.] Denver VA Med Ctr, VA VISN MIRECC 19, Denver, CO USA. RP Wingate, LR (reprint author), Oklahoma State Univ, Dept Psychol, 116 North Murray Hall, Stillwater, OK 74078 USA. EM laricka.wingate@okstate.edu OI Grant, DeMond/0000-0002-5231-6563 NR 35 TC 3 Z9 4 U1 1 U2 15 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0191-8869 J9 PERS INDIV DIFFER JI Pers. Individ. Differ. PD OCT PY 2013 VL 55 IS 7 BP 823 EP 827 DI 10.1016/j.paid.2013.07.008 PG 5 WC Psychology, Social SC Psychology GA 214SL UT WOS:000324156000018 ER PT J AU Fernandez, JF Restrepo, MI AF Fernandez, Juan Felipe Restrepo, Marcos I. TI Too Passive to Prevent Ventilator-Associated Pneumonia SO RESPIRATORY CARE LA English DT Editorial Material ID SUBGLOTTIC SECRETION DRAINAGE; CARE SAFETY NETWORK; ENDOTRACHEAL-TUBES; METAANALYSIS; CUFF C1 [Fernandez, Juan Felipe; Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm Dis & Crit Care, San Antonio, TX 78229 USA. [Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. [Restrepo, Marcos I.] Evidence Based Res Disseminat & Implementat Ctr, San Antonio, TX USA. RP Restrepo, MI (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Pulm Dis & Crit Care, 7400 Merton Minter St,MC 111E, San Antonio, TX 78229 USA. EM Restrepom@uthscsa.edu RI Restrepo, Marcos/H-4442-2014 FU NHLBI NIH HHS [K23 HL096054] NR 13 TC 0 Z9 0 U1 0 U2 0 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 EI 1943-3654 J9 RESP CARE JI Respir. Care PD OCT PY 2013 VL 58 IS 10 BP 1704 EP 1706 DI 10.4187/respcare.02803 PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 245RH UT WOS:000326481000017 PM 24064628 ER PT J AU Flynn, JM O'Leary, MN Zambataro, CA Academia, EC Presley, MP Garrett, BJ Zykovich, A Mooney, SD Strong, R Rosen, CJ Kapahi, P Nelson, MD Kennedy, BK Melov, S AF Flynn, James M. O'Leary, Monique N. Zambataro, Christopher A. Academia, Emmeline C. Presley, Michael P. Garrett, Brittany J. Zykovich, Artem Mooney, Sean D. Strong, Randy Rosen, Clifford J. Kapahi, Pankaj Nelson, Michael D. Kennedy, Brian K. Melov, Simon TI Late-life rapamycin treatment reverses age-related heart dysfunction SO AGING CELL LA English DT Article DE RNA-seq; rapamycin; aging; strain echocardiography; RAD; hypertrophy; mTOR ID CARDIAC-HYPERTROPHY; PRESSURE-OVERLOAD; MAMMALIAN TARGET; MTOR INHIBITION; SPAN; BETA; RAD; DIFFERENTIATION; PERFORMANCE; MODULATION AB Summary Rapamycin has been shown to extend lifespan in numerous model organisms including mice, with the most dramatic longevity effects reported in females. However, little is known about the functional ramifications of this longevity-enhancing paradigm in mammalian tissues. We treated 24-month-old female C57BL/6J mice with rapamycin for 3 months and determined health outcomes via a variety of noninvasive measures of cardiovascular, skeletal, and metabolic health for individual mice. We determined that while rapamycin has mild transient metabolic effects, there are significant benefits to late-life cardiovascular function with a reversal or attenuation of age-related changes in the heart. RNA-seq analysis of cardiac tissue after treatment indicated inflammatory, metabolic, and antihypertrophic expression changes in cardiac tissue as potential mechanisms mediating the functional improvement. Rapamycin treatment also resulted in beneficial behavioral, skeletal, and motor changes in these mice compared with those fed a control diet. From these findings, we propose that late-life rapamycin therapy not only extends the lifespan of mammals, but also confers functional benefits to a number of tissues and mechanistically implicates an improvement in contractile function and antihypertrophic signaling in the aged heart with a reduction in age-related inflammation. C1 [Flynn, James M.; O'Leary, Monique N.; Zambataro, Christopher A.; Academia, Emmeline C.; Presley, Michael P.; Garrett, Brittany J.; Zykovich, Artem; Mooney, Sean D.; Kapahi, Pankaj; Kennedy, Brian K.; Melov, Simon] Buck Inst Res Aging, Novato, CA 94945 USA. [Strong, Randy] UTHSC, South Texas Vet Hlth Care Syst, Dept Pharmacol, San Antonio, TX 78229 USA. [Strong, Randy] UTHSC, South Texas Vet Hlth Care Syst, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Rosen, Clifford J.] Maine Med Ctr, Res Inst, Ctr Clin & Translat Res, Scarborough, ME 04074 USA. [Nelson, Michael D.] Cedars Sinai Med Ctr, Inst Heart, Los Angeles, CA 90048 USA. RP Melov, S (reprint author), Buck Inst Res Aging, 8001 Redwood Blvd, Novato, CA 94945 USA. EM smelov@buckinstitute.org FU Larry L. Hillblom Foundation [2007 2/F]; Ellison Medical Foundation; Glenn Foundation for Medical Research; Investigator Initiated Studies Program [39326, 50196]; [PO1 AG025901]; [RO1 AG033373]; [1U01-AG022307]; [T32AG000266] FX Funding support for this research was generously provided by the following grants; PO1 AG025901(SM), RO1 AG033373 (BKK), 1U01-AG022307 (RS), T32AG000266 (Buck Institute), and partial support from the Larry L. Hillblom Foundation Network grant (2007 2/F), the Ellison Medical Foundation (BKK), and the Glenn Foundation for Medical Research (SM and JF). This research was also supported in part by grants from Merck to SM (Investigator Initiated Studies Program, # 39326, and #50196). NR 45 TC 76 Z9 78 U1 0 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1474-9718 EI 1474-9726 J9 AGING CELL JI Aging Cell PD OCT PY 2013 VL 12 IS 5 BP 851 EP 862 DI 10.1111/acel.12109 PG 12 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA 217RA UT WOS:000324376300013 PM 23734717 ER PT J AU Adrianto, I Dozmorov, MG Wiley, GB Ice, JA Li, H Kelly, JA Rasmussen, A Stone, DU Anaya, JM Segal, BM Rhodus, NL Radfar, L Harley, JB James, JA Montgomery, CG Scofield, RH Gaffney, PM Wren, JD Sivils, KL Lessard, CJ AF Adrianto, Indra Dozmorov, Mikhail G. Wiley, Graham B. Ice, John A. Li, He Kelly, Jennifer A. Rasmussen, Astrid Stone, Donald U. Anaya, Juan-Manuel Segal, Barbara M. Rhodus, Nelson L. Radfar, Lida Harley, John B. James, Judith A. Montgomery, Courtney G. Scofield, R. Hal Gaffney, Patrick M. Wren, Jonathan D. Sivils, Kathy L. Lessard, Christopher J. TI RNA-Sequencing Identifies Novel Differentially Expressed Coding and Non-Coding Transcripts In Sjogren's Syndrome SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Adrianto, Indra; Dozmorov, Mikhail G.; Wiley, Graham B.; Ice, John A.; Kelly, Jennifer A.; Rasmussen, Astrid; Montgomery, Courtney G.; Gaffney, Patrick M.; Wren, Jonathan D.; Sivils, Kathy L.; Lessard, Christopher J.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. [Li, He; Stone, Donald U.; Radfar, Lida; James, Judith A.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. [Anaya, Juan-Manuel] Univ Rosario, Sch Med & Hlth Sci, Bogota, Colombia. [Segal, Barbara M.] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA. [Rhodus, Nelson L.] Univ Minnesota, Minneapolis, MN USA. [Harley, John B.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [James, Judith A.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. [Scofield, R. Hal] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. RI Anaya, Juan-Manuel/J-1960-2016 OI Anaya, Juan-Manuel/0000-0002-6444-1249 NR 0 TC 1 Z9 1 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1489 BP S632 EP S633 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359203467 ER PT J AU Anyanwu, CO Fiorentino, D Chung, L Wang, YL Propert, KJ Werth, VP AF Anyanwu, Cynthia O. Fiorentino, David Chung, Lorinda Wang, Yanli Propert, Kathleen J. Werth, Victoria P. TI Validation Of The Cutaneous Dermatomyositis Disease Area and Severity Index: Characterizing Severity and Assessing Responsiveness To Clinical Change SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Anyanwu, Cynthia O.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Fiorentino, David] Stanford Univ, Sch Med, Redwood City, CA USA. [Chung, Lorinda] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA. [Wang, Yanli; Propert, Kathleen J.] Univ Penn, Philadelphia, PA 19104 USA. [Werth, Victoria P.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1935 BP S824 EP S824 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359204393 ER PT J AU Aquino-Beaton, C Persselin, JE Weinreb, A Fang, MA Singh, JA Duffy, E Elashoff, D Khanna, P Khanna, D AF Aquino-Beaton, Cleopatra Persselin, Jay E. Weinreb, Ari Fang, Meika A. Singh, Jasvinder A. Duffy, Erin Elashoff, David Khanna, Puja Khanna, Dinesh TI Impact Of Educational Attainment On Health-Related Quality Of Life and Healthcare Utilization Among Veterans With Gout SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Aquino-Beaton, Cleopatra; Persselin, Jay E.; Weinreb, Ari; Fang, Meika A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Singh, Jasvinder A.] Univ Alabama, Tuscaloosa, AL USA. [Duffy, Erin] Univ Calif Los Angeles, Los Angeles, CA USA. [Elashoff, David] Univ Calif Los Angeles, Dept Med Stat Core, Los Angeles, CA USA. [Khanna, Puja] Ann Arbor VA, Ann Arbor, MI USA. [Khanna, Dinesh] Univ Michigan, Med Ctr, Ann Arbor, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1984 BP S846 EP S846 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359204442 ER PT J AU Barker, AM Battistone, MJ Beck, JP Butler, J Grotzke, M Huhtala, TA Cannella, AC Daikh, DI Fang, MA Lazzari, AA Roldan, P Von Feldt, JM Cannon, GW AF Barker, Andrea M. Battistone, Michael J. Beck, J. Peter Butler, Jorie Grotzke, Marissa Huhtala, Timothy A. Cannella, Amy C. Daikh, David I. Fang, Meika A. Lazzari, Antonio A. Roldan, Pedro Von Feldt, Joan Marie Cannon, Grant W. TI Objective Assessment Of Musculoskeletal Physical Examination Skills During Continuing Education Programs For Primary Care Providers Adds Significant Information Not Obtained Through Self-Assessment SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Barker, Andrea M.; Battistone, Michael J.; Beck, J. Peter; Butler, Jorie; Grotzke, Marissa; Huhtala, Timothy A.; Cannon, Grant W.] Salt Lake City VA, Salt Lake City, UT USA. [Barker, Andrea M.; Battistone, Michael J.; Beck, J. Peter; Grotzke, Marissa; Huhtala, Timothy A.; Cannon, Grant W.] Univ Utah, Salt Lake City, UT USA. [Cannella, Amy C.] Omaha Vet Affairs Hosp, Omaha, NE USA. [Cannella, Amy C.] Univ Nebraska Med Ctr, Omaha, NE USA. [Daikh, David I.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Fang, Meika A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Lazzari, Antonio A.] Boston VA Med Ctr, Boston, MA USA. [Roldan, Pedro] Leesburg VA CBOC, Leesburg, FL USA. [Von Feldt, Joan Marie] Univ Penn Philadelphia VAMC, Philadelphia, PA USA. RI Beck, James Peter/F-9407-2015 NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 2817 BP S1206 EP S1207 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359206246 ER PT J AU Battistone, MJ Barker, AM Beck, JP Grotzke, M Huhtala, TA Butler, J Cannella, AC Daikh, DI Fang, MA Lazzari, AA Roldan, P Von Feldt, JM Cannon, GW AF Battistone, Michael J. Barker, Andrea M. Beck, J. Peter Grotzke, Marissa Huhtala, Timothy A. Butler, Jorie Cannella, Amy C. Daikh, David I. Fang, Meika A. Lazzari, Antonio A. Roldan, Pedro Von Feldt, Joan Marie Cannon, Grant W. TI Retrospective Self-Assessment Of Pre-Course Competency: A Useful Tool For Musculoskeletal Curriculum Assessment In a Multi-Center, Interprofessional Cohort. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Battistone, Michael J.; Barker, Andrea M.; Beck, J. Peter; Grotzke, Marissa; Huhtala, Timothy A.; Butler, Jorie; Cannon, Grant W.] Salt Lake City VA, Salt Lake City, UT USA. [Battistone, Michael J.; Barker, Andrea M.; Beck, J. Peter; Grotzke, Marissa; Huhtala, Timothy A.; Cannon, Grant W.] Univ Utah, Salt Lake City, UT USA. [Cannella, Amy C.] Omaha Vet Affairs Hosp, Omaha, NE USA. [Cannella, Amy C.] Univ Nebraska, Med Ctr, Omaha, NE USA. [Daikh, David I.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Fang, Meika A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Lazzari, Antonio A.] Boston VA Med Ctr, Boston, MA USA. [Roldan, Pedro] Leesburg VA CBOC, Leesburg, FL USA. [Von Feldt, Joan Marie] Univ Penn, Philadelphia, PA 19104 USA. [Von Feldt, Joan Marie] Philadelphia VAMC, Philadelphia, PA USA. RI Beck, James Peter/F-9407-2015 NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 972 BP S415 EP S415 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359202476 ER PT J AU Bharat, A Singh, JA Khanna, P Aquino-Beaton, C Persselin, JE Duffy, E Elashoff, D Khanna, D AF Bharat, Aseem Singh, Jasvinder A. Khanna, Puja Aquino-Beaton, Cleopatra Persselin, Jay E. Duffy, Erin Elashoff, David Khanna, Dinesh TI Racial/Ethnicity Differences In Health-Related Quality Of Life (HRQOL), Functional Ability and Health Care Utilization In Gout Patients SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Bharat, Aseem] Univ Alabama Birmingham, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama, Tuscaloosa, AL USA. [Khanna, Puja] Univ Michigan, Med Ctr, Ann Arbor, MI USA. [Aquino-Beaton, Cleopatra; Persselin, Jay E.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Duffy, Erin] Univ Calif Los Angeles, Los Angeles, CA USA. [Elashoff, David] Univ Calif Los Angeles, Dept Med, Stat Core, Los Angeles, CA 90024 USA. [Khanna, Dinesh] Univ Michigan, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1996 BP S851 EP S852 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359204454 ER PT J AU Cannon, GW DuVall, SL Hayden, CL Caplan, L Curtis, JR Michaud, K Mikuls, TR Reimold, AM Collier, DH Joseph, G Harrison, DJ Sauer, BC AF Cannon, Grant W. DuVall, Scott L. Hayden, Candace L. Caplan, Liron Curtis, Jeffrey R. Michaud, Kaleb Mikuls, Ted R. Reimold, Andreas M. Collier, David H. Joseph, George Harrison, David J. Sauer, Brian C. TI US Veterans With Rheumatoid Arthritis Who Switch Among Tumor Necrosis Factor Blocking Agents Have No Additional Clinical Benefit With The Change In Therapy and Incur Higher Costs SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Cannon, Grant W.] Salt Lake City VA, Salt Lake City, UT USA. [Cannon, Grant W.] Univ Utah, Salt Lake City, UT USA. [DuVall, Scott L.; Hayden, Candace L.] VA Salt Lake City Hlth Care Syst, Salt Lake City, UT USA. [DuVall, Scott L.; Hayden, Candace L.] Univ Utah, Sch Med, Salt Lake City, UT USA. [Caplan, Liron] Denver Vet Affairs Med Ctr, Denver, CO USA. [Curtis, Jeffrey R.] Univ Alabama Birmingham, Birmingham, AL USA. [Michaud, Kaleb] Natl Data Bank Rheumat Dis, Omaha, NE USA. [Michaud, Kaleb; Mikuls, Ted R.] Univ Nebraska Med Ctr, Omaha, NE USA. [Mikuls, Ted R.] Omaha VA, Omaha, NE USA. [Reimold, Andreas M.] Dallas VA, Dallas, TX USA. [Reimold, Andreas M.] Univ Texas Southwestern, Dallas, TX USA. [Collier, David H.; Joseph, George; Harrison, David J.] Amgen Inc, Thousand Oaks, CA 91320 USA. [Sauer, Brian C.] George E Wahlen Vet Affairs Med Ctr, Salt Lake City, UT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 427 BP S184 EP S185 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359201426 ER PT J AU Daikh, DI Battistone, MJ Barker, AM Avins, AL Grotzke, M Fang, MA Lazzari, AA Cannella, AC Roldan, P Von Feldt, JM Cannon, GW AF Daikh, David I. Battistone, Michael J. Barker, Andrea M. Avins, Andy L. Grotzke, Marissa Fang, Meika A. Lazzari, Antonio A. Cannella, Amy C. Roldan, Pedro Von Feldt, Joan Marie Cannon, Grant W. TI Inter-Professional Training Programs For Primary Care Providers Can Successfully Educate Practitioners With Dramatically Different Educational and Training Background Through a Common Mini-Residency Training Program. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Daikh, David I.] San Francisco VA Med Ctr, San Francisco, CA USA. [Daikh, David I.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Battistone, Michael J.; Barker, Andrea M.; Grotzke, Marissa; Cannon, Grant W.] Salt Lake City VA, Salt Lake City, UT USA. [Battistone, Michael J.; Barker, Andrea M.; Grotzke, Marissa; Cannon, Grant W.] Univ Utah, Salt Lake City, UT USA. [Avins, Andy L.] San Francisco VA Med Ctr, San Francisco, CA USA. [Fang, Meika A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Lazzari, Antonio A.] Boston VA Med Ctr, Boston, MA USA. [Cannella, Amy C.] Omaha Vet Affairs Hosp, Omaha, NE USA. [Cannella, Amy C.] Univ Nebraska, Med Ctr, Omaha, NE USA. [Roldan, Pedro] Leesburg VA CBOC, Leesburg, FL USA. [Von Feldt, Joan Marie] Univ Penn, Philadelphia, PA 19104 USA. [Von Feldt, Joan Marie] Philadelphia VAMC, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 978 BP S417 EP S418 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359202482 ER PT J AU Davis, LA Luong, P Bobba, S Dischinger, H Quinzanos, I Caplan, L AF Davis, Lisa A. Phat Luong Bobba, Sushmitha Dischinger, Hannah Quinzanos, Itziar Caplan, Liron TI Acceptability Of Various Technology-Based Communication Modalities In a Rheumatology Clinic SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Davis, Lisa A.] Denver Hlth & Hosp Author, Denver, CO USA. [Phat Luong; Bobba, Sushmitha; Dischinger, Hannah; Caplan, Liron] Denver Vet Affairs Med Ctr, Denver, CO USA. [Quinzanos, Itziar] Univ Colorado, Sch Med, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1907 BP S812 EP S813 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359204366 ER PT J AU Ding, YN Hsu, HC Li, J Yang, PA Wu, Q Zajac, AJ Mountz, JD AF Ding, Yanna Hsu, Hui-Chen Li, Jun Yang, PingAr Wu, Qi Zajac, Allan J. Mountz, John D. TI IL-21 Inhibited Follicular Regulatory T Cells To Promote Autoreactive Germinal Center Development In Autoimmune BXD2 Mice SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Ding, Yanna; Li, Jun; Yang, PingAr; Wu, Qi; Zajac, Allan J.; Mountz, John D.] Univ Alabama Birmingham, Birmingham, AL USA. [Hsu, Hui-Chen] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 2713 BP S1159 EP S1159 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359206143 ER PT J AU Hill, E Higgs, JB Sky, K Sit, M Collamer, AN AF Hill, Erica Higgs, Jay B. Sky, Karen Sit, Michelle Collamer, Angelique N. TI Does Starting Allopurinol Prolong Acute Treated Gout? SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Hill, Erica; Higgs, Jay B.] San Antonio Mil Med Ctr, Ft Sam Houston, TX USA. [Sky, Karen] Alaska VA Healthcare Syst, US Dept Vet Affairs, Anchorage, AK USA. [Sit, Michelle] David Grant Med Ctr, Travis AFB, CA USA. [Collamer, Angelique N.] Langley AFB Hosp, Langley AFB, VA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1722 BP S730 EP S730 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359204182 ER PT J AU Hirsh, JM Davis, LA Quinzanos, I Keniston, A Caplan, L AF Hirsh, Joel M. Davis, Lisa A. Quinzanos, Itziar Keniston, Angela Caplan, Liron TI Health Literacy Predicts Discrepancies Between Traditional Written Rheumatoid Arthritis Patient Assessments and Verbally-Administered Assessments SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Hirsh, Joel M.; Keniston, Angela] Denver Hlth, Denver, CO USA. [Hirsh, Joel M.; Keniston, Angela] Hosp Author, Denver, CO USA. [Davis, Lisa A.; Quinzanos, Itziar] Univ Colorado, Sch Med, Aurora, CO USA. [Caplan, Liron] Denver Vet Affairs Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1031 BP S439 EP S440 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359203017 ER PT J AU Khanna, P Aquino-Beaton, C Singh, JA Duffy, E Elashoff, D Khanna, D AF Khanna, Puja Aquino-Beaton, Cleopatra Singh, Jasvinder A. Duffy, Erin Elashoff, David Khanna, Dinesh TI Predictors Of Outcomes In Tophaceous Gout-Results From a Prospective Cohort At The Veterans Affairs SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Khanna, Puja] Ann Arbor VA, Ann Arbor, MI USA. [Aquino-Beaton, Cleopatra] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Singh, Jasvinder A.] Univ Alabama, Tuscaloosa, AL USA. [Duffy, Erin] Univ Calif Los Angeles, Los Angeles, CA USA. [Elashoff, David] Univ Calif Los Angeles, Dept Med, Stat Core, Los Angeles, CA 90024 USA. [Khanna, Dinesh] Univ Michigan, Med Ctr, Div Rheumatol, Ann Arbor, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 2005 BP S856 EP S856 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359204463 ER PT J AU Khanna, P Aquino-Beaton, C Singh, JA Duffy, E Elashoff, D Khanna, D AF Khanna, Puja Aquino-Beaton, Cleopatra Singh, Jasvinder A. Duffy, Erin Elashoff, David Khanna, Dinesh TI Performance Of Gout Impact Scale Of The Gout Assessment Questionnaire In a Longitudinal Observational Study Of Patients With Gout SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Khanna, Puja] Univ Michigan, Med Ctr, Ann Arbor, MI USA. [Aquino-Beaton, Cleopatra] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Singh, Jasvinder A.] Univ Alabama, Tuscaloosa, AL USA. [Duffy, Erin] Univ Calif Los Angeles, Los Angeles, CA USA. [Elashoff, David] Univ Calif Los Angeles, Dept Med, Stat Core, Los Angeles, CA 90024 USA. [Khanna, Dinesh] Univ Michigan, Div Rheumatol, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1994 BP S850 EP S851 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359204452 ER PT J AU Koristka, S Cartellieri, M Arndt, C Feldmann, A Michalk, I Bippes, CC Berndt, N Hermsdorf, A Stamova, S Kurien, BT Scofield, RH Farris, AD James, JA Bartsch, H Bachmann, M AF Koristka, Stefanie Cartellieri, Marc Arndt, Claudia Feldmann, Anja Michalk, Irene Bippes, Claudia C. Berndt, Nicole Hermsdorf, Anne Stamova, Slava Kurien, Biji T. Scofield, Robert Hal Farris, A. Darise James, Judith A. Bartsch, Holger Bachmann, Michael TI Bispecific Antibodies For Redirection Of Human Regulatory T Cells To Surface-Inducible Autoantigen La/SS-B SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Koristka, Stefanie; Cartellieri, Marc; Arndt, Claudia; Feldmann, Anja; Michalk, Irene; Bippes, Claudia C.; Berndt, Nicole; Hermsdorf, Anne; Stamova, Slava; Bartsch, Holger; Bachmann, Michael] Carl Gustav Carus TU Dresden, Dresden, Germany. [Kurien, Biji T.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. [Scofield, Robert Hal] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Program, Oklahoma City, OK 73104 USA. [Scofield, Robert Hal] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. [Scofield, Robert Hal] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. [Farris, A. Darise] Oklahoma Med Res Foun, Oklahoma City, OK USA. [James, Judith A.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. RI Bachmann, Michael/E-8850-2010; Feldmann, Anja/D-7843-2014 OI Bachmann, Michael/0000-0002-8029-5755; Feldmann, Anja/0000-0001-5099-2448 NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1641 BP S696 EP S696 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359204105 ER PT J AU Li, H Hsu, HC Wu, Q Li, J Yang, PA Fu, YX Mountz, JD AF Li, Hao Hsu, Hui-Chen Wu, Qi Li, Jun Yang, PingAr Fu, Yang-Xin Mountz, John D. TI Follicular Entry Of Lymphotoxin-Expressing B Cells Via Type I Interferon Disrupts Marginal Zone Barrier Integrity and Exacerbates Systemic Autoimmunity SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Li, Hao; Wu, Qi; Li, Jun; Yang, PingAr; Mountz, John D.] Univ Alabama Birmingham, Birmingham, AL USA. [Hsu, Hui-Chen] Birmingham VA Med Ctr, Birmingham, AL USA. [Fu, Yang-Xin] Univ Chicago, Chicago, IL 60637 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 37 BP S15 EP S16 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359201037 ER PT J AU Li, J Hsu, HC Yang, PA Wu, Q Luo, B Rowse, AL Spalding, DM Mobley, JA Bridges, SL Mountz, JD AF Li, Jun Hsu, Hui-Chen Yang, PingAr Wu, Qi Luo, Bao Rowse, Amber L. Spalding, David M. Mobley, James A. Bridges, S. Louis, Jr. Mountz, John D. TI Reshaping Inflammatory Macrophage Development and Functions by a Monosaccharide Analogue In Rheumatoid Arthritis SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Li, Jun; Yang, PingAr; Wu, Qi; Luo, Bao; Rowse, Amber L.; Spalding, David M.; Mobley, James A.; Bridges, S. Louis, Jr.; Mountz, John D.] Univ Alabama Birmingham, Birmingham, AL USA. [Hsu, Hui-Chen] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 2745 BP S1171 EP S1172 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359206174 ER PT J AU Liu, ML Bashir, M Sharma, M Xu, HH Williams, K Anyanwu, CO Okawa, J Werth, VP AF Liu, Ming-Lin Bashir, Muhammad Sharma, Meena Xu, Honghui Williams, Kevin Anyanwu, Cynthia O. Okawa, Joyce Werth, Victoria P. TI Novel Proinflammatory Microvesicles That Carry LL-37 In Patients With Cutaneous Lupus SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Liu, Ming-Lin; Sharma, Meena] Univ Penn, Philadelphia, PA 19104 USA. [Bashir, Muhammad; Xu, Honghui; Okawa, Joyce] Philadelphia VA Hosp, Philadelphia, PA USA. [Williams, Kevin] Temple Univ, Sch Med, Philadelphia, PA 19122 USA. [Anyanwu, Cynthia O.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Werth, Victoria P.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1860 BP S793 EP S793 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359204319 ER PT J AU Michalk, I Berndt, N Bippes, CC Bartsch, H Koristka, S Arndt, C Feldmann, A Kurien, BT Scofield, RH Farris, AD James, JA Cartellieri, M Bachmann, M AF Michalk, Irene Berndt, Nicole Bippes, Claudia C. Bartsch, Holger Koristka, Stefanie Arndt, Claudia Feldmann, Anja Kurien, Biji T. Scofield, Robert Hal Farris, A. Darise James, Judith A. Cartellieri, Marc Bachmann, Michael TI Redox Dependent Conformational Changes Of The Autoantigen La Are Responsible For Its Shuttling, Translocation and a Pathophysiological Role Of Anti-La Autoantibodies SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Michalk, Irene; Berndt, Nicole; Bippes, Claudia C.; Bartsch, Holger; Koristka, Stefanie; Arndt, Claudia; Feldmann, Anja; Cartellieri, Marc; Bachmann, Michael] Carl Gustav Carus TU Dresden, Dresden, Germany. [Kurien, Biji T.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. [Scofield, Robert Hal] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Program, Oklahoma City, OK 73104 USA. [Scofield, Robert Hal] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. [Scofield, Robert Hal] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. [Farris, A. Darise] Oklahoma Med Res Foun, Oklahoma City, OK USA. [James, Judith A.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. RI Bachmann, Michael/E-8850-2010; Feldmann, Anja/D-7843-2014 OI Bachmann, Michael/0000-0002-8029-5755; Feldmann, Anja/0000-0001-5099-2448 NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 923 BP S396 EP S396 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359202428 ER PT J AU Ruth, NM Kral, MC Nowling, TK Slan, S Passo, MH Gilkeson, GS AF Ruth, Natasha M. Kral, Mary C. Nowling, Tamara K. Slan, Stephanie Passo, Murray H. Gilkeson, Gary S. TI The Usefulness Of Traditional Neurocognitive Testing and N-Methyl-D-Aspartate Receptor Antibodies In Pediatric Lupus Patients SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Ruth, Natasha M.; Kral, Mary C.; Nowling, Tamara K.; Slan, Stephanie; Passo, Murray H.; Gilkeson, Gary S.] Med Univ S Carolina, Charleston, SC 29425 USA. [Nowling, Tamara K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1261 BP S533 EP S533 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359203244 ER PT J AU Sato, S Williams, S Karam, E Zhang, X AF Sato, Shuzo Williams, Sarah Karam, Eva Zhang, Xian TI Fli-1 Regulates Immune Cell Infiltration Through Affecting Local Chemokine Expression and IL-6 Expression In The Kidney Of Lupus Prone Mice SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Sato, Shuzo; Karam, Eva; Zhang, Xian] Med Univ S Carolina, Charleston, SC 29425 USA. [Williams, Sarah; Zhang, Xian] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 558 BP S242 EP S242 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359202070 ER PT J AU Schmajuk, G Yazdany, J Miao, YH Daikh, DI Steinman, M AF Schmajuk, Gabriela Yazdany, Jinoos Miao, Yinghui Daikh, David I. Steinman, Michael TI Folic Acid Prescription Among Older Adult Methotrexate Initiators Is Poor SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Schmajuk, Gabriela] UCSF San Francisco VA Med Ctr, San Francisco, CA USA. [Yazdany, Jinoos; Daikh, David I.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Miao, Yinghui; Steinman, Michael] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1711 BP S725 EP S725 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359204171 ER PT J AU Singh, JA Bharat, A Khanna, P Aquino-Beaton, C Persselin, JE Duffy, E Elashoff, D Khanna, D AF Singh, Jasvinder A. Bharat, Aseem Khanna, Puja Aquino-Beaton, Cleopatra Persselin, Jay E. Duffy, Erin Elashoff, David Khanna, Dinesh TI Health Care Utilization In Gout Patients: A Prospective Multicenter Cohort Study SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Singh, Jasvinder A.] Univ Alabama, Tuscaloosa, AL USA. [Bharat, Aseem] Univ Alabama Birmingham, Birmingham, AL USA. [Khanna, Puja] Univ Michigan, Med Ctr, Ann Arbor, MI USA. [Aquino-Beaton, Cleopatra; Persselin, Jay E.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Duffy, Erin] Univ Calif Los Angeles, Los Angeles, CA USA. [Elashoff, David] Univ Calif Los Angeles, Dept Med, Stat Core, Los Angeles, CA 90024 USA. [Khanna, Dinesh] Univ Michigan, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1997 BP S852 EP S853 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359204455 ER PT J AU Vina, ER Utset, TO Hannon, MJ Roberts, N Masi, CM Kwoh, CK AF Vina, Ernest R. Utset, Tammy O. Hannon, Michael J. Roberts, Nicole Masi, Christopher M. Kwoh, C. Kent TI Racial Differences In Systemic Lupus Erythematosus Patients' Treatment Preferences: A Two-Site Study SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Vina, Ernest R.; Kwoh, C. Kent] Univ Pittsburgh, Pittsburgh, PA USA. [Vina, Ernest R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Utset, Tammy O.] Univ Chicago, Dept Med, Chicago, IL 60637 USA. [Hannon, Michael J.; Roberts, Nicole] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Masi, Christopher M.] NorthShore Univ Hlth Syst, Evanston, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1069 BP S456 EP S457 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359203055 ER PT J AU Werth, VP Khamashta, MA Illei, GG Yoo, S Wang, LW Greth, W AF Werth, Victoria P. Khamashta, Munther A. Illei, Gabor G. Yoo, Stephen Wang, Liangwei Greth, Warren TI Smoking Is Associated With More Severe Skin Disease In Subjects With Moderate To Severe Systemic Lupus Erythematosus (SLE) SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Werth, Victoria P.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Khamashta, Munther A.] Kings Coll London, Sch Med, Rayne Inst, Lupus Res Unit, London, England. [Illei, Gabor G.; Yoo, Stephen; Wang, Liangwei; Greth, Warren] MedImmune LLC, Gaithersburg, MD USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 2512 BP S1072 EP S1073 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359205457 ER PT J AU Werth, VP Fiorentino, D Cohen, SB Fivenson, D Hansen, C Zoog, S Arnold, G Wang, C Boedigheimer, M Welcher, A Chung, J Sullivan, B Martin, DA AF Werth, Victoria P. Fiorentino, David Cohen, Stanley B. Fivenson, David Hansen, Chris Zoog, Steve Arnold, Greg Wang, Christine Boedigheimer, Michael Welcher, Andrew Chung, James Sullivan, Barbara Martin, David A. TI A Phase I Single-Dose Crossover Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy Of AMG 811 (anti-IFN-gamma) In Subjects With Discoid Lupus Erythematosus SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Werth, Victoria P.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Fiorentino, David] Stanford Univ, Sch Med, Redwood City, CA USA. [Cohen, Stanley B.] Metroplex Clin Res Ctr, Dallas, TX USA. [Fivenson, David] Dermatology PLLC, MD, Ann Arbor, MI USA. [Hansen, Chris] Univ Utah, Sch Med, Salt Lake City, UT USA. [Zoog, Steve; Arnold, Greg; Wang, Christine; Boedigheimer, Michael; Welcher, Andrew; Chung, James; Sullivan, Barbara] Amgen Inc, Thousand Oaks, CA USA. [Martin, David A.] Amgen Inc, Seattle, WA USA. NR 0 TC 4 Z9 4 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1608 BP S682 EP S683 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359204072 ER PT J AU Young, K Benissan-Messan, D Duryee, MJ Anderson, D Caplan, L Davis, LA Sayles, H Hunter, CD Klassen, LW O'Dell, JR Mikuls, TR Thiele, GM AF Young, Kathleen Benissan-Messan, Dathe Duryee, Michael J. Anderson, Daniel Caplan, Liron Davis, Lisa A. Sayles, Harlan Hunter, Carlos D. Klassen, Lynell W. O'Dell, James R. Mikuls, Ted R. Thiele, Geoffrey M. TI Antibody To Malondialdehyde-Acetaldehyde Adducts (MAA) Is a Biomarker Of Inflammation and Is Correlated With The Disease Activity In Rheumatoid SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Young, Kathleen; Benissan-Messan, Dathe; Duryee, Michael J.; Anderson, Daniel; Sayles, Harlan; Hunter, Carlos D.; Klassen, Lynell W.; O'Dell, James R.; Mikuls, Ted R.; Thiele, Geoffrey M.] Univ Nebraska Med Ctr, Omaha, NE USA. [Caplan, Liron] Denver Vet Affairs Med Ctr, Denver, CO USA. [Davis, Lisa A.] Denver Hlth & Hosp Author, Denver, CO USA. [Klassen, Lynell W.; Thiele, Geoffrey M.] Omaha VA Med Ctr, Omaha, NE USA. [Mikuls, Ted R.] Omaha VA, Omaha, NE USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 2262 BP S962 EP S962 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359205209 ER PT J AU Zhao, J Giles, BM Taylor, RL Yette, GA Lough, KM Abraham, LJ Wu, H Gaffney, PM Kelly, JA Kaufman, KM Harley, JB Langefeld, CD Brown, EE Edberg, JC Kimberly, RP Ulgiati, D Tsao, BP Boackle, SA AF Zhao, Jian Giles, Brendan M. Taylor, Rhonda L. Yette, Gabriel A. Lough, Kara M. Abraham, Lawrence J. Wu, Hui Gaffney, Patrick M. Kelly, Jennifer A. Kaufman, Kenneth M. Harley, John B. Langefeld, Carl D. Brown, Elizabeth E. Edberg, Jeffrey C. Kimberly, Robert P. Ulgiati, Daniela Tsao, Betty P. Boackle, Susan A. TI An Intronic CR2 Polymorphism Associated With Systemic Lupus Erythematosus Alters CTCF Binding and CR1 Expression SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Zhao, Jian; Wu, Hui; Tsao, Betty P.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Giles, Brendan M.; Yette, Gabriel A.; Lough, Kara M.; Boackle, Susan A.] Univ Colorado, Sch Med, Aurora, CO USA. [Taylor, Rhonda L.; Abraham, Lawrence J.; Ulgiati, Daniela] Univ Western Australia, Perth, WA 6009, Australia. [Gaffney, Patrick M.; Kelly, Jennifer A.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. [Kaufman, Kenneth M.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Kaufman, Kenneth M.] Univ Cincinnati, Cincinnati, OH USA. [Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. [Langefeld, Carl D.] Wake Forest Sch Med, Winston Salem, NC USA. [Brown, Elizabeth E.; Kimberly, Robert P.] Univ Alabama Birmingham, Birmingham, AL USA. [Edberg, Jeffrey C.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 2703 BP S1155 EP S1155 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359206133 ER PT J AU Rahman, M Baimbridge, C Davis, BR Barzilay, JI Basile, JN Henriquez, MA Huml, A Kopyt, N Louis, GT Pressel, SL Rosendorr, C Sastrasinh, S Stanford, C AF Rahman, Mahboob Baimbridge, Charles Davis, Barry R. Barzilay, Joshua I. Basile, Jan N. Henriquez, Mario A. Huml, Anne Kopyt, Nelson Louis, Gail T. Pressel, Sara L. Rosendorr, Clive Sastrasinh, Sithiporn Stanford, Carol CA ALLHAT Collaborative Res Grp TI Pravastatin and cardiovascular outcomes stratified by baseline eGFR in the lipid-lowering component of ALLHAT SO CLINICAL NEPHROLOGY LA English DT Article DE hyperlipidemia; kidney disease; cardiovascular outcomes; chronic renal failure ID CHRONIC KIDNEY-DISEASE; CHRONIC RENAL-INSUFFICIENCY; GLOMERULAR-FILTRATION-RATE; ATTACK TRIAL ALLHAT; USUAL CARE; EVENTS; HEART; ATORVASTATIN; HEMODIALYSIS; CHOLESTEROL AB Background/Aims: The role of statins in preventing cardiovascular outcomes in patients with chronic kidney disease (CKD) is unclear. This paper compares cardiovascular outcomes with pravastatin vs. usual care, stratified by baseline estimated glomerular filtration rate (eGFR). Methods: Post-hoc analyses of a prospective randomized open-label clinical trial; 10,151 participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (lipid-lowering component) were randomized to pravastatin 40 mg/day or usual care. Mean follow-up was 4.8 years. Results: Through Year 6, total cholesterol declined in pravastatin (-20.7%) and usual-care groups (-11.2%). Use of statin therapy in the pravastatin group was 89.8% (Year 2) and 87.0% (Year 6). Usual-care group statin use increased from 8.2% (Year 2) to 23.5% (Year 6). By primary intention-to-treat analyses, no significant differences were seen between groups for coronary heart disease (CHD), total mortality or combined cardiovascular disease; findings were consistent across eGFR strata. In exploratory "as-treated" analyses (patients actually using pravastatin vs. not using), pravastatin therapy was associated with lower mortality (HR = 0.76 (0.68 - 0.85), p < 0.001) and lower CHID (HR = 0.84 (0.73 - 0.97), p = 0.01), but not combined cardiovascular disease (HR = 0.95 (0.88 - 1.04), p = 0.30). Total cholesterol reduction of 10 mg/dL from baseline to Year 2 was associated with 5% lower CHD risk. Conclusions: In hypertensive patients with moderate dyslipidemia, pravastatin was not superior to usual care in preventing total mortality or CHD independent of baseline eGFR level. However, exploratory "as-treated" analyses suggest improved mortality and CHD risk in participants using pravastatin, and decreased CHD events associated with achieved reduction in total cholesterol. Potential benefit from statin therapy may depend on degree of reduction achieved in total and LDL-cholesterol and adherence to therapy. C1 [Rahman, Mahboob; Huml, Anne] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Louis Stokes Cleveland Vet Affairs Med Ctr, Cleveland, OH 44106 USA. [Baimbridge, Charles; Davis, Barry R.; Pressel, Sara L.] Univ Texas Houston, Sch Publ Hlth, Houston, TX 77030 USA. [Barzilay, Joshua I.] Kaiser Permanente Georgia, Tucker, GA USA. [Basile, Jan N.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Henriquez, Mario A.] Bronx Nephrol Hypertens, Bronx, NY USA. [Kopyt, Nelson] Lehigh Valley Hosp, Allentown, PA USA. [Louis, Gail T.] Tulane Univ, Sch Publ Hlth & Trop Med, New Orleans, LA 70118 USA. [Rosendorr, Clive] Mt Sinai Sch Med, New York, NY USA. [Rosendorr, Clive] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Sastrasinh, Sithiporn] Vet Affairs New Jersey Hlth Care Syst, E Orange, NJ USA. [Stanford, Carol] Univ Missouri, Sch Med, Kansas City, MO 64108 USA. RP Pressel, SL (reprint author), Univ Texas Houston, Sch Publ Hlth, Coordinating Ctr Clin Trials, 1200 Herman Pressler St,Suite W908, Houston, TX 77030 USA. EM Sara.L.Pressel@uth.tmc.edu FU National Heart, Lung, and Blood Institute [NO1-HC-35130]; Pfizer FX This study was supported by contract NO1-HC-35130 with the National Heart, Lung, and Blood Institute. The ALLHAT investigators acknowledge contributions of study medications supplied by Pfizer (amlodipine and doxazosin), AstraZeneca (atenolol and lisinopril) and Bristol-Myers Squibb (pravastatin), and financial support provided by Pfizer. NR 23 TC 2 Z9 2 U1 0 U2 4 PU DUSTRI-VERLAG DR KARL FEISTLE PI DEISENHOFEN-MUENCHEN PA BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY SN 0301-0430 J9 CLIN NEPHROL JI Clin. Nephrol. PD OCT PY 2013 VL 80 IS 4 BP 235 EP 248 DI 10.5414/CN107922 PG 14 WC Urology & Nephrology SC Urology & Nephrology GA 241YS UT WOS:000326205200001 PM 23816477 ER PT J AU Metra, M Ponikowski, P Cotter, G Davison, BA Felker, GM Filippatos, G Greenberg, BH Hua, TA Severin, T Unemori, E Voors, AA Teerlink, JR AF Metra, Marco Ponikowski, Piotr Cotter, Gad Davison, Beth A. Felker, G. Michael Filippatos, Gerasimos Greenberg, Barry H. Hua, Tsushung A. Severin, Thomas Unemori, Elaine Voors, Adriaan A. Teerlink, John R. TI Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF SO EUROPEAN HEART JOURNAL LA English DT Article DE Acute heart failure; Serelaxin; Mortality; Subgroups ID NATRIURETIC PEPTIDE; CLINICAL-TRIALS; OUTCOMES; HOSPITALIZATION; ANTAGONIST; PROGRAM; STATE AB Aim Patients hospitalized for acute heart failure (AHF) differ with respect of many clinical characteristics which may influence their prognosis and response to treatment. We have assessed possible differences in the effects of serelaxin on dyspnoea relief, 60 Day outcomes and 180 Day mortality across patient subgroups in the RELAX-AHF trial. Methods and results Subgroups were based on pre-specified covariates (age, sex, race, geographic region, estimated glomerular filtration rate, time from presentation to randomization, baseline systolic blood pressure, history of diabetes, atrial fibrillation, ischaemic heart disease, cardiac devices, i.v. nitrates at randomization). Other covariates which may modify the efficacy of AHF treatment were also analysed. Subgroup analyses did not show any difference in the effects of serelaxin vs. placebo on dyspnoea relief or on the incidence of cardiovascular death or rehospitalizations for heart failure or renal failure at 60 days. Nominally significant interactions between some patient subgroups and the effects of serelaxin on 180 days cardiovascular and all-cause mortality were noted but should be interpreted cautiously due to the number of comparisons and the low incidence of deaths in the subgroups at lower risk. Conclusion The effects of serelaxin vs. placebo appeared to be similar across subgroups of patients in RELAX-AHF. C1 [Metra, Marco] Univ Brescia, Dept Med & Surg Specialties, Brescia, Italy. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland. [Cotter, Gad; Davison, Beth A.] Momentum Res Inc, Durham, NC USA. [Felker, G. Michael] Duke Univ, Sch Med, Duke Heart Ctr, Durham, NC USA. [Filippatos, Gerasimos] Athens Univ Hosp, Athens, Greece. [Greenberg, Barry H.] Univ Calif San Diego, San Diego, CA 92103 USA. [Hua, Tsushung A.] Novartis Pharmaceut, E Hanover, NJ USA. [Severin, Thomas] Novartis Pharma AG, Basel, Switzerland. [Unemori, Elaine] Corthera Inc, San Carlos, CA USA. [Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands. [Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Metra, M (reprint author), Spedali Civil Brescia, Piazza Spedali Civili 1, I-25123 Brescia, Italy. EM metramarco@libero.it RI Lainscak, Mitja/F-3237-2015; Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064; Metra, Marco/0000-0001-6691-8568; Davison, Beth/0000-0003-2374-6449 FU Corthera, Inc.; Novartis Pharma AG, Basel, Switzerland FX The RELAX-AHF trial was supported by Corthera, Inc., a member of the Novartis group of companies. Graham Allcock of CircleScience provided editorial assistance, which was funded by Novartis Pharma AG, Basel, Switzerland. NR 29 TC 29 Z9 31 U1 0 U2 6 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD OCT PY 2013 VL 34 IS 40 BP 3128 EP 3136 DI 10.1093/eurheartj/eht371 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 243BX UT WOS:000326292600012 PM 23999454 ER PT J AU Gensheimer, MF Hummel-Kramer, SM Cain, D Quang, TS AF Gensheimer, M. F. Hummel-Kramer, S. M. Cain, D. Quang, T. S. TI Simple Rule for Prediction of Parotid Gland Sparing Early in the Radiation Treatment Planning Process SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 55th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 22-25, 2013 CL Atlanta, GA SP Amer Soc Radiat Oncol C1 [Gensheimer, M. F.] Univ Washington, Med Ctr, Seattle, WA 98195 USA. [Hummel-Kramer, S. M.; Cain, D.; Quang, T. S.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2013 VL 87 IS 2 SU S BP S588 EP S588 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 219JY UT WOS:000324503602211 ER PT J AU Quang, TS AF Quang, T. S. TI Privilege and Immunity - An Underutilized Tool in the Quality Improvement Program SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 55th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 22-25, 2013 CL Atlanta, GA SP Amer Soc Radiat Oncol C1 [Quang, T. S.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Quang, T. S.] Univ Washington, Med Ctr, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2013 VL 87 IS 2 SU S BP S578 EP S578 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 219JY UT WOS:000324503602185 ER PT J AU Chattergoon, NN Louey, S Stork, PJ Giraud, GD Thornburg, KL AF Chattergoon, N. N. Louey, S. Stork, P. J. Giraud, G. D. Thornburg, K. L. TI SURPRISING SIGNAL TRANSDUCTION CHANGES IN MATURING FETAL OVINE CARDIOMYOCYTES SO PEDIATRIC RESEARCH LA English DT Meeting Abstract C1 [Chattergoon, N. N.; Louey, S.; Stork, P. J.; Giraud, G. D.; Thornburg, K. L.] Oregon Hlth & Sci Univ, Heart Res Ctr, Portland, OR 97201 USA. [Louey, S.; Giraud, G. D.; Thornburg, K. L.] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97201 USA. [Chattergoon, N. N.; Louey, S.; Giraud, G. D.; Thornburg, K. L.] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Portland, OR 97201 USA. [Stork, P. J.] Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA. [Giraud, G. D.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0031-3998 EI 1530-0447 J9 PEDIATR RES JI Pediatr. Res. PD OCT PY 2013 VL 74 IS 4 BP 480 EP 480 PG 1 WC Pediatrics SC Pediatrics GA 239XT UT WOS:000326060000024 ER PT J AU Shapiro, S Traiger, G Hill, W Zhang, LX Doran, AK AF Shapiro, Shelley Traiger, Glenna Hill, Wendy Zhang, Lixia Doran, Aimee K. TI Safety, Tolerability, and Efficacy of Overnight Switching From Sildenafil to Tadalafil in Patients With Pulmonary Arterial Hypertension SO CARDIOVASCULAR THERAPEUTICS LA English DT Article DE Tadalafil; Retrospective; Transition; Sildenafil; Pulmonary arterial hypertension; Phosphodiesterase type 5 inhibitor ID THERAPY; PHARMACOKINETICS AB SummaryAims Tadalafil, a once-daily phosphodiesterase type 5 inhibitor (PDE-5I), offers clinicians an alternative to sildenafil, a 3-times-daily (t.i.d.) PDE-5I for treatment of pulmonary arterial hypertension (PAH). However, there are limited data describing the risks and benefits or recommended methodology of switching patients from sildenafil to tadalafil. Methods Chart reviews were conducted on all World Health Organization group 1 patients on sildenafil for >= 3 months who transitioned to tadalafil with documented clinic visits and 6-min walk tests on both drugs. Most patients were transitioned by discontinuing sildenafil after the evening dose and initiating tadalafil 40 mg/day the next day. Data collected included demographics, PAH etiology, diagnostic hemodynamics, 6-min walk distance (6MWD), PDE-5I side effects, and concomitant medications. Data on B-type natriuretic peptide (BNP) levels were available for most patients also receiving endothelin receptor antagonists (ERAs). Results Medical records from 98 patients were evaluated. Most patients (92%) were on sildenafil for > 1 year, and 78% were receiving sildenafil 80-100 mg t.i.d. Ninety-seven percent of patients (95/98) were successfully transitioned and maintained on 40 mg/day. With a mean duration on tadalafil therapy of 243 +/- 127 days at the time of analysis, 6MWD was unchanged. Patient-reported adverse events included headache (4%) and heartburn (2%). There was minimal change in BNP levels in the subset of patients receiving an ERA concomitantly. Conclusions Transition from sildenafil to tadalafil 40 mg/day appears feasible without clinical deterioration or intolerable side effects. This study provides guidance to physicians considering transition from sildenafil to tadalafil for selecting patients. C1 [Shapiro, Shelley; Hill, Wendy] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA 90073 USA. [Shapiro, Shelley; Traiger, Glenna; Hill, Wendy] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Zhang, Lixia; Doran, Aimee K.] United Therapeut Corp, Res Triangle Pk, NC USA. RP Shapiro, S (reprint author), Greater Los Angeles VA Healthcare Syst, Cardiol Sect 111E, 11301 Wilshire Blvd Bldg 500, Los Angeles, CA 90073 USA. EM Shelley.Shapiro@va.gov FU United Therapeutics FX The site's principal investigators prepared the manuscript without compensation. Assistance with medical writing and editing was provided under the direction of the authors by Larry Nelson and Chris Lawrence, MedThink SciCom, with support from United Therapeutics. Funding was received from United Therapeutics to help supply staff for data collection, for statistician, and for poster and manuscript preparation. The principal investigator received funding from United Therapeutics for other pulmonary hypertension-related studies. NR 16 TC 4 Z9 4 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1755-5914 EI 1755-5922 J9 CARDIOVASC THER JI Cardiovasc. Ther. PD OCT PY 2013 VL 31 IS 5 BP 274 EP 279 DI 10.1111/1755-5922.12038 PG 6 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA 216RY UT WOS:000324302900007 PM 23841794 ER PT J AU Uraizee, I Cheng, S Hung, CL Verma, A Thomas, JD Zile, MR Aurigemma, GP Solomon, SD AF Uraizee, Imran Cheng, Susan Hung, Chung-Lieh Verma, Anil Thomas, James D. Zile, Michael R. Aurigemma, Gerard P. Solomon, Scott D. TI Relation of N-Terminal Pro-B-Type Natriuretic Peptide With Diastolic Function in Hypertensive Heart Disease SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Article DE blood pressure; diastolic function; hypertension; imaging; natriuretic peptides; speckle-tracking echocardiography; strain ID VENTRICULAR SYSTOLIC DYSFUNCTION; BLOOD-PRESSURE; CYCLIC-GMP; FAILURE; AGE; ECHOCARDIOGRAPHY; HYPERTROPHY; ASSOCIATION; RECEPTOR; RECOMMENDATIONS AB BACKGROUND Elevated natriuretic peptide levels in asymptomatic individuals without heart failure are associated with increased risk of adverse cardiovascular outcomes and may reflect subclinical cardiac dysfunction. METHODS In a sample of 313 asymptomatic individuals (51% women, mean age 61 years) with hypertension and diastolic dysfunction, we examined the association of plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) with both conventional and advanced echocardiographic measures of systolic and diastolic function, including myocardial strain, using speckle-tracking-based analyses. RESULTS In univariate analyses, higher NT-proBNP was associated with greater left ventricular mass index (P = 0.003), left atrial volume index (P = 0.007), lateral E' velocity (P < 0.0001), E/E' ratio (P < 0.0001), peak global longitudinal systolic strain (P = 0.015), systolic strain rate (P = 0.021), and early diastolic strain rate (P < 0.0001). In multivariable analyses, NT-proBNP remained associated with measures of diastolic dysfunction, including lateral E' velocity (P = 0.013) and the E/E' ratio (P = 0.008). However, early diastolic strain rate was the echocardiographic parameter most strongly associated with NT-proBNP (P = 0.003). CONCLUSIONS In the setting of asymptomatic hypertensive heart disease and preserved ejection fraction, elevation in natriuretic peptide levels is predominantly associated with subclinical diastolic dysfunction. C1 [Uraizee, Imran; Cheng, Susan; Solomon, Scott D.] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA. [Hung, Chung-Lieh] Mackay Mem Hosp, Taipei, Taiwan. [Verma, Anil] Ochsner Clin Fdn, Dept Cardiol, New Orleans, LA USA. [Thomas, James D.] Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA. [Zile, Michael R.] Ralph H Johnson Dept VA Med Ctr, Charleston, SC USA. [Zile, Michael R.] Med Univ S Carolina, Charleston, SC 29425 USA. [Aurigemma, Gerard P.] Univ Massachusetts, Sch Med, Dept Med, Div Cardiovasc Med, Worcester, MA USA. RP Solomon, SD (reprint author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA. EM ssolomon@rics.bwh.harvard.edu FU Novartis Pharmaceuticals FX The original clinical trial was funded by Novartis Pharmaceuticals. NR 40 TC 4 Z9 6 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0895-7061 EI 1941-7225 J9 AM J HYPERTENS JI Am. J. Hypertens. PD OCT PY 2013 VL 26 IS 10 BP 1234 EP 1241 DI 10.1093/ajh/hpt098 PG 8 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 239TF UT WOS:000326047700014 PM 23792241 ER PT J AU Wang, ZJ Subramanya, AR Satlin, LM Pastor-Soler, NM Carattino, MD Kleyman, TR AF Wang, Zhijian Subramanya, Arohan R. Satlin, Lisa M. Pastor-Soler, Nuria M. Carattino, Marcelo D. Kleyman, Thomas R. TI Regulation of large-conductance Ca2+-activated K+ channels by WNK4 kinase SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY LA English DT Article DE BK channel; familial hyperkalemic hypertension; Maxi-K; With-no-lysine kinase 4; WNK4 ID CORTICAL COLLECTING DUCT; POTASSIUM CHANNELS; APICAL MEMBRANE; CONNECTING TUBULE; INTERCALATED CELLS; SURFACE EXPRESSION; BARTTERS-SYNDROME; DISTAL NEPHRON; ALPHA-SUBUNIT; ROMK AB Large-conductance, Ca2+-activated K+ channels, commonly referred to as BK channels, have a major role in flow-induced K+ secretion in the distal nephron. With-no-lysine kinase 4 (WNK4) is a serine-threonine kinase expressed in the distal nephron that inhibits ROMK activity and renal K+ secretion. WNK4 mutations have been described in individuals with familial hyperkalemic hypertension (FHHt), a Mendelian disorder characterized by low-renin hypertension and hyperkalemia. As BK channels also have an important role in renal K+ secretion, we examined whether they are regulated by WNK4 in a manner similar to ROMK. BK channel activity was inhibited in a rabbit intercalated cell line transfected with WNK4 or a WNK4 mutant found in individuals with FHHt. Coexpression of an epitope-tagged BK alpha-subunit with WNK4 or the WNK4 mutant in HEK293 cells reduced BK alpha-subunit plasma membrane and whole cell expression. A region within WNK4 encompassing the autoinhibitory domain and a coiled coil domain was required for WNK4 to inhibit BK alpha-subunit expression. The relative fraction of BK alpha-subunit that was ubiquitinated was significantly increased in cells expressing WNK4, compared with controls. Our results suggest that WNK4 inhibits BK channel activity, in part, by increasing channel degradation through an ubiquitin-dependent pathway. Based on these results, we propose that WNK4 provides a cellular mechanism for the coordinated regulation of two key secretory K+ channels in the distal nephron, ROMK and BK. C1 [Wang, Zhijian; Subramanya, Arohan R.; Pastor-Soler, Nuria M.; Carattino, Marcelo D.; Kleyman, Thomas R.] Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Pittsburgh, PA USA. [Subramanya, Arohan R.; Pastor-Soler, Nuria M.; Carattino, Marcelo D.; Kleyman, Thomas R.] Univ Pittsburgh, Dept Cell Biol, Pittsburgh, PA USA. [Satlin, Lisa M.] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY USA. [Subramanya, Arohan R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Carattino, MD (reprint author), Dept Med, Renal Electrolyte Div, S828 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. EM mdc4@pitt.edu FU National Institutes of Health [R01 DK-038470, R01 DK-084184, R37 DK-051391, T32 DK-061296, P30 DK0-79307] FX This work was supported by grants from the National Institutes of Health, including R01 DK-038470, R01 DK-084184, R37 DK-051391, T32 DK-061296, and P30 DK0-79307 (Pittsburgh Center for Kidney Research, Univ. of Pittsburgh). NR 48 TC 12 Z9 12 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6143 EI 1522-1563 J9 AM J PHYSIOL-CELL PH JI Am. J. Physiol.-Cell Physiol. PD OCT PY 2013 VL 305 IS 8 BP C846 EP C853 DI 10.1152/ajpcell.00133.2013 PG 8 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 237KV UT WOS:000325869700006 PM 23885063 ER PT J AU Hunnibell, LS Slatore, CG Ballard, EA AF Hunnibell, Laura S. Slatore, Christopher G. Ballard, Ellen A. TI Foundations for Lung Nodule Management for Nurse Navigators SO CLINICAL JOURNAL OF ONCOLOGY NURSING LA English DT Article ID PRACTICAL ALGORITHMIC APPROACH; SMALL PULMONARY NODULES; FLEISCHNER-SOCIETY; CANCER; CT; DIAGNOSIS; GUIDELINES; STATEMENT; DESIGN; SCANS AB Lung cancer remains the most deadly cancer, with more than half of patients dying within one year of diagnosis. However, mortality rates improve with early detection. Until recently, attempts at improving early detection of lung cancer have not been shown to be beneficial, but when results from the National Lung Screening Trial showed a survivor benefit for high-risk patients who had a computed tomography scan, interest grew rapidly in creating guidelines and programs that restructure lung nodule management and screening. Oncology nurse navigators will play a crucial role in the development and administration of tracking methods, data analysis, and program development that will contribute to the multidisciplinary team in screening, tracking, and diagnosing early-stage lung cancer. C1 [Hunnibell, Laura S.] Dayton VA Med Ctr, Dayton, OH USA. [Slatore, Christopher G.] Portland VA Med Ctr, Portland, OR USA. [Slatore, Christopher G.] Portland VA Med Ctr, Sect Pulm & Crit Care Med, Portland, OR USA. [Slatore, Christopher G.] Oregon Hlth & Sci Univ, Dept Med, Div Pulm & Crit Care Med, Portland, OR 97201 USA. [Ballard, Ellen A.] VA Loma Linda Healthcare Syst, Ctr Canc, Loma Linda, CA USA. RP Hunnibell, LS (reprint author), Dayton VA Med Ctr, Dayton, OH USA. EM laura@hunnibell.net OI Slatore, Christopher/0000-0003-0958-8122 NR 34 TC 8 Z9 8 U1 0 U2 0 PU ONCOLOGY NURSING SOC PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 1092-1095 EI 1538-067X J9 CLIN J ONCOL NURS JI Clin. J. Oncol. Nurs. PD OCT PY 2013 VL 17 IS 5 BP 525 EP 531 DI 10.1188/13.CJON.525-531 PG 7 WC Oncology; Nursing SC Oncology; Nursing GA 237ZE UT WOS:000325909400010 PM 24080051 ER PT J AU Burke, RE Ryan, P AF Burke, Robert E. Ryan, Patrick TI Postdischarge Clinics: Hospitalist Attitudes and Experiences SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article ID FOLLOW-UP; CARE; DISCHARGE; TRANSITIONS; CONTINUITY; PHYSICIANS AB Novel methods for improving transitions of care are needed. Hospitalist-run postdischarge clinics (PDCs) may improve access to postdischarge care, but require practice change from providers. We conducted a Web-based cross-sectional survey of hospitalists at 37 academic medical centers across the United States and a large private employer of hospitalists to assess the attitudes of hospitalists toward postdischarge care and PDCs. Two hundred twenty-eight of 814 hospitalists responded to the survey (28%). Responding hospitalists commonly (55%) experienced difficulty arranging outpatient follow-up, and felt that lack of access was responsible for most patient problems after discharge (61%). Despite this, 62% felt hospitalists should not provide postdischarge care in a clinic, and 77% felt they would require extra compensation for work in a PDC. However, 74% thought such a clinic would decrease emergency department visits. Practicing in a PDC was associated with a trend toward positive attitudes about providing postdischarge care (P = 0.054). Responding hospitalists expressed difficulty arranging appropriate postdischarge care, confidence that PDCs would reduce postdischarge utilization, and reservations about working in a PDC, perhaps because of practical or financial concerns. These results are important given the current emphasis on reducing hospital readmissions. Further work evaluating the experience of hospitalists in PDCs is needed. Journal of Hospital Medicine 2013;8:578-581. (c) 2013 Society of Hospital Medicine C1 [Burke, Robert E.] Eastern Colorado Hlth Care Syst, Dept Vet Affairs Med Ctr, Hosp Med Sect, Denver, CO USA. [Burke, Robert E.; Ryan, Patrick] Univ Colorado, Sch Med, Dept Med, Div Gen Internal Med, Denver, CO USA. RP Burke, RE (reprint author), Denver VA Med Ctr, Mailstop 111,1055 Clermont St, Denver, CO 80220 USA. EM Robert.Burke5@va.gov FU Colorado Research Enhancement Award Program FX Dr. Burke had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. Dr. Burke was supported by grant funding from the Colorado Research Enhancement Award Program to Improve Care Coordination for Veterans. Dr. Ryan has no conflicts of interest to disclose. NR 14 TC 4 Z9 4 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD OCT PY 2013 VL 8 IS 10 BP 578 EP 581 DI 10.1002/jhm.2085 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 230NF UT WOS:000325347000007 PM 24101543 ER PT J AU Ersek, M Carpenter, JG AF Ersek, Mary Carpenter, Joan G. TI Geriatric Palliative Care in Long-Term Care Settings with a Focus on Nursing Homes SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID OF-LIFE CARE; RANDOMIZED CONTROLLED-TRIAL; SUSTAINING TREATMENT PROGRAM; QUALITY-IMPROVEMENT PROJECT; PAIN MANAGEMENT-PRACTICES; ADVANCED DEMENTIA; HOSPICE ENROLLMENT; PHYSICIAN ORDERS; REDUCE HOSPITALIZATIONS; IMPLEMENTATION SCIENCE AB Almost 1.7 million older Americans live in nursing homes, representing a large proportion of the frailest, most vulnerable elders needing long-term care. In the future, increasing numbers of older adults are expected to spend time and to die in nursing homes. Thus, understanding and addressing the palliative care needs of this population are critical. The goals of this paper are to describe briefly the current state of knowledge about palliative care needs, processes, and outcomes for nursing home residents; identify gaps in this knowledge; and propose priorities for future research in this area. C1 [Ersek, Mary] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Ersek, Mary] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Carpenter, Joan G.] Univ Utah, Coll Nursing, Hartford Ctr Geriatr Nursing Excellence, Salt Lake City, UT 84112 USA. [Carpenter, Joan G.] Coastal Hosp & Palliat Care, Salisbury, MD USA. RP Ersek, M (reprint author), Philadelphia Vet Affairs Med Ctr, 3900 Woodland Ave Annex, Philadelphia, PA 19104 USA. EM ersekm@nursing.upenn.edu FU John A. Hartford Foundation's National Hartford Centers of Gerontological Nursing Excellence Award Program FX Ms. Carpenter is a 2011-2013 Patricia G. Archbold Scholar supported by the John A. Hartford Foundation's National Hartford Centers of Gerontological Nursing Excellence Award Program. NR 110 TC 7 Z9 7 U1 5 U2 22 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD OCT 1 PY 2013 VL 16 IS 10 BP 1180 EP 1187 DI 10.1089/jpm.2013.9474 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 229LI UT WOS:000325265800009 PM 23984636 ER PT J AU Greenawalt, DS Copeland, LA MacCarthy, AA Sun, FFF Zeber, JE AF Greenawalt, David Sloan Copeland, Laurel Anne MacCarthy, Andrea A. Sun, Fangfang F. Zeber, John Edward TI Posttraumatic stress disorder and odds of major invasive procedures among US Veterans Affairs patients SO JOURNAL OF PSYCHOSOMATIC RESEARCH LA English DT Article DE Posttraumatic stress disorder; Depression; Veterans; Invasive procedures; Surgery ID CORONARY-HEART-DISEASE; ADMINISTRATIVE DATA; HEALTH-CARE; MENTAL-DISORDERS; MEDICAL-CARE; DISPARITIES; DEPRESSION; MORTALITY; PTSD; ASSOCIATION AB Objectives: Although individuals with posttraumatic stress disorder (PTSD) are at heightened risk for several serious health conditions, research has not examined how having PTSD impacts receipt of invasive procedures that may alleviate these problems. We examined whether PTSD, after controlling for major depression, was associated with odds of receiving common types of major invasive procedures, and whether race, ethnicity, and gender was associated with odds of procedures. Methods: Veterans Health Administration patients with PTSD and/or depression were age-matched with patients without these disorders. The odds of invasive hip/knee, digestive system, coronary artery bypass graft/percutaneous coronary intervention (CABG/PCI), and vascular procedures during FY2006-2009 were modeled for the full sample of 501,489 patients and for at-risk subsamples with medical conditions alleviated by the procedures examined. Results: Adjusting for demographic covariates and medical comorbidity, PTSD without depression was associated with decreased odds of all types of procedures (odds ratios [OR] range 0.74-0.82), as was depression without PTSD (OR range 0.59-0.77). In analyses of at-risk patients, those with PTSD only were less likely to undergo hip/knee (OR = 0.78) and vascular procedures (OR = 0.73) but not CABG/PCI. African-Americans and women at-risk patients were less likely to undergo hip/knee, vascular, and CABG/PCI procedures (OR range 031-0.82). Conclusion: With the exception of CABG/PCI among at-risk patients, Veterans with PTSD and/or depression were less likely to undergo all types of procedures examined. Future studies should examine the reasons for this disparity and whether it is associated with subsequent adverse outcomes. Published by Elsevier Inc. C1 [Greenawalt, David Sloan] VISN 17 Ctr Excellence Res Returning War Vet, Waco, TX 76711 USA. [Copeland, Laurel Anne; Sun, Fangfang F.; Zeber, John Edward] Cent Texas Vet Hlth Care Syst, Ctr Appl Hlth Res, Dept Vet Affairs, Temple, TX 76504 USA. [Copeland, Laurel Anne; Sun, Fangfang F.; Zeber, John Edward] Scott & White Healthcare, Ctr Appl Hlth Res, Temple, TX 76502 USA. [MacCarthy, Andrea A.] South Texas Vet Hlth Care Syst, Ctr Improving Vet Hlth Res, San Antonio, TX 78229 USA. RP Greenawalt, DS (reprint author), Albany Stratton VA Med Ctr, 113 Holland Ave 151, Albany, NY 12208 USA. EM mycapemaypoint@yahoo.com OI Copeland, Laurel/0000-0002-9478-0209 FU Veterans Health Administration, Health Services Research and Development [IIR-09-335]; Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment VISN 17 Center of Excellence for Research on Returning War Veterans; Central Texas Veterans Health Care System (CTVHCS); Center for Applied Health Research; CTVHCS; Scott & White Healthcare, Temple, TX FX This study was funded by a grant from the Veterans Health Administration, Health Services Research and Development #IIR-09-335 (PI: Laurel A. Copeland). Preparation of this manuscript was supported by the Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment VISN 17 Center of Excellence for Research on Returning War Veterans, Central Texas Veterans Health Care System (CTVHCS), and the Center for Applied Health Research, a research center jointly sponsored by CTVHCS and Scott & White Healthcare, Temple, TX. NR 57 TC 2 Z9 3 U1 2 U2 7 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3999 EI 1879-1360 J9 J PSYCHOSOM RES JI J. Psychosomat. Res. PD OCT PY 2013 VL 75 IS 4 BP 386 EP 393 DI 10.1016/j.jpsychores.2013.08.012 PG 8 WC Psychiatry SC Psychiatry GA 236ZQ UT WOS:000325838400016 PM 24119948 ER PT J AU Ellis, C Knapp, RG Gilbert, GE Egede, LE AF Ellis, Charles Knapp, Rebecca G. Gilbert, Gregory E. Egede, Leonard E. TI Factors Associated with Delays in Seeking Treatment for Stroke Care in Veterans SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES LA English DT Article DE Stroke; delays seeking treatment; veterans ID SEVERITY; LITERACY; HEALTH; DISPARITIES AB Background: Our objective was to examine the association between delay in seeking treatment (DST) for stroke care and demographic and clinical characteristics variables in a sample of veterans. Methods: We used survey data from 100 veterans with a diagnosis of stroke who were receiving poststroke care at a Veterans Affairs (VA) Medical Center in the southeastern United States to evaluate the relationship between DST and key sample demographic and clinical characteristics. We used backward stepwise logistic regression models to assess the independent association between DSTand demographic and clinical variables. Results: We found that stroke survivors reporting DST were more likely to be black (56.4% versus 32.8%; P = .02) and younger at the time of stroke onset (58.1 years versus 63.7 years; P = .02). In backward stepwise logistic regression models, being black was an independent predictor of DST (odds ratio [OR] 2.76; 95% confidence interval [CI], 1.04-7.30; P = .04) in this veteran population. Conclusions: Race appears to be a key factor associated with an increased likelihood of delays in seeking urgent stroke care in veterans. Future studies need to further examine the complex sociodemographic profile of patients who are most likely to delay seeking care for stroke and to develop interventions to reduce the impact of DST. C1 [Ellis, Charles; Knapp, Rebecca G.; Gilbert, Gregory E.; Egede, Leonard E.] Ralph H Johnson VA Med Ctr, VA Ctr Dis Prevent & Hlth Intervent Diverse Popul, Charleston, SC USA. [Ellis, Charles] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Knapp, Rebecca G.] Med Univ S Carolina, Dept Med, Div Biostat & Epidemiol, Charleston, SC 29425 USA. [Egede, Leonard E.] Med Univ S Carolina, Dept Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. RP Ellis, C (reprint author), Med Univ S Carolina, Dept Hlth Sci & Res, 77 President St,MSC 700, Charleston, SC 29425 USA. EM ellisc@musc.edu RI Gilbert, Gregory/C-7735-2016 OI Gilbert, Gregory/0000-0003-0879-5496 FU Veterans Health Administration Health Services Research and Development program (CDA) [07-012-3] FX Dr Ellis was supported by a career development award (CDA# 07-012-3) from the Veterans Health Administration Health Services Research and Development program for this project. NR 18 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1052-3057 EI 1532-8511 J9 J STROKE CEREBROVASC JI J. Stroke Cerebrovasc. Dis. PD OCT PY 2013 VL 22 IS 7 BP E136 EP E141 DI 10.1016/j.jstrokecerebrovasdis.2012.09.017 PG 6 WC Neurosciences; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 237MK UT WOS:000325874200021 PM 23219014 ER PT J AU Fordham, MT Mulligan, JK Casey, SE Mulligan, RM Wang, EW Sansoni, ER Schlosser, RJ AF Fordham, M. Taylor Mulligan, Jennifer K. Casey, Sarah E. Mulligan, Ryan M. Wang, Eric W. Sansoni, E. Ritter Schlosser, Rodney J. TI Reactive Oxygen Species in Chronic Rhinosinusitis and Secondhand Smoke Exposure SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article DE chronic rhinosinusitis; reactive oxygen species; secondhand smoke; nasal polyps ID OXIDATIVE STRESS; ANTIOXIDANT BALANCE; CHRONIC SINUSITIS; DISEASES; OXIDANT; EPITHELIUM; RADICALS; EXPLANTS; ASTHMA; COPD AB Objective Reactive oxygen species (ROS) can potentiate cellular injury and inflammation. This study aimed to (1) assess the presence of reactive oxygen species in the sinus tissue of patients with chronic rhinosinusitis (CRS) and (2) assess the impact of secondhand smoke (SHS) exposure on reactive oxygen species (ROS) production. Study Design Retrospective cohort study. Setting Academic medical center. Subjects and Methods Sinus tissue samples from patients undergoing sinus surgery were analyzed using diaminobenzidine (DAB) staining to assess for ROS. Stained specimens were photographed at random by a blinded photographer and then quantified by 3 blinded graders. The patient's SHS exposure was determined by hair nicotine levels. Results were compared between non-smoke exposed cohorts and those exposed to secondhand smoke and by diagnosis. Results Sixty-nine adults undergoing sinus surgery were included in the study. For the non-SHS-exposed cohorts, chronic rhinosinusitis with nasal polyps (CRSwNP) had the highest number of DAB+ cells/high-powered field (hpf) followed by chronic rhinosinusitis without nasal polyps (CRSsNP) and controls. When comparing the control patients to their SHS-exposed counterparts, SHS exposure yielded statistically significantly higher levels of DAB-positive cells/hpf. SHS exposure did not affect DAB staining in CRSsNP or CRSwNP patients. Conclusion ROS are differentially expressed in various subtypes of CRS. SHS exposure increases ROS in sinus tissue of control patients, but the clinical significance of this is unclear. C1 [Fordham, M. Taylor; Mulligan, Jennifer K.] Med Univ S Carolina, Dept Otolaryngol, Charleston, SC 29425 USA. [Mulligan, Jennifer K.] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC USA. [Mulligan, Jennifer K.; Wang, Eric W.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. [Casey, Sarah E.; Mulligan, Ryan M.; Wang, Eric W.; Sansoni, E. Ritter; Schlosser, Rodney J.] Med Univ S Carolina, Charleston, SC 29425 USA. [Schlosser, Rodney J.] Ralph H Johnson VA Med Ctr, Dept Surg, Charleston, SC USA. RP Fordham, MT (reprint author), Med Univ S Carolina, Dept Otolaryngol, MSC 550,135 Rutledge Ave, Charleston, SC 29425 USA. EM fordham@musc.edu OI Wang, Eric/0000-0002-1180-5854 FU AAO CORE Resident Research Grant; Flight Attendant Medical Research Institute; VA Merit Grant FX AAO CORE Resident Research Grant, Flight Attendant Medical Research Institute, VA Merit Grant. NR 27 TC 2 Z9 2 U1 0 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 EI 1097-6817 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD OCT PY 2013 VL 149 IS 4 BP 633 EP 638 DI 10.1177/0194599813496377 PG 6 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 218ZR UT WOS:000324472800018 PM 23838308 ER PT J AU Harmon, T Worrall, TJ AF Harmon, Timothy Worrall, Thomas J. TI Retrospective case-control study comparing twice daily insulin glargine and insulin detemir in veteran patients with type 2 diabetes SO PHARMACOTHERAPY LA English DT Meeting Abstract CT Annual Meeting of the American-College-of-Clinical-Pharmacy (ACCP) CY OCT 13-16, 2013 CL Albuquerque, NM SP Amer Coll Clin Pharm C1 [Harmon, Timothy] Ralph H Johnson VAMC, Charleston, SC USA. [Worrall, Thomas J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-0008 EI 1875-9114 J9 PHARMACOTHERAPY JI Pharmacotherapy PD OCT PY 2013 VL 33 IS 10 MA 10 BP E184 EP E184 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 230RM UT WOS:000325360100038 ER PT J AU Higginson, A Pfeifer, M Roberti, A Yi, S McGregor, JC Manning, J Hinton, K Singh, H AF Higginson, Amy Pfeifer, Michelle Roberti, Angie Yi, Stellar McGregor, Jessina C. Manning, Jane Hinton, Kristina Singh, Harleen TI Conversion of Veterans Affairs Patients to Combivent Respimat: A patient follow-up to evaluate adherence, appropriate use, and symptom control. SO PHARMACOTHERAPY LA English DT Meeting Abstract CT Annual Meeting of the American-College-of-Clinical-Pharmacy (ACCP) CY OCT 13-16, 2013 CL Albuquerque, NM SP Amer Coll Clin Pharm C1 [Higginson, Amy; Pfeifer, Michelle; Roberti, Angie; Yi, Stellar; Singh, Harleen] Oregon Hlth & Sci Univ, Oregon State Univ, Coll Pharm, Portland, OR USA. [Manning, Jane] Portland VA Med Ctr, Portland, OR USA. [Hinton, Kristina] Portland VA Med Ctr, Vancouver, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-0008 EI 1875-9114 J9 PHARMACOTHERAPY JI Pharmacotherapy PD OCT PY 2013 VL 33 IS 10 MA 375 BP E294 EP E294 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 230RM UT WOS:000325360100403 ER PT J AU Ranganath, VK Maranian, P Elashoff, DA Woodworth, T Khanna, D Hahn, T Sarkisian, C Kremer, JM Furst, DE Paulus, HE AF Ranganath, Veena K. Maranian, Paul Elashoff, David A. Woodworth, Thasia Khanna, Dinesh Hahn, Theodore Sarkisian, Catherine Kremer, Joel M. Furst, Daniel E. Paulus, Harold E. TI Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis SO RHEUMATOLOGY LA English DT Article DE comorbidities; rheumatoid arthritis; age; remission ID LESS AGGRESSIVE TREATMENT; MINIMAL DISEASE-ACTIVITY; PHYSICAL FUNCTION; CORRONA REGISTRY; ELDERLY-PATIENTS; UNITED-STATES; REMISSION; ETANERCEPT; AGE; POPULATION AB Objective. To evaluate the impact of comorbidities on achieving remission by examining changes in the clinical disease activity index (CDAI) in RA patients in the community-based Consortium of Rheumatology Researchers of North America (CORRONA) registry. Methods. A subcohort of 1548 RA subjects with varying disease duration met the following inclusion criteria: started a DMARD/biologic agent, continued therapy 53 months, CDAI 52.8 at study entry and followed longitudinally from baseline to follow-up (mean time 7.46 months). Patients reported comorbidities according to a standardized list of 33 conditions. Entry characteristics were compared across age categories using one-way analysis of variance. Linear and logistic regression models were constructed to assess characteristics [e. g. age, disease duration, number of previous DMARDs/biologics, baseline modified health assessment questionnaire (MHAQ), baseline CDAI and number of comorbidities] associated with primary outcomes: change in CDAI (baseline to follow-up) and CDAI remission (yes/no). Results. Although disease activity measures at entry were similar across age categories, older patients had more comorbidities, less improvement in CDAI/MHAQ and were less likely to attain remission at follow-up. However, after adjusting covariates an increasing number of patient-reported comorbidities and higher baseline CDAI (but not age) were consistently and independently associated with a lower likelihood of clinical improvement or remission (P<0.001). Conclusion. In this observational cohort of community RA patients an increasing number of patients reported comorbidities, independently correlated with less CDAI improvement over time. These results reaffirm that comorbidities may be an important factor in consideration of treat-to-target recommendations and aid in understanding achievable RA therapeutic goals. C1 [Ranganath, Veena K.; Maranian, Paul; Woodworth, Thasia; Furst, Daniel E.; Paulus, Harold E.] Univ Calif Los Angeles, Dept Med, Div Rheumatol, Los Angeles, CA 90095 USA. [Elashoff, David A.] Univ Calif Los Angeles, Dept Med & Biostat, Los Angeles, CA 90095 USA. [Khanna, Dinesh] Univ Michigan, Div Rheumatol, Ann Arbor, MI 48109 USA. [Hahn, Theodore; Sarkisian, Catherine] Vet Adm Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, Dept Med, Los Angeles, CA USA. [Kremer, Joel M.] Albany Med Coll, Ctr Rheumatol, Albany, NY 12208 USA. RP Ranganath, VK (reprint author), Univ Calif Los Angeles, 1000 Veteran Ave,Rehab Bldg 32-59, Los Angeles, CA 90095 USA. EM vranganath@mednet.ucla.edu FU ACR/REF/ASP Junior Career Development Award in Geriatric Medicine; National Institute of Arthritis and Musculoskeletal and Skin Diseases, part of the National Institutes of Health [NIAMS K23 AR057818-02]; Scleroderma Foundation; National Institutes of Health Award [NIAMS K23 AR053858-04]; Abbvie; Actelion; Amgen; BMS; Gilead; GSK; NIH; Novartis; Pfizer; Roche/Genentech; UCB; Biogen Idec; Janssen; Genetech FX The authors thank Janet Elashoff, PhD, for her editorial comments and insightful discussions. The ACR/REF/ASP Junior Career Development Award in Geriatric Medicine was awarded to V. K. R. The National Institute of Arthritis and Musculoskeletal and Skin Diseases, part of the National Institutes of Health, under award number NIAMS K23 AR057818-02 helped to support V. K. R. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The New Investigator Award from the Scleroderma Foundation and the National Institutes of Health Award (NIAMS K23 AR053858-04) helped to support D.K.'s time.; Disclosure statement: D. E. F is a consultant for and received honoraria and research grants/research support from Abbvie, Actelion, Amgen, BMS, Gilead, GSK, NIH, Novartis, Pfizer, Roche/Genentech, UCB, Biogen Idec and Janssen. J.M.K. is a consultant for Abbvie, Amgen, BMS, Genetech, Pfizer, UCB and Vertex and has received grants from Abbvie, Amgen, BMS, Genetech and Pfizer. All other authors have declared no conflicts of interest. NR 47 TC 20 Z9 21 U1 1 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-0324 EI 1462-0332 J9 RHEUMATOLOGY JI RHEUMATOLOGY PD OCT PY 2013 VL 52 IS 10 BP 1809 EP 1817 DI 10.1093/rheumatology/ket224 PG 9 WC Rheumatology SC Rheumatology GA 239CA UT WOS:000325997900013 PM 23813577 ER PT J AU Smith, MW Bentley, MA Fernandez, AR Gibson, G Schweikhart, SB Woods, DD AF Smith, Michael W. Bentley, Melissa A. Fernandez, Antonio R. Gibson, Gregory Schweikhart, Sharon B. Woods, David D. TI Performance of Experienced Versus Less Experienced Paramedics in Managing Challenging Scenarios: A Cognitive Task Analysis Study SO ANNALS OF EMERGENCY MEDICINE LA English DT Article ID HEALTH-CARE; EXPERTISE; SCENE; WORK AB Study objective: Out-of-hospital care is becoming more complex, thus placing greater reliance on the cognitive abilities of paramedics to manage difficult situations. In adapting to the challenges in their work, paramedics develop expertise. We study the cognitive strategies used by expert paramedics to contribute to understanding how paramedics and the EMS system can adapt to new challenges. Methods: We conducted a "staged-world" cognitive task analysis to explore paramedics' handling of cognitive challenges related to sense-making and to resource and task management. A mixed-fidelity simulation was used to present paramedics with 2 challenging scenarios: a pulmonary embolism initially presenting as a myocardial infarction and a 2-person shooting with limited resources available. Results: Participants were 10 paramedics, 6 more experienced and 4 less experienced. Analysis involved comparing the performance of the 2 groups to identify strategies associated with expertise. The more experienced paramedics made more assessments, explored a wider variety of presumptive diagnoses, and identified the pulmonary embolism earlier. They switched attention between the 2 shooting victims more, used their emergency medical technician basic level partners more, and provided more advanced level care for both patients. Their patients arrived at the emergency department more prepared for specialized emergency care. Conclusion: Our findings correspond to general cognitive attributes of expertise: greater cue gathering and inferential reasoning, and more functional and strategic thinking. These results suggest potential areas and methods to facilitate development of expertise, as well as ways to better support use of expertise. Future studies should expand on these findings through larger sample sizes and more complex scenarios. C1 [Smith, Michael W.; Woods, David D.] Ohio State Univ, Cognit Syst Engn Lab, Inst Ergon, Columbus, OH 43210 USA. [Schweikhart, Sharon B.] Ohio State Univ, Div Hlth Serv Management & Policy, Columbus, OH 43210 USA. [Smith, Michael W.] Baylor Coll Med, Houston VA HSR&D Ctr Excellence, Houston, TX 77030 USA. [Smith, Michael W.] Baylor Coll Med, Ctr Inquiry Improve Outpatient Safety Effect Elec, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Smith, Michael W.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Bentley, Melissa A.] Natl Registry Emergency Med Tech, Columbus, OH USA. [Fernandez, Antonio R.] Univ N Carolina, Dept Emergency Med, Chapel Hill, NC USA. [Gibson, Gregory] Kent State Univ, Dept Sociol, Kent, OH 44242 USA. RP Smith, MW (reprint author), Ohio State Univ, Cognit Syst Engn Lab, Inst Ergon, Columbus, OH 43210 USA. EM ms6@bcm.edu FU National Registry of Emergency Medical Technicians; Google Research Award; Department of Integrated Systems Engineering, College of Engineering, Ohio State University FX By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The authors have stated that no such relationships exist. This research was supported by the National Registry of Emergency Medical Technicians, a Google Research Award, and the Department of Integrated Systems Engineering, College of Engineering, Ohio State University. NR 52 TC 5 Z9 5 U1 1 U2 13 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-0644 J9 ANN EMERG MED JI Ann. Emerg. Med. PD OCT PY 2013 VL 62 IS 4 BP 367 EP 379 DI 10.1016/j.annemergmed.2013.04.026 PG 13 WC Emergency Medicine SC Emergency Medicine GA 229ZZ UT WOS:000325307700016 PM 23787209 ER PT J AU Ganesh, S Guernon, A Chalcraft, L Harton, B Smith, B Pape, TLB AF Ganesh, Shanti Guernon, Ann Chalcraft, Laura Harton, Brett Smith, Bridget Pape, Theresa Louise-Bender TI Medical Comorbidities in Disorders of Consciousness Patients and Their Association With Functional Outcomes SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Brain injuries; Comorbidity; Consciousness disorders; Rehabilitation ID TRAUMATIC BRAIN-INJURY; VEGETATIVE STATE; HEAD-INJURY; FOLLOW-UP; RECOVERY; UNCONSCIOUSNESS; HYDROCEPHALUS; DYSAUTONOMIA; OVERACTIVITY; PREDICTION AB Objective: To identify, for patients in states of seriously impaired consciousness, comorbid conditions present during inpatient rehabilitation and their association with function at 1 year. Design: Abstracted data from a prospective cross-sectional observational study with data collection occurring January 1996 through December 2007. Setting: Four inpatient rehabilitation facilities in metropolitan areas. Participants: The study sample of 68 participants is abstracted from a database of 157 patients remaining in states of seriously impaired consciousness for at least 28 days. Interventions: Not applicable. Main Outcome Measure: One-year cognitive, motor, and total FIM score. Results: The most common medical complications during inpatient rehabilitation for the study sample are active seizures (46%), spasticity (57%), urinary tract infections (47%), and hydrocephalus with and without shunt (38%). Presence of >= 3 medical complications during inpatient rehabilitation, controlling for injury severity, is significantly (P<.05) associated with poorer total FIM and FIM motor scores 1 year after injury. The presence of hydrocephalus with and without shunt (r=-.20, -.21, -.18; P <=.15), active seizures (r=-.31, -.22, -.42), spasticity (r=-.38, -.28, -.40), and urinary tract infections (r=-.25, -.24, -.26) were significantly (P<.10) associated with total FIM, FIM cognitive, and FIM motor scores, respectively. Conclusions: Reported findings indicate that persons in states of seriously impaired consciousness with higher numbers of medical complications during inpatient rehabilitation are more likely to have lower functional levels 1-year postinjury. The findings indicate that persons with >= 3 medical complications during inpatient rehabilitation are at a higher risk for poorer functional outcomes at 1 year. It is, therefore, prudent to evaluate these patients for indications of these complications during inpatient rehabilitation. (c) 2013 by the American Congress of Rehabilitation Medicine C1 [Ganesh, Shanti; Harton, Brett; Smith, Bridget; Pape, Theresa Louise-Bender] US Dept Vet Affairs, Dept Vet Affairs, Res Serv, Edward Hines Jr Vet Affairs Hosp, Hines, IL 60141 USA. [Ganesh, Shanti; Harton, Brett; Smith, Bridget; Pape, Theresa Louise-Bender] US Dept Vet Affairs, Ctr Management Complex Chron Care, Ctr Excellence, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. [Ganesh, Shanti; Chalcraft, Laura] US Dept Vet Affairs, Phys Med & Rehabil Serv, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. [Guernon, Ann] Marianjoy Rehabil Hosp, Wheaton, IL USA. [Smith, Bridget] Loyola Univ Chicago, Program Hlth Serv Res, Stritch Sch Med, Maywood, IL USA. [Pape, Theresa Louise-Bender] Northwestern Univ, Dept Phys Med & Rehabil, Feinberg Sch Med, Chicago, IL 60611 USA. RP Pape, TLB (reprint author), Hines VA Hosp, Ctr Management Complex Chron Care, 5000 S 5th Ave 151H,Bldg 1B260, Hines, IL 60141 USA. EM Theresa.Pape@va.gov OI Pape, Theresa/0000-0001-7738-5963 FU United States Department of Veterans Affairs, Office of Research and Development, Health Services Research and Development Merit [CCN 07-133] FX Supported by the United States Department of Veterans Affairs, Office of Research and Development, Health Services Research and Development Merit (grant no. CCN 07-133). NR 33 TC 9 Z9 10 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD OCT PY 2013 VL 94 IS 10 BP 1899 EP 1907 DI 10.1016/j.apmr.2012.12.026 PG 9 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 231TU UT WOS:000325442100008 PM 23735521 ER PT J AU Wecht, JM Rosado-Rivera, D Weir, JP Ivan, A Yen, C Bauman, WA AF Wecht, Jill M. Rosado-Rivera, Dwindally Weir, Joseph P. Ivan, Adrian Yen, Christina Bauman, William A. TI Hemodynamic Effects of L-Threo-3,4-Dihydroxyphenylserine (Droxidopa) in Hypotensive Individuals With Spinal Cord Injury SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Blood pressure; Droxidopa; Hypotension; Orthostatic hypotension; Paraplegia; Rehabilitation; Tetraplegia ID NEUROGENIC ORTHOSTATIC HYPOTENSION; LOW BLOOD-PRESSURE; L-DIHYDROXYPHENYLSERINE DROXIDOPA; L-THREO-DOPS; COGNITIVE PERFORMANCE; AUTONOMIC FAILURE; TETRAPLEGIC MAN; PREVALENCE; MANAGEMENT; MIDODRINE AB Objectives: To determine the effect of an escalating dose of droxidopa (100, 200, and 400mg) compared with placebo on seated blood pressure (BP) in hypotensive individuals with spinal cord injury (SCI). Secondarily, we aimed to determine the effect of droxidopa on (1) supine BP and heart rate, (2) the change in BP and heart rate when these individuals were transferred from the supine to the seated position, and (3) adverse event (AE) reporting. Design: Open-label dose titration trial. Setting: A Veterans Administration Medical Center. Participants: Participants with SCI (C3-T12) (N=10) were studied during 4 laboratory visits. Subjects visited the laboratory for about 5 hours on each visit, which incorporated a 30-minute seated baseline, a 30- to 60-minute supine, and a 4-hour seated postdrug observation. Interventions: Placebo on visit 1, droxidopa 100mg on visit 2, droxidopa 200mg on visit 3, and droxidopa 400mg on visit 4. Main Outcome Measures: BP and heart rate changes from baseline to the postdrug period, orthostatic heart rate and BP responses, and subjective AE reporting. Results: Seated BP was significantly elevated with 400mg droxidopa compared with placebo and 100mg droxidopa for 3 hours and was elevated for 2 hours compared with 200mg droxidopa. Increase in supine BP was not worsened following droxidopa, and the expected fall in BP when transferred to the seated position was prevented with droxidopa 200 and 400mg. There were no significant differences in the heart rate response or AE reporting among the study visits. Conclusions: Our preliminary findings suggest that droxidopa, at the doses tested, does not cause excessive increases in supine BP and the 400-mg dose appears to be effective at increasing seated BP for up to 3 hours in persons with SCI. (c) 2013 by the American Congress of Rehabilitation Medicine C1 [Wecht, Jill M.; Rosado-Rivera, Dwindally; Ivan, Adrian; Yen, Christina; Bauman, William A.] James J Peters VA Med Ctr, Ctr Excellence, Bronx, NY 10468 USA. [Wecht, Jill M.; Bauman, William A.] James J Peters VA Med Ctr, Med Serv, Bronx, NY 10468 USA. [Wecht, Jill M.; Bauman, William A.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Wecht, Jill M.; Bauman, William A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. [Weir, Joseph P.] Univ Kansas, Dept Hlth Sport & Exercise Sci, Lawrence, KS 66045 USA. RP Wecht, JM (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Rm 7A-13,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM JM.Wecht@va.gov FU Veterans Affairs Rehabilitation Research and Development Service [B2648C] FX Supported by the Veterans Affairs Rehabilitation Research and Development Service (grant no. B2648C). NR 33 TC 3 Z9 3 U1 2 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD OCT PY 2013 VL 94 IS 10 BP 2006 EP 2012 DI 10.1016/j.apmr.2013.03.028 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 231TU UT WOS:000325442100020 PM 23602882 ER PT J AU Trowbridge, RL Dhaliwal, G Cosby, KS AF Trowbridge, Robert L. Dhaliwal, Gurpreet Cosby, Karen S. TI Educational agenda for diagnostic error reduction SO BMJ QUALITY & SAFETY LA English DT Review DE Diagnostic errors; Medical education; Cognitive biases ID COGNITIVE FORCING STRATEGIES; CLINICAL DECISION-MAKING; PATIENT SAFETY; MORTALITY CONFERENCES; MEDICAL ERRORS; MORBIDITY; INTERVENTIONS; PERCEPTIONS; PERFORMANCE; IMPROVEMENT AB Diagnostic errors are a major patient safety concern. Although the majority of diagnostic errors are partially attributable to cognitive mistakes, the most effective means of improving clinician cognition in order to achieve gains in diagnostic reliability are unclear. We propose a tripartite educational agenda for improving diagnostic performance among students, residents and practising physicians. This agenda includes strengthening the metacognitive abilities of clinicians, fostering intuitive reasoning and increasing awareness of the role of systems in the diagnostic process. The evidence supporting initiatives in each of these realms is reviewed and a course of future implementation and study is proposed. The barriers to designing and implementing this agenda are substantial and include limited evidence supporting these initiatives and the challenges of changing the practice patterns of practising physicians. Implementation will need to be accompanied by rigorous evaluation. C1 [Trowbridge, Robert L.] Maine Med Ctr, Dept Med, Portland, ME 04012 USA. [Trowbridge, Robert L.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA. [Dhaliwal, Gurpreet] San Francisco Vet Adm Med Ctr, Med Serv, San Francisco, CA USA. [Dhaliwal, Gurpreet] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA USA. [Cosby, Karen S.] Cook Cty Med Ctr, Dept Emergency Med, Chicago, IL USA. [Cosby, Karen S.] Rush Med Coll, Dept Emergency Med, Chicago, IL 60612 USA. RP Trowbridge, RL (reprint author), Maine Med Ctr, Dept Med, 22 Bramhall St, Portland, ME 04012 USA. EM trowbr@mmc.org NR 57 TC 1 Z9 1 U1 2 U2 13 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-5415 EI 2044-5423 J9 BMJ QUAL SAF JI BMJ Qual. Saf. PD OCT PY 2013 VL 22 SU 2 BP ii28 EP ii32 DI 10.1136/bmjqs-2012-001622 PG 5 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 222NC UT WOS:000324736900005 PM 23764435 ER PT J AU Dawson, DW Hertzer, K Moro, A Donald, G Chang, HH Go, VL Pandol, SJ Lugea, A Gukovskaya, AS Li, G Hines, OJ Rozengurt, E Eibl, G AF Dawson, David W. Hertzer, Kathleen Moro, Aune Donald, Graham Chang, Hui-Hua Go, Vay Liang Pandol, Steven J. Lugea, Aurelia Gukovskaya, Anna S. Li, Gang Hines, Oscar J. Rozengurt, Enrique Eibl, Guido TI High-Fat, High-Calorie Diet Promotes Early Pancreatic Neoplasia in the Conditional Kras(G12D) Mouse Model SO CANCER PREVENTION RESEARCH LA English DT Article ID BODY-MASS INDEX; INTRAEPITHELIAL NEOPLASIA; DUCTAL ADENOCARCINOMA; RISK-FACTORS; CANCER; MICE; CARCINOGENESIS; INFLAMMATION; ENHANCEMENT; PROGRESSION AB There is epidemiologic evidence that obesity increases the risk of cancers. Several underlying mechanisms, including inflammation and insulin resistance, are proposed. However, the driving mechanisms in pancreatic cancer are poorly understood. The goal of the present study was to develop a model of diet- induced obesity and pancreatic cancer development in a state-of-the-art mouse model, which resembles important clinical features of human obesity, for example, weight gain and metabolic disturbances. Offspring of Pdx-1-Cre and LSL-KrasG12D mice were allocated to either a high-fat, highcalorie diet (HFCD; similar to 4,535 kcal/kg; 40% of calories from fats) or control diet (similar to 3,725 kcal/kg; 12% of calories from fats) for 3 months. Compared with control animals, mice fed with the HFCD significantly gained more weight and developed hyperinsulinemia, hyperglycemia, hyperleptinemia, and elevated levels of insulin- like growth factor I (IGF-I). The pancreas of HFCD-fed animals showed robust signs of inflammation with increased numbers of infiltrating inflammatory cells (macrophages and T cells), elevated levels of several cytokines and chemokines, increased stromal fibrosis, and more advanced PanIN lesions. Our results show that a diet high in fats and calories leads to obesity and metabolic disturbances similar to humans and accelerates early pancreatic neoplasia in the conditional KrasG12D mouse model. This model and findings will provide the basis for more robust studies attempting to unravel the mechanisms underlying the cancer-promoting properties of obesity, as well as to evaluate dietary- and chemopreventive strategies targeting obesity-associated pancreatic cancer development. (C)2013 AACR. C1 [Dawson, David W.] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Ctr Excellence Pancreat Dis, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Hertzer, Kathleen; Moro, Aune; Donald, Graham; Chang, Hui-Hua; Hines, Oscar J.; Eibl, Guido] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Ctr Excellence Pancreat Dis, Dept Surg, Los Angeles, CA 90095 USA. [Go, Vay Liang; Pandol, Steven J.; Lugea, Aurelia; Gukovskaya, Anna S.; Rozengurt, Enrique] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Ctr Excellence Pancreat Dis, Dept Med, Los Angeles, CA 90095 USA. [Li, Gang] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA. [Dawson, David W.; Li, Gang; Hines, Oscar J.; Rozengurt, Enrique; Eibl, Guido] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA. [Pandol, Steven J.; Lugea, Aurelia; Gukovskaya, Anna S.] Vet Affairs Greater Los Angeles Hlth Care Syst, Dept Med, Los Angeles, CA USA. [Pandol, Steven J.] Cedars Sinai Med Ctr, Dept Internal Med, Los Angeles, CA 90048 USA. RP Eibl, G (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 LeConte Ave,72-236 CHS, Los Angeles, CA 90095 USA. EM Geibl@mednet.ucla.edu RI Dawson, David/I-5917-2014 FU NIH [P01 CA163200, P01 AT003960, R01 CA122042, P30DK41301]; Department of Veterans Affairs; Hirshberg Foundation for Pancreatic Cancer Research FX This work was supported by NIH ( P01 CA163200, P01 AT003960, R01 CA122042, P30DK41301), Department of Veterans Affairs, and Hirshberg Foundation for Pancreatic Cancer Research. NR 40 TC 30 Z9 30 U1 0 U2 5 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1940-6207 EI 1940-6215 J9 CANCER PREV RES JI Cancer Prev. Res. PD OCT PY 2013 VL 6 IS 10 BP 1064 EP 1073 DI 10.1158/1940-6207.CAPR-13-0065 PG 10 WC Oncology SC Oncology GA 229NE UT WOS:000325272400008 PM 23943783 ER PT J AU Rubinsky, AD Bishop, MJ Maynard, C Henderson, WG Hawn, MT Harris, AHS Beste, LA Tonnesen, H Bradley, KA AF Rubinsky, Anna D. Bishop, Michael J. Maynard, Charles Henderson, William G. Hawn, Mary T. Harris, Alex H. S. Beste, Lauren A. Tonnesen, Hanne Bradley, Katharine A. TI Postoperative risks associated with alcohol screening depend on documented drinking at the time of surgery SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Alcohol; Drinking; AUDIT-C; Postoperative complications; Postoperative health care utilization ID DISORDERS IDENTIFICATION TEST; QUALITY IMPROVEMENT PROGRAM; MAJOR NONCARDIAC SURGERY; ELECTIVE SURGERY; AUDIT-C; VETERANS; CONSUMPTION; MORTALITY; PATIENT; CARE AB Background: Both AUDIT-C alcohol screening scores up to a year before surgery and clinical documentation of drinking over 2 drinks per day immediately prior to surgery ("documented drinking >2 d/d") are associated with increased postoperative complications and health care utilization. The purpose of this study was to evaluate whether documented drinking >2 d/d contributed additional information about postoperative risk beyond past-year AUDIT-C screening results. Method: Male Veterans Affairs (VA) patients who had a non-emergent, non-cardiac, major surgery assessed by the VA's Surgical Quality Improvement Program 10/2003-9/2006 and completed the AUDIT-C by mailed survey in the prior year were eligible for this study. Linear or logistic regression models compared 30-day postoperative complication(s), return to operating room (OR), hospital length of stay (LOS), and intensive care unit (ICU) days across eight groups defined by past-year AUDIT-C score and clinically documented drinking >2 d/d, with AUDIT-C scores 1-4 and no documented drinking >2 d/d as the referent, after adjusting for important covariates. Results: Overall 8811 patients met inclusion criteria. Among patients with documented drinking >2 d/d immediately prior to surgery, postoperative risk varied widely depending on past-year AUDIT-C score; scores >= 5 were associated with increased risk of complication(s), and scores >= 9 with increased hospital LOS and ICU days. Among patients without documentation of drinking >2 d/d, increasing AUDIT-C scores were not associated with these outcomes. Conclusions: Clinical documentation of drinking >2 d/d immediately prior to surgery contributed additional information about postoperative risk beyond past-year AUDIT-C score. However, among patients with documented drinking >2 d/d, postoperative risk varied widely depending on the AUDIT-C score. Published by Elsevier Ireland Ltd. C1 [Rubinsky, Anna D.; Maynard, Charles; Beste, Lauren A.; Bradley, Katharine A.] Dept Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Henderson, William G.] Dept Vet Affairs Eastern Colorado Healthcare Syst, Denver, CO USA. [Harris, Alex H. S.] Dept Vet Affairs Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA 94025 USA. [Hawn, Mary T.] Birmingham Vet Affairs Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA. [Beste, Lauren A.; Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Rubinsky, Anna D.; Maynard, Charles; Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Bishop, Michael J.] Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA. [Henderson, William G.] Univ Colorado, Hlth Outcomes Program, Aurora, CO 80045 USA. [Hawn, Mary T.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35233 USA. [Tonnesen, Hanne] Bispebjerg Hosp, World Hlth Org Collaborating Ctr Evidence Based H, DK-2400 Copenhagen, Denmark. [Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA USA. RP Rubinsky, AD (reprint author), 1660 South Columbian Way S-152, Seattle, WA 98108 USA. EM Anna.Rubinsky@va.gov RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development and Health Services Research and Development [IAC 06-021]; Agency for Healthcare Research and Quality (AHRQ) National Research Services Award (NRSA) at the University of Washington [T32 HS013853] FX The research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development and Health Services Research and Development (IAC 06-021). Dr. Rubinsky was also supported by an Agency for Healthcare Research and Quality (AHRQ) National Research Services Award (NRSA) at the University of Washington (T32 HS013853). The Department of Veterans Affairs and AHRQ had no further role in study design; in the analysis or interpretation of data; in the writing of this report; or in the decision to submit the paper for publication. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs, AHRQ the United States Government, or any of the authors' institutions. NR 36 TC 4 Z9 4 U1 1 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD OCT 1 PY 2013 VL 132 IS 3 BP 521 EP 527 DI 10.1016/j.drugalcdep.2013.03.022 PG 7 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 232RC UT WOS:000325510700018 PM 23683792 ER PT J AU Winston, FK McDonald, CC McGehee, DV AF Winston, Flaura K. McDonald, Catherine C. McGehee, Daniel V. TI Are We Doing Enough to Prevent the Perfect Storm? Novice Drivers, ADHD, and Distracted Driving SO JAMA PEDIATRICS LA English DT Editorial Material ID PROGRAM; TEENS C1 [Winston, Flaura K.; McDonald, Catherine C.] Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA. [Winston, Flaura K.] Univ Penn, Sch Med, Perelman Sch Med, Div Gen Pediat, Philadelphia, PA 19104 USA. [Winston, Flaura K.] Univ Penn, Sch Med, Perelman Sch Med, Leonard David Inst Hlth Econ, Philadelphia, PA 19104 USA. [McDonald, Catherine C.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Ctr Global Womens Hlth, Philadelphia, PA 19104 USA. [McGehee, Daniel V.] Univ Iowa, Human Factors & Vehicle Safety Res Div, Publ Policy Ctr, Injury Prevent Res Ctr, Iowa City, IA USA. RP Winston, FK (reprint author), Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, 3535 Market St,11th Fl, Philadelphia, PA 19104 USA. EM flaura@mail.med.upenn.edu FU NINR NIH HHS [K99 NR013548] NR 15 TC 2 Z9 2 U1 2 U2 16 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6203 EI 2168-6211 J9 JAMA PEDIATR JI JAMA Pediatr. PD OCT PY 2013 VL 167 IS 10 BP 892 EP 894 DI 10.1001/jamapediatrics.2013.2315 PG 3 WC Pediatrics SC Pediatrics GA 232GQ UT WOS:000325480900005 PM 23939682 ER PT J AU Chase, MH AF Chase, Michael H. TI A unified survival theory of the functioning of the hypocretinergic system SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Review DE hypocretin; orexin; behaviors; survival ID CORTICOTROPIN-RELEASING-FACTOR; COERULEUS-NORADRENERGIC SYSTEM; HYPOTHALAMIC DEFENSIVE SYSTEM; SLEEP BEHAVIOR DISORDER; VENTRAL TEGMENTAL AREA; OREXIN KNOCKOUT MICE; BROWN ADIPOSE-TISSUE; HYPOCRETIN/OREXIN NEURONS; ENERGY HOMEOSTASIS; SPINAL-CORD AB This article advances the theory that the hypocretinergic (orexinergic) system initiates, coordinates, and maintains survival behaviors and survival-related processes (i.e., the Unified Survival Theory of the Functioning of the Hypocretinergic System or "Unified Hypocretinergic Survival Theory"). A priori presumptive support for the Unified Hypocretinergic Survival Theory emanates from the fact that neurons that contain hypocretin are located in the key executive central nervous system (CNS) site, the lateral hypothalamus, that for decades has been well-documented to govern core survival behaviors such as fight, flight, and food consumption. In addition, the hypocretinergic system exhibits the requisite morphological and electrophysiological capabilities to control survival behaviors and related processes. Complementary behavioral data demonstrate that all facets of "survival" are coordinated by the hypocretinergic system and that hypocretinergic directives are not promulgated except during survival behaviors. Importantly, it has been shown that survival behaviors are selectively impacted when the hypocretinergic system is impaired or rendered nonfunctional, whereas other behaviors are relatively unaffected. The Unified Hypocretinergic Survival Theory resolves the disparate, perplexing, and often paradoxical-appearing results of previous studies; it also provides a foundation for future hypothesis-driven basic science and clinical explorations of the hypocretinergic system. C1 [Chase, Michael H.] Univ Calif Los Angeles, Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, WebSci Int, Los Angeles, CA 90024 USA. RP Chase, MH (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, WebSci Int, 1251 Westwood Blvd, Los Angeles, CA 90024 USA. EM mchase@websciences.org NR 197 TC 10 Z9 10 U1 1 U2 7 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 EI 1522-1601 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD OCT PY 2013 VL 115 IS 7 BP 954 EP 971 DI 10.1152/japplphysiol.00700.2012 PG 18 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 231YX UT WOS:000325455400002 PM 23640599 ER PT J AU Hanson, LC Ersek, M Lin, FC Carey, TS AF Hanson, Laura C. Ersek, Mary Lin, Feng Chang Carey, Timothy S. TI Outcomes of Feeding Problems in Advanced Dementia in a Nursing Home Population SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE dementia; nutrition; nursing home ID IMPROVING DECISION-MAKING; RESIDENTS; SURVIVAL; TRIAL AB ObjectivesTo describe quality of care for feeding problems in advanced dementia and probability and predictors of weight loss and mortality. DesignProspective cohort. SettingTwenty-four nursing homes (NHs). ParticipantsNursing home residents with advanced dementia and feeding problems and family surrogates (N=256). MeasurementsFamily reported on quality of feeding care at enrollment and 3months. Chart reviews at enrollment and 3, 6, and 9months provided data on feeding problems, treatments, weight loss of more than 5% in 30days or more than 10% in 6months, and mortality. Organizational variables were obtained from administrator surveys and publically reported data. ResultsResidents with advanced dementia and feeding problems had an average age of 85; 80% had chewing and swallowing problems, 11% weight loss, and 48% poor intake. Family reported feeding assistance of moderate quality; 23% felt the resident received less assistance than needed. Mortality risk was significant; 8% died within 3months, 17% within 6months, and 27% within 9months. Residents with advanced dementia who had stable weight over 3months had a 5.4% rate of significant weight loss and a 2.1% risk of death over the next 3months. Residents with advanced dementia and weight loss over 3months had a 38.9% chance of stabilizing weight over the next 3months but also had a 19.2% chance of dying. Weight loss was the only independent predictor of death. ConclusionWeight loss is a predictor of death in advanced dementia. Treatments can often stabilize weight, but weight loss should be used to trigger discussion of goals of care and treatment options. C1 [Hanson, Laura C.] Univ N Carolina, Div Geriatr Med, Chapel Hill, NC 27599 USA. [Hanson, Laura C.] Univ N Carolina, Ctr Aging & Hlth, Chapel Hill, NC 27599 USA. [Hanson, Laura C.; Carey, Timothy S.] Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC 27599 USA. [Ersek, Mary] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Ersek, Mary] Philadelphia Vet Affairs Med Ctr, Natl PROMISE Ctr, Philadelphia, PA USA. [Ersek, Mary] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Lin, Feng Chang] Univ N Carolina, Sch Publ Hlth, Dept Biostat, Chapel Hill, NC 27599 USA. [Carey, Timothy S.] Univ N Carolina, Div Gen Internal Med & Clin Epidemiol, Chapel Hill, NC 27599 USA. RP Hanson, LC (reprint author), Univ N Carolina, Div Geriatr Med, CB 7550, Chapel Hill, NC 27599 USA. EM lhanson@med.unc.edu FU National Institutes of Health National Institute for Nursing Research [R01 NR009826] FX Funding was received from National Institutes of Health National Institute for Nursing Research Grant R01 NR009826: Laura C. Hanson, Mary Ersek, Feng Chang Lin, Timothy S. Carey. NR 18 TC 15 Z9 15 U1 3 U2 18 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD OCT PY 2013 VL 61 IS 10 BP 1692 EP 1697 DI 10.1111/jgs.12448 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 233FG UT WOS:000325551500007 PM 24083403 ER PT J AU Huang, DL Chan, KCG Young, BA AF Huang, Deborah L. Chan, Kwun Chuen Gary Young, Bessie A. TI Poor Oral Health and Quality of Life in Older U.S. Adults with Diabetes Mellitus SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE health-related quality of life; oral health; diabetes mellitus ID UNITED-STATES; CARE VISITS; COMMUNITY; DISEASE AB ObjectiveTo determine the association between health-related quality of life (HRQOL) and oral health in older U.S. adults with diabetes mellitus (DM). DesignCross-sectional. SettingData from the U.S. Behavioral Risk Factor Surveillance System 2006, 2008, and 2010. ParticipantsNationally representative sample of 70,363 adults aged 65 and older with DM. ResultsOlder adults with DM were more likely to report permanent tooth loss due to caries or periodontal disease than those without (82.3% vs 74.3%, P<.001) and less likely to receive dental care in the past year (59.0% vs 70.9%, P<.001). Loss of permanent teeth from caries or periodontal disease was associated with 1.25 times greater odds of worse self-rated general health (95% confidence interval (CI)=1.13-1.37). Lack of dental care in the preceding 12months was associated with 1.34 times greater odds of worse self-rated general health (95% CI=1.25-1.44) than receiving dental care in the preceding 12months. Poor dentition and longer time since last dental visit were associated with more physically unhealthy days. ConclusionsPoor dentition and lack of dental care were associated with worse HRQOL in older adults with DM. Further research is needed to determine whether better oral health improves HRQOL in this population. C1 [Huang, Deborah L.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. [Huang, Deborah L.] Univ Washington, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. [Chan, Kwun Chuen Gary] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Young, Bessie A.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence Hosp & Special, Epidemiol Res & Informat Ctr, Seattle, WA USA. [Young, Bessie A.] Univ Washington, Div Nephrol, Seattle, WA 98195 USA. [Young, Bessie A.] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA. RP Huang, DL (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr S GRECC 182, 1660 S Columbian Way, Seattle, WA 98108 USA. EM huangdx@u.washington.edu FU Veterans Affairs (VA) Puget Sound Health Care System in Seattle, Washington; VA Advanced Fellowship in Geriatrics; VA, from the VA Puget Sound Health Care System, Seattle, Washington; National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases [R01DK079745-01] FX This material is the result of work supported by resources from the Veterans Affairs (VA) Puget Sound Health Care System in Seattle, Washington. Dr. Huang receives salary support from a VA Advanced Fellowship in Geriatrics. Dr. Young receives support from the VA, from the VA Puget Sound Health Care System, Seattle, Washington, and National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Grant R01DK079745-01. NR 28 TC 4 Z9 5 U1 4 U2 17 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD OCT PY 2013 VL 61 IS 10 BP 1782 EP 1788 DI 10.1111/jgs.12452 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 233FG UT WOS:000325551500020 PM 24001058 ER PT J AU Estrella, MM Wyatt, CM Pearce, CL Li, M Shlipak, MG Aouizerat, BE Gustafson, D Cohen, MH Gange, SJ Kao, WHL Parekh, RS AF Estrella, Michelle M. Wyatt, Christina M. Pearce, C. Leigh Li, Man Shlipak, Michael G. Aouizerat, Bradley E. Gustafson, Deborah Cohen, Mardge H. Gange, Stephen J. Kao, W. H. Linda Parekh, Rulan S. TI Host APOL1 genotype is independently associated with proteinuria in HIV infection SO KIDNEY INTERNATIONAL LA English DT Article DE genetic renal disease; HIV; kidney disease; proteinuria ID STAGE RENAL-DISEASE; FOCAL SEGMENTAL GLOMERULOSCLEROSIS; GENOME-WIDE ASSOCIATION; WOMENS INTERAGENCY HIV; KIDNEY-DISEASE; AFRICAN-AMERICANS; ALLOGRAFT SURVIVAL; RISK; VARIANTS; GENE AB Proteinuria is associated with adverse clinical outcomes in HIV infection. Here we evaluated whether APOL1 risk alleles, previously associated with advanced kidney disease, are independently associated with proteinuria in HIV infection in a cross-sectional study of HIV-infected women in the Women's Interagency HIV Study. We estimated the percent difference in urine protein excretion and odds of proteinuria (>= 200 mg/g) associated with two versus one or no APOL1 risk allele using linear and logistic regression, respectively. Of 1285 women successfully genotyped, 379 carried one and 80 carried two risk alleles. Proteinuria was present in 124 women, 78 of whom had proteinuria confirmed on a second sample. In women without prior AIDS, two risk alleles were independently associated with a 69% higher urine protein excretion (95% confidence interval (Cl): 36, 108) and five-fold higher odds of proteinuria (95% CI: 2.45, 10.37) as compared with one or no risk allele. No association was found in women with prior AIDS. Analyses in which women with impaired kidney function were excluded and proteinuria was confirmed by a second urine sample yielded similar estimates. Thus, APOL1 risk alleles are associated with significant proteinuria in HIV-infected persons without prior clinical AIDS, independent of clinical factors traditionally associated with proteinuria. Trials are needed to determine whether APOL1 genotyping identifies individuals who could benefit from earlier intervention to prevent overt renal disease. C1 [Estrella, Michelle M.; Kao, W. H. Linda; Parekh, Rulan S.] Johns Hopkins Univ, Sch Med, Dept Med, Div Nephrol, Baltimore, MD 21205 USA. [Wyatt, Christina M.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Pearce, C. Leigh] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. [Li, Man; Gange, Stephen J.; Kao, W. H. Linda; Parekh, Rulan S.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. [Aouizerat, Bradley E.] Univ Calif San Francisco, Dept Physiol Nursing, Inst Human Genet, San Francisco, CA USA. [Gustafson, Deborah] Suny Downstate Med Ctr, Dept Neurol, Brooklyn, NY 11203 USA. [Gustafson, Deborah] Univ Gothenburg, Sahlgrenska Acad, Neuropsychiat Epidemiol Unit, Sect Psychiat & Neurochem, Gothenburgh, Sweden. [Cohen, Mardge H.] Rush Univ, Med Ctr, Cook Cty Hlth & Hosp Syst, Dept Med, Chicago, IL 60612 USA. [Parekh, Rulan S.] Univ Toronto, Hosp Sick Children, Univ Hlth Network, Toronto, ON M5G 1X8, Canada. RP Estrella, MM (reprint author), Johns Hopkins Univ, Sch Med, Dept Med, Div Nephrol, 1830 E Monument St,Suite 416, Baltimore, MD 21205 USA. EM mestrel1@jhmi.edu OI Gange, Stephen/0000-0001-7842-512X FU National Institute of Diabetes and Digestive and Kidney Diseases [1 K23DK08131]; National Kidney Foundation of Maryland; National Institute of Allergy and Infectious Diseases [UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [UO1-HD-32632]; National Cancer Institute; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Center for Research Resources (UCSF-CTSI) [UL1 RR024131] FX This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (1 K23DK08131 to MME) and through a Mini-Grant provided by the National Kidney Foundation of Maryland (to MME). Data in this manuscript were collected by the Women's Interagency HIV Study (WIHS) Collaborative Study Group with centers (Principal Investigators) at New York City/Bronx Consortium (Kathryn Anastos); Brooklyn, NY (Howard Minkoff); Washington DC, Metropolitan Consortium (Mary Young); The Connie Wofsy Study Consortium of Northern California (Ruth Greenblatt); Los Angeles County/Southern California Consortium (Alexandra Levine); Chicago Consortium (Mardge Cohen); and Data Coordinating Center (Stephen Gange). The WINS is funded by the National Institute of Allergy and Infectious Diseases (UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590) and by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (UO1-HD-32632). The study is cofunded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Funding is also provided by the National Center for Research Resources (UCSF-CTSI Grant number UL1 RR024131). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. NR 39 TC 12 Z9 12 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 EI 1523-1755 J9 KIDNEY INT JI Kidney Int. PD OCT PY 2013 VL 84 IS 4 BP 834 EP 840 DI 10.1038/ki.2013.203 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 229BX UT WOS:000325237900026 PM 23715117 ER PT J AU Bergstrom, AR Nur, F Davis, DL AF Bergstrom, A. Renee Nur, Filsan Davis, Denise Lynne TI Consider the Personhood of Women Who Experienced Genital Cutting SO MAYO CLINIC PROCEEDINGS LA English DT Letter ID FEMALE CIRCUMCISION; CARE C1 [Bergstrom, A. Renee; Nur, Filsan] Mayo Clin, Rochester, MN USA. [Davis, Denise Lynne] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. RP Bergstrom, AR (reprint author), Mayo Clin, Rochester, MN USA. NR 5 TC 1 Z9 1 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0025-6196 EI 1942-5546 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD OCT PY 2013 VL 88 IS 10 BP 1180 EP 1180 DI 10.1016/j.mayocp.2013.08.004 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 232DR UT WOS:000325470800024 PM 24079688 ER PT J AU Steinman, MA Dimaano, L Peterson, CA Heidenreich, PA Knight, SJ Fung, KZ Kaboli, PJ AF Steinman, Michael A. Dimaano, Liezel Peterson, Carolyn A. Heidenreich, Paul A. Knight, Sara J. Fung, Kathy Z. Kaboli, Peter J. TI Reasons for Not Prescribing Guideline-recommended Medications to Adults With Heart Failure SO MEDICAL CARE LA English DT Article DE guideline adherence; heart failure; drug prescribing; performance measurement ID ELECTRONIC HEALTH RECORDS; CORONARY-ARTERY-DISEASE; QUALITY MEASURES; PRIMARY-CARE; PERFORMANCE; PAY; EXCEPTIONS; MANAGEMENT; VETERANS; BARRIERS AB Background:Little is known about how often contextual factors such as patient preferences and competing priorities impact prescribing of guideline-recommended medications, or about the extent to which these factors are documented in medical records and available to performance measurement systems.Methods:Mixed-methods study of 295 veterans aged 50 years and older in 4 VA health care systems who had systolic heart failure and were not prescribed a -blocker and/or an angiotensin converting enzyme inhibitor or angiotensin-receptor blocker. Reasons for nontreatment were identified from clinic notes and from interviews with 62 primary care clinicians caring for these patients. These reasons were classified using a published taxonomy.Results:Among 295 patients not receiving guideline-recommended drugs for heart failure, chart review identified biomedical reasons for nonprescribing in 42%-58% of patients and contextual reasons in 11%-17%. Clinician interviews identified twice as many reasons for nonprescribing as chart review (mean 1.6 vs. 0.8 reasons per patient, P<0.001). In these interviews, biomedical reasons for nonprescribing were cited in 50%-70% of patients, and contextual reasons in 64%-70%. The most common contextual reasons were comanagement with other clinicians (32%-35% of patients), patient preferences and nonadherence (15%-24%), and clinician belief that the medication is not indicated in the patient (12%-20%).Conclusions:Contextual reasons for not prescribing angiotensin converting enzyme inhibitor / angiotensin-receptor blockers and -blockers are present in two thirds of patients with heart failure who did not receive these medications, yet are poorly documented in medical records. The structure of medical records should be improved to facilitate documentation of contextual reasons for not providing guideline-recommended care. C1 [Steinman, Michael A.; Peterson, Carolyn A.; Fung, Kathy Z.] San Francisco VA Med Ctr, Hlth Serv Res & Dev Res Enhancement Award Program, San Francisco, CA 94121 USA. [Steinman, Michael A.; Dimaano, Liezel; Peterson, Carolyn A.; Fung, Kathy Z.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Peterson, Carolyn A.] Univ Oregon, Dept Psychol, Eugene, OR 97403 USA. [Heidenreich, Paul A.] Stanford Univ, Dept Med, Palo Alto VA Hlth Care Syst, Stanford, CA 94305 USA. [Knight, Sara J.] Univ Calif San Francisco, Vet Affairs Off Res & Dev, San Francisco, CA 94143 USA. [Knight, Sara J.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Knight, Sara J.] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA. [Kaboli, Peter J.] Iowa City VA Healthcare Syst, CADRE Ctr, Iowa City, IA USA. [Kaboli, Peter J.] Univ Iowa, Dept Internal Med, Carver Coll Med, Iowa City, IA 52242 USA. RP Steinman, MA (reprint author), San Francisco VA Med Ctr, Hlth Serv Res & Dev Res Enhancement Award Program, POB 181G,4150 Clement St, San Francisco, CA 94121 USA. EM mike.steinman@ucsf.edu FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [IIR 06-080-02, CHF QUERI-04-326]; National Institute on Aging; American Federation for Aging Research [1K23-AG030999] FX Supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (IIR 06-080-02 and CHF QUERI-04-326), and by the National Institute on Aging and the American Federation for Aging Research (1K23-AG030999). The funders had no role in study design, data collection, analysis, interpretation, or the decision to publish this manuscript. NR 28 TC 14 Z9 15 U1 1 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD OCT PY 2013 VL 51 IS 10 BP 901 EP 907 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 222SI UT WOS:000324751000008 PM 23969589 ER PT J AU Lapham, GT Rubinsky, AD Heagerty, PJ Williams, EC Hawkins, EJ Maynard, C Kivlahan, DR Bradley, KA AF Lapham, Gwen T. Rubinsky, Anna D. Heagerty, Patrick J. Williams, Emily C. Hawkins, Eric J. Maynard, Charles Kivlahan, Daniel R. Bradley, Katharine A. TI Annual Rescreening for Alcohol Misuse Diminishing Returns for Some Patient Subgroups SO MEDICAL CARE LA English DT Article DE alcoholism and addictive behaviors; screening; public health ID RANDOMIZED CONTROLLED-TRIAL; IDENTIFICATION TEST AUDIT; SERVICES-TASK-FORCE; PRIMARY-CARE; VETERANS-AFFAIRS; HEALTH-CARE; PREVENTIVE-SERVICES; HAZARDOUS DRINKING; SCREENING SCORES; USE DISORDER AB Background:Routine alcohol screening is widely recommended, and Medicare now reimburses for annual alcohol screening. Although up to 18% of patients will screen positive for alcohol misuse, the value of annual rescreening for patients who repeatedly screen negative is unknown.Objective:To evaluate the probability of converting to a positive alcohol screen at annual rescreening among VA outpatients who previously screened negative 2-4 times.Research Design:Retrospective cohort study.Subjects:A total of 179,035 VA outpatients (10,588 women) who previously screened negative on 2 and up to 4 consecutive annual alcohol screens and were rescreened the next year.Measures:AUDIT-C alcohol screening scores (range, 0-12) were obtained from electronic medical record data. The probability of converting to a positive screen (scores: men 4; women, 3) at rescreening after 2-4 prior negative screens was evaluated overall and across subgroups based on age, sex, and prior negative screen scores (scores: men, 0-3; women, 0-2).Results:The overall probability of converting to a positive subsequent screen decreased modestly from 3.5% to 1.9% as the number of prior consecutive negative screens increased from 2 to 4, yet varied widely across subgroups based on age, sex, and prior negative screen scores (0.6%-38.7%).Conclusions:The likelihood of converting to a positive screen at annual rescreening is strongly influenced by age, sex, and scaled screening scores on prior negative alcohol screens. Algorithms for the frequency of repeat alcohol screening for patients who repeatedly screen negative should be based on these factors. These results may have implications for other routine behavioral health screenings. C1 [Lapham, Gwen T.; Rubinsky, Anna D.; Williams, Emily C.; Hawkins, Eric J.; Maynard, Charles; Kivlahan, Daniel R.; Bradley, Katharine A.] Northwest Ctr Excellence, Hlth Serv Res & Dev HSR&D, Seattle, WA USA. [Lapham, Gwen T.; Rubinsky, Anna D.; Heagerty, Patrick J.; Williams, Emily C.; Maynard, Charles; Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Lapham, Gwen T.; Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA USA. [Heagerty, Patrick J.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Hawkins, Eric J.; Kivlahan, Daniel R.; Bradley, Katharine A.] CESATE, Seattle, WA USA. [Hawkins, Eric J.; Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA USA. RP Lapham, GT (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM gwendolyn.lapham@va.gov RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 FU VA HSR&D Substance Use Disorders Quality Enhancement Research Initiative (QUERI) [RRP 11-021] FX Supported by VA HSR&D Substance Use Disorders Quality Enhancement Research Initiative (QUERI) RRP 11-021. NR 50 TC 5 Z9 5 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD OCT PY 2013 VL 51 IS 10 BP 914 EP 921 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 222SI UT WOS:000324751000010 PM 23969582 ER PT J AU Charalambous, CC Bonilha, HS Kautz, SA Gregory, CM Bowden, MG AF Charalambous, Charalambos C. Bonilha, Heather Shaw Kautz, Steven A. Gregory, Chris M. Bowden, Mark G. TI Rehabilitating Walking Speed Poststroke With Treadmill-Based Interventions: A Systematic Review of Randomized Controlled Trials SO NEUROREHABILITATION AND NEURAL REPAIR LA English DT Article DE cerebrovascular accident; walking; activity-based interventions; rehabilitation ID BODY-WEIGHT SUPPORT; SPINAL-CORD-INJURY; OVERGROUND WALKING; IMPROVES WALKING; STROKE REHABILITATION; ASSISTED WALKING; EXERCISE; OUTCOMES; AMBULATION; SURVIVORS AB Background. In the past several years, several randomized controlled trials (RCTs) have been reported regarding the efficacy of treadmill-based walking-specific rehabilitation programs, either individually (TT) or combined with body weight support (BWSTT), over control group therapies poststroke. No clear consensus exists as to whether treadmill-based interventions are superior in rehabilitating walking speed (WS) poststroke. Objective. To review published RCTs examining TT and BWSTT poststroke and describe the effects on improving and retaining WS. Methods. A systematic literature search in computerized databases was conducted to identify RCTs whose methodological quality was assessed with PEDro. Pre- and post-WS, change in WS, functional outcomes, and follow-up speed were extracted and calculated from each study. Additionally, statistical results of each study were examined, and the intragroup and intergroup effect sizes (ESintra and ESinter, respectively) were calculated. Results. All studies (8 TT; 7 BWSTT) met the inclusion criteria, and their methodological quality was generally good, with a mean PEDro score 6.9/10. Of the 15 studies, 8 studies (4 TT; 4 BWSTT) reported intragroup significant increases of WS, whereas only 4 (4 TT) found superiority of treadmill interventions. Nine studies demonstrated large ESintra (4 TT; 5 BWSTT), yet only 3 showed large ESinter (1 TT; 2 BWSTT). Four studies (2 TT and 2 BWSTT) reported retention of gains in WS, regardless of intervention. Conclusions. Treadmill-based interventions poststroke may increase and retain WS, but their universal superiority to other control group therapies has failed to be established. C1 [Charalambous, Charalambos C.; Bonilha, Heather Shaw; Kautz, Steven A.; Gregory, Chris M.; Bowden, Mark G.] Med Univ S Carolina, Charleston, SC 29425 USA. [Kautz, Steven A.; Gregory, Chris M.; Bowden, Mark G.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Bowden, MG (reprint author), 77 President St,MSC 700, Charleston, SC 29425 USA. EM bowdenm@musc.edu OI Kautz, Steven/0000-0003-3151-8235 FU NIH [KL2 RR029880, KL2 TR000060]; VA RRD [A6776S, B7177M] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This material is the result of work supported with resources and the use of facilities at the Ralph H. Johnson VA Medical Center in Charleston, SC. This work was supported by NIH Grant Numbers KL2 RR029880 and KL2 TR000060 (HSB), VA RR&D A6776S (SAK), and VA RR&D B7177M (MGB). NR 31 TC 2 Z9 2 U1 0 U2 11 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1545-9683 EI 1552-6844 J9 NEUROREHAB NEURAL RE JI Neurorehabil. Neural Repair PD OCT PY 2013 VL 27 IS 8 BP 709 EP 721 DI 10.1177/1545968313491005 PG 13 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 220NQ UT WOS:000324591700005 PM 23764885 ER PT J AU Dobscha, SK AF Dobscha, Steven K. TI Prescription Opioids and Benzodiazepines: Moving Beyond "Just Say No" SO PAIN MEDICINE LA English DT Editorial Material ID PERSISTENT PAIN; THERAPY C1 Portland VA Med Ctr, Ctr Improve Vet Involvement Care CIVIC, Portland, OR USA. RP Dobscha, SK (reprint author), Portland VA Med Ctr, Ctr Improve Vet Involvement Care CIVIC, Portland, OR USA. NR 16 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD OCT PY 2013 VL 14 IS 10 BP 1447 EP 1449 DI 10.1111/pme.12237 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 235BX UT WOS:000325691000003 PM 24588852 ER PT J AU Stephens, C Sackett, N Pierce, R Schopfer, D Schmajuk, G Moy, N Bachhuber, M Wallhagen, MI Lee, SJ AF Stephens, Caroline Sackett, Nathan Pierce, Read Schopfer, David Schmajuk, Gabriela Moy, Nicholas Bachhuber, Melissa Wallhagen, Margaret I. Lee, Sei J. TI Transitional Care Challenges of Rehospitalized Veterans: Listening to Patients and Providers SO POPULATION HEALTH MANAGEMENT LA English DT Article ID HEALTH-CARE; HOSPITAL DISCHARGE; HOMELESS PERSONS; CONTROLLED-TRIAL; PROGRAM; ELDERS AB Readmissions to the hospital are common and costly, often resulting from poor care coordination. Despite increased attention given to improving the quality and safety of care transitions, little is known about patient and provider perspectives of the transitional care needs of rehospitalized Veterans. As part of a larger quality improvement initiative to reduce hospital readmissions, the authors conducted semi-structured interviews with 25 patients and 14 of their interdisciplinary health care providers to better understand their perspectives of the transitional care needs and challenges faced by rehospitalized Veterans. Patients identified 3 common themes that led to rehospitalization: (1) knowledge gaps and deferred power; (2) difficulties navigating the health care system; and (3) complex psychiatric and social needs. Providers identified different themes that led to rehospitalization: (1) substance abuse and mental illness; (2) lack of social or financial support and homelessness; (3) premature discharge and poor communication; and (4) nonadherence with follow-up. Results underscore that rehospitalized Veterans have a complex overlapping profile of real and perceived physical, mental, and social needs. A paradigm of disempowerment and deferred responsibility appears to exist between patients and providers that contributes to ineffective care transitions, resulting in readmissions. These results highlight the cultural constraints on systems of care and suggest that process improvements should focus on increasing the sense of partnership between patients and providers, while simultaneously creating a culture of empowerment, ownership, and engagement, to achieve success in reducing hospital readmissions. (Population Health Management 2013;16:326-331) C1 [Stephens, Caroline; Sackett, Nathan; Moy, Nicholas; Lee, Sei J.] San Francisco VA Med Ctr, Div Geriatr Palliat & Extended Care, San Francisco, CA 94121 USA. [Pierce, Read; Bachhuber, Melissa] San Francisco VA Med Ctr, Dept Hosp Med, San Francisco, CA 94121 USA. [Schopfer, David] San Francisco VA Med Ctr, Dept Cardiol, San Francisco, CA 94121 USA. [Schmajuk, Gabriela] San Francisco VA Med Ctr, Dept Rheumatol, San Francisco, CA 94121 USA. [Stephens, Caroline; Schopfer, David; Schmajuk, Gabriela; Moy, Nicholas; Wallhagen, Margaret I.; Lee, Sei J.] San Francisco VA Med Ctr, Dept VA Qual Scholar, San Francisco, CA 94121 USA. [Stephens, Caroline] Univ Calif San Francisco, San Francisco Sch Nursing, Dept Community Hlth Syst & Social & Behav Sci, San Francisco, CA 94143 USA. [Wallhagen, Margaret I.] Univ Calif San Francisco, San Francisco Sch Nursing, Dept Physiol Nursing, San Francisco, CA 94143 USA. [Stephens, Caroline] John A Hartford Fdn, San Francisco, CA USA. [Sackett, Nathan] Univ Calif Berkeley, Berkeley, CA 94720 USA. [Sackett, Nathan] Univ Calif San Francisco, Joint Med Program, San Francisco, CA 94143 USA. [Pierce, Read; Bachhuber, Melissa] Univ Calif San Francisco, Div Hosp Med, San Francisco, CA 94143 USA. [Schmajuk, Gabriela] Univ Calif San Francisco, Div Rheumatol, San Francisco, CA 94143 USA. [Lee, Sei J.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. RP Stephens, C (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM caroline.stephens@ucsf.edu FU Gordon & Betty Moore Foundation; California Health Care Foundation FX The authors received the following financial support for the research, authorship, and/or publication of this article: The Gordon & Betty Moore Foundation and the California Health Care Foundation provided funding for this project; the VA Quality Scholars program provided postdoctoral training support for Drs. Stephens, Schopfer, Schmajuk, and Moy; the John A. Hartford Foundation/Atlantic Philanthropies Claire M. Fagin Fellows program provided postdoctoral training support for Dr Stephens. NR 32 TC 4 Z9 5 U1 1 U2 7 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1942-7891 EI 1942-7905 J9 POPUL HEALTH MANAG JI Popul. Health Manag. PD OCT 1 PY 2013 VL 16 IS 5 BP 326 EP 331 DI 10.1089/pop.2012.0104 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 216SU UT WOS:000324305200008 PM 23560514 ER PT J AU Babson, KA Heinz, AJ Bonn-Miller, MO AF Babson, Kimberly A. Heinz, Adrienne J. Bonn-Miller, Marcel O. TI HIV Medication Adherence and HIV Symptom Severity: The Roles of Sleep Quality and Memory SO AIDS PATIENT CARE AND STDS LA English DT Article ID ACTIVE ANTIRETROVIRAL THERAPY; AFRICAN-AMERICAN; UNITED-STATES; SUBSTANCE USE; OF-LIFE; INFECTION; WOMEN; DEPRESSION; MORTALITY; ADULTS AB The purpose of the current study was to examine the extent to which self-reported sleep quality, a clinically malleable factor, is associated with both HIV medication adherence and self-reported HIV symptom severity. In addition, we sought to examine whether sleep quality may explain the association between HIV medication adherence and symptom severity, as well as the role of self-reported memory functioning in terms of the above relations. This study took place from April 2010 to March 2012. Participants were 129 HIV-positive individuals who completed an ART pill count and series of structured clinical interviews and self-report questionnaires on sleep, memory, and HIV symptom severity. A series of regressions were conducted to test study hypotheses. After accounting for covariates (i.e., problematic alcohol, nicotine, and cannabis use, and mood disorder diagnosis), results indicated that self-reported sleep quality was associated with HIV medication adherence and self-reported HIV symptom severity, and that sleep quality partially mediated the relation between medication adherence and self-reported HIV symptom severity. In addition, memory functioning moderated the relation between self-reported sleep quality and HIV symptom severity, such that the interaction of poor sleep quality and relatively good memory functioning was associated with heightened self-reported HIV symptom severity. This study highlights the importance of assessing sleep and memory among HIV-infected individuals as they may represent treatment targets for those experiencing poor medication adherence or particularly severe HIV symptoms. Such information could lead to the inclusion of adjunct brief interventions to target sleep and memory functioning in order to reduce symptom severity among HIV-positive individuals with poor medication adherence. C1 [Babson, Kimberly A.; Heinz, Adrienne J.; Bonn-Miller, Marcel O.] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Menlo Pk, CA 94025 USA. [Bonn-Miller, Marcel O.] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Menlo Pk, CA 94025 USA. [Babson, Kimberly A.; Heinz, Adrienne J.] Stanford Sch Med, Dept Psychiat & Behav Sci, Stanford, CA USA. [Bonn-Miller, Marcel O.] Philadelphia VA Med Ctr, Ctr Excellence Subst Abuse Treatment & Educ, Philadelphia, PA USA. [Bonn-Miller, Marcel O.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Babson, KA (reprint author), VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, 795 Willow Rd,152-MPD, Menlo Pk, CA 94025 USA. EM Kimberly.Babson@va.gov FU California HIV/AIDS Research Program IDEA Award [163836]; VA Clinical Science Research and Development (CSR&D) Career Development Award-2; Health Services Research and Development Service funds FX This work was supported, in part, by the following: A California HIV/AIDS Research Program IDEA Award (163836; Bonn-Miller), a VA Clinical Science Research and Development (CSR&D) Career Development Award-2 (Bonn-Miller), and Health Services Research and Development Service funds provided to Drs. Babson and Heinz. The expressed views do not necessarily represent those of the Department of Veterans Affairs. NR 58 TC 9 Z9 10 U1 1 U2 13 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1087-2914 J9 AIDS PATIENT CARE ST JI Aids Patient Care STDS PD OCT 1 PY 2013 VL 27 IS 10 BP 544 EP 552 DI 10.1089/apc.2013.0221 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 229ME UT WOS:000325268600003 PM 24032625 ER PT J AU Tellalian, D Maznavi, K Bredeek, UF Hardy, WD AF Tellalian, David Maznavi, Khalid Bredeek, U. Fritz Hardy, W. David TI Pre-Exposure Prophylaxis (PrEP) for HIV Infection: Results of a Survey of HIV Healthcare Providers Evaluating Their Knowledge, Attitudes, and Prescribing Practices SO AIDS PATIENT CARE AND STDS LA English DT Article ID POSTEXPOSURE PROPHYLAXIS; INTERIM GUIDANCE; PREVENTION; MEN; IMPLEMENTATION; POPULATION; PERCEPTION; WOMEN; SEX; US AB Antiretroviral medications can be taken by HIV-negative persons to prevent HIV infection, also known as pre-exposure prophylaxis (PrEP). PrEP was first shown to be effective during the iPrEX study. We conducted a survey involving HIV healthcare providers to document their attitudes and prescribing practices about PrEP in response to this study. An online survey was completed by 189 members and credentialees of the American Academy of HIV Medicine between April 2011 and September 2011. Ninety percent of respondents were familiar with the results of the iPrEx study, and most (78%) were familiar with CDC's interim guidance regarding the use of PrEP in MSM. Only 19% of respondents had prescribed PrEP. The majority of PrEP prescribers were compliant with CDC interim guidance; however, only 61% screened for hepatitis B. Of PrEP prescribers, 78% prescribed to MSM, 31% to MSW, and 28% to WSM. Greatest concerns about prescribing PrEP included development of antiretroviral resistance (32%), potential increase in high-risk behavior, (22%) and poor medication adherence (21%). Fifty-eight percent stated that HIV serodiscordance within a relationship most influenced their decision to prescribe PrEP to the HIV-seronegative partner. This study demonstrates that, despite awareness of the efficacy of PrEP, its use is limited. Survey participants used PrEP most commonly in MSM; however, a significant percentage also prescribed PrEP to women. The best candidate for PrEP is felt to be individuals in an HIV-serodiscordant relationship. Limitations to our study included a low response rate, changes in the evidence base, and the novelty of PrEP. C1 [Tellalian, David; Hardy, W. David] Cedars Sinai Med Ctr, Dept Internal Med, Div Infect Dis, Los Angeles, CA 90048 USA. [Maznavi, Khalid] Torrance Mem Med Ctr, Torrance, CA USA. [Bredeek, U. Fritz] Metropolis Med, San Francisco, CA USA. [Hardy, W. David] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Tellalian, D (reprint author), VA Greater Los Angeles, Infect Dis Sect IIIF, 11301 Wilshire Blvd,Bldg 500,Ste 4669, Los Angeles, CA 90073 USA. EM dmtellalian@yahoo.com NR 22 TC 44 Z9 44 U1 4 U2 15 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1087-2914 J9 AIDS PATIENT CARE ST JI Aids Patient Care STDS PD OCT 1 PY 2013 VL 27 IS 10 BP 553 EP 559 DI 10.1089/apc.2013.0173 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 229ME UT WOS:000325268600004 PM 24053478 ER PT J AU Froehlich, JC Hausauer, BJ Rasmussen, DD AF Froehlich, Janice C. Hausauer, Brett J. Rasmussen, Dennis D. TI Combining Naltrexone and Prazosin in a Single Oral Medication Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Alcoholism Treatment; Genetic Selection; Naltrexone; Prazosin ID DEPENDENCE-INDUCED INCREASES; RANDOMIZED CONTROLLED-TRIAL; PREFERRING P RATS; RECEPTOR ANTAGONIST; USE DISORDERS; ETHANOL; PREFERENCE; PLACEBO; MODEL; BLOCKADE AB BackgroundNaltrexone (NTX) is underutilized in clinical treatment settings because its efficacy is modest, and it is not effective for all alcoholics and, when it is effective, a significant number of alcoholics fail to maintain initial treatment gains and subsequently relapse to heavy drinking. This has slowed acceptance of NTX by the treatment community, and there is a clear need for additional treatments for alcoholism and alcohol use disorders. Given that NTX and prazosin can each reduce alcohol drinking in rats selectively bred for alcohol preference and high voluntary alcohol drinking (alcohol-preferring P rats), we tested whether a combination of NTX+prazosin is more effective in decreasing alcohol drinking than is either drug alone. MethodsP rats were given access to a 15% (v/v) alcohol solution for 2hours daily. Rats were fed NTX and prazosin, alone or in combination, prior to onset of the daily 2-hour alcohol access period for 4weeks and the effect of drug treatment on alcohol and water intake was assessed. ResultsDuring the first week of treatment, neither a low dose of NTX, nor prazosin, was effective in decreasing alcohol intake when each drug was administered alone, but combining the 2 drugs in a single medication significantly reduced alcohol intake. The combination was as effective as was a higher dose of NTX. Using a low dose of NTX in combination with prazosin may reduce the potential for undesirable side effects early in treatment which, in turn, may improve patient compliance and result in a more successful outcome when NTX is used for treating alcoholism and alcohol use disorders. ConclusionsCombining low-dose NTX and prazosin in a single medication may be more useful than is either drug alone for treating both inpatient and outpatient alcoholics and heavy drinkers early in the treatment process. C1 [Froehlich, Janice C.; Hausauer, Brett J.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Rasmussen, Dennis D.] VA Puget Sound Hlth Care Syst, VISN Mental Illness Res Educ & Clin Ctr 20, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. RP Froehlich, JC (reprint author), Indiana Univ Sch Med, 975 West Walnut St IB 448, Indianapolis, IN 46202 USA. EM jcfroehl@iupui.edu FU NIH [AA018604, AA07611, AA13881] FX We thank Dr. Ting-Kai Li and the Indiana Alcohol Research Center for supplying the selectively bred rats used in this study. This study was supported by NIH grants AA018604 (JCF and DDR), AA07611 (JCF), and AA13881 (DDR). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Alcohol Abuse and Alcoholism or the National Institutes of Health. NR 55 TC 14 Z9 14 U1 1 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD OCT PY 2013 VL 37 IS 10 BP 1763 EP 1770 DI 10.1111/acer.12148 PG 8 WC Substance Abuse SC Substance Abuse GA 229KR UT WOS:000325263500017 PM 23875623 ER PT J AU Durazzo, TC Pennington, DL Schmidt, TP Mon, A Abe, C Meyerhoff, DJ AF Durazzo, Timothy C. Pennington, David L. Schmidt, Thomas P. Mon, Anderson Abe, Christoph Meyerhoff, Dieter J. TI Neurocognition in 1-Month-Abstinent Treatment-Seeking Alcohol-Dependent Individuals: Interactive Effects of Age and Chronic Cigarette Smoking SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Alcohol Use Disorders; Cigarette Smoking; Neurocognition; Alcohol Dependence; Age ID NATIONAL EPIDEMIOLOGIC SURVEY; DSM-IV ALCOHOL; PROCESSING SPEED; COGNITIVE IMPAIRMENT; ABSTINENT ALCOHOLICS; FEMALE ALCOHOLICS; UNITED-STATES; USE DISORDERS; CONSUMPTION; DEFICITS AB BackgroundIncreasing age and chronic cigarette smoking are independently associated with adverse effects on multiple aspects of neurocognition in those seeking treatment for alcohol use disorders. However, the potential interactive effects of age and cigarette smoking on neurocognition in early abstinent alcohol-dependent individuals (ALC) have not investigated. MethodsCross-sectional performances of never-smoking healthy comparison participants (nvsCOM; n=39) and 1-month-abstinent, treatment-seeking, never-smoking (nvsALC; n=30), former-smoking (fsALC; n=21), and actively smoking (asALC; n=68) ALC were compared on a comprehensive neurocognitive battery. Domains of functioning evaluated were cognitive efficiency, executive functions, fine motor skills, general intelligence, learning and memory, processing speed, visuospatial functions and working memory. Participants were between 26 and 71years of age at the time of assessment. ResultsasALC showed steeper age-related effects than nvsCOM on the domains of visuospatial learning, auditory-verbal memory, cognitive efficiency, executive functions, processing speed, and fine motor skills. In pairwise comparisons, fsALC and asALC performed more poorly than both nvsCOM and nvsALC on multiple domains; nvsCOM and nvsALC showed no significant differences. Domain scores for the ALC groups generally fell in the low-to-high-average range of functioning. A clinically significant level of impairment was apparent in only 25% of ALC participants on visuospatial learning, visuospatial memory, and fine motor skills domains. Measures of alcohol use or consumption were not significantly related to neurocognition in the ALC cohorts. ConclusionsThe age-related findings suggest that the combination of active chronic smoking and alcohol dependence in this 1-month-abstinent ALC cohort was associated with greater than normal age-related effects in multiple domains. In general, a low level of clinically significant impairment was observed in the alcohol-dependent participants. The findings from this study, in conjunction with previous research, strongly support smoking cessation interventions for those seeking treatment for alcohol and substance use disorders. C1 [Durazzo, Timothy C.; Pennington, David L.; Schmidt, Thomas P.; Mon, Anderson; Abe, Christoph; Meyerhoff, Dieter J.] San Francisco VA Med Ctr, CIND, San Francisco, CA 94121 USA. [Durazzo, Timothy C.; Pennington, David L.; Abe, Christoph; Meyerhoff, Dieter J.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. RP Durazzo, TC (reprint author), San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis 114 M, 4150 Clement St, San Francisco, CA 94121 USA. EM timothy.durazzo@ucsf.edu OI Abe, Christoph/0000-0002-1680-8480 FU National Institutes of Health [NIH DA24136, NIH AA10788] FX We thank Mary Rebecca Young, Kathleen Altieri, Ricky Chen, and Drs. Peter Banys and Ellen Herbst of the Veterans Administration Substance Abuse Day Hospital, and Dr. David Pating, Karen Moise, and their colleagues at CDRP for their valuable assistance in recruiting participants. We also wish to extend our gratitude to the study participants, who made this research possible. This work was supported by the National Institutes of Health (NIH DA24136 to TCD and NIH AA10788 to DJM) and by the use of resources and facilities at the San Francisco Veterans Administration Medical Center. NR 51 TC 8 Z9 8 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD OCT PY 2013 VL 37 IS 10 BP 1794 EP 1803 DI 10.1111/acer.12140 PG 10 WC Substance Abuse SC Substance Abuse GA 229KR UT WOS:000325263500021 PM 23682867 ER PT J AU Qaseem, A Holty, JEC Owens, DK Dallas, P Starkey, M Shekelle, P AF Qaseem, Amir Holty, Jon-Erik C. Owens, Douglas K. Dallas, Paul Starkey, Melissa Shekelle, Paul CA Amer Coll Phys TI Management of Obstructive Sleep Apnea in Adults: A Clinical Practice Guideline From the American College of Physicians SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID POSITIVE AIRWAY PRESSURE; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; QUALITY-OF-LIFE; CONTROLLED CROSSOVER TRIAL; TEMPERATURE-CONTROLLED-RADIOFREQUENCY; MANDIBULAR REPOSITIONING SPLINT; CORONARY-ARTERY-DISEASE; CHRONIC HEART-FAILURE; 7-YEAR FOLLOW-UP AB Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the management of obstructive sleep apnea (OSA) in adults. Methods: This guideline is based on published literature from 1966 to September 2010 that was identified by using MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews. A supplemental MEDLINE search identified additional articles through October 2012. Searches were limited to English-language publications. The clinical outcomes evaluated for this guideline included cardiovascular disease (such as heart failure, hypertension, stroke, and myocardial infarction), type 2 diabetes, death, sleep study measures (such as the Apnea-Hypopnea Index), measures of cardiovascular status (such as blood pressure), measures of diabetes status (such as hemoglobin A(1c) levels), and quality of life. This guideline grades the evidence and recommendations using ACP's clinical practice guidelines grading system. Recommendation 1: ACP recommends that all overweight and obese patients diagnosed with OSA should be encouraged to lose weight. (Grade: strong recommendation; low-quality evidence) Recommendation 2: ACP recommends continuous positive airway pressure treatment as initial therapy for patients diagnosed with OSA. (Grade: strong recommendation; moderate-quality evidence) Recommendation 3: ACP recommends mandibular advancement devices as an alternative therapy to continuous positive airway pressure treatment for patients diagnosed with OSA who prefer mandibular advancement devices or for those with adverse effects associated with continuous positive airway pressure treatment. (Grade: weak recommendation; low-quality evidence) C1 [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA. Stanford Univ, Stanford, CA 94305 USA. Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. Virginia Tech Univ, Caril Sch Med, Roanoke, VA USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Qaseem, A (reprint author), Amer Coll Physicians, 190 N Independence Mall West, Philadelphia, PA 19106 USA. EM aqaseem@acponline.org FU ACP operating budget FX Financial support for the development of this guideline comes exclusively from the ACP operating budget. NR 163 TC 52 Z9 56 U1 0 U2 18 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD OCT 1 PY 2013 VL 159 IS 7 BP 471 EP U94 DI 10.7326/00030003-4819-159-7-201310010-00704 PG 18 WC Medicine, General & Internal SC General & Internal Medicine GA 234FQ UT WOS:000325628000005 PM 24061345 ER PT J AU Maciejewski, ML Hanlon, JT AF Maciejewski, Matthew L. Hanlon, Joseph T. TI Underreporting Potentially Inappropriate Prescribing for Older Outpatients: Does It Matter? SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material ID BEERS CRITERIA; MEDICATION USE; ADULTS; PEOPLE C1 [Maciejewski, Matthew L.] Duke Univ, Med Ctr, Ctr Hlth Serv Res Primary Care, Durham Vet Affairs Med Ctr, Durham, NC USA. [Maciejewski, Matthew L.] Duke Univ, Med Ctr, Sch Med, Durham, NC 27710 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot & Geriatr Res, Educ & Clin Ctr, Pittsburgh, PA USA. RP Maciejewski, ML (reprint author), Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, 508 Fulton St,Mailstop 152, Durham, NC 27705 USA. FU NIA NIH HHS [K07 AG033174] NR 10 TC 0 Z9 0 U1 0 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD OCT 1 PY 2013 VL 159 IS 7 BP 496 EP U113 DI 10.7326/00030003-4819-159-7-201310010-00012 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 234FQ UT WOS:000325628000010 PM 24081290 ER PT J AU Chen, JQ Bao, Y Lee, J Murray, JL Litton, JK Xiao, L Zhou, R Wu, Y Shen, XY Zhang, H Sahin, AA Katz, RL Bondy, ML Berinstein, NL Hortobagyi, GN Radvanyi, LG AF Chen, J. Q. Bao, Y. Lee, J. Murray, J. L. Litton, J. K. Xiao, L. Zhou, R. Wu, Y. Shen, X. Y. Zhang, H. Sahin, A. A. Katz, R. L. Bondy, M. L. Berinstein, N. L. Hortobagyi, G. N. Radvanyi, L. G. TI Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer SO ANNALS OF ONCOLOGY LA English DT Article DE breast cancer; immunohistochemistry; prognostic marker; TRPS-1 ID TO-MESENCHYMAL TRANSITION; ESTROGEN-RECEPTOR; FINGER PROTEIN; MAMMARY-GLAND; CLAUDIN-LOW; E-CADHERIN; EXPRESSION; GENE; SUBTYPES; APOPTOSIS AB TRPS-1 is a new GATA transcription factor that is differentially expressed in breast cancer (BC) where it been found recently to regulate epithelial-to-mesenchymal transition (EMT). We carried out a quantitative immunohistochemistry (qIHC) analysis of TRPS-1 expression in 341 primary-stage I-III BC samples in relation to patient clinical characteristics as well as its prognostic value, especially in an estrogen receptor-positive (ER+) subgroup. Higher TRPS-1 expression was significantly associated with a number of clinical and pathological characteristics as well as with improved overall survival (OS) and disease-free survival (DFS). Among stage I/II ER+ BC patients who received endocrine therapy alone, those with high TRPS-1 expression had significantly longer OS and DFS. There was also a strong association between TRPS-1 levels and the EMT marker E-cadherin in the ER+ invasive ductal carcinoma cases. Analysis of gene expression data on a panel of BC lines found that TRPS-1 expression was low or absent in BC lines having enriched mesenchymal features. Our data indicated that TRPS-1 is an independent prognostic marker in early-stage BC and a new EMT marker that can distinguish patients with ER+ BC who will respond longer to adjuvant endocrine therapy. C1 [Chen, J. Q.; Bao, Y.; Murray, J. L.; Litton, J. K.; Hortobagyi, G. N.; Radvanyi, L. G.] UT MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX USA. [Chen, J. Q.; Bao, Y.; Radvanyi, L. G.] UT MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX USA. [Lee, J.] UT MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX USA. [Xiao, L.; Wu, Y.; Zhang, H.; Sahin, A. A.; Katz, R. L.] UT MD Anderson Canc Ctr, Dept Pathol, Houston, TX USA. [Xiao, L.] Shanghai Huadong Hosp, Dept Pathol, Shanghai, Peoples R China. [Zhou, R.; Bondy, M. L.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA. [Shen, X. Y.] Baylor Coll Med, Vet Adm Hosp, Dept Pathol, Houston, TX 77030 USA. [Berinstein, N. L.] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada. RP Radvanyi, LG (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Dept Melanoma Med Oncol, Box 904,1515 Holcombe Blvd, Houston, TX 77030 USA. EM lradvanyi@mdanderson.org FU Sanofi Pasteur Canada; Susan G. Komen for the Cure [KG080061]; National Institutes of Health (NIH) [1 P50 CA 116199-01, CA 16672] FX This work was supported in part by a research grant from Sanofi Pasteur Canada (LR), by Susan G. Komen for the Cure grant KG080061 (LR), and by the National Institutes of Health (NIH) grant 1 P50 CA 116199-01 (Breast Cancer SPORE grant), and NIH grant CA 16672 (Cancer Center Support Grant). NR 52 TC 4 Z9 4 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 J9 ANN ONCOL JI Ann. Oncol. PD OCT PY 2013 VL 24 IS 10 BP 2534 EP 2542 DI 10.1093/annonc/mdt190 PG 9 WC Oncology SC Oncology GA 227ZI UT WOS:000325153800012 PM 23729783 ER PT J AU Li, J Yang, PA Wu, Q Li, H Ding, YN Hsu, HC Spalding, DM Mountz, JD AF Li, Jun Yang, PingAr Wu, Qi Li, Hao Ding, Yanna Hsu, Hui-Chen Spalding, David M. Mountz, John D. TI Death Receptor 5-Targeted Depletion of Interleukin-23-Producing Macrophages, Th17, and Th1/17 Associated With Defective Tyrosine Phosphatase in Mice and Patients With Rheumatoid Arthritis SO ARTHRITIS AND RHEUMATISM LA English DT Article ID COLONY-STIMULATING FACTOR; MOTH-EATEN MICE; COLLAGEN-INDUCED ARTHRITIS; DR5 MONOCLONAL-ANTIBODY; CYTOKINE GM-CSF; T-CELLS; SYNOVIAL FIBROBLASTS; EFFECTOR PHASE; T(H)17 CELLS; MUTANT MICE AB ObjectiveBidirectional interactions between granulocyte-macrophage colony-stimulating factor-positive (GM-CSF+) T cells and interferon regulatory factor 5-positive (IRF-5+) macrophages play a major role in autoimmunity. In the absence of SH2 domain-containing phosphatase 1 (SHP-1), GM-CSF-stimulated cells are resistant to death receptor (DR)-mediated apoptosis. The objective of this study was to determine whether TRA-8, an anti-DR5 agonistic antibody, can eliminate inflammatory macrophages and CD4 T cells in the SHP-1-deficient condition. MethodsUbiquitous Cre (Ubc.Cre) human/mouse-chimeric DR5-transgenic mice were crossed with viable SHP-1-defective motheaten (me(v)/me(v)) mice. TRA-8 was administered weekly for up to 4 weeks. The clinical scores, histopathologic severity, and macrophage and CD4 T cell phenotypes were evaluated. The role of TRA-8 in depleting inflammatory macrophages and CD4 T cells was also evaluated, using synovial fluid obtained from patients with rheumatoid arthritis (RA). ResultsThe levels of inflammatory macrophages (interleukin-23-positive [IL-23+] IRF-5+) and CD4 T cells (IL-17+ GM-CSF+) were elevated in me(v)/me(v) mice. In DR5-transgenic me(v)/me(v) mice, DR5 expression was up-regulated in these 2 cell populations. TRA-8 treatment depleted these cell populations and resulted in a significant reduction in inflammation and in the titers of autoantibodies. In synovial cells from patients with RA, the expression of IRF5 and DR5 was negatively correlated with the expression of PTPN6. TRA-8, but not TRAIL, suppressed RA inflammatory macrophages and Th17 cells under conditions in which the expression of SHP-1 is low. ConclusionIn contrast to TRAIL, which lacks the capability to counteract the survival signal in the absence of SHP-1, TRA-8 eliminated both IRF-5+ IL-23+ M1 macrophages and pathogenic GM-CSF+ IL-17+ CD4 T cells in a SHP-1-independent manner. The results of the current study suggest that TRA-8 can deplete inflammatory cell populations that result from a hyperactive GM-CSF/IRF-5 axis. C1 [Li, Jun; Yang, PingAr; Wu, Qi; Li, Hao; Ding, Yanna; Hsu, Hui-Chen; Spalding, David M.; Mountz, John D.] Univ Alabama Birmingham, Birmingham, AL 35294 USA. [Wu, Qi; Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Mountz, JD (reprint author), Univ Alabama Birmingham, SHEL 307,1825 Univ Blvd, Birmingham, AL 35294 USA. EM jdmountz@uab.edu RI Li, Hao/N-7406-2015 OI Li, Hao/0000-0002-2171-8826 FU Arthritis Foundation; Lupus Research Institute; NIH [1R01-AI-083705, 1R01-AI-071110, P30-AR-48311, P30-AR-46031]; Rheumatology Research Foundation grant; Daiichi Sankyo Company, Ltd.; Department of Veterans Affairs [1I01BX000600-01]; University of Alabama at Birmingham Center for Metabolic Bone Disease-Histomorphometry and Molecular Analysis Core Laboratory FX Supported by the Arthritis Foundation (grant to Dr. Li), the Lupus Research Institute (grant to Dr. Hsu), the NIH (grants 1R01-AI-083705 to Dr. Hsu and 1R01-AI-071110 to Dr. Mountz), a Rheumatology Research Foundation grant to Dr. Mountz, Daiichi Sankyo Company, Ltd. (grant to Dr. Mountz), and the Department of Veterans Affairs (Merit Review grant 1I01BX000600-01 to Dr. Mountz). Portions of the study were performed at the University of Alabama at Birmingham Rheumatic Diseases Core Center (Analytical Genomics and Transgenics Core, Comprehensive Flow Cytometry Core, and Analytic Imaging and Immunoreagents Core), supported by NIH grant P30-AR-48311, and the University of Alabama at Birmingham Center for Metabolic Bone Disease-Histomorphometry and Molecular Analysis Core Laboratory, supported by NIH grant P30-AR-46031. NR 43 TC 6 Z9 6 U1 1 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 IS 10 BP 2594 EP 2605 DI 10.1002/art.38057 PG 12 WC Rheumatology SC Rheumatology GA 227TE UT WOS:000325136600013 PM 23818173 ER PT J AU Anyanwu, CO Ang, CC Werth, VP AF Anyanwu, Cynthia O. Ang, Chia Chun Werth, Victoria P. TI Clinical Image: Oral mucosal involvement in bullous lupus SO ARTHRITIS AND RHEUMATISM LA English DT Editorial Material ID ERYTHEMATOSUS; RITUXIMAB C1 [Anyanwu, Cynthia O.] Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Anyanwu, CO (reprint author), Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. FU NIAMS NIH HHS [K24 AR002207] NR 3 TC 2 Z9 4 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 IS 10 BP 2622 EP 2622 DI 10.1002/art.38051 PG 1 WC Rheumatology SC Rheumatology GA 227TE UT WOS:000325136600016 PM 23780804 ER PT J AU Wang, JH New, JS Xie, ST Yang, PA Wu, Q Li, J Luo, B Ding, YN Druey, KM Hsu, HC Mountz, JD AF Wang, John H. New, James S. Xie, Shutao Yang, PingAr Wu, Qi Li, Jun Luo, Bao Ding, Yanna Druey, Kirk M. Hsu, Hui-Chen Mountz, John D. TI Extension of the Germinal Center Stage of B Cell Development Promotes Autoantibodies in BXD2 Mice SO ARTHRITIS AND RHEUMATISM LA English DT Article ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; CYCLIC CITRULLINATED PEPTIDE; INDUCED CYTIDINE DEAMINASE; FOLLICULAR DENDRITIC CELLS; ANTIBODY CLASS SWITCH; RHEUMATOID-ARTHRITIS; PATHOGENIC AUTOANTIBODIES; PLASMA-CELLS; HAPTEN NP; T-CELLS AB ObjectiveRegulator of G protein signaling (RGS) proteins inhibit chemokine signaling by desensitizing G protein-coupled receptor signals. This study was undertaken to determine the mechanisms by which RGS13 promotes the generation of pathogenic autoantibodies in germinal centers (GCs), using BXD2-Rgs13(-/-) mice. MethodsConfocal and light microscopy imaging techniques were used to determine the location of cells that express RGS13 and activation-induced cytidine deaminase (AID) in the mouse spleen, and the number of plasmablasts. The levels of GC and plasma cell program transcripts in GC B cells were determined by real-time quantitative polymerase chain reaction (qPCR). Differential interleukin-17 (IL-17)-mediated expression of RGS13 in GC versus non-GC B cells was analyzed using A20 and 70Z/3 B cells. ResultsIn the spleens of BXD2 mice, RGS13 was mainly expressed by GC B cells and was stimulated by IL-17 but not IL-21. IL-17 up-regulated RGS13 in A20 GC cells but not 70Z/3 non-GC B cells. BXD2- Rgs13(-/-) mice exhibited smaller GCs and lower AID levels, suggesting lower somatic hypermutation and affinity maturation. However, GC B cells from BXD2- Rgs13(-/-) mice showed increased levels of IgM(bright) plasmablasts, up-regulation of the genes encoding plasma program, including interferon regulatory factor 4, B lymphocyte-induced maturation protein 1, and X-box binding protein 1 and the p-CREB target genes Fosb and Obf1, and down-regulation of the GC program genes Aid, Pax5, and Bach2 compared to BXD2 mice. BXD2-Rgs13(-/-) mice had lower titers of IgG autoantibodies and IgG deposits in the glomeruli, suggesting reduced autoantibody pathogenicity. ConclusionRGS13 deficiency is associated with a reduction in GC program genes and the exit of fewer pathogenic IgM plasmablasts in BXD2 mice. Our findings indicate that prolonged GC program, mediated by up-regulation of RGS13, enhances AID expression and enables the generation of pathogenic autoantibodies in autoreactive GCs. C1 [Wang, John H.; New, James S.; Xie, Shutao; Yang, PingAr; Wu, Qi; Li, Jun; Luo, Bao; Ding, Yanna; Hsu, Hui-Chen; Mountz, John D.] Univ Alabama Birmingham, Birmingham, AL 35294 USA. [Druey, Kirk M.] NIAID, NIH, Bethesda, MD 20892 USA. [Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Mountz, JD (reprint author), Univ Alabama Birmingham, SHEL 307,1825 Univ Blvd, Birmingham, AL 35294 USA. EM jdmountz@uab.edu FU NIH (National Institute of Allergy and Infectious Diseases) [1-AI-071110, ARRA 3R01-AI-71110-02S1, 1R01-AI-083705]; NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases) [P30-AR-048311, P30-AI-027767]; NIH (National Institute of Allergy and Infectious Diseases Intramural Research Program); Department of Veterans Affairs [1I01BX000600-01]; Rheumatology Research Foundation; Alliance for Lupus Research; Arthritis Foundation; Lupus Research Institute; NIH [P30-AR-048311, P30-A-I027767] FX Supported by the NIH (National Institute of Allergy and Infectious Diseases grants 1-AI-071110, ARRA 3R01-AI-71110-02S1, and 1R01-AI-083705, National Institute of Arthritis and Musculoskeletal and Skin Diseases grants P30-AR-048311 and P30-AI-027767, and the National Institute of Allergy and Infectious Diseases Intramural Research Program), the Department of Veterans Affairs (Merit Review grant 1I01BX000600-01), the Rheumatology Research Foundation (Within Our Reach grant), the Alliance for Lupus Research, the Arthritis Foundation, and the Lupus Research Institute. Flow cytometry and confocal imaging data acquisition were performed at the University of Alabama at Birmingham Comprehensive Flow Cytometry Core (supported by NIH grants P30-AR-048311 and P30-A-I027767) and Analytic Imaging and Immunoreagents Core (supported by NIH grant P30-AR-048311). NR 48 TC 9 Z9 9 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 IS 10 BP 2703 EP 2712 DI 10.1002/art.38059 PG 10 WC Rheumatology SC Rheumatology GA 227TE UT WOS:000325136600026 PM 23818250 ER PT J AU Boekholdt, SM Arsenault, BJ Hovingh, GK Mora, S Pedersen, TR LaRosa, JC Welch, KMA Amarenco, P DeMicco, DA Tonkin, AM Sullivan, DR Kirby, A Colhoun, HM Hitman, GA Betteridge, DJ Durrington, PN Clearfield, MB Downs, JR Gotto, AM Ridker, PM Kastelein, JJP AF Boekholdt, S. Matthijs Arsenault, Benoit J. Hovingh, G. Kees Mora, Samia Pedersen, Terje R. LaRosa, John C. Welch, K. M. A. Amarenco, Pierre DeMicco, David A. Tonkin, Andrew M. Sullivan, David R. Kirby, Adrienne Colhoun, Helen M. Hitman, Graham A. Betteridge, D. John Durrington, Paul N. Clearfield, Michael B. Downs, John R. Gotto, Antonio M., Jr. Ridker, Paul M. Kastelein, John J. P. TI Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients A Meta-Analysis SO CIRCULATION LA English DT Article DE apolipoproteins; cardiovascular diseases; high-density lipoprotein cholesterol; meta-analysis ID DENSITY-LIPOPROTEIN CHOLESTEROL; RANDOMIZED CONTROLLED-TRIAL; CORONARY-HEART-DISEASE; HIGH-DOSE ATORVASTATIN; PRIMARY PREVENTION; LDL CHOLESTEROL; THERAPY; ATHEROSCLEROSIS; ASSOCIATION; SIMVASTATIN AB Background It is unclear whether levels of high-density lipoprotein cholesterol (HDL-C) or apolipoprotein A-I (apoA-I) remain inversely associated with cardiovascular risk among patients who achieve very low levels of low-density lipoprotein cholesterol on statin therapy. It is also unknown whether a rise in HDL-C or apoA-I after initiation of statin therapy is associated with a reduced cardiovascular risk. Methods and Results We performed a meta-analysis of 8 statin trials in which lipids and apolipoproteins were determined in all study participants at baseline and at 1-year follow-up. Individual patient data were obtained for 38153 trial participants allocated to statin therapy, of whom 5387 suffered a major cardiovascular event. HDL-C levels were associated with a reduced risk of major cardiovascular events (adjusted hazard ratio [HR], 0.83; 95% confidence interval [CI], 0.81-0.86 per 1 standard deviation increment), as were apoA-I levels (HR, 0.79; 95% CI, 0.72-0.82). This association was also observed among patients achieving on-statin low-density lipoprotein cholesterol levels <50 mg/dL. An increase of HDL-C was not associated with reduced cardiovascular risk (HR, 0.98; 95% CI, 0.94-1.01 per 1 standard deviation increment), whereas a rise in apoA-I was (HR, 0.93; 95% CI, 0.90-0.97). Conclusions Among patients treated with statin therapy, HDL-C and apoA-I levels were strongly associated with a reduced cardiovascular risk, even among those achieving very low low-density lipoprotein cholesterol. An apoA-I increase was associated with a reduced risk of major cardiovascular events, whereas for HDL-C this was not the case. These findings suggest that therapies that increase apoA-I concentration require further exploration with regard to cardiovascular risk reduction. C1 [Arsenault, Benoit J.; Hovingh, G. Kees; Kastelein, John J. P.] Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands. [Arsenault, Benoit J.; Hovingh, G. Kees; Kastelein, John J. P.] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands. [Mora, Samia; Ridker, Paul M.] Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Boston, MA 02115 USA. [Pedersen, Terje R.] Oslo Univ Hosp, Ctr Prevent Med, Ulleval, Norway. [Pedersen, Terje R.] Univ Oslo, N-0316 Oslo, Norway. [LaRosa, John C.] SUNY Hlth Sci Ctr, Brooklyn, NY USA. [Welch, K. M. A.] Rosalind Franklin Univ Med & Sci, N Chicago, IL USA. [Amarenco, Pierre] Hop Xavier Bichat, Dept Neurol, Paris, France. [Amarenco, Pierre] Hop Xavier Bichat, Stroke Ctr, Paris, France. [DeMicco, David A.] Global Pharmaceut Pfizer, New York, NY USA. [Tonkin, Andrew M.] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia. [Sullivan, David R.] Univ Sydney, Royal Prince Alfred Hosp, Dept Biochem, Sydney, NSW 2006, Australia. [Sullivan, David R.] Univ Sydney, Royal Prince Alfred Hosp, Lipid Clin, Sydney, NSW 2006, Australia. [Kirby, Adrienne] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia. [Colhoun, Helen M.] Univ Dundee, Med Res Inst, Dundee, Scotland. [Hitman, Graham A.] Queen Mary Univ London, Barts & London Sch Med & Dent, Ctr Diabet, London, England. [Betteridge, D. John] Royal Free & Univ Coll Med Sch, Dept Med, London WC1E 6BT, England. [Durrington, Paul N.] Univ Manchester, Sch Biomed, Manchester, Lancs, England. [Clearfield, Michael B.] Touro Univ, Mare Isl, CA USA. [Downs, John R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Downs, John R.] South Texas Vet Hlth Care Syst, VERDICT, San Antonio, TX USA. [Gotto, Antonio M., Jr.] Weill Cornell Med Coll, New York, NY USA. RP Kastelein, JJP (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands. EM j.j.kastelein@amc.uva.nl RI Boekholdt, Matthijs/G-7562-2014 OI Colhoun, Helen/0000-0002-8345-3288 FU Veni grant from the Netherlands Organisation for Scientific Research (NWO) [91612122)]; National Heart, Lung, and Blood Institute [R01HL117861] FX This study was not supported by any funding. The contributing trials were funded by their respective sponsors. Dr Hovingh is funded by a Veni grant (project number 91612122) from the Netherlands Organisation for Scientific Research (NWO). Dr Mora is funded by a National Heart, Lung, and Blood Institute grant (number R01HL117861). The sponsors of the contributing trials provided the requested data. They did not play any role in the statistical analysis, interpretation of the data, or the decision to submit the manuscript. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 31 TC 62 Z9 65 U1 4 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD OCT 1 PY 2013 VL 128 IS 14 BP 1504 EP 1512 DI 10.1161/CIRCULATIONAHA.113.002670 PG 9 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 228WB UT WOS:000325221500011 PM 23965489 ER PT J AU Borrero, S Farkas, A Dehlendorf, C Rocca, CH AF Borrero, Sonya Farkas, Amy Dehlendorf, Christine Rocca, Corinne H. TI Racial and ethnic differences in men's knowledge and attitudes about contraception SO CONTRACEPTION LA English DT Article DE Race; Disparities; Men; Contraception; Attitudes; Knowledge ID DECISION-MAKING; UNITED-STATES; UNINTENDED PREGNANCY; YOUNG-ADULTS; DISPARITIES; WOMEN AB Background: Little is known about racial/ethnic differences in men's contraceptive knowledge and attitudes. Study Design: We used multivariable logistic regression to examine racial/ethnic differences in contraceptive knowledge and attitudes among 903 men aged 18-29 in the 2009 National Survey of Reproductive and Contraceptive Knowledge. Results: Black and Hispanic men were less likely than Whites to have heard of most contraceptive methods, including female and male sterilization, and also had lower knowledge about hormonal and long-acting reversible methods. They were less likely to know that pills are ineffective when 2-3 pills are missed [Blacks: adjusted odds ratio (aOR)=0.42; Hispanics: aOR=0.53] and that fertility was not delayed after stopping the pill (Blacks: aOR=0.52; Hispanics: aOR=0.27). Hispanics were less likely to know that nulliparous women can use the intrauterine device (aOR=0.47). Condom knowledge was similar by race/ethnicity, but Blacks were less likely to view condoms as a hassle than Whites (aOR=0.46). Conclusions: Efforts to educate men, especially men of color, about contraceptive methods are needed. Published by Elsevier Inc. C1 [Borrero, Sonya] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA 15213 USA. [Borrero, Sonya] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Farkas, Amy] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15213 USA. [Dehlendorf, Christine] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA. [Dehlendorf, Christine; Rocca, Corinne H.] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, Bixby Ctr Global Reprod Hlth, San Francisco, CA 94143 USA. RP Borrero, S (reprint author), Univ Pittsburgh, Ctr Res Hlth Care, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM borrerosp@upmc.edu FU Eunice Kennedy Shriver National Institute of Child Health & Human Development [1R21HD068736-01A1, K23HD067197]; National Campaign to Prevent Teenage and Unplanned Pregnancy [1R21HD068736-01A1, K23HD067197] FX This work was supported by grant numbers 1R21HD068736-01A1 and K23HD067197 from the Eunice Kennedy Shriver National Institute of Child Health & Human Development and the National Campaign to Prevent Teenage and Unplanned Pregnancy. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Eunice Kennedy Shriver National Institute of Child Health & Human Development or the National Institutes of Health. NR 32 TC 7 Z9 7 U1 4 U2 21 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD OCT PY 2013 VL 88 IS 4 BP 532 EP 538 DI 10.1016/j.contraception.2013.04.002 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 225PN UT WOS:000324974900011 PM 23697702 ER PT J AU Bramoweth, AD Germain, A AF Bramoweth, Adam D. Germain, Anne TI Deployment-Related Insomnia in Military Personnel and Veterans SO CURRENT PSYCHIATRY REPORTS LA English DT Article DE Insomnia; Comorbid insomnia; Military personnel; Veterans; PTSD; Depression; Anxiety; Traumatic brain injury; Suicide; Psychotherapy; Pharmacotherapy; Sleep disorders; Psychiatry ID TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; BRIEF BEHAVIORAL TREATMENT; ADVERSE CHILDHOOD EXPERIENCES; SLEEP DISTURBANCES; COMBAT VETERANS; CHRONIC NIGHTMARES; SERVICE MEMBERS; DEPRESSION; IRAQ AB Insomnia is a prevalent disorder that greatly impacts military personnel, especially those deployed in support of combat efforts. Deployment-related stressors like combat exposure, mild traumatic brain injury (mTBI) irregular sleep-wake schedules, and adjustment to the return home all contribute to insomnia. However, insomnia can also exacerbate the deployment experience and is a risk factor for traumatic stress reactions such as PTSD, depression, and suicide. Military personnel with mTBI are significantly impacted by insomnia; the majority experience sleep disruption and this can impede recovery and rehabilitation. As more service members return home from deployment, treatment is vital to reduce the impact of insomnia. Preliminary outcome data, showing positive results for reduction of sleep disruption, has been found with treatments such as combined cognitive behavioral treatment of insomnia (CBTI) and imagery rehearsal therapy (IRT), preference-based interventions, as well as efforts to broadly disseminate CBTI. The recent literature on the impact and treatment of deployment-related insomnia is reviewed. C1 [Bramoweth, Adam D.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA 15206 USA. [Bramoweth, Adam D.; Germain, Anne] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA. [Germain, Anne] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. RP Germain, A (reprint author), Univ Pittsburgh, Sch Med, Dept Psychiat, 3811 OHara St,Sterling Plaza 239, Pittsburgh, PA 15213 USA. EM adam.bramoweth@va.gov; germax@upmc.edu OI Bramoweth, Adam/0000-0002-3535-0292 FU VISN 4 Mental Illness Research, Education and Clinical Center (MIRECC), VA Pittsburgh Healthcare System; Congressionally Directed Medical Research Program [PT073961 W81XWH-08-1-0637, PR054093-W81XWH-07-PTSD-IIRA]; National Institute of Mental Health [MH080696] FX Dr. Bramoweth's work is supported by resources and funding from the VISN 4 Mental Illness Research, Education and Clinical Center (MIRECC, Director: D. Oslin; Pittsburgh Site Director: G. Haas), VA Pittsburgh Healthcare System. Dr. Germain's work is supported by the Congressionally Directed Medical Research Program (PT073961 W81XWH-08-1-0637; PR054093-W81XWH-07-PTSD-IIRA) and the National Institute of Mental Health (MH080696). The contents do not represent the views of the Department of Veterans Affairs, Department of Defense, or the United States Government. NR 65 TC 14 Z9 15 U1 1 U2 18 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3812 J9 CURR PSYCHIAT REP JI Curr. Psychiatry Rep. PD OCT PY 2013 VL 15 IS 10 AR 401 DI 10.1007/s11920-013-0401-4 PG 8 WC Psychiatry SC Psychiatry GA 224JI UT WOS:000324880100003 PM 24005883 ER PT J AU Lu, H Zhang, W Graham, DY AF Lu, Hong Zhang, Wei Graham, David Y. TI Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China SO EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY LA English DT Review DE Helicobacter pylori; quadruple therapy; review; treatment; treatment success ID TRIPLE THERAPY; ANTIBIOTIC-RESISTANCE; DUODENAL-ULCER; PEPTIC-ULCER; OPEN-LABEL; CURE RATE; IN-VITRO; ERADICATION; EFFICACY; INFECTION AB Antimicrobial resistance has continued to undermine many popular anti-Helicobacter pylori therapies. Antibiotic resistance to commonly used anti-H. pylori drugs in China has increased markedly, making China an ideal site to identify regimens that remain effective despite widespread antimicrobial resistance. Bismuth is one of the few antimicrobials to which resistance does not develop. Factors contributing to H. pylori treatment success include host factors (e.g. genetic differences in the metabolism of the drugs used), bacterial factors (e.g. susceptibility), and details of the regimen (e.g. doses, dosing interval, dosing in relation to meals, formulation, etc.). We reviewed the recent experience in China with bismuth-containing quadruple therapies. The experience consists of 16 studies with 25 arms involving 1971 patients to identify successful regimens (defined as reliably obtaining 90% or greater eradication per protocol) deserving further study. Despite high rates of resistance to commonly used antimicrobials, several regimens could achieve high success. These were characteristically 14-day regimens containing a proton pump inhibitor and either tetracycline and metronidazole or furazolidone and amoxicillin. We propose approaches for further development including for optimization and simplification related to convenience and side effects (e.g. twice rather than three or four times daily or administration at the noon and evening meal instead of at breakfast and evening) while maintaining effectiveness of at least 90%. Studies in China identified regimens that were highly effective despite the high prevalence of resistance to metronidazole, fluoroquinolones, and macrolides. Multicenter randomized studies will be required to confirm which is the best. C1 [Lu, Hong; Zhang, Wei] Shanghai Jiao Tong Univ, Key Lab Gastroenterol & Hepatol, Shanghai Inst Digest Dis, Sch Med,GI Div,Ren Ji Hosp,Minist Hlth, Shanghai 200030, Peoples R China. [Graham, David Y.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. RP Graham, DY (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, RM 3A-322 111D,2002 Holcombe Blvd, Houston, TX 77030 USA. EM dgraham@bcm.tmc.edu FU Key Laboratory of Gastroenterology & Hepatology, Ministry of Health (Renji Hospital, Shanghai Jiao-Tong University School of Medicine); National Natural Science Foundation of China [81170355, 81200287]; Office of Research and Development Medical Research Service Department of Veterans Affairs, Public Health Service Grant [DK56338, DK067366, CA116845] FX This study was supported by the grant for Key Laboratory of Gastroenterology & Hepatology, Ministry of Health (Renji Hospital, Shanghai Jiao-Tong University School of Medicine), and the National Natural Science Foundation of China (81170355, 81200287). Dr Graham is supported in part by the Office of Research and Development Medical Research Service Department of Veterans Affairs, Public Health Service Grant DK56338, which funds the Texas Medical Center Digestive Diseases Center, DK067366 and CA116845. NR 58 TC 21 Z9 24 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0954-691X J9 EUR J GASTROEN HEPAT JI Eur. J. Gastroenterol. Hepatol. PD OCT PY 2013 VL 25 IS 10 BP 1134 EP 1140 DI 10.1097/MEG.0b013e3283633b57 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 219SX UT WOS:000324530800002 PM 23778309 ER PT J AU Win, AZ Aparici, CM AF Win, Aung Zaw Aparici, Carina Mari TI Real-time FDG PET/CT-guided bone biopsy in a patient with two primary malignancies SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING LA English DT Editorial Material C1 [Win, Aung Zaw] San Francisco VA Med Ctr, Nucl Med Sect, Dept Radiol, San Francisco, CA 94121 USA. [Aparici, Carina Mari] Univ Calif San Francisco, Dept Radiol, Nucl Med Sect, San Francisco, CA 94143 USA. RP Win, AZ (reprint author), San Francisco VA Med Ctr, Nucl Med Sect, Dept Radiol, 4150 Clement St, San Francisco, CA 94121 USA. EM aungzwin@gmail.com NR 4 TC 3 Z9 3 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1619-7070 J9 EUR J NUCL MED MOL I JI Eur. J. Nucl. Med. Mol. Imaging PD OCT PY 2013 VL 40 IS 11 BP 1787 EP 1788 DI 10.1007/s00259-013-2492-x PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 227QO UT WOS:000325128800017 PM 23828652 ER PT J AU LaVela, SL Gering, J Schectman, G Locatelli, SM Weaver, FM Davies, M AF LaVela, Sherri L. Gering, Jeffrey Schectman, Gordon Locatelli, Sara M. Weaver, Frances M. Davies, Michael TI Improving the quality of telephone-delivered health care: a national quality improvement transformation initiative SO FAMILY PRACTICE LA English DT Article DE Health communication; health care delivery; primary health care; patient preference; patient-centred care; quality improvement ID PATIENT SATISFACTION; CONSULTATION; INFORMATION; CALLERS; VETERAN; ADVICE; ACCESS AB Many Veterans Affairs (VA) primary care (PC) patients prefer telephone-delivered care to other health care delivery modalities. To evaluate PC patients telephone experiences and outcomes before and after a national telephone transformation quality improvement (QI) collaborative. Cross-sectional surveys were conducted pre- and post-collaborative. We used bivariate analyses to assess differences in pre/post outcomes and multivariate regression to identify variables associated with patients perceptions of poor quality care. Patients from 13 VA facilities participated (n 730; pre-intervention 314, post-intervention 416); most of them were males (90%) with a mean age of 62 years. After the collaborative (versus pre-collaborative), few experienced transfers (52% versus 62%, P 0.0006) and most reported timely call answer (88% versus 80%, P 0.003). Improvements in staff understanding why patients were calling and providing needed medical information were also found. There were measurable improvements in patient satisfaction (87% versus 82% very/mostly satisfied, P 0.04) and perceived quality of telephone care (85% versus 78% excellent/good quality, P 0.01) post- collaborative. The proportion of veterans who reported delayed care due to telephone access issues decreased from 41% to 15% after the collaborative, P < 0.0001. Perceptions of poor quality care were higher when calls were for urgent care needs did not result in receipt of needed information and included a transfer or untimely answer. The QI collaborative led to improvements in timeliness of answering calls, patient satisfaction and perceptions of high-quality telephone care and fewer reports of health care delays. Barriers to optimal telephone care quality include untimely answer, transfers, non-receipt of needed information and urgent care needs. C1 [LaVela, Sherri L.; Locatelli, Sara M.; Weaver, Frances M.] US Dept Vet Affairs, Ctr Management Complex Chron Care, Edward Hines Jr VA Hosp, Hines, IL 60141 USA. [LaVela, Sherri L.] Northwestern Univ, Feinberg Sch Med, Inst Publ Hlth & Med, Ctr Healthcare Studies, Chicago, IL 60611 USA. [Gering, Jeffrey] Chillicothe Vet Affairs Med Ctr, Chillicothe, OH USA. [Gering, Jeffrey] Ohio Univ, Chillicothe, OH USA. [Schectman, Gordon] Vet Affairs Cent Off, Off Patient Care Serv, Washington Dc, CO USA. [Schectman, Gordon] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA. [Weaver, Frances M.] Loyola Univ, Stritch Sch Med, Program Hlth Serv Res, Maywood, IL 60153 USA. [Davies, Michael] Vet Affairs Cent Off, Off Syst Redesign, Washington Dc, CO USA. RP LaVela, SL (reprint author), US Dept Vet Affairs, Ctr Management Complex Chron Care, 5000 S 5th Ave,151H, Hines, IL 60141 USA. EM Sherri.LaVela@va.gov FU Office of Systems Redesign of the Department of Veterans Affairs FX The authors wish to thank the PC patients who participated in this study. This material is based upon work supported by the Office of Systems Redesign of the Department of Veterans Affairs. This paper reflects only the authors' opinions and does not necessarily reflect the official position of the Department of Veterans Affairs. A portion of these findings were presented as a poster at the VA HSR&D 2012 annual meeting. NR 24 TC 2 Z9 2 U1 2 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0263-2136 J9 FAM PRACT JI Fam. Pr. PD OCT PY 2013 VL 30 IS 5 BP 533 EP 540 DI 10.1093/fampra/cmt020 PG 8 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 228KF UT WOS:000325184200009 PM 23689516 ER PT J AU Mayer, CL Huber, BR Peskind, E AF Mayer, Cynthia L. Huber, Bertrand R. Peskind, Elaine TI Traumatic Brain Injury, Neuroinflammation, and Post-Traumatic Headaches SO HEADACHE LA English DT Review DE traumatic brain injury; inflammation; glia; microglia; astrocytes; satellite cells; blood brain barrier; cytokines; post-traumatic headaches; inflammatory mediators ID CENTRAL-NERVOUS-SYSTEM; SATELLITE GLIAL-CELLS; CORTICAL SPREADING DEPRESSION; DIFFUSE AXONAL INJURY; TUMOR-NECROSIS-FACTOR; CHRONIC PAIN; HEAD-INJURY; INFLAMMATORY RESPONSE; NEUROPATHIC PAIN; CERVICOGENIC HEADACHE AB Concussions following head and/or neck injury are common, and although most people with mild injuries recover uneventfully, a subset of individuals develop persistent post-concussive symptoms that often include headaches. Post-traumatic headaches vary in presentation and may progress to become chronic and in some cases debilitating. Little is known about the pathogenesis of post-traumatic headaches, although shared pathophysiology with that of the brain injury is suspected. Following primary injury to brain tissues, inflammation rapidly ensues; while this inflammatory response initially provides a defensive/reparative function, it can persist beyond its beneficial effect, potentially leading to secondary injuries because of alterations in neuronal excitability, axonal integrity, central processing, and other changes. These changes may account for the neurological symptoms often observed after traumatic brain injury, including headaches. This review considers selected aspects of the inflammatory response following traumatic brain injury, with an emphasis on the role of glial cells as mediators of maladaptive post-traumatic inflammation. C1 [Mayer, Cynthia L.; Huber, Bertrand R.; Peskind, Elaine] VA Puget Sound Hlth Care Syst, VA Northwest Network Mental Illness Res Educ & Cl, Seattle, WA 98108 USA. [Mayer, Cynthia L.; Peskind, Elaine] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Mayer, CL (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S116 MIRECC, Seattle, WA 98108 USA. EM cmayer@u.washington.edu FU NIA NIH HHS [P50 AG005136] NR 143 TC 27 Z9 28 U1 0 U2 37 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-8748 EI 1526-4610 J9 HEADACHE JI Headache PD OCT PY 2013 VL 53 IS 9 BP 1523 EP 1530 DI 10.1111/head.12173 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 228AH UT WOS:000325156600020 PM 24090534 ER PT J AU Chapman, LW Hsiao, JL Lewis, M Chiu, MW Shellow, WVR AF Chapman, Lance W. Hsiao, Jennifer L. Lewis, Michael Chiu, Melvin W. Shellow, William V. R. TI Progressive violaceous nodules and plaques in an elderly man SO INTERNATIONAL JOURNAL OF DERMATOLOGY LA English DT Article C1 [Chapman, Lance W.; Hsiao, Jennifer L.; Chiu, Melvin W.] Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Los Angeles, CA 90095 USA. [Lewis, Michael] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Pathol, Los Angeles, CA USA. [Lewis, Michael] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Lab Med, Los Angeles, CA USA. [Chiu, Melvin W.; Shellow, William V. R.] Vet Affairs West Los Angeles Healthcare Ctr, Dept Dermatol, Los Angeles, CA USA. RP Chiu, MW (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Dept Med, 200 Med Plaza,Suite 450, Los Angeles, CA 90095 USA. EM mchiu@mednet.ucla.edu NR 7 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0011-9059 J9 INT J DERMATOL JI Int. J. Dermatol. PD OCT PY 2013 VL 52 IS 10 BP 1165 EP 1167 DI 10.1111/ijd.12141 PG 3 WC Dermatology SC Dermatology GA 227EA UT WOS:000325090800001 PM 23834652 ER PT J AU Dubsky, M Jirkovska, A Bem, R Fejfarova, V Skibova, J Schaper, NC Lipsky, BA AF Dubsky, Michal Jirkovska, Alexandra Bem, Robert Fejfarova, Vladimira Skibova, Jelena Schaper, Nicolaas C. Lipsky, Benjamin A. TI Risk factors for recurrence of diabetic foot ulcers: prospective follow-up analysis in the Eurodiale subgroup SO INTERNATIONAL WOUND JOURNAL LA English DT Article DE Diabetic foot ulcer; Risk factors for reulceration; Ulcer recurrence ID PERIPHERAL ARTERIAL-DISEASE; COHORT; INFECTION; PEOPLE; CARE; POPULATION; ULCERATION; AMPUTATION; CONSENSUS; ISCHEMIA AB Few studies have examined factors associated with diabetic foot ulcer (DFU) recurrence. Using data from patients enrolled in the prospective Eurodiale DFU study, we investigated the frequency of and risk factors for DFU recurrence after healing during a 3-year follow-up period. At our site, 93 Eurodiale-enrolled patients had a healed DFU. Among these, 14 were not alive; of the remaining 79 patients we enrolled 73 in this study. On entry to the Eurodiale study, we assessed demographic factors (age, sex and distance from hospital); diabetes-related factors [duration, and glycated haemoglobin (HbA1c) levels]; comorbidities (obesity, renal failure, smoking and alcohol abuse) and DFU-related factors [peripheral arterial disease, ulcer infection, C-reactive protein (CRP) and; foot deformities]. During the 3-year follow-up period, a DFU had recurred in 42 patients (575%). By stepwise logistic regression of findings at initial DFU presentation, the significant independent predictors for recurrence were plantar ulcer location [odds ratio (OR) 862, 95% confidence interval (CI) 22-332]; presence of osteomyelitis (OR 517, 95% CI 14-187); HbA1c > 75% ([DCCT], OR 407, 95% CI 11-156) and CRP > 5 mg/l (OR 427, 95% CI 12-157). In these patients with a healed DFU, the majority had a recurrence of DFU during a 3-year follow-up period, despite intensive foot care. The findings at diagnosis of the initial DFU were independent risk factors associated with ulcer recurrence (plantar location, bone infection, poor diabetes control and elevated CRP) and define those at high risk for recurrence, but may be amenable to targeted interventions. C1 [Dubsky, Michal; Jirkovska, Alexandra; Bem, Robert; Fejfarova, Vladimira; Skibova, Jelena] Inst Clin & Expt Med, Ctr Diabet, Prague 14021 4, Czech Republic. [Schaper, Nicolaas C.] Univ Hosp Maastricht, Dept Internal Med, Maastricht, Netherlands. [Lipsky, Benjamin A.] Univ Washington, Dept Med, Gen Med Serv, VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Dubsky, M (reprint author), Inst Clin & Expt Med, Ctr Diabet, Videnska 1958-9, Prague 14021 4, Czech Republic. EM michal.dubsky@gmail.com RI Schaper, Nicolaas/E-7112-2014 OI Lipsky, Benjamin A./0000-0001-9886-5114 FU [MZO 00023001] FX We thank the members of Eurodiale group for realisation of first step of the study: L. Prompers, M. Huijberts, J. Apelqvist, E. Jude, A. Piaggesi, K. Bakker, M. Edmonds, P. Holstein, D. Mauricio, G. Ragnarson Tennvall, H. Reike, M. Spraul, L. Uccioli, V. Urbancic, K. Van Acker, J. van Baal and F. van Merode. This research was supported by grant MZO 00023001. The authors do not have any competing interests. NR 33 TC 25 Z9 31 U1 0 U2 19 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1742-4801 J9 INT WOUND J JI Int. Wound J. PD OCT PY 2013 VL 10 IS 5 BP 555 EP 561 DI 10.1111/j.1742-481X.2012.01022.x PG 7 WC Dermatology; Surgery SC Dermatology; Surgery GA 227DW UT WOS:000325090300013 PM 22712631 ER PT J AU Erickson, MA Banks, WA AF Erickson, Michelle A. Banks, William A. TI Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Review DE Alzheimer's disease; blood-brain barrier; cerebrospinal fluid; diabetes; inflammation; neurovascular unit ID AMYLOID-BETA-PROTEIN; CEREBROSPINAL-FLUID BARRIER; RECEPTOR-RELATED PROTEIN-1; ENDOTHELIAL GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; MILD COGNITIVE IMPAIRMENT; INDUCED DIABETIC MICE; WHITE-MATTER LESIONS; SMOOTH-MUSCLE-CELLS; P-GLYCOPROTEIN AB The blood-brain barrier (BBB) plays critical roles in the maintenance of central nervous system (CNS) homeostasis. Dysfunction of the BBB occurs in a number of CNS diseases, including Alzheimer's disease (AD). A prevailing hypothesis in the AD field is the amyloid cascade hypothesis that states that amyloid-beta (A beta) deposition in the CNS initiates a cascade of molecular events that cause neurodegeneration, leading to AD onset and progression. In this review, the participation of the BBB in the amyloid cascade and in other mechanisms of AD neurodegeneration will be discussed. We will specifically focus on three aspects of BBB dysfunction: disruption, perturbation of transporters, and secretion of neurotoxic substances by the BBB. We will also discuss the interaction of the BBB with components of the neurovascular unit in relation to AD and the potential contribution of AD risk factors to aspects of BBB dysfunction. From the results discussed herein, we conclude that BBB dysfunction contributes to AD through a number of mechanisms that could be initiated in the presence or absence of A beta pathology. C1 [Erickson, Michelle A.; Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA. [Erickson, Michelle A.; Banks, William A.] Univ Washington, Sch Med, Dept Internal Med, Div Gerontol & Geriatr Med, Seattle, WA 98108 USA. [Erickson, Michelle A.] Univ Penn, Sch Dent Med, Dept Pathol, Seattle, WA USA. RP Banks, WA (reprint author), Univ Washington, Sch Med, Dept Internal Med, Div Gerontol & Geriatr Med, Bldg 1,Room 810A,1660 Columbian Way, Seattle, WA 98108 USA. EM wabanks1@uw.edu FU NIEHS NIH HHS [T32 ES019851] NR 237 TC 108 Z9 113 U1 5 U2 55 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0271-678X EI 1559-7016 J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD OCT PY 2013 VL 33 IS 10 BP 1500 EP 1513 DI 10.1038/jcbfm.2013.135 PG 14 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA 228PV UT WOS:000325199600004 PM 23921899 ER PT J AU Lin, AL Pulliam, DA Deepa, SS Halloran, JJ Hussong, SA Burbank, RR Bresnen, A Liu, YH Podlutskaya, N Soundararajan, A Muir, E Duong, TQ Bokov, AF Viscomi, C Zeviani, M Richardson, AG Van Remmen, H Fox, PT Galvan, V AF Lin, Ai-Ling Pulliam, Daniel A. Deepa, Sathyaseelan S. Halloran, Jonathan J. Hussong, Stacy A. Burbank, Raquel R. Bresnen, Andrew Liu, Yuhong Podlutskaya, Natalia Soundararajan, Anuradha Muir, Eric Duong, Timothy Q. Bokov, Alex F. Viscomi, Carlo Zeviani, Massimo Richardson, Arlan G. Van Remmen, Holly Fox, Peter T. Galvan, Veronica TI Decreased in vitro mitochondrial function is associated with enhanced brain metabolism, blood flow, and memory in Surf1-deficient mice SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE glucose metabolism; memory; mitochondrial complex IV; mitochondrial dysfunction; Surf1 ID ELEGANS LIFE-SPAN; CAENORHABDITIS-ELEGANS; OXIDATIVE STRESS; BINDING PROTEIN; FACTOR 1-ALPHA; RESPIRATION; SENSITIVITY; ANESTHESIA; INCREASES; LONGEVITY AB Recent studies have challenged the prevailing view that reduced mitochondrial function and increased oxidative stress are correlated with reduced longevity. Mice carrying a homozygous knockout (KO) of the Surf1 gene showed a significant decrease in mitochondrial electron transport chain Complex IV activity, yet displayed increased lifespan and reduced brain damage after excitotoxic insults. In the present study, we examined brain metabolism, brain hemodynamics, and memory of Surf1 KO mice using in vitro measures of mitochondrial function, in vivo neuroimaging, and behavioral testing. We show that decreased respiration and increased generation of hydrogen peroxide in isolated Surf1 KO brain mitochondria are associated with increased brain glucose metabolism, cerebral blood flow, and lactate levels, and with enhanced memory in Surf1 KO mice. These metabolic and functional changes in Surf1 KO brains were accompanied by higher levels of hypoxia-inducible factor 1 alpha, and by increases in the activated form of cyclic AMP response element-binding factor, which is integral to memory formation. These findings suggest that Surf1 deficiency-induced metabolic alterations may have positive effects on brain function. Exploring the relationship between mitochondrial activity, oxidative stress, and brain function will enhance our understanding of cognitive aging and of age-related neurologic disorders. C1 [Lin, Ai-Ling; Bresnen, Andrew; Soundararajan, Anuradha; Muir, Eric; Duong, Timothy Q.; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Lin, Ai-Ling; Pulliam, Daniel A.; Deepa, Sathyaseelan S.; Halloran, Jonathan J.; Hussong, Stacy A.; Burbank, Raquel R.; Liu, Yuhong; Podlutskaya, Natalia; Bokov, Alex F.; Richardson, Arlan G.; Van Remmen, Holly; Galvan, Veronica] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. [Lin, Ai-Ling; Pulliam, Daniel A.; Deepa, Sathyaseelan S.; Liu, Yuhong; Podlutskaya, Natalia; Bokov, Alex F.; Richardson, Arlan G.; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78245 USA. [Halloran, Jonathan J.; Hussong, Stacy A.; Burbank, Raquel R.; Podlutskaya, Natalia; Duong, Timothy Q.; Fox, Peter T.; Galvan, Veronica] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78245 USA. [Viscomi, Carlo; Zeviani, Massimo] Ist Neurol C Besta, Mol Neurogenet Unit, Milan, Italy. [Richardson, Arlan G.; Van Remmen, Holly] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. [Richardson, Arlan G.; Van Remmen, Holly] South Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX USA. RP Galvan, V (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, 15355 Lambda Dr, San Antonio, TX 78245 USA. EM lina3@uthscsa.edu; galvanv@uthscsa.edu RI Duong, Timothy/B-8525-2008; Zeviani, Massimo/K-2891-2014; Fox, Peter/B-4725-2010; Viscomi, Carlo/R-1940-2016 OI Fox, Peter/0000-0002-0465-2028; FU Ellison Medical Foundation; William and Ella Owens Medical Research Foundation; CTSA/KL2 [UL1TR000149]; NIA [K01AG040164, T32AG21890] FX This work was supported by an Ellison Medical Foundation Senior Scholar Award in Aging and a New Scholar Award in Aging to HVR and VG, respectively, a William and Ella Owens Medical Research Foundation Grant to VG, and by CTSA/KL2 (UL1TR000149) and an NIA grant K01AG040164 to ALL. SAH is supported by NIA Training Grant T32AG21890. NR 33 TC 13 Z9 13 U1 0 U2 7 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0271-678X J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD OCT PY 2013 VL 33 IS 10 BP 1605 EP 1611 DI 10.1038/jcbfm.2013.116 PG 7 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA 228PV UT WOS:000325199600015 PM 23838831 ER PT J AU Goetz, MB Hoang, T Knapp, H Burgess, J Fletcher, MD Gifford, AL Asch, SM AF Goetz, Matthew Bidwell Tuyen Hoang Knapp, Herschel Burgess, Jane Fletcher, Michael D. Gifford, Allen L. Asch, Steven M. CA QUERI-HIV-Hepatitis Program TI Central Implementation Strategies Outperform Local Ones in Improving HIV Testing in Veterans Healthcare Administration Facilities SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE HIV/AIDS; implementation research; quality improvement; diagnosis ID UNITED-STATES; PRACTICE GUIDELINES; COST-EFFECTIVENESS; FEEDBACK; AUDIT; ADOLESCENTS; REMINDERS; SETTINGS; ADULTS; TRIAL AB Pilot data suggest that a multifaceted approach may increase HIV testing rates, but the scalability of this approach and the level of support needed for successful implementation remain unknown. To evaluate the effectiveness of a scaled-up multi-component intervention in increasing the rate of risk-based and routine HIV diagnostic testing in primary care clinics and the impact of differing levels of program support. Three arm, quasi-experimental implementation research study. Veterans Health Administration (VHA) facilities. Persons receiving primary care between June 2009 and September 2011 A multimodal program, including a real-time electronic clinical reminder to facilitate HIV testing, provider feedback reports and provider education, was implemented in Central and Local Arm Sites; sites in the Central Arm also received ongoing programmatic support. Control Arm sites had no intervention Frequency of performing HIV testing during the 6 months before and after implementation of a risk-based clinical reminder (phase I) or routine clinical reminder (phase II). The adjusted rate of risk-based testing increased by 0.4 %, 5.6 % and 10.1 % in the Control, Local and Central Arms, respectively (all comparisons, p < 0.01). During phase II, the adjusted rate of routine testing increased by 1.1 %, 6.3 % and 9.2 % in the Control, Local and Central Arms, respectively (all comparisons, p < 0.01). At study end, 70-80 % of patients had been offered an HIV test. Use of clinical reminders, provider feedback, education and social marketing significantly increased the frequency at which HIV testing is offered and performed in VHA facilities. These findings support a multimodal approach toward achieving the goal of having every American know their HIV status as a matter of routine clinical practice. C1 [Goetz, Matthew Bidwell] VA Greater Los Angeles Healthcare Syst, Infect Dis Sect 111F, Los Angeles, CA 90073 USA. [Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Tuyen Hoang; Knapp, Herschel; Burgess, Jane; Fletcher, Michael D.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Gifford, Allen L.] Edith Nourse Rogers Mem Vet Hosp, VA Bedford Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Gifford, Allen L.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Gifford, Allen L.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Asch, Steven M.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Asch, Steven M.] Stanford Univ, Sch Med, Div Gen Med Disciplines, Palo Alto, CA 94304 USA. RP Goetz, MB (reprint author), VA Greater Los Angeles Healthcare Syst, Infect Dis Sect 111F, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mgoetz@ucla.edu OI Goetz, Matthew/0000-0003-4542-992X FU Health Services Research & Development Service [SDP 08-002] FX We acknowledge and are grateful for the invaluable support for this project that was provided by Ana Goffin, Barbara Kertz, Thomas Giordano, MD, and Scott Sherman, MD, MPH, as well as the providers and leadership in the many VHA medical facilities that participated in this study. This project was supported by a research grant to Drs. Goetz and Asch by the Health Services Research & Development Service (SDP 08-002). NR 37 TC 14 Z9 14 U1 2 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD OCT PY 2013 VL 28 IS 10 BP 1311 EP 1317 DI 10.1007/s11606-013-2420-6 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 226DP UT WOS:000325015000015 PM 23605307 ER PT J AU Steinhilber, S Rodriguez, JM Estrada, CA Kraemer, RR AF Steinhilber, Starr Rodriguez, J. Martin Estrada, Carlos A. Kraemer, Ryan R. TI A 76-Year-Old Woman with Diaphoresis and Anxiety SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID METACOGNITION; PERCEPTIONS; PERSPECTIVE; STRATEGIES; EXPERTISE; MODEL C1 [Steinhilber, Starr; Kraemer, Ryan R.] Univ Alabama Birmingham, Tinsley Harrison Internal Med Residency Program, Birmingham, AL 35294 USA. [Rodriguez, J. Martin; Estrada, Carlos A.; Kraemer, Ryan R.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Estrada, Carlos A.; Kraemer, Ryan R.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Estrada, Carlos A.] Vet Affairs Qual Scholars Program, Birmingham, AL USA. RP Kraemer, RR (reprint author), Univ Alabama Birmingham, Dept Med, 720 Fac Off Tower 510 20th St, Birmingham, AL 35294 USA. EM rkraemer@uab.edu NR 23 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD OCT PY 2013 VL 28 IS 10 BP 1376 EP 1380 DI 10.1007/s11606-013-2500-7 PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 226DP UT WOS:000325015000026 PM 23729373 ER PT J AU Denby, K Nelson, G Estrada, CA AF Denby, Kara Nelson, George Estrada, Carlos A. TI Bedside Hand Grip Assessment with the Sphygmomanometer SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material DE physical examination; hand Strength; muscle strength dynamometer C1 [Denby, Kara; Nelson, George; Estrada, Carlos A.] Univ Alabama Birmingham, Birmingham, AL 35294 USA. [Nelson, George] Univ Alabama Birmingham, Tinsley Harrison Internal Med Residency Program, Birmingham, AL 35294 USA. [Estrada, Carlos A.] Birmingham Vet Affairs Med Ctr, Vet Affairs Qual Scholars Program, Birmingham, AL USA. [Estrada, Carlos A.] Univ Alabama Birmingham, Div Gen Internal Med, Birmingham, AL 35294 USA. RP Estrada, CA (reprint author), Univ Alabama Birmingham, Div Gen Internal Med, 732 Fac Off Tower,510 20th St South, Birmingham, AL 35294 USA. EM cestrada@uab.edu NR 2 TC 1 Z9 1 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD OCT PY 2013 VL 28 IS 10 BP 1381 EP 1381 DI 10.1007/s11606-013-2426-0 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 226DP UT WOS:000325015000027 PM 23568188 ER PT J AU Sakamoto, M Woods, SP Kolessar, M Kriz, D Anderson, JR Olavarria, H Sasaki, AW Chang, M Flora, KD Loftis, JM Huckans, M AF Sakamoto, Maiko Woods, Steven Paul Kolessar, Michael Kriz, Daniel Anderson, J. Renee Olavarria, Hannah Sasaki, Anna W. Chang, Michael Flora, Kenneth D. Loftis, Jennifer M. Huckans, Marilyn TI Protective effects of higher cognitive reserve for neuropsychological and daily functioning among individuals infected with hepatitis C SO JOURNAL OF NEUROVIROLOGY LA English DT Article DE Hepatitis C; Cognitive reserve; Neuropsychological assessment; Daily functioning ID INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; MAGNETIC-RESONANCE-SPECTROSCOPY; CENTRAL-NERVOUS-SYSTEM; VIRUS-INFECTION; ALZHEIMERS-DISEASE; DSM-IV; HIV; IMPAIRMENT; RISK; METHAMPHETAMINE AB Higher levels of cognitive reserve (CR) can be protective against the neuropsychological manifestation of neural injury across a variety of clinical disorders. However, the role of CR in the expression of neurocognitive deficits among persons infected with the hepatitis C virus (HCV) is not well understood. Thirty-nine HCV-infected participants were classified as having either high (n = 19) or low (n = 20) CR based on educational attainment, oral word reading, and IQ scores. A sample of 40 demographically comparable healthy adults (HA) was also included. All participants completed the Neuropsychological Assessment Battery, Delis-Kaplan Executive Function System, and Behavioral Rating Inventory of Executive Function, Adult Version (BRIEF-A). Linear regression analyses, controlling for gender, depression, and lifetime substance use disorders, found significant effects of HCV/CR group on verbal fluency, executive functions, and daily functioning T scores, but not in learning or the BRIEF-A. Pairwise comparisons revealed that the HCV group with low CR performed significantly below the HCV high CR and HA cohorts, who did not differ from one another. Findings indicate that higher levels of CR may be a protective factor in the neurocognitive and real-world manifestation of neural injury commonly associated with HCV infection. C1 [Sakamoto, Maiko; Woods, Steven Paul] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Kolessar, Michael; Kriz, Daniel; Anderson, J. Renee] Univ Pacific, Sch Profess Psychol, Hillsboro, OR 97123 USA. [Kriz, Daniel] Oregon Hlth & Sci Univ, Inst Dev & Disabil, Portland, OR 97239 USA. [Olavarria, Hannah; Loftis, Jennifer M.; Huckans, Marilyn] Portland VA Med Ctr, Res & Dev Serv, Portland, OR 97239 USA. [Sasaki, Anna W.; Chang, Michael] Portland VA Med Ctr, Gastroenterol Serv, Portland, OR 97239 USA. [Chang, Michael] Oregon Hlth & Sci Univ, Dept Internal Med, Portland, OR 97239 USA. [Flora, Kenneth D.] Oregon Clin, Portland Gastroenterol Div, Clackamas, OR 97015 USA. [Loftis, Jennifer M.; Huckans, Marilyn] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA. [Huckans, Marilyn] Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR 97239 USA. [Huckans, Marilyn] Portland VA Med Ctr, Portland, OR 97239 USA. RP Huckans, M (reprint author), Portland VA Med Ctr, Mailstop P3MHN,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM marilyn.huckans@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development [R25-MH081482] FX This study was supported in part by R25-MH081482 to MS as well as by career development awards to MH and JML from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development. This material is the result of work supported with resources and the use of facilities at the Portland Veterans Affairs Medical Center, Portland, OR. The authors thank the study participants and staff at each of the recruitment sites, especially Betsy Zucker and Janice Voukidis. The authors also acknowledge Peter Hauser, William Hoffman, Diane Howieson, Daniel Storzbach, and Alexander Stevens for study design consultation. NR 55 TC 6 Z9 6 U1 4 U2 14 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 IS 5 BP 442 EP 451 DI 10.1007/s13365-013-0196-4 PG 10 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 228YM UT WOS:000325228100005 PM 24018902 ER PT J AU Chemerinski, E Triebwasser, J Roussos, P Siever, LJ AF Chemerinski, Eran Triebwasser, Joseph Roussos, Panos Siever, Larry J. TI SCHIZOTYPAL PERSONALITY DISORDER SO JOURNAL OF PERSONALITY DISORDERS LA English DT Article ID EVENT-RELATED POTENTIALS; CARD SORTING TEST; SCHIZOPHRENIA SPECTRUM DISORDERS; OBSESSIVE-COMPULSIVE DISORDER; AUDITORY WORKING-MEMORY; PURSUIT EYE-MOVEMENTS; FRONTAL-LOBE FUNCTION; DSM-III; PREPULSE INHIBITION; ROSCOMMON FAMILY AB Early phenomenological descriptions of schizophrenia have acknowledged the existence of milder schizophrenia spectrum disorders characterized by the presence of attenuated symptoms typically present in chronic schizophrenia. The investigation of the schizophrenia spectrum disorders offers an opportunity to elucidate the pathophysiological mechanisms giving rise to schizophrenia. Differences and similarities between subjects with schizotypal personality disorder (SPD), the prototypical schizophrenia personality disorder, and chronic schizophrenia have been investigated with genetic, neurochemical, imaging, and pharmacological techniques. Patients with SPD and the more severely ill patients with chronic schizophrenia share cognitive, social, and attentional deficits hypothesized to result from common neurodevelopmentally based cortical temporal and prefrontal pathology. However, these deficits are milder in SPD patients due to their capacity to recruit other related brain regions to compensate for dysfunctional areas. Individuals with SPD are also less vulnerable to psychosis due to the presence of protective factors mitigating subcortical DA hyperactivity. Given the documented close relationship to other schizophrenic disorders, SPD will be included in the psychosis section of DSM-5 as a schizophrenia spectrum disorder as well as in the personality disorder section. C1 [Chemerinski, Eran; Triebwasser, Joseph; Roussos, Panos; Siever, Larry J.] James J Peters VA Med Ctr, New York, NY USA. RP Siever, LJ (reprint author), Bronx VA Med Ctr OOMH, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM larry.siever@mssm.edu RI Roussos, Panos/J-7090-2013 OI Roussos, Panos/0000-0002-4640-6239 NR 227 TC 4 Z9 4 U1 4 U2 16 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0885-579X J9 J PERS DISORD JI J. Pers. Disord. PD OCT PY 2013 VL 27 IS 5 BP 652 EP 679 PG 28 WC Psychiatry SC Psychiatry GA 226NU UT WOS:000325043900011 PM 22928856 ER PT J AU Merkow, RP Bentrem, DJ Cohen, ME Paruch, JL Weber, SM Ko, CY Bilimoria, KY AF Merkow, Ryan P. Bentrem, David J. Cohen, Mark E. Paruch, Jennifer L. Weber, Sharon M. Ko, Clifford Y. Bilimoria, Karl Y. TI Effect of Cancer Surgery Complexity on Short-Term Outcomes, Risk Predictions, and Hospital Comparisons SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article; Proceedings Paper CT 8th Annual Academic Surgical Congress CY FEB 05-07, 2013 CL New Orleans, LA SP Assoc Acad Surg, Soc Univ Surg ID QUALITY IMPROVEMENT PROGRAM; PATIENT SAFETY; MODELS; ADJUSTMENT; VARIABLES; CARE AB BACKGROUND: Concern exists that oncologic surgical complexity is not adequately captured by the primary procedure code alone. Our objectives were to characterize the association between secondary procedures and 30-day outcomes, evaluate the effect of surgical complexity on risk predictions, and assess the influence of surgical complexity on hospital-quality comparisons. STUDY DESIGN: Patients who underwent colon, rectal, or pancreatic resection for cancer (2007-2011) were identified from theAmerican College of Surgeons NSQIP. Complexity was assessed by creating categorical complexity variables using secondary procedure codes and using total work relative value units. Regression methods were used to evaluate surgical complexity and hospital-quality comparisons. RESULTS: Patients had at least one secondary procedure documented in 48.0% of colon, 55.5% of rectal, and 63.1% of pancreatic cases. Surgical complexity variables were associated with worse outcomes across nearly all complications assessed. For example, serious morbidity was increased after an index colon resection with a synchronous liver resection (odds ratio = 1.39; 95% CI, 1.10-1.76) and a pancreatic resection with vascular reconstruction (odds ratio = 1.21; 95% CI, 1.01-1.45). Based on discrimination improvement indices and the likelihood ratio test, model-based predictions were enhanced with the addition of secondary surgical complexity variables, as well as total work relative value units, for nearly all procedures and outcomes assessed. Models that included total work relative value units had similar or marginally better discrimination compared with models with secondary procedure categories. Hospital performance did not change substantially after complexity adjustment. CONCLUSIONS: Surgical complexity adjustment is feasible and improves risk estimation of 30-day postoperative outcomes for colon, rectal, and pancreatic resections for cancer. Oncology-specific risk-adjustment models should include complexity adjustment using secondary procedure codes. (C) 2013 by the American College of Surgeons C1 [Merkow, Ryan P.; Cohen, Mark E.; Paruch, Jennifer L.; Bilimoria, Karl Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA. [Merkow, Ryan P.; Bentrem, David J.; Bilimoria, Karl Y.] Northwestern Univ, Dept Surg, Surg Outcomes & Qual Improvement Ctr, Feinberg Sch Med, Evanston, IL 60208 USA. [Merkow, Ryan P.; Bentrem, David J.; Bilimoria, Karl Y.] Northwestern Univ, Northwestern Inst Comparat Effectiveness Res Onco, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA. [Merkow, Ryan P.; Paruch, Jennifer L.] Univ Chicago, Dept Surg, Pritzker Sch Med, Chicago, IL 60637 USA. [Bentrem, David J.] Jesse Brown VA Med Ctr, Dept Surg, Chicago, IL USA. [Weber, Sharon M.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Merkow, RP (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,22nd Fl, Chicago, IL 60611 USA. EM RMerkow@facs.org NR 23 TC 19 Z9 19 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2013 VL 217 IS 4 BP 685 EP 693 DI 10.1016/j.jamcollsurg.2013.05.015 PG 9 WC Surgery SC Surgery GA 227YR UT WOS:000325152100017 PM 23830986 ER PT J AU Ramanan, B Gupta, PK Sundaram, A Gupta, H Johanning, JM Lynch, TG MacTaggart, JN Pipinos, II AF Ramanan, Bala Gupta, Prateek K. Sundaram, Abhishek Gupta, Himani Johanning, Jason M. Lynch, Thomas G. MacTaggart, Jason N. Pipinos, Iraklis I. TI Development of a risk index for prediction of mortality after open aortic aneurysm repair SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID SURGICAL CARE; ADJUSTMENT; SURGERY; QUALITY; SCORE AB Objective: Open infrarenal abdominal aortic aneurysm (oAAA) repair is associated with significant morbidity and mortality. Although there has been a shift toward endovascular repair, many patients continue to undergo an open repair due to anatomic considerations. Tools currently existing for estimation of periprocedural risk in patients undergoing open aortic surgery have certain limitations. The objective of this study was to develop a risk index to estimate the risk of 30-day perioperative mortality after elective oAAA repair. Methods: Patients who underwent elective oAAA repair (n = 2845) were identified from the American College of Surgeons' 2007 to 2009 National Surgical Quality Improvement Program (NSQIP), a prospective database maintained at >250 centers. Univariable and multivariable analyses were performed to evaluate risk factors associated with 30-day mortality after oAAA repair and a risk index was developed. Results: The 30-day mortality after oAAA repair was 3.3%. Multivariable analysis identified six preoperative predictors of mortality, and a risk index was created by assigning weighted points to each predictor using the beta-coefficients from the regression analysis. The predictors included dyspnea (at rest: 8 points; on moderate exertion: 2 points; none: 0 points), history of peripheral arterial disease requiring revascularization or amputation (3 points), age >65 years (3 points), preoperative creatinine >1.5 mg/dL (2 points), female gender (2 points), and platelets <150,000/mm(3) or >350,000/mm3 (2 points). Patients were classified as low (<7%), intermediate (7%-15%), and high (>15%) risk for 30-day mortality based on a total point score of <8, 8 to 11, and >11, respectively. There were 2508 patients (88.2%) patients in the low-risk category, 278 (9.8%) in the intermediate-risk category, and 59 (2.1%) in the high-risk category. Conclusions: This risk index has excellent predictive ability for mortality after oAAA repair and awaits validation in subsequent studies. It is anticipated to aid patients and surgeons in informed patient consent, preoperative risk assessment, and optimization. C1 [Ramanan, Bala; Sundaram, Abhishek] Creighton Univ, Dept Surg, Omaha, NE 68178 USA. [Gupta, Prateek K.] Univ Wisconsin Hosp & Clin, Dept Surg, Madison, WI 53792 USA. [Gupta, Himani] William S Middleton Mem Vet Adm Med Ctr, Dept Med, Madison, WI USA. [Johanning, Jason M.; MacTaggart, Jason N.; Pipinos, Iraklis I.] Univ Nebraska Med Ctr, Dept Surg, Omaha, NE 68198 USA. [Johanning, Jason M.; MacTaggart, Jason N.; Pipinos, Iraklis I.] VA Nebraska & Western Iowa Hlth Care Syst, Omaha, NE USA. [Lynch, Thomas G.] Vet Hlth Adm, Washington, DC USA. RP Pipinos, II (reprint author), Univ Nebraska Med Ctr, Dept Surg, Div Gen Surg, 985182 Nebraska Med Ctr, Omaha, NE 68198 USA. EM ipipinos@unmc.edu FU National Institutes of Health [R01-AG-034995]; American Vascular Association; Charles and Mary Heider Fund for Excellence in Vascular Surgery FX This study was partly supported National Institutes of Health Grant R01-AG-034995, the William J. von Liebig Award by the American Vascular Association, and the Charles and Mary Heider Fund for Excellence in Vascular Surgery. NR 15 TC 14 Z9 14 U1 1 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD OCT PY 2013 VL 58 IS 4 BP 871 EP 878 DI 10.1016/j.jvs.2013.03.024 PG 8 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 227RS UT WOS:000325132100002 PM 23676190 ER PT J AU Sobel, M Moreno, KI Yagi, M Kohler, TR Tang, GL Clowes, AW Zhou, XHA Eugenio, E AF Sobel, Michael Moreno, Katherine I. Yagi, Mayumi Kohler, Ted R. Tang, Gale L. Clowes, Alexander W. Zhou, Xiao-Hua A. Eugenio, Evercita TI Low levels of a natural IgM antibody are associated with vein graft stenosis and failure SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID OXIDATION-SPECIFIC EPITOPES; REDUCES ATHEROSCLEROSIS; PROTECTIVE FACTORS; IMMUNE-MODULATION; PHOSPHORYLCHOLINE; BYPASS; SURVEILLANCE; INFLAMMATION; IDENTIFICATION; MULTICENTER AB Background: All humans have natural, protective antibodies directed against phosphorylcholine (PC) epitopes, a common inflammatory danger signal appearing at sites of cell injury, oxidative stress, and on bacterial capsules. In large human cohorts, low levels of anti-PC IgM were associated with a significantly increased risk of stroke or myocardial infarction. However, it is not known if these antibodies protect against the premature closure of arterial reconstructions. Methods: A prospective, observational study of patients undergoing elective, infrainguinal, autogenous vein bypasses for atherosclerotic occlusive disease of the legs was conducted. Clinical data were recorded prospectively, and preoperative levels of anti-PC IgM measured with the CVDefine kit from Athera Biotechnologies (Solna, Sweden). The principal clinical end point was the loss of primary patency (loss of graft flow, or any intervention for stenosis). Patients were followed regularly by duplex ultrasound at 1, 3, 6, 12, 18 months, and yearly thereafter. Results: Fifty-six patients were studied, for an average of 1.3 years. Indications for surgery were claudication (33.9%), ischemic rest pain (17.9%), and ischemia with ulceration or gangrene (48.2%). Seventeen (30.4%) patients experienced loss of primary patency (10 graft occlusions, seven surgical or endovascular revisions of graft stenoses). Kaplan-Meier survival analysis showed that the quartile of patients with the lowest anti-PC IgM levels had significantly worse primary graft patency (log-rank test, P = .0085). Uni- and multivariate Cox proportional hazards analysis revealed that the preoperative anti-PC IgM level was an important predictor of graft failure. Patients with IgM values in the lowest quartile had a 3.6-fold increased risk of graft failure (95% confidence interval: 1.1-12.1), even after accounting for other significant clinical or technical factors such as indication for surgery, site of distal anastomosis, or vein graft diameter. Conclusions: A naturally occurring IgM antibody directed against the proinflammatory epitope PC may be protective against vein graft stenosis and failure, through anti-inflammatory mechanisms. Measurement of this antibody may be a useful prognostic indicator, although larger studies of more diverse populations will be needed to confirm these results. The biological actions of anti-PC IgM suggest it may be useful in developing immunotherapies to improve bypass longevity. C1 [Sobel, Michael; Moreno, Katherine I.; Yagi, Mayumi; Kohler, Ted R.; Tang, Gale L.; Clowes, Alexander W.] VA Puget Sound Hlth Care Syst, Div Vasc Surg, Seattle, WA USA. [Sobel, Michael; Moreno, Katherine I.; Yagi, Mayumi; Kohler, Ted R.; Tang, Gale L.; Clowes, Alexander W.] Univ Washington, Seattle, WA 98195 USA. [Zhou, Xiao-Hua A.; Eugenio, Evercita] VA Puget Sound Hlth Care Syst, Northwest Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. [Zhou, Xiao-Hua A.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. RP Sobel, M (reprint author), VA Puget Sound Hlth Care Syst S112, Div Vasc Surg, 1660 Columbian Way S, Seattle, WA 98108 USA. EM sobelm@uw.edu FU Department of Veterans Affairs, Veterans Health Administration, Merit Review Agency; Research Career Scientist Award [RCS 05-196]; National Institutes of Health [T32 HL007828, R01HL030946] FX This work was supported by grants from the Department of Veterans Affairs, Veterans Health Administration, Merit Review Agency (M.S.) and Research Career Scientist Award (RCS 05-196 - X.H.Z.); and National Institutes of Health T32 HL007828 and R01HL030946 (A.C., M.S.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 40 TC 4 Z9 4 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD OCT PY 2013 VL 58 IS 4 BP 997 EP + DI 10.1016/j.jvs.2013.04.042 PG 11 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 227RS UT WOS:000325132100020 PM 23856610 ER PT J AU Gray, KM Saladin, ME Baker, NL McClure, EA Hartwell, KJ Carpenter, MJ AF Gray, Kevin M. Saladin, Michael E. Baker, Nathaniel L. McClure, Erin A. Hartwell, Karen J. Carpenter, Matthew J. TI Varenicline Versus Nicotine Patch for Smoking Cessation in Women: Efficacy Findings from a 4-Week Double-blind Trial SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [Gray, Kevin M.; Saladin, Michael E.; Baker, Nathaniel L.; McClure, Erin A.; Hartwell, Karen J.; Carpenter, Matthew J.] Med Univ S Carolina, Charleston, SC USA. [Hartwell, Karen J.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD OCT 1 PY 2013 VL 22 IS 10 BP 904 EP 904 PG 1 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 227TD UT WOS:000325136500099 ER PT J AU Wei, CC Adappa, ND Cohen, NA AF Wei, Calvin C. Adappa, Nithin D. Cohen, Noam A. TI Use of Topical Nasal Therapies in the Management of Chronic Rhinosinusitis SO LARYNGOSCOPE LA English DT Review DE Chronic rhinosinusitis; antifungals; antibiotics; antimicrobials; nasal irrigations; topical therapy ID ENDOSCOPIC SINUS SURGERY; RANDOMIZED CONTROLLED-TRIAL; FLUTICASONE PROPIONATE; DOUBLE-BLIND; MOMETASONE FUROATE; AMPHOTERICIN-B; INTRANASAL BUDESONIDE; STAPHYLOCOCCUS-AUREUS; ANTIFUNGAL TREATMENT; SINONASAL SYMPTOMS AB Objectives/HypothesisTo determine whether the use of topical nasal therapies with saline alone and in combination with antibiotics, antifungals, or corticosteroids is effective in the treatment of patients with chronic rhinosinusitis (CRS). Data SourcesA systematic literature search was performed utilizing the MEDLINE database (1966 to May 2012), EMBASE database (1980 to May 2012), and the Cochrane Central Register of Controlled Trials. Review MethodsElectronic databases were searched by three otolaryngologists. Studies on five major categories of topical nasal therapies searched included saline (hypotonic, isotonic and hypertonic); topical antibiotics, topical steroids, and topical antifungals were obtained. Randomized controlled trials and meta-analyses of randomized controlled trials were included. ResultsSixteen randomized controlled trials were identified examining topical saline (hypertonic or isotonic) in CRS patients. Two randomized controlled trials were found studying the effect of topical antibiotics in patients with CRS. Four randomized controlled trials were identified studying topical antifungal treatment for CRS. Twenty-five randomized controlled trials were found studying topical steroids in CRS patients. ConclusionA high aggregate quality of evidence supports the effectiveness of saline irrigations in treating CRS. There is insufficient evidence to support a clear benefit of topical antibiotics in patients with chronic rhinosinusitis. Topical antifungal therapies have not been shown to be significantly different in efficacy than saline controls on CRS outcomes. Topical steroids are beneficial in the treatment of CRS with nasal polyps, but have not been shown to be effective in CRS without nasal polyps. Laryngoscope, 123:2347-2359, 2013 C1 [Wei, Calvin C.] St Lukes Roosevelt Hosp, Dept Otolaryngol Head & Neck Surg, New York, NY 10025 USA. [Adappa, Nithin D.; Cohen, Noam A.] Univ Penn, Sch Med, Hosp Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA. [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Cohen, NA (reprint author), Univ Penn, Sch Med, Hosp Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Ravdin 5th Floor,3400 Spruce St, Philadelphia, PA 19104 USA. EM Noam.Cohen@uphs.upenn.edu OI Cohen, Noam/0000-0002-9462-3932 NR 72 TC 22 Z9 22 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD OCT PY 2013 VL 123 IS 10 BP 2347 EP 2359 DI 10.1002/lary.24066 PG 13 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 227EC UT WOS:000325091100006 PM 23553558 ER PT J AU Pandey, GS Yanover, C Miller-Jenkins, LM Garfield, S Cole, SA Curran, JE Moses, EK Rydz, N Simhadri, V Kimchi-Sarfaty, C Lillicrap, D Viel, KR Przytycka, TM Pierce, GF Howard, TE Sauna, ZE AF Pandey, Gouri Shankar Yanover, Chen Miller-Jenkins, Lisa M. Garfield, Susan Cole, Shelley A. Curran, Joanne E. Moses, Eric K. Rydz, Natalia Simhadri, Vijaya Kimchi-Sarfaty, Chava Lillicrap, David Viel, Kevin R. Przytycka, Teresa M. Pierce, Glenn F. Howard, Tom E. Sauna, Zuben E. CA PATH Personalized Alternative TI Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A SO NATURE MEDICINE LA English DT Article ID COAGULATION-FACTOR VIII; MONOCLONAL-ANTIBODIES; HUMAN-LIVER; INHIBITOR; ANTIGEN; HISTORY; GENE AB Neutralizing antibodies (inhibitors) to replacement factor VIII (FVIII, either plasma derived or recombinant) impair the effective management of hemophilia A1. Individuals with hemophilia A due to major deletions of the FVIII gene (F8) lack antigenically cross-reactive material in their plasma ("CRM-negative"), and the prevalence of inhibitors in these individuals may be as high as 90%. Conversely, individuals with hemophilia A caused by F8 missense mutations are CRM-positive, and their overall prevalence of inhibitors is < 10% (ref. 2). Individuals with the F8 intron 22 inversion (found in similar to 50% of individuals with severe hemophilia A) have been grouped with the former on the basis of their genetic defect and CRM-negative status. However, only similar to 20% of these individuals develop inhibitors3. Here we demonstrate that the levels of F8 mRNA and intracellular FVIII protein in B lymphoblastoid cells and liver biopsies from individuals with the intron 22 inversion are comparable to those in healthy controls. These results support the hypothesis that most individuals with the intron 22 inversion are tolerized to FVIII and thus do not develop inhibitors. Furthermore, we developed a new pharmacogenetic algorithm that permits the stratification of inhibitor risk for individuals and subpopulations by predicting the immunogenicity of replacement FVIII using, as input, the number of putative T cell epitopes in the infused protein and the competence of major histocompatibility complex class II molecules to present such epitopes. This algorithm showed statistically significant accuracy in predicting the presence of inhibitors in 25 unrelated individuals with the intron 22 inversion. C1 [Pandey, Gouri Shankar; Simhadri, Vijaya; Kimchi-Sarfaty, Chava; Sauna, Zuben E.] US FDA, Ctr Biol Evaluat & Res, Div Hematol, Lab Hemostasis, Bethesda, MD 20892 USA. [Yanover, Chen] Fred Hutchinson Canc Res Ctr, Program Computat Biol, Seattle, WA 98104 USA. [Miller-Jenkins, Lisa M.] NCI, Lab Cell Biol, Expt Carcinogenesis Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA. [Garfield, Susan] NCI, Expt Carcinogenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. [Cole, Shelley A.; Curran, Joanne E.; Moses, Eric K.] Texas Biomed Res Inst, Dept Genet, San Antonio, TX USA. [Rydz, Natalia; Lillicrap, David] Queens Univ, Dept Pathol & Mol Med, Kingston, ON, Canada. [Viel, Kevin R.] Histonis, Atlanta, GA USA. [Przytycka, Teresa M.] Natl Ctr Biotechnol Informat, Natl Lib Med, NIH, Bethesda, MD USA. [Pierce, Glenn F.] Biogen Idec Hemophilia, Waltham, MA USA. [Howard, Tom E.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. [Howard, Tom E.] Univ So Calif, Keck Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90033 USA. [Howard, Tom E.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA. RP Sauna, ZE (reprint author), US FDA, Ctr Biol Evaluat & Res, Div Hematol, Lab Hemostasis, Bethesda, MD 20892 USA. EM tom.howard@va.gov; zuben.sauna@fda.hhs.gov RI Yanover, Chen/A-3754-2012 OI Yanover, Chen/0000-0003-3663-4286 FU US National Institute of Allergy and Infectious Diseases Committee on Human Research [10-01178]; modernization of science program of the Center for Biologics Evaluation and Research, US Food and Drug Administration; National Heart, Lung and Blood Institute, National Institutes of Health [1RC2-HL101851, HL-71130, HL-72533)]; Bayer Healthcare Corporation; Bayer Hemophilia Awards Program; Baxter Healthcare Corporation; Clinical Translational Science Institute at the University of Southern California; Intramural Program of the US National Library of Medicine, NIH FX We would like to thank P. Matzinger, B. Golding, J. Lozier, D. Levin, M. Carcao, V. Blanchette, G. Rivard and V. La Terza for helpful comments and J. Sauna for help with the graphics. We thank S. V. Ambudkar (US National Cancer Institute) for the use of facilities, M. J. Lenardo and K. Shafer-Weaver (US National Institute of Allergy and Infectious Diseases) for the gift of the purified C2 domain of FVIII and P. Stock (University of California, San Francisco) for liver tissue samples. These samples were obtained under the University of California University-Wide AIDS Research Program (TP-99-SF-001) Committee on Human Research (H802423454) and the Solid Organ Transplantation in HIV: Multi-Site Study (AI052748) funded by the US National Institute of Allergy and Infectious Diseases Committee on Human Research (10-01178). Research conducted in the laboratory of Z. E. S. is funded by the modernization of science program of the Center for Biologics Evaluation and Research, US Food and Drug Administration. Research conducted in the laboratory of T. E. H. is funded by grants from the National Heart, Lung and Blood Institute, National Institutes of Health (1RC2-HL101851, HL-71130 and HL-72533), the Bayer Healthcare Corporation, Bayer Hemophilia Awards Program, Baxter Healthcare Corporation and the Clinical Translational Science Institute at the University of Southern California. The work of T. M. P. is fully supported by the Intramural Program of the US National Library of Medicine, NIH. NR 22 TC 27 Z9 27 U1 1 U2 18 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD OCT PY 2013 VL 19 IS 10 BP 1318 EP + DI 10.1038/nm.3270 PG 10 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 232YW UT WOS:000325531700032 PM 24037092 ER PT J AU Flickinger, TE Rose, G Wilson, IB Wolfe, H Saha, S Korthuis, PT Massa, M Berry, S Laws, MB Sharp, V Moore, RD Beach, MC AF Flickinger, Tabor E. Rose, Gary Wilson, Ira B. Wolfe, Hannah Saha, Somnath Korthuis, Philip Todd Massa, Michele Berry, Stephen Laws, Michael Barton Sharp, Victoria Moore, Richard D. Beach, Mary Catherine TI Motivational interviewing by HIV care providers is associated with patient intentions to reduce unsafe sexual behavior SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE Motivational interviewing; Physicians; HIV/AIDS; Sexual risk reduction; Counseling ID SAFER SEX; INFECTED PATIENTS; CLIENT LANGUAGE; SUBSTANCE USE; USE OUTCOMES; COMMUNICATION; INTERVENTION; PREVENTION; CLINICIAN; DRINKING AB Objective: Motivational interviewing (MI) can promote behavior change, but HIV care providers rarely have training in MI. Little is known about the use of MI-consistent behavior among untrained providers. This study examines the prevalence of such behaviors and their association with patient intentions to reduce high-risk sexual behavior. Methods: Audio-recorded visits between HIV-infected patients and their healthcare providers were searched for counseling dialog regarding sexual behavior. The association of providers' MI-consistence with patients' statements about behavior change was assessed. Results: Of 417 total encounters, 27 met inclusion criteria. The odds of patient commitment to change were higher when providers used more reflections (p = 0.017), used more MI consistent utterances (p = 0.044), demonstrated more empathy (p = 0.049), and spent more time discussing sexual behavior (p = 0.023). Patients gave more statements in favor of change (change talk) when providers used more reflections (p < 0.001) and more empathy (p < 0.001), even after adjusting for length of relevant dialog. Conclusion: Untrained HIV providers do not consistently use MI techniques when counseling patients about sexual risk reduction. However, when they do, their patients are more likely to express intentions to reduce sexual risk behavior. Practice implications: MI holds promise as one strategy to reduce transmission of HIV and other sexually transmitted infections. (C) 2013 Elsevier Ireland Ltd. All rights reserved. C1 [Flickinger, Tabor E.; Massa, Michele; Berry, Stephen; Moore, Richard D.; Beach, Mary Catherine] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21287 USA. [Rose, Gary] Massachusetts Sch Profess Psychol, Boston, MA USA. [Wilson, Ira B.; Laws, Michael Barton] Brown Univ, Dept Med, Providence, RI 02912 USA. [Wolfe, Hannah; Sharp, Victoria] Dept Med, New York, NY USA. [Saha, Somnath; Korthuis, Philip Todd] Oregon Hlth & Sci Univ, Dept Med, Portland, OR USA. [Saha, Somnath] Portland VA Med Ctr, Dept Med, Portland, OR USA. RP Flickinger, TE (reprint author), Johns Hopkins Univ, Sch Med, 2024 East Monument St,Suite 2-600, Baltimore, MD 21287 USA. EM tflicki1@jhmi.edu RI Wilson, Ira/F-9190-2016 OI Wilson, Ira/0000-0002-0246-738X FU Health Resources Service Administration; National Institutes of Health [5 T32 HL007180-35]; National Institute of Allergy and Infectious Disease [K23 A1084854]; National Institute of Drug Abuse [K23 DA019809]; Department of Veterans Affairs; Agency for Healthcare Research and Quality [K08 HS013903-05, AHRQ 290-01-0012]; NIMH [2K24MH092242]; Robert Wood Johnson Generalist Physician Faculty Scholars Awards FX This research was supported by a contract from the Health Resources Service Administration and the Agency for Healthcare Research and Quality (AHRQ 290-01-0012). In addition, Dr. Flickinger was supported by the National Institutes of Health (5 T32 HL007180-35), Dr. Berry was supported by the National Institute of Allergy and Infectious Disease (K23 A1084854), Dr. Korthuis was supported by the National Institute of Drug Abuse (K23 DA019809), Dr. Saha was supported by the Department of Veterans Affairs, Dr. Beach was supported by the Agency for Healthcare Research and Quality (K08 HS013903-05) and both Drs. Beach and Saha were supported by Robert Wood Johnson Generalist Physician Faculty Scholars Awards. Dr. Wilson was supported by a K24 from NIMH (2K24MH092242). None of the funders had a role in the design and conduct of this analysis, nor was it subject to their final approval. None of the authors have any relevant financial conflicts of interest. NR 51 TC 5 Z9 5 U1 0 U2 9 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD OCT PY 2013 VL 93 IS 1 BP 122 EP 129 DI 10.1016/j.pec.2013.04.001 PG 8 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA 226TE UT WOS:000325058100017 PM 23647982 ER PT J AU Mautner, DB Pang, HC Brenner, JC Shea, JA Gross, KS Frasso, R Cannuscio, CC AF Mautner, Dawn B. Pang, Hauchie Brenner, Jeffrey C. Shea, Judy A. Gross, Kennen S. Frasso, Rosemary Cannuscio, Carolyn C. TI Generating Hypotheses About Care Needs of High Utilizers: Lessons from Patient Interviews SO POPULATION HEALTH MANAGEMENT LA English DT Article ID ADVERSE CHILDHOOD EXPERIENCES; EMERGENCY-DEPARTMENT; HOUSEHOLD DYSFUNCTION; FREQUENT USERS; HEALTH-CARE; CASE-MANAGEMENT; SERVICE USE; RISK; CONTINUITY; ADULTS AB Informed by a largely secondary and quantitative literature, efforts to improve care and outcomes for complex patients with high levels of emergency and hospital-based health care utilization have offered mixed results. This qualitative study identifies psychosocial factors and life experiences described by these patients that may be important to their care needs. Semi-structured interviews were conducted with 19 patients of the Camden Coalition of Healthcare Providers' Care Management Team. Investigators coded transcripts using a priori and inductively-derived codes, then identified 3 key themes: (1) Early-life instability and traumas, including parental loss, unstable or violent relationships, and transiency, informed many participants' health and health care experiences; (2) Many high utilizers described a history of difficult interactions with health care providers during adulthood; (3) Over half of the participants described the importance to their well-being of positive and caring relationships with primary health care providers and the outreach team. Additionally, the transient and vulnerable nature of this complex population posed challenges to follow-up, both for research and care delivery. These themes illuminate potentially important hypotheses to be explored in more generalizable samples using robust and longitudinal methods. Future work should explore the prevalence and impact of adverse childhood experiences among high utilizers, and the different types of relationships they have with providers. Investigators should test new modes of care delivery that attend to patients' trauma histories. This qualitative study was well suited to provide insight into the life stories of these complex, vulnerable patients, informing research questions for further investigation. (Population Health Management 2013;16:S-26-S-33) C1 [Mautner, Dawn B.] Thomas Jefferson Univ, Dept Family & Community Med, Philadelphia, PA 19107 USA. [Mautner, Dawn B.] Thomas Jefferson Univ, Robert Wood Johnson Fdn, Clin Scholars Program, Philadelphia, PA 19107 USA. [Pang, Hauchie; Frasso, Rosemary] Univ Penn, Sch Social Policy & Practice, Ctr Publ Hlth Initiat, Philadelphia, PA 19104 USA. [Brenner, Jeffrey C.; Gross, Kennen S.] Camden Coalit Healthcare Providers, Camden, NJ USA. [Brenner, Jeffrey C.; Gross, Kennen S.] Rowan Univ, Cooper Med Sch, Dept Family Med, Camden, NJ USA. [Shea, Judy A.; Cannuscio, Carolyn C.] Philadelphia VA, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Shea, Judy A.] Univ Penn, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Cannuscio, Carolyn C.] Univ Penn, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA. [Cannuscio, Carolyn C.] Univ Penn, Perelman Sch Med, Mixed Methods Res Lab, Philadelphia, PA 19104 USA. RP Mautner, DB (reprint author), Thomas Jefferson Univ, Dept Family & Community Med, 1015 Walnut St,401 Curtis, Philadelphia, PA 19107 USA. EM dawn.mautner@jefferson.edu FU Robert Wood Johnson Health and Society Scholars Program Fund at the University of Pennsylvania FX The authors appreciate the sponsorship of the Robert Wood Johnson Health and Society Scholars Program Fund at the University of Pennsylvania. We wish to acknowledge the support of Katrina Armstrong, MD, MSCE and Glenda Wrenn, MD, MA throughout the process of developing this project. Finally, we wish to thank the Robert Wood Johnson Foundation Clinical Scholars Program at the University of Pennsylvania for the postdoctoral training support of Dr. Mautner, during which this work was completed. Parts of this work have been presented at the Robert Wood Johnson Clinical Scholars' National Meeting in November 2011. NR 45 TC 12 Z9 12 U1 7 U2 26 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1942-7891 EI 1942-7905 J9 POPUL HEALTH MANAG JI Popul. Health Manag. PD OCT 1 PY 2013 VL 16 SU 1 BP S26 EP S33 DI 10.1089/pop.2013.0033 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 224MT UT WOS:000324891700007 PM 24070247 ER PT J AU Morland, LA Raab, M Mackintosh, MA Rosen, CS Dismuke, CE Greene, CJ Frueh, BC AF Morland, Leslie A. Raab, Michelle Mackintosh, Margaret-Anne Rosen, Craig S. Dismuke, Clara E. Greene, Carolyn J. Frueh, B. Christopher TI Telemedicine: A Cost-Reducing Means of Delivering Psychotherapy to Rural Combat Veterans with PTSD SO TELEMEDICINE AND E-HEALTH LA English DT Article DE medicine; military medicine; telehealth; telepsychiatry ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH-SERVICES; PRIMARY-CARE CLINICS; VIETNAM VETERANS; NONINFERIORITY TRIAL; TELEHEALTH; TELEPSYCHIATRY; ANGER; OUTCOMES; THERAPY AB Background:Although effective psychotherapies for posttraumatic stress disorder (PTSD) exist, high percentages of Veterans in need of services are unable to access them. One particular challenge to providing cost-effective psychological treatments to Veterans with PTSD involves the difficulty and high cost of delivering in-person, specialized psychotherapy to Veterans residing in geographically remote locations. The delivery of these services via clinical videoteleconferencing (CVT) has been presented as a potential solution to this access to care problem.Materials and Methods:This study is a retrospective cost analysis of a randomized controlled trial investigating telemedicine service delivery of an anger management therapy for Veterans with PTSD. The parent trial found that the CVT condition provided clinical results that were comparable to the in-person condition. Several cost outcomes were calculated in order to investigate the clinical and cost outcomes associated with the CVT delivery modality relative to in-person delivery.Results:The CVT condition was significantly associated with lower total costs compared with the in-person delivery condition. The delivery of mental health services via CVT enables Veterans who would not normally receive these services access to empirically based treatments. Additional studies addressing long-term healthcare system costs, indirect cost factors at the patient and societal levels, and the use of CVT in other geographic regions of the United States are needed.Conclusions:The results of this study provide evidence that CVT is a cost-reducing mode of service delivery to Veterans with PTSD relative to in-person delivery. C1 [Morland, Leslie A.; Raab, Michelle; Mackintosh, Margaret-Anne; Greene, Carolyn J.] Dept Vet Affairs Pacific Isl Healthcare Syst, Pacific Isl Div, Natl Ctr PTSD, Honolulu, HI 96819 USA. [Raab, Michelle; Mackintosh, Margaret-Anne] Pacific Hlth Res & Educ Inst, Honolulu, HI USA. [Rosen, Craig S.] Dept Vet Affairs Palo Alto Healthcare Syst, Disseminat & Training Div, Natl Ctr PTSD, Palo Alto, CA USA. [Rosen, Craig S.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA. [Dismuke, Clara E.] Ralph H Johnson VAMC, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Dept Vet Affairs, Charleston, SC USA. [Dismuke, Clara E.] Med Univ S Carolina, Dept Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Greene, Carolyn J.] Dept Vet Affairs Palo Alto Healthcare Syst, Ctr Hlth Care Evaluat, Palo Alto, CA USA. [Frueh, B. Christopher] Menninger Clin, Houston, TX USA. [Frueh, B. Christopher] Univ Hawaii, Hilo, HI 96720 USA. RP Morland, LA (reprint author), Dept Vet Affairs Pacific Isl Healthcare Syst, Pacific Isl Div, Natl Ctr PTSD, 3375 Koapaka St,Suite I-560, Honolulu, HI 96819 USA. EM Leslie.Morland@va.gov OI Mackintosh, Margaret-Anne/0000-0002-2725-3177 FU Veterans Affairs Health Services and Development [TEL 03-080-3]; Office of Research and Development, Medical Research Service, Department of Veterans Affairs FX This work was partially supported by grant TEL 03-080-3 from the Veterans Affairs Health Services and Development. This work was also supported by the Office of Research and Development, Medical Research Service, Department of Veterans Affairs. L. A. M., Principal Investigator of this study, had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. NR 53 TC 16 Z9 16 U1 2 U2 22 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-5627 J9 TELEMED E-HEALTH JI Telemed. e-Health PD OCT 1 PY 2013 VL 19 IS 10 BP 754 EP 759 DI 10.1089/tmj.2012.0298 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 227RU UT WOS:000325132300005 PM 23931729 ER PT J AU Banerjee, A Wang, JM Bodhankar, S Vandenbark, AA Murphy, SJ Offner, H AF Banerjee, Anirban Wang, Jianming Bodhankar, Sheetal Vandenbark, Arthur A. Murphy, Stephanie J. Offner, Halina TI Phenotypic Changes in Immune Cell Subsets Reflect Increased Infarct Volume in Male vs. Female Mice SO TRANSLATIONAL STROKE RESEARCH LA English DT Article DE Experimental stroke; Gender bias; Immune markers; Activated Tcells; Suppressor Tcells; Ischemia ID REGULATORY T-CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FOCAL CEREBRAL-ISCHEMIA; EXPERIMENTAL STROKE; SEX-DIFFERENCES; ALPHA-4 INTEGRIN; MULTIPLE-SCLEROSIS; INFLAMMATORY CELLS; NADPH OXIDASE; BRAIN-INJURY AB Inflammatory responses in the brain after cerebral ischemia have been studied extensively in male mice, but not female mice, thus potentially giving a less-than-accurate view of gender associated pathological processes. In humans, cerebral infarcts are typically smaller in premenopausal females than in age-matched males. In the current study, we confirmed smaller infarcts in female vs. male mice after middle cerebral artery occlusion and 96 h of reperfusion. Moreover, we explored immunological alterations related to this difference and found that the percentage of CD4(+) T lymphocytes was significantly higher in spleens in males than females, with increased expression of the activation markers, CD69 and CD44. In contrast, the percentage of CD8(+) T lymphocytes was significantly higher in spleens of females than males, leading to the identification of a small but distinct population of IL-10-secreting CD8(+)CD122(+) suppressor T cells that were also increased in females. Finally, we observed that males have a greater percentage of activated macrophages/microglia in the brain than females, as well as increased expression of the VLA-4 adhesion molecule in both brain and spleen. This new information suggesting gender-dependent immunological mechanisms in stroke implies that effective treatments for human stroke may also be gender specific. C1 [Banerjee, Anirban; Bodhankar, Sheetal; Vandenbark, Arthur A.; Offner, Halina] Portland VA Med Ctr, Portland, OR USA. [Banerjee, Anirban; Bodhankar, Sheetal; Vandenbark, Arthur A.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Wang, Jianming; Murphy, Stephanie J.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA. [Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. RP Offner, H (reprint author), Portland VA Med Ctr, R&D 31,3710 SW US Vet Hosp Rd, Portland, OR USA. EM offnerva@ohsu.edu FU NIH [NS076013]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development FX The authors wish to thank Dr. Gil Benedek for the helpful discussions and Melissa Barber for the assistance in submitting the manuscript. This work was supported by NIH grant no. NS076013. This material is based upon work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. NR 46 TC 21 Z9 21 U1 2 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1868-4483 J9 TRANSL STROKE RES JI Transl. Stroke Res. PD OCT PY 2013 VL 4 IS 5 BP 554 EP 563 DI 10.1007/s12975-013-0268-z PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 227IN UT WOS:000325106200010 PM 24187596 ER PT J AU Small, AC Tsao, CK Moshier, EL Gartrell, BA Wisnivesky, JP Godbold, J Sonpavde, G Palese, MA Hall, SJ Oh, WK Galsky, MD AF Small, Alexander C. Tsao, Che-Kai Moshier, Erin L. Gartrell, Benjamin A. Wisnivesky, Juan P. Godbold, James Sonpavde, Guru Palese, Michael A. Hall, Simon J. Oh, William K. Galsky, Matthew D. TI Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States SO WORLD JOURNAL OF UROLOGY LA English DT Article DE Renal surgery; Nephrectomy; Nephron-sparing surgery; Kidney cancer ID RENAL-CELL CARCINOMA; RADICAL NEPHRECTOMY; DATA-BASE; TUMORS; OUTCOMES; SURVIVAL; MORTALITY; SURGERY; IMPACT; MASSES AB The incidental detection of early-stage kidney tumors is increasing in the United States. Nephron-sparing approaches (NS) to managing these tumors are equivalent to radical nephrectomy (RN) in oncologic outcomes and have a decreased impact on renal function. Our objective was to evaluate trends in the use of NS over the past decade and the socioeconomic factors associated with its use. The National Cancer Database was queried to identify patients with stage I kidney cancer between 2000 and 2008. Patients were classified by the type of surgery as NS (local destruction and local excision) or RN. Patients were further categorized by age, race, insurance status, and income. Log-binomial regression was used to estimate prevalence ratios (PR) for the proportion of NS to RN according to demographic and socioeconomic characteristics. From 2000 to 2008, there were 142,194 cases of kidney cancer reported to the NCDB. In these cases, 43,034 (30.3 %) patients had NS, and 86,431 (60.78 %) patients had RN. The prevalence of NS increased 10 % per year (PR = 1.10, p < 0.0001)-from 20.0 % in 2000 to 45.1 % in 2008. Older age, lower income, Black race, Hispanic ethnicity, and lack of health insurance were associated with a decreased prevalence of NS. NS as a treatment for stage I kidney cancer has increased steadily since 2000. Age, racial, and socioeconomic differences may exist in the utilization of NS. Additional analyses, with patient level data, are required to address the independent significance of these variables in an effort to develop strategies to mitigate these potential disparities. C1 [Small, Alexander C.; Tsao, Che-Kai; Moshier, Erin L.; Gartrell, Benjamin A.; Godbold, James; Oh, William K.; Galsky, Matthew D.] Mt Sinai Sch Med, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY 10029 USA. [Wisnivesky, Juan P.] Mt Sinai Sch Med, Div Gen Internal Med, New York, NY 10029 USA. [Wisnivesky, Juan P.] Mt Sinai Sch Med, Div Pulm & Crit Care Med, New York, NY 10029 USA. [Sonpavde, Guru] Texas Oncol, Houston, TX USA. [Sonpavde, Guru] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Sect Med Oncol, Houston, TX 77030 USA. [Palese, Michael A.; Hall, Simon J.] Mt Sinai Sch Med, Dept Urol, New York, NY 10029 USA. RP Galsky, MD (reprint author), Mt Sinai Sch Med, Tisch Canc Inst, Div Hematol & Med Oncol, 1 Gustave L Levy Pl, New York, NY 10029 USA. EM matthew.galsky@mssm.edu FU Doris Duke Charitable Foundation FX Source of Funding: Doris Duke Charitable Foundation. NR 29 TC 6 Z9 6 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0724-4983 J9 WORLD J UROL JI World J. Urol. PD OCT PY 2013 VL 31 IS 5 BP 1211 EP 1217 DI 10.1007/s00345-012-0873-6 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 226HJ UT WOS:000325025500030 PM 22622394 ER PT J AU Gerson, LB Vela, MF Katz, PO AF Gerson, Lauren B. Vela, Marcelo F. Katz, Philip O. TI Stretta For Refractory GERD: Now More Than Ever Response SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Letter ID GASTROESOPHAGEAL-REFLUX DISEASE; RADIOFREQUENCY ENERGY; SHAM; SYMPTOMS; TRIAL C1 [Gerson, Lauren B.] Stanford Univ, Div Gastroenterol & Hepatol, Redwood City, CA 94063 USA. [Vela, Marcelo F.] Baylor Coll Med, Houston, TX 77030 USA. [Vela, Marcelo F.] ME DeBakey VA Med Ctr, Houston, TX USA. [Katz, Philip O.] Albert Einstein Med Ctr, Dept Gastroenterol, Philadelphia, PA 19141 USA. RP Gerson, LB (reprint author), Stanford Univ, Div Gastroenterol & Hepatol, 450 Broadway St,Pavil C,Mail Code 5241, Redwood City, CA 94063 USA. EM lgersonmd@yahoo.com NR 9 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2013 VL 108 IS 10 BP 1656 EP 1657 DI 10.1038/ajg.2013.283 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 229OI UT WOS:000325276100018 PM 24091510 ER PT J AU Vela, MF Gerson, LB Katz, PO AF Vela, Marcelo F. Gerson, Lauren B. Katz, Philip O. TI Non-Erosive Reflux Disease is More Complex Than Negative Endoscopy Only Response SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Letter ID GASTROESOPHAGEAL-REFLUX; FUNDOPLICATION; INDEX C1 [Vela, Marcelo F.] Baylor Coll Med, Div Gastroenterol & Hepatol, Houston, TX 77030 USA. [Vela, Marcelo F.] ME DeBakey VA Med Ctr, Houston, TX USA. [Gerson, Lauren B.] Stanford Univ, Div Gastroenterol & Hepatol, Stanford, CA 94305 USA. [Katz, Philip O.] Albert Einstein Med Ctr, Dept Gastroenterol, Philadelphia, PA 19141 USA. RP Vela, MF (reprint author), Baylor Coll Med, Div Gastroenterol, 1 Baylor Plaza,BCM 901, Houston, TX 77030 USA. EM mvela@bcm.edu NR 11 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2013 VL 108 IS 10 BP 1658 EP 1659 DI 10.1038/ajg.2013.284 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 229OI UT WOS:000325276100020 PM 24091512 ER PT J AU Carter, CE Katz, R Kramer, H de Boer, IH Kestenbaum, BR Peralta, CA Siscovick, D Sarnak, MJ Levey, AS Inker, LAS Allison, MA Criqui, MH Shlipak, MG Ix, JH AF Carter, Caitlin E. Katz, Ronit Kramer, Holly de Boer, Ian H. Kestenbaum, Bryan R. Peralta, Carmen A. Siscovick, David Sarnak, Mark J. Levey, Andrew S. Inker, Lesley A. S. Allison, Matthew A. Criqui, Michael H. Shlipak, Michael G. Ix, Joachim H. TI Influence of Urine Creatinine Concentrations on the Relation of Albumin-Creatinine Ratio With Cardiovascular Disease Events: The Multi-Ethnic Study of Atherosclerosis (MESA) SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Urine creatinine concentration; cardiovascular disease events ID GLOMERULAR-FILTRATION-RATE; NONDIABETIC INDIVIDUALS; SERUM CREATININE; BLOOD-PRESSURE; EXCRETION RATE; COOKED MEAT; RISK; MORTALITY; HEART; METAANALYSIS AB Background: Higher urine albumin-creatinine ratio (ACR) is associated with cardiovascular disease (CVD) events, an association that is stronger than that between spot urine albumin on its own and CVD. Urine creatinine excretion is correlated with muscle mass, and low muscle mass also is associated with CVD. Whether low urine creatinine concentration in the denominator of theACRcontributes to the association of ACR with CVD is uncertain. Study Design: Prospective cohort study. Setting & Participants: 6,770 community-living individuals without CVD. Predictors: Spot urine albumin concentration, the reciprocal of the urine creatinine concentration (1/UCr), and ACR. Outcome: Incident CVD events. Results: During a mean of 7.1 years of follow-up, 281 CVD events occurred. Geometric mean values for spot urine creatinine concentration, urine albumin concentration, and ACR were 95 +/- 2 (SD) mg/dL, 0.7 +/- 3.7 mg/dL, and 7.0 +/- 3.1 mg/g. Urine creatinine concentration was lower in older, female, and low-weight individuals. Adjusted HRs per 2-fold higher increment in each urinary measure with CVD events were similar (1/UCr: 1.07 [95% CI, 0.94-1.22]; urine albumin concentration: 1.08 [95% CI, 1.01-1.14]; and ACR: 1.11 [95% CI, 1.04-1.18]). ACR >= 10 mg/g was associated more strongly with CVD events in individuals with low weight (HR for lowest vs highest tertile: 4.34 vs 1.97; P for interaction = 0.006). Low weight also modified the association of urine albumin concentration with CVD (P for interaction = 0.06), but 1/UCr did not (P for interaction = 0.9). Limitations: We lacked 24-hour urine data. Conclusions: Although ACR is associated more strongly with CVD events in persons with low body weight, this association is not driven by differences in spot urine creatinine concentration. Overall, the associations of ACR with CVD events appear to be driven primarily by urine albumin concentration and less by urine creatinine concentration. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is aUS Government Work. There are no restrictions on its use. C1 [Carter, Caitlin E.; Ix, Joachim H.] Univ Calif San Diego, Dept Med, Div Nephrol & Hypertens, San Diego, CA 92161 USA. [Katz, Ronit] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Kramer, Holly] Loyola Med Ctr, Dept Med, Div Nephrol & Hypertens, Maywood, IL USA. [de Boer, Ian H.; Kestenbaum, Bryan R.] Univ Washington, Div Nephrol, Seattle, WA 98195 USA. [de Boer, Ian H.; Kestenbaum, Bryan R.] Univ Washington, Dept Med, Kidney Res Inst, Seattle, WA USA. [Peralta, Carmen A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Siscovick, David] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA. [Siscovick, David] Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Sarnak, Mark J.; Levey, Andrew S.; Inker, Lesley A. S.] Tufts Med Ctr, Dept Med, Boston, MA USA. [Allison, Matthew A.; Criqui, Michael H.; Ix, Joachim H.] Univ Calif San Diego, Dept Family & Prevent Med, Div Prevent Med, San Diego, CA 92161 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, Div Gen Internal Med, San Francisco, CA USA. [Ix, Joachim H.] Vet Affairs San Diego Healthcare Syst, Nephrol Sect, San Diego, CA 92161 USA. RP Ix, JH (reprint author), Univ Calif San Diego, Dept Med, Div Nephrol & Hypertens, 3350 La Jolla Village Dr,Mail Code 111-H, San Diego, CA 92161 USA. EM joeix@ucsd.edu OI Kramer, Holly/0000-0002-6374-837X; Allison, Matthew/0000-0003-0777-8272 FU National Heart, Lung and Blood Institute [R01-HL-096851, T32 HL007261, R21HL091217, N01-HC-95159, N01-HC-95166, N01-HC-95169, R01-HL-071739, R01-HL-072403] FX Supported by the National Heart, Lung and Blood Institute (grants R01-HL-096851, T32 HL007261, and R21HL091217 and contracts N01-HC-95159, N01-HC-95166, N01-HC-95169, R01-HL-071739, and R01-HL-072403). NR 25 TC 4 Z9 4 U1 0 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD OCT PY 2013 VL 62 IS 4 BP 722 EP 729 DI 10.1053/j.ajkd.2013.05.010 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 224CB UT WOS:000324858000013 PM 23830183 ER PT J AU Shariff, N Desai, RV Patel, K Ahmed, MI Fonarow, GC Rich, MW Aban, IB Banach, M Love, TE White, M Aronow, WS Epstein, AE Ahmed, A AF Shariff, Nasir Desai, Ravi V. Patel, Kanan Ahmed, Mustafa I. Fonarow, Gregg C. Rich, Michael W. Aban, Inmaculada B. Banach, Maciej Love, Thomas E. White, Michel Aronow, Wilbert S. Epstein, Andrew E. Ahmed, Ali TI Rate-control versus Rhythm-control Strategies and Outcomes in Septuagenarians with Atrial Fibrillation SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE Atrial fibrillation; Hospitalization; Mortality; Propensity score; Older adults; Rate control; Rhythm control ID RENIN-ANGIOTENSIN INHIBITION; SYSTOLIC HEART-FAILURE; CHRONIC KIDNEY-DISEASE; MANAGEMENT AFFIRM; PROPENSITY SCORE; RANDOMIZED-TRIAL; COSTS; RISK AB BACKGROUND: The prevalence of atrial fibrillation substantially increases after 70 years of age. However, the effect of rate-control versus rhythm-control strategies on outcomes in these patients remains unclear. METHODS: In the randomized Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial, 4060 patients (mean age 70 years, range 49-80 years) with paroxysmal and persistent atrial fibrillation were randomized to rate-control versus rhythm-control strategies. Of these, 2248 were 70-80 years, of whom 1118 were in the rate-control group. Propensity scores for rate-control strategy were estimated for each of the 2248 patients and were used to assemble a cohort of 937 pairs of patients receiving rate-control versus rhythm-control strategies, balanced on 45 baseline characteristics. RESULTS: Matched patients had a mean age of 75 years; 45% were women, 7% were nonwhite, and 47% had prior hospitalizations due to arrhythmias. During 3.4 years of mean follow-up, all-cause mortality occurred in 18% and 23% of matched patients in the rate-control and rhythm-control groups, respectively (hazard ratio [HR] associated with rate control, 0.77; 95% confidence interval [CI], 0.63-0.94; P = .010). HRs (95% CIs) for cardiovascular and noncardiovascular mortality associated with rate control were 0.88 (0.65-1.18) and 0.62 (0.46-0.84), respectively. All-cause hospitalization occurred in 61% and 68% of rate-control and rhythm-control patients, respectively (HR 0.76; 95% CI, 0.68-0.86). HRs (95% CIs) for cardiovascular and noncardiovascular hospitalization were 0.66 (0.56-0.77) and 1.07 (0.91-1.27), respectively. CONCLUSION: In septuagenarian patients with atrial fibrillation, compared with rhythm-control, a rate-control strategy was associated with significantly lower mortality and hospitalization. (c) 2013 Elsevier Inc. All rights reserved. C1 [Shariff, Nasir] Univ Pittsburgh, Pittsburgh, PA USA. [Desai, Ravi V.] Lehigh Valley Hosp, Allentown, PA USA. [Patel, Kanan; Ahmed, Mustafa I.; Aban, Inmaculada B.; Ahmed, Ali] Univ Alabama Birmingham, Birmingham, AL 35294 USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, Los Angeles, CA USA. [Rich, Michael W.] Washington Univ, St Louis, MO USA. [Banach, Maciej] Med Univ Lodz, Lodz, Poland. [Love, Thomas E.] Case Western Reserve Univ, Cleveland, OH 44106 USA. [White, Michel] Montreal Heart Inst, Quebec City, PQ, Canada. [Aronow, Wilbert S.] New York Med Coll, Valhalla, NY 10595 USA. [Epstein, Andrew E.] Vet Affairs Med Ctr, Philadelphia, PA USA. [Epstein, Andrew E.] Univ Penn, Philadelphia, PA 19104 USA. [Ahmed, Ali] Vet Affairs Med Ctr, Birmingham, AL USA. RP Ahmed, A (reprint author), Univ Alabama Birmingham, 1720 2nd Ave South,CH-19,Suite 219, Birmingham, AL 35294 USA. EM aahmed@uab.edu RI Banach, Maciej/A-1271-2009 OI Banach, Maciej/0000-0001-6690-6874 FU National Institutes of Health from the National Heart, Lung, and Blood Institute [R01-HL085561, R01-HL085561-S, R01-HL097047] FX AA was, in part, supported by the National Institutes of Health through grants (R01-HL085561, R01-HL085561-S, and R01-HL097047) from the National Heart, Lung, and Blood Institute and a generous gift from Ms. Jean B. Morris of Birmingham, Alabama. NR 31 TC 10 Z9 12 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 EI 1555-7162 J9 AM J MED JI Am. J. Med. PD OCT PY 2013 VL 126 IS 10 BP 887 EP 893 DI 10.1016/j.amjmed.2013.04.021 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 218YV UT WOS:000324469800024 PM 24054956 ER PT J AU Jin, JF Zhang, XM Lu, ZY Perry, DM Li, YC Russo, SB Cowart, LA Hannun, YA Huang, Y AF Jin, Junfei Zhang, Xiaoming Lu, Zhongyang Perry, David M. Li, Yanchun Russo, Sarah Brice Cowart, L. Ashley Hannun, Yusuf A. Huang, Yan TI Acid sphingomyelinase plays a key role in palmitic acid-amplified inflammatory signaling triggered by lipopolysaccharide at low concentrations in macrophages SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE fatty acid; sphingomyelinase; lipopolysaccharide; toll-like receptor; inflammation ID FATTY-ACIDS; INSULIN-RESISTANCE; HUMAN MONOCYTES; SPHINGOLIPID BIOSYNTHESIS; CERAMIDE SYNTHESIS; INTERLEUKIN-6; MECHANISMS; EXPRESSION; ENDOTOXIN; IL-6 AB Periodontal disease is more prevalent and severe in patients with diabetes than in nondiabetic patients. In addition to diabetes, a large number of studies have demonstrated an association between obesity and chronic periodontal disease. However, the underlying mechanisms have not been well understood. Since plasma free fatty acids (FAs) are elevated in obese patients and saturated FAs such as palmitic acid (PA) have been shown to increase host inflammatory response, we sought to find out how PA interacts with lipopolysaccharide (LPS), an important pathological factor involved in periodontal disease, to enhance inflammation. We found that whereas low concentration of LPS (1 ng/ml) stimulated interleukin (IL)-6 expression in RAW 264.7 macrophages, PA further augmented it fourfold. Besides IL-6, PA amplified the stimulatory effect of LPS on a large amount of Toll-like receptor (TLR) 4-mediated expression of proinflammatory signaling molecules such as IL-1 receptor-associated kinase-like 2 and proinflammatory molecules, including monocyte chemotactic protein-1 and colony-stimulating factor. We also observed that PA augmented TLR4 but not TLR2 signal, and the augmentation was mediated by nuclear factor-kappa B (NF-kappa B) pathways. To further elucidate the regulatory mechanism whereby PA amplifies LPS signal, our studies showed that PA and LPS synergistically increased hydrolysis of sphingomyelin by stimulating acid sphingomyelinase (ASMase) activity, which contributed to a marked increase in ceramide production and IL-6 upregulation. Taken together, this study has demonstrated that PA markedly augments TLR4-mediated proinflammatory signaling triggered by low concentration of LPS in macrophages, and ASMase plays a key role in the augmentation. C1 [Lu, Zhongyang; Cowart, L. Ashley; Huang, Yan] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29403 USA. [Jin, Junfei; Zhang, Xiaoming; Li, Yanchun; Huang, Yan] Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA. [Perry, David M.; Russo, Sarah Brice; Cowart, L. Ashley] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Hannun, Yusuf A.] SUNY Stony Brook, Stony Brook Canc Ctr, Stony Brook, NY 11794 USA. RP Huang, Y (reprint author), Ralph H Johnson Vet Affairs Med Ctr, 114 Doughty St, Charleston, SC 29403 USA. EM huangyan@musc.edu FU Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs; National Institutes of Health [DE-016353, CA-97132]; Lipidomics Shared Resource, Hollings Cancer Center, Medical University of South Carolina [P30 CA138313]; Lipidomics Core in the SC Lipidomics and Pathobiology COBRE [P20 RR017677]; National Center for Research Resources; Office of the Director of the National Institutes of Health [C06 RR-018823] FX This work was supported by the Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs and National Institutes of Health Grant DE-016353 (to Y. Huang) and Grant CA-97132 (to Y. A. Hannun). The work on sphingolipid analysis was supported in part by the Lipidomics Shared Resource, Hollings Cancer Center, Medical University of South Carolina (P30 CA138313), the Lipidomics Core in the SC Lipidomics and Pathobiology COBRE (P20 RR017677), and the National Center for Research Resources and the Office of the Director of the National Institutes of Health through Grant No. C06 RR-018823. NR 54 TC 17 Z9 17 U1 2 U2 10 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD OCT PY 2013 VL 305 IS 7 BP E853 EP E867 DI 10.1152/ajpendo.00251.2013 PG 15 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 230MO UT WOS:000325344800010 PM 23921144 ER PT J AU Gabler, NB Ratcliffe, SJ Wagner, J Asch, DA Rubenfeld, GD Angus, DC Halpern, SD AF Gabler, Nicole B. Ratcliffe, Sarah J. Wagner, Jason Asch, David A. Rubenfeld, Gordon D. Angus, Derek C. Halpern, Scott D. TI Mortality among Patients Admitted to Strained Intensive Care Units SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE critical care; resource allocation; intensive care unit; physician staffing; regionalization ID CRITICALLY-ILL PATIENTS; OUTCOMES; STATES; WORKLOAD; REGIONALIZATION; POPULATION; ALLOCATION; OCCUPANCY; SHORTAGE; CRISIS AB Rationale: The aging population may strain intensive care unit (ICU) capacity and adversely affect patient outcomes. Existing fluctuations in demand for ICU care offer an opportunity to explore such relationships. Objectives: To determine whether transient increases in ICU strain influence patient mortality, and to identify characteristics of ICUs that are resilient to surges in capacity strain. Methods: Retrospective cohort study of 264,401 patients admitted to 155 U. S. ICUs from 2001 to 2008. We used logistic regression to examine relationships of measures of ICU strain (census, average acuity, and proportion of new admissions) near the time of ICU admission with mortality. Measurements and Main Results: A total of 36,465 (14%) patients died in the hospital. ICU census on the day of a patient's admission was associated with increased mortality (odds ratio [OR], 1.02 per standardized unit increase; 95% confidence interval [CI]: 1.00, 1.03). This effect was greater among ICUs employing closed (OR, 1.07; 95% CI: 1.02, 1.12) versus open (OR, 1.01; 95% CI: 0.99, 1.03) physician staffing models (interaction P value = 0.02). The relationship between census and mortality was stronger when the census was composed of higher acuity patients (interaction P value < 0.01). Averaging strain over the first 3 days of patients' ICU stays yielded similar results except that the proportion of new admissions was now also associated with mortality (OR, 1.04 for each 10% increase; 95% CI: 1.02, 1.06). Conclusions: Several sources of ICU strain are associated with small but potentially important increases in patient mortality, particularly in ICUs employing closed staffing models. Although closed ICUs may promote favorable outcomes under static conditions, they are susceptible to being overwhelmed by patient influxes. C1 [Gabler, Nicole B.; Ratcliffe, Sarah J.; Halpern, Scott D.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Gabler, Nicole B.; Wagner, Jason; Angus, Derek C.; Halpern, Scott D.] Univ Penn, Fostering Improvement End of Life Decis Sci FIELD, Philadelphia, PA 19104 USA. [Wagner, Jason; Halpern, Scott D.] Univ Penn, Dept Med, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA. [Asch, David A.; Halpern, Scott D.] Univ Penn, Ctr Innovat, Philadelphia, PA 19104 USA. [Asch, David A.; Halpern, Scott D.] Univ Penn, Ctr Hlth Incent & Behav Econ, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Asch, David A.; Halpern, Scott D.] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA. [Asch, David A.] VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Rubenfeld, Gordon D.] Sunnybrook Hlth Sci Ctr, Program Trauma Crit Care & Emergency Med, Toronto, ON M4N 3M5, Canada. [Angus, Derek C.] Univ Pittsburgh, Sch Med, Dept Crit Care, Pittsburgh, PA USA. RP Halpern, SD (reprint author), Univ Penn, Perelman Sch Med, 719 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM shalpern@exchange.upenn.edu OI Asch, David/0000-0002-7970-286X; Ratcliffe, Sarah/0000-0002-6644-8284 FU Agency for Healthcare Research and Quality [K08HS018406]; Society of Critical Care Medicine Vision Grant FX Supported by K08HS018406 from the Agency for Healthcare Research and Quality and a Society of Critical Care Medicine Vision Grant (S.D.H.). NR 37 TC 27 Z9 28 U1 0 U2 8 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD OCT 1 PY 2013 VL 188 IS 7 BP 800 EP 806 DI 10.1164/rccm.201304-0622OC PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 230OG UT WOS:000325350600010 PM 23992449 ER PT J AU Puterman, E Epel, ES Lin, J Blackburn, EH Gross, JJ Whooley, MA Cohen, BE AF Puterman, Eli Epel, Elissa S. Lin, Jue Blackburn, Elizabeth H. Gross, James J. Whooley, Mary A. Cohen, Beth E. TI Multisystem resiliency moderates the major depression-Telomere length association: Findings from the Heart and Soul Study SO BRAIN BEHAVIOR AND IMMUNITY LA English DT Article DE Major depressive disorder; Telomeres; Cell aging; Resiliency; Social connections; Emotion regulation; Physical activity ID ALL-CAUSE MORTALITY; PHYSICAL-ACTIVITY; SOCIAL SUPPORT; EMOTION REGULATION; OLDER-ADULTS; CARDIOVASCULAR MORTALITY; DISPOSITIONAL OPTIMISM; INDIVIDUAL-DIFFERENCES; POSTMENOPAUSAL WOMEN; OXIDATIVE STRESS AB Major depressive disorder (MDD) has been associated with reduced leukocyte telomere length (LTL). It is not known, however, whether psychosocial and behavioral protective factors moderate this association. In the current study, we examine whether multisystem resiliency - defined by healthy emotion regulation, strong social connections, and health behaviors (sleep and exercise) - predicts LTL and mitigates previously demonstrated associations between depression diagnosis and LTL. LTL was measured, using a quantitative PCR assay, in 954 patients with stable cardiovascular disease in the Heart and Soul Study. In a fully adjusted model, high multisystem resiliency predicted longer LTL (b = 80.00, SE = 27.17, p = .003), whereas each individual factor did not. Multisystem resiliency significantly moderated the MDD-LTL association (p = .02). Specifically, MDD was significantly related to LTL at 1 SD below the mean of multisystem resiliency (b = -142.86, SE = 56.46, p = .01), but not at I SD above the mean (b = 49.07, SE = 74.51, p = .51). This study suggests that MDD associations with biological outcomes should be examined within a psychosocial-behavioral context, because this context shapes the nature of the direct relationship. Further research should explore the cognitive, neural, and other physiological pathways through which multisystem resiliency may confer biological benefit. (c) 2013 Elsevier Inc. All rights reserved. C1 [Puterman, Eli; Epel, Elissa S.; Lin, Jue; Blackburn, Elizabeth H.; Whooley, Mary A.; Cohen, Beth E.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Gross, James J.] Stanford Univ, Stanford, CA 94305 USA. [Whooley, Mary A.; Cohen, Beth E.] San Francisco Vet Adm Med Ctr, San Francisco, CA 94143 USA. RP Puterman, E (reprint author), Univ Calif San Francisco, 3333 Calif St Suite 465, San Francisco, CA 94143 USA. EM eli.puterman@ucsf.edu OI Puterman, Eli/0000-0002-5898-2348 FU NIH/NHLBI Grant [K99HL109247, K23 HL 094765-01]; Robert Wood Johnson Foundation; Irene Perstein Foundation; Department of Veterans Affairs, Washington, DC; National Heart Lung and Blood Institute, Bethesda, MD [R01 HL079235]; American Federation for Aging Research (Paul Beeson Scholars Program), New York, NY; Robert Wood Johnson Foundation (Faculty Scholars Program), Princeton, NJ; Ischemia Research and Education Foundation, South San Francisco, CA; Nancy Kirwan Heart Research Fund, San Francisco, CA FX We thank the study participants for their support and generous contribution of time. This research was supported in part by NIH/NHLBI Grant K99HL109247 and the Robert Wood Johnson Foundation to Dr. Puterman and NIH/NHLBI Grant K23 HL 094765-01 and a Grant from the Irene Perstein Foundation to Dr. Cohen. The Heart and Soul Study was funded by the Department of Veterans Affairs, Washington, DC, the National Heart Lung and Blood Institute (R01 HL079235), Bethesda, MD, the American Federation for Aging Research (Paul Beeson Scholars Program), New York, NY, the Robert Wood Johnson Foundation (Faculty Scholars Program), Princeton, NJ, the Ischemia Research and Education Foundation, South San Francisco, CA, and the Nancy Kirwan Heart Research Fund, San Francisco, CA. This material is the result of work supported with resources and the use of facilities at the Veterans Affairs Medical Center, San Francisco, CA. The funding organizations had no role in the design or conduct of the study; data collection, management, analysis or interpretation of the data; or preparation, review or approval of the manuscript. NR 110 TC 18 Z9 19 U1 3 U2 33 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0889-1591 J9 BRAIN BEHAV IMMUN JI Brain Behav. Immun. PD OCT PY 2013 VL 33 BP 65 EP 73 DI 10.1016/j.bbi.2013.05.008 PG 9 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA 223EU UT WOS:000324788300010 PM 23727245 ER PT J AU Abraham, NS Richardson, P Castillo, D Kane, SV AF Abraham, Neena S. Richardson, Peter Castillo, Diana Kane, Sunanda V. TI Dual Therapy With Infliximab and Immunomodulator Reduces One-Year Rates of Hospitalization and Surgery Among Veterans With Inflammatory Bowel Disease SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE Remicade; Imuran; Anti-Tumor Necrosis Factor (TNF)-alpha; Patient Management; Therapeutic Strategy ID QUALITY-OF-LIFE; CROHNS-DISEASE; MAINTENANCE THERAPY; ULCERATIVE-COLITIS; COMBINATION THERAPY; CERTOLIZUMAB PEGOL; PROPENSITY SCORE; CHARM TRIAL; ADALIMUMAB; REMISSION AB BACKGROUND & AIMS: Effectiveness of early treatment with biologics and immunomodulator therapy on healthcare utilization remains poorly defined. We assessed rates of hospitalization and surgery within 1 year after initiation of infliximab and/or immunomodulator therapy in a United States cohort of patients with inflammatory bowel disease. METHODS: We conducted a retrospective, observational cohort study of veterans with Crohn's disease or ulcerative colitis by using administrative data from 176 Department of Veteran Affairs facilities (October 1, 2001 through September 30, 2009). Inpatient, outpatient, and death records were linked longitudinally with prescription fill data. Each person-day of follow-up was assessed for treatment with infliximab, immunomodulators, both (dual therapy), or neither. We calculated drug exposure time and used Poisson and logistic regression analyses to assess outcomes. RESULTS: The cohort of 20,474 patients included 8042 patients with Crohn's disease and 12,432 with ulcerative colitis (93.9% male; 72.5% white; mean age, 60.9 +/- 14.5 years) prescribed infliximab (0.17%), immunomodulator (1.3%), or dual therapy (1.5%). Adjusted models revealed 50% relative reductions in hospitalization among patients who received 9.2 months of immunomodulator monotherapy, 8 months of infliximab, or 7.7 months of dual therapy. A 50% relative reduction in surgery was observed among patients receiving 7 months of infliximab or 5 months of dual therapy. Analysis of dose-response data revealed 73.1% and 92% reductions in risk of hospitalization and surgery, respectively, after 9 months of dual therapy. CONCLUSIONS: On the basis of a retrospective cohort study, dual therapy with infliximab and an immunomodulator for <8 months is associated with significant reductions in hospitalization and surgery within 1 year of the start of therapy. These findings indicate that patients with IBD are more likely to benefit if dual therapy is initiated earlier in their first year of therapy. C1 [Abraham, Neena S.] Baylor Coll Med, Div Gastroenterol & Hepatol, Sect Digest Dis, Houston, TX 77030 USA. [Abraham, Neena S.; Richardson, Peter; Castillo, Diana] Baylor Coll Med, Houston VA Hlth Serv Res & Dev Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Kane, Sunanda V.] Mayo Clin, Div Gastroenterol & Hepatol, Coll Med, Scottsdale, AZ 85259 USA. RP Abraham, NS (reprint author), Mayo Clin, Div Gastroenterol, 13400 East Shea Blvd, Scottsdale, AZ 85259 USA. EM abraham.neena@mayo.edu FU Janssen Biotech, Inc. FX Supported by an investigator-initiated grant from Janssen Biotech, Inc. NR 42 TC 9 Z9 9 U1 1 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD OCT PY 2013 VL 11 IS 10 BP 1281 EP 1287 DI 10.1016/j.cgh.2013.06.004 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 223QU UT WOS:000324823200016 PM 23792295 ER PT J AU Raab, PA Mackintosh, MA Gros, DF Morland, LA AF Raab, Phillip A. Mackintosh, Margaret-Anne Gros, Daniel F. Morland, Leslie A. TI Influence of Depression on State and Trait Anger in Veterans with Posttraumatic Stress Disorder (vol 37, pg 673, 2013) SO COGNITIVE THERAPY AND RESEARCH LA English DT Correction C1 [Raab, Phillip A.; Mackintosh, Margaret-Anne; Morland, Leslie A.] Natl Ctr Posttraumat Stress Disorder, Dept Vet Affairs Pacific Isl Healthcare Syst, Pacific Isl Div, Honolulu, HI 96819 USA. [Raab, Phillip A.; Mackintosh, Margaret-Anne; Morland, Leslie A.] Pacific Hlth Res & Educ Inst, Honolulu, HI USA. [Gros, Daniel F.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Gros, Daniel F.] Med Univ S Carolina, Charleston, SC 29425 USA. [Morland, Leslie A.] Univ Hawaii Manoa, John A Burns Sch Med, Honolulu, HI 96822 USA. RP Raab, PA (reprint author), Natl Ctr Posttraumat Stress Disorder, Dept Vet Affairs Pacific Isl Healthcare Syst, Pacific Isl Div, 3375 Koapaka,Suite 1-560, Honolulu, HI 96819 USA. EM drewraab@gmail.com NR 1 TC 0 Z9 0 U1 1 U2 4 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0147-5916 J9 COGNITIVE THER RES JI Cogn. Ther. Res. PD OCT PY 2013 VL 37 IS 5 BP 1089 EP 1090 DI 10.1007/s10608-013-9534-3 PG 2 WC Psychology, Clinical SC Psychology GA 223PD UT WOS:000324817600021 ER PT J AU Cohen, R Caravatto, PP Petry, T Cummings, D AF Cohen, Ricardo Caravatto, Pedro Paulo Petry, Tarissa Cummings, David TI Role of Metabolic Surgery in Less Obese or Non-Obese Subjects with Type 2 Diabetes: Influence Over Cardiovascular Events SO CURRENT ATHEROSCLEROSIS REPORTS LA English DT Article DE Type 2 diabetes mellitus; Metabolic surgery; Bariatric surgery; Obesity; Gastrointestinal surgery ID GASTRIC BYPASS-SURGERY; BODY-MASS INDEX; LIFE-STYLE INTERVENTION; BARIATRIC SURGERY; WEIGHT-LOSS; MULTIFACTORIAL INTERVENTION; SLEEVE GASTRECTOMY; MEDICAL THERAPY; PREVALENCE; MORTALITY AB Bariatric surgery was initially developed as a tool for weight reduction only, but it is gaining increasing popularity because of its remarkable effect on glucose metabolism in morbidly obese and less obese patients. Recent publications have shown the good results of metabolic surgery, creating a new field of clinical research that is currently overflowing in the medical community with outstanding high-quality data. In morbidly obese population, there is compelling data on long term cardiovascular risk reduction and mortality, coming from longitudinal prospective studies and systematic reviews. Numbers range from 33 to 92 % of decrease in fatal and nonfatal cardiovascular events. In low body mass index (BMI) diabetics, there is an increasing number of reported good outcomes after metabolic surgery with the aim to treat type 2 diabetes (T2DM). There is scarce information on cardiovascular outcomes in non-morbidly obese subjects, but the extraordinary glucose, lipid and blood pressure control in the published series are suggesting good long-term effects on cardiovascular risk profile and mortality. The papers review was comprehensive, including the available randomized controlled trials, long-term prospective series and systematic reviews. C1 [Cohen, Ricardo; Caravatto, Pedro Paulo; Petry, Tarissa] Oswaldo Cruz Hosp, Ctr Excellence Metab & Bariatr Surg, Sao Paulo, Brazil. [Cummings, David] Univ Washington, Sch Med, Diabet & Obes Ctr Excellence, Seattle, WA USA. [Cummings, David] Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Cohen, R (reprint author), Oswaldo Cruz Hosp, Ctr Excellence Metab & Bariatr Surg, Sao Paulo, Brazil. EM ricardo.cohen@haoc.com.br NR 54 TC 4 Z9 4 U1 0 U2 9 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1523-3804 J9 CURR ATHEROSCLER REP JI Curr. Atheroscleros. Rep. PD OCT PY 2013 VL 15 IS 10 AR 355 DI 10.1007/s11883-013-0355-3 PG 6 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 221EF UT WOS:000324639800001 PM 23955664 ER PT J AU Kwee, TC Cheng, G Lam, MGEH Basu, S Alavi, A AF Kwee, Thomas C. Cheng, Gang Lam, Marnix G. E. H. Basu, Sandip Alavi, Abass TI SUVmax of 2.5 should not be embraced as a magic threshold for separating benign from malignant lesions SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING LA English DT Editorial Material ID DUAL TIME-POINT; PARTIAL VOLUME CORRECTION; STANDARDIZED UPTAKE VALUE; FDG-PET; INDETERMINATE BIOPSY; METABOLIC BIOPSY; NODULES; TOOL C1 [Kwee, Thomas C.; Lam, Marnix G. E. H.] Univ Med Ctr Utrecht, Dept Radiol & Nucl Med, Utrecht, Netherlands. [Cheng, Gang] Philadelphia VA Med Ctr, Dept Radiol, Philadelphia, PA USA. [Cheng, Gang; Alavi, Abass] Hosp Univ Penn, Dept Radiol, Div Nucl Med, Philadelphia, PA 19104 USA. [Basu, Sandip] Tata Mem Ctr Annexe, Bhabha Atom Res Ctr, Radiat Med Ctr, Bombay, Maharashtra, India. RP Alavi, A (reprint author), Hosp Univ Penn, Dept Radiol, Div Nucl Med, 3400 Spruce St,110 Donner Bldg, Philadelphia, PA 19104 USA. EM abass.alavi@uphs.upenn.edu NR 17 TC 11 Z9 11 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1619-7070 J9 EUR J NUCL MED MOL I JI Eur. J. Nucl. Med. Mol. Imaging PD OCT PY 2013 VL 40 IS 10 BP 1475 EP 1477 DI 10.1007/s00259-013-2484-x PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 221GE UT WOS:000324645100001 PM 23801170 ER PT J AU Cooper, JN Fried, L Tepper, P Barinas-Mitchell, E Conroy, MB Evans, RW Brooks, MM Woodard, GA Sutton-Tyrrell, K AF Cooper, Jennifer N. Fried, Linda Tepper, Ping Barinas-Mitchell, Emma Conroy, Molly B. Evans, Rhobert W. Brooks, Maria Mori Woodard, Genevieve A. Sutton-Tyrrell, Kim TI Changes in serum aldosterone are associated with changes in obesity-related factors in normotensive overweight and obese young adults SO HYPERTENSION RESEARCH LA English DT Article DE adipokines; adipose tissue; aldosterone; metabolic syndrome; obesity ID RENIN-ANGIOTENSIN SYSTEM; BLOOD-PRESSURE; WEIGHT-LOSS; PLASMA-ALDOSTERONE; METABOLIC SYNDROME; ADIPOSE-TISSUE; INSULIN-RESISTANCE; MINERALOCORTICOID RECEPTOR; SCIENTIFIC STATEMENT; NERVOUS-SYSTEM AB Recent data suggest excess circulating aldosterone promotes cardiometabolic decline. Weight loss may lower aldosterone levels, but little longitudinal data is available in normotensive adults. We aimed to determine whether, independent of changes in sodium excretion, reductions in serum aldosterone are associated with favorable changes in obesity-related factors in normotensive overweight/obese young adults. We studied 285 overweight/obese young adult participants (body mass index >= 25 and<40 kg m(-2), age 20-45 years) in a clinical trial examining the effects of a 1-year diet and physical activity intervention with or without sodium restriction on vascular health. Body weight, serum aldosterone, 24-h sodium and potassium excretion and obesity-related factors were measured at baseline, 6, 12 and 24 months. Weight loss was significant at 6 (7%), 12 (6%) and 24 months (4%; all P<0.0001). Decreases in aldosterone were associated with decreases in C-reactive protein, leptin, insulin, homeostasis assessment of insulin resistance, heart rate, tonic cardiac sympathovagal balance and increases in adiponectin (all P<0.05) in models adjusting for baseline age, sex, race, intervention arm, time since baseline, and sodium and potassium excretion. Weight loss and reductions in thigh intermuscular fat (intermuscular adipose tissue area; IMAT) were associated with decreases in aldosterone in the subgroup (n = 98) with metabolic syndrome (MetS) at baseline (MetS x weight loss, P = 0.04; MetS x change in IMAT, P 0.04). Favorable changes in obesity-related factors are associated with reductions in aldosterone in young adults with no risk factors besides excess weight, an important finding, given aldosterone's emergence as an important cardiometabolic risk factor. C1 [Cooper, Jennifer N.; Fried, Linda; Tepper, Ping; Barinas-Mitchell, Emma; Conroy, Molly B.; Evans, Rhobert W.; Brooks, Maria Mori; Woodard, Genevieve A.; Sutton-Tyrrell, Kim] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Cooper, Jennifer N.; Brooks, Maria Mori] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [Fried, Linda] VA Pittsburgh Healthcare Syst, Univ Dr Div, Pittsburgh, PA USA. [Conroy, Molly B.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA 15261 USA. RP Cooper, JN (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Epidemiol Data Ctr, 130 DeSoto St, Pittsburgh, PA 15261 USA. EM jennifer.njoroge@gmail.com OI Brooks, Maria/0000-0002-2030-7873; Barinas-Mitchell, Emma/0000-0002-7280-7781 FU National Heart, Lung, and Blood Institute of the National Institutes of Health [R01 HL077525, F31 HL106986] FX This work was supported by Grants R01 HL077525 and F31 HL106986 from the National Heart, Lung, and Blood Institute of the National Institutes of Health. We thank Beth Hauth for expert laboratory analyses. We greatly appreciate the efforts of the SAVE trial volunteers and the study and clinic coordinators (Laura Kinzel and Eileen Cole). NR 42 TC 9 Z9 9 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0916-9636 J9 HYPERTENS RES JI Hypertens. Res. PD OCT PY 2013 VL 36 IS 10 BP 895 EP 901 DI 10.1038/hr.2013.45 PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 230GR UT WOS:000325325600013 PM 23657296 ER PT J AU Richter, HE Morgan, SL Gleason, JL Szychowski, JM Goode, PS Burgio, KL AF Richter, Holly E. Morgan, Sarah L. Gleason, Jonathan L. Szychowski, Jeff M. Goode, Patricia S. Burgio, Kathryn L. TI Pelvic floor symptoms and bone mineral density in women undergoing osteoporosis evaluation SO INTERNATIONAL UROGYNECOLOGY JOURNAL LA English DT Article DE Pelvic floor disorders; Bone mineral density; Pathophysiology ID STRESS URINARY-INCONTINENCE; FECAL INCONTINENCE; ORGAN PROLAPSE; OLDER WOMEN; QUESTIONNAIRES; PREVALENCE; DISORDERS; ADULTS; TRENDS; ICIQ AB Our aim was to characterize pelvic floor symptoms in postmenopausal women who had undergone osteoporosis evaluation and examine their association with bone mineral density (BMD). Pelvic floor symptom questionnaires were mailed to 4,026 women. Multivariate logistic regression models controlling for age, race, body mass index (BMI), and chronic obstructive pulmonary disease (COPD) were performed comparing symptoms in women with osteoporosis (T score a parts per thousand currency sign -2.5) and osteopenia (T score > -2.5 to < -1) at any site to women with normal BMD (T score: a parts per thousand yen -1, referent). There were 1,774/4,026 (44 %) questionnaires returned; 1,655 were included in the analysis (362 osteoporosis, 870 osteopenia, 423 normal BMD). Overall prevalence of any urinary incontinence (UI) was 1,226/1,640 (75 %), with UI a parts per thousand yen2-3 times/week in 699/1,197 (58 %), fecal incontinence over the past month in 247/1,549 (16 %), and prolapse in 162/1,582 (10 %). Multivariate analyses revealed that women with osteopenia had increased risk of incontinence of solid stool [adjusted odds ratio (aOR) 1.7, 95 % confidence interval (CI) 1.1-2.4). Risk of UI a parts per thousand yen2-3 times/week was not increased in women with osteoporosis (aOR 0.9, CI 0.6-1.3) and was lower in women with osteopenia (aOR 0.7, CI 0.5-0.9). In women with osteoporosis, the odds of moderate- to large-volume urine loss versus small/none was higher for those in the lower T-score quartile (lower BMD; aOR 1.43, CI 1.1-1.9). In women undergoing osteoporosis evaluation, those with osteopenia were at increased risk of fecal incontinence but not UI compared with normal women. Osteoporotic women with the lowest T scores had higher risk of moderate- to large-volume UI. It is unclear whether there is a pathophysiologic link between BMD loss and development of pelvic floor symptoms. C1 [Richter, Holly E.; Morgan, Sarah L.; Gleason, Jonathan L.; Szychowski, Jeff M.; Goode, Patricia S.; Burgio, Kathryn L.] Univ Alabama Birmingham, Birmingham, AL 35233 USA. [Goode, Patricia S.; Burgio, Kathryn L.] Birmingham VA Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Birmingham, AL USA. RP Richter, HE (reprint author), Univ Alabama Birmingham, 1700 6th Av South,Suite 10382, Birmingham, AL 35233 USA. EM hrichter@uabmc.edu FU HER-Astellas Consultant, Pelvalon [COI]; SLM-ISCD Board [COI]; JLG; PSG-Pfizer [COI]; KLB-Pfizer Consultant [COI]; University of Alabama at Birmingham, Protective Life Clinical Initiatives (PLCI) Award Program; National Institutes of Diabetes and Digestive and Kidney Diseases [2K24-DK068389] FX HER-Astellas Consultant, Pelvalon research funding, no COI; SLM-ISCD Board and Amgen Consultant, no COI; JLG-no disclosures or COI; JMS-no disclosures or COI; PSG-Pfizer research funding, no COI; KLB-Pfizer Consultant, no COI. Funding sources wer the University of Alabama at Birmingham, Protective Life Clinical Initiatives (PLCI) Award Program; partially supported by the National Institutes of Diabetes and Digestive and Kidney Diseases, 2K24-DK068389 to HER NR 27 TC 4 Z9 4 U1 0 U2 1 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-3462 J9 INT UROGYNECOL J JI Int. Urogynecol. J. PD OCT PY 2013 VL 24 IS 10 BP 1663 EP 1669 DI 10.1007/s00192-013-2056-4 PG 7 WC Obstetrics & Gynecology; Urology & Nephrology SC Obstetrics & Gynecology; Urology & Nephrology GA 221HD UT WOS:000324647700011 PM 23389642 ER PT J AU Steidtmann, D Manber, R Blasey, C Markowitz, JC Klein, DN Rothbaum, BO Thase, ME Kocsis, JH Arnow, BA AF Steidtmann, Dana Manber, Rachel Blasey, Christine Markowitz, John C. Klein, Daniel N. Rothbaum, Barbara O. Thase, Michael E. Kocsis, James H. Arnow, Bruce A. TI Detecting Critical Decision Points in Psychotherapy and Psychotherapy plus Medication for Chronic Depression SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY LA English DT Article DE chronic depression; psychotherapy for depression; psychotherapy nonremission; adaptive designs; receiver operating curve ID STAR-ASTERISK-D; SEQUENCED TREATMENT ALTERNATIVES; ADAPTIVE TREATMENT STRATEGY; PSYCHOMETRIC PROPERTIES; ALGORITHM PROJECT; TREATMENT FAILURE; FEEDBACK; ANTIDEPRESSANTS; DISORDER; OUTCOMES AB Objective: We sought to quantify clinical decision points for identifying depression treatment nonremitters prior to end-of-treatment. Method: Data came from the psychotherapy arms of a randomized clinical trial for chronic depression. Participants (n = 352; 65.6% female; 92.3% White; mean age = 44.3 years) received 12 weeks of cognitive behavioral analysis system of psychotherapy (CBASP) or CBASP plus an antidepressant medication. In half of the sample, receiver operating curve analyses were used to identify efficient percentage of symptom reduction cut points on the Inventory of Depressive Symptoms-Self-Report (IDS-SR) for predicting end-of-treatment nonremission based on the Hamilton Rating Scale for Depression (HRSD). Sensitivity, specificity, predictive values, and Cohen's kappa for identified cut points were calculated using the remaining half of the sample. Results: Percentage of IDS-SR symptom reduction at Weeks 6 and 8 predicted end-of-treatment HRSD remission status in both the combined treatment (Week 6 cut point = 50.0%, Cohen's kappa = .42; Week 8 cut point = 54.3%, Cohen's kappa = .45) and psychotherapy only (Week 6 cut point = 60.7%, Cohen's kappa = .41; Week 8 cut point = 48.7%, Cohen's kappa = .49). Status at Week 8 was more reliable for identifying nonremitters in psychotherapy-only treatment. Conclusions: Those with chronic depression who will not remit in structured, time-limited psychotherapy for depression, either with therapy alone or in combination with antidepressant medication, are identifiable prior to end of treatment. Findings provide an operationalized strategy for designing adaptive psychotherapy interventions. C1 [Steidtmann, Dana; Manber, Rachel; Blasey, Christine; Arnow, Bruce A.] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Markowitz, John C.] Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA. [Markowitz, John C.] New York State Psychiat Inst & Hosp, New York, NY 10032 USA. [Klein, Daniel N.] SUNY Stony Brook, Dept Psychol, Stony Brook, NY USA. [Rothbaum, Barbara O.] Emory Univ, Sch Med, Dept Psychiat, Atlanta, GA 30322 USA. [Thase, Michael E.] Univ Penn, Dept Psychiat, Sch Med, Philadelphia, PA 19104 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Kocsis, James H.] Weill Cornell Med Coll, Dept Psychiat, New York, NY USA. RP Steidtmann, D (reprint author), Stanford Univ, Dept Psychiat & Behav Sci, 401 Quarry Rd, Stanford, CA 94305 USA. EM dsteidt@stanford.edu FU NIMH NIH HHS [T32 MH019938] NR 44 TC 9 Z9 9 U1 1 U2 12 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0022-006X EI 1939-2117 J9 J CONSULT CLIN PSYCH JI J. Consult. Clin. Psychol. PD OCT PY 2013 VL 81 IS 5 BP 783 EP 792 DI 10.1037/a0033250 PG 10 WC Psychology, Clinical SC Psychology GA 223CE UT WOS:000324780500004 PM 23750462 ER PT J AU Karlin, BE Trockel, M Taylor, CB Gimeno, J Manber, R AF Karlin, Bradley E. Trockel, Mickey Taylor, C. Barr Gimeno, Julia Manber, Rachel TI National Dissemination of Cognitive Behavioral Therapy for Insomnia in Veterans: Therapist- and Patient-Level Outcomes SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY LA English DT Article DE cognitive-behavioral therapy; insomnia; dissemination; training; US Department of Veterans Affairs ID RANDOMIZED CONTROLLED-TRIAL; PSYCHOLOGICAL TREATMENTS; PERSISTENT INSOMNIA; METAANALYSIS; SLEEP; PHARMACOTHERAPY; DEPRESSION; EFFICACY; DISORDER AB Objective: To evaluate the effects of national training in and implementation of Cognitive Behavioral Therapy for Insomnia (CBT-I) in the U.S. Department of Veterans Affairs (VA) health care system on clinicians' competency and patients' insomnia severity, symptoms of depression, and quality of life. Method: A prospective cohort of 102 VA clinicians (including mental health staff in various mental health and primary care settings) participated in the VA CBT-I Training Program during 2011 and 2012. Patients included 182 veterans treated by clinicians enrolled in the training. Clinicians were rated on taped therapy sessions, using a standardized competency rating form. Patients' symptoms were assessed using the Insomnia Severity Index (ISI) and standardized measures of depression and quality of life. Results: Of 102 clinicians attending workshop training, 94 (92%) met all training requirements, including minimum competency score criteria. Of 182 patients, 122 (67%) completed treatment. The mixed effects model revealed significant reductions in average patient ISI score (from 19.9 to 10.2, standard error = 3.0). Patients also improved on measures of depression and quality of life. Conclusion: National training in and implementation of CBT-I resulted in a significant increase in therapist competency to deliver CBT-I for almost all clinicians and in a large reduction in insomnia severity and improvement in depression and quality of life among veterans. Observed effect sizes are comparable to results of randomized clinical trials. These results suggest CBT-I can be feasibly and effectively disseminated to routine clinical settings, with very favorable patient outcomes. C1 [Karlin, Bradley E.] US Dept Vet Affairs, Cent Off, Mental Hlth Serv, Washington, DC 20420 USA. [Karlin, Bradley E.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD 21218 USA. [Trockel, Mickey; Taylor, C. Barr; Gimeno, Julia; Manber, Rachel] Stanford Univ, Med Ctr, Dept Psychiat, Stanford, CA 94305 USA. [Trockel, Mickey; Taylor, C. Barr; Gimeno, Julia; Manber, Rachel] Vet Affairs Palo Alto Hlth Care Syst, Sierra Pacific Mental Illness Res Educ & Clin Ctr, Dept Psychiat, Palo Alto, CA USA. RP Karlin, BE (reprint author), US Dept Vet Affairs, Cent Off, Mental Hlth Serv 10P4M, 810 Vermont Ave NW, Washington, DC 20420 USA. EM Bradley.Karlin2@va.gov NR 21 TC 30 Z9 30 U1 0 U2 20 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0022-006X J9 J CONSULT CLIN PSYCH JI J. Consult. Clin. Psychol. PD OCT PY 2013 VL 81 IS 5 BP 912 EP 917 DI 10.1037/a0032554 PG 6 WC Psychology, Clinical SC Psychology GA 223CE UT WOS:000324780500017 PM 23586730 ER PT J AU Lina, TT Pinchuk, IV House, J Yamaoka, Y Graham, DY Beswick, EJ Reyes, VE AF Lina, Taslima T. Pinchuk, Irina V. House, Jennifer Yamaoka, Yoshio Graham, David Y. Beswick, Ellen J. Reyes, Victor E. TI CagA-Dependent Downregulation of B7-H2 Expression on Gastric Mucosa and Inhibition of Th17 Responses during Helicobacter pylori Infection SO JOURNAL OF IMMUNOLOGY LA English DT Article ID INDUCIBLE COSTIMULATOR LIGAND; T-CELL RESPONSE; EPITHELIAL-CELLS; POTENTIAL ROLE; IV SECRETION; MICE; PATHOGENESIS; ACTIVATION; PROTEIN; INTERLEUKIN-8 AB Gastric epithelial cells (GECs) are the primary target for Helicobacter pylori infection and may act as APCs regulating local T cell responses. We previously reported that H. pylori infection of GECs induces the expression of the T cell coinhibitory molecule B7-H1 on GECs. This process contributes to the hyporesponsiveness of CD4(+) effector T cells and accumulation of regulatory T cells. In the present study, we investigated the impact of H. pylori cytotoxin-associated gene A (CagA) on the modulation of the expression of the T cell costimulator B7-H2 by GECs. B7-H2 is involved in promoting Th17 type responses. H. pylori infection downregulates B7-H2 expression by GECs in a CagA-dependent manner. IFN-gamma, which is increased in the H. pylori-infected gastric mucosa, synergizes with H. pylori in downregulating B7-H2 expression by GECs. CagA-mediated modulation of B7-H2 on GECs involves p70 S6 kinase phosphorylation. The CagA-dependent B7-H2 downregulation in GECs correlates with a decrease in Th17 type responses in vitro and in vivo. Furthermore, CagA-dependent modulation of Th17 responses was inversely correlated with the H. pylori colonization levels in vivo. Our data suggest that CagA contributes to the ability of H. pylori to evade Th17-mediated clearance by modulating expression of B7-H2 and, thus, to the establishment of the H. pylori chronic infection. C1 [Lina, Taslima T.; Pinchuk, Irina V.; Reyes, Victor E.] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA. [Pinchuk, Irina V.] Univ Texas Med Branch, Dept Internal Med, Galveston, TX 77555 USA. [House, Jennifer; Reyes, Victor E.] Univ Texas Med Branch, Dept Pediat, Galveston, TX 77555 USA. [Yamaoka, Yoshio; Graham, David Y.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. [Beswick, Ellen J.] Univ New Mexico, Hlth Sci Ctr, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA. RP Reyes, VE (reprint author), Univ Texas Med Branch, Childrens Hosp, Dept Pediat, 301 Univ Blvd, Galveston, TX 77555 USA. EM vreyes@utmb.edu RI Pinchuk, Irina/A-7227-2008 OI Pinchuk, Irina/0000-0003-1505-5779 FU National Institutes of Health [AI68712, DK090090-01, CA127022, 1U54RR02614, 8UL1TR000041]; American Gastroenterological Association; University of Texas Medical Branch; University of Texas Medical Branch Sealy Center for Vaccine Development; American Cancer Society [RSG-10-159-01-LIB]; University of New Mexico Clinical and Translational Science Center FX This work was supported by National Institutes of Health Grants AI68712, DK090090-01, and CA127022; the American Gastroenterological Association Research Scholar Award; National Institutes of Health Grant 1U54RR02614; the University of Texas Medical Branch Clinical and Translational Sciences Award; a University of Texas Medical Branch Sealy Center for Vaccine Development predoctoral fellowship (to T.T.L.); American Cancer Society Grant RSG-10-159-01-LIB; National Institutes of Health Grant 8UL1TR000041; and by the University of New Mexico Clinical and Translational Science Center. NR 60 TC 10 Z9 11 U1 0 U2 3 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD OCT 1 PY 2013 VL 191 IS 7 BP 3838 EP 3846 DI 10.4049/jimmunol.1300524 PG 9 WC Immunology SC Immunology GA 221CH UT WOS:000324634500039 PM 23997227 ER PT J AU Lafosse, JM Mitchell, SM Corboy, JR Filley, CM AF Lafosse, Jose M. Mitchell, Sandra M. Corboy, John R. Filley, Christopher M. TI The Nature of Verbal Memory Impairment in Multiple Sclerosis: A List-Learning and Meta-analytic Study SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY LA English DT Article DE Multiple sclerosis; Memory; Learning; White matter disease; Neuropsychological tests; Meta analysis ID COGNITIVE IMPAIRMENT; WHITE-MATTER; NEUROPSYCHOLOGICAL IMPAIRMENT; WORKING-MEMORY; MS; PERFORMANCE; DEFICITS; ATROPHY; RECALL; SPEED AB The primary purpose of this study was to test the hypothesis that multiple sclerosis (MS) patients have impaired acquisition rather than a retrieval deficit. Verbal memory impairment in MS was examined in 53 relapsing-remitting MS patients and 31 healthy controls (HC), and in a meta-analysis of studies that examined memory functioning in MS with list-learning tasks. The MS group demonstrated significantly lower acquisition and delayed recall performance than the HC group, and the meta-analysis revealed that the largest effect sizes were obtained for acquisition measures relative to delayed recall and recognition. Our data argue against a retrieval deficit as the sole explanation for verbal memory impairment in MS, and make a consistent case for the position that deficient acquisition contributes to the memory dysfunction of MS patients. Deficient acquisition may result from demyelination in relevant white matter tracts that reduces encoding efficiency as a result of impaired speed of information processing. C1 [Lafosse, Jose M.] Regis Univ, Dept Psychol & Neurosci, Denver, CO 80221 USA. [Mitchell, Sandra M.] New Mexico Vet Affairs Healthcare Syst, Albuquerque, NM USA. [Corboy, John R.; Filley, Christopher M.] Univ Colorado, Sch Med, Dept Neurol, Denver, CO USA. [Corboy, John R.; Filley, Christopher M.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Filley, Christopher M.] Univ Colorado, Sch Med, Dept Psychiat, Denver, CO 80262 USA. RP Lafosse, JM (reprint author), Regis Univ, Dept Psychol & Neurosci, 3333 Regis Blvd,D-12, Denver, CO 80221 USA. EM jlafosse@regis.edu FU Regis University FX None of the authors have any conflict of interest to report. This research received no specific grant from any funding agency, commercial or not-for-profit sectors, but was supported by a sabbatical leave to Dr. Lafosse from Regis University. We thank Nancy L. Leech, Ph.D. for her assistance with meta-analytic techniques, Ted Krmpotich for his assistance with data collection, and the Regis University students enrolled in Neuropsychology during spring 2013 for their helpful reviews of the manuscript. NR 100 TC 5 Z9 5 U1 0 U2 7 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1355-6177 J9 J INT NEUROPSYCH SOC JI J. Int. Neuropsychol. Soc. PD OCT PY 2013 VL 19 IS 9 BP 995 EP 1008 DI 10.1017/S1355617713000957 PG 14 WC Clinical Neurology; Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 223RY UT WOS:000324827700006 PM 24059259 ER PT J AU Karlin, JD Koontz, BF Freedland, SJ Moul, JW Grob, BM Wan, W Hagan, MP Anscher, MS Moghanaki, D AF Karlin, Jeremy D. Koontz, Bridget F. Freedland, Stephen J. Moul, Judd W. Grob, Baruch M. Wan, Wen Hagan, Michael P. Anscher, Mitchell S. Moghanaki, Drew TI Identifying Appropriate Patients for Early Salvage Radiotherapy after Prostatectomy SO JOURNAL OF UROLOGY LA English DT Article DE prostate; prostatic neoplasms; prostate-specific antigen; salvage therapy; radiotherapy ID RADICAL PROSTATECTOMY; RADIATION-THERAPY; BIOCHEMICAL RECURRENCE; POSTOPERATIVE RADIOTHERAPY; ADJUVANT RADIOTHERAPY; TREATMENT FAILURE; CANCER; RISK; TRIAL; CONSENSUS AB Purpose: It remains unclear whether relapsed prostate specific antigen at postprostatectomy salvage radiotherapy impacts outcomes as long it is 1.0 ng/ml or less. Materials and Methods: We performed a retrospective cohort study of 197 patients treated with salvage radiotherapy in the setting of detectable relapsed prostate specific antigen 1.0 ng/ml or less. Patients were excluded from analysis if they had lymph node involvement or received androgen deprivation therapy. Freedom from prostate specific antigen progression after salvage radiotherapy was analyzed by a Cox regression model. Results: Median relapsed prostate specific antigen was 0.33 ng/ml (range 0.07 to 1.0). There was 86% freedom from prostate specific antigen progression at a median followup of 52 months. Relapsed prostate specific antigen (HR 1.9, p = 0.004), Gleason score 8-10 (HR 5.2, p <0.001) and negative margin status (HR 2.0, p = 0.02) were independently associated with an increased risk of prostate specific antigen progression after salvage radiotherapy. We identified interaction between relapsed prostate specific antigen and Gleason score (p = 0.04) but not margin status. A significant association was noted between higher relapsed prostate specific antigen and prostate specific antigen progression after salvage radiotherapy in patients with Gleason score 8-10 but not 7 or less. In patients with Gleason score 8-10 the rate of freedom from prostate specific antigen progression at 53 months was 77% vs 26% when salvage radiotherapy was initiated at a relapsed prostate specific antigen of 0.33 or less vs 0.34 to 1.0 ng/ml (log rank p = 0.003). Conclusions: Different relapsed prostate specific antigen thresholds for unsuccessful salvage radiotherapy may exist based on Gleason score. These data suggest that patients with Gleason score 8-10 should be offered salvage radiotherapy at the earliest detectable relapsed prostate specific antigen, even 0.33 ng/ml or less. Those with Gleason score 7 or less may have the opportunity to be followed with serial prostate specific antigen measurements to improve risk stratification, and delay and/or avoid the potential toxicity of salvage radiotherapy. C1 [Karlin, Jeremy D.; Hagan, Michael P.; Anscher, Mitchell S.; Moghanaki, Drew] Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23284 USA. [Wan, Wen] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA USA. [Grob, Baruch M.] Hunter Holmes McGuire Vet Affairs Med Ctr, Urol Serv, Richmond, VA USA. [Hagan, Michael P.; Moghanaki, Drew] Hunter Holmes McGuire Vet Affairs Med Ctr, Radiat Oncol Serv, Richmond, VA USA. [Hagan, Michael P.] US Dept Vet Affairs, Natl Radiat Oncol Program, Richmond, VA USA. [Koontz, Bridget F.] Duke Univ Med Ctr, Dept Radiat Oncol, Durham, NC USA. [Freedland, Stephen J.; Moul, Judd W.] Duke Univ Med Ctr, Div Urol Surg, Durham, NC USA. [Freedland, Stephen J.; Moul, Judd W.] Duke Univ Med Ctr, Duke Canc Inst, Durham, NC USA. [Freedland, Stephen J.] Durham Vet Affairs Med Ctr, Urol Serv, Durham, NC USA. [Freedland, Stephen J.] Duke Univ Sch Med, Dept Pathol, Durham, NC USA. RP Moghanaki, D (reprint author), Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23284 USA. OI Anscher, Mitchell/0000-0003-4480-111X NR 22 TC 6 Z9 6 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD OCT PY 2013 VL 190 IS 4 BP 1410 EP 1415 DI 10.1016/j.juro.2013.04.078 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 227EH UT WOS:000325091700103 PM 23648223 ER PT J AU Dubin, RF Teerlink, JR Schiller, NB Alokozai, D Peralta, CA Johansen, KL AF Dubin, Ruth F. Teerlink, John R. Schiller, Nelson B. Alokozai, Dean Peralta, Carmen A. Johansen, Kirsten L. TI Association of segmental wall motion abnormalities occurring during hemodialysis with post-dialysis fatigue SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article DE end-stage renal disease; hemodialysis; post-dialysis fatigue ID DIALYSIS; DYSFUNCTION; DEPRESSION; MORTALITY; OUTCOMES; IMPACT AB Post-dialysis fatigue (PDF) is a common, debilitating symptom that remains poorly understood. Cardiac wall motion abnormalities (WMAs) may worsen during dialysis, but it is unknown whether WMA are associated with PDF. Forty patients were recruited from University of California San Francisco-affiliated dialysis units between January 2010 and February 2011. Participants underwent echocardiograms before and during the last hour of 79 dialysis sessions. Myocardial segments were graded 14 by a blinded reviewer, with four representing the worst WMA, and the segmental scores were summed for each echocardiogram. Patients completed questionnaires about their symptoms. Severe PDF (defined as lasting 2 h after dialysis) was analysed using a generalized linear model with candidate predictors including anemia, intradialytic hemodynamics and cardiac function. Forty-four percent of patients with worsened WMA (n9) had severe PDF, compared with 13 of patients with improved or unchanged WMA (P 0.04). A one-point increase in the WMA score during dialysis was associated with a 10 higher RR of severe PDF [RR: 1.1, 95 CI (1.1, 1.2), P 0.001]. After multivariable adjustment, every point increase in the WMA score was associated with a 2-fold higher risk of severe PDF [RR: 1.9, 95 CI (1.4, 2.6), P 0.001]. History of depression was associated with severe PDF after adjustment for demographics and comorbidities [RR: 3.4, 95 CI (1.3, 9), P 0.01], but anemia, hemodynamics and other parameters of cardiac function were not. Although cross-sectional, these results suggest that some patients may experience severe PDF as a symptom of cardiac ischemia occurring during dialysis. C1 [Dubin, Ruth F.; Peralta, Carmen A.; Johansen, Kirsten L.] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Med Nephrol, San Francisco, CA 94143 USA. [Teerlink, John R.; Schiller, Nelson B.] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Med Cardiol, San Francisco, CA 94143 USA. [Alokozai, Dean] Cardiocore, San Francisco, CA USA. RP Dubin, RF (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Med Nephrol, San Francisco, CA 94143 USA. EM ruth.dubin@ucsf.edu FU University of California San Francisco Academic Senate, San Francisco, CA, USA; Research Evaluation and Allocation Committee in the University of California San Francisco, School of Medicine Dean's Office, San Francisco, CA, USA; National Institute of Diabetes and Digestive and Kidney Diseases [1K24-DK085153-02, 1K23-DK092354-01A1]; UCSF Clinical and Translational Science Institute [UL1 TR000004] FX Funding for this project came from the following sources. (i) Individual Investigator Grant, University of California San Francisco Academic Senate, San Francisco, CA, USA. (ii) Grant Huntington Fund provided by the Research Evaluation and Allocation Committee in the University of California San Francisco, School of Medicine Dean's Office, San Francisco, CA, USA. (iii) National Institute of Diabetes and Digestive and Kidney Diseases, 1K24-DK085153-02. (iv) National Institute of Diabetes and Digestive and Kidney Diseases, 1K23-DK092354-01A1. (v) UCSF Clinical and Translational Science Institute grant number UL1 TR000004. NR 18 TC 8 Z9 8 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD OCT PY 2013 VL 28 IS 10 BP 2580 EP 2585 DI 10.1093/ndt/gft097 PG 6 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA 228JU UT WOS:000325183100024 PM 23743019 ER PT J AU Schafer, AL Burghardt, AJ Sellmeyer, DE Palermo, L Shoback, DM Majumdar, S Black, DM AF Schafer, A. L. Burghardt, A. J. Sellmeyer, D. E. Palermo, L. Shoback, D. M. Majumdar, S. Black, D. M. TI Postmenopausal women treated with combination parathyroid hormone (1-84) and ibandronate demonstrate different microstructural changes at the radius vs. tibia: the PTH and Ibandronate Combination Study (PICS) SO OSTEOPOROSIS INTERNATIONAL LA English DT Article DE Bisphosphonate; Bone microstructure; Cortical; High-resolution peripheral quantitative computed tomography; Parathyroid hormone; Trabecular ID BONE-MINERAL DENSITY; QUANTITATIVE COMPUTED-TOMOGRAPHY; VERTEBRAL FRACTURE RISK; FINITE-ELEMENT-ANALYSIS; IN-VIVO ASSESSMENT; DISTAL RADIUS; CORTICAL BONE; HR-PQCT; INTRACORTICAL POROSITY; RANDOMIZED-TRIAL AB In postmenopausal women receiving combination parathyroid hormone (PTH) (1-84) therapy and ibandronate, we evaluated bone microarchitecture and biomechanics using high-resolution peripheral quantitative computed tomography (HR-pQCT). Cortical and trabecular changes were different at the nonweight-bearing radius vs. the weight-bearing tibia, with more favorable overall changes at the tibia. Introduction PTH therapy and bisphosphonates decrease fracture risk in postmenopausal osteoporosis, but their effects on bone microstructure and strength have not been fully characterized, particularly during combination therapy. PTH increases trabecular bone mineral density (BMD) substantially but may decrease cortical BMD, possibly by stimulating intracortical remodeling. We evaluated bone microarchitecture and biomechanics with HR-pQCT at the radius (a nonweight-bearing site) and tibia (weight bearing) in women receiving combination PTH(1-84) and ibandronate. Methods Postmenopausal women with low bonemass (n=43) were treated with 6 months of PTH(1-84) (100 mu g/day), either as one 6- or two 3-month courses, in combination with ibandronate (150 mg/month) over 2 years. HR-pQCT was performed before and after therapy. Results Because changes in HR-pQCT parameters did not differ between treatment arms, groups were pooled into one cohort for analysis. Trabecular BMD increased at both radius and tibia (p<0.01 for each). Cortical thickness and BMD decreased at the radius (p<0.01), consistent with changes in dual-energy X-ray absorptiometry, while these parameters did not change at the tibia (p=0.02 for difference between radius and tibia). In contrast, cortical porosity increased at the tibia (p<0.01) but not radius. Stiffness and failure load decreased at the radius (p<0.0001) but did not change at the tibia. Conclusions Cortical and trabecular changes in response to the PTH/ibandronate treatment combinations utilized in this study were different at the nonweight-bearing radius vs. the weight-bearing tibia, with more favorable overall changes at the tibia. Our findings support the possibility that weight bearing may optimize the effects of osteoporosis therapy. C1 [Schafer, A. L.; Shoback, D. M.] San Francisco VA Med Ctr, Endocrine Res Unit, San Francisco, CA 94121 USA. [Schafer, A. L.; Shoback, D. M.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Burghardt, A. J.; Majumdar, S.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Sellmeyer, D. E.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA. [Palermo, L.; Black, D. M.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Schafer, AL (reprint author), San Francisco VA Med Ctr, Endocrine Res Unit, 4150 Clement St,111N, San Francisco, CA 94121 USA. EM anne.schafer@ucsf.edu FU Genentech, Inc.; NPS Pharmaceuticals [PTH[1-84]]; Genentech; Bayer; Department of Veterans Affairs through an Advanced Fellowship in Women's Health; Career Development Award [5 IK2 CX000549-02]; Research Enhancement Award Program; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) [R01-AR055588, R01-AR060700]; NIAMS; National Institute on Aging; National Institute of Biomedical Imaging and Bioengineering [R01-AG017762] FX The PICS trial was supported by an investigator-initiated grant (to DMB) from Genentech, Inc., a member of the Roche group. The sponsor was involved in study design but not in the collection, analysis, or interpretation of data, nor in the writing of the article. Study drugs were supplied by NPS Pharmaceuticals (PTH[1-84]), Genentech (ibandronate), and Bayer (calcium citrate+D3). Reagents for bone turnover marker assays were provided by Roche Diagnostics. The authors have full control of all data. Additional support was provided by the Department of Veterans Affairs through an Advanced Fellowship in Women's Health (to ALS), a Career Development Award under contract 5 IK2 CX000549-02 (to ALS), and the Research Enhancement Award Program (to DMS); by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under contracts R01-AR055588 (to DMS) and R01-AR060700 (to AJB); and by NIAMS, the National Institute on Aging, and the National Institute of Biomedical Imaging and Bioengineering under contract R01-AG017762 (to SM). The authors thank Jean Hietpas, Lucy Wu, and Laurel Denton for their roles in study direction and data coordination; Rayshawnda Davis, Natasha Rathbun, Andrea Hacker, and Makani da Silva for study coordination and DXA scan acquisition; Melissa Guan, Thelma Munoz, and S. Paran Yap for their roles in HR-pQCT coordination, image acquisition, and analysis; and Richard Eastell, MD, and Fatma Gossiel for analysis of bone turnover markers. NR 48 TC 12 Z9 12 U1 0 U2 9 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-941X EI 1433-2965 J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD OCT PY 2013 VL 24 IS 10 BP 2591 EP 2601 DI 10.1007/s00198-013-2349-y PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 219UN UT WOS:000324536200006 PM 23589163 ER PT J AU Chahine, LM Daley, J Horn, S Duda, JE Colcher, A Hurtig, H Cantor, C Dahodwala, N AF Chahine, Lama M. Daley, Joseph Horn, Stacy Duda, John E. Colcher, Amy Hurtig, Howard Cantor, Charles Dahodwala, Nabila TI Association between dopaminergic medications and nocturnal sleep in early-stage Parkinson's disease SO PARKINSONISM & RELATED DISORDERS LA English DT Article ID REM-SLEEP; BEHAVIOR DISORDER; L-DOPA; PRAMIPEXOLE; SYMPTOMS; RECEPTOR; RAT; MICROSTRUCTURE; WAKEFULNESS; LEVODOPA AB Background: Poor nocturnal sleep is common in Parkinson's disease (PD) and negatively impacts quality of life. There is little data on how dopaminergic drugs influence nocturnal sleep in PD, particularly in relation to medication timing. We examined the association between dopaminergic medications and subjective and objective nocturnal sleep in PD. Methods: Individuals with PD were recruited from the outpatient clinic. Demographics and disease information were collected. Patients underwent one-night polysomnography and responded to SCOPA-SLEEP, a self-administered questionnaire which includes a section on nighttime sleep and an overall measure of sleep quality; higher scores indicate worse sleep. Medication intake, including medication timing in relation to bedtime, was obtained and converted to levodopa equivalents. Results: 41 Males and 21 females, median age 63.9 years, participated. Median disease duration was 5 years. After adjusting for age, sex, disease severity, and disease duration, greater total levodopa equivalent intake within 4 h of sleep was associated with higher total SCOPA-nighttime score (p = 0.009) and greater wake time after sleep onset (p = 0.049). Greater dopaminergic medication intake prior to sleep was also associated with less rapid eye movement (REM) sleep as a percent of total sleep time (p = 0.004). Conclusions: Higher amounts of dopaminergic medications taken prior to sleep were associated with poor sleep quality and less REM sleep. Although poor nocturnal sleep in PD is likely multi-factorial in etiology, our findings suggest that timing and dose of medications prior to sleep need to be considered in its management. (c) 2013 Elsevier Ltd. All rights reserved. C1 [Chahine, Lama M.; Horn, Stacy; Duda, John E.; Colcher, Amy; Hurtig, Howard; Cantor, Charles; Dahodwala, Nabila] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19107 USA. [Chahine, Lama M.; Cantor, Charles] Univ Penn, Perelman Sch Med, Div Sleep Med, Philadelphia, PA 19107 USA. [Daley, Joseph] Univ Alabama Birmingham, Sch Med, Birmingham VA Med Ctr, Birmingham, AL 35233 USA. [Daley, Joseph] Univ Alabama Birmingham, Sch Med, Dept Neurol, Birmingham, AL 35233 USA. [Duda, John E.] Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA 19104 USA. RP Chahine, LM (reprint author), Univ Penn, Perelman Sch Med, Dept Neurol, 330 S 9th St, Philadelphia, PA 19107 USA. EM lamachahine@hotmail.com NR 38 TC 13 Z9 14 U1 0 U2 12 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8020 J9 PARKINSONISM RELAT D JI Parkinsonism Relat. Disord. PD OCT PY 2013 VL 19 IS 10 BP 859 EP 863 DI 10.1016/j.parkreldis.2013.05.009 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 223EZ UT WOS:000324788800002 PM 23751512 ER PT J AU Johnson, TJ Weaver, MD Borrero, S Davis, EM Myaskovsky, L Zuckerbraun, NS Kraemer, KL AF Johnson, Tiffani J. Weaver, Matthew D. Borrero, Sonya Davis, Esa M. Myaskovsky, Larissa Zuckerbraun, Noel S. Kraemer, Kevin L. TI Association of Race and Ethnicity With Management of Abdominal Pain in the Emergency Department SO PEDIATRICS LA English DT Article DE abdominal pain; disparities; emergency department; racial difference ID ANALGESIC TREATMENT; TRAUMA PATIENTS; CLINICAL-TRIAL; PUBLIC-HEALTH; CHEST-PAIN; DISPARITIES; CHILDREN; RACE/ETHNICITY; CARE; QUALITY AB OBJECTIVE: To determine if race/ethnicity-based differences exist in the management of pediatric abdominal pain in emergency departments (EDs). METHODS: Secondary analysis of data from the 2006-2009 National Hospital Ambulatory Medical Care Survey regarding 2298 visits by patients <= 21 years old who presented to EDs with abdominal pain. Main outcomes were documentation of pain score and receipt of any analgesics, analgesics for severe pain (defined as >= 7 on a 10-point scale), and narcotic analgesics. Secondary outcomes included diagnostic tests obtained, length of stay (LOS), 72-hour return visits, and admission. RESULTS: Of patient visits, 70.1% were female, 52.6% were from non-Hispanic white, 23.5% were from non-Hispanic black, 20.6% were from Hispanic, and 3.3% were from "other" racial/ethnic groups; patients' mean age was 14.5 years. Multivariate logistic regression models adjusting for confounders revealed that non-Hispanic black patients were less likely to receive any analgesic (odds ratio [OR]: 0.61; 95% confidence interval [CI]: 0.43-0.87) or a narcotic analgesic (OR: 0.38; 95% CI: 0.18-0.81) than non-Hispanic white patients (referent group). This finding was also true for non-Hispanic black and "other" race/ethnicity patients with severe pain (ORs [95% CI]: 0.43 [0.22-0.87] and 0.02 [0.00-0.19], respectively). Non-Hispanic black and Hispanic patients were more likely to have a prolonged LOS than non-Hispanic white patients (ORs [95% CI]: 1.68 [1.13-2.51] and 1.64 [1.09-2.47], respectively). No significant race/ethnicity-based disparities were identified in documentation of pain score, use of diagnostic procedures, 72-hour return visits, or hospital admissions. CONCLUSIONS: Race/ethnicity-based disparities exist in ED analgesic use and LOS for pediatric abdominal pain. Recognizing these disparities may help investigators eliminate inequalities in care. C1 [Johnson, Tiffani J.] Childrens Hosp Philadelphia, Div Pediat Emergency Med, Philadelphia, PA 19104 USA. [Johnson, Tiffani J.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. [Weaver, Matthew D.; Kraemer, Kevin L.] Univ Pittsburgh, Sch Med, Dept Emergency Med, Pittsburgh, PA USA. [Borrero, Sonya; Davis, Esa M.; Myaskovsky, Larissa; Kraemer, Kevin L.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Zuckerbraun, Noel S.] Univ Pittsburgh, Sch Med, Dept Pediat, Div Pediat Emergency Med, Pittsburgh, PA 15261 USA. [Borrero, Sonya; Myaskovsky, Larissa] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Johnson, TJ (reprint author), Childrens Hosp Philadelphia, Div Pediat Emergency Med, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM johnsont6@email.chop.edu FU Agency for Healthcare Research and Quality [T32HS017587] FX Supported by grant T32HS017587 from the Agency for Healthcare Research and Quality to Drs Johnson and Kraemer. NR 38 TC 21 Z9 22 U1 2 U2 9 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD OCT PY 2013 VL 132 IS 4 BP E851 EP E858 DI 10.1542/peds.2012-3127 PG 8 WC Pediatrics SC Pediatrics GA 227FI UT WOS:000325095400006 PM 24062370 ER PT J AU Lomond, KV Henry, SM Jacobs, JV Hitt, JR Horak, FB Cohen, RG Schwartz, D Dumas, JA Naylor, MR Watts, R DeSarno, MJ AF Lomond, Karen V. Henry, Sharon M. Jacobs, Jesse V. Hitt, Juvena R. Horak, Fay B. Cohen, Rajal G. Schwartz, Daniel Dumas, Julie A. Naylor, Magdalena R. Watts, Richard DeSarno, Michael J. TI Protocol to assess the neurophysiology associated with multi-segmental postural coordination SO PHYSIOLOGICAL MEASUREMENT LA English DT Article DE postural coordination; MRI; EMG; cerebral cortex; multi-segmental ID LOW-BACK-PAIN; LIMB MOVEMENT; ADJUSTMENTS; SIGNALS; PEOPLE; CORTEX AB Anticipatory postural adjustments (APAs) stabilize potential disturbances to posture caused by movement. Impaired APAs are common with disease and injury. Brain functions associated with generating APAs remain uncertain due to a lack of paired tasks that require similar limb motion from similar postural orientations, but differ in eliciting an APA while also being compatible with brain imaging techniques (e. g., functional magnetic resonance imaging; fMRI). This study developed fMRI-compatible tasks differentiated by the presence or absence of APAs during leg movement. Eighteen healthy subjects performed two leg movement tasks, supported leg raise (SLR) and unsupported leg raise (ULR), to elicit isolated limb motion (no APA) versus multi-segmental coordination patterns (including APA), respectively. Ground reaction forces under the feet and electromyographic activation amplitudes were assessed to determine the coordination strategy elicited for each task. Results demonstrated that the ULR task elicited a multi-segmental coordination that was either minimized or absent in the SLR task, indicating that it would serve as an adequate control task for fMRI protocols. A pilot study with a single subject performing each task in an MRI scanner demonstrated minimal head movement in both tasks and brain activation patterns consistent with an isolated limb movement for the SLR task versus multi-segmental postural coordination for the ULR task. C1 [Lomond, Karen V.] Cent Michigan Univ, Sch Hlth Sci, Mt Pleasant, MI 48859 USA. [Lomond, Karen V.; Henry, Sharon M.; Jacobs, Jesse V.; Hitt, Juvena R.] Univ Vermont, Dept Rehabil & Movement Sci, Burlington, VT USA. [Horak, Fay B.; Cohen, Rajal G.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Cohen, Rajal G.] Univ Idaho, Dept Psychol & Commun Studies, Moswow, ID 83843 USA. [Schwartz, Daniel] Portland VA Med Ctr, Methamphetamine Abuse Res Ctr, Portland, OR USA. [Schwartz, Daniel] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Schwartz, Daniel] Portland VA Med Ctr, Res Serv, Portland, OR USA. [Dumas, Julie A.; Naylor, Magdalena R.] Univ Vermont, Dept Psychiat, Burlington, VT 05405 USA. [Watts, Richard] Univ Vermont, MRI Ctr Bioimaging, Dept Radiol, Burlington, VT 05405 USA. [DeSarno, Michael J.] Univ Vermont, Dept Med Biostat, Burlington, VT 05405 USA. RP Lomond, KV (reprint author), Cent Michigan Univ, Sch Hlth Sci, Mt Pleasant, MI 48859 USA. EM lomon2k@cmich.edu FU National Institutes of Health [NIH2R01HD040909-06A2] FX The authors wish to thank our research subjects for their participation as well as Rebecca Ouelette-Morton and Kristen Zielinski for their assistance in data collection. The study was supported by the National Institutes of Health NIH2R01HD040909-06A2 (Principal Investigator: Henry SM). NR 21 TC 2 Z9 2 U1 0 U2 3 PU IOP PUBLISHING LTD PI BRISTOL PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND SN 0967-3334 J9 PHYSIOL MEAS JI Physiol. Meas. PD OCT PY 2013 VL 34 IS 10 BP N97 EP N105 DI 10.1088/0967-3334/34/10/N97 PG 9 WC Biophysics; Engineering, Biomedical; Physiology SC Biophysics; Engineering; Physiology GA 224GN UT WOS:000324871100002 PM 24065623 ER PT J AU Zhang, XY Yao, JK AF Zhang, Xiang Yang Yao, Jeffrey K. TI Oxidative stress and therapeutic implications in psychiatric disorders SO PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY LA English DT Editorial Material DE Antioxidant defense system; Antioxidant therapy; Bipolar disorders; Major depression; Schizophrenia; Tardive dyskinesia ID TARDIVE-DYSKINESIA; BIPOLAR DISORDER; N-ACETYLCYSTEINE; SCHIZOPHRENIA; INVOLVEMENT; DEPRESSION; RELEVANCE; EPISODES AB Increasing evidence indicates that disturbances of antioxidant defense system and presence of oxidative stress can play a part in a wide range of neuropsychiatric disorders, including schizophrenia, bipolar disorder, and major depression, as well as antipsychotic-induced tardive dyskinesia (TD). Moreover, researchers have embarked on using antioxidant treatment as adjunct therapy for psychiatry disorders. Evidence from clinical, pre-clinical and epidemiological studies suggests that a benefit of using antioxidant compounds should be considered as an adjunctive therapy in these patients. These are some of the main perspectives that are reviewed by four articles in this special section. Overall, there has been growing recognition of the importance of oxidative stress in the pathophysiology of psychiatric disorders and the development of TD. The collection of articles in this special section will contribute to providing more efficacious treatments arising from a better appreciation of the roles of oxidative stress in these psychiatric disorders. (C) 2013 Elsevier Inc. All rights reserved. C1 [Zhang, Xiang Yang] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Zhang, Xiang Yang] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Zhang, Xiang Yang] Peking Univ, Beijing Hui Long Guan Hosp, Psychiat Res Ctr, Beijing, Peoples R China. [Yao, Jeffrey K.] VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA USA. [Yao, Jeffrey K.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Yao, Jeffrey K.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA. RP Zhang, XY (reprint author), Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. EM xyzhang@bcm.edu NR 29 TC 25 Z9 26 U1 3 U2 19 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0278-5846 J9 PROG NEURO-PSYCHOPH JI Prog. Neuro-Psychopharmacol. Biol. Psychiatry PD OCT 1 PY 2013 VL 46 BP 197 EP 199 DI 10.1016/j.pnpbp.2013.03.003 PG 3 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 219CA UT WOS:000324480900029 PM 23523744 ER PT J AU Wu, JQ Kosten, TR Zhang, XY AF Wu, Jing Qin Kosten, Thomas R. Zhang, Xiang Yang TI Free radicals, antioxidant defense systems, and schizophrenia SO PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY LA English DT Article DE Antioxidant defense systems; Free radicals; Neuroleptics; Oxidative stress; Schizophrenia; Tardive dyskinesia ID ABNORMAL INVOLUNTARY MOVEMENTS; VITAMIN-E TREATMENT; MEMBRANE-LIPID PEROXIDATION; GENE ALA-9VAL POLYMORPHISM; CT-SCAN ABNORMALITIES; NITRIC-OXIDE SYNTHASE; TARDIVE-DYSKINESIA; SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; GLUTATHIONE-PEROXIDASE AB The etiopathogenic mechanisms of schizophrenia are to date unknown, although several hypotheses have been suggested. Accumulating evidence suggests that excessive free radical production or oxidative stress may be involved in the pathophysiology of schizophrenia as evidenced by increased production of reactive oxygen or decreased antioxidant protection in schizophrenic patients. This review aims to summarize the basic molecular mechanisms of free radical metabolism, the impaired antioxidant defense system and membrane pathology in schizophrenia, their interrelationships with the characteristic clinical symptoms and the implications for antipsychotic treatments. In schizophrenia, there is accumulating evidence of altered antioxidant enzyme activities and increased levels of lipid peroxidation, as well as altered levels of plasma antioxidants. Moreover, free radical-mediated abnormalities may contribute to specific aspects of schizophrenic symptomatology and complications of its treatment with antipsychotic drugs, as well as the development of tardive dyskinesia (TD). Finally, the potential therapeutic strategies implicated by the accumulating data on oxidative stress mechanisms for the treatment of schizophrenia are discussed. (C) 2013 Elsevier Inc. All rights reserved. C1 [Wu, Jing Qin] Univ Newcastle, Fac Hlth, Sch Biomed Sci & Pharm, Callaghan, NSW 2308, Australia. [Wu, Jing Qin] Schizophrenia Res Inst, Sydney, NSW, Australia. [Wu, Jing Qin; Kosten, Thomas R.; Zhang, Xiang Yang] Peking Univ, Beijing Hui Long Guan Hosp, Psychiat Res Ctr, Beijing 100096, Peoples R China. [Kosten, Thomas R.; Zhang, Xiang Yang] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX USA. [Kosten, Thomas R.; Zhang, Xiang Yang] Michael E DeBakey VA Med Ctr, Houston, TX USA. RP Zhang, XY (reprint author), VA Med Ctr, Res Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA. EM xyzhang@bcm.edu FU Stanley Medical Research Institute [03T-459, 05T-726]; Department of Veterans Affairs, VISN 16, Mental Illness Research, Education and Clinical Center (MIRECC); United States National Institute of Health [K05-DA0454, P50-DA18827, U01-MH79639]; NHMRC FX This work was funded by the grant from the Stanley Medical Research Institute (03T-459 and 05T-726), and the Department of Veterans Affairs, VISN 16, Mental Illness Research, Education and Clinical Center (MIRECC), United States National Institute of Health K05-DA0454, P50-DA18827 and U01-MH79639. JQW received an NHMRC postdoctoral training fellowship. These sources had no further role in study design, data collection and analysis, decision to publish, or preparation of the article. NR 100 TC 54 Z9 57 U1 9 U2 41 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0278-5846 J9 PROG NEURO-PSYCHOPH JI Prog. Neuro-Psychopharmacol. Biol. Psychiatry PD OCT 1 PY 2013 VL 46 BP 200 EP 206 DI 10.1016/j.pnpbp.2013.02.015 PG 7 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 219CA UT WOS:000324480900030 PM 23470289 ER PT J AU Baker, DA Eudaly, J Smith, CD Obeid, LM Gilkeson, GS AF Baker, DeAnna A. Eudaly, Jackie Smith, Charles D. Obeid, Lina M. Gilkeson, Gary S. TI Impact of sphingosine kinase 2 deficiency on the development of TNF-alpha-induced inflammatory arthritis SO RHEUMATOLOGY INTERNATIONAL LA English DT Article DE Sphingosine kinase 2; Inflammatory arthritis; Sphingolipids; TNF ID FUNCTIONAL-CHARACTERIZATION; MOLECULAR-CLONING; DISTINCT ROLES; SPHINGOSINE-1-PHOSPHATE; COLITIS; FTY720; TRAFFICKING; SUPPRESSION; MODULATION; ACTIVATION AB Sphingolipids are components of the plasma membrane whose metabolic manipulation is of interest as a potential therapeutic approach in a number of diseases. Sphingosine kinase 1 (SphK1), the major kinase that phosphorylates sphingosine to sphingosine-1-phosphate (S1P), was previously shown by our group and others to modulate inflammation in murine models of inflammatory arthritis, inflammatory bowel disease and asthma. Sphingosine kinase 2's (SphK2) impact on inflammation is less well known, as variable results were reported depending on the disease model. A specific SphK2 inhibitor inhibited inflammatory arthritis in one model, while siRNA knockdown of SphK2 worsened arthritis in another. We previously demonstrated that SphK1 deficient mice are protected against development of hTNF-alpha-induced arthritis. To investigate the role of SphK2 in TNF-alpha-induced arthritis, we developed SphK2 deficient hTNF-alpha overexpressing mice and separately treated hTNF-alpha mice with ABC294640, a SphK2-specific inhibitor. Our data show that genetic inhibition of SphK2 did not significantly impact the severity or progression of inflammatory arthritis, while pharmacologic inhibition of SphK2 led to significantly more severe arthritis. Compared to vehicle-treated mice, ABC294640 treated mice also had less S1P in whole blood and inflamed joint tissue, although the differences were not significant. ABC294640 treatment did not affect SphK1 activity in the inflamed joint while little SphK2 activity was detected in the joint. We conclude that the differences in the inflammatory phenotype in genetic inhibition versus pharmacologic inhibition of SphK2 can be attributed to the amount of ABC294640 used in the experiments versus the impact of acute inhibition of SphK2 with ABC294640 versus genetically induced life-long SphK2 deficiency. Thus, inhibition of SphK2 appears to be proinflammatory in contrast to the clear anti-inflammatory effects of blocking SphK1. Therapies directed at this sphingosine kinase pathways will need to be specific in their targeting of sphingosine kinases. C1 [Baker, DeAnna A.] Dept Microbiol, Charleston, SC 29425 USA. [Baker, DeAnna A.] Dept Immunol, Charleston, SC 29425 USA. [Eudaly, Jackie; Gilkeson, Gary S.] Med Univ S Carolina, Div Rheumatol, Charleston, SC 29425 USA. [Smith, Charles D.] South Carolina Coll Pharm Pharmaceut & Biomed Sci, Charleston, SC 29425 USA. [Obeid, Lina M.; Gilkeson, Gary S.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Obeid, Lina M.] Dept Biochem, Charleston, SC 29425 USA. [Obeid, Lina M.] Dept Mol Biol, Charleston, SC 29425 USA. [Obeid, Lina M.; Gilkeson, Gary S.] Ralph H Johnson VA Med Ctr, Med Res Serv, Charleston, SC USA. [Gilkeson, Gary S.] Med Univ S Carolina, Dept Med, Div Rheumatol, Charleston, SC 29425 USA. RP Gilkeson, GS (reprint author), Med Univ S Carolina, Dept Med, Div Rheumatol, 114 Doughty St,STB 425, Charleston, SC 29425 USA. EM gilkeson@musc.edu OI obeid, lina/0000-0002-0734-0847 FU NIAMS NIH HHS [T32 AR050958] NR 22 TC 9 Z9 9 U1 0 U2 5 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0172-8172 J9 RHEUMATOL INT JI Rheumatol. Int. PD OCT PY 2013 VL 33 IS 10 BP 2677 EP 2681 DI 10.1007/s00296-012-2493-2 PG 5 WC Rheumatology SC Rheumatology GA 223RC UT WOS:000324824500033 PM 23011090 ER PT J AU Phillips, J Cardile, AP Patterson, TF Lewis, JS AF Phillips, Jason Cardile, Anthony P. Patterson, Thomas F. Lewis, James S., II TI Daptomycin-induced acute eosinophilic pneumonia: Analysis of the current data and illustrative case reports SO SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Daptomycin; acute eosinophilic pneumonia ID OF-THE-LITERATURE; PULMONARY SURFACTANT; IMPACT AB Acute eosinophilic pneumonia (AEP) is a rare but important complication of daptomycin therapy. We describe 2 cases of daptomycin-associated AEP, compile available data from another 22 published cases, and propose a revised set of diagnostic criteria. C1 [Phillips, Jason; Patterson, Thomas F.; Lewis, James S., II] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Cardile, Anthony P.] Brooke Army Med Ctr, Infect Dis Serv, Ft Sam Houston, TX 78234 USA. [Patterson, Thomas F.] South Texas Vet Hlth Care Syst, Med Serv, San Antonio, TX USA. RP Cardile, AP (reprint author), Brooke Army Med Ctr, Infect Dis Serv MCHE MDI, 3851 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA. EM anthony.cardile@us.army.mil NR 18 TC 10 Z9 10 U1 0 U2 7 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0036-5548 J9 SCAND J INFECT DIS JI Scand. J. Infect. Dis. PD OCT PY 2013 VL 45 IS 10 BP 804 EP 808 DI 10.3109/00365548.2013.805427 PG 5 WC Infectious Diseases SC Infectious Diseases GA 220JN UT WOS:000324579200013 PM 23826793 ER PT J AU Bhatt, SP Dransfield, MT AF Bhatt, Surya P. Dransfield, Mark T. TI Chronic obstructive pulmonary disease and cardiovascular disease SO TRANSLATIONAL RESEARCH LA English DT Review ID CORONARY-HEART-DISEASE; PARTICULATE AIR-POLLUTION; VENTRICULAR DIASTOLIC DYSFUNCTION; 3RD NATIONAL-HEALTH; ANGIOTENSIN-CONVERTING ENZYME; INCREASED ARTERIAL STIFFNESS; NUTRITION EXAMINATION SURVEY; ACUTE MYOCARDIAL-INFARCTION; INTIMA-MEDIA THICKNESS; IMPAIRED LUNG-FUNCTION AB Chronic obstructive pulmonary disease (COPD) is an inflammatory disease of the lung associated with progressive airflow limitation and punctuated by episodes of acute exacerbation. There is growing recognition that the inflammatory state associated with COPD is not confined to the lungs but also involves the systemic circulation and can impact nonpulmonary organs. Epidemiologic and mechanistic studies indicate that COPD is associated with a high frequency of coronary artery disease, congestive heart failure and cardiac arrhythmias, independent of shared risk factors. Possible pathways include complex interrelationships between chronic low-grade systemic inflammation and oxidative stress as well as shared risk factors such as age, cigarette smoking, and environmental pollutants. In this review, we provide an overview of the epidemiologic data linking COPD with cardiovascular disease, comment on the interrelationships among COPD, inflammation, and cardiovascular disease, and highlight diagnostic and therapeutic challenges. C1 [Dransfield, Mark T.] Univ Alabama Birmingham, UAB Lung Hlth Ctr, Birmingham, AL 35209 USA. Birmingham VA Med Ctr, Birmingham, AL USA. RP Dransfield, MT (reprint author), Univ Alabama Birmingham, UAB Lung Hlth Ctr, Birmingham, AL 35209 USA. EM mdrans99@uab.edu FU National Institutes of Health; Aeris; Astra Zeneca; Boehringer Ingelheim; Boston Scientific; Centocor; Forest; GlaxoSmithKline; Ikaria; Medimmune; Otsuka; Pfizer FX M. T. Dransfield has served as a consultant to Boehringer Ingelheim, GlaxoSmithKline, and Ikaria, and his institution has received research support from the National Institutes of Health, Aeris, Astra Zeneca, Boehringer Ingelheim, Boston Scientific, Centocor, Forest, GlaxoSmithKline, Ikaria, Medimmune, Otsuka, and Pfizer. S. P. Bhatt has no conflicts of interest to declare pertinent to the content of this article. Both authors have read the journal's policy on disclosure of potential conflicts of interest. NR 198 TC 48 Z9 52 U1 2 U2 22 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1931-5244 J9 TRANSL RES JI Transl. Res. PD OCT PY 2013 VL 162 IS 4 BP 237 EP 251 DI 10.1016/j.trsl.2013.05.001 PG 15 WC Medical Laboratory Technology; Medicine, General & Internal; Medicine, Research & Experimental SC Medical Laboratory Technology; General & Internal Medicine; Research & Experimental Medicine GA 226RZ UT WOS:000325055000004 PM 23727296 ER PT J AU Sillivan, SE Whittard, JD Jacobs, MM Ren, YH Mazloom, AR Caputi, FF Horvath, M Keller, E Ma'ayan, A Pan, YX Chiang, LW Hurd, YL AF Sillivan, Stephanie E. Whittard, John D. Jacobs, Michelle M. Ren, Yanhua Mazloom, Amin R. Caputi, Francesca F. Horvath, Monika Keller, Eva Ma'ayan, Avi Pan, Ying-Xian Chiang, Lillian W. Hurd, Yasmin L. TI ELK1 Transcription Factor Linked to Dysregulated Striatal Mu Opioid Receptor Signaling Network and OPRM1 Polymorphism in Human Heroin Abusers SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Addiction; MAPK; opioid; rat; self-administration; transcriptome ID IN-VIVO; NUCLEAR TRANSLOCATION; BEHAVIORAL-RESPONSES; REWARDING PROPERTIES; SYNAPTIC PLASTICITY; OPIATE ADDICTION; GENE-EXPRESSION; CALCIUM CURRENT; MICE LACKING; PHOSPHORYLATION AB Background: Abuse of heroin and prescription opiate medications has grown to disturbing levels. Opioids mediate their effects through mu opioid receptors (MOR), but minimal information exists regarding MOR-related striatal signaling relevant to the human condition. The striatum is a structure central to reward and habitual behavior and neurobiological changes in this region are thought to underlie the pathophysiology of addiction disorders. Methods: We examined molecular mechanisms related to MOR in postmortem human brain striatal specimens from a homogenous European Caucasian population of heroin abusers and control subjects and in an animal model of heroin self-administration. Expression of ets-like kinase 1 (ELK1) was examined in relation to polymorphism of the MOR gene OPRM1 and drug history. Results: A characteristic feature of heroin abusers was decreased expression of MOR and extracellular regulated kinase signaling networks, concomitant with dysregulation of the downstream transcription factor ELK1. Striatal ELK1 in heroin abusers associated with the polymorphism rs2075572 in OPRM1 in a genotype dose-dependent manner and correlated with documented history of heroin use, an effect reproduced in an animal model that emphasizes a direct relationship between repeated heroin exposure and ELK1 dysregulation. A central role of ELK1 was evidenced by an unbiased whole transcriptome microarray that revealed similar to 20% of downregulated genes in human heroin abusers are ELK1 targets. Using chromatin immune precipitation, we confirmed decreased ELK1 promoter occupancy of the target gene Use1. Conclusions: ELK1 is a potential key transcriptional regulatory factor in striatal disturbances associated with heroin abuse and relevant to genetic mutation of OPRM1. C1 [Sillivan, Stephanie E.; Whittard, John D.; Jacobs, Michelle M.; Ren, Yanhua; Caputi, Francesca F.; Hurd, Yasmin L.] Ichan Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Sillivan, Stephanie E.; Whittard, John D.; Jacobs, Michelle M.; Ren, Yanhua; Caputi, Francesca F.; Hurd, Yasmin L.] Ichan Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. [Sillivan, Stephanie E.; Jacobs, Michelle M.; Ren, Yanhua; Mazloom, Amin R.; Caputi, Francesca F.; Ma'ayan, Avi; Hurd, Yasmin L.] Ichan Sch Med Mt Sinai, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA. [Hurd, Yasmin L.] James J Peters VA Med Ctr, Bronx, NY USA. [Horvath, Monika] Uppsala Univ, Dept Forens Med, Uppsala, Sweden. [Horvath, Monika; Keller, Eva] Semmelweis Univ, Dept Forens Med, H-1085 Budapest, Hungary. [Pan, Ying-Xian] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA. [Pan, Ying-Xian] Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program Y XP, New York, NY 10021 USA. [Chiang, Lillian W.] Purdue Pharma LP, Cranbury, NJ USA. RP Hurd, YL (reprint author), Ichan Sch Med Mt Sinai, Dept Psychiat, 1 Gustave L Levy Pl,Box 1065, New York, NY 10029 USA. EM yasmin.hurd@mssm.edu FU National Institute on Drug Abuse [DA015446, DA013997, T32DA007135, ETT/098/2009]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development FX This work was funded by grants from the National Institute on Drug Abuse DA015446 (YLH), DA013997 (Y-XP), and T32DA007135 (MMJ), as well as Grant ETT/098/2009 (EK). The study was also supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development. NR 80 TC 8 Z9 8 U1 2 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD OCT 1 PY 2013 VL 74 IS 7 BP 511 EP 519 DI 10.1016/j.biopsych.2013.04.012 PG 9 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 216UJ UT WOS:000324310000008 PM 23702428 ER PT J AU Peterson, YK Cameron, RB Wills, LP Trager, RE Lindsey, CC Beeson, CC Schnellmann, RG AF Peterson, Yuri K. Cameron, Robert B. Wills, Lauren P. Trager, Richard E. Lindsey, Chris C. Beeson, Craig C. Schnellmann, Rick G. TI beta(2)-Adrenoceptor agonists in the regulation of mitochondrial biogenesis SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS LA English DT Article DE Adrenoceptor; Biogenesis; Mitochondria; Pharmacophore; Chemical similarity; Clustering; Renal ID NEURAL STEM-CELLS; FUNCTIONAL SELECTIVITY; RECEPTOR LIGANDS; CAMP; BETA(2); CULTURE; GLUCONEOGENESIS; AVAILABILITY; ADRENOCEPTOR; METABOLISM AB The stimulation of mitochondrial biogenesis (MB) via cell surface G-protein coupled receptors is a promising strategy for cell repair and regeneration. Here we report the specificity and chemical rationale of a panel of beta(2)-adrenoceptor agonists with regards to MB. Using primary cultures of renal cells, a diverse panel of beta(2)-adrenoceptor agonists elicited three distinct phenotypes: full MB, partial MB, and non-MB. Full MB compounds had efficacy in the low nanomolar range and represent two chemical scaffolds containing three distinct chemical clusters. Interestingly, the MB phenotype did not correlate with reported receptor affinity or chemical similarity. Chemical clusters were then subjected to pharmacophore modeling creating two models with unique and distinct features, consisting of five conserved amongst full MB compounds were identified. The two discrete pharmacophore models were coalesced into a consensus pharmacophore with four unique features elucidating the spatial and chemical characteristics required to stimulate MB. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved. C1 [Peterson, Yuri K.; Cameron, Robert B.; Wills, Lauren P.; Trager, Richard E.; Lindsey, Chris C.; Beeson, Craig C.; Schnellmann, Rick G.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. [Schnellmann, Rick G.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Schnellmann, RG (reprint author), Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, 280 Calhoun St, Charleston, SC 29425 USA. EM schnell@musc.edu FU National Institutes of Health [T32 CA119945-04, F32 ES020103-01, ES012878, DK071997, GM084147]; Biomedical LaboratoryResearch and Development Program of the Department of Veterans Affairs [1BX000851]; [T32 GM08716] FX R.B.C. is funded by T32 GM08716. L.P.W. is funded by the National Institutes of Health grant T32 CA119945-04 and F32 ES020103-01. R.G.S. is funded by the National Institutes of Health grants ES012878, DK071997 and GM084147, and the Biomedical LaboratoryResearch and Development Program of the Department of Veterans Affairs [1BX000851]. The authors also thank Kathryn Appleton and Louis Luttrell for thoughtful discussions and Gyda Beeson for technical assistance. NR 39 TC 8 Z9 8 U1 0 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-894X J9 BIOORG MED CHEM LETT JI Bioorg. Med. Chem. Lett. PD OCT 1 PY 2013 VL 23 IS 19 BP 5376 EP 5381 DI 10.1016/j.bmcl.2013.07.052 PG 6 WC Chemistry, Medicinal; Chemistry, Organic SC Pharmacology & Pharmacy; Chemistry GA 216RX UT WOS:000324302800023 PM 23954364 ER PT J AU Varghese, FP Cummings, DL AF Varghese, Femina P. Cummings, Devon L. TI Introduction: Why Apply Vocational Psychology to Criminal Justice Populations? SO COUNSELING PSYCHOLOGIST LA English DT Editorial Material DE vocational; career; work; social justice; offender; criminal ID PRISONER REENTRY; CORRECTIONAL PSYCHOLOGISTS; CAREER-DEVELOPMENT; CLINICAL-PRACTICE; PUBLIC-POLICY; WORK; OFFENDERS; EMPLOYMENT; CRIME; EXPECTANCIES AB The criminal justice population has experienced exponential growth in recent decades. Yet, counseling and vocational psychology has not kept pace in addressing the vocational needs of this population. A recent literature search in counseling and vocational journals found that in the last quarter century, only 14 articles have been published that focus on this topic. Among these, even fewer are focused on developing effective vocational interventions for this population. The articles in this major contribution endeavor to begin filling this gap by (a) demonstrating the need and applicability for applying counseling and vocational psychology in developing vocational interventions for the criminal justice population, (b) providing an example and initial empirical findings of a vocational intervention used with this population, and (c) informing readers of best practices in interdisciplinary research for theoretical integration to work with this population. C1 [Varghese, Femina P.] Univ Cent Arkansas, Counseling Psychol Program, Conway, AR 72035 USA. [Cummings, Devon L.] Univ Cent Arkansas, Conway, AR 72035 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Varghese, FP (reprint author), Univ Cent Arkansas, Dept Psychol & Counseling, 201 Donaghey Ave, Conway, AR 72035 USA. EM fvarghese@uca.edu NR 106 TC 2 Z9 2 U1 9 U2 35 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0011-0000 J9 COUNS PSYCHOL JI Couns. Psychol. PD OCT PY 2013 VL 41 IS 7 BP 961 EP 989 DI 10.1177/0011000012459363 PG 29 WC Psychology, Applied SC Psychology GA 211HD UT WOS:000323896200002 ER PT J AU Berg, AT Caplan, R Baca, CB Vickrey, BG AF Berg, Anne T. Caplan, Rochelle Baca, Christine B. Vickrey, Barbara G. TI Early-onset epilepsy, cognition, and behaviour: continuity and challenge Reply SO DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY LA English DT Letter ID MRI AB Please also see the reply to this letter by . C1 [Berg, Anne T.] Ann & Robert H Lurie Childrens Hosp Chicago, Epilepsy Ctr, Chicago, IL USA. [Berg, Anne T.] Northwest Mem Feinberg Sch Med, Dept Pediat, Chicago, IL USA. [Caplan, Rochelle] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA. [Baca, Christine B.; Vickrey, Barbara G.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Baca, Christine B.; Vickrey, Barbara G.] VA Greater Los Angeles Hlth Care Syst, Dept Neurol, Los Angeles, CA USA. RP Berg, AT (reprint author), Ann & Robert H Lurie Childrens Hosp Chicago, Epilepsy Ctr, Chicago, IL USA. EM atberg@luriechildrens.org FU NINDS NIH HHS [R37 NS031146, R01 NS031146] NR 5 TC 0 Z9 0 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0012-1622 J9 DEV MED CHILD NEUROL JI Dev. Med. Child Neurol. PD OCT PY 2013 VL 55 IS 10 BP 964 EP 965 DI 10.1111/dmcn.12203 PG 2 WC Clinical Neurology; Pediatrics SC Neurosciences & Neurology; Pediatrics GA 213OK UT WOS:000324067100017 PM 23889464 ER PT J AU Zhang, XY Al Jurdi, RK Zoghbi, AW Chen, DC Xiu, MH Tan, YL Yang, FD Kosten, TR AF Zhang, Xiang Yang Al Jurdi, Rayan K. Zoghbi, Anthony William Chen, Da Chun Xiu, Mei Hong Tan, Yun Long Yang, Fu De Kosten, Thomas R. TI Prevalence, demographic and clinical correlates of suicide attempts in Chinese medicated chronic inpatients with schizophrenia SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Schizophrenia; Suicide; Risk factors; Smoking; China ID RANDOMIZED CONTROLLED-TRIAL; NEGATIVE SYNDROME SCALE; 1ST EPISODE PSYCHOSIS; QUALITY-OF-LIFE; CIGARETTE-SMOKING; RISK-FACTORS; 1ST-EPISODE PSYCHOSIS; REVISED NOMENCLATURE; PSYCHIATRIC-PATIENTS; SPECTRUM DISORDERS AB The high prevalence of suicide in schizophrenia may be related to its demographic and clinical characteristics. Because suicide prevalence and its associations with clinical variables are less well characterized in Chinese than European patients with schizophrenia, we assessed the suicide attempts in 520 Chinese inpatients with schizophrenia. The suicide attempt data were collected from medical case notes and interviews with the patients and their family members. Patients were rated on the Positive and Negative Syndrome Scale (PANSS), the Simpson and Angus Extrapyramidal Symptom Rating Scale (SAES), and the Abnormal Involuntary Movement Scale (AIMS). Smoking severity was evaluated using clinician-administered questionnaires and the Fagerstrom Test for Nicotine Dependence (FTND). We found a suicide attempt rate of 9.2% in these schizophrenic inpatients. The attempters were single, had a significantly younger age but more hospitalizations, had higher depressive symptoms, and began smoking at an earlier age, smoked more cigarettes each day and had higher FTND total scores than patients without suicide attempts. The logistic regression analysis also indicated that suicide attempts were associated with the number of hospitalizations, depressive symptoms and FTND total scores. These results suggest that Chinese inpatients with schizophrenia attempt suicide more often than the general population. Further, some demographic and clinical variables are risk factors for suicide attempts in schizophrenia. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Zhang, Xiang Yang; Al Jurdi, Rayan K.; Zoghbi, Anthony William; Kosten, Thomas R.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Zhang, Xiang Yang; Al Jurdi, Rayan K.; Zoghbi, Anthony William; Kosten, Thomas R.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Zhang, Xiang Yang; Chen, Da Chun; Xiu, Mei Hong; Tan, Yun Long; Yang, Fu De; Kosten, Thomas R.] Peking Univ, Beijing HuiLongGuan Hosp, Beijing 100871, Peoples R China. RP Zhang, XY (reprint author), VA Med Ctr, Res Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA. EM xyzhang@bcm.edu; kosten@bcm.edu FU Stanley Medical Research Institute [03T-459, 05T-726]; Department of Veterans Affairs, VISN 16, Mental Illness Research, Education and Clinical Center (MIRECC), United States National Institute of Health [K05-DA0454, P50-DA18827, U01-MH79639] FX This study was supported by the Stanley Medical Research Institute (03T-459 and 05T-726), and the Department of Veterans Affairs, VISN 16, Mental Illness Research, Education and Clinical Center (MIRECC), United States National Institute of Health K05-DA0454, P50-DA18827 and U01-MH79639. These sources had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. NR 54 TC 6 Z9 7 U1 2 U2 11 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD OCT PY 2013 VL 47 IS 10 BP 1370 EP 1375 DI 10.1016/j.jpsychires.2013.05.024 PG 6 WC Psychiatry SC Psychiatry GA 212TC UT WOS:000324004700013 PM 23791457 ER PT J AU Corcorran, MA Olson, JM Hecht, C Knezevich, S Vary, JC AF Corcorran, Maria A. Olson, Jonathan M. Hecht, Corinne Knezevich, Stevan Vary, Jay C. TI Eruptive squamous cell carcinoma in a patient receiving abatacept for rheumatoid arthritis SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Letter C1 [Corcorran, Maria A.] Univ Washington, Sch Med, Seattle, WA 98195 USA. [Olson, Jonathan M.; Hecht, Corinne; Vary, Jay C.] Univ Washington, Dept Med, Div Dermatol, Seattle, WA 98195 USA. [Knezevich, Stevan] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Olson, Jonathan M.; Hecht, Corinne; Knezevich, Stevan; Vary, Jay C.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Vary, JC (reprint author), Univ Washington, Sch Med, Div Dermatol, Dept Med, 1959 NE Pacific St,Rm BB 1353,Box 356524, Seattle, WA 98195 USA. EM jvary@uw.edu NR 5 TC 1 Z9 1 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD OCT PY 2013 VL 69 IS 4 BP E178 EP E179 DI 10.1016/j.jaad.2013.04.018 PG 3 WC Dermatology SC Dermatology GA 215VM UT WOS:000324238900009 PM 24034388 ER PT J AU Jin, J Limburg, S Joshi, SK Landman, R Park, M Zhang, Q Kim, HT Kuo, AC AF Jin, Jenny Limburg, Sonja Joshi, Sunil K. Landman, Rebeccah Park, Michelle Zhang, Qia Kim, Hubert T. Kuo, Alfred C. TI Peripheral Nerve Repair in Rats Using Composite Hydrogel-Filled Aligned Nanofiber Conduits with Incorporated Nerve Growth Factor SO TISSUE ENGINEERING PART A LA English DT Article ID INTRATHECAL DELIVERY-SYSTEM; HYALURONIC-ACID; SCIATIC-NERVE; CONTROLLED-RELEASE; NEURON OUTGROWTH; COLLAGEN MATRIX; AXONAL GROWTH; FIBER GROWTH; SPINAL-CORD; REGENERATION AB Repair of peripheral nerve defects with current synthetic, tubular nerve conduits generally shows inferior recovery when compared with using nerve autografts, the current gold standard. We tested the ability of composite collagen and hyaluronan hydrogels, with and without the nerve growth factor (NGF), to stimulate neurite extension on a promising aligned, nanofiber poly-L-lactide-co-caprolactone (PLCL) scaffold. In vitro, the hydrogels significantly increased neurite extension from dorsal root ganglia explants. Consistent with these results, the addition of hydrogels as luminal fillers within aligned, nanofiber tubular PLCL conduits led to improved sensory function compared to autograft repair in a critical-size defect in the sciatic nerve in a rat model. Sensory recovery was assessed 3 and 12 weeks after repair using a withdrawal assay from thermal stimulation. The addition of hydrogel did not enhance recovery of motor function in the rat model. The NGF led to dose-dependent improvements in neurite out-growth in vitro, but did not have a significant effect in vivo. In summary, composite collagen/hyaluronan hydrogels enhanced sensory neurite outgrowth in vitro and sensory recovery in vivo. The use of such hydrogels as luminal fillers for tubular nerve conduits may therefore be useful in assisting restoration of protective sensation following peripheral nerve injury. C1 [Jin, Jenny; Limburg, Sonja; Joshi, Sunil K.; Landman, Rebeccah; Park, Michelle; Zhang, Qia; Kim, Hubert T.; Kuo, Alfred C.] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA USA. [Jin, Jenny; Limburg, Sonja; Joshi, Sunil K.; Landman, Rebeccah; Park, Michelle; Zhang, Qia; Kim, Hubert T.; Kuo, Alfred C.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Kuo, AC (reprint author), San Francisco VA Med Ctr, 4150 Clement St Box 112, San Francisco, CA 94121 USA. EM KuoAC@orthosurg.ucsf.edu FU Department of Defense [W81XWH-05-2-0094] FX We thank Professor Song Li and Shyam Patel for informative discussions, Bora Shin and Judy Shigenaga for technical assistance, and Eva Grotkopp for statistical assistance. This work was supported by the Department of Defense Grant (W81XWH-05-2-0094), which was administered by the Northern California Institute for Research and Education, and with resources of the Veterans Affairs Medical Center, San Francisco, California. NR 53 TC 8 Z9 10 U1 3 U2 91 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1937-3341 J9 TISSUE ENG PT A JI Tissue Eng. Part A PD OCT 1 PY 2013 VL 19 IS 19-20 BP 2138 EP 2146 DI 10.1089/ten.tea.2012.0575 PG 9 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology SC Cell Biology; Biotechnology & Applied Microbiology GA 211TI UT WOS:000323933400006 PM 23659607 ER PT J AU Horning, SM Wilkins, SS Dhanani, S Henriques, D AF Horning, Sheena M. Wilkins, Stacy S. Dhanani, Shawkat Henriques, Donna TI A Case of Elder Abuse and Undue Influence: Assessment and Treatment From a Geriatric Interdisciplinary Team SO CLINICAL CASE STUDIES LA English DT Article DE elder abuse; undue influence; dementia; decision-making capacity ID UNITED-STATES; MISTREATMENT; PREVALENCE AB Elder abuse is a pervasive problem that can have lasting emotional and physical consequences, increasing its victims' risk of mortality. Healthcare providers are frequently involved in the detection and intervention of elder abuse. Because of the complexity of these cases, applying treatment interventions within an interdisciplinary care team has been recommended to ensure older adults' safety and welfare. Psychologists in particular are frequently relied upon in these situations because of their expertise in cognitive, psychiatric, and capacity assessment, as well as their ability to intervene in a variety of difficult situations. The following is a report examining the case of Mr. B, who was a victim of elder abuse involving financial exploitation and undue influence. Assessment and treatment interventions were used within the context of an interdisciplinary care team, using a bio-psychosocial approach. A decision-tree model describing the steps to take in assessing and treating financial elder abuse is proposed. C1 [Horning, Sheena M.; Wilkins, Stacy S.; Dhanani, Shawkat; Henriques, Donna] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90025 USA. [Wilkins, Stacy S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Dhanani, Shawkat] Univ Calif Los Angeles, Los Angeles, CA USA. RP Horning, SM (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Psychol, 11301 Wilshire Blvd, Los Angeles, CA 90025 USA. EM Sheena.Horning@va.gov OI Horning, Sheena/0000-0002-9704-0070 NR 23 TC 1 Z9 1 U1 1 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1534-6501 EI 1552-3802 J9 CLIN CASE STUD JI Clin. Case Stud. PD OCT PY 2013 VL 12 IS 5 BP 373 EP 387 DI 10.1177/1534650113496143 PG 15 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA AW9OT UT WOS:000346587700004 ER PT J AU Rinker, JR Cossey, TC Cutter, GR Culpepper, WJ AF Rinker, John R., II Cossey, Tiffany C. Cutter, Gary R. Culpepper, William J. TI A retrospective review of lithium usage in veterans with multiple sclerosis SO MULTIPLE SCLEROSIS AND RELATED DISORDERS LA English DT Review DE Multiple sclersosi; Lithium; Veteran; Retrospective study; Drug toxicity; Drug tolerance AB Objective: Lithium (Li) reduces disease activity in animal models of multiple sclerosis (MS), but has not been previously studied in human MS. While developing a clinical trial to test the effects of Li in MS, we performed a retrospective chart review to determine the safety and tolerability of Li among US veterans with MS. Methods: We identified all veterans with MS prescribed Li from 1998 to 2009 using the Department of Veterans Affairs Pharmacy Benefits Management. Charts were reviewed for Li-related adverse events and effects on the MS disease course. Results: Among 21,847 veterans with MS, 101 met inclusion criteria and took Li >6 months. Eighteen percent of subjects experienced a Li-associated adverse event. Later age of MS onset was associated with increased risk of Li-related adverse events (p=0.004). Associations between Li use and MS disease activity were mixed: Li was not associated with increased risk of enhancing MRI lesions (p=0.655), but annualized relapse rates were higher on Li (0.34 vs. 0.20, p=0.044). In contrast, change in Expanded Disability Status Scale scores was greater in the off-Li period than the on-Li period (0.8 vs. 0.3, p=0.003). Conclusion: Adverse events occur in a minority of Li-treated MS patients. A consistent effect of Li on MS disease activity was not apparent. These findings indicate a clinical trial will be needed to ascertain Lis effects on the MS disease course. Published by Elsevier B.V. C1 [Rinker, John R., II; Cossey, Tiffany C.] Birmingham VA Med Ctr, Birmingham, AL 35233 USA. [Rinker, John R., II] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA. [Cossey, Tiffany C.] Univ Alabama Birmingham, Dept Internal Med, Birmingham, AL 35294 USA. [Cutter, Gary R.] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA. [Culpepper, William J.] Baltimore VA Med Ctr, VA Multiple Sclerosis Ctr Excellence East, Baltimore, MD 20201 USA. RP Rinker, JR (reprint author), Univ Alabama Birmingham, SC 440,1720 7th Ave South, Birmingham, AL 35233 USA. EM rinkerj@uab.edu FU Department of Veterans Affairs Career Development Award (CDA2); VA MS Center of Excellence East FX Dr. John Rinker is supported by a Department of Veterans Affairs Career Development Award (CDA2).; Dr. Joel Culpepper is supported by the VA MS Center of Excellence East. He reports no conflicts in regards to this work. NR 25 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2211-0348 EI 2211-0356 J9 MULT SCLER RELAT DIS JI Mult. Scler. Relat. Disord. PD OCT PY 2013 VL 2 IS 4 BP 327 EP 333 DI 10.1016/j.msard.2013.03.004 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA V37LE UT WOS:000209276500007 PM 25877842 ER PT J AU Zhao, S Cao, L Freeman, JW AF Zhao, S. Cao, L. Freeman, J. W. TI Knockdown of RON receptor kinase delays but does not prevent tumor progression while enhancing HGF/MET signaling in pancreatic cancer cell lines SO ONCOGENESIS LA English DT Article DE RON; MET; pancreatic cancer; cancer therapy AB In this study, the role of RON (receptor originated from nantes) in tumor progression was further investigated in context with MET expression and activity. RON and MET expressions were not detected in an immortalized normal human pancreas cell line (HPNE), but were co-expressed in five of seven pancreatic ductal adenocarcinoma (PDAC) cell lines (PANC-1, BxPC-3, Capan-2, CFPAC-1 and AsPC-1). RON expression was knocked down by an shRNA approach in two PDAC cell lines (BxPC-3 and CFPAC-1) that co-express MET. Knockdown of RON significantly inhibited cell growth, clonogenicity and macrophage stimulating protein (MSP), RON ligand induced invasion by in vitro assays and significantly inhibited tumor growth (P<0.001) and metastasis (P<0.009) in an orthotopic pancreatic cancer mouse model at week 7. However, by week 9, the mice implanted with RON knockdown cells had developed similar size primary tumors and metastases compared with that seen in the control group at week 7. Western blotting and immunohistochemistry analyses showed that MET remains highly expressed in cells and tumor tissues where RON was knocked down. Moreover, knockdown of RON did not prevent hepatocyte growth factor (HGF) stimulated invasion in in vitro Matrigel assays. Treating cells with MSP induced the transphosphorylation of MET, suggesting that signaling may be modulated by relative levels of RON and MET receptors and their corresponding ligands. To this point, HGF treatment of RON knockdown cells caused an increase in intensity and duration of MET signaling, suggesting that MET signaling may compensate for loss of RON signaling. Treatment of cells with an MET inhibitor, PHA-665752, had minimal effects on inhibiting cell growth but significantly inhibited cell invasion induce by ligands for either MET or RON. These results suggest that HGF/MET signaling may have a more important role in tumor cell invasion and metastasis rather than in tumor cell proliferation. This study indicates that specific inhibition of RON delays but does not prevent progression of PDAC. Moreover, specific signaling may be modulated by the interaction of RON and MET receptors. This dynamic interaction of RON and MET in pancreatic cancer cells suggests that dual targeting of both RON and MET will be preferable to inhibition of either target alone. C1 [Zhao, S.; Cao, L.; Freeman, J. W.] Univ Texas Hlth Sci Ctr San Antonio, Div Med Oncol, Dept Med, San Antonio, TX 78229 USA. [Freeman, J. W.] Canc Therapy & Res Ctr S Texas, Expt & Dev Therapeut Program, San Antonio, TX 78229 USA. [Freeman, J. W.] Audie L Murphy Mem Vet Adm Med Ctr, Res & Dev, San Antonio, TX USA. RP Freeman, JW (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Med Oncol, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM freemanjw@uthscsa.edu FU VA merit award; Cancer Center Grant [NIH-RO1CA069122, NIH-P30CA054174] FX We thank Jenny Wang (University of Nebraska Medical Center, Omaha, NE) for the pSuper-shRNA-RON and Ricardo Aguiar (University of Texas Health Science Center, San Antonio, TX) for the PMMP-luciferase plasmids. We thank the University of Texas Health Science Center Animal Care and Use Committee and the Optical Imaging Facility Core of University of Texas Health Science Center (San Antonio, TX) for housing the mice and facility the animal images; and we thank the Histology and Pathology Laboratory (University of Texas Health Science Center, San Antonio, TX) for the histopathology and immunohistochemistry analysis. Grants to JWF, VA merit award, and NIH-RO1CA069122, Cancer Center Grant to CTRC, NIH-P30CA054174, supported this work. NR 50 TC 7 Z9 7 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 2157-9024 J9 ONCOGENESIS JI Oncogenesis PD OCT PY 2013 VL 2 AR UNSP e76 DI 10.1038/oncsis.2013.36 PG 10 WC Oncology SC Oncology GA V36OI UT WOS:000209220600002 PM 24100611 ER PT J AU Clark-Cutaia, MN Ren, DX Hoffman, LA Snetselaar, L Sevick, MA AF Clark-Cutaia, Maya N. Ren, Dianxu Hoffman, Leslie A. Snetselaar, Linda Sevick, Mary Ann TI Psychometric Validation of the Self-Efficacy for Restricting Dietary Salt in Hemodialysis Scale SO TOPICS IN CLINICAL NUTRITION LA English DT Article DE consistency; construct validity; convergent validity; dietary sodium intake; fluid restriction; hemodialysis; psychometrics AB The development and progression of left ventricular hypertrophy is a consequence of multiple comorbid conditions associated with end-stage renal disease and large variations in interdialytic weight gains. The literature suggests that dietary sodium restriction alone significantly reduces interdialytic weight gains. A total of 124 hemodialysis participants in an ongoing randomized control trial participated in the validation in which psychometric properties of a self-efficacy survey were a secondary analysis. We evaluated the internal consistency, construct validity, and convergent validity of the instrument. The overall Cronbach alpha was 0.93. Three factors extracted explain 67.8% of the variance of the white and African American participants. The Self-Efficacy Survey has adequate internal consistency and construct and convergent validity. Future research is needed to evaluate the stability and discriminant validity of the instrument. C1 [Clark-Cutaia, Maya N.] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Ren, Dianxu] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA. [Hoffman, Leslie A.] Univ Pittsburgh, Nursing Clin & Translat Sci, Pittsburgh, PA USA. [Snetselaar, Linda] Univ Iowa, Dept Epidemiol, Preventat Nutr Educ, Iowa City, IA USA. [Sevick, Mary Ann] US Dept Vet Affairs, VA Pittsburgh Healthcare Syst, Washington, DC USA. [Sevick, Mary Ann] Univ Pittsburgh, Ctr Res Hlth Care, Publ Hlth Clin & Translat Sci, Pittsburgh, PA USA. RP Clark-Cutaia, MN (reprint author), Univ Penn, Sch Nursing, Claire M Fagin Hall,418 Curie Blvd, Philadelphia, PA 19104 USA. EM Mayan@nursing.upenn.edu FU [NIH-R01-NR010135]; [NIH-K24-NR012226]; [1F31NR013410] FX This study was supported through grants from NIH-R01-NR010135, NIH-K24-NR012226 received by Mary Ann Sevick, and 1F31NR013410 received by Maya N. Clark, PhD, ACNP-BC, RN. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article . NR 38 TC 2 Z9 2 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0883-5691 EI 1550-5146 J9 TOP CLIN NUTR JI Top. Clin. Nutr. PD OCT-DEC PY 2013 VL 28 IS 4 BP 384 EP 391 DI 10.1097/01.TIN.0000437407.76867.65 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA V41NM UT WOS:000209552900008 PM 26213444 ER PT J AU Karlamangla, AS Mori, T Merkin, SS Seeman, TE Greendale, GA Binkley, N Crandall, CJ AF Karlamangla, Arun S. Mori, Takahiro Merkin, Sharon S. Seeman, Teresa E. Greendale, Gail A. Binkley, Neil Crandall, Carolyn J. TI Childhood socioeconomic status and adult femoral neck bone strength: Findings from the Mid life in the United States Study SO BONE LA English DT Article DE Bone strength; Femoral neck; Childhood socioeconomic advantage; Health behaviors ID HIP FRACTURE RISK; PHYSICAL-ACTIVITY QUESTIONNAIRE; CORONARY HEART-DISEASE; MINERAL DENSITY; POSTMENOPAUSAL WOMEN; SOCIAL-CLASS; RANCHO-BERNARDO; ALLOSTATIC LOAD; WHITE WOMEN; ELDERLY-MEN AB Purpose: Bone acquisition in childhood impacts adult bone mass, and can be influenced by childhood socioeconomic conditions. Socioeconomic status is also associated with body weight which affects the load that bone is exposed to in a fall. We hypothesized that socioeconomic advantage in childhood is associated with greater bone strength relative to load in adulthood. Methods: Hip dual x-ray absorptiometry scans from 722 participants in the Midlife in the United States Study were used to measure femoral neck size and bone mineral density, and combined with body weight and height to create composite indices of femoral neck strength relative to load in different failure modes: compression, bending, and impact. A childhood socioeconomic advantage score was created for the same participants from parental education, self-rated financial status relative to others, and not being on welfare. Multiple linear regression was used to determine the association of childhood socioeconomic advantage with femoral neck composite strength indices, stratified by gender and race (white/non-white), and adjusted for study site, age, menopause status in women; education, and current financial advantage. Results: Childhood socioeconomic advantage was independently associated with higher indices of all three composite strength indices in white men (adjusted standardized effect sizes, 0.19 to 0.27, all p values < 0.01), but not in the other three race/gender groups. Additional adjustment for adult obesity, physical activity in different life stages, smoking, and heavy drinking over the life-course significantly attenuated the associations in white men. Conclusions: Socioeconomic disadvantage in childhood is associated with lower hip strength relative to load in white men, and these influences are dampened by healthy lifestyle choices. (C) 2013 Elsevier Inc. All rights reserved. C1 [Karlamangla, Arun S.; Merkin, Sharon S.; Seeman, Teresa E.; Greendale, Gail A.] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Dept Med, Los Angeles, CA 90095 USA. [Mori, Takahiro] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA 90073 USA. [Binkley, Neil] Univ Wisconsin, Madison Osteoporosis Clin Ctr & Res Prog, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Crandall, Carolyn J.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. RP Karlamangla, AS (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Dept Med, 10945 Le Conte Ave,Suite 2339, Los Angeles, CA 90095 USA. EM akarlamangla@mednet.ucla.edu FU National Institutes of Health [1R01AG033067, R01-AG-032271, P01-AG-020166]; UCLA GCRC [M01-RR000865] FX This research was supported by the National Institutes of Health grant numbers 1R01AG033067, R01-AG-032271, and P01-AG-020166. The UCLA GCRC helped support this study (UCLA GCRC grant # M01-RR000865). NR 86 TC 4 Z9 4 U1 1 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 8756-3282 J9 BONE JI Bone PD OCT PY 2013 VL 56 IS 2 BP 320 EP 326 DI 10.1016/j.bone.2013.06.021 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 210VX UT WOS:000323864000014 PM 23810840 ER PT J AU Gorin, Y Block, K AF Gorin, Yves Block, Karen TI Nox as a target for diabetic complications SO CLINICAL SCIENCE LA English DT Review DE diabetes; diabetic complications; hyperglycaemia; oxidative stress; Nox; reactive oxygen species; small-molecule inhibitor ID SMOOTH-MUSCLE-CELLS; ENDOTHELIAL GROWTH-FACTOR; GLYCATION END-PRODUCTS; RENIN-ANGIOTENSIN SYSTEM; NITRIC-OXIDE SYNTHASE; PROTEIN-KINASE-C; TUBULAR EPITHELIAL-CELLS; INDUCED OXIDATIVE STRESS; ALPHA-LIPOIC ACID; DINUCLEOTIDE PHOSPHATE OXIDASE AB Oxidative stress has been linked to the pathogenesis of the major complications of diabetes in the kidney, the heart, the eye or the vasculature. NADPH oxidases of the Nox family are a major source of ROS (reactive oxygen species) and are critical mediators of redox signalling in cells from different organs afflicted by the diabetic milieu. In the present review, we provide an overview of the current knowledge related to the understanding of the role of Nox in the processes that control cell injury induced by hyperglycaemia and other predominant factors enhanced in diabetes, including the renin angiotensin system, TGF-beta (transforming growth factor-beta) and AGEs (advanced glycation end-products). These observations support a critical role for Nox homologues in diabetic complications and indicate that NADPH oxidases are an important therapeutic target. Therefore the design and development of small-molecule inhibitors that selectively block Nox oxidases appears to be a reasonable approach to prevent or retard the complications of diabetes in target organs. The bioefficacy of these agents in experimental animal models is also discussed in the present review. C1 [Gorin, Yves; Block, Karen] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Block, Karen] South Texas Vet Hlth Care Syst, Audie L Murphy Mem Hosp Div, San Antonio, TX 78229 USA. RP Gorin, Y (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. EM gorin@uthscsa.edu OI Gorin, Yves/0000-0003-4048-6925 FU Juvenile Diabetes Research Foundation; National Institutes of Health [RO1 DK 079996, RO1 CA 131272]; Veterans Administration FX Our own work was supported by the Juvenile Diabetes Research Foundation [Multiproject grants (to Y.G and K.B.)], the National Institutes of Health [grant number RO1 DK 079996 (to Y.G.), RO1 CA 131272 (to K.B)] and the Veterans Administration (to K.B.). NR 310 TC 49 Z9 52 U1 1 U2 50 PU PORTLAND PRESS LTD PI LONDON PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND SN 0143-5221 J9 CLIN SCI JI Clin. Sci. PD OCT PY 2013 VL 125 IS 7-8 BP 361 EP 382 DI 10.1042/CS20130065 PG 22 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 210RQ UT WOS:000323852600006 PM 23767990 ER PT J AU Weintraub, D Duda, JE Carlson, K Luo, P Sagher, O Stern, M Follett, KA Reda, D Weaver, FM AF Weintraub, Daniel Duda, John E. Carlson, Kimberly Luo, Ping Sagher, Oren Stern, Matthew Follett, Kenneth A. Reda, Domenic Weaver, Frances M. CA CSP 468 Study Grp TI Suicide ideation and behaviours after STN and GPi DBS surgery for Parkinson's disease: results from a randomised, controlled trial SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY LA English DT Article DE PARKINSON'S DISEASE; BEHAVIOURAL DISORDER; SURGERY ID DEEP-BRAIN-STIMULATION; SUBTHALAMIC NUCLEUS STIMULATION; HEALTH SURVEY SF-36; MOVEMENT-DISORDERS; MEDICAL THERAPY; DEPRESSION; OUTCOMES; MOOD; RISK AB Background The risk of suicide behaviours post-deep brain stimulation (DBS) surgery in Parkinson's disease (PD) remains controversial. We assessed if suicide ideation and behaviours are more common in PD patients (1) randomised to DBS surgery versus best medical therapy (BMT); and (2) randomised to subthalamic nucleus (STN) versus globus pallidus interna (GPi) DBS surgery. Methods In Phase 1 of the Veterans Affairs CSP 468 study, 255 PD patients were randomised to DBS surgery (n=121) or 6months of BMT (n=134). For Phase 2, a total of 299 patients were randomised to STN (n=147) or GPi (n=152) DBS surgery. Patients were assessed serially with the Unified Parkinson's Disease Rating Scale Part I depression item, which queries for suicide ideation; additionally, both suicide behaviour adverse event data and proxy symptoms of increased suicide risk from the Parkinson's Disease Questionnaire (PDQ-39) and the Short Form Health Survey (SF-36) were collected. Results In Phase 1, no suicide behaviours were reported, and new-onset suicide ideation was rare (1.9% for DBS vs 0.9% for BMT; Fisher's exact p=0.61). Proxy symptoms of relevance to suicide ideation were similar in the two groups. Rates of suicide ideation at 6months were similar for patients randomised to STN versus GPi DBS (1.5% vs 0.7%; Fisher's exact p=0.61), but several proxy symptoms were worse in the STN group. Conclusions Results from the randomised, controlled phase of a DBS surgery study in PD patients do not support a direct association between DBS surgery and an increased risk for suicide ideation and behaviours. C1 [Weintraub, Daniel; Duda, John E.; Stern, Matthew] Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr PADRECC, Philadelphia, PA USA. [Weintraub, Daniel] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Weintraub, Daniel; Duda, John E.; Stern, Matthew] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Carlson, Kimberly; Luo, Ping; Reda, Domenic] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Dept Vet Affairs Cooperat Studies, Program Coordinating Ctr, Hines, IL 60141 USA. [Sagher, Oren] Univ Michigan, Sch Med, Dept Neurosurg, Ann Arbor, MI USA. [Follett, Kenneth A.] Univ Nebraska, Med Ctr, Omaha VA Med Ctr, Omaha, NE USA. [Follett, Kenneth A.] Univ Nebraska, Med Ctr, Div Neurosurg, Omaha, NE USA. [Weaver, Frances M.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hlth Serv Res Ctr, Hines, IL 60141 USA. [Weaver, Frances M.] Loyola Univ, Stritch Sch Med, Dept Med, Chicago, IL 60611 USA. RP Weintraub, D (reprint author), Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia VA Med Ctr, 3615 Chestnut St 330, Philadelphia, PA 19104 USA. EM daniel.weintraub@uphs.upenn.edu FU Cooperative Studies Programme of the Department of Veterans Affairs Office of Research and Development; National Institute of Neurological Disorders and Stroke; Medtronic Neuromodulation [NCT00056563, NCT 01076452.] FX The Cooperative Studies Programme of the Department of Veterans Affairs Office of Research and Development, the National Institute of Neurological Disorders and Stroke, and Medtronic Neuromodulation provided financial support for this study NCT00056563 and NCT 01076452. NR 30 TC 30 Z9 30 U1 0 U2 18 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0022-3050 J9 J NEUROL NEUROSUR PS JI J. Neurol. Neurosurg. Psychiatry PD OCT PY 2013 VL 84 IS 10 BP 1113 EP 1118 DI 10.1136/jnnp-2012-304396 PG 6 WC Clinical Neurology; Psychiatry; Surgery SC Neurosciences & Neurology; Psychiatry; Surgery GA 209SH UT WOS:000323779800013 PM 23667214 ER PT J AU Kim, JY Kim, N Zheng, Z Lee, JE Yenari, MA AF Kim, Jong Youl Kim, Nuri Zheng, Zhen Lee, Jong Eun Yenari, Midori A. TI The 70 kDa heat shock protein protects against experimental traumatic brain injury SO NEUROBIOLOGY OF DISEASE LA English DT Article DE Brain injury; Heat shock protein; Cerebral hemorrhage ID OXYGEN-GLUCOSE DEPRIVATION; MATRIX METALLOPROTEINASES; EXPERIMENTAL STROKE; CEREBRAL-ISCHEMIA; INFLAMMATORY RESPONSE; BARRIER DISRUPTION; STRESS-RESPONSE; OVEREXPRESSION; BLOOD; MATRIX-METALLOPROTEINASE-9 AB Traumatic brain injury (TBI) causes disruption of the blood brain barrier (BBB) leading to hemorrhage which can complicate an already catastrophic illness. Matrix metalloproteinases (MMPs) involved in the breakdown of the extracellular matrix may lead to brain hemorrhage. We explore the contribution of the 70 kDa heat shock protein (Hsp70) to outcome and brain hemorrhage in a model of TBI. Male, wildtype (Wt), Hsp70 knockout (Ko) and transgenic (Tg) mice were subjected to TBI using controlled cortical impact (CCI). Motor function, brain hemorrhage and lesion size were assessed at 3, 7 and 14 days. Brains were evaluated for the effects of Hsp70 on MMPs. In Hsp70 Tg mice, CCI led to smaller brain lesions, decreased hemorrhage and reduced expression and activation of MMPs compared to Wt. CCI also significantly decreased right-biased swings and corner turns in the Hsp70 Tg mice. Conversely, Hsp70 Ko mice had significantly increased lesion size, worsened brain hemorrhage and increased expression and activation of MMPs with worsened behavioral outcomes compared to Wt. Hsp70 is protective in experimental TBI. To our knowledge, this is the direct demonstration of brain protection by Hsp70 in a TBI model. Our data demonstrate a new mechanism linking TBI-induced hemorrhage and neuronal injury to the suppression of MMPs by Hsp70, and support the development of Hsp70 enhancing strategies for the treatment of TBI. Published by Elsevier Inc. C1 [Kim, Jong Youl; Kim, Nuri; Zheng, Zhen; Yenari, Midori A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. [Kim, Jong Youl; Kim, Nuri; Zheng, Zhen; Yenari, Midori A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Lee, Jong Eun] Yonsei Univ, Coll Med, Dept Anat, Seoul, South Korea. [Lee, Jong Eun] Yonsei Univ, Coll Med, BK Project Med Sci 21, Seoul, South Korea. RP Yenari, MA (reprint author), VAMC 4150 Clement St, San Francisco, CA 94121 USA. EM yenari@alum.mit.edu OI Lee, Jong Eun/0000-0001-6203-7413 FU National Institutes of Health [NS40516]; Veteran's Merit Award; American Heart Association Western States Affiliate Postdoctoral Fellowship [13POST14810019]; NRF of KOREA; Ministry of Education, Science and Technology [2012-0005827] FX This work was supported by grants from the National Institutes of Health (NS40516) and the Veteran's Merit Award to MY, an American Heart Association Western States Affiliate Postdoctoral Fellowship (13POST14810019) to JYK and Basic Science Research Program through the NRF of KOREA funded by the Ministry of Education, Science and Technology (2012-0005827) to JEL. Grants to MY and JYK were administered by the Northern California Institute for Research and Education, and supported by resources of the Veterans Affairs Medical Center, San Francisco, California. The authors wish to thank Dr. Linda Noble-Haeusslein for helpful discussion and advice. NR 56 TC 18 Z9 19 U1 0 U2 16 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0969-9961 J9 NEUROBIOL DIS JI Neurobiol. Dis. PD OCT PY 2013 VL 58 BP 289 EP 295 DI 10.1016/j.nbd.2013.06.012 PG 7 WC Neurosciences SC Neurosciences & Neurology GA 207GC UT WOS:000323585900033 PM 23816752 ER PT J AU Mallampalli, RK Kaercher, L Snavely, C Pulijala, R Chen, BB Coon, T Zhao, J Agassandian, M AF Mallampalli, Rama K. Kaercher, Leah Snavely, Courtney Pulijala, Roopa Chen, Bill B. Coon, Tiffany Zhao, Jing Agassandian, Marianna TI Fbxl12 triggers G1 arrest by mediating degradation of calmodulin kinase I SO CELLULAR SIGNALLING LA English DT Article DE F-box protein; CaMKI; Calcium signaling; Proteasome degradation; p27(kip1); cdk4/cyclin D1; PKB/AKT ID CELL-CYCLE ARREST; ACTIVATED PROTEIN-KINASE; NUCLEAR EXPORT SIGNAL; SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR-BETA; DEPENDENT PHOSPHORYLATION; P27(KIP1) PHOSPHORYLATION; SUBCELLULAR-LOCALIZATION; CYTOPLASMIC LOCALIZATION; P27 STABILIZATION AB Cell cycle progression through its regulatory control by changes in intracellular Ca2+ levels at the Gl/S transition mediates cellular proliferation and viability. Ca2+/CaM-dependent kinase 1 (CaMKI) appears critical in regulating the assembly of the cyclin D1 /cdk4 complex essential for G1 progression, but how this occurs is unknown. Cyclin D1/cdk4 assembly in the early G1 phase is also regulated via binding to p27. Here, we show that a ubiquitin E3 ligase component, F-box protein Fbxl12, mediates CaMKI degradation via a proteasome-directed pathway leading to disruption of cyclin D1/cdk4 complex assembly and resultant G1 arrest in lung epithelia. We also demonstrate that i) CaMKI phosphorylates p27 at Thr(157) and Thr(198) in human cells and at Thr(170) and Thr(197) in mouse cells to modulate its subcellular localization; ii) Fbxl12-induced CaMKI degradation attenuates p27 phosphorylation at these sites in early G1 and iii) activation of CaMIG during G1 transition followed by p27 phosphorylation appears to be upstream to other p27 phosphorylation events, an effect abrogated by Fbxl12 overexpression. Lastly, known inducers of G1 arrest significantly increase Fbxl12 levels in cells. Thus, Fbxl12 may be a previously uncharacterized, functional growth inhibitor regulating cell cycle progression that might be used for mechanism-based therapy. (C) 2013 The Authors. Published by Elsevier Inc. All rights reserved. C1 [Mallampalli, Rama K.; Kaercher, Leah; Snavely, Courtney; Pulijala, Roopa; Chen, Bill B.; Coon, Tiffany; Zhao, Jing; Agassandian, Marianna] Univ Pittsburgh, Acute Lung Injury Ctr Excellence, Dept Med, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15213 USA. RP Agassandian, M (reprint author), Univ Pittsburgh, BST 1,W1200-5B,200 Lothrop St, Pittsburgh, PA 15213 USA. EM agassandianm@upmc.edu FU US Department of Veterans Affairs; National Institutes of Health [HL096376, HL097376, HL098174, HL116472]; American Heart Association (AHA) [12SDG9050005] FX We greatly appreciate Cheryl Lyn Walker, Director of Institute of Biosciences & Technology Center for Translational Cancer Research of University of Texas's kind gifts of p27WT, p27T170A, p27T197A and p27T170A/197A plasmids. This material is based upon work supported, in part, by the US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. This work was supported by a Merit Review Award from the US Department of Veterans Affairs and the National Institutes of Health R01 grants HL096376, HL097376 and HL098174 (to R.K.M.), and HL116472 (to B.B.C.) and from the American Heart Association (AHA) awards 12SDG9050005 (J.Z.). The contents presented do not represent the views of the Department of Veterans Affairs or the United States Government. NR 74 TC 5 Z9 9 U1 0 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0898-6568 J9 CELL SIGNAL JI Cell. Signal. PD OCT PY 2013 VL 25 IS 10 BP 2047 EP 2059 DI 10.1016/j.cellsig.2013.05.012 PG 13 WC Cell Biology SC Cell Biology GA 198SX UT WOS:000322943700012 PM 23707388 ER PT J AU Dodson, M Darley-Usmar, V Zhang, JH AF Dodson, Matthew Darley-Usmar, Victor Zhang, Jianhua TI Cellular metabolic and autophagic pathways: Traffic control by redox signaling SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Review DE Autophagy; Mitophagy; Oxidative stress; Redox signaling; Cellular bioenergetics; Mitochondria; Glucose; Glycolysis; Glutathione; Aging; Cardiovascular disease; Neurodegeneration; Diabetes; Free radicals ID MITOCHONDRIA-TARGETED ANTIOXIDANT; ENDOPLASMIC-RETICULUM STRESS; ELECTRON-TRANSPORT-CHAIN; NEGATIVELY REGULATES AUTOPHAGY; CHAPERONE-MEDIATED AUTOPHAGY; LIPID-PEROXIDATION PRODUCTS; PENTOSE-PHOSPHATE PATHWAY; EMBRYONIC STEM-CELLS; OXIDATIVE STRESS; ENDOTHELIAL-CELLS AB It has been established that the key metabolic pathways of glycolysis and oxidative phosphorylation are intimately related to redox biology through control of cell signaling. Under physiological conditions glucose metabolism is linked to control of the NADH/NAD redox couple, as well as providing the major reductant, NADPH, for thiol-dependent antioxidant defenses. Retrograde signaling from the mitochondrion to the nucleus or cytosol controls cell growth and differentiation. Under pathological conditions mitochondria are targets for reactive oxygen and nitrogen species and are critical in controlling apoptotic cell death. At the interface of these metabolic pathways, the autophagy-lysosomal pathway functions to maintain mitochondrial quality and generally serves an important cytoprotective function. In this review we will discuss the autophagic response to reactive oxygen and nitrogen species that are generated from perturbations of cellular glucose metabolism and bioenergetic function. (C) 2013 Elsevier Inc. All rights reserved. C1 [Dodson, Matthew; Darley-Usmar, Victor; Zhang, Jianhua] Ctr Free Rad Biol, Birmingham, AL 35294 USA. [Dodson, Matthew; Darley-Usmar, Victor; Zhang, Jianhua] Univ Alabama Birmingham, Birmingham, AL 35294 USA. [Dodson, Matthew; Darley-Usmar, Victor; Zhang, Jianhua] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Zhang, Jianhua] Birmingham VA Med Ctr, Dept Vet Affairs, Birmingham, AL 35233 USA. RP Zhang, JH (reprint author), Univ Alabama Birmingham, Dept Pathol, 901 19th St South,BMR2 534, Birmingham, AL 35294 USA. EM zhanja@uab.edu OI Zhang, Jianhua/0000-0002-2128-9574 FU VA merit award; NIH [ES10167, AA13395, DK 75865]; [NIHR01-NS064090] FX The authors acknowledge funding from the following sources: Dr. Jianhua Zhang was supported by NIHR01-NS064090 and a VA merit award. Dr. Victor Darley-Usmar was supported by NIH Grants ES10167, AA13395, and DK 75865. NR 209 TC 101 Z9 111 U1 13 U2 151 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD OCT PY 2013 VL 63 SI SI BP 207 EP 221 DI 10.1016/j.freeradbiomed.2013.05.014 PG 15 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 200TV UT WOS:000323094700019 PM 23702245 ER PT J AU Sun, XB Cao, ZB Yeh, CK Sun, YY AF Sun, Xinbo Cao, Zhengbing Yeh, Chih-Ko Sun, Yuyu TI Antifungal activity, biofilm-controlling effect, and biocompatibility of poly(N-vinyl-2-pyrrolidinone)-grafted denture materials SO COLLOIDS AND SURFACES B-BIOINTERFACES LA English DT Article DE Drug delivery; Denture; Biofilm; Poly(N-vinyl-2-pyrrolidinone); Biocompatibility ID PLASMA SURFACE MODIFICATION; DRUG-DELIVERY SYSTEMS; CANDIDA-ALBICANS; BIOMEDICAL APPLICATIONS; ANTIBACTERIAL ACTIVITY; TISSUE CONDITIONERS; MICROBIAL BIOFILMS; DENTAL COMPOSITES; SILVER-ZEOLITE; IN-VITRO AB Colonization and biofilm-formation of Candida species on denture surfaces cause Candida-associated denture stomatitis (CADS), a common, recurring disease affecting up to 67% of denture wearers. We developed poly(N-vinyl-2-pyrrolidinone)-grafted denture materials that can be repeatedly recharged with various antifungal drugs to achieve long-term antifungal and biofilm-controlling effects. The monomer, N-vinyl-2-pyrrolidinone (NVP), was grafted onto poly(methyl methacrylate) denture resins through plasma-initiated grafting polymerization. The physical properties and biocompatibility of the resulting resins were not negatively affected by the presence of up to 7.92% of grafted poly (N-vinyl-2-pyrrolidinone) (PNVP). Miconazole and chlorhexidine digluconate (CD) were used as model antifungal drugs. PNVP grafting significantly increased the drug absorption capability of the resulting denture materials. Further, the new materials showed sustained drug release and provided anti fungal effects for weeks (in the case of CD) to months (in the case of miconazole). The drug-depleted resins could be recharged with the same or a different class of antifungal drug to further extend antifungal duration. If needed, drugs on the PNVP-grafted denture materials could be "washed out" (quenched) by treating with PNVP aqueous solutions to stop drug release. These results point to great potentials of the new materials in controlling biofilm-formation in a wide range of device-related applications. (c) 2013 Elsevier B.V. All rights reserved. C1 [Sun, Xinbo; Cao, Zhengbing] Medetech Dev Corp, Lynnwood, WA 98087 USA. [Yeh, Chih-Ko] Univ Texas Hlth Sci Ctr San Antonio, Dept Dent Diagnost Sci, San Antonio, TX 78229 USA. [Yeh, Chih-Ko] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Audie L Murphy Div, San Antonio, TX 78229 USA. [Sun, Yuyu] Univ Massachusetts Lowell, Dept Chem, Lowell, MA 01854 USA. RP Sun, YY (reprint author), Univ Massachusetts Lowell, Dept Chem, Lowell, MA 01854 USA. EM yuyu_sun@uml.edu FU NIDCR, NIH [R01 DE021084]; VA Merit Review [1101BX001103] FX This study was supported by NIDCR, NIH (R01 DE021084) and VA Merit Review (1101BX001103). NR 70 TC 8 Z9 8 U1 1 U2 73 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0927-7765 J9 COLLOID SURFACE B JI Colloid Surf. B-Biointerfaces PD OCT 1 PY 2013 VL 110 BP 96 EP 104 DI 10.1016/j.colsurfb.2013.04.043 PG 9 WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials SC Biophysics; Chemistry; Materials Science GA 185BM UT WOS:000321940200014 PM 23708753 ER PT J AU Wang, LY Murphy, RR Hanscom, B Li, G Millard, SP Petrie, EC Galasko, DR Sikkema, C Raskind, MA Wilkinson, CW Peskind, ER AF Wang, Lucy Y. Murphy, Richard R. Hanscom, Brett Li, Ge Millard, Steven P. Petrie, Eric C. Galasko, Douglas R. Sikkema, Carl Raskind, Murray A. Wilkinson, Charles W. Peskind, Elaine R. TI Cerebrospinal fluid norepinephrine and cognition in subjects across the adult age span SO NEUROBIOLOGY OF AGING LA English DT Article DE Noradrenergic system; Norepinephrine; Cognition; Aging ID ALZHEIMERS-DISEASE; PLASMA NOREPINEPHRINE; NORADRENERGIC MODULATION; PREFRONTAL CORTEX; LOCUS-COERULEUS; WORKING-MEMORY; STRESS; CORTISOL; KINETICS; ENHANCEMENT AB Adequate central nervous system noradrenergic activity enhances cognition, but excessive noradrenergic activity may have adverse effects on cognition. Previous studies have also demonstrated that noradrenergic activity is higher in older than younger adults. We aimed to determine relationships between cerebrospinal fluid (CSF) norepinephrine (NE) concentration and cognitive performance by using data from a CSF bank that includes samples from 258 cognitively normal participants aged 21-100 years. After adjusting for age, gender, education, and ethnicity, higher CSF NE levels (units of 100 pg/mL) are associated with poorer performance on tests of attention, processing speed, and executive function (Trail Making A: regression coefficient 1.5, standard error [SE] 0.77, p = 0.046; Trail Making B: regression coefficient 5.0, SE 2.2, p = 0.024; Stroop Word-Color Interference task: regression coefficient 6.1, SE 2.0, p = 0.003). Findings are consistent with the earlier literature relating excess noradrenergic activity with cognitive impairment. Published by Elsevier Inc. C1 [Wang, Lucy Y.; Murphy, Richard R.; Li, Ge; Millard, Steven P.; Petrie, Eric C.; Raskind, Murray A.; Peskind, Elaine R.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res & Educ Clin Ctr, Seattle, WA USA. [Wang, Lucy Y.; Li, Ge; Petrie, Eric C.; Raskind, Murray A.; Wilkinson, Charles W.; Peskind, Elaine R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Murphy, Richard R.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Hanscom, Brett] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Galasko, Douglas R.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. [Sikkema, Carl; Wilkinson, Charles W.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. RP Wang, LY (reprint author), VA Puget Sound Healthcare Syst, Mental Illness Res & Educ Clin Ctr, 1660 South Columbian Way,S-116 MIRECC, Seattle, WA 98115 USA. EM wanglucy@u.washington.edu FU VA Puget Sound Mental Illness Research, Education and Clinical Center (MIRECC); VA Puget Sound Geriatric Research, Education, and Clinical Center; VA Special Fellowship in Advanced Psychiatry (MIRECC); University of Washington's ADRC Pilot Study Award; NIH/NIA [P50AG005136] FX This study was supported by the VA Puget Sound Mental Illness Research, Education and Clinical Center (MIRECC), the VA Puget Sound Geriatric Research, Education, and Clinical Center, the VA Special Fellowship in Advanced Psychiatry (MIRECC), the University of Washington's ADRC Pilot Study Award, and NIH/NIA grant P50AG005136. NR 48 TC 3 Z9 3 U1 0 U2 26 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD OCT PY 2013 VL 34 IS 10 BP 2287 EP 2292 DI 10.1016/j.neurobiolaging.2013.04.007 PG 6 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 187JM UT WOS:000322113800006 PM 23639207 ER PT J AU Weisbart, RH Chan, G Li, E Farmani, N Heinze, E Rubell, A Nishimura, RN Colburn, K AF Weisbart, Richard H. Chan, Grace Li, Erica Farmani, Niloofar Heinze, Emil Rubell, Antonia Nishimura, Robert N. Colburn, Keith TI BRAF splice variants in rheumatoid arthritis synovial fibroblasts activate MAPK through CRAF SO MOLECULAR IMMUNOLOGY LA English DT Article DE Rheumatoid arthritis; Oncogene; MAPK cascade ID TYPE-1 MATRIX-METALLOPROTEINASE; MUTATIONS; CELLS; AUTOANTIBODIES; INFLAMMATION; INHIBITORS; CARTILAGE; CANCER AB Rheumatoid arthritis (RA) is a destructive polyarthritis in which synovial-like fibroblasts (SFs) invade and erode cartilage by expressing membrane-anchored type 1 matrix metalloproteinase (MT1-MMP). The mitogen activated protein kinase (MAPK) pathway is activated in RA SFs, but the mechanism of activation is unknown. Here we identify aberrant BRAF splice variants with deletions in both the kinase domain and RAS-binding domain (RBD) in SFs from the majority of RA patients and show that these BRAF splice variants constitutively activate MAPK through CRAF, increase expression of MT1-MMP, and enhance fibroblast invasion of collagen. Published by Elsevier Ltd. C1 [Weisbart, Richard H.; Chan, Grace; Li, Erica; Rubell, Antonia] Vet Affairs Greater Los Angeles Health Care Syst, Sepulveda, CA 91343 USA. [Farmani, Niloofar; Heinze, Emil] Olive View UCLA Med Ctr, Dept Med, Sylmar, CA 91342 USA. [Nishimura, Robert N.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA. [Colburn, Keith] Vet Affairs Med Ctr, Loma Linda, CA 92357 USA. [Colburn, Keith] Loma Linda Univ, Loma Linda, CA 92350 USA. RP Weisbart, RH (reprint author), Vet Affairs Greater Los Angeles Health Care Syst, Dept Res, 16111 Plummer St 111S, Sepulveda, CA USA. EM rweisbar@ucla.edu FU Veterans Affairs FX This work was sponsored by a grant from the Veterans Affairs. NR 30 TC 2 Z9 5 U1 1 U2 51 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0161-5890 J9 MOL IMMUNOL JI Mol. Immunol. PD OCT PY 2013 VL 55 IS 3-4 BP 247 EP 252 DI 10.1016/j.molimm.2013.02.001 PG 6 WC Biochemistry & Molecular Biology; Immunology SC Biochemistry & Molecular Biology; Immunology GA 152OE UT WOS:000319540200008 PM 23517740 ER PT J AU Milanak, ME Gros, DF Magruder, KM Brawman-Mintzer, O Frueh, BC AF Milanak, Melissa E. Gros, Daniel F. Magruder, Kathryn M. Brawman-Mintzer, Olga Frueh, B. Christopher TI Prevalence and features of generalized anxiety disorder in Department of Veteran Affairs primary care settings SO PSYCHIATRY RESEARCH LA English DT Article DE Posttraumatic stress disorder; Veterans; Comorbidity; Healthcare utilization ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; VA PRIMARY-CARE; PSYCHOMETRIC PROPERTIES; MENTAL-HEALTH; MAJOR DEPRESSION; US VETERANS; DSM-IV; COMORBIDITY; CLINICS AB Generalized anxiety disorder (GAD) is a highly prevalent distressing condition for individuals in both community and community primary care settings. However, despite the high prevalence of GAD identified in epidemiological studies, little is known about GAD and its related symptoms and impairments in veteran populations. The present study investigated the prevalence, comorbidity, physical and mental health impairment, and healthcare utilization of veteran participants with GAD, as well as comparing symptoms of GAD and posttraumatic stress disorder (PTSD). Veterans (N=884) participated in a cross-sectional investigation in primary care clinics in four Veteran Affairs Medical Centers (VAMCs) and completed diagnostic interviews and self-report questionnaires; a chart review was conducted to assess their VAMC healthcare utilization. A large number of participants (12%) met diagnostic criteria for GAD, reporting significantly worse emotional health, pain, and general health, in addition to increased mental healthcare utilization and antidepressant medications. In addition, GAD was found in 40% of participants with PTSD, resulting in more severe symptoms and impairment than in patients with GAD alone. These findings provide evidence of high prevalence and severe impairment associated with GAD in veterans and highlight the need for improved recognition, assessment, and treatments for GAD. (c) 2013 Elsevier Ireland Ltd. All rights reserved. C1 [Milanak, Melissa E.; Gros, Daniel F.; Magruder, Kathryn M.; Brawman-Mintzer, Olga] Med Univ S Carolina, Charleston, SC 29403 USA. [Gros, Daniel F.; Magruder, Kathryn M.; Brawman-Mintzer, Olga] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Frueh, B. Christopher] Univ Hawaii, Dept Psychol, Hilo, HI 96720 USA. [Frueh, B. Christopher] Menninger Clin, Houston, TX USA. RP Milanak, ME (reprint author), Med Univ S Carolina, Natl Crime Victims Ctr, 67 President St, Charleston, SC 29403 USA. EM milanak@musc.edu FU Veterans Affairs Health Services Research and Development [VCR-99-010-2] FX This work was partially supported by a grant from Veterans Affairs Health Services Research and Development (VCR-99-010-2). NR 36 TC 11 Z9 11 U1 3 U2 9 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD SEP 30 PY 2013 VL 209 IS 2 BP 173 EP 179 DI 10.1016/j.psychres.2013.03.031 PG 7 WC Psychiatry SC Psychiatry GA 223GA UT WOS:000324791500008 PM 23659756 ER PT J AU Chao, L Weiner, M Neylan, T AF Chao, Linda Weiner, Michael Neylan, Thomas TI Regional cerebral volumes in veterans with current versus remitted posttraumatic stress disorder SO PSYCHIATRY RESEARCH-NEUROIMAGING LA English DT Article DE Posttraumatic stress disorder; Magnetic resonance imaging; Hippocampus; Anterior cingulate; Insula ID SURFACE-BASED ANALYSIS; HIPPOCAMPAL VOLUME; GRAY-MATTER; AMYGDALA VOLUME; BRAIN VOLUME; GULF-WAR; CHILDHOOD MALTREATMENT; ANOREXIA-NERVOSA; DENTATE GYRUS; SEXUAL-ABUSE AB We previously reported that hippocampal volume was associated with current, but not lifetime posttraumatic stress disorder (PTSD) symptom severity. In the present study, we test the hypothesis that like the hippocampus, the volumes of other brain regions previously implicated in PTSD, are also negatively related to current, but not lifetime PTSD symptom severity. One hundred ninety-one veterans underwent structural magnetic resonance imaging (MRI) on a 4 T scanner. Seventy-five veterans were trauma unexposed, 43 were trauma exposed without PTSD, 39 were trauma exposed with current PTSD, and 34 were trauma exposed veterans with remitted PTSD. Hippocampal, amygdala, rostral and caudal anterior cingulate, insula, and corpus callosum volumes, quantified with Freesurfer version 4.5, were analyzed by group using multivariate analysis of covariance. Veterans with PTSD had smaller hippocampal, caudal anterior cingulate, insula, and corpus callosum volumes than the unexposed controls (p <= 0.009); smaller hippocampal, caudal anterior cingulate, insula (p <= 0.009) and marginally smaller corpus callosum (p=0.06) than veterans with remitted PTSD; and smaller hippocampal and caudal anterior cingulate volumes than veterans without PTSD (p <= 0.04). In contrast, there was no significant volume differences between veterans with remitted PTSD compared to those without PTSD or unexposed controls. The finding that current but not lifetime PTSD accounts for the volumes of multiple brain regions suggests that either smaller brain volume is a vulnerability factor that impedes recovery from PTSD or that recovery from PTSD is accompanied by a wide-spread restoration of brain tissue. (C) 2013 Elsevier Ireland Ltd. All rights reserved. C1 [Chao, Linda; Weiner, Michael] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94121 USA. [Chao, Linda; Weiner, Michael] Univ Calif San Francisco, Dept Biomed Imaging, San Francisco, CA 94121 USA. [Chao, Linda; Weiner, Michael; Neylan, Thomas] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. [Chao, Linda; Weiner, Michael] Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA. [Neylan, Thomas] Dept Vet Affairs Med Ctr, Mental Hlth Serv, San Francisco, CA USA. RP Chao, L (reprint author), Univ Calif San Francisco, San Francisco VAMC, Dept Radiol, 4150 Clement St,114M, San Francisco, CA 94121 USA. EM linda.chao@ucsf.edu FU Mental Illness Research and Education Clinical Center of the US Veterans Health Administration, Office of Research and Development, Department of Defense [W81XWH-05-2-0094]; Mental Illness Research and Education Clinical Center of Department of Veterans Affairs VA GWI [B3776] FX This study was supported in part by grants from the Mental Illness Research and Education Clinical Center of the US Veterans Health Administration, Office of Research and Development, Department of Defense (No. W81XWH-05-2-0094), and Department of Veterans Affairs VA GWI (No. B3776). Resources and the use of facilities were provided by the Veterans Administration Medical Center, San Francisco, California. NR 96 TC 19 Z9 21 U1 1 U2 16 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0925-4927 J9 PSYCHIAT RES-NEUROIM JI Psychiatry Res. Neuroimaging PD SEP 30 PY 2013 VL 213 IS 3 BP 193 EP 201 DI 10.1016/j.pscychresns.2013.03.002 PG 9 WC Clinical Neurology; Neuroimaging; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 211TV UT WOS:000323934800003 PM 23816189 ER PT J AU Rao, MN Blackwell, T Redline, S Punjabi, NM Barrett-Connor, E Neylan, TC Stone, KL AF Rao, Madhu N. Blackwell, Terri Redline, Susan Punjabi, Naresh M. Barrett-Connor, Elizabeth Neylan, Thomas C. Stone, Katie L. CA Osteoporotic Fractures Men MrOS St TI Association between Sleep Duration and 24-Hour Urine Free Cortisol in the MrOS Sleep Study SO PLOS ONE LA English DT Article ID SELF-REPORTED SLEEP; OSTEOPOROTIC FRACTURES; DEPRIVATION; ACTIGRAPHY; FREQUENCY; RELEASE; ADULTS; MEN AB Context: Short sleep duration is associated with adverse health outcomes, but the mechanisms involved are unknown. It has been postulated that short sleep duration may elevate cortisol levels, but studies have had conflicting results. It is unclear whether these differing findings may be due to methodological issues, such as assessment of sleep duration. Specifically, objective versus subjective methods of measuring habitual sleep duration may account for the conflicting results found in epidemiological studies. Objective: Our goal was to determine whether habitual sleep duration, measured objectively (by actigraphy) and subjectively (by self-report), was associated with 24-hour urine free cortisol (UFC), a measure of integrated cortisol secretion. Our secondary goal was to determine whether slow wave sleep (SWS, determined by polysomnography) was associated with 24-hour UFC. Design/Setting: Cross sectional study of community dwelling older men. Patients/Participants: 325 men (mean age = 76.6 years, SD = 5.5) from the Portland site of the MrOS Sleep Study, who underwent 24-hour urine collection, polysomnography, actigraphy and sleep questionnaire. Primary Outcome: 24-hour UFC. Results: In this study of community dwelling older men, self-reported sleep duration was inversely related to 24-hour UFC levels. Participants reporting <5 hours of habitual sleep had an adjusted mean 24-hour UFC of 29.8 ug, compared to 28.0 ug in participants reporting >5 to <8 hours of sleep 25.5 ug in those reporting >8 hours of habitual sleep. However, sleep duration determined by actigraphy was not associated with 24-hour UFC in either univariable or multivariable regression models. SWS was not associated with 24-hour UFC. Conclusion: Objectively measured (i.e., actigraphic) sleep duration is not associated with 24-hour UFC in these community dwelling older men. This finding, together with prior studies, suggests that elevated levels of integrated cortisol secretion is not the mechanisms by which short sleep duration leads to adverse health outcomes. C1 [Rao, Madhu N.] Univ Calif San Francisco, Div Endocrinol, San Francisco, CA 94143 USA. [Blackwell, Terri; Stone, Katie L.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Redline, Susan] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Redline, Susan] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. [Punjabi, Naresh M.] Johns Hopkins Univ, Div Pulm & Crit Care Med, Baltimore, MD USA. [Barrett-Connor, Elizabeth] Univ Calif San Diego, Dept Epidemiol, La Jolla, CA 92093 USA. [Neylan, Thomas C.] San Francisco VA Med Ctr, San Francisco, CA USA. [Neylan, Thomas C.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. RP Rao, MN (reprint author), Univ Calif San Francisco, Div Endocrinol, San Francisco, CA 94143 USA. EM Madhu.Rao@ucsf.edu FU National Institutes of Health; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Institute on Aging (NIA); National Cancer Institute (NCI); National Center for Research Resources (NCRR); NIH Roadmap for Medical Research [U01 AR45580, U01 AR45614, U01 AR45632, U01 AR45647, U01 AR45654, U01 AR45583, U01 AG18197, U01-AG027810, UL1 RR024140]; National Heart, Lung, and Blood Institute (NHLBI) [R01 HL071194, R01 HL070848, R01 HL070847, R01 HL070842, R01 HL070841, R01 HL070837, R01 HL070838, R01 HL070839]; NIH Heart, Lung and Blood Institute [K23HL096832] FX The Osteoporotic Fractures in Men (MrOS) Study is supported by National Institutes of Health funding. The following institutes provide support: the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute on Aging (NIA), the National Cancer Institute (NCI), the National Center for Research Resources (NCRR) and NIH Roadmap for Medical Research under the following grant numbers: U01 AR45580, U01 AR45614, U01 AR45632, U01 AR45647, U01 AR45654, U01 AR45583, U01 AG18197, U01-AG027810, and UL1 RR024140. The National Heart, Lung, and Blood Institute (NHLBI) provides funding for the MrOS Sleep ancillary study "Outcomes of Sleep Disorders in Older Men" under the following grant numbers: R01 HL071194, R01 HL070848, R01 HL070847, R01 HL070842, R01 HL070841, R01 HL070837, R01 HL070838, and R01 HL070839. Dr. Rao received funding from the NIH Heart, Lung and Blood Institute (K23HL096832), which also paid for measurement of 24-hour urine free cortisol. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 36 TC 5 Z9 5 U1 1 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 27 PY 2013 VL 8 IS 9 AR e75205 DI 10.1371/journal.pone.0075205 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 228WY UT WOS:000325223900037 PM 24228086 ER PT J AU Le, DE Pascotto, M Leong-Poi, H Sari, I Micari, A Kaul, S AF Le, D. Elizabeth Pascotto, Marco Leong-Poi, Howard Sari, Ibrahim Micari, Antonio Kaul, Sanjiv TI Anti-inflammatory and pro-angiogenic effects of beta blockers in a canine model of chronic ischemic cardiomyopathy: comparison between carvedilol and metoprolol SO BASIC RESEARCH IN CARDIOLOGY LA English DT Article DE Ischemic cardiomyopathy; Beta blockers; Regional flow; Regional function; Cytokines; Angiogenesis ID CHRONIC HEART-FAILURE; LEFT-VENTRICULAR DYSFUNCTION; ACUTE MYOCARDIAL-INFARCTION; HIBERNATING MYOCARDIUM; ADRENERGIC-BLOCKADE; LIPID-PEROXIDATION; OXIDATIVE STRESS; BLOOD-FLOW; INTERLEUKIN-1-BETA; EXERCISE AB There is controversy regarding the superiority of carvedilol (C) over metoprolol (M) in congestive heart failure. We hypothesized that C is superior to M in chronic ischemic cardiomyopathy because of its better anti-inflammatory and pro-angiogenic effects. In order to test our hypothesis we used a chronic canine model of multivessel ischemic cardiomyopathy where myocardial microcatheters were placed from which interstitial fluid was collected over time to measure leukocyte count and cytokine levels. After development of left ventricular dysfunction, the animals were randomized into four groups: sham (n = 7), placebo (n = 8), M (n = 11), and C (n = 10), and followed for 3 months after treatment initiation. Tissue was examined for immunohistochemistry, oxidative stress, and capillary density. At 3 months both rest and stress wall thickening were better in C compared to the other groups. At the end of 3 months of treatment end-systolic wall stress also decreased the most in C. Similarly resting myocardial blood flow (MBF) improved the most in C as did the stress endocardial/epicardial MBF. Myocardial interstitial fluid showed greater attenuation of leukocytosis with C compared to M, which was associated with less fibrosis and oxidative stress. C also had higher IL-10 level and capillary density. In conclusion, in a chronic canine model of multivessel ischemic cardiomyopathy we found 3 months of C treatment resulted in better resting global and regional function as well as better regional function at stress compared to M. These changes were associated with higher myocardial levels of the anti-inflammatory cytokine IL-10 and less myocardial oxidative stress, leukocytosis, and fibrosis. Capillary density and MBF were almost normalized. Thus in the doses used in this study, C appears to be superior to M in a chronic canine model of ischemic cardiomyopathy from beneficial effects on inflammation and angiogenesis. Further studies are required for comparing additional doses of these drugs. C1 [Le, D. Elizabeth] Portland VA Med Ctr, Portland, OR USA. [Le, D. Elizabeth] Knight Cardiovasc Inst, Portland, OR USA. [Le, D. Elizabeth; Kaul, Sanjiv] OHSU, Knight Cardiovasc Inst, Portland, OR 97239 USA. [Pascotto, Marco] Buon Consiglio Fatebenefratelli Hosp, I-80123 Naples, Italy. [Leong-Poi, Howard] Heart & Stroke Fdn Canada, Ottawa, ON, Canada. [Leong-Poi, Howard] Canadian Inst Hlth Res, Ottawa, ON, Canada. [Sari, Ibrahim] Turkish Cardiac Soc, Istanbul, Turkey. [Micari, Antonio] Aventis Fdn, Italian Soc Cardiol, Milan, Italy. RP Kaul, S (reprint author), OHSU, Knight Cardiovasc Inst, UHN62,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM kauls@ohsu.edu FU National Institutes of Health [K-08-HL0742901, R01-HL660346] FX Supported in part by grants from the National Institutes of Health (K-08-HL0742901, D. Elizabeth Le and R01-HL660346, Sanjiv Kaul). The radiolabeled microspheres were provided by Dupont Pharmaceuticals, North Billerica, MA, and the ultrasound equipment was supplied by Philips Ultrasound, Andover, MA. NR 42 TC 14 Z9 16 U1 0 U2 9 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0300-8428 J9 BASIC RES CARDIOL JI Basic Res. Cardiol. PD SEP 27 PY 2013 VL 108 IS 6 AR 384 DI 10.1007/s00395-013-0384-7 PG 13 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 226IL UT WOS:000325028700001 PM 24072434 ER PT J AU Bowling, CB Sharma, P Fox, CS O'Hare, AM Muntner, P AF Bowling, C. Barrett Sharma, Pradeep Fox, Caroline S. O'Hare, Ann M. Muntner, Paul TI Prevalence of Reduced Estimated Glomerular Filtration Rate Among the Oldest Old From 1988-1994 Through 2005-2010 SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter ID CHRONIC KIDNEY-DISEASE; AGE C1 [Bowling, C. Barrett] Vet Affairs Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Atlanta, GA 30033 USA. [Sharma, Pradeep; Muntner, Paul] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL USA. [Fox, Caroline S.] NHLBI, Ctr Populat Studies, Bethesda, MD 20892 USA. [O'Hare, Ann M.] VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA. RP Bowling, CB (reprint author), Atlanta Vet Affairs Med Ctr, 1670 Clairmont Rd 11B, Decatur, GA 30033 USA. EM cbbowli@emory.edu FU CSRD VA [IK2 CX000856]; NHLBI NIH HHS [Y1-HC-8039]; NIA NIH HHS [R03 AG042336, R03AG042336-01] NR 6 TC 14 Z9 14 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD SEP 25 PY 2013 VL 310 IS 12 BP 1284 EP 1286 DI 10.1001/jama.2013.252441 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 222SO UT WOS:000324751800026 PM 24065016 ER PT J AU Berg, AT Baca, CB Loddenkemper, T Vickrey, BG Dlugos, D AF Berg, Anne T. Baca, Christine B. Loddenkemper, Tobias Vickrey, Barbara G. Dlugos, Dennis TI Priorities in pediatric epilepsy research Improving children's futures today SO NEUROLOGY LA English DT Review ID QUALITY STANDARDS SUBCOMMITTEE; INFANTILE SPASMS; INTRACTABLE EPILEPSY; AMERICAN-ACADEMY; UNITED-STATES; PRACTICE PARAMETER; NEUROLOGY SOCIETY; ONSET EPILEPSY; TEMPORAL-LOBE; CARE AB The Priorities in Pediatric Epilepsy Research workshop was held in the spirit of patient-centered and patient-driven mandates for developing best practices in care, particularly for epilepsy beginning under age 3 years. The workshop brought together parents, representatives of voluntary advocacy organizations, physicians, allied health professionals, researchers, and administrators to identify priority areas for pediatric epilepsy care and research including implementation and testing of interventions designed to improve care processes and outcomes. Priorities highlighted were 1) patient outcomes, especially seizure control but also behavioral, academic, and social functioning; 2) early and accurate diagnosis and optimal treatment; 3) role and involvement of parents (communication and shared decision-making); and 4) integration of school and community organizations with epilepsy care delivery. Key factors influencing pediatric epilepsy care included the child's impairments and seizure presentation, parents, providers, the health care system, and community systems. Care was represented as a sequential process from initial onset of seizures to referral for comprehensive evaluation when needed. We considered an alternative model in which comprehensive care would be utilized from onset, proactively, rather than reactively after pharmacoresistance became obvious. Barriers, including limited levels of evidence about many aspects of diagnosis and management, access to care-particularly epilepsy specialty and behavioral health care-and implementation, were identified. Progress hinges on coordinated research efforts that systematically address gaps in knowledge and overcoming barriers to access and implementation. The stakes are considerable, and the potential benefits for reduced burden of refractory epilepsy and lifelong disabilities may be enormous. C1 [Berg, Anne T.] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA. [Baca, Christine B.; Vickrey, Barbara G.] Epilepsy Ctr, Chicago, IL USA. [Baca, Christine B.; Vickrey, Barbara G.] Northwestern Mem Feinberg Sch Med, Dept Pediat, Chicago, IL USA. [Baca, Christine B.; Vickrey, Barbara G.] Calif State Univ Los Angeles, Dept Neurol, Los Angeles, CA 90032 USA. [Loddenkemper, Tobias] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Loddenkemper, Tobias] Div Epilepsy & Clin Neurophysiol, Los Angeles, CA USA. [Dlugos, Dennis] Harvard Univ, Sch Med, Dept Neurol, Boston Childrens Hosp, Boston, MA 02115 USA. [Dlugos, Dennis] Univ Penn, Pediat Reg Epilepsy Program, Philadelphia, PA 19104 USA. [Dlugos, Dennis] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. [Dlugos, Dennis] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. RP Berg, AT (reprint author), Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA. EM atberg@luriechildrens.org FU Citizens United for Research on Epilepsy (CURE) FX Citizens United for Research on Epilepsy (CURE) provided funding for travel and accommodations for many of the speakers and participants and made possible the meeting summarized in this report. Additional support for the meeting was provided by the Foundation of Ann & Robert H. Lurie Children's Hospital of Chicago. NR 59 TC 14 Z9 14 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD SEP 24 PY 2013 VL 81 IS 13 BP 1166 EP 1175 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA AA0EL UT WOS:000330768000017 PM 23966254 ER PT J AU Singh, JA Lewallen, DG AF Singh, Jasvinder A. Lewallen, David G. TI Patients with osteoarthritis and avascular necrosis have better functional outcomes and those with avascular necrosis worse pain outcomes compared to rheumatoid arthritis after primary hip arthroplasty: a cohort study SO BMC MEDICINE LA English DT Article DE Total hip replacement; Diagnosis; Osteoarthritis; Rheumatoid arthritis; Avascular necrosis; Pain; Function; Arthroplasty; Joint replacement; Patient-reported outcomes; Risk factors ID TOTAL JOINT ARTHROPLASTY; QUALITY-OF-LIFE; KNEE REPLACEMENT SURGERY; FOLLOW-UP; PREDICTORS; RESPONSIVENESS; QUESTIONNAIRE; RESPONSES; RATES; SCORE AB Background: This study was conducted to assess whether patient-reported outcomes (PROs) differ by the underlying diagnosis (rheumatoid arthritis (RA)/inflammatory arthritis, osteoarthritis (OA), avascular necrosis of bone (AVN), other) in patients undergoing primary total hip arthroplasty (THA). Methods: We used prospectively collected data to assess the association of diagnosis with index hip function and pain. Moderate-severe activity limitation and moderate-severe pain were assessed at two-and five-year follow-up after primary THA using multivariable-adjusted logistic regression analyses. Odds ratios (OR) and 95% confidence intervals (CI) were calculated. Results: There were 5,707 primary THAs at two-years and 3,289 at five-years, 51% were women and the mean age was 65 years. The underlying diagnosis was RA in 3%, OA in 87%, AVN in 7% and other in 3%. In multivariable-adjusted analyses, compared to RA, diagnoses of OA and AVN were significantly associated with lower odds of moderate-severe activities of daily living limitations with an OR (95% CI) of 0.5 (0.3 to 0.8) (P = 0.01) and 0.4 (0.2 to 0.8) (P = 0.01), respectively, at two-years, but not at five-years, 0.7 (0.4 to 1.4) (P = 0.36) and 0.9 (0.4 to 1.8) (P = 0.78), respectively. At two-years, neither OA nor AVN were significantly associated with higher odds of moderate-severe pain (1.6 (0.6 to 4.5) (P = 0.40) and 2.8 (0.9 to 8.5) (P = 0 0.06)), respectively. At five-years, AVN was associated with higher odds of moderate-severe pain with OR 4.1 (1.2 to 14.1) (P = 0.02), but not OA, 2.1 (0.7 to 6.5) (P = 0.22). Conclusions: We found that patients with OA and AVN had better functional outcomes and those with AVN worse pain outcomes after primary THA, compared to patients with RA/inflammatory arthritis. Insights into mediators of these relationships are needed to better understand these associations. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Lewallen, David G.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL 35294 USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. EM Jasvinder.md@gmail.com OI singh, jasvinder/0000-0003-3485-0006 FU Mayo Clinic Orthopedic Surgery research funds; National Institutes of Health (NIH) Clinical Translational Science Award [1 KL2 RR024151-01]; Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs); National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS); National Institute of Aging (NIA); National Cancer Institute (NCI) FX This study was supported by research funds from the Mayo Clinic Orthopedic Surgery research funds, National Institutes of Health (NIH) Clinical Translational Science Award 1 KL2 RR024151-01 (Mayo Clinic Center for Clinical and Translational Research) and the resources and use of facilities at the Birmingham VA Medical Center, Alabama, USA. JAS is also supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs), National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS), National Institute of Aging (NIA) and National Cancer Institute (NCI). The funding agencies played no role in the design, collection, analysis, and interpretation of data; in the writing of the manuscript; or in the decision to submit the manuscript for publication. This study was presented as an oral abstract presentation at the 2012 American College of Rheumatology Annual meeting in Washington, DC in November 2012. NR 38 TC 6 Z9 6 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1741-7015 J9 BMC MED JI BMC Med. PD SEP 24 PY 2013 VL 11 AR 210 DI 10.1186/1741-7015-11-210 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 241PO UT WOS:000326179600001 PM 24063410 ER PT J AU Caverly, TJ Prochazka, AV AF Caverly, Tanner J. Prochazka, Allan V. TI General Health Checks in Adults Reply SO JAMA INTERNAL MEDICINE LA English DT Letter C1 [Caverly, Tanner J.] Univ Colorado, Sch Med, Div Gen Internal Med, Aurora, CO USA. [Prochazka, Allan V.] Denver VA Med Ctr, Denver, CO 80200 USA. RP Prochazka, AV (reprint author), Denver VA Med Ctr, 1055 Clermont, Denver, CO 80200 USA. EM Allan.Prochazka@va.gov NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 J9 JAMA INTERN MED JI JAMA Intern. Med. PD SEP 23 PY 2013 VL 173 IS 17 BP 1658 EP 1658 DI 10.1001/jamainternmed.2013.8194 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 228SU UT WOS:000325210600028 PM 24061395 ER PT J AU Kayani, WT Bandeali, SJ Lee, VV Elayda, M Khan, A Nambi, V Jneid, H Alam, M Wilson, JM Huang, HD Birnbaum, Y Ballantyne, CM Virani, SS AF Kayani, Waleed T. Bandeali, Salman J. Lee, Vei-Vei Elayda, MacArthur Khan, Anam Nambi, Vijay Jneid, Hani Alam, Mahboob Wilson, James M. Huang, Henry D. Birnbaum, Yochai Ballantyne, Christie M. Virani, Salim S. TI Association between statins and infections after coronary artery bypass grafting SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Article DE Statins; Infection; Coronary artery bypass grafting ID COMMUNITY-ACQUIRED PNEUMONIA; SURGICAL SITE INFECTIONS; PREOPERATIVE STATIN; CARDIAC-SURGERY; MORTALITY; RISK; THERAPY; INHIBITORS; OUTCOMES; DISEASE AB Background: We determined whether pre-operative statin therapy is associated with a decrease in the incidence of infections after coronary artery bypass grafting (CABG). Methods: A retrospective cohort study of 6253 patients undergoing isolated CABG, from the Texas Heart Institute Database from January 1, 2000 to December 31, 2010 (3869 receiving statins and 2384 not receiving statins) was conducted. Primary outcome was the development of any postoperative infection (composite of deep-sternal wound infection, leg harvest-site infection, pneumonia, or sepsis) after CABG. Secondary outcome was the association between pre-operative statin use and individual incidence of each aforementioned infection. Logistic regression analyses were performed. Results: Incidence of any postoperative infection in patients who received statins pre-operatively was 6.5% compared to 8.3% in patients who did not receive statins. Pre-operative statin therapy was associated with a significant reduction in the primary outcome (odds ratio (OR) 0.74, 95% confidence interval (CI) 0.60-0.90) in adjusted models. Among individual secondary outcomes, pre-operative statin therapy was associated with a reduced incidence of sternal wound infections (2.5% vs. 3.2%, OR 0.6, 95% CI 0.5-0.8) and leg harvest site infections (0.6% vs. 1.3%, OR 0.46, 95% CI 0.2-0.8). Pre-operative statin therapy was not associated with a reduced incidence of pneumonia or sepsis. Conclusion: Pre-operative statin use is associated with a decrease in overall incidence of post-operative infections after CABG. We propose immunomodulatory effects of statins leading to a dampening of inflammatory cascade as the cause of our findings. (C) 2012 Elsevier Ireland Ltd. All rights reserved. C1 [Kayani, Waleed T.; Bandeali, Salman J.; Nambi, Vijay; Jneid, Hani; Birnbaum, Yochai; Ballantyne, Christie M.; Virani, Salim S.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Virani, Salim S.] Hlth Serv Res & Dev Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Hlth Policy & Qual Program, Houston, TX USA. [Lee, Vei-Vei; Elayda, MacArthur] St Lukes Episcopal Hosp, Texas Heart Inst, Dept Epidemiol & Biostat, Houston, TX USA. [Nambi, Vijay; Ballantyne, Christie M.; Virani, Salim S.] Baylor Coll Med, Sect Cardiovasc Res, Houston, TX 77030 USA. [Nambi, Vijay; Ballantyne, Christie M.; Virani, Salim S.] Methodist DeBakey Heart & Vasc Ctr, Ctr Cardiovasc Dis Prevent, Houston, TX USA. [Virani, Salim S.] Michael E DeBakey VA Med Ctr, Cardiol Sect, Houston, TX USA. [Alam, Mahboob] Memphis Vet Affairs Med Ctr, Cardiol Sect, Memphis, TN USA. [Wilson, James M.] St Lukes Episcopal Hosp, Texas Heart Inst, Dept Cardiol, Houston, TX USA. [Nambi, Vijay; Jneid, Hani; Huang, Henry D.; Birnbaum, Yochai; Ballantyne, Christie M.; Virani, Salim S.] Baylor Coll Med, Dept Med, Cardiol Sect, Houston, TX 77030 USA. [Khan, Anam] Aga Khan Univ, Karachi, Pakistan. RP Kayani, WT (reprint author), Baylor Coll Med, Dept Med, 1 Baylor Plaza, Houston, TX 77030 USA. EM kayani@bcm.edu OI Virani, Salim/0000-0001-9541-6954 FU Department of Veterans Affairs Health Services Research and Development Service (HSR&D) Career Development Award [CDA-09-028]; Abbott; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Genentech; Kowa; Merck; Novartis; Roche; Sanofi-Synthelabo; Takeda; NIH; ADA; AHA; Anthera Pharmaceuticals Research collaboration GE; Medipattern; Tomtec FX Vijay Nambi: disclosures-National monitor, study sponsored by Anthera Pharmaceuticals Research collaboration GE, Medipattern, Tomtec.; Christie M Ballantyne: grant/research support (all paid to institution, not individual): Abbott, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Genentech, Kowa, Merck, Novartis, Roche, Sanofi-Synthelabo, Takeda, NIH, ADA, AHA.; Salim S. Virani: Dr. Virani is supported by a Department of Veterans Affairs Health Services Research and Development Service (HSR&D) Career Development Award (grant number: CDA-09-028). NR 37 TC 11 Z9 13 U1 0 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-5273 EI 1874-1754 J9 INT J CARDIOL JI Int. J. Cardiol. PD SEP 20 PY 2013 VL 168 IS 1 BP 117 EP 120 DI 10.1016/j.ijcard.2012.09.060 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 231IL UT WOS:000325409800032 PM 23046597 ER PT J AU Wiechers, IR Perin, NC Cook-Deegan, R AF Wiechers, Ilse R. Perin, Noah C. Cook-Deegan, Robert TI The emergence of commercial genomics: analysis of the rise of a biotechnology subsector during the Human Genome Project, 1990 to 2004 SO GENOME MEDICINE LA English DT Article AB Background: Development of the commercial genomics sector within the biotechnology industry relied heavily on the scientific commons, public funding, and technology transfer between academic and industrial research. This study tracks financial and intellectual property data on genomics firms from 1990 through 2004, thus following these firms as they emerged in the era of the Human Genome Project and through the 2000 to 2001 market bubble. Methods: A database was created based on an early survey of genomics firms, which was expanded using three web-based biotechnology services, scientific journals, and biotechnology trade and technical publications. Financial data for publicly traded firms was collected through the use of four databases specializing in firm financials. Patent searches were conducted using firm names in the US Patent and Trademark Office website search engine and the DNA Patent Database. Results: A biotechnology subsector of genomics firms emerged in parallel to the publicly funded Human Genome Project. Trends among top firms show that hiring, capital improvement, and research and development expenditures continued to grow after a 2000 to 2001 bubble. The majority of firms are small businesses with great diversity in type of research and development, products, and services provided. Over half the public firms holding patents have the majority of their intellectual property portfolio in DNA-based patents. Conclusions: These data allow estimates of investment, research and development expenditures, and jobs that paralleled the rise of genomics as a sector within biotechnology between 1990 and 2004. C1 [Wiechers, Ilse R.; Perin, Noah C.; Cook-Deegan, Robert] Duke Univ, Inst Genome Sci & Policy, Ctr Publ Genom, Durham, NC 27708 USA. [Cook-Deegan, Robert] Duke Univ, Sanford Sch Publ Policy, Durham, NC 27708 USA. [Wiechers, Ilse R.] Yale Univ, Sch Med, Johnson Fdn Clin Scholars Program, New Haven, CT 06520 USA. [Wiechers, Ilse R.] US Dept Vet Affairs, New Haven, CT 06520 USA. RP Wiechers, IR (reprint author), Duke Univ, Inst Genome Sci & Policy, Ctr Publ Genom, Box 90141, Durham, NC 27708 USA. EM ilse.wiechers@yale.edu OI Cook-Deegan, Robert/0000-0002-8251-4237 FU Ewing Marion Kauffman Foundation; US Department of Energy [P50 HG003391]; Duke Endowment; National Human Genome Research Institute FX This work was supported in part by grants from the Ewing Marion Kauffman Foundation, the National Human Genome Research Institute and US Department of Energy (P50 HG003391) and the Duke Endowment. The views do not necessarily represent those of the funders. The authors would like to thank the following students and research assistants at the Center for Genome Ethics, Law & Policy whose countless hours of data gathering and entry were invaluable: Phebe Ko, Suparna Salil, Whitney Laemmli, Joe Fore, Alessandra Colaianni, Daidree Tofano, Molly Nicholson, Stacy Lavin, Britt Russert, Marjorie Gurganus, Anupama Kotha, and Cindy Wang. NR 19 TC 1 Z9 1 U1 2 U2 20 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-994X J9 GENOME MED JI Genome Med. PD SEP 20 PY 2013 VL 5 AR 83 DI 10.1186/gm487 PG 9 WC Genetics & Heredity SC Genetics & Heredity GA 230GD UT WOS:000325324000001 PM 24050173 ER PT J AU Leentjens, AFG Moonen, AJH Dujardin, K Marsh, L Martinez-Martin, P Richard, IH Starkstein, SE Kohler, S AF Leentjens, Albert F. G. Moonen, Anja J. H. Dujardin, Kathy Marsh, Laura Martinez-Martin, Pablo Richard, Irene H. Starkstein, Sergio E. Kohler, Sebastian TI Modeling depression in Parkinson disease Disease-specific and nonspecific risk factors SO NEUROLOGY LA English DT Article ID QUALITY-OF-LIFE; RATING-SCALES; ANXIETY; RECOMMENDATIONS; PREVALENCE; VALIDATION; DEMENTIA; MARKERS; MINI AB Objective: To construct a model for depression in Parkinson disease (PD) and to study the relative contribution of PD-specific and nonspecific risk factors to this model. Methods: Structural equation modeling of direct and indirect associations of risk factors with the latent depression outcome using a cross-sectional dataset of 342 patients with PD. Results: A model with acceptable fit was generated that explained 41% of the variance in depression. In the final model, 3 PD-specific variables (increased disease duration, more severe motor symptoms, the use of levodopa) and 6 nonspecific variables (female sex, history of anxiety and/or depression, family history of depression, worse functioning on activities of daily living, and worse cognitive status) were maintained and significantly associated with depression. Nonspecific risk factors had a 3-times-higher influence in the model than PD-specific risk factors. Conclusion: In this cross-sectional study, we showed that nonspecific factors may be more prominent markers of depression than PD-specific factors. Accordingly, research on depression in PD should focus not only on factors associated with or specific for PD, but should also examine a wider scope of factors including general risk factors for depression, not specific for PD. C1 [Leentjens, Albert F. G.; Moonen, Anja J. H.] Maastricht Univ, Med Ctr, Dept Psychiat, Maastricht, Netherlands. [Leentjens, Albert F. G.; Moonen, Anja J. H.; Kohler, Sebastian] Maastricht Univ, Sch Mental Hlth & Neurosci, Maastricht, Netherlands. [Dujardin, Kathy] Univ Lille, Med Ctr, Neurol & Movement Disorders Unit, Lille, France. [Marsh, Laura] Michael E DeBakey Vet Adm Med Ctr, Houston, TX USA. [Marsh, Laura] Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA. [Marsh, Laura] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. [Martinez-Martin, Pablo] Carlos III Inst Hlth, Alzheimer Ctr Reina Sofia Fdn, Alzheimer Dis Res Unit, Madrid, Spain. [Martinez-Martin, Pablo] Carlos III Inst Hlth, Alzheimer Ctr Reina Sofia Fdn, CIBERNED, Madrid, Spain. [Richard, Irene H.] Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA. [Richard, Irene H.] Univ Rochester, Sch Med & Dent, Dept Psychiat, Rochester, NY 14642 USA. [Starkstein, Sergio E.] Univ Western Australia, Sch Psychiat, Fremantle, WA, Australia. [Starkstein, Sergio E.] Fremantle Hosp, Fremantle, WA, Australia. RP Leentjens, AFG (reprint author), Maastricht Univ, Med Ctr, Dept Psychiat, Maastricht, Netherlands. EM a.leentjens@maastrichtuniversity.nl FU Michael J. Fox Foundation for Parkinson's Research FX This study did not receive any funding. The study on which database this analysis was performed received funding from the Michael J. Fox Foundation for Parkinson's Research. NR 32 TC 12 Z9 13 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD SEP 17 PY 2013 VL 81 IS 12 BP 1036 EP 1043 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA AA0EK UT WOS:000330767900007 PM 23946309 ER PT J AU Neve, KA Ford, CP Buck, DC Grandy, DK Neve, RL Phillips, TJ AF Neve, K. A. Ford, C. P. Buck, D. C. Grandy, D. K. Neve, R. L. Phillips, T. J. TI NORMALIZING DOPAMINE D2 RECEPTOR-MEDIATED RESPONSES IN D2 NULL MUTANT MICE BY VIRUS-MEDIATED RECEPTOR RESTORATION: COMPARING D2(L) AND D2(S) SO NEUROSCIENCE LA English DT Article DE dopamine D2 receptor; methamphetamine; D2 receptor null mutant mouse; potassium channel ID DEFICIENT MICE; AUTORECEPTOR FUNCTION; D2-DOPAMINE RECEPTOR; IN-VIVO; ISOFORMS; NEURONS; EXPRESSION; METHAMPHETAMINE; STIMULATION; FORMS AB D2 receptor null mutant (Drd2(-/-)) mice have altered responses to the rewarding and locomotor effects of psychostimulant drugs, which is evidence of a necessary role for D2 receptors in these behaviors. Furthermore, work with mice that constitutively express only the D2 receptor short form (D2(S)), as a result of genetic deletion of the long form (D2(L)), provides the basis for a current model in which D2(L) is thought to be the postsynaptic D2 receptor on medium spiny neurons in the basal forebrain, and D2(S) the autoreceptor that regulates the activity of dopamine neurons and dopamine synthesis and release. Because constitutive genetic deletion of the D2 or D2(L) receptor may cause compensatory changes that influence functional outcomes, our approach is to identify aspects of the abnormal phenotype of a Drd2(-/-) mouse that can be normalized by virus-mediated D2 receptor expression. Drd2(-/-) mice are deficient in basal and methamphetamine-induced locomotor activation and lack D2 receptor agonist-induced activation of G protein-regulated inward rectifying potassium channels (GIRKs) in dopaminergic neurons. Here we show that virus-mediated expression of D2(L) in the nucleus accumbens significantly restored methamphetamine-induced locomotor activation, but not basal locomotor activity, compared to mice receiving the control virus. It also restored the effect of methamphetamine to decrease time spent in the center of the activity chamber in female but not male Drd2(-/-) mice. Furthermore, the effect of expression of D2(S) was indistinguishable from D2(L). Similarly, virus-mediated expression of either D2(S) or D2(L) in substantia nigra neurons restored D2 agonist-induced activation of GIRKs. In this acute expression system, the alternatively spliced forms of the D2 receptor appear to be equally capable of acting as postsynaptic receptors and autoreceptors. Published by Elsevier Ltd. on behalf of IBRO. C1 [Neve, K. A.; Buck, D. C.; Phillips, T. J.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Res Serv, Portland, OR 97239 USA. [Neve, K. A.; Buck, D. C.; Phillips, T. J.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. [Neve, K. A.; Buck, D. C.; Phillips, T. J.] Oregon Hlth & Sci Univ, Methamphetamine Abuse Res Ctr, Portland, OR 97239 USA. [Ford, C. P.] Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA. [Grandy, D. K.] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA. [Neve, R. L.] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA. RP Neve, KA (reprint author), VA Med Ctr, Res Serv R&D 30, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM nevek@ohsu.edu; cpf21@case.edu; buckd@ohsu.edu; grandyd@ohsu.edu; rneve@MIT.EDU; phillipt@ohsu.edu FU NIH [MH045372, DA018165, DA026416]; VA Merit Review program; Career Scientist program FX This work was support by NIH Grants MH045372, DA018165, and DA026416, and the VA Merit Review and Career Scientist programs. NR 33 TC 7 Z9 7 U1 0 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 EI 1873-7544 J9 NEUROSCIENCE JI Neuroscience PD SEP 17 PY 2013 VL 248 BP 479 EP 487 DI 10.1016/j.neuroscience.2013.06.035 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 299UV UT WOS:000330422100044 PM 23811070 ER PT J AU Humphrey, LL Deffebach, M Pappas, M Baumann, C Artis, K Mitchell, JP Zakher, B Fu, RW Slatore, CG AF Humphrey, Linda L. Deffebach, Mark Pappas, Miranda Baumann, Christina Artis, Kathryn Mitchell, Jennifer Priest Zakher, Bernadette Fu, Rongwei Slatore, Christopher G. TI Screening for Lung Cancer With Low-Dose Computed Tomography: A Systematic Review to Update the U. S. Preventive Services Task Force Recommendation SO ANNALS OF INTERNAL MEDICINE LA English DT Review ID 2-YEAR FOLLOW-UP; SMOKING-CESSATION; SPIRAL CT; RANDOMIZED FEASIBILITY; CUMULATIVE INCIDENCE; CHEST RADIOGRAPH; FORMER SMOKERS; ITALUNG TRIAL; DANTE TRIAL; RISK AB Background: Lung cancer is the leading cause of cancer-related death in the United States. Because early-stage lung cancer is associated with lower mortality than late-stage disease, early detection and treatment may be beneficial. Purpose: To update the 2004 review of screening for lung cancer for the U.S. Preventive Services Task Force, focusing on screening with low-dose computed tomography (LDCT). Data Sources: MEDLINE (2000 to 31 May 2013), the Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews (through the fourth quarter of 2012), Scopus, and reference lists. Study Selection: English-language randomized, controlled trials or cohort studies that evaluated LDCT screening for lung cancer. Data Extraction: One reviewer extracted study data about participants, design, analysis, follow-up, and results, and a second reviewer checked extractions. Two reviewers rated study quality using established criteria. Data Synthesis: Four trials reported results of LDCT screening among patients with smoking exposure. One large good-quality trial reported that screening was associated with significant reductions in lung cancer (20%) and all-cause (6.7%) mortality. Three small European trials showed no benefit of screening. Harms included radiation exposure, overdiagnosis, and a high rate of falsepositive findings that typically were resolved with further imaging. Smoking cessation was not affected. Incidental findings were common. Limitations: Three trials were underpowered and of insufficient duration to evaluate screening effectiveness. Overdiagnosis, an important harm of screening, is of uncertain magnitude. No studies reported results in women or minority populations. Conclusion: Strong evidence shows that LDCT screening can reduce lung cancer and all-cause mortality. The harms associated with screening must be balanced with the benefits. C1 Oregon Hlth & Sci Univ, Pacific Northwest Evidence Based Practice Ctr, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR USA. RP Humphrey, LL (reprint author), Oregon Hlth & Sci Univ, Mailcode BICC, Pacific Northwest Evidence Based Practice Ctr, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM linda.humphrey@va.gov OI Slatore, Christopher/0000-0003-0958-8122 FU AHRQ [HHSA-290-2007-10057-IEPC3]; Portland Veterans Affairs Medical Center; Veterans Affairs Health Services Research and Development Career Development Award FX By AHRQ under contract HHSA-290-2007-10057-IEPC3, task order 13, and the Portland Veterans Affairs Medical Center. Drs. Humphrey, Deffebach, and Slatore are supported by resources from the Portland Veterans Affairs Medical Center. Dr. Slatore is sponsored by a Veterans Affairs Health Services Research and Development Career Development Award. NR 100 TC 161 Z9 167 U1 2 U2 22 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD SEP 17 PY 2013 VL 159 IS 6 BP 411 EP + DI 10.7326/0003-4819-159-6-201309170-00690 PG 18 WC Medicine, General & Internal SC General & Internal Medicine GA 234EY UT WOS:000325625900017 PM 23897166 ER PT J AU Vengust, M Staempfli, H Viel, L Swenson, ER Heigenhauser, G AF Vengust, Modest Staempfli, Henry Viel, Laurent Swenson, Erik R. Heigenhauser, George TI Acetazolamide attenuates transvascular fluid flux in equine lungs during intense exercise SO JOURNAL OF PHYSIOLOGY-LONDON LA English DT Article ID CARBONIC-ANHYDRASE INHIBITION; PULMONARY VASCULAR-RESISTANCE; HUMAN ERYTHROCYTE-MEMBRANE; RED-CELL MEMBRANE; ACID-BASE CONTROL; MAXIMAL EXERCISE; HEAVY EXERCISE; GAS-EXCHANGE; WATER PERMEABILITY; CAPILLARY-PRESSURE AB During intense exercise in horses the transvascular fluid flux in the pulmonary circulation (J(v-a)) represents 4% of cardiac output . This fluid flux has been attributed to an increase in pulmonary transmural hydrostatic forces, increases in perfused microvascular surface area, and reversible alterations in capillary permeability under conditions of high flow and pressure. Erythrocyte fluid efflux, however, accounts for a significant fraction of J(v-a). In the lung the Jacobs-Stewart cycle occurs with diffusion of CO2 into alveolar space with possible accompanying chloride (Cl-) and water movement from the erythrocyte directly into the pulmonary interstitium. We hypothesised that inhibition of carbonic anhydrase in erythrocytes inhibits the Jacobs-Stewart cycle and attenuates J(v-a). Five horses were exercised on a treadmill until fatigue without (control) and with acetazolamide treatment (30 mg kg(-1) 30 min before exercise). Erythrocyte fluid efflux, plasma fluid flux across the lung and J(v-a) were calculated using haemoglobin, haematocrit, plasma protein and Q. Fluid fluxes were used to calculate erythrocyte, plasma and whole blood Cl- fluxes across the lung. Cardiac output was not different between control and acetazolamide treatment. During exercise erythrocyte fluid efflux and J(v-a) increased in control (9.3 +/- 3.3 and 11.0 +/- 4.4 l min(-1), respectively) and was higher than after acetazolamide treatment (3.8 +/- 1.6 and 1.2 +/- 1.2 l min(-1), respectively) (P < 0.05). Plasma fluid flux did not change from rest in control and decreased after acetazolamide treatment (-4.5 +/- 1.5 l min(-1)) (P < 0.05). Erythrocyte Cl- flux increased during exercise in control and after acetazolamide treatment (P < 0.05). During exercise plasma Cl- flux across the lung did not change in control; however, it increased with acetazolamide treatment (P= 0.0001). During exercise whole blood Cl- flux increased across the lung in control (P < 0.05) but not after acetazolamide treatment. The results indicate that J(v-a) in the lung is dependent on the Jacobs-Stewart cycle and mostly independent of transmural hydrostatic forces. It also appears that J(v-a) is mediated by Cl- and water egress from erythrocytes directly into the interstitium without transit through plasma. C1 [Vengust, Modest] Univ Ljubljana, Fac Vet, SI-1115 Ljubljana, Slovenia. [Vengust, Modest; Viel, Laurent] Univ Guelph, Firestone Equine Resp Res Lab, Guelph, ON N1G 2W1, Canada. [Staempfli, Henry; Viel, Laurent] Univ Guelph, Dept Clin Studies, Guelph, ON N1G 2W1, Canada. [Swenson, Erik R.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Heigenhauser, George] McMaster Univ, Dept Med, Med Ctr, Hamilton, ON L8N 3Z5, Canada. RP Vengust, M (reprint author), Univ Ljubljana, Fac Vet, POB 3425, SI-1115 Ljubljana, Slovenia. EM modest.vengust@vf.uni-lj.si FU Ontario Ministry of Agriculture and Food - Equine Program; Department of Clinical Studies at the University of Guelph; Canadian Institutes of Health Research; Slovenian Research Agency [P4-0053] FX This study was supported by the Ontario Ministry of Agriculture and Food - Equine Program, Department of Clinical Studies at the University of Guelph, Canadian Institutes of Health Research and the Slovenian Research Agency grant P4-0053. NR 62 TC 1 Z9 1 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3751 EI 1469-7793 J9 J PHYSIOL-LONDON JI J. Physiol.-London PD SEP 15 PY 2013 VL 591 IS 18 BP 4499 EP 4513 DI 10.1113/jphysiol.2013.257956 PG 15 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 219AU UT WOS:000324476900020 PM 23818694 ER PT J AU Schoneburg, B Mancini, M Horak, F Nutt, JG AF Schoneburg, Bernadette Mancini, Martina Horak, Fay Nutt, John G. TI Framework for Understanding Balance Dysfunction in Parkinson's Disease SO MOVEMENT DISORDERS LA English DT Review DE balance; gait; posture; Parkinson's disease ID DEEP BRAIN-STIMULATION; ANTICIPATORY POSTURAL ADJUSTMENTS; SUBTHALAMIC NUCLEUS; STEP INITIATION; DUAL TASKING; GAIT VARIABILITY; STOOPED POSTURE; OLDER-ADULTS; SWAY; LEVODOPA AB People with Parkinson's disease (PD) suffer from progressive impairment in their mobility. Locomotor and balance dysfunction that impairs mobility in PD is an important cause of physical and psychosocial disability. The recognition and evaluation of balance dysfunction by the clinician are an essential component of managing PD. In this review, we describe a framework for understanding balance dysfunction in PD to help clinicians recognize patients who are at risk for falling and impaired mobility. (c) 2013 International Parkinson and Movement Disorder Society C1 [Schoneburg, Bernadette; Mancini, Martina; Horak, Fay; Nutt, John G.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Schoneburg, Bernadette; Nutt, John G.] Portland VA Med Ctr, Portland, OR USA. RP Nutt, JG (reprint author), Parkinson Ctr Oregon, 3181 SW Sam Jackson Pk Rd W OP32, Portland, OR 97239 USA. EM nuttj@ohsu.edu FU PADRECC fellowship; National Institute of Aging; National Parkinson Foundation; National Institute of Neurological Disorders and Stroke; Ceregene FX This study has support from a PADRECC fellowship, the National Institute of Aging, the National Parkinson Foundation, the National Institute of Neurological Disorders and Stroke, and Ceregene. NR 96 TC 36 Z9 36 U1 6 U2 35 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD SEP 15 PY 2013 VL 28 IS 11 SI SI BP 1474 EP 1482 DI 10.1002/mds.25613 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 238VI UT WOS:000325979100002 PM 23925954 ER PT J AU Luo, JH Rossouw, J Tong, E Giovino, GA Lee, CC Chen, C Ockene, JK Qi, LH Margolis, KL AF Luo, Juhua Rossouw, Jacques Tong, Elisa Giovino, Gary A. Lee, Cathy C. Chen, Chu Ockene, Judith K. Qi, Lihong Margolis, Karen L. TI Smoking and Diabetes: Does the Increased Risk Ever Go Away? SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE risk factors; smoking; smoking cessation; type 2 diabetes ID BASE-LINE CHARACTERISTICS; MIDDLE-AGED MEN; CIGARETTE-SMOKING; UNITED-STATES; WEIGHT-GAIN; INSULIN-RESISTANCE; CESSATION; MELLITUS; PARTICIPANTS; HAZARDS AB Recent studies reported that smoking cessation leads to higher short-term risk of type 2 diabetes than continuing to smoke. However, the duration of increased diabetes risk following smoking cessation needs further investigation. We followed 135,906 postmenopausal women aged 50-79 years enrolled in the Women's Health Initiative between September 1, 1993, and December 31, 1998, over an average of 11 years to examine the association between smoking cessation and risk of diabetes using Cox proportional hazard multivariable-adjusted regression models. Compared with that for never smokers, the risk for diabetes was significantly elevated in current smokers (hazard ratio = 1.28, 95% confidence interval: 1.20, 1.36) but was even higher in women who quit smoking during the first 3 years of follow-up (hazard ratio = 1.43, 95% confidence interval: 1.26, 1.63). Among former smokers, the risk of diabetes decreased significantly as the time since quitting increased and was equal to that of never smokers following a cessation period of 10 years. In new quitters with low cumulative exposure (<20 pack-years), diabetes risk was not elevated following smoking cessation. In conclusion, the risk of diabetes in former smokers returns to that in never smokers 10 years after quitting, and even more quickly in lighter smokers. C1 [Luo, Juhua] W Virginia Univ, Dept Community Med, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA. [Rossouw, Jacques] NHLBI, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA. [Tong, Elisa] Univ Calif Davis, Med Ctr, Div Gen Internal Med, Sacramento, CA 95817 USA. [Giovino, Gary A.] SUNY Buffalo, Dept Community Hlth & Hlth Behav, Sch Publ Hlth & Hlth Profess, Buffalo, NY 14260 USA. [Lee, Cathy C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Internal Med, Div Geriatr, Los Angeles, CA 90095 USA. [Lee, Cathy C.] Vet Affairs Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, Los Angeles, CA USA. [Chen, Chu] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA. [Ockene, Judith K.] Univ Massachusetts, Sch Med, Dept Med, Div Prevent & Behav Med, Worcester, MA USA. [Qi, Lihong] Univ Calif Davis, Div Biostat, Dept Publ Hlth Sci, Sch Med, Davis, CA 95616 USA. [Margolis, Karen L.] HealthPartners Res Fdn, Minneapolis, MN USA. RP Luo, JH (reprint author), Indiana Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, 1025 East 7th St, Bloomington, IN 47405 USA. EM juhluo@indiana.edu FU National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services [N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, 44221]; [HHSN268201100003C] FX The Women's Health Initiative program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services, through contracts N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, and 44221, and by HHSN268201100003C. NR 41 TC 12 Z9 12 U1 2 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD SEP 15 PY 2013 VL 178 IS 6 BP 937 EP 945 DI 10.1093/aje/kwt071 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 227YC UT WOS:000325150600016 PM 23817918 ER PT J AU Bratcher, PE Gaggar, A AF Bratcher, Preston E. Gaggar, Amit TI Characterization and Prevention of the Adsorption of Surfactant Protein D to Polypropylene SO PLOS ONE LA English DT Article ID LUNG AB Surfactant Protein D (SP-D) is a multifunctional protein present in the lung and in respiratory secretions. In the process of developing new experimental approaches to examine SP-D function, we observed that SP-D adsorbs to polypropylene tubes to a great extent, thereby depleting SP-D from the solution. Although it is well known that proteins adsorb nonspecifically to plastic, this effect is usually diminished by treatments to make the plastic "low-retention" or "low-binding". However, these treatments actually increased the binding of SP-D to the plastic. In addition, this adsorption affected the results of several assays, including proteolytic cleavage assays. In order to block SP-D from adsorbing to polypropylene and the effects caused by this adsorption, we coated the tubes with bovine serum albumin (BSA), as is commonly performed for ELISAs. This coating greatly diminished the amount of SP-D sticking to the plastic, providing an inexpensive and effective method for preventing adsorption and the artifacts resulting from this adsorption. C1 [Bratcher, Preston E.; Gaggar, Amit] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Gaggar, Amit] Univ Alabama Birmingham, Gregory Fleming James Cyst Fibrosis Res Ctr, Birmingham, AL 35294 USA. [Gaggar, Amit] Univ Alabama Birmingham, Lung Hlth Ctr, Birmingham, AL 35294 USA. [Gaggar, Amit] Med Serv, US Dept Vet Affairs, Med Ctr, Birmingham, AL USA. RP Bratcher, PE (reprint author), Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. EM bratcher@uab.edu FU National Institutes of Health [HL102371, 5T32HL105346-02]; Cystic Fibrosis Foundation [GAGGAR07] FX This work is supported by the National Institutes of Health (HL102371 to AG, 5T32HL105346-02 to PEB) and the Cystic Fibrosis Foundation (GAGGAR07 to AG). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 11 TC 5 Z9 5 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 11 PY 2013 VL 8 IS 9 AR e73467 DI 10.1371/journal.pone.0073467 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 248VW UT WOS:000326734500034 PM 24039953 ER PT J AU Venkatasubbarao, K Peterson, L Zhao, SJ Hill, P Cao, L Zhou, Q Nawrocki, ST Freeman, JW AF Venkatasubbarao, Kolaparthi Peterson, Lindsay Zhao, Shujie Hill, Ping Cao, Lin Zhou, Qing Nawrocki, Steffan T. Freeman, James W. TI Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer SO MOLECULAR CANCER LA English DT Article DE Pancreatic cancer; STAT3; EGFR inhibitor; Cancer therapy ID GROWTH-FACTOR RECEPTOR; CELL-LINE; STAT3; CARCINOMA; APOPTOSIS; SURVIVAL; THERAPY; PATHWAY; ADENOCARCINOMA; CHEMOTHERAPY AB Background: Among the solid tumors, human pancreatic ductal adenocarcinoma (PDAC) has the worst prognosis. Gemcitabine is the standard first line of therapy for pancreatic cancer but has limited efficacy due to inherent or rapid development of resistance and combining EGFR inhibitors with this regimen results in only a modest clinical benefit. The goal of this study was to identify molecular targets that are activated during gemcitabine therapy alone or in combination with an EGFR inhibitor. Methods: PDAC cell lines were used to determine molecular changes and rates of growth after treatment with gemcitabine or an EGFR inhibitor, AG1478, by Western blot analysis and MTT assays respectively. Flow cytometric analysis was performed to study the cell cycle progression and rate of apoptosis after gemcitabine treatment. ShRNA was used to knockdown STAT3. An in vivo orthotopic animal model was used to evaluate STAT3 as a target. Immunohistochemical analysis was performed to analyze Ki67 and STAT3 expression in tumors. Results: Treatment with gemcitabine increased the levels of EGFR(Tyr1068) and ERK phosphorylation in the PDAC cell lines tested. The constitutive STAT3(Tyr705) phosphorylation observed in PDAC cell lines was not altered by treatment with gemcitabine. Treatment of cells with gemcitabine or AG1478 resulted in differential rate of growth inhibition. AG1478 efficiently blocked the phosphorylation of EGFR(Tyr1068) and inhibited the phosphorylation of down-stream effectors AKT and ERKs, while STAT3(Tyr705) phosphorylation remained unchanged. Combining these two agents neither induced synergistic growth suppression nor inhibited STAT3(Tyr705) phosphorylation, thus prompting further studies to assess whether targeting STAT3 improves the response to gemcitabine or AG1478. Indeed, knockdown of STAT3 increased sensitivity to gemcitabine by inducing pro-apoptotic signals and by increasing G1 cell cycle arrest. However, knockdown of STAT3 did not enhance the growth inhibitory potential of AG1478. In vivo orthotopic animal model results show that knockdown of STAT3 caused a significant reduction in tumor burden and delayed tumor progression with increased response to gemcitabine associated with a decrease in the Ki-67 positive cells. Conclusions: This study suggests that STAT3 should be considered an important molecular target for therapy of PDAC for enhancing the response to gemcitabine. C1 [Venkatasubbarao, Kolaparthi; Peterson, Lindsay; Zhao, Shujie; Hill, Ping; Cao, Lin; Zhou, Qing; Nawrocki, Steffan T.; Freeman, James W.] Univ Texas San Antonio, Hlth Sci Ctr, Div Hematol & Oncol, Dept Med, San Antonio, TX 78229 USA. [Venkatasubbarao, Kolaparthi; Peterson, Lindsay; Zhao, Shujie; Hill, Ping; Cao, Lin; Zhou, Qing; Nawrocki, Steffan T.; Freeman, James W.] Canc Therapy & Res Ctr S Texas, Expt & Dev Therapeut Program, San Antonio, TX 78229 USA. [Freeman, James W.] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78229 USA. RP Freeman, JW (reprint author), Univ Texas San Antonio, Hlth Sci Ctr, Div Hematol & Oncol, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM FREEMANJW@UTHSCSA.EDU FU NIH/NCI [RO1 CA69122]; VA-Merit Award; Cancer Center Grant NIH/NCI [P30CA054174] FX This study was supported by NIH/NCI grant RO1 CA69122 and VA-Merit Award to JWF and Cancer Center Grant NIH/NCI P30CA054174 in support of the UTHSCSA Core Flow Cytometry Facility. The authors would like to thank Dr. Subrata Haldar and Ms. Susan Beardales, Division of Scientific Writing, CTRC, UTHSCSA for helpful suggestions during the preparation of this manuscript. NR 34 TC 12 Z9 13 U1 0 U2 13 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1476-4598 J9 MOL CANCER JI Mol. Cancer PD SEP 11 PY 2013 VL 12 AR 104 DI 10.1186/1476-4598-12-104 PG 12 WC Biochemistry & Molecular Biology; Oncology SC Biochemistry & Molecular Biology; Oncology GA 220BE UT WOS:000324554900001 PM 24025152 ER PT J AU Eckhouse, SR Logdon, CB Oelsen, JM Patel, RK Rice, AD Stroud, RE Wince, WB Mukherjee, R Spinale, FG Ikonomidis, JS Jones, JA AF Eckhouse, Shaina R. Logdon, Christina B. Oelsen, J. Marshall Patel, Risha K. Rice, Allison D. Stroud, Robert E. Wince, W. Benjamin Mukherjee, Rupak Spinale, Francis G. Ikonomidis, John S. Jones, Jeffrey A. TI Reproducible Porcine Model of Thoracic Aortic Aneurysm SO CIRCULATION LA English DT Article; Proceedings Paper CT Scientific Sessions of the American-Heart-Association (AHA) CY NOV 03-07, 2012 CL Los Angeles, CA SP Amer Heart Assoc DE animal models; aortic diseases; aneurysm; cardiovascular disease; remodeling ID MATRIX METALLOPROTEINASES; MURINE MODEL; TISSUE INHIBITORS; ABDOMINAL-AORTA; VALVES; EXPRESSION; DISSECTIONS; INDUCTION; INFUSION; DISEASE AB Background-Thoracic aortic aneurysms (TAAs) develop secondary to abnormal aortic extracellular matrix remodeling, resulting in a weakened and dilated aortic wall that progressed to rupture if left unattended. Currently, no diagnostic/prognostic tests are available for the detection of TAA disease. This is largely driven by the lack of a large animal model, which would permit longitudinal/mechanistic studies. Accordingly, the objective of the present study was to establish a reproducible porcine model of aortic dilatation, which recapitulates the structural and biochemical changes observed during human TAA development. Methods and Results-Descending TAAs were induced in Yorkshire pigs (20-25 kg; n=7) through intra-adventitial injections of collagenase (5 mL, 0.35 mg/mL) and periadventitial application of crystalline CaCl2 (0.5 g). Three weeks after TAA induction, aortas were harvested and tissue was collected for biochemical and histological measurements. A subset of animals underwent MRI preoperatively and at terminal surgery. Results were compared with sham-operated controls (n=6). Three weeks after TAA induction, aortic luminal area increased by 38 +/- 13% (P=0.018 versus control). Aortic structural changes included elastic lamellar degradation and decreased collagen content. The protein abundance of matrix metalloproteinases 3, 8, 9, and 12 increased in TAA tissue homogenates, whereas tissue inhibitors of metalloproteinases 1 and 4 decreased. Conclusions-These data demonstrate aortic dilatation, aortic medial degeneration, and alterations in matrix metalloproteinase/tissue inhibitors of metalloproteinase abundance, consistent with TAA formation. This study establishes for the first time a large animal model of TAA that recapitulates the hallmarks of human disease and provides a reproducible test bed for examining diagnostic, prognostic, and therapeutic strategies. C1 [Eckhouse, Shaina R.; Logdon, Christina B.; Oelsen, J. Marshall; Patel, Risha K.; Rice, Allison D.; Stroud, Robert E.; Mukherjee, Rupak; Ikonomidis, John S.; Jones, Jeffrey A.] Med Univ S Carolina, Div Cardiothorac Surg, Dept Surg, Charleston, SC 29425 USA. [Wince, W. Benjamin] Med Univ S Carolina, Dept Med, Div Cardiol, Charleston, SC 29425 USA. [Jones, Jeffrey A.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA. [Spinale, Francis G.] Univ S Carolina, Sch Med, Dept Cell Biol & Anat, Columbia, SC USA. [Spinale, Francis G.] Wm Jennings Bryan Dorn Vet Affairs Med Ctr, Columbia, SC USA. RP Jones, JA (reprint author), Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Strom Thurmond Res Bldg,114 Doughty St,Suite 326C, Charleston, SC 29425 USA. EM jonesja@musc.edu FU NHLBI NIH HHS [T32 HL007260] NR 39 TC 4 Z9 4 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD SEP 10 PY 2013 VL 128 IS 11 SU 1 BP S186 EP S193 DI 10.1161/CIRCULATIONAHA.112.000363 PG 8 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 301MD UT WOS:000330535500023 PM 24030405 ER PT J AU Richard, EM Thiyagarajan, T Bunni, MA Basher, F Roddy, PO Siskind, LJ Nietert, PJ Nowling, TK AF Richard, Erin Morris Thiyagarajan, Thirumagal Bunni, Marlene A. Basher, Fahmin Roddy, Patrick O. Siskind, Leah J. Nietert, Paul J. Nowling, Tamara K. TI Reducing FLI1 Levels in the MRL/lpr Lupus Mouse Model Impacts T Cell Function by Modulating Glycosphingolipid Metabolism SO PLOS ONE LA English DT Article ID TRANSCRIPTION FACTOR; CYTOKINE PRODUCTION; RENAL-DISEASE; ETS FAMILY; DECREASED EXPRESSION; ANTIGEN RECEPTOR; MURINE LUPUS; MICE; ERYTHEMATOSUS; LYMPHOCYTES AB Systemic Lupus erythematosus (SLE) is an autoimmune disease caused, in part, by abnormalities in cells of the immune system including B and T cells. Genetically reducing globally the expression of the ETS transcription factor FLI1 by 50% in two lupus mouse models significantly improves disease measures and survival through an unknown mechanism. In this study we analyze the effects of reducing FLI1 in the MRL/lpr lupus prone model on T cell function. We demonstrate that adoptive transfer of MRL/lpr Fli1(+/+) or Fli1(+/-) T cells and B cells into Rag1-deficient mice results in significantly decreased serum immunoglobulin levels in animals receiving Fli1(+/-) lupus T cells compared to animals receiving Fli1(+/+) lupus T cells regardless of the genotype of co-transferred lupus B cells. Ex vivo analyses of MRL/lpr T cells demonstrated that Fli1(+/-) T cells produce significantly less IL-4 during early and late disease and exhibited significantly decreased TCR-specific activation during early disease compared to Fli1(+/+) T cells. Moreover, the Fli1(+/-) T cells expressed significantly less neuraminidase 1 (Neu1) message and decreased NEU activity during early disease and significantly decreased levels of glycosphingolipids during late disease compared to Fli1(+/+) T cells. FLI1 dose-dependently activated the Neu1 promoter in mouse and human T cell lines. Together, our results suggest reducing FLI1 in lupus decreases the pathogenicity of T cells by decreasing TCR-specific activation and IL-4 production in part through the modulation of glycosphingolipid metabolism. Reducing the expression of FLI1 or targeting the glycosphingolipid metabolic pathway in lupus may serve as a therapeutic approach to treating lupus. C1 [Richard, Erin Morris; Thiyagarajan, Thirumagal; Basher, Fahmin; Nowling, Tamara K.] Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA. [Bunni, Marlene A.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. [Nietert, Paul J.] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [Roddy, Patrick O.; Siskind, Leah J.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. [Siskind, Leah J.; Nowling, Tamara K.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29425 USA. RP Nowling, TK (reprint author), Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA. EM nowling@musc.edu FU Veteran's Administration [BX000115]; National Institutes of Health [NCRR P20 RR17677 COBRE, NIDDK R01 DK093462, NCRR UL1TR000062, NIAMS 1P60 AR062755-01]; Cancer Center Support Grant [P30 CA138313] FX These studies were supported by funding from the Veteran's Administration (Merit Review Grant BX000115 to TKN) and in part by National Institutes of Health (NCRR P20 RR17677 COBRE in Lipidomics and Pathobiology pilot project and NIDDK R01 DK093462 to LJS) and Lipidomics Shared Resource of the Hollings Cancer Center at the Medical University of South Carolina supported by a Cancer Center Support Grant (P30 CA138313). Support for PJN was provided by the National Institutes of Health (NCRR UL1TR000062 and NIAMS 1P60 AR062755-01). The contents of this publication do not represent the views of the Department of Veterans Affairs or the United States Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 46 TC 9 Z9 10 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 10 PY 2013 VL 8 IS 9 AR e75175 DI 10.1371/journal.pone.0075175 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 259PK UT WOS:000327538600131 PM 24040398 ER PT J AU Hatano, H Somsouk, M Sinclair, E Harvill, K Gilman, L Cohen, M Hoh, R Hunt, PW Martin, JN Wong, JK Deeks, SG Yukl, SA AF Hatano, Hiroyu Somsouk, Ma Sinclair, Elizabeth Harvill, Kara Gilman, Lee Cohen, Michelle Hoh, Rebecca Hunt, Peter W. Martin, Jeffrey N. Wong, Joseph K. Deeks, Steven G. Yukl, Steven A. TI Comparison of HIV DNA and RNA in gut-associated lymphoid tissue of HIV-infected controllers and noncontrollers SO AIDS LA English DT Article DE controllers; gut-associated lymphoid tissue; HIV; viral reservoir ID HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL RESPONSES; SUPPRESSIVE ANTIRETROVIRAL THERAPY; LOW-LEVEL VIREMIA; ELITE CONTROLLERS; TYPE-1 RNA; REPLICATION; PLASMA; INDIVIDUALS; ACTIVATION AB Objectives:HIV-infected controllers have provided novel insights into mechanisms of viral control. We investigated the degree to which HIV DNA and RNA are present in gut-associated lymphoid tissue (GALT) of controllers. Design:Cross-sectional cohort study. Methods:Colorectal biopsy pieces were obtained from five untreated noncontrollers, five ART-suppressed patients, and nine untreated controllers. Results:Rectal HIV DNA was lower in controllers (median 496copies/10(6) CD4(+) T cells) than in untreated noncontrollers (117483copies/10(6) CD4(+) T cells, P=0.001) and ART-suppressed patients (6116copies/10(6) CD4(+) T cells, P=0.004). Similarly, rectal HIV RNA was lower in controllers (19copies/10(6) CD4(+) T cells) than in noncontrollers (15210copies/10(6) CD4(+) T cells, P=0.001) and ART-suppressed patients (1625copies/10(6) CD4(+) T cells, P=0.0599). Rectal HIV RNA/DNA ratios were not statistically different between the three groups. Conclusion:Despite being able to maintain very low plasma HIV RNA levels in the absence of antiretroviral therapy (ART), HIV-infected controllers have readily measurable levels of HIV DNA and RNA in GALT. As expected, controllers had lower rectal HIV DNA and RNA compared with untreated noncontrollers and ART-suppressed individuals. Compared with the mechanisms of natural' viral control of controllers, long-term ART does not reduce the total HIV reservoir to the level of controllers. C1 [Hatano, Hiroyu; Somsouk, Ma; Sinclair, Elizabeth; Harvill, Kara; Gilman, Lee; Cohen, Michelle; Hoh, Rebecca; Hunt, Peter W.; Wong, Joseph K.; Deeks, Steven G.; Yukl, Steven A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Martin, Jeffrey N.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA. [Wong, Joseph K.; Yukl, Steven A.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Hatano, H (reprint author), San Francisco Gen Hosp, Bldg 80,Ward 84,995 Potrero Ave, San Francisco, CA 94110 USA. EM hhatano@php.ucsf.edu FU National Institute of Allergy and Infectious Diseases [R01 AI087145, K23 AI075985, K24 AI069994, R56 AI091573, R01 NS051132]; National Cancer Institute [K23 CA157929]; Delaney AIDS Research Enterprise (DARE) [U19 AI0961090]; California HIV/AIDS Research Program [ID08-SF-004]; American Foundation for AIDS Research [106710-40-RGRL]; UCSF/Gladstone Institute of Virology & Immunology CFAR [P30 AI027763]; UCSF Clinical and Translational Research Institute Clinical Research Center [UL1 RR024131]; Center for AIDS Prevention Studies [P30 MH62246]; CFAR Network of Integrated Systems [R24 AI067039]; U.S. Department of Veterans Affairs [1 IK2 CX000520-01, 5101BX001048] FX This work was supported by grants from the National Institute of Allergy and Infectious Diseases (R01 AI087145, K23 AI075985, K24 AI069994, R56 AI091573, R01 NS051132), the National Cancer Institute (K23 CA157929), the Delaney AIDS Research Enterprise (DARE; U19 AI0961090), California HIV/AIDS Research Program (grant number ID08-SF-004), American Foundation for AIDS Research (106710-40-RGRL), the UCSF/Gladstone Institute of Virology & Immunology CFAR (P30 AI027763), the UCSF Clinical and Translational Research Institute Clinical Research Center (UL1 RR024131), the Center for AIDS Prevention Studies (P30 MH62246), the CFAR Network of Integrated Systems (R24 AI067039), and the U.S. Department of Veterans Affairs (1 IK2 CX000520-01, 5101BX001048). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the article. NR 30 TC 10 Z9 10 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD SEP 10 PY 2013 VL 27 IS 14 BP 2255 EP 2260 DI 10.1097/QAD.0b013e328362692f PG 6 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 248LZ UT WOS:000326702700012 PM 24157906 ER PT J AU Driver, TH Scherzer, R Peralta, CA Tien, PC Estrella, MM Parikh, CR Butch, AW Anastos, K Cohen, MH Nowicki, M Sharma, A Young, MA Abraham, A Shlipak, MG AF Driver, Todd H. Scherzer, Rebecca Peralta, Carmen A. Tien, Phyllis C. Estrella, Michelle M. Parikh, Chirag R. Butch, Anthony W. Anastos, Kathryn Cohen, Mardge H. Nowicki, Marek Sharma, Anjali Young, Mary A. Abraham, Alison Shlipak, Michael G. TI Comparisons of creatinine and cystatin C for detection of kidney disease and prediction of all-cause mortality in HIV-infected women SO AIDS LA English DT Article DE creatinine; cystatin C; glomerular filtration rate; HIV; kidney; mortality; women ID GLOMERULAR-FILTRATION-RATE; STAGE RENAL-DISEASE; ANTIRETROVIRAL THERAPY; CARDIOVASCULAR EVENTS; SERUM CREATININE; HIV-1-INFECTED PATIENTS; ELDERLY PERSONS; INTERAGENCY HIV; RISK; MUSCLE AB Background:Cystatin C could improve chronic kidney disease (CKD) classification in HIV-infected women relative to serum creatinine. Design:Retrospective cohort analysis. Methods:Cystatin C and creatinine were measured from specimens taken and stored during the 1999-2000 examination among 908 HIV-infected participants in the Women's Interagency HIV study (WIHS). Mean follow-up was 10.2 years. Predictors of differential glomerular filtration rate (GFR) estimates were evaluated with multivariable linear regression. The associations of baseline categories (<60, 60-90, and >90ml/min per 1.73m(2)) of creatinine estimated GFR (eGFR(cr)), cystatin C eGFR (eGFR(cys)), and combined creatinine-cystatin C eGFR (eGFR(cr-cys)) with all-cause mortality were evaluated using multivariable Cox regression. The net reclassification index (NRI) was calculated to evaluate the effect of cystatin C on reclassification of CKD staging. Results:CKD risk factors were associated with lower eGFR(cys) and eGFR(cr-cys) values compared with eGFR(cr). Relative to eGFR more than 90, the eGFR less than 60 category by eGFR(cys) (Adjusted hazard ratio: 2.56; 95% confidence interval: 1.63-4.02), eGFR(cr-cys) (3.11; 1.94-5.00), and eGFR(cr) (2.34; 1.44-3.79) was associated with increased mortality risk. However, the eGFR 60-90 category was associated with increased mortality risk for eGFR(cys) (1.80; 1.28-2.53) and eGFR(cr-cys) (1.91; 1.38-2.66) but not eGFR(cr) (1.20; 0.85-1.67). The overall NRI for mortality was 26% when reclassifying from eGFR(cr) to eGFR(cys) (P<0.001) and was 20% when reclassifying from eGFR(cr) to eGFR(cr-cys) (P<0.001). Conclusion:The addition of cystatin C may improve mortality risk prediction by stages of kidney function relative to creatinine. CKD risk factors are associated with an overestimate of GFR by serum creatinine relative to cystatin C. C1 [Driver, Todd H.] Univ Calif San Francisco, Sch Med, San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. [Scherzer, Rebecca; Peralta, Carmen A.; Tien, Phyllis C.; Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. [Peralta, Carmen A.; Tien, Phyllis C.; Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. [Estrella, Michelle M.; Abraham, Alison] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Parikh, Chirag R.] Yale Univ, Dept Med, Nephrol Sect, New Haven, CT 06520 USA. [Parikh, Chirag R.] Yale Univ, Program Appl Translat Res, New Haven, CT USA. [Butch, Anthony W.] Univ Calif Los Angeles, Clin Immunol Res Lab, Los Angeles, CA USA. [Anastos, Kathryn] Albert Einstein Coll Med, Dept Med & Epidemiol & Populat Hlth, Bronx, NY 10467 USA. [Cohen, Mardge H.] Stroger Hosp, Dept Med, Chicago, IL USA. [Cohen, Mardge H.] Rush Univ, Chicago, IL 60612 USA. [Nowicki, Marek] Univ So Calif, Los Angeles, CA USA. [Sharma, Anjali] Suny Downstate Med Ctr, Dept Med, Div Infect Dis, Brooklyn, NY 11203 USA. [Young, Mary A.] Georgetown Univ, Med Ctr, Washington, DC 20007 USA. RP Shlipak, MG (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Box 111A1, San Francisco, CA 94121 USA. EM michael.shlipak@ucsf.edu FU UCSF-CTSI [TL1 TR000144]; [R01 AG034853-03] FX Sources of Support: R01 AG034853-03 (Shlipak); UCSF-CTSI Grant Number TL1 TR000144 (Driver). NR 48 TC 12 Z9 13 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD SEP 10 PY 2013 VL 27 IS 14 BP 2291 EP 2299 DI 10.1097/QAD.0b013e328362e874 PG 9 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 248LZ UT WOS:000326702700016 PM 23669156 ER PT J AU Hage, FG Wackers, FJT Bansal, S Chyun, DA Young, LH Inzucchi, SE Iskandrian, AE AF Hage, Fadi G. Wackers, Frans J. Th Bansal, Shanti Chyun, Deborah A. Young, Lawrence H. Inzucchi, Silvio E. Iskandrian, Ami E. TI The heart rate response to adenosine: A simple predictor of adverse cardiac outcomes in asymptomatic patients with type 2 diabetes SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Article DE Type 2 diabetes mellitus; Heart rate; Adenosine; Myocardial perfusion imaging; Autonomic function ID CARDIOVASCULAR AUTONOMIC NEUROPATHY; MYOCARDIAL-ISCHEMIA; DIAD; REGADENOSON; MELLITUS; RISK; DIPYRIDAMOLE; ASSOCIATION; DYSFUNCTION; MORTALITY AB Background: The Detection of Ischemia in Asymptomatic Diabetics (DIAD) study demonstrated a low 5-year hard cardiac event rate. We hypothesized that a blunted heart rate response (HRR, maximum percent change) to adenosine, a simple marker of cardiac autonomic neuropathy, will identify a cohort at higher cardiac risk. Methods: In DIAD, 518 participants were randomized to screening adenosine myocardial perfusion imaging (MPI) and had available data. HRR <20% was considered abnormal. The primary endpoint was a composite of nonfatal myocardial infarction and cardiac death. Results: During 4.7+/-0.9 years of follow-up 15 (3%) participants experienced the primary outcome. Participants with lower HRR experienced more events than those with higher HRR (8%, 3%, 1%, for HRR <20% (n=79), 20-39% (n=182) and >= 40% (n=257), respectively, p=0.01). In a Cox proportional regression model that included MPI abnormalities and HRR, both were independently associated with cardiac events (p for model <0.001). HRR <20% was associated with 9-fold increased risk (p=0.007) and moderate/large abnormal MPI was associated with 6-fold increased risk (p=0.004). Participants with both abnormal MPI and HRR (n=8) were at highest risk for cardiac events (38%) whereas those with HRR >= 40%, irrespective of MPI abnormalities (n=234), were at extremely low risk (>= 1%, log-rank p<0.001). Conclusions: In DIAD, abnormal HRR to adenosine infusion is an independent predictor of cardiac events. This easily obtained marker of cardiac autonomic neuropathy identifies asymptomatic patients with type 2 diabetes mellitus at increased risk, particularly when associated with abnormal MPI, who may warrant further testing and more aggressive cardiovascular risk factor management. (C) 2012 Elsevier Ireland Ltd. All rights reserved. C1 [Hage, Fadi G.; Iskandrian, Ami E.] Univ Alabama Birmingham, Birmingham, AL USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Wackers, Frans J. Th; Bansal, Shanti; Young, Lawrence H.; Inzucchi, Silvio E.] Yale Univ, Sch Med, New Haven, CT USA. [Chyun, Deborah A.] NYU, New York, NY USA. RP Hage, FG (reprint author), Zeigler Res Bldg 1024,703 19th St South, Birmingham, AL 35294 USA. EM fadihage@uab.edu OI Hage, Fadi/0000-0002-1397-4942 FU General Clinical Research Centers at Yale University (National Institutes of Health) [M01-RR-00125]; University of Rochester [NIH 5M01-RR-00847]; Tulane University [NIH 6M01-RR-05096] FX Financial disclosure: This work was performed with the support of the General Clinical Research Centers at Yale University (National Institutes of Health M01-RR-00125), University of Rochester (NIH 5M01-RR-00847), and Tulane University (NIH 6M01-RR-05096). NR 21 TC 8 Z9 8 U1 0 U2 4 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-5273 J9 INT J CARDIOL JI Int. J. Cardiol. PD SEP 10 PY 2013 VL 167 IS 6 BP 2952 EP 2957 DI 10.1016/j.ijcard.2012.08.011 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 219BH UT WOS:000324478400102 PM 22981277 ER PT J AU Korrapati, MC Howell, LH Shaner, BE Megyesi, JK Siskind, LJ Schnellmann, RG AF Korrapati, Midhun C. Howell, Lauren H. Shaner, Brooke E. Megyesi, Judit K. Siskind, Leah J. Schnellmann, Rick G. TI Suramin: A Potential Therapy for Diabetic Nephropathy SO PLOS ONE LA English DT Article ID TUBULAR EPITHELIAL-CELLS; KAPPA-B ACTIVATION; KIDNEY-DISEASE; RENAL INJURY; DB/DB MOUSE; TGF-BETA; FIBROSIS; MECHANISMS; RATS; MICE AB Objective: To determine whether delayed administration of a single dose of suramin, a drug that has been used extensively in humans to treat trypanosomiasis, attenuates renal injury in a leptin receptor deficient C57BLKS/J db/db type 2 diabetic nephropathy (T2DN) mouse model. Research Design and Methods: Groups of female non-diabetic (control) db/m and diabetic db/db mice of 8 and 16 weeks of age, respectively, were treated with suramin (10 mg/kg) or saline i.v. All animals were euthanized one week later. Measurements in mice 1 week following treatment included the following: body weight; blood glucose; urinary protein excretion; pathological lesions in glomeruli and proximal tubules; changes in protein expression of pro-inflammatory transcription factor nuclear factor kappa B (NF-kappa B) and intracellular adhesion molecule-1 (ICAM-1), profibrotic transforming growth factor-beta 1 (TGF-beta 1), phospho-SMAD-3 and alpha-smooth muscle actin (alpha-SMA); and immunohistochemical analysis of leukocyte infiltration and collagen 1A2 (COL1A2) deposition. Results: Immunoblot analysis revealed increased NF-kappa B, ICAM-1, TGF-beta 1, phospho-SMAD-3, and alpha-SMA proteins in both 9 and 17 week db/db mice as compared to db/m control mice. Immunohistochemical analysis revealed moderate leukocyte infiltration and collagen 1A2 (COL1A2) deposition in 9 week db/db mice that was increased in the 17 week db/db mice. Importantly, suramin significantly decreased expression of all these markers in 9 week db/db mice and partially decreased in 17 week db/db mice without altering body weight, blood glucose or urinary protein excretion. There was no difference in creatinine clearance between 9 week db/m and db/db mice +/- suramin. Importantly, in the 17 week db/db mice suramin intervention reversed the impaired creatinine clearance and overt histological damage. Conclusions: Delayed administration of a single dose of suramin in a model of T2DN attenuated inflammation and fibrosis as well as improved renal function, supporting the use of suramin in T2DN. C1 [Korrapati, Midhun C.; Howell, Lauren H.; Shaner, Brooke E.; Siskind, Leah J.; Schnellmann, Rick G.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. [Megyesi, Judit K.] Univ Arkansas Med Sci, Div Nephrol, Coll Med, Dept Internal Med, Little Rock, AR 72205 USA. [Siskind, Leah J.; Schnellmann, Rick G.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Siskind, LJ (reprint author), Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. EM leah.siskind@louisville.edu FU National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health [R01DK093462]; Cancer Center Support Grant [P30 CA138313]; Centers of Biomedical Research Excellence in Lipidomics and Pathobiology [NIH/NCRR P20 RR17677]; South Carolina Centers of Biomedical Research Excellence in Oxidants, Redox Balance and Stress Signaling [P20 GM103542]; National Institutes of Health [GM 084147, C06 RR-015455]; Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs; South Carolina Clinical & Translational Research (SCTR) Institute; Medical University of South Carolina CTSA, NIH/NCRR [UL1RR029882] FX Research reported in this publication was supported in part by National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, [R01DK093462] (to L.J.S.), the Lipidomics Shared Resource of the Hollings Cancer Center at the Medical University of South Carolina supported by a Cancer Center Support Grant [P30 CA138313], pilot project from the [NIH/NCRR P20 RR17677] Centers of Biomedical Research Excellence in Lipidomics and Pathobiology (to L.J.S), South Carolina Centers of Biomedical Research Excellence in Oxidants, Redox Balance and Stress Signaling [P20 GM103542], pilot project from the [NIH/NCRR P20 RR17677], National Institutes of Health Grant [GM 084147] and by the Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs. Animal facilities were funded by National Institutes of Health grant [C06 RR-015455]. This reseach was supported in part by the South Carolina Clinical & Translational Research (SCTR) Institute, with an academic home at the Medical University of South Carolina CTSA, NIH/NCRR Grant Number UL1RR029882. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH, VA, or National Center for Research Resources. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 48 TC 8 Z9 8 U1 1 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 9 PY 2013 VL 8 IS 9 AR e73655 DI 10.1371/journal.pone.0073655 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 244QV UT WOS:000326405300104 PM 24040012 ER PT J AU Lam, KD Miao, YH Steinman, MA AF Lam, Khoa D. Miao, Yinghui Steinman, Michael A. TI Cumulative Changes in the Use of Long-term Medications: A Measure of Prescribing Complexity SO JAMA INTERNAL MEDICINE LA English DT Letter ID REGIMEN C1 [Lam, Khoa D.; Steinman, Michael A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Lam, Khoa D.; Miao, Yinghui; Steinman, Michael A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Miao, Yinghui; Steinman, Michael A.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. RP Steinman, MA (reprint author), San Francisco VA Med Ctr, 4150 Clement St,POB 181G, San Francisco, CA 94121 USA. EM mike.steinman@ucsf.edu FU NIA NIH HHS [RC1 AG036377, RC1-AG036377, 1K23-AG030999, K23 AG030999, P30 AG044281] NR 5 TC 3 Z9 3 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 J9 JAMA INTERN MED JI JAMA Intern. Med. PD SEP 9 PY 2013 VL 173 IS 16 BP 1546 EP 1547 DI 10.1001/jamainternmed.2013.7060 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 218VS UT WOS:000324461200015 PM 23752793 ER PT J AU Bodhankar, S Chen, YX Vandenbark, AA Murphy, SJ Offner, H AF Bodhankar, Sheetal Chen, Yingxin Vandenbark, Arthur A. Murphy, Stephanie J. Offner, Halina TI PD-L1 enhances CNS inflammation and infarct volume following experimental stroke in mice in opposition to PD-1 SO JOURNAL OF NEUROINFLAMMATION LA English DT Article DE Co-inhibitory pathway; Inflammatory states; MCAO; Programmed death-1 ligand 1 and 2 ID REGULATORY T-CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; ISCHEMIC-STROKE; PERIPHERAL TOLERANCE; DEFICIENT MICE; EXPRESSION; RESPONSES; LIGANDS; PATHWAY; IMMUNITY AB Background: Stroke severity is worsened by recruitment of inflammatory immune cells into the brain. This process depends in part on T cell activation, in which the B7 family of co-stimulatory molecules plays a pivotal role. Previous studies demonstrated more severe infarcts in mice lacking programmed death-1 (PD-1), a member of the B7 family, thus implicating PD-1 as a key factor in limiting stroke severity. The purpose of this study was to determine if this protective effect of PD-1 involves either of its ligands, PD-L1 or PD-L2. Methods: Central nervous system (CNS) inflammation and infarct volume were evaluated in male PD-L1 and PD-L2 knockout ((-/-)) mice undergoing 60 minutes of middle cerebral artery occlusion (MCAO) followed by 96 hours of reperfusion and compared to wild-type (WT) C57BL/6J mice. Results: PD-L1(-/-) and PD-L2(-/-) mice had smaller total infarct volumes compared to WT mice. The PD-L1-/-and to a lesser extent PD-L2(-/-) mice had reduced levels of proinflammatory activated microglia and/or infiltrating monocytes and CD4(+) T cells in the ischemic hemispheres. There was a reduction in ischemia-related splenic atrophy accompanied by lower activation status of splenic T cells and monocytes in the absence of PD-L1, suggesting a pathogenic rather than a regulatory role for both PD-1 ligands (PD-Ls). Suppressor T cells (IL-10-producing CD8(+) CD122(+) T cells) trafficked to the brain in PD-L1(-/-) mice and there was decreased expression of CD80 on splenic antigen-presenting cells (APCs) as compared to the WT and PD-L2(-/-) mice. Conclusions: Our novel observations are the first to implicate PD-L1 involvement in worsening outcome of experimental stroke. The presence of suppressor T cells in the right MCAO-inflicted hemisphere in mice lacking PDL1 implicates these cells as possible key contributors for controlling adverse effects of ischemia. Increased expression of CD80 on APCs in WT and PD-L2(-/-) mice suggests an overriding interaction leading to T cell activation. Conversely, low CD80 expression by APCs, along with increased PD-1 and PD-L2 expression in PD-L1(-/-) mice suggests alternative T cell signaling pathways, leading to a suppressor phenotype. These results suggest that agents (for example antibodies) that can target and neutralize PD-L1/2 may have therapeutic potential for treatment of human stroke. C1 [Bodhankar, Sheetal; Vandenbark, Arthur A.; Offner, Halina] Portland VA Med Ctr, R&D 31, Portland, OR 97239 USA. [Bodhankar, Sheetal; Vandenbark, Arthur A.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA. [Chen, Yingxin; Murphy, Stephanie J.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA. [Murphy, Stephanie J.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. RP Offner, H (reprint author), Portland VA Med Ctr, R&D 31, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM offnerva@ohsu.edu FU NIH/National Institute of Neurological Disorders and Stroke (NINDS) [1RO1 NS075887]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development; Biomedical Laboratory Research and Development FX The authors wish to thank Melissa Barber for assistance with manuscript submission. This work was supported by NIH/National Institute of Neurological Disorders and Stroke (NINDS): 1RO1 NS075887. This material is based upon work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, and Biomedical Laboratory Research and Development. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. NR 47 TC 21 Z9 21 U1 0 U2 11 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-2094 J9 J NEUROINFLAMM JI J. Neuroinflamm. PD SEP 9 PY 2013 VL 10 AR 111 DI 10.1186/1742-2094-10-111 PG 15 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA 214OL UT WOS:000324143300001 PM 24015822 ER PT J AU Tanner, RM Calhoun, DA Bell, EK Bowling, CB Gutierrez, OM Irvin, MR Lackland, DT Oparil, S Warnock, D Muntner, P AF Tanner, Rikki M. Calhoun, David A. Bell, Emmy K. Bowling, C. Barrett Gutierrez, Orlando M. Irvin, Marguerite R. Lackland, Daniel T. Oparil, Suzanne Warnock, David Muntner, Paul TI Prevalence of Apparent Treatment-Resistant Hypertension among Individuals with CKD SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID CHRONIC KIDNEY-DISEASE; HIGH-BLOOD-PRESSURE; ENDOTHELIAL DYSFUNCTION; UNITED-STATES; RISK; MICROALBUMINURIA; ATHEROSCLEROSIS; SPIRONOLACTONE; PREVENTION; COMMITTEE AB Background and objectivesApparent treatment-resistant hypertension is defined as systolic/diastolic BP140/90 mmHg with concurrent use of three or more antihypertensive medication classes or use of four or more antihypertensive medication classes regardless of BP level.Design, setting, participants, & measurementsThe prevalence of apparent treatment-resistant hypertension among Reasons for Geographic and Racial Differences in Stroke study participants treated for hypertension (n=10,700) was determined by level of estimated GFR and albumin-to-creatinine ratio, and correlates of apparent treatment-resistant hypertension among those participants with CKD were evaluated. CKD was defined as an albumin-to-creatinine ratio30 mg/g or estimated GFR<60 ml/min per 1.73 m(2).ResultsThe prevalence of apparent treatment-resistant hypertension was 15.8%, 24.9%, and 33.4% for those participants with estimated GFR60, 45-59, and <45 ml/min per 1.73 m(2), respectively, and 12.1%, 20.8%, 27.7%, and 48.3% for albumin-to-creatinine ratio<10, 10-29, 30-299, and 300 mg/g, respectively. The multivariable-adjusted prevalence ratios (95% confidence intervals) for apparent treatment-resistant hypertension were 1.25 (1.11 to 1.41) and 1.20 (1.04 to 1.37) for estimated GFR levels of 45-59 and <45 ml/min per 1.73 m(2), respectively, versus 60 ml/min per 1.73 m(2) and 1.54 (1.39 to 1.71), 1.76 (1.57 to 1.97), and 2.44 (2.12 to 2.81) for albumin-to-creatinine ratio levels of 10-29, 30-299, and 300 mg/g, respectively, versus albumin-to-creatinine ratio<10 mg/g. After multivariable adjustment, men, black race, larger waist circumference, diabetes, history of myocardial infarction or stroke, statin use, and lower estimated GFR and higher albumin-to-creatinine ratio levels were associated with apparent treatment-resistant hypertension among individuals with CKD.ConclusionsThis study highlights the high prevalence of apparent treatment-resistant hypertension among individuals with CKD. C1 [Tanner, Rikki M.; Irvin, Marguerite R.; Muntner, Paul] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL 35294 USA. [Calhoun, David A.; Oparil, Suzanne] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Bell, Emmy K.; Gutierrez, Orlando M.; Warnock, David] Univ Alabama Birmingham, Dept Med, Div Nephrol, Birmingham, AL 35294 USA. [Bowling, C. Barrett] Univ Alabama Birmingham, Dept Med, Div Gerontol, Birmingham, AL 35294 USA. [Bowling, C. Barrett] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Lackland, Daniel T.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. RP Muntner, P (reprint author), Univ Alabama Birmingham, Dept Epidemiol, 1665 Univ Blvd,Suite 230J, Birmingham, AL 35294 USA. EM pmuntner@uab.edu FU National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Services [U01 NS041588]; Amgen Corporation FX This research project is supported by Cooperative Agreement U01 NS041588 from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Services. Additional funding was provided by an investigator-initiated grant-in-aid from Amgen Corporation. NR 26 TC 33 Z9 39 U1 0 U2 8 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD SEP 6 PY 2013 VL 8 IS 9 BP 1583 EP 1590 DI 10.2215/CJN.00550113 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 235GR UT WOS:000325705500018 PM 23868902 ER PT J AU Weisbord, SD Gallagher, M Kaufman, J Cass, A Parikh, CR Chertow, GM Shunk, KA McCullough, PA Fine, MJ Mor, MK Lew, RA Huang, GD Conner, TA Brophy, MT Lee, J Soliva, S Palevsky, PM AF Weisbord, Steven D. Gallagher, Martin Kaufman, James Cass, Alan Parikh, Chirag R. Chertow, Glenn M. Shunk, Kendrick A. McCullough, Peter A. Fine, Michael J. Mor, Maria K. Lew, Robert A. Huang, Grant D. Conner, Todd A. Brophy, Mary T. Lee, Joanne Soliva, Susan Palevsky, Paul M. TI Prevention of Contrast-Induced AKI: A Review of Published Trials and the Design of the Prevention of Serious Adverse Events following Angiography (PRESERVE) Trial SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID ACUTE KIDNEY INJURY; RANDOMIZED CONTROLLED-TRIAL; PERCUTANEOUS CORONARY INTERVENTION; RADIOCONTRAST-INDUCED NEPHROPATHY; ELEVATION MYOCARDIAL-INFARCTION; INTRAVENOUS N-ACETYLCYSTEINE; ISOTONIC SODIUM-BICARBONATE; ASSOCIATION TASK-FORCE; RENAL-INSUFFICIENCY; PRIMARY ANGIOPLASTY AB Contrast-induced AKI (CI-AKI) is a common condition associated with serious, adverse outcomes. CI-AKI may be preventable because its risk factors are well characterized and the timing of renal insult is commonly known in advance. Intravenous (IV) fluids and N-acetylcysteine (NAC) are two of the most widely studied preventive measures for CI-AKI. Despite a multitude of clinical trials and meta-analyses, the most effective type of IV fluid (sodium bicarbonate versus sodium chloride) and the benefit of NAC remain unclear. Careful review of published trials of these interventions reveals design limitations that contributed to their inconclusive findings. Such design limitations include the enrollment of small numbers of patients, increasing the risk for type I and type II statistical errors; the use of surrogate primary endpoints defined by small increments in serum creatinine, which are associated with, but not necessarily causally related to serious, adverse, patient-centered outcomes; and the inclusion of low-risk patients with intact baseline kidney function, yielding low event rates and reduced generalizability to a higher-risk population. The Prevention of Serious Adverse Events following Angiography (PRESERVE) trial is a randomized, double-blind, multicenter trial that will enroll 8680 high-risk patients undergoing coronary or noncoronary angiography to compare the effectiveness of IV isotonic sodium bicarbonate versus IV isotonic sodium chloride and oral NAC versus oral placebo for the prevention of serious, adverse outcomes associated with CI-AKI. This article discusses key methodological issues of past trials investigating IV fluids and NAC and how they informed the design of the PRESERVE trial. C1 [Weisbord, Steven D.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA. RP Weisbord, SD (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, 7E Room 120,111F-U, Pittsburgh, PA 15240 USA. EM weisbordsd@upmc.edu OI Palevsky, Paul/0000-0002-7334-5400 FU Department of Veterans Affairs Cooperative Studies Program FX This work was supported by the Department of Veterans Affairs Cooperative Studies Program. NR 97 TC 35 Z9 35 U1 0 U2 7 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD SEP 6 PY 2013 VL 8 IS 9 BP 1618 EP 1631 DI 10.2215/CJN.11161012 PG 14 WC Urology & Nephrology SC Urology & Nephrology GA 235GR UT WOS:000325705500024 PM 23660180 ER PT J AU Million, M Zhao, JF Luckey, A Czimmer, J Maynard, GD Kehne, J Hoffman, DC Tache, Y AF Million, Mulugeta Zhao, Jing-Fang Luckey, Andrew Czimmer, Jozsef Maynard, George D. Kehne, John Hoffman, Diane C. Tache, Yvette TI The Newly Developed CRF1-Receptor Antagonists, NGD 98-2 and NGD 9002, Suppress Acute Stress-Induced Stimulation of Colonic Motor Function and Visceral Hypersensitivity in Rats SO PLOS ONE LA English DT Article ID CORTICOTROPIN-RELEASING-FACTOR; IRRITABLE-BOWEL-SYNDROME; CRF1 RECEPTOR ANTAGONIST; FACTOR SIGNALING PATHWAYS; FACTOR TYPE-1 RECEPTOR; COLORECTAL DISTENSION; NONPEPTIDE ANTAGONIST; RECTAL DISTENSION; MAJOR DEPRESSION; PAIN AB Corticotropin releasing factor receptor 1 (CRF1) is the key receptor that mediates stress-related body responses. However to date there are no CRF1 antagonists that have shown clinical efficacy in stress-related diseases. We investigated the inhibitory effects of a new generation, topology 2 selective CRF1 antagonists, NGD 98-2 and NGD 9002 on exogenous and endogenous CRF-induced stimulation of colonic function and visceral hypersensitivity to colorectal distension (CRD) in conscious rats. CRF1 antagonists or vehicle were administered orogastrically (og) or subcutaneously (sc) before either intracerebroventricular (icv) or intraperitoneal (ip) injection of CRF (10 mu g/kg), exposure to water avoidance stress (WAS, 60 min) or repeated CRD (60 mmHg twice, 10 min on/off at a 30 min interval). Fecal pellet output (FPO), diarrhea and visceromotor responses were monitored. In vehicle (og)-pretreated rats, icv CRF stimulated FPO and induced diarrhea in >50% of rats. NGD 98-2 or NGD 9002 (3, 10 and 30 mg/kg, og) reduced the CRF-induced FPO response with an inhibitory IC50 of 15.7 and 4.3 mg/kg respectively. At the highest dose, og NGD 98-2 or NGD 9002 blocked icv CRF-induced FPO by 67-87% and decreased WAS-induced-FPO by 23-53%. When administered sc, NGD 98-2 or NGD 9002 (30 mg/kg) inhibited icv and ip CRF-induced-FPO. The antagonists also prevented the development of nociceptive hyper-responsivity to repeated CRD. These data demonstrate that topology 2 CRF1 antagonists, NGD 98-2 and NGD 9002, administered orally, prevented icv CRF-induced colonic secretomotor stimulation, reduced acute WAS-induced defecation and blocked the induction of visceral sensitization to repeated CRD. C1 [Million, Mulugeta; Zhao, Jing-Fang; Luckey, Andrew; Czimmer, Jozsef; Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Div Digest Dis,Dept Med, Los Angeles, CA 90095 USA. [Million, Mulugeta; Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, Oppenheimer Family Ctr Neurobiol Stress, Div Digest Dis,Dept Med, Los Angeles, CA 90095 USA. [Million, Mulugeta; Zhao, Jing-Fang; Luckey, Andrew; Czimmer, Jozsef; Tache, Yvette] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Maynard, George D.; Kehne, John; Hoffman, Diane C.] Neurogen Corp, Branford, CT USA. RP Million, M (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Div Digest Dis,Dept Med, Los Angeles, CA 90095 USA. EM millionmulugeta@mednet.ucla.edu FU Neurogen-Aventis CRF Collaboration, Branford, Connecticut, USA; Veterans Administration Research Career Scientist Award; NIH [RO1 DK-078676, R01 DK-57238, P50 DK-64539, DK-41301] FX This work was supported by an investigator initiated fund from the Neurogen-Aventis CRF Collaboration, Branford, Connecticut, USA (YT, MM); The Veterans Administration Research Career Scientist Award (YT), Center Grant NIH DK-41301 (Animal Model Core, YT, MM); RO1 DK-078676 (MM); R01 DK-57238 (YT) and P50 DK-64539 (YT, MM). The funders had no decision role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 61 TC 10 Z9 10 U1 0 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 6 PY 2013 VL 8 IS 9 AR e73749 DI 10.1371/journal.pone.0073749 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 224BO UT WOS:000324856500059 PM 24040053 ER PT J AU Sudore, RL Stewart, AL Knight, SJ McMahan, RD Feuz, M Miao, YH Barnes, DE AF Sudore, Rebecca L. Stewart, Anita L. Knight, Sara J. McMahan, Ryan D. Feuz, Mariko Miao, Yinghui Barnes, Deborah E. TI Development and Validation of a Questionnaire to Detect Behavior Change in Multiple Advance Care Planning Behaviors SO PLOS ONE LA English DT Article ID DIVERSE OLDER-ADULTS AB Introduction: Advance directives have traditionally been considered the gold standard for advance care planning. However, recent evidence suggests that advance care planning involves a series of multiple discrete behaviors for which people are in varying stages of behavior change. The goal of our study was to develop and validate a survey to measure the full advance care planning process. Methods: The Advance Care Planning Engagement Survey assesses "Process Measures'' of factors known from Behavior Change Theory to affect behavior (knowledge, contemplation, self-efficacy, and readiness, using 5-point Likert scales) and "Action Measures'' (yes/no) of multiple behaviors related to surrogate decision makers, values and quality of life, flexibility for surrogate decision making, and informed decision making. We administered surveys at baseline and 1 week later to 50 diverse, older adults from San Francisco hospitals. Internal consistency reliability of Process Measures was assessed using Cronbach's alpha (only continuous variables) and test-retest reliability of Process and Action Measures was examined using intraclass correlations. For discriminant validity, we compared Process and Action Measure scores between this cohort and 20 healthy college students (mean age 23.2 years, SD 2.7). Results: Mean age was 69.3 (SD 10.5) and 42% were non-White. The survey took a mean of 21.4 minutes (+/- 6.2) to administer. The survey had good internal consistency (Process Measures Cronbach's alpha, 0.94) and test-retest reliability (Process Measures intraclass correlation, 0.70; Action Measures, 0.87). Both Process and Action Measure scores were higher in the older than younger group, p<.001. Conclusion: A new Advance Care Planning Engagement Survey that measures behavior change (knowledge, contemplation, self-efficacy, and readiness) and multiple advance care planning actions demonstrates good reliability and validity. Further research is needed to assess whether survey scores improve in response to advance care planning interventions and whether scores are associated with receipt of care consistent with one's wishes. C1 [Sudore, Rebecca L.; McMahan, Ryan D.; Feuz, Mariko; Miao, Yinghui; Barnes, Deborah E.] San Francisco VA Med Ctr, San Francisco, CA USA. [Sudore, Rebecca L.; Feuz, Mariko; Miao, Yinghui] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [Stewart, Anita L.] Univ Calif San Francisco, Inst Hlth & Aging, San Francisco, CA USA. [Knight, Sara J.] Vet Adm, Hlth Serv Res & Dev Serv, Washington, DC USA. [Knight, Sara J.; Barnes, Deborah E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Barnes, Deborah E.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Sudore, RL (reprint author), San Francisco VA Med Ctr, San Francisco, CA USA. EM rebecca.sudore@ucsf.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, HSRD; National Palliative Care Research Center; National Institute on Aging, National Institutes of Health [P30-AG15272] FX This study was funded in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, HSR&D, the National Palliative Care Research Center, and by Grant P30-AG15272 under the Resource Centers for Minority Aging Research program by the National Institute on Aging, National Institutes of Health. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. The contents of this manuscript do not represent the views of the Department of Veterans Affairs or the United States Government. NR 20 TC 11 Z9 11 U1 1 U2 12 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 5 PY 2013 VL 8 IS 9 AR e72465 DI 10.1371/journal.pone.0072465 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 219CG UT WOS:000324481600032 PM 24039772 ER PT J AU Huang, E Ngo, M Yee, S Held, L Norman, K Scremin, AME Scremin, O AF Huang, Emerald Ngo, Mai Yee, Stuart Held, Laura Norman, Keith Scremin, A. M. Erika Scremin, Oscar TI Repeated blast exposure alters open field behavior recorded under low illumination SO BRAIN RESEARCH LA English DT Article DE Brain injury; Blast injury; Rat ID TRAUMATIC BRAIN-INJURY; RAT; CONCUSSION; HEADACHE; MODEL; MICE; AGE AB Blast-induced traumatic brain injury (bTBI) can have devastating behavioral consequences. This study was designed to evaluate the behavioral consequences of single or repeated bTBI, as evaluated by an open field (OF) test conducted in near-darkness to avoid confounding effects of illumination and photophobia. Sprague-Dawley rats under isoflurane anesthesia were exposed to a series of 3 sub-lethal blasts into a compressed air-driven blast chamber separated by 2 week intervals (n=11). Sham controls received anesthesia but without blast exposure (n=11). OF tests were performed 1 or 7 days after each blast using a computerized video tracking system in near-darkness to monitor spontaneous activity. Spatial and temporal variables calculated for both blast and sham groups were: Distance moved (cm) and time (s) spent in the center or periphery zones of the field, total distance traveled, speed in center and periphery zones, rearing events and non-linear regressions of distance moved and rearing events on time. Results showed that the sham group expressed the expected decrease (habituation) in total distance walked, and distance walked as well as speed in center and periphery in successive exposures to the OF while the blast group did not, a sign of impaired learning. The blast group also walked more and faster and demonstrated more rearing behavior, both considered OF signs of anxiety. These results indicate that OF outcomes of bTBI in animals have resemblance to alterations observed in human subjects with this condition and might be useful in evaluating the response of behavioral outcomes of bTBI to experimental treatments. Published by Elsevier B.V. C1 [Huang, Emerald; Ngo, Mai; Yee, Stuart] Univ Calif Los Angeles, VA Multicampus Residency Program, Los Angeles, CA USA. [Held, Laura; Scremin, A. M. Erika] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. [Norman, Keith; Scremin, Oscar] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. [Scremin, A. M. Erika] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Scremin, Oscar] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA. RP Scremin, O (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Dept Res, 11301 Wilshire Blvd,Bldg 115,Room 319, Los Angeles, CA 90073 USA. EM oscremin@ucla.edu FU Department of Veterans Affairs Rehabilitation Research & Development Merit Review (VARRD) [B5089R]; VA RR&D Research Career Scientist award FX This work was supported by Department of Veterans Affairs Rehabilitation Research & Development Merit Review (VARR&D) #B5089R, and a VA RR&D Research Career Scientist award (to O.U.S.). NR 29 TC 4 Z9 4 U1 0 U2 10 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD SEP 5 PY 2013 VL 1529 BP 125 EP 133 DI 10.1016/j.brainres.2013.06.042 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 221KQ UT WOS:000324658200013 PM 23850767 ER PT J AU Proctor, EK Landsverk, J Baumann, AA Mittman, BS Aarons, GA Brownson, RC Glisson, C Chambers, D AF Proctor, Enola K. Landsverk, John Baumann, Ana A. Mittman, Brian S. Aarons, Gregory A. Brownson, Ross C. Glisson, Charles Chambers, David TI The implementation research institute: training mental health implementation researchers in the United States SO IMPLEMENTATION SCIENCE LA English DT Article DE Dissemination research; Implementation research; Training; Translational research ID COMORBIDITY SURVEY REPLICATION; KNOWLEDGE TRANSLATION; DISSEMINATION; SCIENCE; STRATEGIES; DISORDERS; FRAMEWORK; TRAINEES; SERVICES; QUALITY AB Background: The Implementation Research Institute (IRI) provides two years of training in mental health implementation science for 10 new fellows each year. The IRI is supported by a National Institute of Mental Health (NIMH) R25 grant and the Department of Veterans Affairs (VA). Fellows attend two annual week-long trainings at Washington University in St. Louis. Training is provided through a rigorous curriculum, local and national mentoring, a 'learning site visit' to a federally funded implementation research project, pilot research, and grant writing. Methods: This paper describes the rationale, components, outcomes to date, and participant experiences with IRI. Results: IRI outcomes include 31 newly trained implementation researchers, their new grant proposals, contributions to other national dissemination and implementation research training, and publications in implementation science authored by the Core Faculty and fellows. Former fellows have obtained independent research funding in implementation science and are beginning to serve as mentors for more junior investigators. Conclusions: Based on the number of implementation research grant proposals and papers produced by fellows to date, the IRI is proving successful in preparing new researchers who can inform the process of making evidence-based mental healthcare more available through real-world settings of care and who are advancing the field of implementation science. C1 [Proctor, Enola K.; Baumann, Ana A.] Washington Univ, George Warren Brown Sch Social Work, Ctr Mental Hlth Serv Res, St Louis, MO 63130 USA. [Landsverk, John] San Diego Childrens Hosp, Child & Adolescent Serv Res Ctr, San Diego, CA USA. [Mittman, Brian S.] VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. [Aarons, Gregory A.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Brownson, Ross C.] Washington Univ, Sch Med, St Louis, MO 63130 USA. [Glisson, Charles] Univ Tennessee, Childrens Mental Hlth Serv Res Ctr, Knoxville, TN USA. [Chambers, David] NIMH, Div Serv & Intervent Res, Bethesda, MD 20892 USA. RP Proctor, EK (reprint author), Washington Univ, George Warren Brown Sch Social Work, Ctr Mental Hlth Serv Res, 1 Brookings Dr Campus,Box 1196, St Louis, MO 63130 USA. EM ekp@wustl.edu OI Baumann, Ana/0000-0002-4523-0147; Mittman, Brian/0000-0003-3589-9178 FU National Institute of Mental Health through the Center for Mental Health Services Research [NIMH P30 MH068579]; National Institute of Mental Health through the Implementation Research Institute [NIMH R25 MH080916]; US Department of Veterans Affairs Quality Enhancement Research Initiative (QUERI) FX Preparation of this paper was supported by the National Institute of Mental Health through the Center for Mental Health Services Research (NIMH P30 MH068579) and the Implementation Research Institute (NIMH R25 MH080916) and the US Department of Veterans Affairs Quality Enhancement Research Initiative (QUERI). We gratefully acknowledge learning site hosts who make invaluable contribution to IRI training; administrative support from the Brown School, Washington University in St. Louis; and the volunteer research assistants who contribute to the Institute's success. NR 30 TC 11 Z9 11 U1 2 U2 10 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD SEP 5 PY 2013 VL 8 AR 105 DI 10.1186/1748-5908-8-105 PG 12 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 214JQ UT WOS:000324129400001 PM 24007290 ER PT J AU Menees, DS Peterson, ED Wang, Y Curtis, JP Messenger, JC Rumsfeld, JS Gurm, HS AF Menees, Daniel S. Peterson, Eric D. Wang, Yongfei Curtis, Jeptha P. Messenger, John C. Rumsfeld, John S. Gurm, Hitinder S. TI Door-to-Balloon Time and Mortality among Patients Undergoing Primary PCI SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID ACUTE-MYOCARDIAL-INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; CARDIOVASCULAR DATA REGISTRY; PRIMARY ANGIOPLASTY; REPERFUSION; STRATEGIES; OUTCOMES; QUALITY; TRENDS; ASSOCIATION AB BACKGROUND Current guidelines for the treatment of ST-segment elevation myocardial infarction recommend a door-to-balloon time of 90 minutes or less for patients undergoing primary percutaneous coronary intervention (PCI). Door-to-balloon time has become a performance measure and is the focus of regional and national quality-improvement initiatives. However, it is not known whether national improvements in door-to-balloon times have been accompanied by a decline in mortality. METHODS We analyzed annual trends in door-to-balloon times and in-hospital mortality using data from 96,738 admissions for patients undergoing primary PCI for ST-segment elevation myocardial infarction from July 2005 through June 2009 at 515 hospitals participating in the CathPCI Registry. In a subgroup analysis using a linked Medicare data set, we assessed 30-day mortality. RESULTS Median door-to-balloon times declined significantly, from 83 minutes in the 12 months from July 2005 through June 2006 to 67 minutes in the 12 months from July 2008 through June 2009 (P<0.001). Similarly, the percentage of patients for whom the door-to-balloon time was 90 minutes or less increased from 59.7% in the first year to 83.1% in the last year (P<0.001). Despite improvements in door-to-balloon times, there was no significant overall change in unadjusted in-hospital mortality (4.8% in 2005-2006 and 4.7% in 2008-2009, P=0.43 for trend) or in risk-adjusted in-hospital mortality (5.0% in 2005-2006 and 4.7% in 2008-2009, P=0.34), nor was a significant difference observed in unadjusted 30-day mortality (P=0.64). CONCLUSIONS Although national door-to-balloon times have improved significantly for patients undergoing primary PCI for ST-segment elevation myocardial infarction, in-hospital mortality has remained virtually unchanged. These data suggest that additional strategies are needed to reduce in-hospital mortality in this population. C1 [Menees, Daniel S.; Gurm, Hitinder S.] Univ Michigan, Ann Arbor, MI 48109 USA. [Menees, Daniel S.; Gurm, Hitinder S.] Vet Affairs VA Ann Arbor Hlth Care Syst, Ann Arbor, MI USA. [Peterson, Eric D.] Duke Univ, Durham, NC USA. [Wang, Yongfei; Curtis, Jeptha P.] Yale Univ, New Haven, CT USA. [Messenger, John C.; Rumsfeld, John S.] Univ Colorado, Sch Med, Aurora, CO USA. [Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA. RP Menees, DS (reprint author), Univ Michigan, Dept Internal Med, Div Cardiovasc Med, 1500 East Med Ctr Dr,2A396, Ann Arbor, MI 48109 USA. EM dmenees@umich.edu OI Gurm, Hitinder/0000-0002-1646-0218 FU National Cardiovascular Data Registry of the American College of Cardiology Foundation FX Funded by the National Cardiovascular Data Registry of the American College of Cardiology Foundation. NR 23 TC 183 Z9 189 U1 0 U2 9 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD SEP 5 PY 2013 VL 369 IS 10 BP 901 EP 909 DI 10.1056/NEJMoa1208200 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 211KV UT WOS:000323906900007 PM 24004117 ER PT J AU Shlipak, MG Matsushita, K Arnlov, J Inker, LA Katz, R Polkinghorne, KR Rothenbacher, D Sarnak, MJ Astor, BC Coresh, J Levey, AS Gansevoort, RT AF Shlipak, Michael G. Matsushita, Kunihiro Arnlov, Johan Inker, Lesley A. Katz, Ronit Polkinghorne, Kevan R. Rothenbacher, Dietrich Sarnak, Mark J. Astor, Brad C. Coresh, Josef Levey, Andrew S. Gansevoort, Ron T. CA CKD Prognosis Consortium TI Cystatin C versus Creatinine in Determining Risk Based on Kidney Function SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID GLOMERULAR-FILTRATION-RATE; STAGE RENAL-DISEASE; COLLABORATIVE METAANALYSIS; POPULATION COHORTS; HIGHER ALBUMINURIA; ESTIMATED GFR; ALL-CAUSE; GENERAL-POPULATION; HEART-FAILURE; CKD-EPI AB BACKGROUND Adding the measurement of cystatin C to that of serum creatinine to determine the estimated glomerular filtration rate (eGFR) improves accuracy, but the effect on detection, staging, and risk classification of chronic kidney disease across diverse populations has not been determined. METHODS We performed a meta-analysis of 11 general-population studies (with 90,750 participants) and 5 studies of cohorts with chronic kidney disease (2960 participants) for whom standardized measurements of serum creatinine and cystatin C were available. We compared the association of the eGFR, as calculated by the measurement of creatinine or cystatin C alone or in combination with creatinine, with the rates of death (13,202 deaths in 15 cohorts), death from cardiovascular causes (3471 in 12 cohorts), and end-stage renal disease (1654 cases in 7 cohorts) and assessed improvement in reclassification with the use of cystatin C. RESULTS In the general-population cohorts, the prevalence of an eGFR of less than 60 ml per minute per 1.73 m(2) of body-surface area was higher with the cystatin C-based eGFR than with the creatinine-based eGFR (13.7% vs. 9.7%). Across all eGFR categories, the reclassification of the eGFR to a higher value with the measurement of cystatin C, as compared with creatinine, was associated with a reduced risk of all three study outcomes, and reclassification to a lower eGFR was associated with an increased risk. The net reclassification improvement with the measurement of cystatin C, as compared with creatinine, was 0.23 (95% confidence interval [CI], 0.18 to 0.28) for death and 0.10 (95% CI, 0.00 to 0.21) for end-stage renal disease. Results were generally similar for the five cohorts with chronic kidney disease and when both creatinine and cystatin C were used to calculate the eGFR. CONCLUSIONS The use of cystatin C alone or in combination with creatinine strengthens the association between the eGFR and the risks of death and end-stage renal disease across diverse populations. C1 [Shlipak, Michael G.] Univ Calif San Francisco, Div Gen Internal Med, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med Epidemiol & Biostat, San Francisco, CA 94143 USA. [Matsushita, Kunihiro; Coresh, Josef] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Arnlov, Johan] Geriatr Uppsala Univ, Dept Publ Hlth & Caring Sci, Uppsala, Sweden. [Arnlov, Johan] Dalarna Univ, Sch Hlth & Social Studies, Falun, Sweden. [Inker, Lesley A.; Sarnak, Mark J.; Levey, Andrew S.] Tufts Med Ctr, Div Nephrol, Boston, MA USA. [Katz, Ronit] Univ Washington, Seattle, WA 98195 USA. [Polkinghorne, Kevan R.] Monash Univ, Dept Nephrol, Monash Med Ctr, Melbourne, Vic 3004, Australia. [Polkinghorne, Kevan R.] Monash Univ, Dept Med, Melbourne, Vic, Australia. [Rothenbacher, Dietrich] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany. [Rothenbacher, Dietrich] Univ Ulm, Inst Epidemiol & Med Biometry, Ulm, Germany. [Astor, Brad C.] Univ Wisconsin, Dept Populat Hlth Sci, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Gansevoort, Ron T.] Univ Groningen, Univ Med Ctr Groningen, Dept Nephrol, Groningen, Netherlands. RP Coresh, J (reprint author), Chron Kidney Dis Prognosis Consortium Data Coordi, 615 Wolfe St, Baltimore, MD 21205 USA. RI Arnlov, Johan/N-9886-2013; Schottker, Ben/F-8183-2014; Wetzels, Jack/A-1720-2014; Kronenberg, Florian/B-1736-2008; Brenner, Hermann/B-4627-2017 OI Schottker, Ben/0000-0002-1217-4521; Kronenberg, Florian/0000-0003-2229-1120; Brenner, Hermann/0000-0002-6129-1572; Klein, Ronald/0000-0002-4428-6237; Townend, Jonathan/0000-0002-5881-5806 FU National Kidney Foundation FX Funded by the National Kidney Foundation and others. NR 52 TC 225 Z9 240 U1 4 U2 29 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD SEP 5 PY 2013 VL 369 IS 10 BP 932 EP 943 DI 10.1056/NEJMoa1214234 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 211KV UT WOS:000323906900010 PM 24004120 ER PT J AU Peng, ZC Zhang, NH Wei, WZ Huang, CS Cetina, Y Otis, TS Houser, CR AF Peng, Zechun Zhang, Nianhui Wei, Weizheng Huang, Christine S. Cetina, Yliana Otis, Thomas S. Houser, Carolyn R. TI A Reorganized GABAergic Circuit in a Model of Epilepsy: Evidence from Optogenetic Labeling and Stimulation of Somatostatin Interneurons SO JOURNAL OF NEUROSCIENCE LA English DT Article ID TEMPORAL-LOBE EPILEPSY; KAINATE-TREATED RATS; SPONTANEOUS RECURRENT SEIZURES; FIBER SYNAPTIC REORGANIZATION; PILOCARPINE-INDUCED SEIZURES; CA1 PYRAMIDAL CELLS; DENTATE GYRUS; MOUSE MODEL; GRANULE CELLS; FASCIA-DENTATA AB Axonal sprouting of excitatory neurons is frequently observed in temporal lobe epilepsy, but the extent to which inhibitory interneurons undergo similar axonal reorganization remains unclear. The goal of this study was to determine whether somatostatin (SOM)-expressing neurons in stratum (s.) oriens of the hippocampus exhibit axonal sprouting beyond their normal territory and innervate granule cells of the dentate gyrus in a pilocarpine model of epilepsy. To obtain selective labeling of SOM-expressing neurons in s. oriens, a Cre recombinase-dependent construct for channelrhodopsin2 fused to enhanced yellow fluorescent protein (ChR2-eYFP) was virally delivered to this region in SOM-Cre mice. In control mice, labeled axons were restricted primarily to s. lacunosum-moleculare. However, in pilocarpine-treated animals, a rich plexus of ChR2-eYFP-labeled fibers and boutons extended into the dentate molecular layer. Electron microscopy with immunogold labeling demonstrated labeled axon terminals that formed symmetric synapses on dendritic profiles in this region, consistent with innervation of granule cells. Patterned illumination of ChR2-labeled fibers in s. lacunosum-moleculare of CA1 and the dentate molecular layer elicited GABAergic inhibitory responses in dentate granule cells in pilocarpine-treated mice but not in controls. Similar optical stimulation in the dentate hilus evoked no significant responses in granule cells of either group of mice. These findings indicate that under pathological conditions, SOM/GABAergic neurons can undergo substantial axonal reorganization beyond their normal territory and establish aberrant synaptic connections. Such reorganized circuitry could contribute to functional deficits in inhibition in epilepsy, despite the presence of numerous GABAergic terminals in the region. C1 [Peng, Zechun; Zhang, Nianhui; Huang, Christine S.; Cetina, Yliana; Otis, Thomas S.; Houser, Carolyn R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. [Wei, Weizheng] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Otis, Thomas S.; Houser, Carolyn R.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. Vet Adm Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. RP Houser, CR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, CHS 73-235,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM houser@mednet.ucla.edu FU National Institutes of Health [NS075245, RR029267, NS068408]; Veterans Affairs Medical Research Funds FX This work was supported by National Institutes of Health Grants NS075245 (C. R. H.), RR029267 (T.S.O.), and NS068408 (T.S.O.) and Veterans Affairs Medical Research Funds (C. R. H.). We gratefully acknowledge Dr. Karl Deisseroth for making reagents available through Addgene and the Penn Vector Core in the School of Medicine Gene Therapy Program at the University of Pennsylvania for preparation of the viral vector. We thank Dr. Istvan Mody for helpful discussions. NR 61 TC 31 Z9 31 U1 1 U2 28 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD SEP 4 PY 2013 VL 33 IS 36 BP 14392 EP 14405 DI 10.1523/JNEUROSCI.2045-13.2013 PG 14 WC Neurosciences SC Neurosciences & Neurology GA 214VQ UT WOS:000324165500013 PM 24005292 ER PT J AU Castiblanco, J Arcos-Burgos, M Anaya, JM AF Castiblanco, John Arcos-Burgos, Mauricio Anaya, Juan-Manuel TI What is next after the genes for autoimmunity? SO BMC MEDICINE LA English DT Review DE Autoimmunity; Common; Genetics; Genomics; Personalized; Predictive medicine; Polyautoimmunity; Translational medicine ID GENOME-WIDE ASSOCIATION; DISEASE GENETICS; MEDICINE; MECHANISMS; BIOINFORMATICS; HERITABILITY; ENVIRONMENT; MICROBIOME; EXPRESSION; DISORDERS AB Clinical pathologies draw us to envisage disease as either an independent entity or a diverse set of traits governed by common physiopathological mechanisms, prompted by environmental assaults throughout life. Autoimmune diseases are not an exception, given they represent a diverse collection of diseases in terms of their demographic profile and primary clinical manifestations. Although they are pleiotropic outcomes of non-specific disease genes underlying similar immunogenetic mechanisms, research generally focuses on a single disease. Drastic technologic advances are leading research to organize clinical genomic multidisciplinary approaches to decipher the nature of human biological systems. Once the currently costly omic-based technologies become universally accessible, the way will be paved for a cleaner picture to risk quantification, prevention, prognosis and diagnosis, allowing us to clearly define better phenotypes always ensuring the integrity of the individuals studied. However, making accurate predictions for most autoimmune diseases is an ambitious challenge, since the understanding of these pathologies is far from complete. Herein, some pitfalls and challenges of the genetics of autoimmune diseases are reviewed, and an approximation to the future of research in this field is presented. C1 [Castiblanco, John; Anaya, Juan-Manuel] Univ Rosario, Ctr Autoimmune Dis Res CREA, Sch Med & Hlth Sci, Bogota, Colombia. [Castiblanco, John] Univ Rosario, Doctoral Program Biomed Sci, Bogota, Colombia. [Castiblanco, John] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, Ctr Personalized Med, San Antonio, TX 78229 USA. [Castiblanco, John] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Arcos-Burgos, Mauricio] Australian Natl Univ, John Curtin Sch Med Res, Genome Biol Dept, ANU Coll Med Biol & Environm, Canberra, ACT 2601, Australia. RP Anaya, JM (reprint author), Univ Rosario, Ctr Autoimmune Dis Res CREA, Sch Med & Hlth Sci, Carrera 24 63-C-69, Bogota, Colombia. EM juan.anaya@urosario.edu.co RI CASTIBLANCO, JOHN/B-6599-2009; Anaya, Juan-Manuel/J-1960-2016 OI CASTIBLANCO, JOHN/0000-0002-7965-9822; Anaya, Juan-Manuel/0000-0002-6444-1249; Universidad del Rosario, Biblioteca/0000-0003-3491-9392 FU Universidad del Rosario; Colciencias, Bogota, Colombia [122254531722] FX This work was supported by Universidad del Rosario and Colciencias (122254531722), Bogota, Colombia. NR 60 TC 10 Z9 10 U1 0 U2 19 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1741-7015 J9 BMC MED JI BMC Med. PD SEP 4 PY 2013 VL 11 AR 197 DI 10.1186/1741-7015-11-197 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 211KM UT WOS:000323905900001 PM 24107170 ER PT J AU Deswal, A Basra, SS AF Deswal, Anita Basra, Sukhdeep S. TI Incident Cancer in Patients With Heart Failure Causation or Mere Association? SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Editorial Material DE cancer; epidemiology; follow-up studies; heart failure; risk C1 [Deswal, Anita] Michael E DeBakey VAMC, Sect Cardiol, Houston, TX USA. [Deswal, Anita; Basra, Sukhdeep S.] Baylor Coll Med, Cardiol Sect, Houston, TX 77030 USA. RP Deswal, A (reprint author), Michael E DeBakey VA Med Ctr 111B, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM adeswal@bcm.edu NR 10 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD SEP 3 PY 2013 VL 62 IS 10 BP 887 EP 888 DI 10.1016/j.jacc.2013.04.087 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 211IO UT WOS:000323900300006 PM 23810872 ER PT J AU Beach, MC Roter, D Korthuis, PT Epstein, RM Sharp, V Ratanawongsa, N Cohn, J Eggly, S Sankar, A Moore, RD Saha, S AF Beach, Mary Catherine Roter, Debra Korthuis, P. Todd Epstein, Ronald M. Sharp, Victoria Ratanawongsa, Neda Cohn, Jonathon Eggly, Susan Sankar, Andrea Moore, Richard D. Saha, Somnath TI A Multicenter Study of Physician Mindfulness and Health Care Quality SO ANNALS OF FAMILY MEDICINE LA English DT Article DE patient-physician relations; patient-physician communication; mindfulness; HIV; acquired immunodeficiency syndrome ID PATIENT-PROVIDER COMMUNICATION; STRESS REDUCTION; CLINICAL-PRACTICE; MEDICAL-STUDENTS; HIV; SATISFACTION; PROGRAM; PARTICIPATION; CENTEREDNESS; ADHERENCE AB PURPOSE Mindfulness (ie, purposeful and nonjudgmental attentiveness to one's own experience, thoughts, and feelings) is associated with physician well-being. We sought to assess whether clinician self-rated mindfulness is associated with the quality of patient care. METHODS We conducted an observational study of 45 clinicians (34 physicians, 8 nurse practitioners, and 3 physician assistants) caring for patients infected with the human immunodeficiency virus (HIV) who completed the Mindful Attention Awareness Scale and 437 HIV-infected patients at 4 HIV specialty clinic sites across the United States. We measured patient-clinician communication quality with audio-recorded encounters coded using the Roter Interaction Analysis System (RIAS) and patient ratings of care. RESULTS In adjusted analyses comparing clinicians with highest and lowest tertile mindfulness scores, patient visits with high-mindfulness clinicians were more likely to be characterized by a patient-centered pattern of communication (adjusted odds ratio of a patient-centered visit was 4.14; 95% CI, 1.58-10.86), in which both patients and clinicians engaged in more rapport building and discussion of psychosocial issues. Clinicians with high-mindfulness scores also displayed more positive emotional tone with patients (adjusted beta = 1.17; 95% CI, 0.46-1.9). Patients were more likely to give high ratings on clinician communication (adjusted prevalence ratio [APR] = 1.48; 95% CI, 1.17-1.86) and to report high overall satisfaction (APR = 1.45; 95 CI, 1.15-1.84) with high-mindfulness clinicians. There was no association between clinician mindfulness and the amount of conversation about biomedical issues. CONCLUSIONS Clinicians rating themselves as more mindful engage in more patient-centered communication and have more satisfied patients. Interventions should determine whether improving clinician mindfulness can also improve patient health outcomes. C1 [Beach, Mary Catherine; Roter, Debra; Moore, Richard D.] Johns Hopkins Univ, Baltimore, MD USA. [Korthuis, P. Todd; Saha, Somnath] Oregon Hlth & Sci Univ, Portland, OR USA. [Epstein, Ronald M.] Univ Rochester, Rochester, NY USA. [Sharp, Victoria] St Lukes Roosevelt Hosp, New York, NY USA. [Ratanawongsa, Neda] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Cohn, Jonathon; Eggly, Susan; Sankar, Andrea] Wayne State Univ, Detroit, MI USA. [Saha, Somnath] Portland VA Med Ctr, Portland, OR USA. RP Beach, MC (reprint author), Johns Hopkins Univ, Div Gen Internal Med, Room 2-511,2024 East Monument St, Baltimore, MD 21287 USA. EM mcbeach@jhmi.edu RI Roter, Debra/N-8830-2014 OI Eggly, Susan/0000-0002-8137-6098 FU Health Resources Service Administration; Agency for Healthcare Research and Quality [AHRQ 290-01-0012, K08 HS013903-05]; National Institute of Drug Abuse [K23 DA019809]; Department of Veterans Affairs; Robert Wood Johnson Generalist Physician Faculty Scholars Awards FX This research was supported by a contract from the Health Resources Service Administration and the Agency for Healthcare Research and Quality (AHRQ 290-01-0012). In addition, Dr Korthuis was supported by the National Institute of Drug Abuse (K23 DA019809), Dr Saha was supported by the Department of Veterans Affairs, Dr Beach was supported by the Agency for Healthcare Research and Quality (K08 HS013903-05), and both Drs Beach and Saha were supported by Robert Wood Johnson Generalist Physician Faculty Scholars Awards. NR 39 TC 34 Z9 34 U1 3 U2 11 PU ANNALS FAMILY MEDICINE PI LEAWOOD PA 11400 TOMAHAWK CREEK PARKWAY, LEAWOOD, KS 66211-2672 USA SN 1544-1709 EI 1544-1717 J9 ANN FAM MED JI Ann. Fam. Med. PD SEP-OCT PY 2013 VL 11 IS 5 BP 421 EP 428 DI 10.1370/afm.1507 PG 8 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA AI3XN UT WOS:000336799100006 PM 24019273 ER PT J AU Dadu, RT Dodge, R Nambi, V Virani, SS Hoogeveen, RC Smith, NL Chen, FJ Pankow, JS Guild, C Tang, WHW Boerwinkle, E Hazen, SL Ballantyne, CM AF Dadu, Razvan T. Dodge, Rhiannon Nambi, Vijay Virani, Salim S. Hoogeveen, Ron C. Smith, Nicholas L. Chen, Fengju Pankow, James S. Guild, Cameron Tang, W. H. Wilson Boerwinkle, Eric Hazen, Stanley L. Ballantyne, Christie M. TI Ceruloplasmin and Heart Failure in the Atherosclerosis Risk in Communities Study SO CIRCULATION-HEART FAILURE LA English DT Article DE cardiovascular diseases; ceruloplasmin; heart failure; polymorphism; single nucleotide ID SENSITIVE PLASMA-PROTEINS; ACUTE-PHASE PROTEINS; C-REACTIVE PROTEIN; MYOCARDIAL-INFARCTION; SERUM CERULOPLASMIN; CARDIOVASCULAR RISK; OXIDATIVE STRESS; NITRIC-OXIDE; DISEASE; ASSOCIATION AB Background Ceruloplasmin (Cp) decreases nitric oxide bioavailability in blood and has been associated with cardiovascular disease (CVD) in clinical studies. We assessed the associations between Cp and incident heart failure (HF), death, and CVD in the Atherosclerosis Risk in Communities (ARIC) study. Methods and Results Cp was measured at ARIC visit 4 (1996-1998). We studied 9240 individuals without HF or CVD at ARIC visit 4 and followed them for a mean of 10.5 years. Genome-wide association study was performed to identify genetic determinants of Cp levels and evaluate their association with incident HF in ARIC participants. Cp levels (meanSD) were higher in women versus men (335 +/- 79 versus 258 +/- 44 mg/L; P<0.0001), women on versus not on hormone-replacement therapy (398 +/- 89 versus 291 +/- 60 mg/L; P<0.0001), and African Americans versus whites (299 +/- 63 versus 293 +/- 74 mg/L; P=0.0005). After adjusting for traditional risk factors, high-sensitivity C-reactive protein, N-terminal pro-B-type natriuretic peptide, and high-sensitivity cardiac troponin T, higher levels of Cp were associated with HF (hazard ratio, 1.44; 95% confidence interval, 1.13-1.83) and mortality (hazard ratio, 1.38; 95% confidence interval, 1.11-1.63). A locus on the ceruloplasmin gene on chromosome 3 was significantly associated with Cp levels (normal 295.56 +/- 77.60 mg/L; heterozygote 316.72 +/- 88.02 mg/L; homozygote 331.04 +/- 85.40 mg/L; P=8.3x10(-13)) but not with incident HF. After adjustment for traditional risk factors, Cp levels were also weekly associated with CVD. Conclusions Cp was associated with incident HF, mortality, and CVD in the ARIC population. A single locus on chromosome 3 was associated with Cp levels but not with HF. C1 [Dadu, Razvan T.; Nambi, Vijay; Virani, Salim S.; Hoogeveen, Ron C.; Ballantyne, Christie M.] Baylor Coll Med, Dept Med, Sect Cardiovasc Res, Houston, TX 77030 USA. [Virani, Salim S.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Ballantyne, Christie M.] Baylor Coll Med, Dept Med, Cardiol Sect, Houston, TX 77030 USA. [Dadu, Razvan T.; Nambi, Vijay; Virani, Salim S.; Hoogeveen, Ron C.; Ballantyne, Christie M.] Methodist DeBakey Heart & Vasc Ctr, Ctr Cardiovasc Dis Prevent, Houston, TX USA. [Dodge, Rhiannon; Chen, Fengju; Boerwinkle, Eric] Univ Texas Hlth Sci Ctr Houston, Ctr Human Genet, Houston, TX 77030 USA. [Virani, Salim S.] Michael E DeBakey VA Med Ctr Hlth Serv, Res & Dev Ctr Excellence, Hlth Policy & Qual Program, Houston, TX USA. [Pankow, James S.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Guild, Cameron] Univ Mississippi, Med Ctr, Div Cardiovasc Dis, Jackson, MS 39216 USA. [Tang, W. H. Wilson; Hazen, Stanley L.] Cleveland Clin Fdn, Cleveland, OH USA. [Smith, Nicholas L.] Univ Washington, Dept Cardiovasc Res, Seattle, WA 98195 USA. RP Ballantyne, CM (reprint author), Baylor Coll Med, 6565 Fannin St,MS A601, Houston, TX 77030 USA. EM cmb@bcm.edu OI Virani, Salim/0000-0001-9541-6954; Pankow, James/0000-0001-7076-483X FU National Heart, Lung, and Blood Institute [HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN26820110 0009C, HHSN268201100010C, HHSN268201100011C, HHSN 268201100012C, R01HL087641, R01HL59367, R01HL 086694]; National Human Genome Research Institute [U01HG004402]; National Institutes of Health (NIH) [HHSN268200625226C]; NIH [UL1RR025005, 2P01HL076491, 1R01HL103931]; NIH Roadmap for Medical Research FX The Atherosclerosis Risk in Communities study is performed as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN26820110 0009C, HHSN268201100010C, HHSN268201100011C, and HHSN 268201100012C), R01HL087641, R01HL59367, and R01HL 086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health (NIH) contract HHSN268200625226C. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the NIH and NIH Roadmap for Medical Research. This work was also supported by NIH grants 2P01HL076491 (Dr Hazen) and 1R01HL103931 (Dr Tang). NR 29 TC 12 Z9 13 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-3289 EI 1941-3297 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD SEP PY 2013 VL 6 IS 5 BP 936 EP 943 DI 10.1161/CIRCHEARTFAILURE.113.000270 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AG2GO UT WOS:000335234500012 PM 23861484 ER PT J AU Homma, S Thompson, JLP Sanford, AR Mann, DL Sacco, RL Levin, B Pullicino, PM Freudenberger, RS Teerlink, JR Graham, S Mohr, JP Massie, BM Labovitz, AJ Di Tullio, MR Gabriel, AP Lip, GYH Estol, CJ Lok, DJ Ponikowski, P Anker, SD AF Homma, Shunichi Thompson, John L. P. Sanford, Alexandra R. Mann, Douglas L. Sacco, Ralph L. Levin, Bruce Pullicino, Patrick M. Freudenberger, Ronald S. Teerlink, John R. Graham, Susan Mohr, J. P. Massie, Barry M. Labovitz, Arthur J. Di Tullio, Marco R. Gabriel, Andre P. Lip, Gregory Y. H. Estol, Conrado J. Lok, Dirk J. Ponikowski, Piotr Anker, Stefan D. CA WARCEF Investigators TI Benefit of Warfarin Compared With Aspirin in Patients With Heart Failure in Sinus Rhythm A Subgroup Analysis of WARCEF, a Randomized Controlled Trial SO CIRCULATION-HEART FAILURE LA English DT Article DE aspirin; heart failure; sinus rhythm; stroke; warfarin ID ATRIAL-FIBRILLATION; SURVIVAL; THERAPY; DISEASE; STROKE AB Background The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial found no difference in the primary outcome between warfarin and aspirin in 2305 patients with reduced left ventricular ejection fraction in sinus rhythm. However, it is unknown whether any subgroups benefit from warfarin or aspirin. Methods and Results We used a Cox model stepwise selection procedure to identify subgroups that may benefit from warfarin or aspirin on the WARCEF primary outcome. A secondary analysis added major hemorrhage to the outcome. The primary efficacy outcome was time to the first to occur of ischemic stroke, intracerebral hemorrhage, or death. Only age group was a significant treatment effect modifier (P for interaction, 0.003). Younger patients benefited from warfarin over aspirin on the primary outcome (4.81 versus 6.76 events per 100 patient-years: hazard ratio, 0.63; 95% confidence interval, 0.48-0.84; P=0.001). In older patients, therapies did not differ (9.91 versus 9.01 events per 100 patient-years: hazard ratio, 1.09; 95% confidence interval, 0.88-1.35; P=0.44). With major hemorrhage added, in younger patients the event rate remained lower for warfarin than aspirin (5.41 versus 7.25 per 100 patient-years: hazard ratio, 0.68; 95% confidence interval, 0.52-0.89; P=0.005), but in older patients it became significantly higher for warfarin (11.80 versus 9.35 per 100 patient-years: hazard ratio, 1.25; 95% confidence interval, 1.02-1.53; P=0.03). Conclusions In patients <60 years, warfarin improved outcomes over aspirin with or without inclusion of major hemorrhage. In patients 60 years, there was no treatment difference, but the aspirin group had significantly better outcomes when major hemorrhage was included. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT00041938. C1 [Homma, Shunichi; Di Tullio, Marco R.; Gabriel, Andre P.] Columbia Univ, Med Ctr, Dept Med, Div Cardiol, New York, NY 10032 USA. [Mohr, J. P.] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA. [Thompson, John L. P.; Sanford, Alexandra R.; Levin, Bruce] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY 10032 USA. [Mann, Douglas L.] Washington Univ, Dept Med, St Louis, MO USA. [Sacco, Ralph L.] Univ Miami, Miller Sch Med, Dept Neurol, Coral Gables, FL 33124 USA. [Pullicino, Patrick M.] Univ Kent, Kent Inst Med & Hlth Sci, Canterbury, Kent, England. [Freudenberger, Ronald S.] Lehigh Valley Hosp, Dept Med, Div Cardiol, Allentown, PA USA. [Teerlink, John R.; Massie, Barry M.] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Med, Cardiol Sect, San Francisco, CA USA. [Graham, Susan] SUNY Upstate Med Univ, Dept Med, Div Cardiol, Buffalo, NY USA. [Labovitz, Arthur J.] Univ S Florida, Dept Cardiovasc Med, Tampa, FL USA. [Lip, Gregory Y. H.] Univ Birmingham, City Hosp, Ctr Cardiovasc Sci, Birmingham, W Midlands, England. [Estol, Conrado J.] Ctr Neurol Tratamiento & Rehabil, Buenos Aires, DF, Argentina. [Lok, Dirk J.] Deventer Hosp, Dept Cardiol, Deventer, Netherlands. [Ponikowski, Piotr] Wroclaw Med Univ, Mil Hosp, Dept Heart Dis, Wroclaw, Poland. [Anker, Stefan D.] Charite, Campus Virchow Klinikum, Dept Cardiol, D-13353 Berlin, Germany. RP Homma, S (reprint author), Columbia Univ, Med Ctr, PH 3-342,622 W 168th St, New York, NY 10032 USA. EM sh23@columbia.edu RI Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064; Mann, Douglas /0000-0002-2516-0145 FU National Institute of Neurological Diseases and Stroke [U01-NS-043975, U01-NS-039143] FX The WARCEF trial was supported by grant nos. U01-NS-043975 to Dr Homma and U01-NS-039143 to Dr Thompson from the National Institute of Neurological Diseases and Stroke. Warfarin and warfarin placebo were provided by Taro Pharmaceuticals USA, and aspirin and aspirin placebo by Bayer HealthCare. NR 21 TC 13 Z9 15 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-3289 EI 1941-3297 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD SEP PY 2013 VL 6 IS 5 BP 988 EP 997 DI 10.1161/CIRCHEARTFAILURE.113.000372 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AG2GO UT WOS:000335234500018 PM 23881846 ER PT J AU Platt, AB Wick, LC Hurley, S Soto-Calderon, H Wieland, W Staley, B Maislin, G Gurubhagavatula, I AF Platt, Alec B. Wick, Lindsay C. Hurley, Sharon Soto-Calderon, Haideliza Wieland, Will Staley, Beth Maislin, Greg Gurubhagavatula, Indira TI Hits and Misses Screening Commercial Drivers for Obstructive Sleep Apnea Using Guidelines Recommended by a Joint Task Force SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID MOTOR-VEHICLE CRASH; RISK; METAANALYSIS; ACCIDENTS; DIAGNOSIS; OBESITY; ADULTS AB Objective: To evaluate joint task force criteria-based screening for severe obstructive sleep apnea (s-OSA) in commercial drivers. Methods: Among a community-based cohort of licensed commercial vehicle drivers, we assessed utility of the joint task force criteria. We conducted full, 14-channel overnight polysomnography in all drivers, defining s-OSA as an apnea-hypopnea index of 30 or more per hour. Results: One hundred of 104 drivers with successful polysomnography studies were predominantly obese (median body mass index = 32.8 kg/m(2); interquartile range = 26.8 to 37.4) and had a median apnea-hypopnea index of 20.6 per hour (interquartile range = 10.0 to 34.2). Examination-based criteria were more effective (sensitivity = 80%; negative posttest probability [nPTP] = 17%) than symptom-based criteria (sensitivity = 63%; nPTP = 23%). Examination and symptom-based criteria combined had high sensitivity (97%) and low nPTP (7%), but poor specificity (19%). Conclusions: Examination-based criteria missed 20% of s-OSA cases. Combining examination with confidentially reported symptoms improved sensitivity but required confirmatory polysomnography in 86%, supporting universal screening of all drivers. C1 [Platt, Alec B.] Resp Specialists, Wyomissing, PA USA. [Platt, Alec B.; Gurubhagavatula, Indira] Univ Penn, Perelman Sch Med, Div Sleep Med, Philadelphia, PA 19104 USA. [Wick, Lindsay C.; Hurley, Sharon; Soto-Calderon, Haideliza; Wieland, Will; Staley, Beth; Maislin, Greg; Gurubhagavatula, Indira] Univ Penn, Med Ctr, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA. [Gurubhagavatula, Indira] Philadelphia VA Med Ctr, Pulm Crit Care & Sleep Sect, Philadelphia, PA USA. RP Platt, AB (reprint author), 2608 Keiser Blvd, Wyomissing, PA 19610 USA. EM alecplatt@gmail.com FU NIOSH/CDC [R01-OH009149] FX The study was supported by NIOSH/CDC R01-OH009149. Embla Inc provided an unrestricted loan of sleep diagnostic equipment. NR 25 TC 8 Z9 8 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD SEP PY 2013 VL 55 IS 9 BP 1035 EP 1040 DI 10.1097/JOM.0b013e318298fb0e PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 300EY UT WOS:000330448400007 PM 23969501 ER PT J AU Lawson, EH Hall, BL Ko, CY AF Lawson, Elise H. Hall, Bruce Lee Ko, Clifford Y. TI Risk Factors for Superficial vs Deep/Organ-Space Surgical Site Infections Implications for Quality Improvement Initiatives SO JAMA SURGERY LA English DT Article ID COLORECTAL SURGERY; WOUND-INFECTION; CARE; MORTALITY; PROGRAM; HOSPITALIZATION; SURVEILLANCE; ASSOCIATION; RESECTION; COLON AB IMPORTANCE Surgical site infections (SSIs) are the focus of numerous quality improvement initiatives because they are a common and costly cause of potentially preventable patient morbidity. Superficial and deep/organ-space SSIs differ in terms of anatomical location and clinical severity. OBJECTIVE To identify risk factors that are uniquely predictive of superficial vs deep/organ-space SSIs occurring after colectomy procedures. DESIGN Retrospective cohort study. SETTING American College of Surgeons National Surgical Quality Improvement Program. PARTICIPANTS Patients undergoing colectomy procedures in 2011 were identified by Current Procedural Terminology codes. INTERVENTION Colectomy procedures. MAIN OUTCOMES AND MEASURES We compared rates of superficial SSI and deep/organ-space SSI associated with perioperative variables of interest: demographics; preoperative clinical severity, risk factors, and comorbidities and variables related to the hospitalization or procedure. Hierarchical multivariable logistic regression models were developed to identify risk-adjusted predictors of each SSI type. RESULTS Among 27 011 patients identified from 305 hospitals, 6.2% developed a superficial SSI and 4.7% developed a deep/organ-space SSI. Risk factors common to the occurrence of both SSI types were identified: open surgery (vs laparoscopic) and current smoker. Risk factors with differential effects on each SSI type included specific postoperative diagnoses, disseminated cancer, and irradiation therapy, which were all associated with increased odds of deep/organ-space SSI only. The graded relationship between increasing body mass index and SSI occurrence appeared to be stronger for superficial SSI. CONCLUSIONS AND RELEVANCE Risk factors for superficial SSI and deep/organ-space SSI vary in terms of magnitude and significance, suggesting that these SSI types are somewhat different disease processes. Groups interested in preventing SSIs might improve success by considering these SSI types independently for root-cause analyses and development of best practices and interventions. C1 [Lawson, Elise H.; Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Hall, Bruce Lee] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA. [Hall, Bruce Lee] Barnes Jewish Hosp, St Louis, MO 63110 USA. [Hall, Bruce Lee] St Louis Vet Affairs Med Ctr, Ctr Hlth Policy, St Louis, MO USA. [Hall, Bruce Lee] Washington Univ, John M Olin Sch Business, St Louis, MO 63130 USA. [Hall, Bruce Lee; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Lawson, EH (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 Le Conte Ave,72-215 CHS, Los Angeles, CA 90095 USA. EM elawson@mednet.ucla.edu FU VA Health Services Research and Development program grant [RWJ 65-020]; ACS through the Robert Wood Johnson Foundation Clinical Scholars Program FX Dr Lawson's time was supported by VA Health Services Research and Development program grant RWJ 65-020 and the ACS through the Robert Wood Johnson Foundation Clinical Scholars Program. Dr Hall is a consultant for the ACS and Dr Ko is staff at the ACS. NR 30 TC 30 Z9 31 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD SEP PY 2013 VL 148 IS 9 BP 849 EP 858 DI 10.1001/jamasurg.2013.2925 PG 10 WC Surgery SC Surgery GA 228TE UT WOS:000325212300014 PM 23864108 ER PT J AU Cook, JM Pilver, C Dinnen, S Schnurr, PP Hoff, R AF Cook, Joan M. Pilver, Corey Dinnen, Stephanie Schnurr, Paula P. Hoff, Rani TI Prevalence of Physical and Sexual Assault and Mental Health Disorders in Older Women: Findings From a Nationally Representative Sample SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE Geriatric; interpersonal violence; PTSD; women ID POSTTRAUMATIC-STRESS-DISORDER; INTIMATE PARTNER VIOLENCE; TRAUMATIC EVENTS; COMORBIDITY-SURVEY; DOMESTIC VIOLENCE; VERBAL ABUSE; RISK-FACTORS; ADULTS; POPULATION; IMPACT AB Objectives: This study presents prevalence and characteristics of physical and sexual assaults, and their relationship to posttraumatic stress disorder (PTSD), and mood and anxiety disorders in a nationally representative sample of older women. Design and Setting: Face-to-face interviews conducted with adult participants from wave 2 of the National Epidemiological Survey on Alcohol and Related Conditions. Participants: A total of 3,354 community-residing women of age 65 years and older. Measurement: Alcohol Use Disorder and Associated Disabilities Interview Schedule for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, current mood and anxiety disorders. Results: Almost 14% of participants reported a history of physical or sexual assault or both during their lifetimes. Assaults were often repeated rather than isolated events. Although the majority of participants did not identify interpersonal violence as their "worst" traumatic event, those who experienced interpersonal violence were generally more likely than those without such history to meet the criteria for past-year and lifetime PTSDs, depression, and anxiety. Conclusions: Some women who have been physically or sexually assaulted decades earlier continue to report significant levels of mood and anxiety disorders into late adulthood. Several ways to increase the identification and treatment of older female trauma survivors by healthcare providers are suggested. C1 [Cook, Joan M.; Pilver, Corey; Dinnen, Stephanie; Hoff, Rani] Yale Univ, Sch Med, New Haven, CT USA. [Cook, Joan M.; Schnurr, Paula P.] US Dept Vet Affairs, Natl Ctr PTSD, Washington, DC USA. [Schnurr, Paula P.] Geisel Sch Med, Dartmouth Med Sch, Hanover, NH USA. RP Cook, JM (reprint author), Yale Univ, Sch Med, Natl Ctr PTSD, NEPEC 182,950 Campbell Ave, West Haven, CT 06516 USA. EM Joan.Cook@yale.edu NR 41 TC 5 Z9 5 U1 7 U2 18 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD SEP PY 2013 VL 21 IS 9 BP 877 EP 886 DI 10.1016/j.jagp.2013.01.016 PG 10 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 298YW UT WOS:000330361900009 PM 23567392 ER PT J AU Chen, LX Mao, JJ Fernandes, S Galantino, ML Guo, WS LaRiccia, P Teal, VL Bowman, MA Schumacher, HR Farrar, JT AF Chen, Lan X. Mao, Jun J. Fernandes, Shawn Galantino, Mary Lou Guo, Wensheng LaRiccia, Patrick Teal, Valerie L. Bowman, Marjorie A. Schumacher, H. Ralph Farrar, John T. TI Integrating Acupuncture With Exercise-Based Physical Therapy for Knee Osteoarthritis A Randomized Controlled Trial SO JCR-JOURNAL OF CLINICAL RHEUMATOLOGY LA English DT Article DE acupuncture; physical therapy; osteoarthritis of the knee; placebo-controlled randomized trial; obese patients; African American ID CHRONIC PAIN; ALTERNATIVE MEDICINE; CLINICAL IMPORTANCE; PATIENT; EXPECTATIONS; OUTCOMES; RECOMMENDATIONS; COMPLEMENTARY AB Background: Knee osteoarthritis is a chronic disease associated with significant morbidity and economic cost. The efficacy of acupuncture in addition to traditional physical therapy has received little study. Objective: The objective of this study was to compare the efficacy and safety of integrating a standardized true acupuncture protocol versus nonpenetrating acupuncture into exercise-based physical therapy (EPT). Methods: This was a randomized, double-blind, controlled trial at 3 physical therapy centers in Philadelphia, PA. We studied 214 patients (66% African Americans) with at least 6 months of chronic knee pain and x-ray-confirmed Kellgren scores of 2 or 3. Patients received 12 sessions of acupuncture directly following EPT over 6 to 12 weeks. Acupuncture was performed at the same 9 points dictated by the traditional Chinese "Bi" syndrome approach to knee pain, using either standard needles or Streitberger non-skin-puncturing needles. The primary outcome was the proportion of patients with at least a 36% improvement in Western Ontario and McMaster Universities Osteoarthritis Index score at 12 weeks. Results: Both treatment groups showed improvement from combined therapy with no difference between true (31.6%) and nonpenetrating acupuncture (30.3%) in Western Ontario and McMaster Universities Osteoarthritis Index response rate (P = 0.5) or report of minor adverse events. A multivariable logistic regression prediction model identified an association between a positive expectation of relief from acupuncture and reported improvement. No differences were noted by race, sex, or age. Conclusions: Puncturing acupuncture needles did not perform any better than nonpuncturing needles integrated with EPT. Whether EPT, acupuncture, or other factors accounted for any improvement noted in both groups could not be determined in this study. Expectation for relief was a predictor of reported benefit. C1 [Chen, Lan X.] Univ Penn, Penn Presbyterian Med Ctr, Philadelphia, PA 19104 USA. [Mao, Jun J.; Fernandes, Shawn; Galantino, Mary Lou; Guo, Wensheng; LaRiccia, Patrick; Teal, Valerie L.; Bowman, Marjorie A.; Farrar, John T.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Mao, Jun J.] Univ Penn, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA. [Galantino, Mary Lou] Univ Penn, Div Rheumatol, Philadelphia, PA 19104 USA. [Schumacher, H. Ralph] Richard Stockton Coll New Jersey, Program Phys Therapy, Galloway, NJ USA. [Schumacher, H. Ralph] Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Farrar, JT (reprint author), Univ Penn, Sch Med, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Blockley Hall,Room 816,423 Guardian Dr, Philadelphia, PA 19104 USA. EM jfarrar@mail.med.upenn.edu FU National Institutes of Health/National Center for Complementary and Alternative Medicine (NCCAM) [R01-AT000304]; NCCAM [K23 AT004112] FX This study is supported by a grant from the National Institutes of Health/National Center for Complementary and Alternative Medicine (NCCAM) R01-AT000304. Dr Mao is also supported by NCCAM K23 AT004112. The funding agency had no role in the design and conduct of this study. NR 37 TC 10 Z9 11 U1 3 U2 19 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-1608 EI 1536-7355 J9 JCR-J CLIN RHEUMATOL JI JCR-J. Clin. Rheumatol. PD SEP PY 2013 VL 19 IS 6 BP 308 EP 316 DI 10.1097/RHU.0b013e3182a21848 PG 9 WC Rheumatology SC Rheumatology GA 300KC UT WOS:000330461800002 PM 23965480 ER PT J AU Hawkins, EJ Malte, CA Grossbard, J Saxon, AJ Imel, ZE Kivlahan, DR AF Hawkins, Eric J. Malte, Carol A. Grossbard, Joel Saxon, Andrew J. Imel, Zac E. Kivlahan, Daniel R. TI Comparative Safety of Benzodiazepines and Opioids Among Veterans Affairs Patients With Posttraumatic Stress Disorder SO JOURNAL OF ADDICTION MEDICINE LA English DT Article DE Posttraumatic stress disorder; antidepressants; opioids; benzodiazepines; adverse events ID PRESCRIPTION OPIOIDS; MILITARY SERVICE; NONCANCER PAIN; METAANALYSIS; OVERDOSE; PTSD; MORTALITY; PATTERNS; TRENDS; FALLS AB Objectives: Although Veterans Affairs (VA) patients with posttraumatic stress disorder (PTSD) are prescribed benzodiazepines and opioids in addition to recommended pharmacotherapies, little is known about the safety of these medications. This study compared the 2-year incidence of adverse events among VA patients with PTSD exposed to combinations of selective serotonin reuptake inhibitors (SSRIs) or serotonin/norepinephrine reuptake inhibitors (SNRIs), benzodiazepines, and opioids. Methods: This retrospective cohort study used VA administrative data from 2004 to 2010 to identify and follow 5236 VA patients with PTSD with new episodes of (1) SSRIs/SNRIs only; (2) concurrent SSRIs/SNRIs and benzodiazepines; and (3) concurrent SSRIs/SNRIs, benzodiazepines, and opioids. Outcome measures were the 2-year incidence and adjusted hazard ratios (AHR) of mental health and medicine/surgery hospitalizations, emergency department visits, harmful events (eg, injuries and death), and any adverse event after adjustment for demographics, clinical covariates, and adverse event history. Results: Comparedwith SSRIs/SNRIs only, the adjusted risk of mental health hospitalizations (AHR: 1.87; 95% confidence interval [CI]: 1.37-2.53) was greater among patients prescribed SSRIs/SNRIs and benzodiazepines concurrently. The AHR of mental health hospitalizations (AHR: 2.00; 95% CI: 1.35-2.98), medicine/surgery hospitalizations (AHR: 4.86; 95% CI: 3.30-7.14), emergency department visits (AHR: 2.01; 95% CI: 1.53-2.65), any harmful event (2.92; 95% CI: 2.21-3.84), and any adverse event (AHR: 2.65; 95% CI: 2.18-3.23) were all significantly greater among patients prescribed SSRIs/SNRIs, benzodiazepines, and opioids than among those prescribed SSRIs/SNRIs only. Conclusions: Concurrently prescribing SSRIs/SNRIs, benzodiazepines, and opioids among patients with PTSD is associated with adverse events. Although efforts are warranted to monitor patients who are prescribed combinations of these medications to prevent adverse events, these results should be interpreted with caution until they are replicated. C1 [Hawkins, Eric J.; Malte, Carol A.; Grossbard, Joel; Kivlahan, Daniel R.] Hlth Serv Res & Dev, Seattle, WA USA. [Hawkins, Eric J.; Malte, Carol A.; Saxon, Andrew J.; Kivlahan, Daniel R.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98108 USA. [Hawkins, Eric J.; Saxon, Andrew J.; Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Imel, Zac E.] Univ Utah, Dept Educ Psychol, Salt Lake City, UT 84112 USA. RP Hawkins, EJ (reprint author), VA Puget Sound Hlth Care Syst, Seattle Div S116ATC, 1660 S Columbian Way, Seattle, WA 98108 USA. EM Eric.Hawkins@va.gov OI imel, zachary/0000-0001-9645-7184 FU U.S. Department of Veterans Affairs, Veterans Health Administration; Center of Excellence in Substance Abuse Treatment and Education FX This material is based on the work supported by the U.S. Department of Veterans Affairs, Veterans Health Administration, and Center of Excellence in Substance Abuse Treatment and Education. Supporting organizations had no further role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. NR 34 TC 1 Z9 1 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1932-0620 EI 1935-3227 J9 J ADDICT MED JI J. Addict. Med. PD SEP-OCT PY 2013 VL 7 IS 5 BP 354 EP 362 DI 10.1097/ADM.0b013e31829e3957 PG 9 WC Substance Abuse SC Substance Abuse GA 300KR UT WOS:000330463300008 PM 24091764 ER PT J AU Pompili, M Sher, L Serafini, G Forte, A Innamorati, M Dominici, G Lester, D Amore, M Girardi, P AF Pompili, Maurizio Sher, Leo Serafini, Gianluca Forte, Alberto Innamorati, Marco Dominici, Giovanni Lester, David Amore, Mario Girardi, Paolo TI Posttraumatic Stress Disorder and Suicide Risk Among Veterans A Literature Review SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Review DE Suicidal behavior; PTSD; veterans; risk factors; prevention ID AFGHANISTAN WAR VETERANS; VIETNAM VETERANS; DEPRESSED-PATIENTS; PTSD; IDEATION; COMORBIDITY; MILITARY; IRAQ; EXPOSURE; BEHAVIOR AB Posttraumatic stress disorder (PTSD) is frequently associated with suicidal ideation and suicide attempts. Suicide is an important cause of death in veterans, and the risk for intentional death continues to be high many years after service. The aim of the present study was to investigate whether there is a relationship between PTSD and suicidal behavior among veterans. We also discussed the risk factors of suicide among war veterans with PTSD. A systematic review was conducted focusing on war-related PTSD and suicidal behavior. A total of 80 articles from peer-reviewed journals were identified, 34 were assessed for eligibility, and 16 were included. Having a history of PTSD is associated with higher rates of morbidity and mortality and increased the risk for suicidal behavior. The association between PTSD and suicidal behavior was confirmed by the presence of other risk factors and high rates of comorbidity. Current suicidal behavior should be adequately assessed in war veterans. C1 [Pompili, Maurizio; Serafini, Gianluca; Forte, Alberto; Innamorati, Marco; Dominici, Giovanni; Girardi, Paolo] Univ Roma La Sapienza, Dept Neurosci Mental Hlth & Sensory Organs, Suicide Prevent Ctr, St Andrea Hosp, I-00185 Rome, Italy. [Sher, Leo] James J Peters Vet Adm Med Ctr, New York, NY USA. [Sher, Leo] Mt Sinai Sch Med, New York, NY USA. [Lester, David] Richard Stockton Coll New Jersey, Galloway, NJ USA. [Amore, Mario] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Sect Psychiat, Genoa, Italy. RP Pompili, M (reprint author), Univ Roma La Sapienza, Dept Psychiat, St Andrea Hosp, 1035 Via Grottarossa, I-00189 Rome, Italy. EM maurizio.pompili@uniroma1.it OI Pompili, Maurizio/0000-0003-1886-4977 FU Italian Ministry of University Research-PRIN Project FX This study was supported, in part, by a grant from the Italian Ministry of University Research-PRIN Project (M. P., G. S., P. G.). NR 54 TC 30 Z9 31 U1 5 U2 35 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 EI 1539-736X J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD SEP PY 2013 VL 201 IS 9 BP 802 EP 812 DI 10.1097/NMD.0b013e3182a21458 PG 11 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 299DM UT WOS:000330375300012 PM 23995037 ER PT J AU McNichol, L Lund, C Rosen, T Gray, M AF McNichol, Laurie Lund, Carolyn Rosen, Ted Gray, Mikel TI Medical Adhesives and Patient Safety: State of the Science Consensus Statements for the Assessment, Prevention, and Treatment of Adhesive-Related Skin Injuries SO ORTHOPAEDIC NURSING LA English DT Reprint ID TAPE; INFECTION; OUTBREAK; BACTERIA; ZYGOMYCOSIS AB Skin injury related to medical adhesive usage is a prevalent but underrecognized complication that occurs across all care settings and among all age groups. If proper technique for application and/or removal of adhesive products is not used, tissue trauma can occur, impacting patient safety and quality of life and increasing healthcare costs. Little guidance exists in the literature regarding appropriate selection and proper use of adhesive products to minimize medical adhesive-related skin injury, as well as best practices for skin care preventive strategies, application and removal techniques, and assessment and treatment of such injuries. In an effort to define best practices for prevention of such injury, a consensus panel of 23 recognized key opinion leaders convened to establish consensus statements on the assessment, prevention, and treatment of medical adhesive-related skin injury. The consensus summit was held in December 2012 and was made possible by an unrestricted educational grant from 3M. This document details the consensus definitions and statements and identifies research priorities for development of new adhesive technologies and protocols for skin protection. KEY WORDS: Bandages, Dressings, Medical adhesive, Skin integrity, Skin stripping, Skin tear, Surgical tape C1 [McNichol, Laurie] Cone Hlth Syst, Greensboro, NC USA. [Lund, Carolyn] Childrens Hosp, Oakland, CA 94609 USA. [Lund, Carolyn] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA. [Rosen, Ted] Baylor Coll Med, Houston, TX 77030 USA. [Rosen, Ted] Houston Vet Affairs Med Ctr, Houston, TX USA. [Gray, Mikel] Univ Virginia, Charlottesville, VA 22908 USA. RP Gray, M (reprint author), Univ Virginia, Dept Urol, POB 800422, Charlottesville, VA 22908 USA. EM MG5K@hscmail.mcc.virginia.edu NR 79 TC 2 Z9 2 U1 2 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0744-6020 EI 1538-8654 J9 ORTHOP NURS JI Orthop. Nurs. PD SEP-OCT PY 2013 VL 32 IS 5 BP 267 EP 281 DI 10.1097/NOR.0b013e3182a39caf PG 15 WC Nursing; Orthopedics SC Nursing; Orthopedics GA 298VA UT WOS:000330351400007 PM 24022422 ER PT J AU Sarraf, D Chan, C Rahimy, E Abraham, P AF Sarraf, David Chan, Clement Rahimy, Ehsan Abraham, Prema TI PROSPECTIVE EVALUATION OF THE INCIDENCE AND RISK FACTORS FOR THE DEVELOPMENT OF RPE TEARS AFTER HIGH- AND LOW-DOSE RANIBIZUMAB THERAPY SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES LA English DT Article DE age-related macular degeneration; antivascular endothelial growth factor; ranibizumab; retinal pigment epithelial tears; vascularized pigment epithelial detachment ID PIGMENT EPITHELIAL TEAR; INTRAVITREAL BEVACIZUMAB INJECTION; OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION SECONDARY; PROLIFERATIVE DIABETIC-RETINOPATHY; MACULAR DEGENERATION; CLINICOPATHOLOGICAL CORRELATION; RETINAL-DETACHMENT; AVASTIN; PATHOGENESIS AB Purpose: To prospectively determine the incidence and risk factors for retinal pigment epithelial (RPE) tears in eyes with vascularized pigment epithelial detachments (PED) and exudative age-related macular degeneration receiving antivascular endothelial growth factor therapy. Methods: Eyes were prospectively randomized into 1 of 4 arms: 1) 0.5 mg of ranibizumab monthly for 12 months; 2) 0.5 mg of ranibizumab monthly for 3 months and then pro re nata on the basis of clinical and optical coherence tomography-guided indications; 3) high-dose 2.0 mg of ranibizumab monthly for 12 months; or 4) 2.0 mg of ranibizumab monthly for 3 months and then pro re nata thereafter. All PEDs were measured for height, greatest linear diameter, and surface area at baseline. The incidence of RPE tears in the entire 4-arm cohort was determined at the end of 12 months. Eyes were divided into two groups (tear vs. nontear) and statistically compared to determine risk factors for the development of RPE tear. Results: Of 37 eyes, a total of 5 developed postranibizumab RPE tears during the course of the study (incidence 14%). Four of the 5 tears occurred in the high-dose 2.0-mg groups. Baseline PED height, surface area, and greatest linear diameter were significantly greater in the group that developed RPE tears versus the nontear group (P = 0.018, 0.031, and 0.048, respectively). There were significantly more eyes with PED height >550 microns in the RPE tear group (4 of 5, 80%) compared with the nontear group (9 of 32, 18%) (P = 0.042). The presence of PED height >550 microns was associated with an increased tear rate from 14% to 31%. Furthermore, retrospective identification of a ring sign or Grade 1 tear at baseline, in addition to PED height >550 microns, was associated with a further increase in the tear rate to 67%. Conclusion: In this study, the prospective incidence of RPE tears was similar to 14%. A baseline PED height >550 microns and presence of a Grade 1 tear, or positive ring sign, were identified as high-risk factors for the subsequent development of an RPE tear. C1 [Sarraf, David; Rahimy, Ehsan] Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA 90095 USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. [Chan, Clement] Southern Calif Desert Retina Consultants, Med Grp, Palm Desert, CA USA. [Chan, Clement] Loma Linda Univ, Dept Ophthalmol, Loma Linda, CA 92350 USA. [Abraham, Prema] Black Hills Reg Eye Inst, Rapid City, SD USA. RP Sarraf, D (reprint author), Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, 100 Stein Plaza, Los Angeles, CA 90095 USA. EM dsarraf@ucla.edu FU Genentech; Karl Kirchgessner Foundation at the Jules Stein Eye Institute FX Supported by an Investigator-Supported Trial grant from Genentech and by a grant (D. S.) from the Karl Kirchgessner Foundation at the Jules Stein Eye Institute. NR 51 TC 19 Z9 19 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0275-004X EI 1539-2864 J9 RETINA-J RET VIT DIS JI Retin.-J. Retin. Vitr. Dis. PD SEP PY 2013 VL 33 IS 8 BP 1551 EP 1557 PG 7 WC Ophthalmology SC Ophthalmology GA 297CP UT WOS:000330233200009 PM 23652578 ER PT J AU Dion, GR Weitzel, EK McMains, KC AF Dion, Gregory Robert Weitzel, Erik K. McMains, Kevin C. TI Current Approaches to Diagnosis and Management of Rhinitis SO SOUTHERN MEDICAL JOURNAL LA English DT Review DE allergic rhinitis; infectious rhinitis; nasal airway obstruction; nonallergic rhinitis; nonallergic rhinitis with eosinophilia syndrome; rhinitis; vasomotor rhinitis ID AZELASTINE NASAL SPRAY; ALLERGIC RHINITIS; NONALLERGIC RHINITIS; SUBLINGUAL IMMUNOTHERAPY; GUSTATORY RHINITIS; ATOPIC MARCH; ASTHMA; MEDICAMENTOSA; SWIMMERS; EFFICACY AB Rhinitis affects >20% of the population and is a common reason patients visit their primary care physician. Proper therapeutic intervention initially requires differentiating rhinitis from acute and chronic rhinosinusitis. After establishing rhinitis as the etiology of a patient's symptoms, a careful, thoughtful history and physical examination aids the cause. Rhinitis can be allergic, nonallergic, or mixed (having features of both allergic and nonallergic rhinitis). Therapeutic interventions vary, depending on the etiology of rhinitis. Symptoms that are refractory to avoidance and pharmacotherapy warrant referral to an allergist or otolaryngologist for consideration of immunotherapy or surgical intervention. In many cases, adhering to an evidence-based therapeutic treatment algorithm will allow physicians to effectively manage rhinitis. C1 San Antonio Mil Med Ctr, Ft Sam Houston, TX USA. Wilford Hall Ambulatory Surg Ctr, San Antonio, TX USA. Audie L Murphy Vet Hosp, San Antonio, TX USA. RP Dion, GR (reprint author), ATTN MCHE SDT Oto, Dept Otolaryngol, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA. EM greg.r.dion@us.army.mil OI Weitzel, Erik/0000-0001-9155-3556 NR 56 TC 1 Z9 1 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0038-4348 EI 1541-8243 J9 SOUTH MED J JI South.Med.J. PD SEP PY 2013 VL 106 IS 9 BP 526 EP 531 DI 10.1097/SMJ.0b013e3182a5f0f6 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 298UE UT WOS:000330349200010 PM 24002559 ER PT J AU Deyo, RA Hickam, D Duckart, JP Piedra, M AF Deyo, Richard A. Hickam, David Duckart, Jonathan P. Piedra, Mark TI Complications After Surgery for Lumbar Stenosis in a Veteran Population SO SPINE LA English DT Article DE spinal stenosis; lumbar stenosis; lumbar fusion; complications; surgical complications; postoperative mortality; prediction rule; patient safety; risk prediction; receiver operating characteristic (ROC) ID SPINE SURGERY; RISK-FACTORS; WOUND INFECTIONS; FUSION SURGERY; INSTRUMENTATION; RATES AB Study Design. Secondary analysis of the prospectively collected Veterans Affairs National Surgical Quality Improvement Program database. Objective. Determine rates of major medical complications, wound complications, and mortality among patients undergoing surgery for lumbar stenosis and examine risk factors for these complications. Summary of Background Data. Surgery for spinal stenosis is concentrated among older adults, in whom complications are more frequent than among middle-aged patients. Many studies have focused on infections or device complications, but fewer studies have focused on major cardiopulmonary complications, using prospectively collected data. Methods. We identified patients who underwent surgery for a primary diagnosis of lumbar stenosis between 1998 and 2009 from the Veterans Affairs National Surgical Quality Improvement Program database. We created a composite of major medical complications, including acute myocardial infarction, stroke, pulmonary embolism, pneumonia, systemic sepsis, coma, and cardiac arrest. Results. Among 12,154 eligible patients, major medical complications occurred in 2.1%, wound complications in 3.2%, and 90-day mortality in 0.6%. Major medical complications, but not wound complications, were strongly associated with age. American Society of Anesthesiologists (ASA) class was a strong predictor of compli-cations. Insulin use, long-term corticosteroid use, and preoperative functional status were also significant predictors. Fusion procedures were associated with higher complication rates than with decompression alone. In logistic regressions, ASA class and age were the strongest predictors of major medical complications (odds ratio for ASA class 4 vs. class 1 or 2: 2.97; 95% confidence interval, 1.68-5.25; P = 0.0002). After adjustment for comorbidity, age, and functional status, fusion procedures remained associated with higher medical complication rates than were decompressions alone (odds ratio = 2.85; 95% confidence interval, 2.14-3.78; P < 0.0001). Conclusion. ASA class, age, type of surgery, insulin or corticosteroid use, and functional status were independent risk factors for major medical complications. These factors may help in selecting patients and planning procedures, improving patient safety. C1 [Deyo, Richard A.] Oregon Hlth & Sci Univ, Dept Family Med, Portland, OR 97239 USA. [Deyo, Richard A.; Hickam, David] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA. [Deyo, Richard A.] Oregon Hlth & Sci Univ, Dept Publ Hlth, Portland, OR 97239 USA. [Deyo, Richard A.] Oregon Hlth & Sci Univ, Dept Prevent Med, Portland, OR 97239 USA. [Deyo, Richard A.] Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Portland, OR 97239 USA. [Piedra, Mark] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97239 USA. [Hickam, David; Duckart, Jonathan P.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, Portland, OR USA. RP Deyo, RA (reprint author), Oregon Hlth & Sci Univ, Dept Family Med, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM deyor@ohsu.edu FU National Institute for Arthritis, Musculoskeletal and Skin Diseases [R01 AR054912]; National Center for Research Resources grant [UL1 RR024140]; Research Enhancement Award Program of the Veterans Health Administration FX National Institute for Arthritis, Musculoskeletal and Skin Diseases (R01 AR054912), National Center for Research Resources grant funds (UL1 RR024140), and the Research Enhancement Award Program of the Veterans Health Administration funds were received to support this work. This material is the result of work supported with resources and the use of facilities at the Portland VA Medical Center, Portland, OR. NR 18 TC 7 Z9 7 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0362-2436 EI 1528-1159 J9 SPINE JI SPINE PD SEP 1 PY 2013 VL 38 IS 19 BP 1695 EP 1702 DI 10.1097/BRS.0b013e31829f65c1 PG 8 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA 299AN UT WOS:000330366800020 PM 23778366 ER PT J AU Dick, AAS Mercer, LD Smith, JM McDonald, RA Young, B Healey, PJ AF Dick, Andre A. S. Mercer, Laina D. Smith, Jodi M. McDonald, Ruth A. Young, Bessie Healey, Patrick J. TI Donor and Recipient Size Mismatch in Adolescents Undergoing Living-Donor Renal Transplantation Affect Long-Term Graft Survival SO TRANSPLANTATION LA English DT Article DE Body surface area; Renal transplantation; Pediatrics and living donor; Size mismatch; Graft survival ID KIDNEY-TRANSPLANTATION; RACIAL-DIFFERENCES; UNITED-STATES; DISPARITIES; GENDER; OUTCOMES; OVERUSE; FAILURE; WEIGHT; ACCESS AB Background. Controversies exist in the adult literature regarding the use of kidneys from small donors into larger recipients. Little is known regarding this issue in pediatric kidney transplantation. To assess the impact of donor/recipient size mismatch on long-term renal graft survival in pediatric patients undergoing living-donor renal transplantation. Methods. We reviewed the United Network for Organ Sharing database from 1987 to 2010 for adolescent (11-18 years old) patients who underwent primary living-donor renal transplantation. According to donor/recipient body surface area (BSA) ratio, patients were stratified into two categories: BSA ratio <0.9 and >= 0.9. Graft survival rates were compared between these two groups using Kaplan-Meier survival curves and Cox proportional hazards models. Results. Of the 1880 patients identified, 116 (6.2%) had a donor/recipient BSA ratio <0.9 and 1764 (93.8%) had a donor/recipient BSA ratio >= 0.9 group. BSA ratio <0.9 conferred an increased risk of graft loss (adjusted hazard ratio, 1.61; 95% confidence interval, 1.13-2.27; P=0.008). Patients with a donor/recipient BSA ratio >= 0.9 group had a significantly longer graft survival compared with those with a donor/recipient BSA ratio <0.9 after adjustment for donor age and gender, recipient age, gender, ethnicity, cause of renal failure, as well as clinical factors, such as cold and warm ischemia time and HLA mismatch. Conclusion. We conclude that low donor/recipient BSA ratio was associated with an increased risk of graft loss. Appropriate size matching conferred better long-term graft survival in adolescents receiving live-donor kidney transplants. C1 [Dick, Andre A. S.; Healey, Patrick J.] Seattle Childrens Hosp, Dept Surg, Div Pediat Transplantat, Seattle, WA 98105 USA. [Dick, Andre A. S.; Healey, Patrick J.] Univ Washington, Med Ctr, Seattle, WA 98105 USA. [Mercer, Laina D.] Seattle Childrens Res Inst, Core Biomed Stat, Seattle, WA USA. [Smith, Jodi M.; McDonald, Ruth A.] Seattle Childrens, Dept Pediat, Div Nephrol, Seattle, WA USA. [Young, Bessie] Univ Washington, Kidney Res Inst, VA Puget Sound Hlth Care Syst, Div Nephrol, Seattle, WA 98105 USA. RP Dick, AAS (reprint author), Seattle Childrens Hosp, Dept Surg, Div Pediat Transplantat, 4800 Sand Point Way Northeast,M-S W-7800, Seattle, WA 98105 USA. EM Andre.dick@seattlechildrens.org FU Seattle Children's Center for Clinical and Translational Research Faculty Research Support Fund; Center for Clinical and Translational Research at the Seattle Children's Research Institute; National Institutes of Health/National Center for Research Resources [UL1RR025014]; VA Puget Sound; National Institutes of Health [DK079745] FX This publication was funded by the Seattle Children's Center for Clinical and Translational Research Faculty Research Support Fund. The Seattle Children's Core for Biomedical Statistics is supported by the Center for Clinical and Translational Research at the Seattle Children's Research Institute and the National Institutes of Health/National Center for Research Resources grant UL1RR025014. B.Y. is supported by the VA Puget Sound and by the National Institutes of Health grant DK079745. NR 24 TC 4 Z9 4 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD SEP PY 2013 VL 96 IS 6 BP 555 EP 559 DI 10.1097/TP.0b013e31829d672c PG 5 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA 299GK UT WOS:000330383900013 PM 23838999 ER PT J AU Sun, HY Cacciarelli, TV Singh, N AF Sun, Hsin-Yun Cacciarelli, Thomas V. Singh, Nina TI Micafungin Versus Amphotericin B Lipid Complex for the Prevention of Invasive Fungal Infections in High-Risk Liver Transplant Recipients SO TRANSPLANTATION LA English DT Article DE Fungal infections; Liver transplant; Antifungal prophylaxis ID SOLID-ORGAN TRANSPLANTATION; ANTIFUNGAL PROPHYLAXIS; PREEMPTIVE THERAPY; ASPERGILLOSIS; CYTOMEGALOVIRUS; VALGANCICLOVIR; FORMULATIONS; CASPOFUNGIN; MANAGEMENT; MORTALITY AB Background. Limited data exist regarding echinocandins as antifungal prophylaxis in liver transplant recipients. Methods. The efficacy and safety of targeted prophylaxis with micafungin or amphotericin B lipid complex (ABLC) was assessed in a sequential cohort of high-risk patients (posttransplantation dialysis, retransplantation, or reoperation) and compared with those without high risk who did not receive prophylaxis. Outcomes were assessed at 90 days. Results. Micafungin versus ABLC recipients were older (P=0.0065) and more likely to have hepatocellular carcinoma (P=0.025). High-risks, that is, dialysis (55.6% vs. 79.2%), retransplantation (5.6% vs. 12.5%), and reoperation (38.9% vs. 20.8%) did not differ between the two groups. Invasive fungal infections developed in 11.1% (2 of 18) of micafungin recipients, 8.3% (2 of 24) of ABLC recipients, and 3% (7 of 234) of patients without high risks (P=0.12). In nondialyzed patients, ABLC versus micafungin recipients had significantly higher serum creatinine on day 14 (P=0.04). However, renal and hepatic function, rejection, graft loss, and mortality did not differ for the two groups on day 90. Conclusions. Targeted prophylaxis with micafungin or ABLC decreased the risk of mycoses in high-risk recipients compared with that in low-risk recipients. Compared with ABLC, however, micafungin appeared to be associated with lower early-renal dysfunction and no additional risk of hepatic dysfunction. C1 [Sun, Hsin-Yun; Cacciarelli, Thomas V.; Singh, Nina] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Sun, Hsin-Yun] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan. [Sun, Hsin-Yun] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan. [Cacciarelli, Thomas V.; Singh, Nina] Univ Pittsburgh, Pittsburgh, PA USA. RP Singh, N (reprint author), Vet Affairs Med Ctr, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA. EM nis5@pitt.edu OI SUN, HSIN-YUN/0000-0003-0074-7721 FU Astellas; Pfizer, Inc.; Astellas Pharma FX This material is the result of work supported with resources and the use of facilities at the Veterans Affairs Pittsburgh Healthcare System (Pittsburgh, PA). The contents do not represent the views of the Department of Veterans Affairs or the U.S. Government. The study was supported through an investigator-initiated grant program of Astellas. The sponsor had no role in study design, conduct, analyses, and interpretation of the results. N.S. has received research support from Pfizer, Inc., and Astellas Pharma. NR 28 TC 16 Z9 18 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD SEP PY 2013 VL 96 IS 6 BP 573 EP 578 DI 10.1097/TP.0b013e31829d674f PG 6 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA 299GK UT WOS:000330383900016 PM 23842191 ER PT J AU Sibila, O Laserna, E Mortensen, EM Anzueto, A Restrepo, MI AF Sibila, Oriol Laserna, Elena Mortensen, Eric M. Anzueto, Antonio Restrepo, Marcos I. TI Effects of Inhaled Corticosteroids on Pneumonia Severity and Antimicrobial Resistance SO RESPIRATORY CARE LA English DT Article DE drug resistance; inhaled corticosteroids; pneumonia; severity of illness index ID OBSTRUCTIVE PULMONARY-DISEASE; COMMUNITY-ACQUIRED PNEUMONIA; LONG-TERM USE; COPD PATIENTS; SALMETEROL/FLUTICASONE PROPIONATE; RISK-FACTORS; METAANALYSIS; SALMETEROL; EXACERBATIONS; FLUTICASONE AB BACKGROUND: Limited information is available regarding the impact of prior use of inhaled corticosteroids (ICS) in patients subsequently developing community-acquired pneumonia (CAP). We assessed the effects of prior ICS use on severity of illness and microbiology in CAP hospitalized patients. METHODS: A retrospective cohort study of subjects with CAP (by the International Classification of Diseases, 9th Revision, Clinical Modification) was conducted over a 4-year period at 2 tertiary teaching hospitals. Subjects were considered to be ICS users if they received ICS prior to admission. Primary outcomes were severity of illness and microbiology at admission. RESULTS: Data were abstracted on 664 subjects: 89 prior ICS users (13.4%) and 575 non-users (86.6%). Prior ICS users had higher severity of illness at admission: mean +/- SD Pneumonia Severity Index 100.8 +/- 31.4 vs 68.8 +/- 33.4, P = .001, and CURB-65 (confusion, urea nitrogen, respiratory rate, blood pressure, >= 65 years of age) score 1.56 +/- 1.02 vs 1.19 +/- 1.02, P = .002. Prior ICS use was independently associated with antimicrobial-resistant pathogens: 11.2% vs 5.9%, odds ratio 2.6, 95% CI 1.1-6.1, P = .04. CONCLUSIONS: Prior ICS use was associated with higher severity of illness at admission and higher incidence of antimicrobial-resistant pathogens in CAP hospitalized patients. C1 [Sibila, Oriol; Laserna, Elena; Anzueto, Antonio; Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Mortensen, Eric M.] Vet Affairs North Texas Hlth Care Syst, San Antonio, TX 78229 USA. [Mortensen, Eric M.] Univ Texas Sothwestern Med Ctr, San Antonio, TX USA. [Sibila, Oriol] Hosp Santa Creu & Sant Pau, Serv Pneumol, Barcelona, Spain. [Laserna, Elena] Hosp Comarcal Mollet, Mollet Del Valles, Spain. [Anzueto, Antonio; Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Restrepo, MI (reprint author), South Texas Vet Hlth Care Syst, ALMD 7400,Merton Minter Blvd, San Antonio, TX 78229 USA. EM restrepom@uthscsa.edu RI Restrepo, Marcos/H-4442-2014 OI Mortensen, Eric/0000-0002-3880-5563 FU Howard Hughes Medical Institute [00378-001]; Department of Veteran Affairs Veterans Integrated Service Network 17; Instituto de Salud Carlos III [BAE11/00102]; Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR); Societat Catalana de Pneumologia; Fundacio Catalana de Pneumologia; National Heart, Lung, and Blood Institute [K23HL096054] FX Dr Anzueto has disclosed a relationship with Boehringer Ingelheim, GlaxoSmithKline, Forest Laboratories, Astra-Zeneca, Pfizer, Intermune, Amgen, Bayer-Schering Pharma, Lilly, and the National Institutes of Health. Dr Restrepo has disclosed relationships with Theravance, Forest Laboratories, Johnson & Johnson, Trius, Novartis, and Pfizer. This research was supported by Howard Hughes Medical Institute faculty start-up grant 00378-001, and by a Department of Veteran Affairs Veterans Integrated Service Network 17 new faculty grant. Dr Sibila was supported by Instituto de Salud Carlos III (BAE11/00102). Drs Sibila and Laserna were supported by Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR), Societat Catalana de Pneumologia and Fundacio Catalana de Pneumologia. Dr Restrepo was partly supported grant K23HL096054 from the National Heart, Lung, and Blood Institute. The funding agencies had no role in the preparation, review, or approval of the manuscript. The views expressed in this report are those of the authors and do not represent the views of the Department of Veterans Affairs. NR 33 TC 5 Z9 5 U1 0 U2 0 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 EI 1943-3654 J9 RESP CARE JI Respir. Care PD SEP PY 2013 VL 58 IS 9 BP 1489 EP 1494 DI 10.4187/respcare.02191 PG 6 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 295EP UT WOS:000330099700011 PM 23345471 ER PT J AU Sabin, AT Gallun, FJ Souza, PE AF Sabin, Andrew T. Gallun, Frederick J. Souza, Pamela E. TI Acoustical correlates of performance on a dynamic range compression discrimination task SO JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA LA English DT Article ID MODULATION TRANSFER-FUNCTIONS; HEARING-AID; AMPLITUDE-MODULATION; GAP DETECTION; SPECTROTEMPORAL MODULATION; SPEECH-INTELLIGIBILITY; RELEASE TIME; NOISE; RECOGNITION; FREQUENCY AB Dynamic range compression is widely used to reduce the difference between the most and least intense portions of a signal. Such compression distorts the shape of the amplitude envelope of a signal, but it is unclear to what extent such distortions are actually perceivable by listeners. Here, the ability to distinguish between compressed and uncompressed versions of a noise vocoded sentence was initially measured in listeners with normal hearing while varying the threshold, ratio, attack, and release parameters. This narrow condition was selected in order to characterize perception under the most favorable listening conditions. The average behavioral sensitivity to compression was highly correlated to several acoustical indices of modulation depth. In particular, performance was highly correlated to the Euclidean distance between the modulation spectra of the uncompressed and compressed signals. Suggesting that this relationship is not restricted to the initial test conditions, the correlation remained largely unchanged both (1) when listeners with normal hearing were tested using a time-compressed version of the original signal, and (2) when listeners with impaired hearing were tested using the original signal. If this relationship generalizes to more ecologically valid conditions, it will provide a straightforward method for predicting the detectability of compression-induced distortions. (C) 2013 Acoustical Society of America. C1 [Sabin, Andrew T.; Souza, Pamela E.] Northwestern Univ, Dept Commun Sci & Disorders, Evanston, IL 60201 USA. [Gallun, Frederick J.] Portland VA Med Ctr, VA RR&D Natl Ctr Rehabil Auditory Res NCRAR, Portland, OR 97239 USA. [Gallun, Frederick J.] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97239 USA. RP Sabin, AT (reprint author), Northwestern Univ, Dept Commun Sci & Disorders, 2240 Campus Dr, Evanston, IL 60201 USA. EM a-sabin@northwestern.edu FU NIH [DC60014]; Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service (Center of Excellence Award) [C4844C] FX Efoe Nyatepe-Coo and Alex Evanoff helped with data collected. Morten Jepsen, Eric Hoover and Richard Wright provided helpful conversations in the development of this work. This work was funded by NIH grant DC60014 and by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service (Center of Excellence Award C4844C). NR 54 TC 3 Z9 3 U1 0 U2 3 PU ACOUSTICAL SOC AMER AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0001-4966 EI 1520-8524 J9 J ACOUST SOC AM JI J. Acoust. Soc. Am. PD SEP PY 2013 VL 134 IS 3 BP 2136 EP 2147 DI 10.1121/1.4816410 PG 12 WC Acoustics; Audiology & Speech-Language Pathology SC Acoustics; Audiology & Speech-Language Pathology GA 294LG UT WOS:000330047000041 PM 23967944 ER PT J AU Hosain, GMM Latini, DM Kauth, MR Goltz, HH Helmer, DA AF Hosain, G. M. Monawar Latini, David M. Kauth, Michael R. Goltz, Heather Honore Helmer, Drew A. TI Racial Differences in Sexual Dysfunction Among Postdeployed Iraq and Afghanistan Veterans SO AMERICAN JOURNAL OF MENS HEALTH LA English DT Article DE race; ethnicity; sexual dysfunction; postdeployment; veterans ID POSTTRAUMATIC-STRESS-DISORDER; ERECTILE DYSFUNCTION; CARDIOVASCULAR-DISEASE; UNITED-STATES; RISK-FACTORS; PREVALENCE; MEN; SYMPTOMS; HEALTH; SATISFACTION AB This study examined the racial/ethnic differences in prevalence and risk factors of sexual dysfunction among postdeployed Iraqi/Afghanistan veterans. A total of 3,962 recently deployed veterans were recruited from Houston Veterans Affairs medical center. The authors examined sociodemographic, medical, mental-health, and lifestyle-related variables. Sexual dysfunction was diagnosed by ICD9-CM code and/or medicines prescribed for sexual dysfunction. Analyses included chi-square, analysis of variance, and multivariate logistic regression. Sexual dysfunction was observed 4.7% in Whites, 7.9% in African Americans, and 6.3% in Hispanics. Age, marital status, smoking, and hypertension were risk factors for Whites, whereas age, marital status, posttraumatic stress disorder and hypertension were significant for African Americans. For Hispanics, only age and posttraumatic stress disorder were significant. This study identified that risk factors of sexual dysfunction varied by race/ethnicity. All postdeployed veterans should be screened; and psychosocial support and educational materials should address race/ethnicity-specific risk factors. C1 [Hosain, G. M. Monawar; Latini, David M.; Kauth, Michael R.; Goltz, Heather Honore] Houston VA HSR&D Ctr Excellence, Houston, TX 77030 USA. [Hosain, G. M. Monawar; Latini, David M.; Kauth, Michael R.; Goltz, Heather Honore] Baylor Coll Med, Houston, TX 77030 USA. [Kauth, Michael R.] VA South Cent Mental Illness Res Educ & Clin Ctr, Houston, TX USA. [Goltz, Heather Honore] Univ Houston Downtown, Houston, TX USA. [Helmer, Drew A.] VA RRD Ctr Excellence & PrimeCare, Houston, TX USA. [Helmer, Drew A.] VA New Jersey Hlth Care Serv, E Orange, NJ USA. [Helmer, Drew A.] Univ Med & Dent New Jersey, Newark, NJ 07103 USA. RP Hosain, GMM (reprint author), Houston VA HSR&D Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM monawarhosain@gmail.com OI Latini, David/0000-0002-6161-4861 FU NIDDK NIH HHS [K12 DK0083014, K12 DK083014] NR 31 TC 0 Z9 0 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1557-9883 EI 1557-9891 J9 AM J MENS HEALTH JI Am. J. Mens Health PD SEP PY 2013 VL 7 IS 5 BP 374 EP 381 DI 10.1177/1557988312471842 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 287WY UT WOS:000329574200003 PM 23300201 ER PT J AU Li, L Sun, Z Yang, J Waldron, RT Lugea, A Pandol, SJ AF Li, L. Sun, Z. Yang, J. Waldron, R. T. Lugea, A. Pandol, S. J. TI Hyperglycaemia and hyperinsulinaemia promote fibrogenesis: increased risk of pancreatic cancer SO DIABETOLOGIA LA English DT Meeting Abstract CT 49th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD) CY SEP 23-27, 2013 CL Barcelona, SPAIN SP European Assoc Study Diabet C1 [Li, L.; Sun, Z.; Yang, J.] Southeast Univ, Zhongda Hosp, Nanjing, Jiangsu, Peoples R China. [Li, L.; Waldron, R. T.; Lugea, A.; Pandol, S. J.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Waldron, R. T.; Pandol, S. J.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X EI 1432-0428 J9 DIABETOLOGIA JI Diabetologia PD SEP PY 2013 VL 56 SU 1 MA 803 BP S321 EP S321 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 282TQ UT WOS:000329196901460 ER PT J AU Marx, N Rosenstock, J Kahn, SE Zinman, B Kastelein, JJ Lachin, J Espeland, MA Bluhmki, E Mattheus, M Patel, S Johansen, O Woerle, HJ AF Marx, N. Rosenstock, J. Kahn, S. E. Zinman, B. Kastelein, J. J. Lachin, J. Espeland, M. A. Bluhmki, E. Mattheus, M. Patel, S. Johansen, O. Woerle, H. -J. TI Baseline characteristics of participants enrolled in the cardiovascular outcome study of linagliptin versus glimepiride in early type 2 diabetes (CAROLINA) SO DIABETOLOGIA LA English DT Meeting Abstract CT 49th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD) CY SEP 23-27, 2013 CL Barcelona, SPAIN SP European Assoc Study Diabet C1 [Marx, N.] Univ Hosp Aachen, Dept Internal Med 1, Aachen, Germany. [Rosenstock, J.] Dallas Diabet & Endocrine Ctr, Dallas, TX USA. [Kahn, S. E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Kahn, S. E.] Univ Washington, Dept Med, Seattle, WA USA. [Zinman, B.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada. [Zinman, B.] Univ Toronto, Div Endocrinol, Toronto, ON M5S 1A1, Canada. [Kastelein, J. J.] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands. [Lachin, J.] George Washington Univ, Biostat Ctr, Rockville, MD USA. [Espeland, M. A.] Wake Forest Univ Hlth Sci, Dept Biostat Sci, Winston Salem, NC USA. [Bluhmki, E.] Boehringer Ingelheim GmbH & Co KG, Biberach, Germany. [Mattheus, M.; Johansen, O.; Woerle, H. -J.] Boehringer Ingelheim KG, Ingelheim, Germany. [Patel, S.] Boehringer Ingelheim GmbH & Co KG, Bracknell, Berks, England. NR 0 TC 1 Z9 1 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X EI 1432-0428 J9 DIABETOLOGIA JI Diabetologia PD SEP PY 2013 VL 56 SU 1 MA 73 BP S36 EP S37 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 282TQ UT WOS:000329196900074 ER PT J AU Eknoyan, D Hurley, RA Taber, KH AF Eknoyan, Donald Hurley, Robin A. Taber, Katherine H. TI The Neurobiology of Placebo and Nocebo: How Expectations Influence Treatment Outcomes SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Article ID PARKINSONS-DISEASE; DOPAMINE RELEASE; SPINAL-CORD; ANALGESIA; PAIN; RESPONSES; SYSTEM; ACTIVATION; MECHANISMS; BRAIN C1 [Eknoyan, Donald] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Eknoyan, Donald] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Hurley, Robin A.] Vet Affairs Mid Atlantic Mental Illness Res Educ, Durham, NC 27701 USA. [Hurley, Robin A.] WG Hefner Vet Affairs Med Ctr Salisbury, Salisbury, NC USA. [Hurley, Robin A.] Wake Forest Sch Med Winston Salem, Dept Psychiat, Winston Salem, NC USA. [Hurley, Robin A.] Wake Forest Sch Med Winston Salem, Dept Radiol, Winston Salem, NC USA. [Hurley, Robin A.] Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Taber, Katherine H.] Via Coll Osteopath Med Blacksburg, Div Biomed Sci, Blacksburg, VA USA. [Taber, Katherine H.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA. RP Hurley, RA (reprint author), Vet Affairs Mid Atlantic Mental Illness Res Educ, Durham, NC 27701 USA. EM Robin.Hurley@va.gov NR 38 TC 0 Z9 0 U1 1 U2 6 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0895-0172 EI 1545-7222 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD FAL PY 2013 VL 25 IS 4 BP 250 EP 254 PG 5 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 286TN UT WOS:000329491700001 ER PT J AU Avidan, A Hays, RD Diaz, N Bordelon, Y Thompson, AW Vassar, SD Vickrey, BG AF Avidan, Alon Hays, Ron D. Diaz, Natalie Bordelon, Yvette Thompson, Alexander W. Vassar, Stefanie D. Vickrey, Barbara G. TI Associations of Sleep Disturbance Symptoms With Health-Related Quality of Life in Parkinson's Disease SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Article ID MEDICAL OUTCOMES; DISORDERS; DEPRESSION; SCALE; RECOMMENDATIONS; RESPIRATION; PROGRESSION; INSOMNIA; ONSET AB The authors examined associations of various sleep-disturbance symptoms with health-related quality of life (HRQOL) in 153 adults with Parkinson's disease (PD). PD patients reported more snoring, sleep inadequacy, daytime somnolence, and sleep-maintenance problems than the general population. Symptoms having the broadest and strongest unique associations with generic HRQOL (eight scales; two composites of SF-36) were daytime somnolence (five scales; one composite), sleep initiation (eight scales; two composites), and awakening short of breath or with headache (six scales; two composites). Associations of selected sleep-disturbance symptoms-some unanticipated-suggest that assessing specific symptoms is worthwhile in clinical care. C1 [Avidan, Alon] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Hlth Policy & Management, Los Angeles, CA 90024 USA. Harbor UCLA, Dept Neurol, Los Angeles, CA USA. Behav Hlth Serv, Grp Hlth Cooperat, Seattle, WA USA. Parkinsons Dis Res Educ & Clin Ctr, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Avidan, A (reprint author), Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. EM avidan@mednet.ucla.edu FU Parkinson Alliance; National Institute of Neurological Disorders and Stroke [NS038367]; Veteran's Administration; National Institute of Aging [P30AG021684]; National Center on Minority Health and Health Disparities [P20MD000182] FX Study support was provided by the Parkinson Alliance, by National Institute of Neurological Disorders and Stroke NS038367, and by the Veteran's Administration. Dr. Hays was supported in part by a National Institute of Aging (P30AG021684) and National Center on Minority Health and Health Disparities (P20MD000182) grants. NR 41 TC 4 Z9 4 U1 0 U2 5 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0895-0172 EI 1545-7222 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD FAL PY 2013 VL 25 IS 4 BP 319 EP 326 PG 8 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 286TN UT WOS:000329491700040 PM 24247858 ER PT J AU Walker, RJ Smalls, BL Bonilha, HS Campbell, JA Egede, LE AF Walker, Rebekah J. Smalls, Brittany L. Bonilha, Heather Shaw Campbell, Jennifer A. Egede, Leonard E. TI BEHAVIORAL INTERVENTIONS TO IMPROVE GLYCEMIC CONTROL IN AFRICAN AMERICANS WITH TYPE 2 DIABETES: A SYSTEMATIC REVIEW SO ETHNICITY & DISEASE LA English DT Article DE Diabetes; Glucose Control; African Americans; Ethnic Groups; Lifestyle ID SELF-MANAGEMENT EDUCATION; HEALTH DISPARITIES; RACIAL-DIFFERENCES; ADULTS; OLDER; METAANALYSIS; DISEASE; IMPACT; BLACK; TRIAL AB Objective: The use of behavioral interventions has been shown to improve glycemic control, however, the effectiveness of different behavioral interventions in one of the most high risk populations, African Americans, remains unclear. Our systematic review identified and examined findings of published behavioral interventions targeted at African Americans to improve glycemic control. The goal of our study was to distinguish which interventions were effective and identify areas for future research. Design: Medline, PsychInfo, and CINAHL were searched for articles published from January 2000 through January 2012 using a reproducible strategy. Study eligibility criteria included interventions aimed at changing behavior in adult African Americans with type 2 diabetes and measured glycemic control. Results: Ten studies met the inclusion criteria, of which five showed a statistically significant change in HbA1c in the intervention group when compared to the control group. Summary information and characteristics of the reviewed studies are provided. Conclusions: Characteristics of successful interventions included using problem solving with the patient, culturally tailoring the intervention, and using a nurse educator. Limitations include the limited number of intervention studies available using glycemic control as the outcome measure. Clinical trials are needed to determine how best to tailor interventions to this largely underserved population and studies should describe details of cultural tailoring to provide information for future programs. C1 [Walker, Rebekah J.; Smalls, Brittany L.; Campbell, Jennifer A.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Disparities Res, Charleston, SC 29425 USA. [Walker, Rebekah J.; Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC USA. [Walker, Rebekah J.; Smalls, Brittany L.; Bonilha, Heather Shaw] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Egede, Leonard E.] Med Univ S Carolina, Dept Med, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Disparities Res, 135 Rutledge Ave,Room 280G,POB 250593, Charleston, SC 29425 USA. EM egedel@musc.edu NR 34 TC 4 Z9 4 U1 4 U2 8 PU INT SOC HYPERTENSION BLACKS-ISHIB PI ATLANTA PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA SN 1049-510X EI 1945-0826 J9 ETHNIC DIS JI Ethn. Dis. PD FAL PY 2013 VL 23 IS 4 BP 401 EP 408 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 280HN UT WOS:000329019400002 PM 24392600 ER PT J AU Betancourt, RM Degnan, KO Long, JA AF Betancourt, Renee M. Degnan, Kathleen O. Long, Judith A. TI RACIAL DIFFERENCES IN GLUCOSE CONTROL AMONG PATIENTS WITH TYPE 2 DIABETES: A SURVEY ON DIETARY TEMPTATIONS, COPING, AND TRUST IN PHYSICIANS SO ETHNICITY & DISEASE LA English DT Article DE Disparities; Diabetes Mellitus; Glucose Control; Psychosocial Factors ID AFRICAN-AMERICAN; GLYCEMIC CONTROL; CARE; DISPARITIES; SCALE; OUTCOMES; BEHAVIORS; MORTALITY; ADHERENCE; QUALITY AB Objective: A quantitative evaluation of self-care behaviors, psychosocial stressors, and patient relationships to health care to better understand racial disparities in these domains. Research Design and Methods: A cross-sectional study of adult patients with type 2 diabetes in University of Pennsylvania Healthcare System who had a HbA1c test within one month of survey administration. The survey instrument included among other items, the Dieter's Inventory of Eating Temptations Self-Efficacy instrument (DIET-SE), the Jalowiec Coping Scale (JCS), and the Trust in Physician (TIP) scale. Results: 332 individuals completed the survey. Poor glucose control was significantly associated with Black race, lower income level, other demographic variables, non-perfect medication adherence, and poorer diet quality. It was also associated with lower self-efficacy to resist social dietary temptations, and among White patients it was associated was decreased use of a confrontive coping style. However, these factors did not explain the racial differences in glucose control between Blacks and Whites. Conclusions: Interventions aimed at dietary temptations, coping styles, or trust in physicians may not reduce racial disparities in glucose control. However, interventions that focus on dietary temptations may positively affect all diabetic patients. C1 [Betancourt, Renee M.] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA. [Degnan, Kathleen O.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Long, Judith A.] Univ Penn, Div Gen Internal Med, Philadelphia VA Ctr Hlth Equ Res & Promot, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Betancourt, RM (reprint author), 995 Potrero Ave,Bldg 83, San Francisco, CA 94110 USA. EM betancourtr@fcm.ucsf.edu NR 33 TC 2 Z9 2 U1 1 U2 5 PU INT SOC HYPERTENSION BLACKS-ISHIB PI ATLANTA PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA SN 1049-510X EI 1945-0826 J9 ETHNIC DIS JI Ethn. Dis. PD FAL PY 2013 VL 23 IS 4 BP 409 EP 414 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 280HN UT WOS:000329019400003 PM 24392601 ER PT J AU Doherty, JE Woodard, LE Bear, AS Foster, AE Wilson, MH AF Doherty, Joseph E. Woodard, Lauren E. Bear, Adham S. Foster, Aaron E. Wilson, Matthew H. TI An adaptable system for improving transposon-based gene expression in vivo via transient transgene repression SO FASEB JOURNAL LA English DT Article DE piggyBac; inducible expression; gene transfer ID IMMUNE-RESPONSE; MAMMALIAN-CELLS; HYDRODYNAMIC INJECTION; FIREFLY LUCIFERASE; ADENOVIRAL VECTORS; THERAPY; LIVER; MICE; DELIVERY; TETRACYCLINE AB Transposons permit permanent cellular genome engineering in vivo. However, transgene expression falls rapidly postdelivery due to a variety of mechanisms, including immune responses. We hypothesized that delaying initial transgene expression would improve long-term transgene expression by using an engineered piggyBac transposon system that can regulate expression. We found that a 2-part nonviral Tet-KRAB inducible expression system repressed expression of a luciferase reporter in vitro. However, we also observed nonspecific promoter-independent repression. Thus, to achieve temporary transgene repression after gene delivery in vivo, we utilized a nonintegrating version of the repressor plasmid while the gene of interest was delivered in an integrating piggyBac transposon vector. When we delivered the luciferase transposon and repressor to immunocompetent mice by hydrodynamic injection, initial luciferase expression was repressed by 2 orders of magnitude. When luciferase expression was followed long term in vivo, we found that expression was increased >200-fold compared to mice that received only the luciferase transposon and piggyBac transposase. We found that repression of early transgene expression could prevent the priming of luciferase-specific T cells in vivo. Therefore, transient transgene repression postgene delivery is an effective strategy for inhibiting the antitransgene immune response and improving long-term expression in vivo without using immunosuppression.Doherty, J. E., Woodard, L. E., Bear, A. S., Foster, A. E., Wilson, M. H. An adaptable system for improving transposon-based gene expression in vivo via transient transgene repression. C1 [Doherty, Joseph E.; Bear, Adham S.; Foster, Aaron E.; Wilson, Matthew H.] Baylor Coll Med, Med Scientist Training Program, Houston, TX 77030 USA. [Doherty, Joseph E.; Wilson, Matthew H.] Baylor Coll Med, Interdept Program Cell & Mol Biol, Houston, TX 77030 USA. [Doherty, Joseph E.; Woodard, Lauren E.; Wilson, Matthew H.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Bear, Adham S.; Foster, Aaron E.; Wilson, Matthew H.] Baylor Coll Med, Interdept Program Translat Biol & Mol Med, Houston, TX 77030 USA. [Bear, Adham S.; Foster, Aaron E.; Wilson, Matthew H.] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA. [Wilson, Matthew H.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Wilson, MH (reprint author), Baylor Coll Med, 1 Baylor Plaza,MS BCM395,ABBR R704, Houston, TX 77030 USA. EM mhwilson@bcm.edu FU U.S. National Institutes of Health (NIH) [T32GM007330]; NIH [T32DK064717, T32DK062706, T32DK060445, R01 DK093660]; U.S. Department of Veterans Affairs FX J.E.D. was supported by U.S. National Institutes of Health (NIH) Medical Scientist Training Program grant T32GM007330, and subsequently by NIH Cell and Gene Therapy Training grant T32DK064717 and the generous support of Bill and Mary Jo Robbins. L. E. W. was supported by NIH grant T32DK062706 and subsequently by NIH grant T32DK060445. M. H. W. was supported in part by a career development award from the U.S. Department of Veterans Affairs and NIH grant R01 DK093660. This work was also made possible by the generous support of Dr. and Mrs. Harold M. Selzman. NR 53 TC 3 Z9 3 U1 1 U2 9 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD SEP PY 2013 VL 27 IS 9 BP 3753 EP 3762 DI 10.1096/fj.13-232090 PG 10 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 277SV UT WOS:000328840500033 PM 23752206 ER PT J AU Ioannou, GN AF Ioannou, George N. TI Chronic Hepatitis B Infection: A Global Disease Requiring Global Strategies SO HEPATOLOGY LA English DT Editorial Material ID PUBLIC-HEALTH MANAGEMENT; UNITED-STATES; VIRUS INFECTION; LIVER-CANCER; RECOMMENDATIONS; IDENTIFICATION; MODEL C1 [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA 98108 USA. [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, Seattle, WA 98108 USA. [Ioannou, George N.] Univ Washington, Dept Med, Div Gastroenterol, Seattle, WA USA. RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Gastroenterol, S-111 Gastro,1660 S Columbian Way, Seattle, WA 98108 USA. EM georgei@medicine.washington.edu NR 20 TC 11 Z9 11 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD SEP PY 2013 VL 58 IS 3 BP 839 EP 843 DI 10.1002/hep.26516 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 283YX UT WOS:000329284000001 PM 23703788 ER PT J AU Lawson, CM Daley, BJ Sams, VG Martindale, R Kudsk, KA Miller, KR AF Lawson, Christy M. Daley, Brian J. Sams, Valerie G. Martindale, Robert Kudsk, Kenneth A. Miller, Keith R. TI Factors That Impact Patient Outcome: Nutrition Assessment SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION LA English DT Article DE nutrition assessment; body mass index; malnutrition; elective surgery ID TOTAL PARENTERAL-NUTRITION; ENTERAL NUTRITION; MALNUTRITION; UNDERNUTRITION; RISK AB Defining malnutrition and nutrition risk has been a topic of many papers and discussions throughout the modern literature. Multiple definitions have been proposed, ranging from simple body weight measurements to a more all-encompassing concept looking at disease-specific inflammatory states. Biochemical markers, elements of a history examination, physical examination findings, calculations, and technical tests have all been proposed to help further characterize and delineate those who might be at risk for malnutrition, translating to an increased risk of adverse outcomes after major surgery. The purpose of this paper is to summarize some of the most utilized and most reliable ways to determine nutrition status within the scope of the North American Surgical Nutrition Summit (2012) and discuss how to incorporate these methods into the way that patients are screened preoperatively for elective surgery. C1 [Lawson, Christy M.; Daley, Brian J.; Sams, Valerie G.] Univ Tennessee, Med Ctr, Dept Surg, Knoxville, TN 37920 USA. [Martindale, Robert] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR USA. [Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Veteran Adm Surg Serv, Madison, WI USA. [Miller, Keith R.] Univ Louisville, Dept Surg, Louisville, KY 40292 USA. RP Lawson, CM (reprint author), Univ Tennessee, Med Ctr, Dept Surg, 1924 Alcoa Highway,Box U-11, Knoxville, TN 37920 USA. EM cmlawson@utmck.edu FU Nestle Healthcare Nutrition FX The publication of the supplement in which this article appears is supported by an educational grant from Nestle Healthcare Nutrition. Authors received an honorarium from the Nestle Nutrition Institute for their participation in the North American Surgical Nutrition Summit. NR 29 TC 3 Z9 4 U1 2 U2 6 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0148-6071 EI 1941-2444 J9 JPEN-PARENTER ENTER JI J. Parenter. Enter. Nutr. PD SEP PY 2013 VL 37 IS 5 SU S BP 30S EP 38S DI 10.1177/0148607113499372 PG 9 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 276XL UT WOS:000328782900003 PM 24009247 ER PT J AU Pierre, JF Heneghan, AF Lawson, CM Wischmeyer, PE Kozar, RA Kudsk, KA AF Pierre, Joseph F. Heneghan, Aaron F. Lawson, Christy M. Wischmeyer, Paul E. Kozar, Rosemary A. Kudsk, Kenneth A. TI Pharmaconutrition Review: Physiological Mechanisms SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION LA English DT Review DE immunonutrition; pharmaconutrition; immune modulation; nutrition therapy ID CRITICALLY-ILL PATIENTS; GAMMA-LINOLENIC ACID; INTENSIVE-CARE-UNIT; NITRIC-OXIDE SYNTHASE; ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME; TOTAL PARENTERAL-NUTRITION; DOUBLE-BLIND TRIAL; SEVERE BURN INJURY; BACTERIAL-INFECTION RATES AB The search to improve outcomes in critically ill patients through nutrition support has steadily progressed over the past 4 decades. One current approach to this problem is the addition of specific nutrients as primary therapy to improve host defenses and improve the outcome of critically ill patients. The field is referred to as pharmaconutrition, with the hope of focusing investigations on each nutrient to understand its pharmacological effects on immune and clinical outcomes. The purpose of this review is to describe some of the known physiological mechanisms of pharmaconutrients such as glutamine, arginine, -3 fatty acids, and selenium. C1 [Pierre, Joseph F.; Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA. [Pierre, Joseph F.; Heneghan, Aaron F.; Kudsk, Kenneth A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI 53792 USA. [Lawson, Christy M.] Univ Tennessee, Med Ctr, Dept Surg, Knoxville, TN 37920 USA. [Wischmeyer, Paul E.] Univ Colorado, Dept Anesthesiol, Denver, CO 80202 USA. [Kozar, Rosemary A.] Univ Texas Houston, Hlth Sci Ctr, Dept Surg, Houston, TX USA. RP Kudsk, KA (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Nutr Sci, H4-736 Clin Sci Ctr,600 Highland Ave, Madison, WI 53792 USA. EM kudsk@surgery.wisc.edu FU Nestle Healthcare Nutrition FX The publication of the supplement in which this article appears is supported by an educational grant from Nestle Healthcare Nutrition. Authors received an honorarium from the Nestle Nutrition Institute for their participation in the North American Surgical Nutrition Summit. NR 225 TC 17 Z9 17 U1 3 U2 13 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0148-6071 EI 1941-2444 J9 JPEN-PARENTER ENTER JI J. Parenter. Enter. Nutr. PD SEP PY 2013 VL 37 IS 5 SU S BP 51S EP 65S DI 10.1177/0148607113493326 PG 15 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 276XL UT WOS:000328782900005 PM 24009249 ER PT J AU Hughes, J Jouldjian, S Washington, DL Alessi, CA Martin, JL AF Hughes, Jaime Jouldjian, Stella Washington, Donna L. Alessi, Cathy A. Martin, Jennifer L. TI Insomnia and Symptoms of Post-traumatic Stress Disorder Among Women Veterans SO BEHAVIORAL SLEEP MEDICINE LA English DT Article ID COGNITIVE-BEHAVIORAL THERAPY; MAJOR DEPRESSIVE DISORDER; SLEEP QUALITY INDEX; PSYCHIATRIC-DISORDERS; HEALTH-CARE; OF-LIFE; QUESTIONNAIRE; DISTURBANCES; EPIDEMIOLOGY; AFGHANISTAN AB Women will account for 10% of the Veteran population by 2020, yet there has been little focus on sleep issues among women Veterans. In a descriptive study of 107 women Veterans with insomnia (mean age = 49 years, 44% non-Hispanic white), 55% had probable post traumatic stress disorder (PTSD) (total score 33). Probable PTSD was related to more severe self-reported sleep disruption and greater psychological distress. In a regression model, higher PTSD Checklist-Civilian (PCL-C) total score was a significant independent predictor of worse insomnia severity index score while other factors were not. Women Veterans preferred behavioral treatments over pharmacotherapy in general, and efforts to increase the availability of such treatments should be undertaken. Further research is needed to better understand the complex relationship between insomnia and PTSD among women Veterans. C1 [Hughes, Jaime; Jouldjian, Stella] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Washington, Donna L.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Ctr Excellence Study Healthcare Provider Behav, Los Angeles, CA 90095 USA. [Alessi, Cathy A.; Martin, Jennifer L.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA 90095 USA. RP Martin, JL (reprint author), 16111 Plummer St 11E, North Hills, CA 91343 USA. EM Jennifer.Martin@va.gov FU VA Health Services Research and Development [PPO 09-282-1]; VA Rehabilitation Research and Development [1RX000135-01]; National Institute on Aging [K23 AG028452]; VAGLAHS Geriatric Research, Education, and Clinical Center (GRECC) FX Supported by: VA Health Services Research and Development (PPO 09-282-1), VA Rehabilitation Research and Development (1RX000135-01), National Institute on Aging (K23 AG028452), and the VAGLAHS Geriatric Research, Education, and Clinical Center (GRECC). NR 51 TC 7 Z9 7 U1 5 U2 16 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1540-2002 EI 1540-2010 J9 BEHAV SLEEP MED JI Behav. Sleep Med. PD SEP 1 PY 2013 VL 11 IS 4 BP 258 EP 274 DI 10.1080/15402002.2012.683903 PG 17 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 268QR UT WOS:000328186100002 PM 23205531 ER PT J AU Fredericks, WJ McGarvey, T Wang, HY Zheng, YM Fredericks, NJ Yin, HK Wang, LP Hsiao, W Lee, R Weiss, JS Nickerson, ML Kruth, HS Rauscher, FJ Malkowicz, SB AF Fredericks, William J. McGarvey, Terry Wang, Huiyi Zheng, Yongmu Fredericks, Nathaniel J. Yin, Hankun Wang, Li-Ping Hsiao, Wayland Lee, Rob Weiss, Jayne S. Nickerson, Michael L. Kruth, Howard S. Rauscher, Frank J., III Malkowicz, S. Bruce TI The TERE1 Protein Interacts With Mitochondrial TBL2: Regulation of Trans-Membrane Potential, ROS/RNS and SXR Target Genes SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Article DE TERE1; TBL2; MITOCHONDRIA; LIPID METABOLISM; ROS; SXR TARGET GENES ID BREAST-CANCER CELLS; CARCINOMA-CELLS; NITRIC-OXIDE; BLADDER; UBIAD1; CHOLESTEROL; VITAMIN-K-2; ACTIVATION; RECEPTOR; INHIBITION AB We originally discovered TERE1 as a potential tumor suppressor protein based upon reduced expression in bladder and prostate cancer specimens and growth inhibition of tumor cell lines/xenografts upon ectopic expression. Analysis of TERE1 (aka UBIAD1) has shown it is a prenyltransferase enzyme in the natural bio-synthetic pathways for both vitamin K-2 and COQ10 production and exhibits multiple subcellular localizations including mitochondria, endoplasmic reticulum, and golgi. Vitamin K-2 is involved in mitochondrial electron transport, SXR nuclear hormone receptor signaling and redox cycling: together these functions may form the basis for tumor suppressor function. To gain further insight into mechanisms of growth suppression and enzymatic regulation of TERE1 we isolated TERE1 associated proteins and identified the WD40 repeat, mitochondrial protein TBL2. We examined whether disease specific mutations in TERE1 affected interactions with TBL2 and the role of each protein in altering mitochondrial function, ROS/RNS production and SXR target gene regulation. Biochemical binding assays demonstrated a direct, high affinity interaction between TERE1 and TBL2 proteins; TERE1 was localized to both mitochondrial and non-mitochondrial membranes whereas TBL2 was predominantly mitochondrial; multiple independent single amino acid substitutions in TERE1 which cause a human hereditary corneal disease reduced binding to TBL2 strongly suggesting the relevance of this interaction. Ectopic TERE1 expression elevated mitochondrial trans-membrane potential, oxidative stress, NO production, and activated SXR targets. A TERE1-TBL2 complex likely functions in oxidative/nitrosative stress, lipid metabolism, and SXR signaling pathways in its role as a tumor suppressor. J. Cell. Biochem. 114: 2170-2187, 2013. (c) 2013 Wiley Periodicals, Inc. C1 [Fredericks, William J.; Wang, Huiyi; Zheng, Yongmu; Fredericks, Nathaniel J.; Yin, Hankun; Malkowicz, S. Bruce] Univ Penn, Dept Surg, Div Urol, Philadelphia, PA 19104 USA. [Fredericks, William J.; Wang, Huiyi; Zheng, Yongmu; Fredericks, Nathaniel J.; Yin, Hankun; Lee, Rob; Malkowicz, S. Bruce] Vet Affairs Med Ctr Philadelphia, Philadelphia, PA 19104 USA. [McGarvey, Terry] Kirksville Osteopath Med Sch, Dept Anat, Kirksville, MO 63501 USA. [Wang, Li-Ping] Univ Penn, Med Ctr, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Hsiao, Wayland] Weill Cornell Med Coll, Dept Urol, New York, NY USA. [Lee, Rob] Univ Penn, Dept Otorhinolaryngol, Philadelphia, PA 19104 USA. [Weiss, Jayne S.] Louisiana State Univ, Dept Ophthalmol, New Orleans, LA USA. [Weiss, Jayne S.] Louisiana State Univ, Ctr Eye, New Orleans, LA 70112 USA. [Nickerson, Michael L.] NCI, Canc & Inflammat Program, Ft Detrick, MD 21702 USA. [Kruth, Howard S.] NIH, Sect Expt Atherosclerosis, Bethesda, MD 20892 USA. [Rauscher, Frank J., III] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA. RP Fredericks, WJ (reprint author), VA Med Ctr Philadelphia, Res Bldg 21,Room A418,Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM wjfredericks@verizon.net OI Lee, Robert/0000-0001-5826-6686 FU Veterans Affairs Merit Review; Innisfree Foundation of Bryn Mawr, PA; Castleman Family Fund FX Grant sponsor: Veterans Affairs Merit Review; Grant sponsor: The Innisfree Foundation of Bryn Mawr, PA; Grant sponsor: The Castleman Family Fund. NR 50 TC 11 Z9 11 U1 0 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0730-2312 EI 1097-4644 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD SEP PY 2013 VL 114 IS 9 BP 2170 EP 2187 DI 10.1002/jcb.24567 PG 18 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 261YA UT WOS:000327699500024 PM 23564352 ER PT J AU Kilbourne, AM Deeghan, T Jones, KR AF Kilbourne, Amy M. Deeghan, Tisha Jones, Kenneth R. TI Serious Mental Illness and Weight Management Interventions SO PSYCHIATRIC SERVICES LA English DT Letter C1 [Kilbourne, Amy M.] US Dept Vet Affairs, Hlth Serv Res & Dev Serv, Ctr Clin Management Res, Ann Arbor, MI USA. [Deeghan, Tisha] Genesee Hlth Syst, Flint, MI USA. [Jones, Kenneth R.] VHA Natl Ctr Hlth Promot & Dis Prevent, Durham, NC USA. RP Kilbourne, AM (reprint author), US Dept Vet Affairs, Hlth Serv Res & Dev Serv, Ctr Clin Management Res, Ann Arbor, MI USA. NR 5 TC 0 Z9 0 U1 6 U2 7 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD SEP PY 2013 VL 64 IS 9 BP 931 EP 931 PG 1 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 255ZC UT WOS:000327277600021 PM 24026842 ER PT J AU Okwemba, R Medvedeva, E Wang, A AF Okwemba, Robert Medvedeva, Elina Wang, Andrew TI Medication Adherence Among Patients With Comorbid Diabetes SO PSYCHIATRIC SERVICES LA English DT Letter ID SCHIZOPHRENIA C1 [Okwemba, Robert; Medvedeva, Elina; Wang, Andrew] Ctr Hlth Equ Res & Promot, Dept Vet Affairs, Philadelphia, PA USA. RP Okwemba, R (reprint author), Ctr Hlth Equ Res & Promot, Dept Vet Affairs, Philadelphia, PA USA. NR 3 TC 1 Z9 1 U1 0 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD SEP PY 2013 VL 64 IS 9 BP 934 EP 935 PG 3 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 255ZC UT WOS:000327277600025 PM 24026846 ER PT J AU Aspinall, SL Zhao, XH Good, CB Stone, RA Smith, KJ Cunningham, FE AF Aspinall, Sherrie L. Zhao, Xinhua Good, Chester B. Stone, Roslyn A. Smith, Kenneth J. Cunningham, Francesca E. TI FDA Warning and Removal of Rosiglitazone From VA National Formulary SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID CARDIOVASCULAR EVENTS; DIABETES-MELLITUS; RISK; PIOGLITAZONE; METAANALYSIS; OUTCOMES; IMPACT; CARE AB Objectives: To describe changes in rosiglitazone prescribing following the US Food and Drug Administration (FDA) warning of potentially increased risk of myocardial infarction and removal from the Department of Veterans Affairs National Formulary (VANF), assess patient-level factors associated with rosiglitazone discontinuation, and evaluate changes in glucose control. Study Design: Historical cohort. Methods: Veterans with an active outpatient prescription for rosiglitazone on April 1, 2007, were followed until June 30, 2008. Incidence rate ratios (IRRs) of rosiglitazone discontinuation were compared over time using Poisson methods. We identified patient-level factors associated with stopping rosiglitazone using multivariable Poisson regression and compared glycated hemoglobin (A1C) values across time among patients who discontinued/continued rosiglitazone using linear mixed models. Results: Of 95,539 veterans with an active outpatient rosiglitazone prescription, 86.7% discontinued rosiglitazone. Discontinuation rates increased significantly after the FDA warning, with IRRs from 1.6 to 1.8. After removal from the VANF, rosiglitazone discontinuation rates again increased significantly. Discontinuing rosiglitazone was associated with the FDA warning, removal from the VANF, female sex, black race, Hispanic ethnicity, comorbidity,A1C greater than 9%, and use of rosiglitazone as first- or second-line therapy. Among patients who did and did not receive a replacement medication, the mean changes in A1C from baseline were 0.12% and 0.46%, respectively. for those who continued rosiglitazone, the mean change in A1C was 0.02%. Conclusion: The rosiglitazone discontinuation rate increased following the FDA warning and increased further following removal of rosiglitazone from the VANE Glucose control may have declined among those who discontinued rosiglitazone. C1 [Aspinall, Sherrie L.; Zhao, Xinhua; Good, Chester B.; Cunningham, Francesca E.] VA Ctr Medicat Safety, Hines, IL USA. [Aspinall, Sherrie L.; Zhao, Xinhua; Good, Chester B.; Stone, Roslyn A.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA. [Aspinall, Sherrie L.; Good, Chester B.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA. [Good, Chester B.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Stone, Roslyn A.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. [Smith, Kenneth J.] Univ Pittsburgh, Div Clin Modeling & Decis Sci, Pittsburgh, PA USA. RP Aspinall, SL (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr 151C-H, Pittsburgh, PA 15206 USA. EM sherrie.aspinall@va.gov NR 21 TC 6 Z9 6 U1 0 U2 0 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD SEP PY 2013 VL 19 IS 9 BP 748 EP 758 PG 11 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 244WF UT WOS:000326420200005 PM 24304257 ER PT J AU Oyer, SL Nagel, W Mulligan, JK AF Oyer, Samuel L. Nagel, Whitney Mulligan, Jennifer K. TI Differential expression of adhesion molecules by sinonasal fibroblasts among control and chronic rhinosinusitis patients SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY LA English DT Article ID NASAL POLYPOSIS; EOSINOPHIL INFILTRATION; TNF-ALPHA; ENDOTHELIAL-CELLS; CHRONIC SINUSITIS; LUNG FIBROBLASTS; INFLAMMATION; BUDESONIDE; VCAM-1; ICAM-1 AB Background: Chronic rhinosinusitis (CRS) is characterized by inflammatory cell migration into sinus tissue with resultant inflammation fueled by a milieu of cytokines. Fibroblasts may contribute to inflammation through expression of leukocyte adhesion molecules such as vascular cell adhesion molecule (VCAM) and intercellular adhesion molecule (ICAM). VCAM attracts eosinophils and mast cells contributing to Th2 skewing, and ICAM attracts neutrophils and to a lesser degree, eosinophils, and contributes to mixed Th1/Th2 skewing. The purpose of this study was to compare sinus fibroblast adhesion molecule expression ex vivo among CRS subtypes and in vitro after cytokine stimulation. Methods: Sinus biopsy specimens were taken from control patients (n = 13), CRS without nasal polyposis (CRSsNP, n = 6), and CRS with nasal polyposis (CRSwNP, n = 15). Ex vivo levels of VCAM and ICAM were measured by flow cytometry from single cell suspensions of tissue biopsy specimens. Changes in VCAM and ICAM expression to cytokine exposure were assessed using in vitro cultured sinonasal fibroblasts treated with tumor necrosis factor (TNF)-alpha, interleukin (IL)-4, or interferon (IFN)-gamma. Results: Ex vivo VCAM expression was lowest in controls, higher in CRSsNP, and highest in CRSwNP. In vitro stimulation with TNF-alpha and IL-4, but not IFN-gamma, increased VCAM among CRSsNP, while expression in CRSwNP remained elevated with all treatments except IFN-gamma. Ex vivo ICAM expression was elevated in both CRS subtypes. In vitro stimulation with TNF-alpha and IFN-gamma, but not IL-4, increased ICAM expression in all patients with the largest effects among the CRSsNP subgroup. Conclusion: Sinonasal fibroblast expression of adhesion molecules in sinusitis varies by disease state and is selectively influenced by exposure to inflammatory cytokines. C1 [Oyer, Samuel L.; Nagel, Whitney; Mulligan, Jennifer K.] Med Univ S Carolina, Div Rhinol & Sinus Surg, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. [Oyer, Samuel L.; Nagel, Whitney; Mulligan, Jennifer K.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. [Mulligan, Jennifer K.] Ralph H Johnson Vet Affairs Med Ctr, Dept Surg, Res Serv, Charleston, SC USA. RP Mulligan, JK (reprint author), MSC 550,135 Rutledge Ave, Charleston, SC 29425 USA. EM konopa@musc.edu FU American Rhinologic Society as part of the Centralized Otolaryngology Research Efforts (CORE) Grants program; Flight Attendant Medical Research Institutes FX Funded by a grant to SL Oyer from the American Rhinologic Society as part of the Centralized Otolaryngology Research Efforts (CORE) Grants program, and a grant to JK Mulligan from the Flight Attendant Medical Research Institutes. The remaining author has no conflicts of interest to declare pertaining to this article NR 28 TC 5 Z9 5 U1 0 U2 0 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1945-8924 EI 1945-8932 J9 AM J RHINOL ALLERGY JI Am. J. Rhinol. Allergy PD SEP-OCT PY 2013 VL 27 IS 5 BP 381 EP 386 DI 10.2500/ajra.2013.27.3934 PG 6 WC Otorhinolaryngology SC Otorhinolaryngology GA 249EL UT WOS:000326759700014 PM 24119601 ER PT J AU Privette, ED Werth, VP AF Privette, Emily D. Werth, Victoria P. TI Update on pathogenesis and treatment of CLE SO CURRENT OPINION IN RHEUMATOLOGY LA English DT Review DE Cutaneous Lupus Disease Area and Severity Index; Cutaneous Lupus Erythematous; hydroxychloroquine; interferon ID CUTANEOUS LUPUS-ERYTHEMATOSUS; AICARDI-GOUTIERES SYNDROME; BLOOD MONONUCLEAR-CELLS; DISEASE-ACTIVITY; SEVERITY INDEX; RENAL-DISEASE; EFFICACY; THERAPY; SMOKING; HYDROXYCHLOROQUINE AB Purpose of review Cutaneous Lupus Erythematous (CLE) is an autoimmune disease in which patients may present with isolated skin findings or have CLE associated with underlying systemic disease. The most significant recent studies on its pathogenesis and therapeutic management are reviewed here. Recent findings Patients with subacute and Discoid Lupus Erythematous had elevated Interferon score, about a third of all cases of SCLE could be attributed to previous drug exposure, and smoking may be more closely associated with CLE than Systemic Lupus Erythematous (SLE). An underlying genetic defect in some subsets of CLE patients may also be shared with SLE. Efficacy of antimalarial therapy is enhanced by increasing treatment duration or maintaining higher blood drug concentrations. Combination antimalarials that include quinacrine, thalidomide analogs, and Mycophenalate Mofetil may also be effective in refractory CLE. Summary The pathogenesis of CLE remains unclear, and is likely multifactorial. Identified associations with subsets of CLE suggest future research questions in CLE pathogenesis. Subsets of CLE associated with interface dermatitis may share an underlying genetic defect in interferon signaling with SLE. The Cutaneous Lupus Disease Area and Severity Index is a valuable and widely used tool allowing standardized assessment and reporting of cutaneous disease activity and damage. More evidence is available to guide treatment of refractory CLE, but larger studies are needed. Video abstract http://links.lww.com/COR/A4. C1 [Privette, Emily D.; Werth, Victoria P.] Univ Penn, Sch Med, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Privette, Emily D.; Werth, Victoria P.] Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA. RP Werth, VP (reprint author), Perelman Ctr Adv Med, Dept Dermatol, Suite 1-330A,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu FU Department of Veterans Affairs (Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development); National Institutes of Health [NIH K24-AR 02207] FX This material is based upon work supported by a Merit Review Grant from the Department of Veterans Affairs (Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development) and by the National Institutes of Health (NIH K24-AR 02207) to V.P.W. NR 43 TC 7 Z9 8 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-8711 EI 1531-6963 J9 CURR OPIN RHEUMATOL JI Curr. Opin. Rheumatol. PD SEP PY 2013 VL 25 IS 5 BP 584 EP 590 DI 10.1097/BOR.0b013e32836437ba PG 7 WC Rheumatology SC Rheumatology GA 248KD UT WOS:000326697400004 PM 23872903 ER PT J AU Jacobs, RL Harper, N He, W Rather, CG Castiblanco, J Carrillo, A Manoharan, M Avadhanam, N Liu, Y Ingale, P Andrews, CP Ramirez, DA Ahuja, SK AF Jacobs, R. L. Harper, N. He, W. Rather, C. G. Castiblanco, J. Carrillo, A. Manoharan, M. Avadhanam, N. Liu, Y. Ingale, P. Andrews, C. P. Ramirez, D. A. Ahuja, S. K. TI Evaluation of ultra-rush immunotherapy for Virginia live oak in a pollen challenge chamber identifies cytokine and transcriptional correlates of protection SO ALLERGY LA English DT Meeting Abstract CT World Allergy and Asthma Congress of the European-Academy-of-Allergy-and-Clinical-Immunology and World-Allergy-Organization CY JUN 22-26, 2013 CL Milan, ITALY SP European Acad Allergy & Clin Immunol, World Allergy Org C1 [Jacobs, R. L.; Rather, C. G.; Andrews, C. P.; Ramirez, D. A.] Biogen Res Chamber, San Antonio, TX USA. [Harper, N.; He, W.; Castiblanco, J.; Carrillo, A.; Manoharan, M.; Avadhanam, N.; Liu, Y.; Ingale, P.; Ahuja, S. K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Harper, N.; He, W.; Castiblanco, J.; Carrillo, A.; Manoharan, M.; Avadhanam, N.; Liu, Y.; Ingale, P.; Ahuja, S. K.] South Texas Vet Hlth Care Syst, Vet Adm Ctr Personalized Med, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0105-4538 EI 1398-9995 J9 ALLERGY JI Allergy PD SEP PY 2013 VL 68 SU 97 SI SI BP 20 EP 20 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 227VH UT WOS:000325142900044 ER PT J AU Land, AM Nelson, GA Bell, SG Denby, KJ Estrada, CA Willett, LL AF Land, Andrew M. Nelson, George A. Bell, Stephen G. Denby, Kara J. Estrada, Carlos A. Willett, Lisa L. TI Widening the Differential for Brain Masses in Human Immunodeficiency Virus-Positive Patients: Syphilitic Cerebral Gummata SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Article DE Syphilis; HIV; Neurosyphilis; Gumma ID HIV-INFECTION; NEUROSYPHILIS AB A 39-year-old man with newly diagnosed human immunodeficiency virus (HIV) infection was admitted with right-sided weakness, right-sided vision loss and slurred speech, which worsened over several weeks. Brain imaging revealed bilateral intraparenchymal ring-enhancing lesions and enhancement of the right optic nerve. Serological findings were positive for venereal disease research laboratory test, whereas the cerebrospinal fluid venereal disease research laboratory test was nonreactive. Brain biopsy suggested a diagnosis of syphilitic cerebral gummata, and the patient's improvement with penicillin and dexamethasone further supported this etiology. Syphilitic cerebral gummata have rarely been reported in patients with HIV infection. This patient demonstrates that cerebral gummata should be considered in the differential diagnosis in immunocompromised patients with characteristic brain masses, that HIV and syphilis often coexist with early neurosyphilis appearing more frequently in this patient population and that normal cerebrospinal fluid studies may not represent a true lack of syphilitic activity in HIV patients. C1 [Land, Andrew M.; Nelson, George A.; Bell, Stephen G.] Univ Alabama Birmingham, Tinsley Harrison Internal Med Residency Program, Birmingham, AL 35294 USA. [Denby, Kara J.] Univ Alabama Birmingham, Sch Med, Birmingham, AL 35294 USA. [Estrada, Carlos A.; Willett, Lisa L.] Univ Alabama Birmingham, Birmingham Hosp, Div Gen Internal Med, Birmingham, AL 35294 USA. [Estrada, Carlos A.] Birmingham Vet Affairs Med Ctr, Vet Affairs Qual Scholars Fellowship Program, Birmingham, AL USA. RP Land, AM (reprint author), Univ Alabama Birmingham, BDB 327,1720 2nd Ave South, Birmingham, AL 35294 USA. EM amland@uab.edu FU Department of Veterans Affairs National Quality Scholars Fellowship (VAQS); Department of Veterans Affairs Office of Academic Affiliations (OAA) FX The Department of Veterans Affairs National Quality Scholars Fellowship (VAQS) is funded by the Department of Veterans Affairs Office of Academic Affiliations (OAA). The opinions expressed in this article are those of the contributing authors alone and do not necessarily reflect the views, opinions or policies of the Department of Veterans Affairs. NR 13 TC 2 Z9 3 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-9629 EI 1538-2990 J9 AM J MED SCI JI Am. J. Med. Sci. PD SEP PY 2013 VL 346 IS 3 BP 253 EP 255 DI 10.1097/MAJ.0b013e31828c9f22 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 242MX UT WOS:000326247500020 PM 23588265 ER PT J AU Bersohn, MM Turner, MP Traiger, GL Frost, AE Shapiro, S AF Bersohn, Malcolm M. Turner, Michelle P. Traiger, Glenna L. Frost, Adaani E. Shapiro, Shelley TI Systemic BP and Heart Rate as Prognostic Indicators in Pulmonary Arterial Hypertension SO CHEST LA English DT Article ID REVEAL REGISTRY; DISEASE MANAGEMENT; FAILURE; PREDICTORS; INSIGHTS; OUTCOMES; ASSOCIATION; GUIDELINES; DIAGNOSIS; MORTALITY AB Background: Heart rate (HR) and systolic BP (SBP) are significant multivariate predictors of survival in patients with pulmonary arterial hypertension (PAH) as part of a 19-element formula. To what extent HR and BP alone predict survival and future hospitalization in patients with PAH is unknown. Methods: We analyzed data from the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL Registry), a prospective, observational study of patients with PAH. Patients were analyzed by quintile (Q) according to values of HR, SBP, and SBP/HR. Kaplan-Meier curves were calculated by Q for survival and freedom from hospitalization. Results: For patients in the worst Q, 1-year survival after enrollment was 85% +/- 2% for SBP, 86% +/- 2% for HR, and 84% +/- 2% for SBP/HR vs 91% +/- 1% for the middle three Qs (P < .001). Hospitalization occurred more frequently than mortality but with a similar pattern among Qs. One-year survival after first follow-up of patients in the worst Q for change (Delta) in SBP since enrollment was 85% +/- 2% (P = .004), 86% +/- 2% for Delta HR (P = .12), and 84% +/- 2% for Delta SBP/HR (P = .024) vs the middle three Qs (Delta SBP: 91% +/- 1%; Delta HR: 90% +/- 1%; Delta SBP/HR: 90% +/- 1%). Conclusions: Changes in vital signs from enrollment to first follow-up were less predictive of mortality than the values of vital-sign parameters at either enrollment or first follow-up. HR, SBP, and SBP/HR at enrollment identified high-risk groups with survival differences of 5% to 7% and freedom from hospitalization differences of 9% to 11% vs lower-risk groups. SBP/HR defines the highest-risk group, including most of the high-risk patients defined by HR and SBP separately. C1 [Bersohn, Malcolm M.; Shapiro, Shelley] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Bersohn, Malcolm M.; Shapiro, Shelley] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Turner, Michelle P.] ICON Late Phase & Outcomes Res, San Francisco, CA USA. [Traiger, Glenna L.] Univ Calif Los Angeles, Los Angeles, CA USA. [Frost, Adaani E.] Baylor Coll Med, Houston, TX 77030 USA. RP Bersohn, MM (reprint author), VA Greater Angeles Healthcare Syst, Cardiol 111E,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mbersohn@ucla.edu FU Cotherix Inc FX Funding and support for the REVEAL Registry were provided by Cotherix Inc, and its affiliate Actelion Pharmaceuticals US Inc. NR 15 TC 3 Z9 3 U1 3 U2 4 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 EI 1931-3543 J9 CHEST JI Chest PD SEP PY 2013 VL 144 IS 3 BP 959 EP 965 DI 10.1378/chest.12-2572 PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 241JC UT WOS:000326161700034 PM 23598723 ER PT J AU Yusin, JS Klaustermeyer, W Simmons, CW Baum, M AF Yusin, J. S. Klaustermeyer, W. Simmons, C. W. Baum, M. TI Desensitization in patients with beta-lactam drug allergy SO ALLERGOLOGIA ET IMMUNOPATHOLOGIA LA English DT Article DE Beta-lactam antibiotic; Hypersensitivity; Desensitization ID PENICILLIN ALLERGY; IMMEDIATE HYPERSENSITIVITY; CLINICAL HISTORY; CROSS-REACTIVITY; TOLERABILITY; EXPERIENCE; REAGENTS; IMIPENEM AB Background: Patients with a history of beta-lactam antibiotic allergy are often admitted to the hospital with severe or life-threatening infections requiring beta-lactam antibiotics. Strict avoidance of beta lactams to such patients may prevent them from getting adequate coverage and can lead to an increase in the use of alternative antibiotics, which can predispose to antibiotic resistance. Past studies revealed a lower incidence of pen allergy then patients' histories suggest. Fortunately today, there are three options for patients presenting with a history of beta-lactam allergy. Penicillin skin testing, beta-lactam challenge or beta-lactam desensitization. Recently Pre Pen has been FDA re-approved and when combined with Pen G is a valid way to determine if patients are able to tolerate beta-lactam antibiotic. When these agents are not available one must decide about desensitization or challenge. When a patient has a positive penicillin skin test, desensitization or beta-lactam avoidance are the only options. This paper reviews the safety of beta-lactam desensitization. Objective: To perform a chart review on patients desensitised with beta lactam to determine if desensitizations can be performed safely without minimal complications. Methods: A retrospective chart review was performed on allergy and immunology inpatient consultations for beta-lactam desensitization between September 2003 and August 2006 at the Cedars-Sinai Medical Centre in Los Angeles. Patient data and outcomes of desensitization were analysed. Results: A total of 13 intravenous desensitizations were performed on 12 patients. The patients consisted of eight females and four males with an average age of 65 years. Age range was 36-92 years old. All 13 intravenous desensitizations were completed without complications. No patient required a slower rate of desensitization or discontinuance of the desensitization. Patients were able to tolerate the initial therapeutic dose of their beta-lactam antibiotic and were then able to complete full therapeutic courses of their antibiotic. Conclusion: Beta-lactam antibiotic sensitivity continues to present a challenging problem for physicians. Patients with drug resistant infections who are unable to obtain skin testing or who test positive to skin tests may need either a challenge or desensitization. Desensitization, saved for those with a convincing beta-lactam hypersensitivity history is often the choice of last resort given the associated cost and risk of anaphylaxis. However, once desensitization is complete, patients are usually able to tolerate full doses of antibiotics for full treatment length with minimal side effects. Published by Elsevier Espana, S.L. on behalf of SEICAP. C1 [Yusin, J. S.; Simmons, C. W.; Baum, M.] Greater Los Angeles VA Hlth Care Syst, Los Angeles, CA USA. [Klaustermeyer, W.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. RP Yusin, JS (reprint author), Greater Los Angeles VA Hlth Care Syst, Los Angeles, CA USA. EM Joseph.Yusin2@va.gov FU Department of Veterans Affairs FX This material is based upon work supported by the Department of Veterans Affairs. NR 23 TC 2 Z9 2 U1 0 U2 4 PU ELSEVIER DOYMA SL PI BARCELONA PA TRAVESERA DE GARCIA, 17-21, BARCELONA, 08021, SPAIN SN 0301-0546 EI 1578-1267 J9 ALLERGOL IMMUNOPATH JI Allergol. Immunopath. PD SEP-OCT PY 2013 VL 41 IS 5 BP 298 EP 303 DI 10.1016/j.aller.2012.06.003 PG 6 WC Allergy; Immunology SC Allergy; Immunology GA 237BL UT WOS:000325843100004 PM 23177979 ER PT J AU Clark, KB AF Clark, Kevin B. TI New Therapeutic Bearings for Repositioned Drugs SO CURRENT TOPICS IN MEDICINAL CHEMISTRY LA English DT Editorial Material C1 Vet Affairs Greater Los Angeles Healthcare Syst, Res & Dev Serv, Los Angeles, CA 90073 USA. RP Clark, KB (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Res & Dev Serv, 4229 SE Harney St, Los Angeles, CA 90073 USA. NR 0 TC 3 Z9 3 U1 1 U2 6 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1568-0266 EI 1873-4294 J9 CURR TOP MED CHEM JI Curr. Top. Med. Chem. PD SEP PY 2013 VL 13 IS 18 BP 2281 EP 2282 PG 2 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA 238EX UT WOS:000325926500006 PM 24059466 ER PT J AU Clark, KB Eisenstein, EM Krahl, SE AF Clark, Kevin B. Eisenstein, Edward M. Krahl, Scott E. TI Calcium Antagonists: A Ready Prescription for Treating Infectious Diseases? SO CURRENT TOPICS IN MEDICINAL CHEMISTRY LA English DT Review DE Antibiotic tolerance or resistance; antimicrobial drugs; biotechnology; disease transmission and virulence; microbial pathogens and parasites; pharmaceuticals ID WORLD-HEALTH-ORGANIZATION; LEISHMANIA L. CHAGASI; ANTIMICROBIAL AGENTS; ANTIBIOTIC-RESISTANCE; CA2+ CHANNEL; OLD DRUGS; IN-VITRO; PROTOZOAN PARASITES; FILAMENTOUS FUNGUS; CANDIDA-ALBICANS AB Emergence of new and medically resistant pathogenic microbes continues to escalate toward worldwide public health, wild habitat, and commercial crop and livestock catastrophes. Attempts at solving this problem with sophisticated modern biotechnologies, such as smart vaccines and microbicidal and microbistatic drugs that precisely target parasitic bacteria, fungi, and protozoa, remain promising without major clinical and industrial successes. However, discovery of a more immediate, broad spectrum prophylaxis beyond conventional epidemiological approaches might take no longer than the time required to fill a prescription at your neighborhood pharmacy. Findings from a growing body of research suggest calcium antagonists, long approved and marketed for various human cardiovascular and neurological indications, may produce safe, efficacious antimicrobial effects. As a general category of drugs, calcium antagonists include compounds that disrupt passage of Ca2+ molecules across cell membranes and walls, sequestration and mobilization of free intracellular Ca2+, and downstream binding proteins and sensors of Ca2+-dependent regulatory pathways important for proper cell function. Administration of calcium antagonists alone at current therapeutically relevant doses and schedules, or with synergistic compounds and additional antimicrobial medications, figures to enhance host immunoprotection by directly altering pathogen infection sequences, life cycles, homeostasis, antibiotic tolerances, and numerous other infective, survival, and reproductive processes. Short of being miracle drugs, calcium antagonists are welcome old drugs with new tricks capable of controlling some of the most virulent and pervasive global infectious diseases of plants, animals, and humans, including Chagas' disease, malaria, and tuberculosis. C1 [Eisenstein, Edward M.; Krahl, Scott E.] Vet Affairs Greater Los Angeles Hlth Care Syst, Res & Dev Serv, Los Angeles, CA 90073 USA. [Krahl, Scott E.] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA USA. RP Clark, KB (reprint author), 4229 S E Harney St, Portland, OR 97206 USA. EM kbclarkphd@yahoo.com NR 143 TC 3 Z9 3 U1 1 U2 15 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1568-0266 EI 1873-4294 J9 CURR TOP MED CHEM JI Curr. Top. Med. Chem. PD SEP PY 2013 VL 13 IS 18 BP 2291 EP 2305 PG 15 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA 238EX UT WOS:000325926500008 PM 24059464 ER PT J AU Garvey, WT AF Garvey, W. Timothy TI NEW TOOLS FOR WEIGHT-LOSS THERAPY ENABLE A MORE ROBUST MEDICAL MODEL FOR OBESITY TREATMENT: RATIONALE FOR A COMPLICATIONS-CENTRIC APPROACH SO ENDOCRINE PRACTICE LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; LIFE-STYLE INTERVENTION; BODY-MASS INDEX; CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE; LIPOPROTEIN SUBCLASS PROFILE; TOPIRAMATE EXTENDED-RELEASE; TYPE-2 DIABETES-MELLITUS; OBSTRUCTIVE SLEEP-APNEA; CARDIOVASCULAR RISK; METABOLIC SYNDROME AB Objective: Recent advances in lifestyle intervention programs, pharmacotherapy, and bariatric surgery have enabled the development of medical models for the treatment of obesity. Regarding pharmacotherapy, in 2012 the U.S. Food and Drug Administration approved two new effective and safe weight-loss medications, phentermine/topiramate extended release and lorcaserin, which has greatly augmented options for medically assisted weight loss. Methods: The rationale for advantages of a complications- centric medical model over current body mass index (BMI)-centric indications for therapy is examined. Results: Currently, the baseline BMI level is the principle determinant of indications for obesity treatment using medication and surgery. However, the BMI-centric approach fails to target therapy to those obese patients who will benefit most from weight loss. In contrast, a complications- centric medical model is proposed that will earmark the modality and intensity of the therapeutic intervention based on the presence and severity of complications that can be ameliorated by weight loss. Conclusion: The complications-centric approach to "medicalizing" obesity care employs weight loss primarily as a tool to treat obesity-related complications and promotes the optimization of health outcomes, the benefit/ risk ratio, and the cost-effectiveness of therapy. C1 [Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL USA. RP Garvey, WT (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, Webb 232,1720 2nd Ave South, Birmingham, AL 35294 USA. EM garveyt@uab.edu FU Weight Watchers International Inc.; Amylin; Merck FX Dr. Garvey is an advisor for Alkermes Plc, Daiichi-Sankyo Inc, LipoScience, VIVUS Inc, Janssen Pharmaceuticals, Novo Nordisk, Eisai, AstraZeneca/Bristol-Myers-Squibb, and Tethys. He is a speaker for Merck & Company and Amylin Pharmaceuticals Inc and holds stock in Bristol-Myers Squibb Company, Isis/Genzyme, Merck, Pfizer Inc, Eli Lilly and Company, and VIVUS Inc. He has received research support from Amylin, Merck, and Weight Watchers International Inc. NR 77 TC 16 Z9 17 U1 0 U2 6 PU AMER ASSOC CLINICAL ENDOCRINOLOGISTS PI JACKSONVILLE PA 245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA SN 1530-891X EI 1934-2403 J9 ENDOCR PRACT JI Endocr. Pract. PD SEP-OCT PY 2013 VL 19 IS 5 BP 864 EP 874 DI 10.4158/EP13263.RA PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 235WC UT WOS:000325750800022 PM 24014010 ER PT J AU Loewenstein, G Friedman, JY McGill, B Ahmad, S Linck, S Sinkula, S Beshears, J Choi, JJ Kolstad, J Laibson, D Madrian, BC List, JA Volpp, KG AF Loewenstein, George Friedman, Joelle Y. McGill, Barbara Ahmad, Sarah Linck, Suzanne Sinkula, Stacey Beshears, John Choi, James J. Kolstad, Jonathan Laibson, David Madrian, Brigitte C. List, John A. Volpp, Kevin G. TI Consumers' misunderstanding of health insurance SO JOURNAL OF HEALTH ECONOMICS LA English DT Article DE Insurance; Behavioral economics; Simplification ID INFORMATION; MARKETS; CHOICE; COVERAGE AB We report results from two surveys of representative samples of Americans with private health insurance. The first examines how well Americans understand, and believe they understand, traditional health insurance coverage. The second examines whether those insured under a simplified all-copay insurance plan will be more likely to engage in cost-reducing behaviors relative to those insured under a traditional plan with deductibles and coinsurance, and measures consumer preferences between the two plans. The surveys provide strong evidence that consumers do not understand traditional plans and would better understand a simplified plan, but weaker evidence that a simplified plan would have strong appeal to consumers or change their healthcare choices. (C) 2013 Elsevier B.V. All rights reserved. C1 [Loewenstein, George] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA. [Friedman, Joelle Y.] Univ Penn, Leonard Davis Inst, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA. [McGill, Barbara] Colchester Consulting Grp, Glencoe, IL 60022 USA. [Linck, Suzanne] Humana, Strateg Consultant Product Dev Small Business, Green Bay, WI 54344 USA. [Sinkula, Stacey] Humana, Managing Actuary Small Business, Green Bay, WI 54344 USA. [Beshears, John] Stanford Grad Sch Business, Stanford, CA 94305 USA. [Choi, James J.] Yale Sch Management, New Haven, CT 06520 USA. [Kolstad, Jonathan] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [Laibson, David] Harvard Univ, Dept Econ, Cambridge, MA 02138 USA. [Madrian, Brigitte C.] Harvard Univ, Cambridge, MA 02138 USA. [List, John A.] Univ Chicago, Chicago, IL USA. [Volpp, Kevin G.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Volpp, Kevin G.] Leonard Davis Inst, Ctr Hlth Incent & Behav Econ, Davis, CA USA. [Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [Ahmad, Sarah] Dev Humana, Commercial Product, Louisville, KY 40202 USA. RP Loewenstein, G (reprint author), Carnegie Mellon Univ, 5000 Forbes Ave,319 C Porter Hall, Pittsburgh, PA 15213 USA. EM gl20@andrew.cmu.edu; bmcgill@colchesterconsultinggroup.com; sahmad@humana.com; ssinkula@humana.com; beshears@stanford.edu; james.choi@yale.edu; jkolstad@wharton.upenn.edu; Dlaibson@harvard.edu; brigitte_madrian@harvard.edu; jlist@uchicago.edu RI Choi, James/D-4706-2012 NR 29 TC 28 Z9 28 U1 2 U2 29 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-6296 EI 1879-1646 J9 J HEALTH ECON JI J. Health Econ. PD SEP PY 2013 VL 32 IS 5 BP 850 EP 862 DI 10.1016/j.jhealeco.2013.04.004 PG 13 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 239YD UT WOS:000326061000008 PM 23872676 ER PT J AU Ganguly, K Byl, NN Abrams, GM AF Ganguly, Karunesh Byl, Nancy N. Abrams, Gary M. TI Neurorehabilitation: Motor Recovery After Stroke as an Example SO ANNALS OF NEUROLOGY LA English DT Article ID TRANSCRANIAL MAGNETIC STIMULATION; INDUCED MOVEMENT THERAPY; UPPER-LIMB RECOVERY; SPINAL-CORD-INJURY; FUNCTIONAL RECOVERY; BRAIN-STIMULATION; ISCHEMIC-STROKE; CORTICAL STIMULATION; CONTROLLED-TRIAL; CLINICAL-TRIALS AB The field of neurorehabilitation aims to translate neuroscience research toward the goal of maximizing functional recovery after neurological injury. A growing body of research indicates that the fundamental principles of neurological rehabilitation are applicable to a broad range of congenital, degenerative, and acquired neurological disorders. In this perspective, we will focus on motor recovery after acquired brain injuries such as stroke. Over the past few decades, a large body of basic and clinical research has created an experimental and theoretical foundation for approaches to neurorehabilitation. Recent randomized clinical trials all emphasize the requirement for intense progressive rehabilitation programs to optimally enhance recovery. Moreover, advances in multimodal assessment of patients with neuroimaging and neurophysiological tools suggest the possibility of individualized treatment plans based on recovery potential. There are also promising indications for medical as well as noninvasive brain stimulation paradigms to facilitate recovery. Ongoing or planned clinical studies should provide more definitive evidence. We also highlight unmet needs and potential areas of research. Continued research built upon a robust experimental and theoretical foundation should help to develop novel treatments to improve recovery after neurological injury. Ann Neurol 2013;74:373-381 C1 [Ganguly, Karunesh; Abrams, Gary M.] Univ Calif San Francisco, San Francisco Vet Adm Med Ctr, Dept Neurol & Rehabil, San Francisco, CA 94143 USA. [Ganguly, Karunesh; Abrams, Gary M.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Byl, Nancy N.] Univ Calif San Francisco, Dept Phys Therapy & Rehabil Sci, San Francisco, CA 94143 USA. RP Ganguly, K (reprint author), 127 Neurol,4150 Clement St, San Francisco, CA 94121 USA. EM Karunesh.Ganguly@ucsf.edu FU Department of Veterans Affairs [B6674W]; American Heart Association [0875016N]; Burroughs Wellcome Fund (CAMS); University of California, California Institute for Technology, Research and Innovation Science (CITRIS) [A115093, P0036258] FX Supported by grants to K. G. and G. A. from the Department of Veterans Affairs (B6674W) and to K. G. from the American Heart Association (0875016N) and the Burroughs Wellcome Fund (CAMS). Also supported by funding to N.N.B. from the University of California, California Institute for Technology, Research and Innovation Science (CITRIS) Award# A115093, P0036258 (PI Jacob Rosen). NR 105 TC 4 Z9 4 U1 1 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0364-5134 EI 1531-8249 J9 ANN NEUROL JI Ann. Neurol. PD SEP PY 2013 VL 74 IS 3 BP 373 EP 381 DI 10.1002/ana.23994 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 232BJ UT WOS:000325463100013 PM 25813243 ER PT J AU Li, PY Gan, Y Sun, BL Zhang, F Lu, BF Gao, YQ Liang, WM Thomson, AW Chen, J Hu, XM AF Li, Peiying Gan, Yu Sun, Bao-Liang Zhang, Feng Lu, Binfeng Gao, Yanqin Liang, Weimin Thomson, Angus W. Chen, Jun Hu, Xiaoming TI Adoptive Regulatory T-Cell Therapy Protects Against Cerebral Ischemia SO ANNALS OF NEUROLOGY LA English DT Article ID BLOOD-BRAIN-BARRIER; EXPERIMENTAL STROKE; NEUTROPHIL INFILTRATION; REG CELLS; IN-VIVO; MATRIX-METALLOPROTEINASE-9; DISEASE; INJURY; GAMMA; VITRO AB ObjectiveRecent evidence suggests that functional deficiency in regulatory T cells (Tregs), an innate immunomodulator, exacerbates brain damage after cerebral ischemia. We therefore evaluated the effect of Treg transfer in rodent models of ischemic stroke and further investigated the mechanism underlying Treg-afforded neuroprotection. MethodsWe examined the therapeutic potential of Tregs and the mechanisms of neuroprotection in vivo in 2 rodent models of ischemic stroke and in vitro in Treg-neutrophil cocultures using a combined approach including cell-specific depletion, gene knockout mice, and bone marrow chimeras. ResultsSystemic administration of purified Tregs at 2, 6, or even 24 hours after middle cerebral artery occlusion resulted in a marked reduction of brain infarct and prolonged improvement of neurological functions lasting out to 4 weeks. Treg-afforded neuroprotection was accompanied by attenuated blood-brain barrier (BBB) disruption during early stages of ischemia, decreased cerebral inflammation, and reduced infiltration of peripheral inflammatory cells into the lesioned brain. Surprisingly, Tregs exerted early neuroprotection without penetrating into the brain parenchyma or inhibiting the activation of residential microglia. Rather, both in vivo and in vitro studies demonstrated that Tregs suppressed peripheral neutrophil-derived matrix metallopeptidase-9 production, thus preventing proteolytic damage of the BBB. In addition to its potent central neuroprotection, Treg treatment was shown to ameliorate poststroke lymphopenia, suggesting a beneficial effect on immune status. InterpretationOur study suggests that Treg adoptive therapy is a novel and potent cell-based therapy targeting poststroke inflammatory dysregulation and neurovascular disruption. Ann Neurol 2013;74:458-471 C1 [Li, Peiying; Zhang, Feng; Gao, Yanqin; Liang, Weimin; Chen, Jun; Hu, Xiaoming] Fudan Univ, Huashan Hosp, Dept Anesthesiol, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China. [Li, Peiying; Zhang, Feng; Gao, Yanqin; Liang, Weimin; Chen, Jun; Hu, Xiaoming] Fudan Univ, Inst Brain Sci, Shanghai 200433, Peoples R China. [Li, Peiying; Gan, Yu; Zhang, Feng; Chen, Jun; Hu, Xiaoming] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA USA. [Sun, Bao-Liang] Shandong Univ, Affiliated Hosp, Taishan Med Coll, Dept Neurol, Tai An, Shandong, Peoples R China. [Sun, Bao-Liang] Shandong Univ, Affiliated Hosp, Taishan Med Coll, Key Lab Cerebral Microcirculat, Tai An, Shandong, Peoples R China. [Lu, Binfeng; Thomson, Angus W.] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA USA. [Thomson, Angus W.] Univ Pittsburgh, Sch Med, Dept Surg, Starzl Transplantat Inst, Pittsburgh, PA USA. [Chen, Jun; Hu, Xiaoming] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Hu, XM (reprint author), Univ Pittsburgh, Med Ctr, Dept Neurol, Pittsburgh, PA 15213 USA. EM chenj2@upmc.edu; hux2@upmc.edu RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819 FU Veterans Health Administration (GRECC); NIH NINDS [NS36736, NS43802, NS45048]; American Heart Association [10POST4150028, 10SDG2560122]; Chinese Natural Science Foundation [8107094] FX This work was supported by the Veterans Health Administration (GRECC pilot grant to J.C.), NIH NINDS grants (NS36736, NS43802, and NS45048 to J.C.), and grants from the American Heart Association (10POST4150028 to X. H., 10SDG2560122 to F.Z.). B.-L. S. was supported by Chinese Natural Science Foundation grants (8107094). NR 38 TC 49 Z9 52 U1 4 U2 30 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0364-5134 EI 1531-8249 J9 ANN NEUROL JI Ann. Neurol. PD SEP PY 2013 VL 74 IS 3 BP 458 EP 471 DI 10.1002/ana.23815 PG 14 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 232BJ UT WOS:000325463100024 PM 23674483 ER PT J AU Baruch, L Sherman, O AF Baruch, Lawrence Sherman, Olga TI Inaccuracy of Point-of-Care International Normalized Ratio in Rivaroxaban-Treated Patients SO ANNALS OF PHARMACOTHERAPY LA English DT Article DE rivaroxaban; point-of-care INR; INR; anticoagulation; factor Xa inhibitor; deep vein thrombosis AB Objective: To report 2 cases in which point-of-care international normalized ratios (POC-INRs) measured using a Hemochron Jr. Signature Elite device (International Technidyne Corporation) were inaccurate in rivaroxaban-treated patients. Case Summaries: Therapy in an 86-year-old man with atrial fibrillation was converted from warfarin to rivaroxaban 15 mg twice daily because of a deep venous thrombotic event despite an INR of 2.4, which was within the therapeutic range. One week later a POC-INR was inadvertently measured, which was 6.3. In light of the POC-INR being markedly elevated, a laboratory test for INR was performed, which gave a result of 2.74. Therapy in a 66-year-old man was converted from war-farin to rivaroxaban 15 mg twice daily because of unstable INRs and a pulmonary embolism despite a therapeutic INR. Seven days after rivaroxaban was started, the patient's POC-INR was 9.2; simultaneously measured laboratory-determined INR was 2.0. For both patients, coagulation tests performed on follow-up visits revealed continued discordance between the POC and laboratory assays. Discussion: Rivaroxaban is an oral factor Xa inhibitor with a predictable pharmacokinetic profile, allowing for a fixed-dose regimen without the need for coagulation monitoring. When patients' therapy is switched from rivaroxaban to warfarin, it is recommended that the drugs be given concurrently until the INR is 2.0 or higher, to ensure adequate anticoagulation during this well-recognized vulnerable period for stroke. POC testing is a common method of INR assessment in clinical practice. During ROCKET-AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation), POC-INRs were measured exclusively with the INRatio device (Hemosense), and values above 4 were seen very rarely (0.25%), which indicates that the values determined in our patients were highly unusual. Conclusions: Our 2 patients receiving rivaroxaban had POC-INRs elevated beyond what was expected; these measurements were discordant from INRs simultaneously measured via the laboratory. A prospective evaluation assessing the accuracy of other commonly used POC-INR devices in patients receiving rivaroxaban would determine whether our findings extend to other devices. Until that time, laboratory measurement of INR or POC-INR using an INRatio device is recommended when patients' therapy is transitioned from rivaroxaban to warfarin. C1 [Baruch, Lawrence] James J Peters VA Med Ctr, Program Med, Bronx, NY USA. [Baruch, Lawrence] Mt Sinai Sch Med, Dept Cardiol, New York, NY USA. [Sherman, Olga] James J Peters VA Med Ctr, Pharm Program, Bronx, NY USA. RP Baruch, L (reprint author), James J Peters VA Med Ctr, Program Med, Bronx, NY USA. EM lawrence.baruch@va.gov NR 1 TC 0 Z9 0 U1 0 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1060-0280 EI 1542-6270 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD SEP PY 2013 VL 47 IS 9 BP 1210 EP 1212 DI 10.1177/1060028013503129 PG 3 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 225UR UT WOS:000324989700014 PM 24259738 ER PT J AU Groeneveld, PW AF Groeneveld, Peter W. TI Can Advanced Healthcare Technology Save Money? SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Editorial Material DE Editorials; chest pain diagnosis; computed tomographic angiography; emergency medicine; health economics; hospital costs ID CORONARY; ANGIOGRAPHY; PREDICTORS; IMPACT; TRIAL; SCORE; RISK C1 [Groeneveld, Peter W.] Philadelphia Vet Affairs Med Ctr, Dept Vet Affairs, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Groeneveld, Peter W.] Univ Penn, Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Groeneveld, Peter W.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Groeneveld, PW (reprint author), Univ Penn, Sch Med, 1229 Blockley Hall,423 Serv Dr, Philadelphia, PA 19104 USA. EM petergro@mail.med.upenn.edu NR 13 TC 0 Z9 0 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7705 EI 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD SEP PY 2013 VL 6 IS 5 BP 509 EP 510 DI 10.1161/CIRCOUTCOMES.113.000533 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 219RM UT WOS:000324526400003 PM 24021698 ER PT J AU Ulu, A Harris, TR Morisseau, C Miyabe, C Inoue, H Schuster, G Dong, H Iosif, AM Liu, JY Weiss, RH Chiamvimonvat, N Imig, JD Hammock, BD AF Ulu, Arzu Harris, Todd R. Morisseau, Christophe Miyabe, Christina Inoue, Hiromi Schuster, Gertrud Dong, Hua Iosif, Ana-Maria Liu, Jun-Yan Weiss, Robert H. Chiamvimonvat, Nipavan Imig, John D. Hammock, Bruce D. TI Anti-inflammatory Effects of omega-3 Polyunsaturated Fatty Acids and Soluble Epoxide Hydrolase Inhibitors in Angiotensin-II-Dependent Hypertension SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY LA English DT Article DE omega-3 polyunsaturated fatty acids; EPA; DHA; soluble epoxide hydrolase inhibitors; angiotensin-II-dependent hypertension ID PLACEBO-CONTROLLED TRIAL; LONG-CHAIN OMEGA-3-FATTY-ACIDS; BLOOD-PRESSURE; DOCOSAHEXAENOIC ACID; CARDIOVASCULAR-DISEASE; CYTOCHROME-P450 EPOXYGENASES; KNOCKOUT MICE; DOUBLE-BLIND; FISH-OIL; METABOLITES AB The mechanisms underlying the anti-inflammatory and antihypertensive effects of long-chain -3 polyunsaturated fatty acids (-3 PUFAs) are still unclear. The epoxides of an -6 fatty acid, arachidonic acid epoxyeicosatrienoic acids also exhibit antihypertensive and anti-inflammatory effects. Thus, we hypothesized that the major -3 PUFAs, including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), may lower the blood pressure and attenuate renal markers of inflammation through their epoxide metabolites. Here, we supplemented mice with an -3 rich diet for 3 weeks in a murine model of angiotensin-II-dependent hypertension. Also, because EPA and DHA epoxides are metabolized by soluble epoxide hydrolase (sEH), we tested the combination of an sEH inhibitor and the -3 rich diet. Our results show that -3 rich diet in combination with the sEH inhibitor lowered Ang-II, increased the blood pressure, further increased the renal levels of EPA and DHA epoxides, reduced renal markers of inflammation (ie, prostaglandins and MCP-1), downregulated an epithelial sodium channel, and upregulated angiotensin-converting enzyme-2 message and significantly modulated cyclooxygenase and lipoxygenase metabolic pathways. Overall, our findings suggest that epoxides of the -3 PUFAs contribute to lowering systolic blood pressure and attenuating inflammation in part by reduced prostaglandins and MCP-1 and by upregulation of angiotensin-converting enzyme-2 in angiotensin-II-dependent hypertension. C1 [Ulu, Arzu; Harris, Todd R.; Morisseau, Christophe; Miyabe, Christina; Dong, Hua; Liu, Jun-Yan; Hammock, Bruce D.] Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA. [Ulu, Arzu; Harris, Todd R.; Morisseau, Christophe; Miyabe, Christina; Dong, Hua; Liu, Jun-Yan; Hammock, Bruce D.] Univ Calif Davis, UC Davis Comprehens Canc Ctr, Davis, CA 95616 USA. [Inoue, Hiromi; Weiss, Robert H.] Univ Calif Davis, Sch Med, Div Nephrol, Davis, CA 95616 USA. [Schuster, Gertrud] Univ Calif Davis, Sch Med, Dept Nutr, Davis, CA 95616 USA. [Chiamvimonvat, Nipavan] Univ Calif Davis, Sch Med, Dept Internal Med, Div Cardiovasc Med, Davis, CA 95616 USA. [Iosif, Ana-Maria] Univ Calif Davis, Sch Med, Dept Publ Hlth, Div Biostat, Davis, CA 95616 USA. [Weiss, Robert H.; Chiamvimonvat, Nipavan] US Dept Vet Affairs, Med Ctr, Sacramento, CA USA. [Imig, John D.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA. RP Hammock, BD (reprint author), Univ Calif Davis, Dept Entomol, 1 Shields Ave, Davis, CA 95616 USA. EM bdhammock@ucdavis.edu RI Liu, Jun-Yan/D-8890-2014 OI Imig, John/0000-0002-9668-2899 FU NIEHS [R01 ES002710]; NIEHS Superfund Research Program [P42 ES004699]; NIH [5UO1CA86402, 1R01CA135401-01A1, 1R01DK082690-01A1, HL59699, DK38226]; Medical Service of the US Department of Veterans' Affairs; NIDDK [U24 DK097154]; National Center for Advancing Translational Sciences, NIH [UL1 TR000002]; NIH T32 training grant in basic and translational cardiovascular science [T32 HL86350] FX Supported by NIEHS grant R01 ES002710 and NIEHS Superfund Research Program grant P42 ES004699; NIH grants 5UO1CA86402 (Early Detection Research Network), 1R01CA135401-01A1, and 1R01DK082690-01A1; and the Medical Service of the US Department of Veterans' Affairs (all to R. H. W.). Analytical work was partially supported by the NIH and NIDDK grant U24 DK097154. Studies and analyses performed by J. D. Imig were supported by NIH grants HL59699 and DK38226. Analyses performed by A.-M. Iosif were supported by the National Center for Advancing Translational Sciences, NIH, through grant UL1 TR000002. T. R. Harris is supported by NIH T32 training grant in basic and translational cardiovascular science (T32 HL86350). B. D. Hammock is a George and Judy Marcus senior fellow of the American Asthma Foundation, and was supported by NIEHS grant R01 ES002710 and NIEHS Superfund Research Program grant P42 ES004699. NR 65 TC 29 Z9 31 U1 4 U2 20 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0160-2446 EI 1533-4023 J9 J CARDIOVASC PHARM JI J. Cardiovasc. Pharmacol. PD SEP PY 2013 VL 62 IS 3 BP 285 EP 297 DI 10.1097/FJC.0b013e318298e460 PG 13 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA 219WX UT WOS:000324543400008 PM 23676336 ER PT J AU Choi, SY Chacon-Heszele, MF Huang, LW McKenna, S Wilson, FP Zuo, XF Lipschutz, JH AF Choi, Soo Young Chacon-Heszele, Maria F. Huang, Liwei McKenna, Sarah Wilson, F. Perry Zuo, Xiaofeng Lipschutz, Joshua H. TI Cdc42 Deficiency Causes Ciliary Abnormalities and Cystic Kidneys SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID IN-SITU HYBRIDIZATION; RAC1 SMALL GTPASES; CELL-POLARITY; EPITHELIAL-CELLS; PRIMARY CILIOGENESIS; SPINDLE ORIENTATION; KUPFFERS VESICLE; PRIMARY CILIUM; KIF3A SUBUNIT; KINESIN-II AB Ciliogenesis and cystogenesis require the exocyst, a conserved eight-protein trafficking complex that traffics ciliary proteins. In culture, the small GTPase Cdc42 co-localizes with the exocyst at primary cilia and interacts with the exocyst component Sec10. The role of Cdc42 in vivo, however, is not well understood. Here, knockdown of cdc42 in zebrafish produced a phenotype similar to sec10 knockdown, including tail curvature, glomerular expansion, and mitogen-activated protein kinase (MAPK) activation, suggesting that cdc42 and sec10 cooperate in ciliogenesis. In addition, cdc42 knockdown led to hydrocephalus and loss of photoreceptor cilia. Furthermore, there was a synergistic genetic interaction between zebrafish cdc42 and sec10, suggesting that cdc42 and sec10 function in the same pathway. Mice lacking Cdc42 specifically in kidney tubular epithelial cells died of renal failure within weeks of birth. Histology revealed cystogenesis in distal tubules and collecting ducts, decreased ciliogenesis in cyst cells, increased tubular cell proliferation, increased apoptosis, increased fibrosis, and led to MAPK activation, all of which are features of polycystic kidney disease, especially nephronophthisis. Taken together, these results suggest that Cdc42 localizes the exocyst to primary cilia, whereupon the exocyst targets and docks vesicles carrying ciliary proteins. Abnormalities in this pathway result in deranged ciliogenesis and polycystic kidney disease. C1 [Choi, Soo Young; Chacon-Heszele, Maria F.; Huang, Liwei; McKenna, Sarah; Wilson, F. Perry; Zuo, Xiaofeng; Lipschutz, Joshua H.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Wilson, F. Perry] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Lipschutz, Joshua H.] Philadelphia Vet Affairs Med Ctr, Dept Med, Philadelphia, PA USA. RP Lipschutz, JH (reprint author), Room 405C,Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA. EM jhlipsch@mail.med.upenn.edu FU Department of Veterans Affairs [1L01BX00820]; National Institutes of Health [DK069909, DK047757, DK093625]; Satellite Healthcare; NephHope Postdoctoral Fellowship; University of Pennsylvania Translational Medicine Institute FX This work was supported in part by grants from the Department of Veterans Affairs (VA Merit Award 1L01BX00820 to J.H.L.), National Institutes of Health (DK069909 and DK047757 to J.H.L., and DK093625 to L. H.), Satellite Healthcare (Norman S. Coplon Extramural Research Grant to J.H.L), a NephHope Postdoctoral Fellowship (to M. F. C. H.), and the University of Pennsylvania Translational Medicine Institute (pilot grant to J.H.L). NR 63 TC 20 Z9 20 U1 0 U2 7 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 EI 1533-3450 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD SEP PY 2013 VL 24 IS 9 BP 1435 EP 1450 DI 10.1681/ASN.2012121236 PG 16 WC Urology & Nephrology SC Urology & Nephrology GA 227EO UT WOS:000325092900015 PM 23766535 ER PT J AU Arterburn, D Livingston, EH Olsen, MK Smith, VA Kavee, AL Kahwati, LC Henderson, WG Maciejewski, ML AF Arterburn, David Livingston, Edward H. Olsen, Maren K. Smith, Valerie A. Kavee, Andrew L. Kahwati, Leila C. Henderson, William G. Maciejewski, Matthew L. TI Predictors of initial weight loss after gastric bypass surgery in twelve veterans affairs medical centers SO OBESITY RESEARCH & CLINICAL PRACTICE LA English DT Article DE Gastric bypass surgery ID LONG-TERM MORTALITY; BARIATRIC SURGERY; SURGICAL CARE; OUTCOMES; QUALITY; IMPACT; IMPROVEMENT; OPERATIONS; FACILITIES; PROGRAM AB The objective of this study was to identify determinants of significant weight loss one year after gastric bypass surgery among United States veterans. Using data from the Veterans Affairs (VA) Surgical Quality Improvement Program, we identified 516 veterans who had gastric bypass surgery (24% laparoscopic) in one of twelve VA bariatric centers in 2000-2006 and one or more postoperative weight measures. The probability of losing 30% or more of baseline weight at one year was estimated via logistic regression, examining the following potential predictor variables: age, gender, race, marital status, body mass index (BMI), American Society of Anesthesiologists class, comorbidity burden, smoking status, diabetes medications taken and surgical procedure (open or laparoscopic). The 516 cases had a mean BMI of 49 kg/m(2), mean age of 51.5 years, 74% were male, 77% were Caucasian, and 55% were married. The predicted mean weight loss was 76 (95% CI: 73-79) pounds (22%) at six months and 109 (95% CI: 104-114) pounds (32%) at one-year. Based upon estimated individual trajectories of 370 patients with adequate follow-up data, 58% of the sample lost 30% or more of their baseline weight at one year; and <1% lost <10% of their baseline weight at 1 year. In the logistic regression, patients were more likely to Lose 30% or more of their baseline weight if they were female (odds ratio (OR) = 2.5, p < 0.01) or Caucasian (OR = 2.3, p < 0.01). We conclude that gastric bypass surgery yields significant weight loss for most patients in Veterans Affairs Medical Centers, but is particularly effective for female and Caucasian patients. (C) 2012 Asian Oceanian Association for the Study of Obesity. Published by Elsevier Ltd. All rights reserved. C1 [Arterburn, David] Grp Hlth Res Inst, Seattle, WA USA. [Arterburn, David] Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA 98195 USA. [Livingston, Edward H.] Univ Texas SW Med Ctr Dallas, Div Gastrointestinal & Endocrine Surg, Dallas, TX 75390 USA. [Livingston, Edward H.] Vet Adm North Texas Hlth Care Syst, Dallas, TX USA. [Livingston, Edward H.] Univ Texas Arlington, Dept Biomed Engn, Arlington, TX 76019 USA. [Olsen, Maren K.; Smith, Valerie A.; Kavee, Andrew L.; Maciejewski, Matthew L.] Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC 27705 USA. [Olsen, Maren K.] Duke Univ, Dept Biostat & Bioinformat, Durham, NC 27706 USA. [Henderson, William G.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Henderson, William G.] Univ Colorado, Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA. [Henderson, William G.] Univ Colorado, Hlth Sci Ctr, Colorado Hlth Outcomes Program, Aurora, CO USA. [Maciejewski, Matthew L.] Duke Univ, Dept Med, Div Gen Internal Med, Durham, NC 27706 USA. RP Maciejewski, ML (reprint author), Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care 152, 411 West Chapel Hill St,Suite 600, Durham, NC 27705 USA. EM arterburn.d@ghc.org; matthew.maciejewski@va.gov FU Office of Research and Development, Health Services Research and Development Service, Department of Veterans Affairs [IIR 05-201, SHP 08-137]; Takeda Pharmaceuticals; Novartis; Surgical Review Corporation FX This work was supported by the Office of Research and Development, Health Services Research and Development Service, Department of Veterans Affairs (IIR 05-201, SHP 08-137). The authors also would like to acknowledge the VA Surgical Quality Data Use Group (SQDUG) for its role as scientific advisors and for the critical review of data use and analysis presented in this manuscript. Dr. Arterburn was formerly with the Cincinnati VA and Dr. Livingston was formerly with the Dallas VA. Dr. Maciejewski has received consultation funds from Takeda Pharmaceuticals, Novartis and the Surgical Review Corporation, and owns stock in Amgen. The views expressed are those of the authors and do not reflect the views of the Department of Veterans Affairs, the United States Government, Duke University, the University of Texas Southwestern Medical Center, the University of Texas, the University of Colorado, the Group Health Research Institute, or the University of Washington. NR 28 TC 7 Z9 7 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1871-403X EI 1878-0318 J9 OBES RES CLIN PRACT JI Obes. Res. Clin. Pract. PD SEP-OCT PY 2013 VL 7 IS 5 BP E367 EP E376 DI 10.1016/j.orcp.2012.02.009 PG 10 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 232EU UT WOS:000325475100006 PM 24304479 ER PT J AU Aschbacher, K O'Donovan, A Wolkowitz, OM Dhabhar, FS Su, YL Epel, E AF Aschbacher, Kirstin O'Donovan, Aoife Wolkowitz, Owen M. Dhabhar, Firdaus S. Su, Yali Epel, Elissa TI Good stress, bad stress and oxidative stress: Insights from anticipatory cortisol reactivity SO PSYCHONEUROENDOCRINOLOGY LA English DT Article DE Oxidative stress; Biological aging; Chronic stress; Acute stress; DNA/RNA damage; Cortisol; Hypothalamic-pituitaryadrenal axis; Eustress; Resilience; Reactive oxygen species ID PSYCHOLOGICAL STRESS; IMMUNE FUNCTION; MEDIATION ANALYSIS; PERCEIVED STRESS; TELOMERE LENGTH; FREE-RADICALS; DNA-DAMAGE; RESPONSES; DISEASE; ALLOSTASIS AB Chronic psychological stress appears to accelerate biological aging, and oxidative damage is an important potential mediator of this process. However, the mechanisms by which psychological stress promotes oxidative damage are poorly understood. This study investigates the theory that cortisol increases in response to an acutely stressful event have the potential to either enhance or undermine psychobiological resilience to oxidative damage, depending on the body's prior exposure to chronic psychological stress. In order to achieve a range of chronic stress exposure, forty-eight post-menopausal women were recruited in a case-control design that matched women caring for spouses with dementia (a chronic stress model) with similarly aged control women whose spouses were healthy. Participants completed a questionnaire assessing perceived stress over the previous month and provided fasting blood. Three markers of oxidative damage were assessed: 8-iso-prostaglandin F-2 alpha (IsoP), lipid peroxidation, 8-hydroxyguanosine (8-oxoG) and 8-hydroxy-2'-deoxyguanosine (8-OHdG), reflecting oxidative damage to RNA/DNA respectively. Within approximately one week, participants completed a standardized acute laboratory stress task while salivary cortisol responses were measured. The increase from 0 to 30 min was defined as "peak" cortisol reactivity, while the increase from 0 to 15 min was defined as "anticipatory" cortisol reactivity, representing a cortisol response that began while preparing for the stress task. Women under chronic stress had higher 8-oxoG, oxidative damage to RNA (p < .01). A moderated mediation model was tested, in which it was hypothesized that heightened anticipatory cortisol reactivity would mediate the relationship between perceived stress and elevated oxidative stress damage, but only among women under chronic stress. Consistent with this model, bootstrapped path analysis found significant indirect paths from perceived stress to 8-oxoG and IsoP (but not 8-OHdG) via anticipatory cortisol reactivity, showing the expected relations among chronically stressed participants ( p <= .01) Intriguingly, among those with low chronic stress exposure, moderate (compared to low) levels of perceived stress were associated with reduced levels of oxidative damage. Hence, this study supports the emerging model that chronic stress exposure promotes oxidative damage through frequent and sustained activation of the hypothalamic-pituitary-adrenal axis. It also supports the less studied model of 'eustress' - that manageable levels of life stress may enhance psychobiological resilience to oxidative damage. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Aschbacher, Kirstin; O'Donovan, Aoife; Wolkowitz, Owen M.; Epel, Elissa] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Aschbacher, Kirstin] Inst Integrat Hlth, Baltimore, MD USA. [O'Donovan, Aoife] San Francisco VA Med Ctr, San Francisco, CA USA. [Dhabhar, Firdaus S.] Stanford Univ, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA. [Dhabhar, Firdaus S.] Stanford Univ, Stanford Inst Immun Transplantat & Infect, Palo Alto, CA 94304 USA. [Su, Yali] SilverCreek Technol, Gilbert, AZ USA. RP Aschbacher, K (reprint author), Univ Calif San Francisco, Sch Med, Dept Psychiat, 3333 Calif St,Suite 465, San Francisco, CA 94143 USA. EM kirstin.aschbacher@ucsf.edu FU NIH/NIA [R01 AG030424-01A2]; NIH/NHLBI [K23 HL112955]; Institute for Integrative Health, Baltimore, MD; NIH/NCRR UCSF-CTSI [UL1 RR024131] FX This research was supported in part by funding from the NIH/NIA grant R01 AG030424-01A2, as well as support for the first author from the NIH/NHLBI grant K23 HL112955 and The Institute for Integrative Health, Baltimore, MD. The CTSI CCRC and the Core Immunology Lab were supported by NIH/NCRR UCSF-CTSI Grant No. UL1 RR024131. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. NR 54 TC 48 Z9 50 U1 8 U2 63 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD SEP PY 2013 VL 38 IS 9 BP 1698 EP 1708 DI 10.1016/j.psyneuen.2013.02.004 PG 11 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA 228LM UT WOS:000325188300024 PM 23490070 ER PT J AU Loftis, JM AF Loftis, Jennifer M. TI Indolamine 2,3-dioxygenase regulation and neuropsychiatric symptoms SO PSYCHONEUROENDOCRINOLOGY LA English DT Letter DE Anxiety; Depression; Cytokine; Inflammation; Tryptophan ID DEPRESSION C1 [Loftis, Jennifer M.] Portland VA Med Ctr, Res & Dev Serv, Portland, OR 97239 USA. [Loftis, Jennifer M.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA. RP Loftis, JM (reprint author), Portland VA Med Ctr, Res & Dev Serv, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM loftisj@ohsu.edu FU BLRD VA [I01 BX002061]; NIDA NIH HHS [P50 DA018165] NR 8 TC 1 Z9 1 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD SEP PY 2013 VL 38 IS 9 BP 1829 EP 1830 DI 10.1016/j.psyneuen.2013.05.020 PG 2 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA 228LM UT WOS:000325188300039 PM 23810316 ER PT J AU Yehuda, R Hildebrandt, T Spiegel, D AF Yehuda, Rachel Hildebrandt, Tom Spiegel, David TI Introduction to Special Issue of Psychoneuroendocrinology "Enduring effects of Traumatic Stress: Molecular and Hormonal Mechanisms" SO PSYCHONEUROENDOCRINOLOGY LA English DT Editorial Material C1 [Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Psychiat, Traumat Stress Studies Div, New York, NY USA. [Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Mental Hlth Care Ctr, Bronx, NY 10468 USA. [Yehuda, Rachel] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, New York, NY USA. [Hildebrandt, Tom] Icahn Sch Med Mt Sinai, Dept Psychiat, Eating & Weight Disorders Program, New York, NY USA. [Spiegel, David] Stanford Univ, Sch Med, Dept Psychiat, Stanford, CA 94305 USA. RP Yehuda, R (reprint author), James J Peters Vet Affairs Med Ctr, Mt Sinai Sch Med, Dept Psychiat, Traumat Stress Studies Div, 526 OOMH PTSD 116-A,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM rachel.yehuda@va.gov OI Hildebrandt, Thomas/0000-0001-7054-9590 NR 6 TC 0 Z9 0 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD SEP PY 2013 VL 38 IS 9 BP 1832 EP 1834 DI 10.1016/j.psyneuen.2013.06.018 PG 3 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA 228LM UT WOS:000325188300041 PM 23849599 ER PT J AU Daskalakis, NP Bagot, RC Parker, KJ Vinkers, CH de Kloet, ER AF Daskalakis, Nikolaos P. Bagot, Rosemary C. Parker, Karen J. Vinkers, Christiaan H. de Kloet, E. R. TI The three-hit concept of vulnerability and resilience: Toward understanding adaptation to early-life adversity outcome SO PSYCHONEUROENDOCRINOLOGY LA English DT Article DE Vulnerability; Resilience; Stress adaptation; Three hit; HPA axis; Developmental programming; Epigenetics Genetic predisposition; Early life environment; Later life environment ID PITUITARY-ADRENAL AXIS; CORTICOTROPIN-RELEASING-FACTOR; GLUCOCORTICOID-RECEPTOR GENE; POSTTRAUMATIC-STRESS-DISORDER; MARMOSET CALLITHRIX-JACCHUS; INFANT SQUIRREL-MONKEYS; EARLY SOCIAL ENRICHMENT; MATERNAL-CARE; DIFFERENTIAL SUSCEPTIBILITY; ADRENOCORTICAL-RESPONSE AB Stressful experiences during early-life can modulate the genetic programming of specific brain circuits underlying emotional and cognitive aspects of behavioral adaptation to stressful experiences later in life. Although this programming effect exerted by experience-related factors is an important determinant of mental health, its outcome depends on cognitive inputs and hence the valence an individual assigns to a given environmental context. From this perspective we will highlight, with studies in rodents, non-human primates and humans, the three-hit concept of vulnerability and resilience to stress-related mental disorders, which is based on gene environment interactions during critical phases of perinatal and juvenile brain development. The three-hit (i.e., hit-1: genetic predisposition, hit-2: early-life environment, and hit-3: later-life environment) concept accommodates the cumulative stress hypothesis stating that in a given context vulnerability is enhanced when failure to cope with adversity accumulates. Alternatively, the concept also points to the individual's predictive adaptive capacity, which underlies the stress inoculation and match/mismatch hypotheses. The latter hypotheses propose that the experience of relatively mild early-life adversity prepares for the future and promotes resilience to similar challenges in later-life; when a mismatch occurs between early and later-life experience, coping is compromised and vulnerability is enhanced. The three-hit concept is fundamental for understanding how individuals can either be prepared for coping with life to come and remain resilient or are unable to do so and succumb to a stress-related mental disorder, under seemingly identical circumstances. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Daskalakis, Nikolaos P.] Icahn Sch Med Mt Sinai, Dept Psychiat, Traumat Stress Studies Div, New York, NY USA. [Daskalakis, Nikolaos P.] Icahn Sch Med Mt Sinai, Dept Psychiat, Lab Mol Neuropsychiat, New York, NY USA. [Daskalakis, Nikolaos P.] James J Peters Vet Affairs Med Ctr, Mental Hlth Care Ctr, PTSD Clin Res Program, Bronx, NY USA. [Daskalakis, Nikolaos P.] James J Peters Vet Affairs Med Ctr, Lab Clin Neuroendocrinol & Neurochem, Bronx, NY USA. [Daskalakis, Nikolaos P.; de Kloet, E. R.] Leiden Univ, Leiden Acad, Ctr Drug Res, Div Med Pharmacol, Leiden, Netherlands. [Daskalakis, Nikolaos P.; de Kloet, E. R.] Leiden Univ, Leiden Univ Med Ctr, Leiden, Netherlands. [Bagot, Rosemary C.] Douglas Mental Hlth Univ Inst, Neurosci Div, Montreal, PQ, Canada. [Bagot, Rosemary C.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, Fishberg Dept Neurosci, Lab Mol Psychiat, New York, NY USA. [Parker, Karen J.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Vinkers, Christiaan H.] Univ Med Ctr Utrecht, Rudolf Magnus Inst Neurosci, Dept Psychiat, Utrecht, Netherlands. [Vinkers, Christiaan H.] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacol, Utrecht, Netherlands. [Vinkers, Christiaan H.] Univ Utrecht, Rudolf Magnus Inst Neurosci, Utrecht, Netherlands. RP Daskalakis, NP (reprint author), Mt Sinai Sch Med, Lab Mol Neuropsychiat, 1 Gustave L Levy Pl,Box 1668, New York, NY 10029 USA. EM Nikolaos.daskalakis@mssm.edu RI Daskalakis, Nikolaos/B-7930-2014; Parker, Karen/G-1347-2012 OI Daskalakis, Nikolaos/0000-0003-1660-9112; Parker, Karen/0000-0002-6836-6338 FU Dutch Top-Institute Pharma [T5-209]; Royal Netherlands Academy for Sciences; [NIH-R01HD67175] FX We would like to thank the organizers of 42nd ISPNE Conference for choosing our proposal for a Symposium. We would like to thank Dr. Esther Nederhof for participating as a speaker in the Symposium. ND and EdK were supported by the Dutch Top-Institute Pharma T5-209, and KP by the NIH-R01HD67175. EdK was also supported by the Royal Netherlands Academy for Sciences. NR 200 TC 75 Z9 75 U1 10 U2 74 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD SEP PY 2013 VL 38 IS 9 BP 1858 EP 1873 DI 10.1016/j.psyneuen.2013.06.008 PG 16 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA 228LM UT WOS:000325188300045 PM 23838101 ER PT J AU Daskalakis, NP Yehuda, R Diamond, DM AF Daskalakis, Nikolaos P. Yehuda, Rachel Diamond, David M. TI Animal models in translational studies of PTSD SO PSYCHONEUROENDOCRINOLOGY LA English DT Article DE Post-traumatic stress disorder; PTSD; Animal model; Translational; Bionnarkers; Therapeutics; Individual differences ID POSTTRAUMATIC-STRESS-DISORDER; HIPPOCAMPUS-DEPENDENT MEMORY; NATIONAL COMORBIDITY SURVEY; BDNF VAL66MET POLYMORPHISM; MENSTRUAL-CYCLE MODULATION; MEDIAL PREFRONTAL CORTEX; HIGH-DOSE CORTICOSTERONE; LONG-TERM POTENTIATION; HEALTHY-YOUNG MEN; DSM-IV DISORDERS AB Understanding the neurobiological mechanisms of post-traumatic stress disorder (PTSD) is of vital importance for developing biomarkers and more effective pharmacotherapy for this disorder. The design of bidirectional translational studies addressing all facets of PTSD is needed. Animal models of PTSD are needed not only to capture the complexity of PTSD behavioral characteristics, but also to address experimentally the influence of variety of factors which might determine an individual's vulnerability or resilience to trauma, e.g., genetic predisposition, early-life experience and social support. The current review covers recent translational approaches to bridge the gap between human and animal PTSD research and to create a framework for discovery of biomarkers and novel therapeutics. Published by Elsevier Ltd. C1 [Daskalakis, Nikolaos P.; Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Psychiat, Traumat Stress Studies Div, New York, NY USA. [Daskalakis, Nikolaos P.; Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Psychiat, Lab Mol Neuropsychiat, New York, NY USA. [Daskalakis, Nikolaos P.; Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Mental Hlth Care Ctr, PTSD Clin Res Program, Bronx, NY USA. [Daskalakis, Nikolaos P.; Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Lab Clin Neuroendocrinol & Neurochem, Bronx, NY USA. [Diamond, David M.] Vet Affairs Hosp, Res & Dev Serv, Tampa, FL USA. [Diamond, David M.] Univ S Florida, Dept Psychol, Ctr Preclin & Clin Res PTSD, Tampa, FL 33620 USA. [Diamond, David M.] Univ S Florida, Dept Mol Pharmacol & Physiol, Ctr Preclin & Clin Res PTSD, Tampa, FL 33620 USA. RP Diamond, DM (reprint author), Univ S Florida, Dept Psychol, 4202 E Fowler Ave,PCD 4118G, Tampa, FL 33620 USA. EM ddiamond@usf.edu RI Daskalakis, Nikolaos/B-7930-2014 OI Daskalakis, Nikolaos/0000-0003-1660-9112 FU Department of Defense grant; Veterans Affairs Department FX We would like to thank the organizers of 42nd ISPNE Conference for choosing our proposal for a Symposium. We would like to thank Dr. Israel Liberzon and Dr. Joseph Rayman for participating as speakers in the Symposium. DMD was supported by Career Scientist and Merit Review Awards from the Veterans Affairs Department during the production of this review. NPD and RY were supported by a Department of Defense grant. The opinions expressed in this review are those of the authors and not of the Department of Veterans Affairs, Department of Defense or the US government. NR 276 TC 38 Z9 39 U1 8 U2 43 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD SEP PY 2013 VL 38 IS 9 BP 1895 EP 1911 DI 10.1016/j.psyneuen.2013.06.006 PG 17 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA 228LM UT WOS:000325188300048 PM 23845512 ER PT J AU Yehuda, R Neylan, TC Flory, JD McFarlane, AC AF Yehuda, Rachel Neylan, Thomas C. Flory, Janine D. McFarlane, Alexander C. TI The use of biomarkers in the military: From theory to practice SO PSYCHONEUROENDOCRINOLOGY LA English DT Article DE Biomarker; PTSD; Trauma; Military; Risk; Resilience; Neurobiology; Combat exposure ID POSTTRAUMATIC-STRESS-DISORDER; RISK-FACTORS; TRAUMA; PTSD; RESILIENCE; DEPRESSION; DEPLOYMENT; VETERANS; EXPOSURE; IDENTIFICATION AB This paper provides a summary of relevant issues covered in the conference, "The Use of Biomarkers in the Military: Theory to Practice" held at the New York Academy of Science on September 14, 2012. The conference covered the state of the science in identification of PTSD biomarkers, including, the definition of different classes of biomarkers pertaining to PTSD. The aim of the satellite conference was to bring together researchers who have been supported by the Department of Defense, Veterans Administration, National Institutes of Health, and other agencies around the world, who are interested in the identification of biomarkers for PTSD risk, diagnosis, symptom severity and treatment response, for a discussion of salient issues regarding biomarker development for PTSD, as well as special considerations for the use of biomarkers in the military. (C) 2013 Published by Elsevier Ltd. C1 [Yehuda, Rachel; Flory, Janine D.] James J Peters VAMC, Dept Psychiat, Bronx, NY 10468 USA. [Yehuda, Rachel; Flory, Janine D.] Mt Sinai Sch Med, Dept Psychiat & Neurosci, New York, NY USA. [Neylan, Thomas C.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Neylan, Thomas C.] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA. [McFarlane, Alexander C.] Univ Adelaide, Dept Psychiat, Adelaide, SA, Australia. RP Yehuda, R (reprint author), James J Peters VAMC, 526 OOMH,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM rachel.yehuda@va.gov FU DOD [W81XWH-10-2-0072, W81XWH-09-2-0044] FX This work was supported by the following funding: DOD W81XWH-10-2-0072 (RY) and DOD W81XWH-09-2-0044 (RY) NR 43 TC 13 Z9 13 U1 0 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD SEP PY 2013 VL 38 IS 9 BP 1912 EP 1922 DI 10.1016/j.psyneuen.2013.06.009 PG 11 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA 228LM UT WOS:000325188300049 PM 23927936 ER PT J AU Hula, WD Cherney, LR Worrall, LE AF Hula, William D. Cherney, Leora R. Worrall, Linda E. TI Setting a Research Agenda to Inform Intensive Comprehensive Aphasia Programs SO TOPICS IN STROKE REHABILITATION LA English DT Article DE aphasia; cost-benefit analysis; rehabilitation; treatment efficacy; treatment effectiveness; treatment outcome ID CLINICAL-OUTCOME RESEARCH; INDUCED LANGUAGE THERAPY; RANDOMIZED-TRIALS; CLUSTER RANDOMIZATION; CONSORT STATEMENT; BROCAS APHASIA; STROKE; RECOVERY; EFFICACY; HEALTH AB Research into intensive comprehensive aphasia programs (ICAPs) has yet to show that this service delivery model is efficacious, effective, has cost utility, or can be broadly implemented. This article describes a phased research approach to the study of ICAPs and sets out a research agenda that considers not only the specific issues surrounding ICAPs, but also the phase of the research. Current ICAP research is in the early phases, with dosing and outcome measurement as prime considerations as well as refinement of the best treatment protocol. Later phases of ICAP research are outlined, and the need for larger scale collaborative funded research is recognized. The need for more rapid translation into practice is also acknowledged, and the use of hybrid models of phased research is encouraged within the ICAP research agenda. C1 [Hula, William D.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Hula, William D.] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA 15260 USA. [Cherney, Leora R.] Rehabil Inst Chicago, Ctr Aphasia Res & Treatment, Chicago, IL USA. [Cherney, Leora R.] Northwestern Univ, Chicago, IL 60611 USA. [Worrall, Linda E.] Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld, Australia. RP Hula, WD (reprint author), VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RI Worrall, Linda/D-2579-2010 OI Worrall, Linda/0000-0002-3283-7038 FU Veterans Affairs Rehabilitation Research and Development Career Development Award [C6210M]; NHMRC [569935] FX We acknowledge the Veterans Affairs Rehabilitation Research and Development Career Development Award C6210M and NHMRC grant 569935 to the Centre for Clinical Research Excellence in Aphasia Rehabilitation. NR 69 TC 4 Z9 4 U1 2 U2 13 PU THOMAS LAND PUBLISHERS, INC PI ST LOUIS PA 255 JEFFERSON RD, ST LOUIS, MO 63119-3627 USA SN 1074-9357 J9 TOP STROKE REHABIL JI Top. Stroke Rehabil. PD SEP-OCT PY 2013 VL 20 IS 5 BP 409 EP 420 DI 10.1310/tsr2005-409 PG 12 WC Rehabilitation SC Rehabilitation GA 231WE UT WOS:000325448300005 PM 24091283 ER PT J AU Juan, J Hind, J Jones, C McCulloch, T Gangnon, R Robbins, J AF Juan, Junerose Hind, Jacqueline Jones, Corinne McCulloch, Timothy Gangnon, Ron Robbins, JoAnne TI Case Study: Application of Isometric Progressive Resistance Oropharyngeal Therapy Using the Madison Oral Strengthening Therapeutic Device SO TOPICS IN STROKE REHABILITATION LA English DT Article DE deglutition; dysphagia; rehabilitation; strengthening; stroke ID NECK-CANCER PATIENTS; PENETRATION-ASPIRATION SCALE; QOL OUTCOMES TOOL; SWAL-QOL; DYSPHAGIA; STROKE; ADULTS; PNEUMONIA; EXERCISE; MUSCLE AB Purpose: Isometric progressive resistance oropharyngeal (I-PRO) therapy improves swallowing function; however, current devices utilize a single sensor that provides limited information or are prohibitively expensive. This single-subject study presents results of I-PRO therapy, detraining, and maintenance using the 5-sensor Madison Oral Strengthening Therapeutic (MOST) device combined with upper esophageal sphincter (UES) dilatation. Methods: A 56-year-old female nurse who was 27 months post stroke and subsequent to traditional behavioral interventions and UES dilatations presented limited to gastrostomy tube intake only and expectorating all saliva. She completed 8 weeks of I-PRO therapy, 5 weeks of detraining, and 9 weeks of I-PRO maintenance (reduced frequency) followed by a third UES dilatation post intervention. Data included diet inventory, lingual pressures (MOST), lingual volume (magnetic resonance imaging), postswallow residue (videofluoroscopy), UES and pharyngeal pressures (high-resolution manometry), and quality of life (QOL). Results: Findings after 8 weeks of I-PRO therapy were progression to general oral diet, 15 lb weight gain, increased isometric pressures (Delta > 16 kPa) with transference to swallowing pressures, increased lingual volume (8.3%), reduced pharyngeal wall residue (P = .03), increased pharyngeal pressures (Delta > 43 mm Hg) and increased UES opening (nadir) pressures(Delta > 9 mm Hg) with improved temporopressure coordination across the pharynx, and improved QOL. After detraining, decreased isometric pressures and reduced UES opening were noted. After I-PRO maintenance, isometric anterior lingual pressures returned to levels noted after the 8 weeks of intervention. Conclusion: I-PRO therapy, facilitated by the MOST device combined with instrumental UES dilatation, improved swallow safety, increased oropharyngeal intake, and facilitated UES opening while enriching QOL. C1 [Juan, Junerose; Hind, Jacqueline; Robbins, JoAnne] Univ Wisconsin, Dept Med, Madison, WI USA. [Juan, Junerose; Hind, Jacqueline; Robbins, JoAnne] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ Clin Ctr, Madison, WI USA. [Jones, Corinne; McCulloch, Timothy] Univ Wisconsin, Dept Surg, Madison, WI USA. [Gangnon, Ron] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA. RP Juan, J (reprint author), Univ Wisconsin, Dept Med, Madison, WI USA. FU VA Merit Grant [C4796R] FX This article is the result of work supported by VA Merit Grant C4796R and resources at the Geriatric Research, Education, and Clinical Center (GRECC) in the William S. Middleton Memorial Veterans Hospital. This is GRECC manuscript #09. The senior author, Dr. Robbins, serves in a leadership position for Swallow Solutions, LLC, and is an equity holder. NR 31 TC 1 Z9 1 U1 2 U2 11 PU THOMAS LAND PUBLISHERS, INC PI ST LOUIS PA 255 JEFFERSON RD, ST LOUIS, MO 63119-3627 USA SN 1074-9357 J9 TOP STROKE REHABIL JI Top. Stroke Rehabil. PD SEP-OCT PY 2013 VL 20 IS 5 BP 450 EP 470 DI 10.1310/tsr2005-450 PG 21 WC Rehabilitation SC Rehabilitation GA 231WE UT WOS:000325448300009 PM 24091287 ER PT J AU Bowles, DW Weickhardt, A Jimeno, A AF Bowles, D. W. Weickhardt, A. Jimeno, A. TI AFATINIB FOR THE TREATMENT OF PATIENTS WITH EGFR-POSITIVE NON-SMALL CELL LUNG CANCER SO DRUGS OF TODAY LA English DT Article DE Afatinib; EGFR; Non-small cell lung cancer; BIBW-2992; Dual inhibitor ID GROWTH-FACTOR RECEPTOR; ADVANCED SOLID TUMORS; ERBB FAMILY BLOCKER; TYROSINE KINASE INHIBITOR; METASTATIC BREAST-CANCER; I DOSE-ESCALATION; PHASE-I; OPEN-LABEL; ACQUIRED-RESISTANCE; BIBW 2992 AB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are valuable treatments for EGFR-mutated non-small cell lung cancer (NSCLC). Anti-EGFR anti-bodies are widely used in the treatment of head and neck squamous cell carcinomas (HNSCC) and in KRAS wildtype colorectal cancer. The first-generation, reversible EGFR inhibitors erlotinib and gefitinib in the first-line setting provide superior progression-free survival and quality of life compared to conventional chemotherapy in NSCLC harboring activating EGFR mutations. However, these therapies eventually fail and new options are needed. Afatinib is a novel irreversible inhibitor of the ErbB family members EGFR, tyrosine kinase-type cell surface receptors HER2 and HER4. It shows preclinical efficacy in NSCLC with common EGFR-activating mutations and the T790M mutation typically associated with EGFR TKI resistance. Preclinical activity is seen in other tumor types as well, including HNSCC. Clinically, afatinib has been evaluated in the broad-reaching LUX Lung trial program, with significant activity seen in the first and later-line settings. It is also under investigation in multiple other tumor types. This review will stress on afatinib's preclinical pharmacology, pharmacokinetics and clinical activity with a focus on NSCLC. C1 [Bowles, D. W.; Jimeno, A.] Univ Colorado, Sch Med, Div Med Oncol, Denver, CO USA. [Bowles, D. W.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Weickhardt, A.] Austin Hosp, Olivia Newton John Canc & Wellness Ctr, Melbourne, Vic 3084, Australia. RP Jimeno, A (reprint author), Univ Colorado Denver, Div Med Oncol, 12801 East 17th Ave,MS 8117, Aurora, CO 80045 USA. EM antonio.jimeno@ucdenver.edu NR 73 TC 7 Z9 8 U1 0 U2 18 PU PROUS SCIENCE, SAU-THOMSON REUTERS PI BARCELONA PA 398 PROVENCA, 08025 BARCELONA, SPAIN SN 1699-3993 J9 DRUG TODAY JI Drugs Today PD SEP PY 2013 VL 49 IS 9 BP 523 EP 535 DI 10.1358/dot.2013.49.9.2016610 PG 13 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 225SO UT WOS:000324982800001 PM 24086949 ER PT J AU Daskalakis, NP Lehrner, A Yehuda, R AF Daskalakis, Nikolaos P. Lehrner, Amy Yehuda, Rachel TI Endocrine Aspects of Post-traumatic Stress Disorder and Implications for Diagnosis and Treatment SO ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA LA English DT Article DE Stress; Sympathetic; Hypothalamic-pituitary-adrenal axis; Cortisol; Post-traumatic stress disorder ID GLUCOCORTICOID-RECEPTOR EXPRESSION; NATIONAL COMORBIDITY SURVEY; COMBAT VETERANS; RISK-FACTORS; LOW CORTISOL; HOLOCAUST SURVIVORS; MAJOR DEPRESSION; ANIMAL-MODEL; HPA AXIS; PTSD AB Post-traumatic stress disorder (PTSD) is a serious, multisystem disorder with multiple medical comorbidities. This article reviews the current literature on the endocrine aspects of PTSD, specifically hypothalamic-pituitary-adrenal axis alterations indicative of low cortisol and increased glucocorticoid sensitivity, and the proposed mechanisms whereby these alterations increase risk or reflect pathophysiology. Discussion includes novel treatment innovations and directions for future research. C1 [Daskalakis, Nikolaos P.; Lehrner, Amy; Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Psychiat, Traumat Stress Studies Div, New York, NY 10029 USA. [Daskalakis, Nikolaos P.; Lehrner, Amy; Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Psychiat, Lab Mol Neuropsychiat, New York, NY 10029 USA. [Daskalakis, Nikolaos P.; Lehrner, Amy; Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, PTSD Program, Mental Hlth Care Ctr, Bronx, NY 10468 USA. [Daskalakis, Nikolaos P.; Lehrner, Amy; Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Lab Clin Neuroendocrinol & Neurochem, Bronx, NY 10468 USA. [Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. RP Daskalakis, NP (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, Lab Mol Neuropsychiat, Gustave L Levy Pl,Box 1668, New York, NY 10029 USA. EM nikolaos.daskalakis@mssm.edu RI Daskalakis, Nikolaos/B-7930-2014 OI Daskalakis, Nikolaos/0000-0003-1660-9112 NR 68 TC 38 Z9 42 U1 6 U2 34 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8529 J9 ENDOCRIN METAB CLIN JI Endocrinol. Metabol. Clin. North Amer. PD SEP PY 2013 VL 42 IS 3 BP 503 EP + DI 10.1016/j.ecl.2013.05.004 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 228MO UT WOS:000325191100007 PM 24011883 ER PT J AU Thomas, WW Harvey, RJ Rudmik, L Hwang, PH Schlosser, RJ AF Thomas, W. Walsh, III Harvey, Richard J. Rudmik, Luke Hwang, Peter H. Schlosser, Rodney J. TI Distribution of topical agents to the paranasal sinuses: an evidence-based review with recommendations SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY LA English DT Article DE sinusitis; topical; spray; irrigation; nebulizer; therapies; anatomy; surgery ID CLINICAL-PRACTICE GUIDELINES; NASAL IRRIGATION; MIDDLE MEATUS; HEAD POSITION; CHRONIC RHINOSINUSITIS; SINONASAL IRRIGATION; INTRANASAL DELIVERY; PULSATING AEROSOLS; CONTROLLED-TRIAL; NOSE DROPS AB BackgroundThe objective of this work was to review the literature concerning the distribution of topical therapeutics to the sinuses versus nasal cavity regarding: surgical state, delivery device, head position, and nasal anatomy and to provide evidence-based recommendations. MethodsA systematic review was conducted using Medline, EMBASE, and Cochrane databases to perform a Medical Subject Heading search of the literature from 1946 until the last week of May 2012. Articles were independently reviewed and graded for level of evidence. All authors came to consensus on recommendations through an iterative process. ResultsRecommendations were made for: improved sinus delivery with high-volume devices and after standard sinus surgery. Recommendations were made against low-volume delivery devices, such as drops, sprays, or simple nebulizers as they do not reliably reach the sinuses. If large-volume devices are not tolerated, low-volume devices are recommended using the lying head back or lateral head low positions to improve nasal cavity distribution to the middle meatus or olfactory cleft. ConclusionSurgery, volume of device, head position, and nasal anatomy were shown to impact distribution to the sinuses. Recommendations are made based upon this evidence as to how to best maximize therapeutic distribution to the sinuses. C1 [Thomas, W. Walsh, III; Schlosser, Rodney J.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29403 USA. [Thomas, W. Walsh, III; Schlosser, Rodney J.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29403 USA. [Harvey, Richard J.] Univ New S Wales, Div Rhinol & Endoscop Skull Base Surg, Sydney, NSW, Australia. [Harvey, Richard J.] St Vincents Hosp, Sydney, NSW 2010, Australia. [Rudmik, Luke] Univ Calgary, Div Otolaryngol Head & Neck Surg, Calgary, AB T2N 1N4, Canada. [Hwang, Peter H.] Stanford Univ, Dept Otolaryngol Head & Neck Surg, Palo Alto, CA 94304 USA. RP Schlosser, RJ (reprint author), Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,MSC 550, Charleston, SC 29403 USA. EM schlossr@musc.edu NR 42 TC 28 Z9 28 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2042-6976 J9 INT FORUM ALLERGY RH JI Int. Forum Allergy Rhinol. PD SEP PY 2013 VL 3 IS 9 BP 691 EP 703 DI 10.1002/alr.21172 PG 13 WC Otorhinolaryngology SC Otorhinolaryngology GA 227KL UT WOS:000325111500002 PM 23729216 ER PT J AU Jenkins, AJ Yu, J Alaupovic, P Basu, A Klein, RL Lopes-Virella, M Baker, NL Hunt, KJ Lackland, DT Garvey, WT Lyons, TJ AF Jenkins, Alicia J. Yu, Jeremy Alaupovic, Petar Basu, Arpita Klein, Richard L. Lopes-Virella, Maria Baker, Nathaniel L. Hunt, Kelly J. Lackland, Daniel T. Garvey, W. Timothy Lyons, Timothy J. CA DCCT EDIC Res Grp TI Apolipoprotein-defined lipoproteins and apolipoproteins: Associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort SO JOURNAL OF DIABETES AND ITS COMPLICATIONS LA English DT Article DE Type 1 diabetes; Nephropathy; Albuminuria; Lipoproteins; Apolipoproteins ID CARDIOVASCULAR RISK-FACTOR; B-CONTAINING LIPOPROTEINS; VASCULAR-DISEASE RISK; DCCT/EDIC COHORT; RENAL-INSUFFICIENCY; INSULIN-RESISTANCE; C-III; DENSITY-LIPOPROTEIN; CENTRAL OBESITY; NEPHROPATHY AB Aims: Dyslipoproteinemia has been associated with nephropathy in diabetes, with stronger correlations in men than in women. We aimed to characterize and compare plasma lipoprotein profiles associated with normal and increased albuminuria in men and women using apolipoprotein-defined lipoprotein subclasses and simple apolipoprotein measures. Methods: This is a cross-sectional study in a subset (154 women and 282 men) of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort, using samples obtained in 1997-9. Immunochemical methods were used to quantify plasma apolipoprotein-based lipoprotein subclasses and individual apolipoprotein levels. Results: In adjusted analyses, elevated Lipoprotein-B (Lp-B) was significantly associated with macroalbuminuria in men [odds ratios (OR) and 95% confidence interval (CI): 2.13 (1.15-3.97)] and women [3.01 (1.11-8.12)], while association with Lp-B:C was observed only in men [1.84 (1.19-2.86)]. For individual apolipoproteins the following significant associations with macroalbuminuria were observed in men only: Apolipoprotein B (ApoB) [1.97 (1.20-3.25)], Apo-AII [0.52 (0.29-0.93)], ApoC-III [1.95 (1.16-3.30)], "ApoC-III in VLDL" (heparin-manganese precipitate) [1.88 (1.16-3.04)1, and "ApoCIII in HDL" (heparin-manganese supernatant) [2.03 (1.27-3.26)], all P < 0.05). Conclusions: Atherogenic apolipoprotein-based profiles are associated with nephropathy in Type 1 diabetic men and to a lesser extent in women. The difference could result from the greater prevalence and severity of dyslipoproteinemia, and from the greater prevalence of renal dysfunction, in men vs women. (C) 2013 Elsevier Inc. All rights reserved. C1 [Jenkins, Alicia J.; Yu, Jeremy; Lyons, Timothy J.] Univ Oklahoma, Harold Hamm Diabet Ctr, Hlth Sci Ctr, Oklahoma City, OK 73104 USA. [Jenkins, Alicia J.; Yu, Jeremy; Lyons, Timothy J.] Univ Oklahoma, Hlth Sci Ctr, Sect Endocrinol & Diabet, Oklahoma City, OK 73104 USA. [Alaupovic, Petar] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. [Basu, Arpita] Oklahoma State Univ, Dept Nutr Sci, Stillwater, OK 74078 USA. [Klein, Richard L.; Lopes-Virella, Maria] Med Univ S Carolina, Div Endocrinol, Charleston, SC 29425 USA. [Klein, Richard L.; Lopes-Virella, Maria] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. [Baker, Nathaniel L.; Hunt, Kelly J.] Med Univ S Carolina, Div Biostat & Epidemiol, Charleston, SC 29425 USA. [Lackland, Daniel T.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr, Birmingham, AL 35294 USA. RP Lyons, TJ (reprint author), Harold Hamm Diabet Ctr, 1000 North Lincoln Blvd,Suite 2900, Oklahoma City, OK 73104 USA. EM t.lyons@qub.ac.uk FU American Diabetes Association, the National Institutes of Health NIH [PO1 HL55782]; Juvenile Diabetes Research Foundation [4-1998-272, 996001, 197028]; Diabetes Research and Wellness Foundation, Inc. (Fairfax, Virginia); Presbyterian Health Foundation of Oklahoma City; Division of Diabetes, Endocrinology and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH (NCRR) [M01-RR-1070, M01 RR-14467]; OUHSC; Genentech, Inc.; NIDDK FX Grants were provided by: the American Diabetes Association, the National Institutes of Health NIH (PO1 HL55782), Juvenile Diabetes Research Foundation (# 4-1998-272, 996001, and 197028), the Diabetes Research and Wellness Foundation, Inc. (Fairfax, Virginia), and the Presbyterian Health Foundation of Oklahoma City. The DCCT/EDIC is sponsored through research contracts from the Division of Diabetes, Endocrinology and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Additional support was provided by the NIH (NCRR) Grants M01-RR-1070 and M01 RR-14467 to the General Clinical Research Centers at MUSC and OUHSC, and by Genentech, Inc. through a Cooperative Research and Development Agreement with the NIDDK. NR 48 TC 2 Z9 4 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1056-8727 J9 J DIABETES COMPLICAT JI J. Diabetes Complications PD SEP-OCT PY 2013 VL 27 IS 5 BP 447 EP 453 DI 10.1016/j.jdiacomp.2013.06.002 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 229WX UT WOS:000325299700007 PM 23850262 ER PT J AU Henry, RR Chilton, R Garvey, WT AF Henry, Robert R. Chilton, Robert Garvey, W. Timothy TI New options for the treatment of obesity and type 2 diabetes mellitus (narrative review) SO JOURNAL OF DIABETES AND ITS COMPLICATIONS LA English DT Review DE Phentermine; Topiramate extended-release; Obesity; Type 2 diabetes; Cardiovascular ID CARDIOVASCULAR RISK-FACTORS; CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE; RANDOMIZED CONTROLLED-TRIAL; LIFE-STYLE INTERVENTION; HIGH BLOOD-PRESSURE; BODY-MASS INDEX; FREE FATTY-ACID; WEIGHT-LOSS; INSULIN-RESISTANCE; BARIATRIC SURGERY AB Moderate weight loss (>5%), which has been associated with improvements in glycemic parameters in patients with dysglycemia, also reduces the presence of other comorbidities, including dyslipidemia and hypertension, culminating in a reduced risk of cardiovascular disease. Lifestyle changes are the recommended preliminary approach to weight loss, with an initial weight-loss goal of 10% of body weight achieved over 6 months at a rate of 1-2 pounds per week selected as an appropriate target to decrease the severity of obesity-related risk factors. Implementing and maintaining the lifestyle changes associated with weight loss can, however, be challenging for many patients. Therefore, additional interventions sometimes may be necessary. Bariatric surgery can also be a highly effective option for weight loss and comorbidity reduction, but surgery carries considerable risks and is still applicable only to selected patients with type 2 diabetes. Thus, attention is turning to the use of weight-loss medications, including 2 recently approved compounds: twice-daily lorcaserin and a once-daily combination of phentermine and topiramate extended-release, both shown to be safe and effective therapies in the management of obesity in patients with type 2 diabetes. (C) 2013 Elsevier Inc. All rights reserved. C1 [Henry, Robert R.] VA San Diego Healthcare Syst, Ctr Metab Res, San Diego, CA USA. [Henry, Robert R.] Univ Calif San Diego, San Diego, CA 92103 USA. [Chilton, Robert] Cardiovasc Dis & Intervent Cardiol Univ Hosp, San Antonio, TX USA. [Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL USA. RP Henry, RR (reprint author), VA San Diego Healthcare Syst, Ctr Metab Res, San Diego, CA USA. EM rrhenry@vapop.ucsd.edu FU VIVUS, Inc. FX We would like to acknowledge and thank The Lockwood Group for editorial assistance (funding was provided by VIVUS, Inc.), and VIVUS, Inc. internal contributors. NR 66 TC 14 Z9 17 U1 1 U2 26 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1056-8727 J9 J DIABETES COMPLICAT JI J. Diabetes Complications PD SEP-OCT PY 2013 VL 27 IS 5 BP 508 EP 518 DI 10.1016/j.jdiacomp.2013.04.011 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 229WX UT WOS:000325299700017 PM 23726071 ER PT J AU Erickson, CS Barlow, AJ Pierre, JF Heneghan, AF Epstein, ML Kudsk, KA Gosain, A AF Erickson, Christopher S. Barlow, Amanda J. Pierre, Joseph F. Heneghan, Aaron F. Epstein, Miles L. Kudsk, Kenneth A. Gosain, Ankush TI Colonic enteric nervous system analysis during parenteral nutrition SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE Enteric nervous system; nNOS; Neurotransmitter; Motility; TPN; Parenteral nutrition; Bombesin ID MOUSE MODEL; HIRSCHSPRUNGS-DISEASE; BARRIER FUNCTION; NEUROTRANSMITTER EXPRESSION; GASTROINTESTINAL-TRACT; LYMPHOID-TISSUE; BOMBESIN; MOTILITY; MICE; IMMUNITY AB Introduction: Parenteral nutrition (PN) is a necessary therapy used to feed patients with gastrointestinal dysfunction. Unfortunately, PN results in intestinal atrophy and changes to host immune function. PN may also induce additional effects on gut motility that we hypothesized would result from changes in the enteric nervous system. Methods: Mice received an intravenous (IV) catheter and were randomized to chow (n = 5), IV PN (n = 6), or IV PN + bombesin (BBS, 15 mu g/kg, 3 x/d) (n = 6) for 5 d. Colons were removed and dissected to measure the length and circumference. Enteric neuronal density and neurotransmitter expression were determined by co-immunostaining whole-mount tissue with Hu and neuronal nitric oxide synthase (nNOS). Results: The number of myenteric neurons expressing Hu and nNOS increased per unit length in the mid-colon during PN treatment compared with chow. This increase was abrogated by the addition of BBS to the PN regimen. However, the percentage of nNOS-expressing neurons was not significantly altered by PN. Morphometric analysis revealed a decrease in the length and circumference of the colon during PN administration that was partially normalized by supplementation of PN with BBS. A significant reduction in total fecal output was observed in PN animals compared with chow and was increased by mice receiving BBS in addition to PN. Conclusions: PN causes a constriction of the bowel wall, reducing not only the length but also the circumference of the colon. These changes cause a condensation of enteric neurons but no difference in neurotransmitter expression. BBS supplementation partially restores the constriction and increases the fecal output during PN treatment compared with PN treatment alone. (C) 2013 Elsevier Inc. All rights reserved. C1 [Erickson, Christopher S.; Epstein, Miles L.] Univ Wisconsin, Madison Sch Med & Publ Hlth, Dept Neurosci, Madison, WI 53792 USA. [Barlow, Amanda J.; Pierre, Joseph F.; Heneghan, Aaron F.; Kudsk, Kenneth A.; Gosain, Ankush] Univ Wisconsin, Madison Sch Med & Publ Hlth, Dept Surg, Madison, WI 53792 USA. [Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA. RP Gosain, A (reprint author), Univ Wisconsin, Dept Surg, 600 Highland Ave,K4-752 CSC, Madison, WI 53792 USA. EM gosain@surgery.wisc.edu OI Gosain, Ankush/0000-0002-0428-1503 FU Central Surgical Association Foundation Turcotte Award; NIH-NIDDK [RO1DK081634]; Biomedical Laboratory Research & Development Service of the VA Office of Research and Development [I01BX001672] FX This research is supported by a Central Surgical Association Foundation Turcotte Award (AG), NIH-NIDDK RO1DK081634 grant (MLE), and grant I01BX001672 from the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development (KAK). The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government. NR 27 TC 3 Z9 3 U1 0 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 J9 J SURG RES JI J. Surg. Res. PD SEP PY 2013 VL 184 IS 1 BP 132 EP 137 DI 10.1016/j.jss.2013.02.044 PG 6 WC Surgery SC Surgery GA 207NX UT WOS:000323609400022 PM 23601532 ER PT J AU Gracz, AD Fuller, MK Wang, FC Li, LH Stelzner, M Dunn, JCY Martin, MG Magness, ST AF Gracz, Adam D. Fuller, Megan K. Wang, Fengchao Li, Linheng Stelzner, Matthias Dunn, James C. Y. Martin, Martin G. Magness, Scott T. TI Brief Report: CD24 and CD44 Mark Human Intestinal Epithelial Cell Populations with Characteristics of Active and Facultative Stem Cells SO STEM CELLS LA English DT Article DE Tissue-specific stem cells; Cell surface markers; Fluorescence-activated cell sorting; Flow cytometry; Cell culture ID EXPRESSION MARKS; IN-VITRO; LGR5; EXPANSION; ORGANOIDS; COLON AB Recent seminal studies have rapidly advanced the understanding of intestinal epithelial stem cell (IESC) biology in murine models. However, the lack of techniques suitable for isolation and subsequent downstream analysis of IESCs from human tissue has hindered the application of these findings toward the development of novel diagnostics and therapies with direct clinical relevance. This study demonstrates that the cluster of differentiation genes CD24 and CD44 are differentially expressed across LGR5 positive active stem cells as well as HOPX positive facultative stem cells. Fluorescence-activated cell sorting enables differential enrichment of LGR5 (CD24-/CD44+) and HOPX (CD24+/CD44+) cells for gene expression analysis and culture. These findings provide the fundamental methodology and basic cell surface signature necessary for isolating and studying intestinal stem cell populations in human physiology and disease. STEM Cells2013;31:2024-2030 C1 [Gracz, Adam D.; Magness, Scott T.] Univ N Carolina, Dept Med, Div Gastroenterol & Hepatol, Chapel Hill, NC 27599 USA. [Gracz, Adam D.; Magness, Scott T.] Univ N Carolina, Dept Cell Biol & Physiol, Chapel Hill, NC 27599 USA. [Fuller, Megan K.] Univ N Carolina, Dept Surg, Chapel Hill, NC 27599 USA. [Magness, Scott T.] Univ N Carolina, Chapel Hill, NC 27599 USA. [Wang, Fengchao; Li, Linheng] Stowers Inst Med Res, Kansas City, MO USA. [Fuller, Megan K.] VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. [Stelzner, Matthias; Dunn, James C. Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Martin, Martin G.] Univ Calif Los Angeles, Dept Pediat, Div Gastroenterol, Los Angeles, CA 90024 USA. RP Magness, ST (reprint author), Univ N Carolina, 111 Mason Farm Rd,CB 7032,MBRB Rm 4337, Chapel Hill, NC 27599 USA. EM magness@med.unc.edu FU NC TraCS Institute Pilot Grant Program [2KR271103, 2KR381202]; Center for Gastrointestinal Biology and Disease [5P30DK034987-27]; University Cancer Research Fund Innovation Award; NIH National Center for Research Resources; National Center for Advancing Translational Sciences, National Institutes of Health FX We thank the UNC flow cytometry facility (P30CA06086) and the neuroscience confocal facility, which is cofunded by the National Institute of Neurological Disorders and Stroke and the National Institute of Child Health and Human Development (P30NS045892). Drs. Timothy Farrell and Wayne Overby, and Myra Jones, Karen Colton, and Lisa Prestia, for coordinating the collection of deidentified remnant jejunal tissue from gastric-bypass operations. The Duke Human Vaccine Institute flow cytometry core, and Dr. John Whitesides and Ian Cumming, for technical assistance. Drs. Tope Keku and Robert Sandler for unpublished data regarding mucosal biopsy weight. Drs. P. Kay Lund, Susan Henning (SJH), and Christopher Dekaney for useful discussions and critical review of the manuscript. This work was funded by the NC TraCS Institute Pilot Grant Program, 2KR271103 (Gracz/Fuller) and 2KR381202 (Gracz), the Center for Gastrointestinal Biology and Disease, 5P30DK034987-27 (Magness), and a University Cancer Research Fund Innovation Award (Magness). The NC TraCS Institute is supported by Grants UL1RR025747, KL2RR025746, and TLRR025745 from the NIH National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health. The National Institute of Diabetes and Digestive and Kidney Diseases/National Institute of Allergy and Infectious Disease Intestinal Stem Cell Consortium (U01DK085541-SJH; U01DK85507-LL/FW; U01DK85535-MGM/JCYD/MS). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. NR 19 TC 29 Z9 29 U1 0 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1066-5099 J9 STEM CELLS JI Stem Cells PD SEP PY 2013 VL 31 IS 9 BP 2024 EP 2030 DI 10.1002/stem.1391 PG 7 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology GA 229II UT WOS:000325255700027 PM 23553902 ER PT J AU Li, G Bekris, LM Leong, L Steinbart, EJ Shofer, JB Crane, PK Larson, EB Peskind, ER Bird, TD Yu, CE AF Li, Ge Bekris, Lynn M. Leong, Lesley Steinbart, Ellen J. Shofer, Jane B. Crane, Paul K. Larson, Eric B. Peskind, Elaine R. Bird, Thomas D. Yu, Chang-En TI TOMM40 intron 6 poly-T length, age at onset, and neuropathology of AD in individuals with APOE epsilon 3/epsilon 3 SO ALZHEIMERS & DEMENTIA LA English DT Article DE Alzheimer's disease; Age at onset; Genetic; APOE; TOMM40; PSEN1 mutation; PSEN2 mutation; Neuropathology ID FAMILIAL ALZHEIMERS-DISEASE; GENOME-WIDE ASSOCIATION; APOLIPOPROTEIN-E; PROTEIN-LEVELS; DIAGNOSIS; DEMENTIA; COHORT; LOCI; PRESENILIN-1; SENSITIVITY AB Background: This study investigates the association between TOMM40 poly-T length, age at onset, and neuropathology in individuals with Alzheimer's disease (AD) with the apolipoprotein E (APOE) epsilon 3/epsilon 3 allele. Methods: Thirty-two presenilin 1 (PSEN1) mutation carriers with AD, 27 presenilin 2 (PSEN2) mutation carriers with AD, 59 participants with late-onset AD (LOAD), and 168 autopsied subjects from a community-based cohort were genotyped for TOMM40 intron 6 poly-T (rs10524523) length using short tandem repeat assays. Results: Among AD individuals with PSEN2 mutations, the presence of a long poly-T was associated with an earlier age at onset, whereas there were no such associations for subjects with PSEN1 mutations or LOAD. In community-based participants, the presence of a long poly-T was associated with increased neuritic tangles and a greater likelihood of pathologically diagnosed AD. Conclusion: TOMM40 intron 6 poly-T length may explain some of the variation in age at onset in PSEN2 familial AD and may be associated with AD neuropathology in persons with APOE epsilon 3/epsilon 3. (C) 2013 The Alzheimer's Association. All rights reserved. C1 [Li, Ge; Shofer, Jane B.; Peskind, Elaine R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Bekris, Lynn M.; Crane, Paul K.; Larson, Eric B.; Yu, Chang-En] Univ Washington, Dept Med, Seattle, WA USA. [Bekris, Lynn M.; Leong, Lesley; Steinbart, Ellen J.; Bird, Thomas D.; Yu, Chang-En] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Steinbart, Ellen J.; Bird, Thomas D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Larson, Eric B.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA. [Peskind, Elaine R.] VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. RP Li, G (reprint author), Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. EM gli@u.washington.edu RI Crane, Paul/C-8623-2014 FU National Institute of Aging [AG033693, AG006781, AG05136, AG034214]; U.S. Department of Veterans Affairs, Office of Research and Development, Biomedical Laboratory Research Program FX This study was supported by grants AG033693, AG006781, AG05136, and AG034214 from the National Institute of Aging and by the U.S. Department of Veterans Affairs, Office of Research and Development, Biomedical Laboratory Research Program. The study sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, and approval of the manuscript. NR 43 TC 5 Z9 5 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD SEP PY 2013 VL 9 IS 5 BP 554 EP 561 DI 10.1016/j.jalz.2012.06.009 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 222IN UT WOS:000324724500009 PM 23183136 ER PT J AU Geda, YE Schneider, LS Gitlin, LN Miller, DS Smith, GS Bell, J Evans, J Lee, M Porsteinsson, A Lanctot, KL Rosenberg, PB Sultzer, DL Francis, PT Brodaty, H Padala, PP Onyike, CU Ortiz, LA Ancoli-Israel, S Bliwise, DL Martin, JL Vitiello, MV Yaffe, K Zee, PC Herrmann, N Sweet, RA Ballard, C Khin, NA Alfaro, C Murray, PS Schultz, S Lyketsos, CG AF Geda, Yonas E. Schneider, Lon S. Gitlin, Laura N. Miller, David S. Smith, Gwenn S. Bell, Joanne Evans, Jovier Lee, Michael Porsteinsson, Anton Lanctot, Krista L. Rosenberg, Paul B. Sultzer, David L. Francis, Paul T. Brodaty, Henry Padala, Prasad P. Onyike, Chiadikaobi U. Ortiz, Luis Agueera Ancoli-Israel, Sonia Bliwise, Donald L. Martin, Jennifer L. Vitiello, Michael V. Yaffe, Kristine Zee, Phyllis C. Herrmann, Nathan Sweet, Robert A. Ballard, Clive Khin, Ni A. Alfaro, Cara Murray, Patrick S. Schultz, Susan Lyketsos, Constantine G. CA Neuropsychiat Syndromes TI Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future SO ALZHEIMERS & DEMENTIA LA English DT Article DE Neuropsychiatric symptoms; Behavioral and psychological symptoms of dementia; Agitation/aggression; Sleep disorders; Depression; Apathy; Psychosis; Delusions; Hallucinations; Dementia; Alzheimer's disease; Mild cognitive impairment; Mild behavioral impairment ID MILD COGNITIVE IMPAIRMENT; VASCULAR DEPRESSION HYPOTHESIS; PITTSBURGH COMPOUND-B; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; BEHAVIORAL SYMPTOMS; NATIONAL INSTITUTE; RANDOMIZED-TRIAL; RATING-SCALE; DOUBLE-BLIND AB Neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) are widespread and disabling. This has been known since Dr. Alois Alzheimer's first case, Frau Auguste D., presented with emotional distress and delusions of infidelity/excessive jealousy, followed by cognitive symptoms. Being cognizant of this, in 2010 the Alzheimer's Association convened a research roundtable on the topic of NPS in AD. A major outcome of the roundtable was the founding of a Professional Interest Area (PIA) within the International Society to Advance Alzheimer's Research and Treatment (ISTAART). The NPS-PIA has prepared a series of documents that are intended to summarize the literature and provide more detailed specific recommendations for NPS research. This overview paper is the first of these living documents that will be updated periodically as the science advances. The overview is followed by syndrome-specific synthetic reviews and recommendations prepared by NPS-PIA workgroups on depression, apathy, sleep, agitation, and psychosis. (C) 2013 The Alzheimer's Association. All rights reserved. C1 [Geda, Yonas E.] Mayo Clin, Coll Med, Dept Psychiat, Scottsdale, AZ USA. [Geda, Yonas E.] Mayo Clin, Coll Med, Dept Neurol, Scottsdale, AZ USA. [Schneider, Lon S.] Univ So Calif, Los Angeles, CA USA. [Gitlin, Laura N.] Johns Hopkins Univ, Sch Nursing, Baltimore, MD USA. [Miller, David S.] Bracket, Wayne, PA USA. [Smith, Gwenn S.; Rosenberg, Paul B.; Onyike, Chiadikaobi U.; Lyketsos, Constantine G.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Div Geriatr Psychiat & Neuropsychiat, Baltimore, MD 21218 USA. [Evans, Jovier] NIMH, Geriatr Res Branch, Geriatr Translat Neurosci & MultiModal Interv Pro, Geriatr Pharmacol Intervent, Bethesda, MD 20892 USA. [Lee, Michael] Univ Minnesota, Inst Translat Neurosci, Dept Neurosci, Minneapolis, MN USA. [Lee, Michael] Univ Minnesota, Inst Translat Neurosci, Ctr Neurodegenerat Dis, Minneapolis, MN USA. [Porsteinsson, Anton] Univ Rochester, Sch Med & Dent Rochester, Dept Psychiat, Rochester, NY USA. [Lanctot, Krista L.] Sunnybrook Res Inst, Brain Sci Program, Toronto, ON, Canada. [Lanctot, Krista L.] Univ Toronto, Dept Psychiat, Toronto, ON, Canada. [Lanctot, Krista L.] Univ Toronto, Dept Pharmacol, Toronto, ON, Canada. [Lanctot, Krista L.] Univ Toronto, Dept Toxicol, Toronto, ON, Canada. [Sultzer, David L.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Sultzer, David L.] VA Greater Angeles Healthcare Syst, Psychiat Serv, Los Angeles, CA USA. [Francis, Paul T.] Kings Coll London, Wolfson Ctr Age Related Dis, London, England. [Brodaty, Henry] Univ New S Wales, Dementia Collaborat Res Ctr, Sydney, NSW, Australia. [Padala, Prasad P.] Cent Arkansas Vet Healthcare Syst, Geriatr Res Educ & Clin Ctr, Little Rock, AR USA. [Padala, Prasad P.] Univ Arkansas Med Sci, Dept Psychiat, Little Rock, AR 72205 USA. [Ortiz, Luis Agueera] C1BERSAM, Madrid, Spain. [Ortiz, Luis Agueera] Univ Hosp Doce Octubre, Madrid, Spain. [Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA. [Bliwise, Donald L.] Emory Univ, Sch Med, Wesley Woods Hlth Ctr, Dept Neurol, Atlanta, GA USA. [Martin, Jennifer L.] Univ Calif Los Angeles, Educ & Clin Ctr, VA Greater Angeles Healthcare Geriatr Res, Los Angeles, CA USA. [Martin, Jennifer L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Vitiello, Michael V.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Zee, Phyllis C.] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA. [Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Sweet, Robert A.; Murray, Patrick S.] VA Pittsburgh Healthcare Syst, VISN 4 Mental Illness Res Educ & Clin Ctr MIRECC, Pittsburgh, PA USA. [Ballard, Clive] Kings Coll London, Wolfson Ctr Age Related Dis, Biomed Res Unit, Inst Psychiat & Alzheimers Soc, London WC2R 2LS, England. [Khin, Ni A.; Alfaro, Cara] US FDA, Ctr Drug Evaluat & Res, Off Drug Evaluat 1 OND, Div Psychiat Prod, Silver Spring, MD USA. [Schultz, Susan] Univ Iowa, Carver Coll Med, Dept Psychiat, Iowa City, IA USA. RP Lyketsos, CG (reprint author), Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Div Geriatr Psychiat & Neuropsychiat, Baltimore, MD 21218 USA. RI Lee, Michael/D-9491-2013; Francis, Paul/A-9199-2008 OI Lee, Michael/0000-0001-5865-9682; Murray, Patrick/0000-0002-6525-2888; Vitiello, Michael/0000-0002-9776-0473; Lanctot, Krista L./0000-0001-7024-6637 FU NIMH [K01-MH68351, R24-MH074779, R01-MH079814, RC1-MH090770-01]; NIA [U01-AG006786]; National Center for Research Resources [RR024150]; Robert Wood Johnson Foundation; European Union Regional Development Fund [FNUSA-ICRC: CZ.1.05/1.1.00/02.0123]; Baxter; Elan Pharmaceuticals; Johnson Johnson; Eli Lilly; Myriad; Novartis; Pfizer; Abbott Laboratories; AC Immune; Allergan; Allon; Alzheimer Drug Discovery Foundation; AstraZeneca; Bristol-Myers Squibb; Elan; Exonhit; Forest; GlaxoSmithKline; Ipsen Pharmaceuticals; Lundbeck; Medavante; Medivation; Merck; Merz; Roche; Sanofi-Aventis; Schering-Plough; Schwabe; Toyama; Transition Therapeutics; Alzheimer's Association [IIRG-07-28686]; Johns Hopkins Alzheimer's Disease Research Center [P50-AG005146]; NIMH, MA; Associated Jewish Federation of Baltimore; Weinberg Foundation; Eisai; Lilly; Ortho-McNeil; Bristol-Myers; National Football League; Functional Neuromodulation Inc. FX The authors thank Dr. Michelle M. Mielke for her helpful comments and feedback on early drafts of this manuscript. Dr. Geda was supported by NIMH grant K01-MH68351, NIA grant U01-AG006786 (the Mayo Clinic Study of Aging), National Center for Research Resources grant RR024150 (Mayo Clinic CTSA [Career Transition Award]), the Robert Wood Johnson Foundation (Harold Amos Scholar), and the European Union Regional Development Fund (Project FNUSA-ICRC: CZ.1.05/1.1.00/02.0123). Dr. Schneider reports being an editor on the Cochrane Collaboration Dementia and Cognitive Improvement Group, which oversees systematic reviews of drugs for cognitive impairment and dementia. He received a grant from the Alzheimer's Association for a registry for dementia and cognitive impairment trials; he is also in receipt of grant or research support from Baxter, Elan Pharmaceuticals, Johnson & Johnson, Eli Lilly, Myriad, Novartis, and Pfizer. He has served as a consultant for or received consulting fees from Abbott Laboratories, AC Immune, Allergan, Allon, the Alzheimer Drug Discovery Foundation, AstraZeneca, Bristol-Myers Squibb, Elan, Eli Lilly, Exonhit, Forest, GlaxoSmithKline, Ipsen Pharmaceuticals, Johnson & Johnson, Lundbeck, Myriad, Medavante, Medivation, Merck, Merz, Novartis, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, Schwabe, Toyama, and Transition Therapeutics. Dr. Gitlin was supported by NIMH grants R24-MH074779, R01-MH079814, and RC1-MH090770-01 and Alzheimer's Association grant IIRG-07-28686 and served on the Phillips Life Line Falls Advisory Board. Dr. Miller is a full-time employee of Bracket. Dr. Lyketsos was supported by the Johns Hopkins Alzheimer's Disease Research Center (P50-AG005146). He has received grant support (research or CME) from NIMH, MA, the Associated Jewish Federation of Baltimore, the Weinberg Foundation, Forest, GlaxoSmithKline, Eisai, Pfizer, AstraZeneca, Lilly, Ortho-McNeil, Bristol-Myers, Novartis, the National Football League, Elan, and Functional Neuromodulation Inc. He has served as consultant/advisor for AstraZeneca, GlaxoSmithKline, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Lilly, Pfizer, Genentech, Elan, the NFL Players Association, the NFL Benefits Office, Avanir, and Zinfandel. He has also received honorarium or travel support from Pfizer, Forest, GlaxoSmithKline, and Health Monitor. NR 68 TC 76 Z9 77 U1 6 U2 43 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD SEP PY 2013 VL 9 IS 5 BP 602 EP 608 DI 10.1016/j.jalz.2012.12.001 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 222IN UT WOS:000324724500015 PM 23562430 ER PT J AU Watson, GS Cholerton, BA Gross, RG Weintraub, D Zabetian, CP Trojanowski, JQ Montine, TJ Siderowf, A Leverenz, JB AF Watson, G. Stennis Cholerton, Brenna A. Gross, Rachel G. Weintraub, Daniel Zabetian, Cyrus P. Trojanowski, John Q. Montine, Thomas J. Siderowf, Andrew Leverenz, James B. TI Neuropsychologic assessment in collaborative Parkinson's disease research: A proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson's Disease Research at the University of Pennsylvania and the University of Washington SO ALZHEIMERS & DEMENTIA LA English DT Article ID MONTREAL COGNITIVE ASSESSMENT; DEMENTIA; MOCA; IMPAIRMENT; SYMPTOMS; VALIDITY; COHORT; MMSE; MCI AB Cognitive impairment (CI) and behavioral disturbances can be the earliest symptoms of Parkinson's disease (PD), ultimately afflict the vast majority of PD patients, and increase caregiver burden. Our two Morris K. Udall Centers of Excellence for Parkinson's Disease Research were supported by the National Institute of Neurological Disorders and Stroke (NINDS) in an effort to recommend a comprehensive yet practical approach to cognitive and behavioral assessment to further collaborative research. We recommend a stepwise approach with two levels of standardized evaluation to establish a common battery, as well as an alternative testing recommendation for severely impaired subjects, and review supplemental tests that may be useful in specific research settings. Our flexible approach may be applied to studies with varying emphasis on cognition and behavior, does not place undue burden on participants or resources, and has a high degree of compatibility with existing test batteries to promote collaboration. (C) 2013 The Alzheimer's Association. All rights reserved. C1 [Watson, G. Stennis; Cholerton, Brenna A.; Leverenz, James B.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Gross, Rachel G.; Weintraub, Daniel; Siderowf, Andrew] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Gross, Rachel G.; Weintraub, Daniel; Siderowf, Andrew] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Zabetian, Cyrus P.] Vet AffairsPuget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Zabetian, Cyrus P.; Leverenz, James B.] Vet Affairs Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA. [Zabetian, Cyrus P.; Leverenz, James B.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Trojanowski, John Q.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA. [Trojanowski, John Q.] Univ Penn, Inst Aging, Philadelphia, PA 19104 USA. [Trojanowski, John Q.] Univ Penn, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA. [Montine, Thomas J.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Leverenz, James B.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. RP Leverenz, JB (reprint author), Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. EM leverenz@uw.edu FU NINDS [NS062684, NS053488]; Nancy and Buster Alvord Endowment FX This study was funded by NINDS (NS062684, NS053488) and the Nancy and Buster Alvord Endowment. The authors thank Dr Kathy Montine for editorial assistance. NR 27 TC 4 Z9 4 U1 4 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD SEP PY 2013 VL 9 IS 5 BP 609 EP 614 DI 10.1016/j.jalz.2012.07.006 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 222IN UT WOS:000324724500016 PM 23164549 ER PT J AU Lysack, C Leach, C Russo, T Paulson, D Lichtenberg, PA AF Lysack, Cathy Leach, Carrie Russo, Theresa Paulson, Daniel Lichtenberg, Peter A. TI DVD Training for Depression Identification and Treatment in Older Adults: A Two-Group, Randomized, Wait-List Control Study SO AMERICAN JOURNAL OF OCCUPATIONAL THERAPY LA English DT Article DE depression; education, continuing; geriatric assessment; staff development; teaching ID LATE-LIFE DEPRESSION; HOME-CARE; OCCUPATIONAL-THERAPY; TREATING DEPRESSION; CONTROLLED-TRIAL; HEALTH-STATUS; INTERVENTION; RECOGNITION; SCALE; MOOD AB OBJECTIVE. To test the effectiveness of an educational intervention aimed at improving mental health. knowledge and skills in occupational therapists working with older rehabilitation patients. METHOD. The DVD-format educational intervention was evaluated using a two-group randomized wait-list control design. Occupational therapists (n = 75) completed a 32-item knowledge questionnaire at three time points. Patient charts were reviewed (n = 960) at 3 months before and 3 and 6 months after DVD training to evaluate clinical practice change. RESULTS. A two-way analysis of variance showed knowledge scores increased significantly for both groups after DVD training. A significant Group x Time interaction and significant main effects for time and group were found. Chart review data also showed significant increases in desired clinical behaviors in both groups after training. The greatest single item of clinical practice change was use of a standardized depression screen. CONCLUSION. DVD-based training can significantly improve mental health practice. C1 [Lysack, Cathy; Leach, Carrie; Lichtenberg, Peter A.] Wayne State Univ, Inst Gerontol, Detroit, MI 48202 USA. [Russo, Theresa] Alzheimers Assoc Greater Michigan Chapter, Southfield, MI USA. [Paulson, Daniel] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA. [Paulson, Daniel] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Lichtenberg, Peter A.] Wayne State Univ, Dept Psychiat & Behav Neurosci, Detroit, MI 48202 USA. RP Lysack, C (reprint author), Wayne State Univ, Inst Gerontol, Room 231,Knapp Bldg,87 East Ferry St, Detroit, MI 48202 USA. EM c.lysack@wayne.edu NR 30 TC 1 Z9 1 U1 1 U2 7 PU AMER OCCUPATIONAL THERAPY ASSOC, INC PI BETHESDA PA 4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA SN 0272-9490 J9 AM J OCCUP THER JI Am. J. Occup. Ther. PD SEP-OCT PY 2013 VL 67 IS 5 BP 584 EP 593 DI 10.5014/ajot.2013.008060 PG 10 WC Rehabilitation SC Rehabilitation GA 220EQ UT WOS:000324565400012 PM 23968797 ER PT J AU Stengel, A Goebel-Stengel, M Wang, L Hu, E Karasawa, H Pisegna, JR Tache, Y AF Stengel, Andreas Goebel-Stengel, Miriam Wang, Lixin Hu, Eugenia Karasawa, Hiroshi Pisegna, Joseph R. Tache, Yvette TI High-protein diet selectively reduces fat mass and improves glucose tolerance in Western-type diet-induced obese rats SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE diet-induced obesity; food intake; high-protein diet; gut hormones ID CONDITIONED TASTE-AVERSION; WEIGHT-LOSS DIETS; FOOD-INTAKE; BODY-WEIGHT; INDUCED THERMOGENESIS; RESPIRATION CHAMBER; CEREBROSPINAL-FLUID; ENERGY RESTRICTION; METABOLIC SYNDROME; INSULIN-SECRETION AB Obesity is an increasing health problem. Because drug treatments are limited, diets remain popular. High-protein diets (HPD) reduce body weight (BW), although the mechanisms are unclear. We investigated physiological mechanisms altered by switching diet induced obesity (DIO) rats from Western-type diet (WTD) to HPD. Male rats were fed standard (SD) or WTD (45% calories from fat). After developing DIO (50% of rats), they were switched to SD (15% calories from protein) or HPD (52% calories from protein) for up to 4 weeks. Food intake (FI), BW, body composition, glucose tolerance, insulin sensitivity, and intestinal hormone plasma levels were monitored. Rats fed WTD showed an increased FI and had a 25% greater BW gain after 9 wk compared with SD (P < 0.05). Diet-induced obese rats switched from WTD to HPD reduced daily FI by 30% on day 1, which lasted to day 9 (-9%) and decreased BW during the 2-wk period compared with SD/SD (P < 0.05). During these 2 wk, WTD/HPD rats lost 72% more fat mass than WTD/SD (P < 0.05), whereas lean mass was unaltered. WTD/HPD rats had lower blood glucose than WTD/SD at 30 min postglucose gavage (P < 0.05). The increase of pancreatic polypeptide and peptide YY during the 2-h dark-phase feeding was higher in WTD/HPD compared with WTD/SD (P < 0.05). These data indicate that HPD reduces BW in WTD rats, which may be related to decreased FI and the selective reduction of fat mass accompanied by improved glucose tolerance, suggesting relevant benefits of HPD in the treatment of obesity. C1 [Stengel, Andreas; Goebel-Stengel, Miriam; Wang, Lixin; Hu, Eugenia; Karasawa, Hiroshi; Pisegna, Joseph R.; Tache, Yvette] Univ Calif Los Angeles, Dept Med, Ctr Neurobiol Stress, CURE,Digest Dis Res Ctr,Digest Dis Div, Los Angeles, CA 90024 USA. [Stengel, Andreas; Goebel-Stengel, Miriam; Wang, Lixin; Hu, Eugenia; Karasawa, Hiroshi; Pisegna, Joseph R.; Tache, Yvette] VA Greater Angeles Hlth Care Syst, Los Angeles, CA USA. [Stengel, Andreas] Charite Ctr Internal Med & Dermatol, Obes Ctr Berlin, D-13353 Berlin, Germany. [Stengel, Andreas] Charite, D-13353 Berlin, Germany. [Goebel-Stengel, Miriam] Inst Neurogastroenterol & Motility, Dept Internal Med, Berlin, Germany. [Goebel-Stengel, Miriam] Martin Luther Hosp, Berlin, Germany. RP Tache, Y (reprint author), CURE, VA GLA Healthcare Syst, Bldg 115,Rm 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu RI Biguzzi, Felipe/E-4724-2015 FU VA Merit award; National Institute of Health center grant [DK-41301]; VA Career Scientist Award; [5 RC1 DK-086150-02] FX This article was supported by VA Merit award (to Y. Tache and J. R. Pisegna), National Institute of Health center grant DK-41301 (Animal Core, to Y. Tache), VA Career Scientist Award (to Y. Tache) and 5 RC1 DK-086150-02 (S. B., C.P.). NR 62 TC 8 Z9 8 U1 0 U2 4 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD SEP PY 2013 VL 305 IS 6 BP R582 EP R591 DI 10.1152/ajpregu.00598.2012 PG 10 WC Physiology SC Physiology GA 222TA UT WOS:000324753200003 PM 23883680 ER PT J AU Sonne, SC Andrews, JO Gentilin, SM Oppenheimer, S Obeid, J Brady, K Wolf, S Davis, R Magruder, K AF Sonne, Susan C. Andrews, Jeannette O. Gentilin, Stephanie M. Oppenheimer, Stephanie Obeid, Jihad Brady, Kathleen Wolf, Sharon Davis, Randal Magruder, Kathryn TI Development and pilot testing of a video-assisted informed consent process SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE Informed consent process; Videos; Electronic forms; Tablet computing ID RANDOMIZED CONTROLLED-TRIAL; COMPREHENSION; INFORMATION; MULTIMEDIA; LITERACY AB The informed consent process for research has come under scrutiny, as consent documents are increasingly long and difficult to understand. Innovations are needed to improve comprehension in order to make the consent process truly informed. We report on the development and pilot testing of video clips that could be used during the consent process to better explain research procedures to potential participants. Based on input from researchers and community partners, 15 videos of common research procedures/concepts were produced. The utility of the videos was then tested by embedding them in mock-informed consent documents that were presented via an online electronic consent system designed for delivery via iPad. Three mock consents were developed, each containing five videos. All participants (n = 61) read both a paper version and the video-assisted iPad version of the same mock consent and were randomized to which format they reviewed first. Participants were given a competency quiz that posed specific questions about the information in the consent after reviewing the first consent document to which they were exposed. Most participants (78.7%) preferred the video-assisted format compared to paper (12.9%). Nearly all (96.7%) reported that the videos improved their understanding of the procedures described in the consent document; however, the comprehension of material did not significantly differ by consent format. Results suggest videos may be helpful in providing participants with information about study procedures in a way that is easy to understand. Additional testing of video consents for complex protocols and with subjects of lower literacy is warranted. (C) 2013 Elsevier Inc. All rights reserved. C1 [Sonne, Susan C.; Andrews, Jeannette O.; Gentilin, Stephanie M.; Oppenheimer, Stephanie; Obeid, Jihad; Brady, Kathleen; Wolf, Sharon; Davis, Randal; Magruder, Kathryn] Med Univ S Carolina, Charleston, SC 29425 USA. [Brady, Kathleen; Magruder, Kathryn] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. RP Sonne, SC (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 125 Doughty St,Suite 190, Charleston, SC 29425 USA. EM sonnesc@musc.edu OI Obeid, Jihad/0000-0002-7193-7779 FU South Carolina Clinical and Translational Research (SCTR) Institute; Medical University of South Carolina, through NIH [UL1 RR029882, UL1 TR000062]; [RC2 LM010796] FX This publication was supported by the South Carolina Clinical and Translational Research (SCTR) Institute, with an academic home at the Medical University of South Carolina, through NIH grant numbers UL1 RR029882 and UL1 TR000062 as well as RC2 LM010796. NR 18 TC 10 Z9 10 U1 1 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD SEP PY 2013 VL 36 IS 1 BP 25 EP 31 DI 10.1016/j.cct.2013.05.011 PG 7 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA 225KH UT WOS:000324961300003 PM 23747986 ER PT J AU Trivedi, RB Szarka, JG Beaver, K Brousseau, K Nevins, E Yancy, WS Slade, A Voils, CI AF Trivedi, Ranak B. Szarka, Jackie G. Beaver, Kristine Brousseau, Koriann Nevins, Elaine Yancy, William S., Jr. Slade, Alecia Voils, Corrine I. TI Recruitment and retention rates in behavioral trials involving patients and a support person: A systematic review SO CONTEMPORARY CLINICAL TRIALS LA English DT Review DE Dyad; Caregiver; Couple; Intervention; Recruitment; Retention ID RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; CANCER PAIN MANAGEMENT; BREAST-CANCER; FAMILY CAREGIVERS; ALZHEIMER-DISEASE; CLINICAL-TRIAL; BRAIN-INJURY; STROKE PATIENTS; INTERVENTION AB Background: Recruitment and retention challenges impede the study of behavioral interventions among patient-support person dyads. Purpose: The aim of the study was to characterize recruitment and retention rates of behavioral interventions involving dyads. Methods: Using PRISMA guidelines and with the guidance of a medical librarian, we searched Medline, EMBASE, Cochrane Controlled Trials, PsycInfo, and CINAHL from inception until July 2011. Eligible articles involved RCTs of behavioral interventions targeting adult patients with a non-psychiatric illness and a support person. Sample and study characteristics, recruitment and retention strategies, and recruitment and retention rates were abstracted in duplicate. Quality of reporting was determined on a 5-point scale. Due to the heterogeneity in data reporting and missing data, a narrative synthesis was undertaken Results: 53 unique studies involving 8081 dyads were included. 9 studies were ascertained to have a "high quality" of reporting. A majority of the studies did not report target sample size, time to complete recruitment, and sample sizes at each follow-up time point. Strategies employed to recruit support persons were rarely reported. 16 studies did not report the number of dyads screened. The mean recruitment rate was 51.2% (range: 4.3%-95.4%), and mean retention rate was 77.5% (range: 36%-100%). Conclusions: Details regarding recruitment and retention methodology were sparse in these interventions. Where available, data suggests that resources need to be devoted towards recruitment of sample but that retention rates are generally adequate. Published by Elsevier Inc. C1 [Trivedi, Ranak B.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Trivedi, Ranak B.; Szarka, Jackie G.; Beaver, Kristine; Brousseau, Koriann; Nevins, Elaine] VA Puget Sound Hlth Care Syst, Northwest HSR&D Ctr Excellence, Seattle, WA 98101 USA. [Yancy, William S., Jr.; Slade, Alecia; Voils, Corrine I.] Ctr Hlth Serv Res Primary Care, Dept Vet Affairs, Durham, NC 27705 USA. [Yancy, William S., Jr.; Voils, Corrine I.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. RP Trivedi, RB (reprint author), VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat MPD 152, 795 Willow Rd, Menlo Pk, CA 94025 USA. EM ranak.trivedi@va.gov; Jackie.szarka@va.gov; kaakullia@gmail.com; Koriann.brousseau@va.gov; Elaine.nevins@va.gov; Yancy006@mc.duke.edu; Alecia.slade@gmail.com; voils001@mc.duke.edu OI Voils, Corrine/0000-0003-1913-663X FU Department of Veterans Affairs (VA); Veterans Health Administration Health Services Research and Development (HSRD) Service, IHI [IHI 02-062]; VA HSR&D Career Development Award [CDA-09-206] FX This work was supported by the Department of Veterans Affairs (VA), Veterans Health Administration Health Services Research and Development (HSR&D) Service, IHI 02-062. Dr. Trivedi was supported by a VA HSR&D Career Development Award, CDA-09-206. VA Puget Sound Health Care System and the VA Palo Alto Health Care System provided resources to support this research. The authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. NR 68 TC 8 Z9 8 U1 3 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD SEP PY 2013 VL 36 IS 1 BP 307 EP 318 DI 10.1016/j.cct.2013.07.009 PG 12 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA 225KH UT WOS:000324961300034 PM 23916918 ER PT J AU Fisher, V Fernandez, MP Krejci-Manwaring, J AF Fisher, Valerie Fernandez, Martin P. Krejci-Manwaring, Jennifer TI Lichen Planus Mimicking Recalcitrant Ulcerative Psoriasis: When Is It Time to Biopsy? SO CUTIS LA English DT Article ID EFFICACY AB LP verrucosus, is a rare disorder that presents as verrucous plaques, typically on the lower extremities and ankles. This variant differs from the common presentation of LP, which appears as flat, polygonal, pink-purple papules spread diffusely on the flexor wrists, trunk, shins, and dorsal aspects of the feet, frequently involving the oral mucosa. Clinically, hypertrophic LP can be confused with psoriasis and usually does not respond to therapy with biologics. We present a case of hypertrophic LP in a 42-year-old woman who had been treated extensively for psoriasis. Although the morphology and location of the hyperkeratotic plaques mimicked psoriasis, biopsy results exhibited characteristic features of hypertrophic LP, and the lesions responded to treatment with acitretin,. clobetasol propionate ointment, hydroxychloroquine, and simple wound care. The hypertrophic variant of LP can be extremely challenging to differentiate from psoriasis. Physicians who treat patients with scaly plaques should think beyond psoriasis and consider the hypertrophic variant of LP as a potential diagnosis. C1 [Fisher, Valerie; Fernandez, Martin P.; Krejci-Manwaring, Jennifer] Univ Texas Hlth Sci Ctr San Antonio, Div Dermatol & Cutaneous Surg, San Antonio, TX 78229 USA. [Krejci-Manwaring, Jennifer] Audie L Murphy Mem Vet Adm Med Ctr, Div Dermatol, San Antonio, TX 78229 USA. RP Krejci-Manwaring, J (reprint author), Audie L Murphy Mem Vet Adm Med Ctr, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM krejcimanwar@uthscsa.edu NR 9 TC 1 Z9 1 U1 0 U2 0 PU QUADRANT HEALTHCOM INC PI PARSIPPANY PA 7 CENTURY DRIVE, STE 302, PARSIPPANY, NJ 07054-4603 USA SN 0011-4162 J9 CUTIS JI Cutis PD SEP PY 2013 VL 92 IS 3 BP 136 EP 139 PG 4 WC Dermatology SC Dermatology GA 223FW UT WOS:000324791100010 PM 24153142 ER PT J AU Ghose, T Fiellin, DA Gordon, AJ Metraux, S Goetz, MB Blackstock, O McInnes, K Rodriguez-Barradas, MC Justice, AC AF Ghose, T. Fiellin, D. A. Gordon, A. J. Metraux, S. Goetz, M. B. Blackstock, O. McInnes, K. Rodriguez-Barradas, M. C. Justice, A. C. TI Hazardous drinking and its association with homelessness among veterans in care SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Hazardous drinking; Homelessness; Veteran care; Alcohol use; Longitudinal analysis; Veterans Aging Cohort Study ID DSM-III-R; ALCOHOL-USE; SUBSTANCE-ABUSE; MENTAL-ILLNESS; HEALTH-CARE; GENERAL-POPULATION; SUICIDAL IDEATION; WAR VETERANS; DRUG-ABUSE; DRINKERS AB Background: While scholarship on alcohol use and homelessness has focused on the impact of alcohol abuse and dependence, little is known about the effects of lower levels of misuse such as hazardous use. Veterans receiving care in the Department of Veterans Affairs Health Care System (VA) constitute a population that is vulnerable to alcohol misuse and homelessness. This research examines the effects of hazardous drinking on homelessness in the Veterans Aging Cohort Study, a sample of 2898 older veterans (mean age=50.2), receiving care in 8 VAs across the country. Methods: Logistic regression models examined the associations between (1) hazardous drinking at baseline and homelessness at 1-year follow-up, (2) transitions into and out of hazardous drinking from baseline to follow-up and homelessness at follow-up, and (3) transitioning to hazardous drinking and transitioning to homelessness from baseline to follow-up during that same time-period. Results: After controlling for other correlates including alcohol dependence, hazardous drinking at baseline increased the risk of homelessness at follow-up (adjusted odds ratio [AOR] = 1.39, 95% confidence interval [CI] = 1.02, 1.88). Transitioning to hazardous drinking more than doubled the risk of homelessness at follow-up (AOR=2.42,95% CI=1.41, 4.15), while more than doubling the risk of transitioning from being housed at baseline to being homeless at follow-up (AOR=2.49, 95% CI=1.30, 4.79). Conclusions: Early intervention that seeks to prevent transitioning into hazardous drinking could increase housing stability among veterans. Brief interventions which have been shown to be effective at lower levels of alcohol use should be implemented with veterans in VA care. Published by Elsevier Ireland Ltd. C1 [Ghose, T.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19130 USA. [Fiellin, D. A.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. [Fiellin, D. A.] Yale Univ, Sch Med, Ctr Interdisciplinary Res AIDS, New Haven, CT 06510 USA. [Gordon, A. J.] Univ Pittsburgh, Sch Med, VA Pittsburgh HealthCare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA. [Metraux, S.] Univ Sci, Dept Hlth Policy & Publ Hlth, Philadelphia, PA 19104 USA. [Goetz, M. B.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Blackstock, O.; Justice, A. C.] VA Connecticut Healthcare Syst, West Haven, CT 06516 USA. [Blackstock, O.; Justice, A. C.] Yale Univ, Sch Med, New Haven, CT 06510 USA. [McInnes, K.] ENRM VA Med Ctr, VA QUERI Program, Bedford, MA 01730 USA. [McInnes, K.] ENRM VA Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA. [McInnes, K.] Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA. [Rodriguez-Barradas, M. C.] Michael E DeBakey VAMC, Houston, TX 77030 USA. [Rodriguez-Barradas, M. C.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. RP Ghose, T (reprint author), Univ Penn, Sch Social Policy & Practice, D17 Caster Bldg,3701 Locust Walk, Philadelphia, PA 19130 USA. EM toorjo@sp2.upenn.edu OI Goetz, Matthew/0000-0003-4542-992X; Fiellin, David/0000-0002-4006-010X FU National Institutes of Health: NIAAA [U10-AA13566]; NHLBI [R01-HL095136, R01-HL090342, RCI-HL100347]; NIA [R01-AG029154, K23 AG024896] FX This work was financially supported by National Institutes of Health: NIAAA (U10-AA13566), NHLBI (R01-HL095136; R01-HL090342; RCI-HL100347), and NIA (R01-AG029154; K23 AG024896). The funding helped support the implementation of the study, i.e., the implementation of the study design, the data collection process and preparation of the data for analysis. The funders played no role in the analysis of the data, the preparation of the manuscript or decisions regarding where to submit it. NR 45 TC 3 Z9 3 U1 0 U2 12 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD SEP 1 PY 2013 VL 132 IS 1-2 BP 202 EP 206 DI 10.1016/j.drugalcdep.2013.02.004 PG 5 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 216KE UT WOS:000324281400028 PM 23474200 ER PT J AU Hoef, LWV Paige, AL Riley, KO Cure, J Soltani, M Williams, FB Kennedy, RE Szaflarski, JP Knowlton, RC AF Hoef, Lawrence W. Ver Paige, A. LeBron Riley, Kristen O. Cure, Joel Soltani, Mehdi Williams, Frank B. Kennedy, Richard E. Szaflarski, Jerzy P. Knowlton, Robert C. TI Evaluating hippocampal internal architecture on MRI: Inter-rater reliability of a proposed scoring system SO EPILEPSY RESEARCH LA English DT Article DE Hippocampus; Temporal lobe epilepsy; MRI; Ammon's horn; Inter-rater reliability; Internal architecture ID SCLEROSIS; EPILEPSY; ATROPHY AB Background: Asymmetry of hippocampal internal architecture (HIA) has been reported to be a frequent imaging finding in epilepsy patients with temporal lobe epilepsy (TLE) who exhibit other signs of hippocampal sclerosis. HIA asymmetry may also be an independent predictor of the side of seizure onset in patients with otherwise normal MRI scans. The study of HIA asymmetry and its relationship to the laterality of TLE would benefit from a reliable method of assessing the clarity of HIA in MRI scans. We propose a visual scoring system that rates HIA clarity from 1 (imperceptible) to 4 (excellent) and report the inter-rater reliability (IRR) of this system. Methods: In the initial preliminary phase of this study we examined IRR using a kappa statistic (K) among a mixed group of expert and non-expert reviewers using only a brief description of the scoring system to score single images from a series of patients. In the second phase we explored the effect of training on the use of our HIA scoring system by assessing IRR among neuroimaging experts before and after a brief interactive training session. In this phase, multiple slices from each patient were scored. Separate K values and intraclass correlation coefficients (ICC) were calculated from the scores given to each hippocampal image and from the asymmetry of scores between left and right for each slice. In the third phase the effect of training on non-expert reviewers was explored using a similar approach as with the expert reviewers. Results: In the preliminary phase of the study, HIA scoring of single images showed substantial agreement among expert reviewers (kappa(HIA) = 0.65), fair agreement among non-expert reviewers (kappa(HIA) = 0.27), and a fair to moderate degree of agreement among all the reviewers as a whole (kappa(HIA) = 0.40). In the second phase, prior to training there was substantial agreement among expert reviewers in regard to the individual HIA scores (kappa(HIA) = 0.62; ICCHIA = 0.81) but only moderate agreement on the degree of asymmetry (kappa(Asym) = 0.47; ICCAsym = 0.71). Training improved agreement on the individual HIA scores (kappa(HIA) = 0.58-0.72; ICCHIA = 0.76-0.84) and on the degree of asymmetry (kappa(Asym) = 0.61-0.67; ICCAsym = 081-0.85). Among non-expert reviewers, scores improved from only a fair degree of agreement pre-training (kappa(HIA) = 0.25, kappa(Asym) = 0.25; ICCHIA = 0.68, ICCAsym = 0.66) to a moderate level of agreement after training (kappa(HIA) = 0.54, kappa(Asym) = 0.52; ICCHIA = 0.78, ICCAsym = 0.81). Conclusions: The proposed HIA scoring system has a substantial degree of inter-rater reliability among experienced neuroimaging reviewers. Training improves the detection of asymmetries in HIA score in particular. Non-expert reviewers can employ the system with a moderate degree of reliability, and training has an even greater impact on the improvement of scoring reliability. (C) 2013 Elsevier B.V. All rights reserved. C1 [Hoef, Lawrence W. Ver; Soltani, Mehdi; Szaflarski, Jerzy P.] Univ Alabama Birmingham, Dept Neurol, UAB Epilepsy Ctr, Birmingham, AL 35294 USA. [Hoef, Lawrence W. Ver; Soltani, Mehdi] Birmingham VA Med Ctr, Neurol Serv, Birmingham, AL USA. [Paige, A. LeBron; Soltani, Mehdi] Univ Iowa, Dept Neurol, Iowa Comprehens Epilepsy Program, Iowa City, IA 52242 USA. [Riley, Kristen O.; Soltani, Mehdi] Univ Alabama Birmingham, Div Neurosurg, Birmingham, AL USA. [Cure, Joel; Soltani, Mehdi] Univ Alabama Birmingham, Dept Radiol, Birmingham, AL USA. [Soltani, Mehdi; Williams, Frank B.; Kennedy, Richard E.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA. [Soltani, Mehdi; Knowlton, Robert C.] Univ Texas Houston, Texas Comprehens Epilepsy Program, Dept Neurol, Houston, TX USA. RP Hoef, LWV (reprint author), Suite 312 CIRC,1719 6th Ave South, Birmingham, AL 35205 USA. EM LVERHOEF@UAB.EDU; LeBron-Paige@uiowa.edu; KRILEY@UAB.EDU; CUREJ@UAB.EDU; soltanim_20@yahoo.com; FBW@UAB.EDU; RKennedy@ms.soph.uab.edu; SZAFLAJ@UAB.EDU; Robert.C.Knowlton@uth.tmc.edu RI Williams, Frank/H-2220-2016 OI Williams, Frank/0000-0001-7507-4870; Riley, Kristen/0000-0001-5895-6855 FU National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health [1K23EB008452-01A1] FX Research reported in this publication was supported by the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health under Award Number 1K23EB008452-01A1. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 18 TC 1 Z9 1 U1 1 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-1211 EI 1872-6844 J9 EPILEPSY RES JI Epilepsy Res. PD SEP PY 2013 VL 106 IS 1-2 BP 146 EP 154 DI 10.1016/j.eplepsyres.2013.05.009 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 221NM UT WOS:000324665600016 ER PT J AU Hoef, LWV Williams, FB Kennedy, RE Szaflarski, JP Knowlton, RC AF Hoef, Lawrence W. Ver Williams, Frank B. Kennedy, Richard E. Szaflarski, Jerzy P. Knowlton, Robert C. TI Predictive value of hippocampal internal architecture asymmetry in temporal lobe epilepsy SO EPILEPSY RESEARCH LA English DT Article DE Hippocampus; Temporal lobe epilepsy; MRI; Ammon's horn; Hippcampal internal architecture; Imaging ID HIGH-RESOLUTION MRI; SCLEROSIS; ATROPHY; SUBFIELDS; AGE AB Background: Asymmetry of hippocampal internal architecture (HIA) clarity has been suggested to be a sign of hippocampal sclerosis (HS) and is frequently associated with other MRI findings of HS. The goal of this work is to use a previously developed HIA visual scoring system (Ver Hoef et al., 2013) to quantify HIA asymmetry in a retrospective series of consecutive temporal lobe epilepsy (TLE) patients and evaluate its value in predicting laterality of seizure onset both in patients with other signs of HS (HS+) and those without (HS-). Methods: The HIA scoring system was used to rate hippocampal asymmetry and to assess the agreement between HIA and seizure lateralization. The median values of the average HIA scores for each hippocampus were compared for HS+ epileptogenic hippocampi, HS- epileptogenic hippocampi, and non-epileptogenic hippocampi with a Kruskal Wallis one-way analysis of variance by ranks. Pair-wise differences between groups were evaluated with the two-tailed Mann Whitney U test. A logistic regression model examined the utility of average HIA asymmetry score in predicting the true laterality of seizure onset as determined by video-EEG. Sensitivity and specificity are calculated using various asymmetry thresholds in each patient group. Results: Fifty-five patients were identified who met inclusion criteria. Thirteen patients (24%) were found to have hippocampal atrophy and/or signal abnormality indicative of HS (HS+) and 42 did not (HS-). Significant differences were observed in the distribution of individual and average HIA scores between each of the groups of hippocampi, with HS+ hippocampi having the lowest HIA scores and non-epileptogenic hippocampi having the highest. Logistic regression analysis showed that the average HIA asymmetry score was a strong predictor of the laterality of seizure onset (beta = 3.93508, p < 0.001). HIA asymmetry remained significant even after adjustment for HS+/HS- status (beta = 3.8854, p < 0.001). Among HS- patients, when the average HIA asymmetry score was equal to or exceeded a threshold value of 0.5, the specificity for correctly predicting the side of seizure onset was between 95% and 100% with a sensitivity of 40-45%. Among HS+ patients, a threshold of 0.3 yielded a sensitivity of 85% and specificity of 100%. Conclusions: In this report we show for the first time that HIA asymmetry is a significant predictor of the laterality of seizure onset in TLE patients with otherwise normal MRI findings, and that the proposed HIA scoring system has high specificity and moderate sensitivity for lateralizing seizure onset in patients with TLE. (C) 2013 Elsevier B.V. All rights reserved. C1 [Hoef, Lawrence W. Ver; Szaflarski, Jerzy P.] Univ Alabama Birmingham, Dept Neurol, UAB Epilepsy Ctr, Birmingham, AL 35294 USA. [Hoef, Lawrence W. Ver] Birmingham VA Med Ctr, Neurol Serv, Birmingham, AL USA. [Williams, Frank B.; Kennedy, Richard E.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA. [Knowlton, Robert C.] Univ Texas Houston, Texas Comprehens Epilepsy Program, Dept Neurol, Houston, TX USA. RP Hoef, LWV (reprint author), Suite 312 CIRC,1719 6th Ave South, Birmingham, AL 35205 USA. EM LVERHOEF@UAB.EDU; FBW@UAB.EDU; RKennedy@ms.soph.uab.edu; SZAFLAJ@UAB.EDU; Robert.C.Knowlton@uth.tmc.edu RI Williams, Frank/H-2220-2016 OI Williams, Frank/0000-0001-7507-4870 FU National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health [1K23EB008452-01A1] FX Research reported in this publication was supported by the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health under Award Number 1K23EB008452-01A1. NR 19 TC 3 Z9 3 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-1211 EI 1872-6844 J9 EPILEPSY RES JI Epilepsy Res. PD SEP PY 2013 VL 106 IS 1-2 BP 155 EP 163 DI 10.1016/j.eplepsyres.2013.05.008 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 221NM UT WOS:000324665600017 ER PT J AU Ponticorvo, A Cardenas, D Dunn, AK Ts'o, D Duong, TQ AF Ponticorvo, Adrien Cardenas, Damon Dunn, Andrew K. Ts'o, Daniel Duong, Timothy Q. TI Laser speckle contrast imaging of blood flow in rat retinas using an endoscope SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE laser speckle imaging; retinal imaging; gas challenge; flicker stimulation ID OPTIC-NERVE; PHOTOGRAPHY; RESOLUTION; IMAGES; FUNDUS AB Laser speckle contrast imaging (LSCI) offers a cost-effective means to image blood flow in vivo. However, it is not commonly used to image rodent retinas because of the challenges associated with imaging through the curved cornea and delivering light through the highly scattering lens. A solution to overcome these problems by using LSCI in conjunction with an endoscope to obtain high spatiotemporal blood flow images is described. Its utility is demonstrated by imaging blood flow changes in rat retinas using hyperoxic, hypercapnic, and visual (flicker) stimulations. Hypercapnia increases blood flow, hyperoxia decreases blood flow, and visual stimulation increases blood flow in the retina relative to basal conditions. The time-to-peak of the LSCI response to visual stimulation is also measured. This approach may prove useful to investigate dysregulation in blood flow-evoked responses in retinal diseases and to evaluate treatment strategies in rodents. (C) The Authors. Published by SPIE under a Creative Commons Attribution 3.0 Unported License. Distribution or reproduction of this work in whole or in part requires full attribution of the original publication, including its DOI. C1 [Ponticorvo, Adrien; Cardenas, Damon; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Dunn, Andrew K.] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA. [Ts'o, Daniel] SUNY Upstate Med Univ, Dept Neurosurg & Neurosci, Syracuse, NY 13210 USA. [Duong, Timothy Q.] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78229 USA. RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. EM duongt@uthscsa.edu RI Duong, Timothy/B-8525-2008; Dunn, Andrew/I-9527-2014 FU Department of Veterans Affairs (VA MERIT Award); NIH [R01 EY018855, R01 EY014211] FX This work was supported in part by the Department of Veterans Affairs (VA MERIT Award) and NIH (R01 EY018855 and R01 EY014211). NR 22 TC 9 Z9 9 U1 0 U2 7 PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 J9 J BIOMED OPT JI J. Biomed. Opt. PD SEP PY 2013 VL 18 IS 9 AR 090501 DI 10.1117/1.JBO.18.9.090501 PG 3 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 222QX UT WOS:000324747300001 PM 24064947 ER PT J AU Iyer, RS Bhargava, P Sandstrom, CK Dicks, DL Reddy, GP AF Iyer, Ramesh S. Bhargava, Puneet Sandstrom, Claire K. Dicks, Demetrius L. Reddy, Gautham P. TI Establishing a Fellowship Education Committee SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Editorial Material ID DIAGNOSTIC-RADIOLOGY; RESIDENTS; PROGRAMS C1 [Iyer, Ramesh S.] Seattle Childrens Hosp, Dept Radiol, Seattle, WA USA. [Bhargava, Puneet] VA Puget Sound Hlth Care Syst, Dept Radiol, Seattle, WA USA. [Sandstrom, Claire K.; Dicks, Demetrius L.; Reddy, Gautham P.] Univ Washington, Med Ctr, Dept Radiol, Seattle, WA 98105 USA. RP Iyer, RS (reprint author), Univ Washington, Sch Med, Seattle Childrens Hosp, 4800 Sand Point Way NE, Seattle, WA 98105 USA. EM riyer@uw.edu OI Bhargava, Puneet/0000-0002-3849-9666 NR 16 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD SEP PY 2013 VL 10 IS 9 BP 718 EP 720 DI 10.1016/j.jacr.2012.07.024 PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 222IB UT WOS:000324723300018 PM 23332609 ER PT J AU Banks, WA AF Banks, William A. TI Artificial Emotions: Robots Caring for the Elderly SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Editorial Material ID ANIMAL-ASSISTED THERAPY; LONELINESS; DOGS C1 [Banks, William A.] Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Banks, William A.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. RP Banks, WA (reprint author), VA PSH CSI GRECC S-182,Bldg 1,Rm 810A,1600 S Colu, Seattle, WA 98108 USA. EM wabanks1@u.washington.edu NR 8 TC 3 Z9 3 U1 3 U2 29 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD SEP PY 2013 VL 14 IS 9 BP 635 EP 636 DI 10.1016/j.jamda.2013.04.011 PG 2 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 217AS UT WOS:000324329500003 PM 23764538 ER PT J AU Boockvar, K Signor, D Ramaswamy, R Hung, W AF Boockvar, Kenneth Signor, Daniel Ramaswamy, Ravishankar Hung, William TI Delirium During Acute Illness in Nursing Home Residents SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Article DE Nursing homes; delirium; nosocomial infection; activities of daily living ID CONFUSION ASSESSMENT METHOD; ELDERLY MEDICAL PATIENTS; PREDICTIVE MODEL; SYMPTOMS; PREVALENCE; PERSISTENT; MORTALITY; SCALE; RISK; CARE AB Objectives: To ascertain the incidence of delirium during acute illness in nursing home residents, describe the timing of delirium after acute illness onset, describe risk factors for delirium, and explore the relationship between delirium and complications of acute illness. Design: Prospective observational cohort study. Setting: Three nursing homes in metropolitan New York. Participants: Individuals who were expected to remain in the nursing home for at least 2 months, who, as part of a parent study, were receiving opioids, antidepressants, or antipsychotics on a routine basis, and who did not have an acute medical illness at the time of screening. Acute illness surveillance was performed twice weekly through communication with nursing home nursing staff and medical providers using established clinical criteria for incipient cases. Measurements: We followed patients for 14 days after illness onset, and, if applicable, an additional 14 days each after hospital admission and hospital discharge. Delirium was assessed 3 times weekly using the Confusion Assessment Method (CAM). Physical function decline was calculated using change in the Minimum Data Set Activities of Daily Living Scale (MDS-ADL) and cognitive function decline using change in the Minimum Data Set Cognitive performance scale (MDS-CPS). Falls were ascertained by record review. Results: Among 136 nursing home patients followed for a mean of 11.7 months, 78 experienced 232 acute illnesses, of which 162 (71%) were managed in the nursing home. The most common diagnoses were urinary tract infection (20%), cellulitis (15%), and lower respiratory tract infection (9%). Subjects experienced delirium during 41 (17.7%) of 232 acute illnesses. Female sex was associated with a greater risk of delirium (odds ratio 2.59; 95% confidence interval [CI] 1.04-6.43) but there were no other risk factors identified. Delirium was a risk factor for cognitive function decline (odds ratio 4.59; 95% CI 1.99-10.59; P = .0004), but not ADL function decline or falling. Conclusion: Delirium occurred frequently as a complication of acute illness in the nursing home, and was a risk factor for cognitive function decline. This finding supports the rationale to target individuals at the onset of an acute medical problem in the design of interventions to prevent delirium in the nursing home setting. Published by Elsevier Inc. on behalf of the American Medical Directors Association, Inc. C1 [Boockvar, Kenneth; Signor, Daniel; Hung, William] James J Peters VA Med Ctr, Bronx, NY USA. [Boockvar, Kenneth] Jewish Home Lifecare, New York, NY 10025 USA. [Boockvar, Kenneth; Ramaswamy, Ravishankar; Hung, William] Mt Sinai, Icahn Sch Med, New York, NY USA. RP Boockvar, K (reprint author), Jewish Home Lifecare, 120 West 106th St, New York, NY 10025 USA. EM kenneth.boockvar@mssm.edu OI Boockvar, Kenneth/0000-0003-1165-5558 FU VA Health Services Research and Development Grants [ARCD 03-027-1, REA 08-260]; Greenwall Foundation FX This study was funded by VA Health Services Research and Development Grants ARCD 03-027-1 and REA 08-260. Dr. Boockvar was supported by the Greenwall Foundation. NR 34 TC 15 Z9 15 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD SEP PY 2013 VL 14 IS 9 BP 656 EP 660 DI 10.1016/j.jamda.2013.06.004 PG 5 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 217AS UT WOS:000324329500008 PM 23896369 ER PT J AU Yoo, JW Choi, JB Kim, SJ Shin, HP Kim, K Ryu, WS Min, TJ Kim, S Nakagawa, S AF Yoo, Ji Won Choi, Jong Bum Kim, Sun Jung Shin, Hyun P. Kim, Kyudam Ryu, Woo Sang Min, Too Jae Kim, Sulgi Nakagawa, Shunichi TI Factors Associated With Remaining in a Skilled Nursing Facility for Over 90 Days from Admission: Residents' Participation in Therapy and Desire to Return to the Community SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Article DE Nursing home; patient participation; skilled nursing facility ID MINIMUM DATA SET; HOME RESIDENTS; DETERMINANTS; TRANSITIONS; POSTACUTE; DELIRIUM AB Background: To identify the factors associated with stay in a skilled nursing facility (SNF) among new enrollees who did not fully participate in therapy sessions. Methods: Data (n = 36,133) were obtained from the Minimum Data Set version 2.0 in the state of Michigan in 2009. Study participants were new SNF enrollees (n = 699) who did not fully participate in therapy sessions despite their desire to return to the community. Multivariate logistic regressions were performed to identify factors contributing to remaining in a nursing home for 91 days or longer. Results: New SNF enrollees were more likely to remain in nursing home when they were depressed (odds ratio [OR] 1.41; 95% confidence interval [CI], 1.09-2.08; P = .01), experiencing delirium (OR = 3.20; 95% CI, 1.48-5.92; P < .001), were not in pain (OR = 0.83; 95% CI, 0.60-0.95; P = .03), or in less complex care (OR = 0.57; 95% CI, 0.44-0.81; P < .01). Conclusions: A higher number of new SNF enrollees than previously reported were likely to stay in nursing homes (28.0%). Depression and delirium were associated with stay in an SNF, while pain and higher complexity of care were associated with returning to the community. Copyright (C) 2013 - American Medical Directors Association, Inc. C1 [Yoo, Ji Won] Aurora Hlth Care, Ctr Senior Hlth & Longev, Milwaukee, WI USA. [Yoo, Ji Won] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. [Choi, Jong Bum] Yonsei Univ, Coll Med, Dept Pain Med & Anesthesia, Seoul, South Korea. [Kim, Sun Jung] Yonsei Univ, Coll Med, Dept Publ Hlth, Seoul, South Korea. [Kim, Sun Jung] Yonsei Univ, Coll Med, Inst Hlth Serv Res, Seoul, South Korea. [Shin, Hyun P.] Kyung Hee Univ, Coll Med, East West Neo Med Ctr, Dept Internal Med, Seoul, South Korea. [Kim, Kyudam] Korea Adv Inst Sci & Technol, Taejon 305701, South Korea. [Ryu, Woo Sang] Korea Univ, Coll Med, Clin Res Ctr, Seoul 136705, South Korea. [Min, Too Jae] Korea Univ, Coll Med, Dept Pain Med & Anesthesia, Seoul 136705, South Korea. [Kim, Sulgi] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Nakagawa, Shunichi] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA. [Nakagawa, Shunichi] James J Peters Vet Affairs Med Ctr, Ctr Clin, Bronx, NY USA. RP Yoo, JW (reprint author), Univ Michigan, Sch Med, Dept Internal Med, 300 North Ingalls Bldg,Room 932, Ann Arbor, MI 48109 USA. EM yoojiw@trinity-health.org NR 20 TC 1 Z9 1 U1 10 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD SEP PY 2013 VL 14 IS 9 AR UNSP 710.e1 DI 10.1016/j.jamda.2013.05.022 PG 4 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 217AS UT WOS:000324329500020 PM 23860264 ER PT J AU Cotofana, S Wyman, BT Benichou, O Dreher, D Nevitt, M Gardiner, J Wirth, W Hitzl, W Kwoh, CK Eckstein, F Frobell, RB AF Cotofana, S. Wyman, B. T. Benichou, O. Dreher, D. Nevitt, M. Gardiner, J. Wirth, W. Hitzl, W. Kwoh, C. K. Eckstein, F. Frobell, R. B. CA OAI Investigators Grp TI Relationship between knee pain and the presence, location, size and phenotype of femorotibial denuded areas of subchondral bone as visualized by MRI SO OSTEOARTHRITIS AND CARTILAGE LA English DT Article DE Pain; Cartilage; MRI; Denuded area of subchondral bone ID INITIATIVE PROGRESSION SUBCOHORT; ARTICULAR-CARTILAGE; IMAGING FINDINGS; OSTEOCHONDRAL JUNCTION; RADIOGRAPHIC FEATURES; SENSORY INNERVATION; REGIONAL-ANALYSIS; OSTEOARTHRITIS; ASSOCIATION; JOINT AB Objective: Conflicting associations between imaging biomarkers and pain in knee osteoarthritis (OA) have been reported. A relation between pain and denuded areas of subchondral bone (dABs) has been suggested and this study explores this relationship further by relating the presence, phenotype, location and size of dABs to different measures of knee pain. Methods: 633 right knees from the Osteoarthritis Initiative (OAI) (250 men, age 61.7 +/- 9.6 yrs, BMI 29.4 +/- 4.7 kg/m(2)) were included. Manual segmentation of the femorotibial cartilage plates was performed on 3 T coronal fast low angle shot with water excitation (FLASHwe) images. dABs were defined as areas where the subchondral bone was uncovered by cartilage. The following measures of pain were used: weightbearing-, non-weightbearing-, moderate-to-severe-, infrequent- and frequent knee pain. Results: Using pain measures from subjects without dABs as a reference, those with at least one dAB had a 1.64-fold higher prevalence ratio [PR, 95% confidence interval (CI) 1.24-2.18] to have frequent and 1.45-fold higher for moderate-to-severe knee pain (95% CI 1.13-1.85). Subjects with dABs in central subregions had a 1.53-fold increased prevalence of having weightbearing pain (95% Cl 1.20-1.97), especially when the central subregion was moderately (>10%) denuded (PR 1.81, 95% CI 135-2.42). Individuals with cartilage-loss-type dABs had a slightly higher prevalence (PR 1.13, 95% CI 1.00-1.27) of having frequent knee pain compared to individuals with intra-chondral-osteophyte-type dABs. Conclusion: This study supports a positive relation between femorotibial dABs and knee pain, especially when the dABs are located centrally (i.e., in weightbearing regions) or when the respective central subregion is moderately denuded. (C) 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved. C1 [Cotofana, S.; Wirth, W.; Hitzl, W.; Eckstein, F.; Frobell, R. B.] Paracelsus Med Univ, Salzburg, Austria. [Cotofana, S.; Wirth, W.; Eckstein, F.] Chondrometr GmbH, Ainring, Germany. [Wyman, B. T.; Gardiner, J.] Pfizer Inc, Groton, CT 06340 USA. [Benichou, O.] Eli Lilly & Co, Indianapolis, IN 46285 USA. [Dreher, D.] Merck Serono, Geneva, Switzerland. [Nevitt, M.] UCSF, San Francisco, CA USA. [Kwoh, C. K.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Kwoh, C. K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Frobell, R. B.] Lund Univ, Dept Orthoped, Clin Sci Lund, Lund, Sweden. RP Cotofana, S (reprint author), PMU, Inst Anat & Musculoskeletal Res, Strubergasse 21, A-5020 Salzburg, Austria. EM sebastian.cotofana@pmu.ac.at RI Wirth, Wolfgang/C-8724-2011 OI Wirth, Wolfgang/0000-0002-2297-8283 FU Pfizer Inc.; Eli Lilly Co; Merck Serono SA - Geneva, Switzerland; GlaxoSmithKline; Centocor Inc.; National Institutes of Health, a branch of the Department of Health and Human Services [N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, N01-AR-2-2262]; Novartis Pharmaceuticals Corporation; Merck Research Laboratories FX The image analysis of this study was funded by an industry consortium consisting of Pfizer Inc., Eli Lilly & Co, Merck Serono SA - Geneva, Switzerland, GlaxoSmithKline, and Centocor Inc.; The OAI is a public-private partnership comprised five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Pfizer Inc.; Novartis Pharmaceuticals Corporation; Merck Research Laboratories; and GlaxoSmithKline. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript has received the approval of the OAI Publications Committee based on a review of its scientific content and data interpretation. NR 48 TC 11 Z9 11 U1 1 U2 6 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1063-4584 J9 OSTEOARTHR CARTILAGE JI Osteoarthritis Cartilage PD SEP PY 2013 VL 21 IS 9 SI SI BP 1214 EP 1222 DI 10.1016/j.joca.2013.04.001 PG 9 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA 225KQ UT WOS:000324962200011 PM 23973133 ER PT J AU Switzer, GE Robinson, GFWB Rubio, DM Fowler, NR Kapoor, WN AF Switzer, Galen E. Robinson, Georgeanna F. W. B. Rubio, Doris M. Fowler, Nicole R. Kapoor, Wishwa N. TI Doctoral Programs to Train Future Leaders in Clinical and Translational Science SO ACADEMIC MEDICINE LA English DT Article ID AWARDS AB Purpose Although the National Institutes of Health (NIH) has made extensive investments in educational programs related to clinical and translational science (CTS), there has been no systematic investigation of the number and characteristics of PhD programs providing training to future leaders in CTS. The authors undertook to determine the number of institutions that, having had received NIH-funded Clinical and Translational Science Awards (CTSAs), currently had or were developing PhD programs in CTS; to examine differences between programs developed before and after CTSA funding; and to provide detailed characteristics of new programs. Method In 2012, CTS program leaders at the 60 CTSA-funded institutions completed a cross-sectional survey focusing on four key domains related to PhD programs in CTS: program development and oversight; students; curriculum and research; and milestones. Results Twenty-two institutions had fully developed PhD programs in CTS, and 268 students were earning PhDs in this new field; 13 institutions were planning PhD programs. New programs were more likely to have fully developed PhD competencies and more likely to include students in medical school, students working only on their PhD, students working on a first doctoral degree, and students working in T1 translational research. They were less likely to include physicians and students working in clinical or T2 research. Conclusions Although CTS PhD programs have similarities, they also vary in their characteristics and management of students. This may be due to diversity in translational science itself or to the relative infancy of CTS as a discipline. C1 [Switzer, Galen E.] Univ Pittsburgh, Pittsburgh, PA USA. [Switzer, Galen E.; Fowler, Nicole R.] Univ Pittsburgh, Dept Med, PhD Program Clin & Translat Sci, Pittsburgh, PA USA. [Switzer, Galen E.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Robinson, Georgeanna F. W. B.; Rubio, Doris M.] Univ Pittsburgh, Sch Med, Inst Clin Res Educ, Pittsburgh, PA USA. [Rubio, Doris M.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Rubio, Doris M.] Univ Pittsburgh, Sch Med, Ctr Data, Ctr Res Hlth, Pittsburgh, PA USA. [Rubio, Doris M.] Univ Pittsburgh, Sch Med, Off Evaluat, Pittsburgh, PA USA. [Rubio, Doris M.] Univ Pittsburgh, Sch Med, Dept Med, Off Lifelong Learning, Pittsburgh, PA 15213 USA. [Kapoor, Wishwa N.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. [Kapoor, Wishwa N.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Kapoor, Wishwa N.] Univ Pittsburgh, Inst Clin Res Educ, Pittsburgh, PA USA. [Kapoor, Wishwa N.] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA USA. [Kapoor, Wishwa N.] Univ Pittsburgh, RAND Univ Pittsburgh Hlth Inst, Pittsburgh, PA USA. [Kapoor, Wishwa N.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA USA. RP Switzer, GE (reprint author), Iroquois Bldg 502,3600 Forbes Ave, Pittsburgh, PA 15213 USA. EM switzerge@upmc.edu OI Robinson, Georgeanna/0000-0001-6205-2867 FU National Institutes of Health (NIH) [UL1 RR024153, UL1TR000005] FX The project described was supported by the National Institutes of Health (NIH) through grant numbers UL1 RR024153 and UL1TR000005. NR 10 TC 3 Z9 3 U1 0 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 J9 ACAD MED JI Acad. Med. PD SEP PY 2013 VL 88 IS 9 BP 1332 EP 1339 DI 10.1097/ACM.0b013e31829e7bce PG 8 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 208AN UT WOS:000323647300040 PM 23899901 ER PT J AU Robinson, GFWB Switzer, GE Cohen, ED Primack, BA Kapoor, WN Seltzer, DL Bakken, LL Rubio, DM AF Robinson, Georgeanna F. W. B. Switzer, Galen E. Cohen, Elan D. Primack, Brian A. Kapoor, Wishwa N. Seltzer, Deborah L. Bakken, Lori L. Rubio, Doris McGartland TI A Shortened Version of the Clinical Research Appraisal Inventory: CRAI-12 SO ACADEMIC MEDICINE LA English DT Article ID PHYSICIAN-SCIENTISTS; SELF-EFFICACY; CAREER AB Purpose The original Clinical Research Appraisal Inventory (CRAI), which assesses the self-confidence of trainees in performing different aspects of clinical research, comprises 92 items. Completing the lengthy CRAI is time-consuming and represents a considerable burden to respondents, yet the CRAI provides useful data for evaluating research training programs. The purpose of this study is to develop a shortened version of the CRAI and to test its validity and reliability. Method Trainees in clinical research degree and career development programs at the University of Pittsburgh's Institute for Clinical Research Education completed the 92-item CRAI between 2007 and 2012, inclusive. The authors conducted, first, exploratory factor analysis on a training dataset (2007-2010) to reduce the number of items and, then, confirmatory factor analyses on a testing dataset (2011-2012) to test the psychometric properties of the shortened version. Results Of 546 trainees, 394 (72%) provided study data. Exploratory factor analysis revealed six distinct factors, and confirmatory factor analysis identified the two items with the highest loadings per factor, for a total of 12 items. Cronbach alpha for the six new factors ranged from 0.80 to 0.94. Factors in the 12-item CRAI were strongly and significantly associated with factors in the 92-item CRAI; correlations ranged from 0.82 to0.96 (P < .001 for each). Conclusions The 12-item CRAI is faster and less burdensome to complete but retains the strong psychometric properties of the original CRAI. C1 [Robinson, Georgeanna F. W. B.] Univ Pittsburgh, Sch Med, Inst Clin Res Educ, Pittsburgh, PA USA. [Switzer, Galen E.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Switzer, Galen E.; Primack, Brian A.; Rubio, Doris McGartland] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Cohen, Elan D.; Rubio, Doris McGartland] Univ Pittsburgh, Sch Med, Ctr Res Hlth Care Data Ctr, Pittsburgh, PA USA. [Kapoor, Wishwa N.; Seltzer, Deborah L.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Kapoor, Wishwa N.; Seltzer, Deborah L.] Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, Pittsburgh, PA USA. [Kapoor, Wishwa N.; Seltzer, Deborah L.; Rubio, Doris McGartland] Univ Pittsburgh, Sch Med, Inst Clin Res Educ, Pittsburgh, PA USA. [Kapoor, Wishwa N.] Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA USA. [Bakken, Lori L.] Univ Wisconsin, Sch Human Ecol, Dept Interdisciplinary Studies, Madison, WI USA. RP Robinson, GFWB (reprint author), Inst Clin Res Educ, 200 Meyran Ave,Suite 200, Pittsburgh, PA 15213 USA. EM gwrobins@pitt.edu OI Robinson, Georgeanna/0000-0001-6205-2867 FU National Institutes of Health [UL1 RR024153, UL1TR000005] FX The National Institutes of Health supported this study through grant numbers UL1 RR024153 and UL1TR000005. NR 11 TC 2 Z9 2 U1 4 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 EI 1938-808X J9 ACAD MED JI Acad. Med. PD SEP PY 2013 VL 88 IS 9 BP 1340 EP 1345 DI 10.1097/ACM.0b013e31829e75e5 PG 6 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 208AN UT WOS:000323647300041 PM 23886999 ER PT J AU Campbell, KH Huang, ES Dale, W Parker, MM John, PM Young, BA Moffet, HH Laiteerapong, N Karter, AJ AF Campbell, Kellie Hunter Huang, Elbert S. Dale, William Parker, Melissa M. John, Priya M. Young, Bessie A. Moffet, Howard H. Laiteerapong, Neda Karter, Andrew J. TI Association Between Estimated GFR, Health-Related Quality of Life, and Depression Among Older Adults With Diabetes: The Diabetes and Aging Study SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Aging; chronic kidney disease (CKD); depression; quality of life ID CHRONIC KIDNEY-DISEASE; NORTHERN CALIFORNIA DISTANCE; GLOMERULAR-FILTRATION-RATE; RENAL-DISEASE; DIALYSIS; HOSPITALIZATION; INITIATION; EQUATION; PROFILE; COHORT AB Background: Although chronic kidney disease (CKD) is a highly prevalent condition among older adults with diabetes, the associations between health-related quality of life (HRQoL) and severity of CKD in this population are not well understood. The objective of this study was to assess HRQoL and depressive symptoms across estimated glomerular filtration rate (eGFR) stages. Study Design: Cross-sectional. Setting & Participants: 5,805 members of Kaiser Permanente Northern California, 60 years or older with diabetes, from the 2005-2006 Diabetes Study of Northern California (DISTANCE) survey. Predictor: eGFR categories were defined as >= 90 (referent category), 75-89, 60-74, 45-59, 30-44, or <= 29 mL/min/1.73 m(2). Outcomes: HRQoL was measured using the modified Short Form -8 Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. Depressive symptoms were measured using the Patient Health Questionnaire -8. Results: In unadjusted linear regression analyses, physical (PCS) and mental (MCS) HRQoL scores were significantly lower with worsening eGFR level. However, after adjustment for sociodemographics, diabetes duration, obesity, and cardiovascular comorbid conditions and taking into account interactions with proteinuria, none of the eGFR categories was significantly or substantively associated with PCS or MCS score. In both unadjusted and adjusted analyses, higher risk of depressive symptoms was observed in respondents with eGFR <= 29 mL/min/1.73 m(2) (relative risk, 2.02; 95% CI, 1.10-3.71; P < 0.05) compared with the referent group. However, this eGFR-depression relationship was no longer significant after adjusting for hemoglobin level. Limitations: Participants are part of a single health care delivery system. Conclusions: Our findings suggest the need for greater attention to and potential interventions for depression in patients with reduced eGFR. (C) 2013 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. C1 [Campbell, Kellie Hunter; Huang, Elbert S.; Dale, William; John, Priya M.; Laiteerapong, Neda] Univ Chicago, Dept Med, Chicago, IL 60637 USA. [Parker, Melissa M.; Moffet, Howard H.; Karter, Andrew J.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [Young, Bessie A.] Univ Washington, Div Nephrol, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Young, Bessie A.] Kidney Res Inst, Seattle, WA USA. RP Campbell, KH (reprint author), Univ Chicago, Sect Geriatr & Palliat Med, 5841 S Maryland Ave,MC 6098, Chicago, IL 60637 USA. EM kcampbel@medicine.bsd.uchicago.edu FU T. Franklin Williams Scholars Award; Atlantic Philanthropies, Inc; American Geriatrics Society Foundation for Health in Aging; John A. Hartford Foundation; Association of Specialty Professors; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R01DK081796, R01DK080726, R01DK65664]; Centers for Diabetes Translation Research at Kaiser Permanente; University of California, San Francisco [P30 DK092924]; University of Chicago [P30 DK092949]; VA Puget Sound Health Care System, Seattle, WA; National Institutes of Health, NIDDK [DK079745] FX Dr Campbell is supported by a T. Franklin Williams Scholars Award. Funding was provided by Atlantic Philanthropies, Inc; the American Geriatrics Society Foundation for Health in Aging; the John A. Hartford Foundation; and the Association of Specialty Professors. The Diabetes and Aging Study was supported by funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK; grants R01DK081796, R01DK080726, and R01DK65664). Investigators also were supported by the Centers for Diabetes Translation Research at Kaiser Permanente and University of California, San Francisco (P30 DK092924) and the University of Chicago (P30 DK092949). The sponsors played no role in the design or interpretation of the study. Dr Young's contribution is supported by resources from the VA Puget Sound Health Care System, Seattle, WA, and by the National Institutes of Health, NIDDK (DK079745). None of the mentioned funders had input into the content of this manuscript and did not report any potential conflicts of interest relevant to this article. NR 36 TC 5 Z9 5 U1 1 U2 10 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD SEP PY 2013 VL 62 IS 3 BP 541 EP 548 DI 10.1053/j.ajkd.2013.03.039 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 212ZZ UT WOS:000324023700015 PM 23746376 ER PT J AU Shlipak, MG Mattes, MD Peralta, CA AF Shlipak, Michael G. Mattes, Monica D. Peralta, Carmen A. TI Update on Cystatin C: Incorporation Into Clinical Practice SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Review DE Cystatin C; glomerular filtration rate (GFR) estimation; chronic kidney disease ID GLOMERULAR-FILTRATION-RATE; CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; SERUM CREATININE; FUNCTION DECLINE; ELDERLY PERSONS; OLDER-ADULTS; RISK-FACTOR; US ADULTS; ALL-CAUSE AB Kidney function monitoring using creatinine-based glomerular filtration rate estimation is a routine part of clinical practice. Emerging evidence has shown that cystatin C may improve classification of glomerular filtration rate for defining chronic kidney disease in certain clinical populations and assist in understanding the complications of chronic kidney disease. In this review and update, we summarize the overall literature on cystatin C, critically evaluate recent high-impact studies, highlight the role of cystatin C in recent kidney disease guidelines, and suggest a practical approach for clinicians to incorporate cystatin C into practice. We conclude by addressing frequently asked questions related to implementing cystatin C use in a clinical setting. (C) 2013 by the National Kidney Foundation, Inc. C1 [Shlipak, Michael G.; Mattes, Monica D.; Peralta, Carmen A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Shlipak, Michael G.; Mattes, Monica D.; Peralta, Carmen A.] Univ Calif San Francisco, San Francisco, CA 94121 USA. RP Shlipak, MG (reprint author), Univ Calif San Francisco, Vet Affairs Med Ctr 111A1, 4150 Clement St, San Francisco, CA 94121 USA. EM michael.shlipak@ucsf.edu FU National Institute of Health (NIH)/National Institute on Aging [5R01AG034853-03, 5R01AG027002-06]; NIH/National Institute of Diabetes and Digestive and Kidney Diseases [1R01DK087961-01A1, K23 DK082793] FX Dr Shlipak was supported by National Institute of Health (NIH)/National Institute on Aging grants 5R01AG034853-03 and 5R01AG027002-06, and NIH/National Institute of Diabetes and Digestive and Kidney Diseases grant 1R01DK087961-01A1. Dr Peralta was supported by NIH/National Institute of Diabetes and Digestive and Kidney Diseases grant K23 DK082793. NR 52 TC 48 Z9 51 U1 4 U2 10 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD SEP PY 2013 VL 62 IS 3 BP 595 EP 603 DI 10.1053/j.ajkd.2013.03.027 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 212ZZ UT WOS:000324023700022 PM 23701892 ER PT J AU Baxter, SL Pistilli, M Pujari, SS Liesegang, TL Suhler, EB Thorne, JE Foster, CS Jabs, DA Levy-Clarke, GA Nussenblatt, RB Rosenbaum, JT Kempen, JH AF Baxter, Sally L. Pistilli, Maxwell Pujari, Siddharth S. Liesegang, Teresa L. Suhler, Eric B. Thorne, Jennifer E. Foster, C. Stephen Jabs, Douglas A. Levy-Clarke, Grace A. Nussenblatt, Robert B. Rosenbaum, James T. Kempen, John H. TI Risk of Choroidal Neovascularization among the Uveitides SO AMERICAN JOURNAL OF OPHTHALMOLOGY LA English DT Article ID PUNCTATE INNER CHOROIDOPATHY; INTRAVITREAL BEVACIZUMAB; MULTIFOCAL CHOROIDITIS; REGRESSION-ANALYSIS; DISEASES; VEGF; COMPLICATIONS; NOMENCLATURE; PANUVEITIS; SECONDARY AB PURPOSE: To evaluate the risk, risk factors, and visual impact of choroidal neovascularization (CNV) in uveitis cases. DESIGN: Retrospective cohort study. METHODS: Standardized medical record review at 5 tertiary centers. RESULTS: Among 15 137 uveitic eyes (8868 patients), CNV was rare in the cases of anterior or intermediate uveitis. Among the 4041 eyes (2307 patients) with posterior uveitis or panuveitis, 81(2.0%) had CNV at presentation. Risk factors included posterior uveitis in general and specific uveitis syndromes affecting the outer retina retinal pigment epithelium choroid interface. Among the 2364 eyes (1357 patients) with posterior uveitis or panuveitis and free of CNV at the time of cohort entry, the cumulative 2-year incidence of CNV was 2.7% (95% confidence interval [CI], 1.8% to 3.5%). Risk factors for incident CNV included currently active inflammation (adjusted hazard ratio [aHR], 2.13; 95% CI, 1.26 to 3.60), preretinal neovascularization (aHR, 3.19; 95% CI, 1.30 to 7.80), and prior diagnosis of CNV in the contralateral eye (aHR, 5.79; 95% CI, 2.77 to 12.09). Among specific syndromes, the incidence was greater in Vogt-Koyanagi-Harada syndrome (aHR, 3.37; 95% CI, 1.52 to 7.46) and punctate inner choroiditis (aHR, 8.67; 95% CI, 2.83 to 26.54). Incident CNV was associated with a 2-line loss of visual acuity (+0.19 logarithm of the minimal angle of resolution units; 95% CI, 0.079 to 0.29) from the preceding visit. CONCLUSIONS: CNV is an uncommon complication Of uveitis associated with visual impairment that occurs more commonly in forms affecting the outer retina retinal pigment epithelium choroid interface, during periods of inflammatory activity, in association with preretinal neovascularization, and in second eyes of patients with unilateral CNV. Because CNV is treatable, a systematic approach to early detection in high-risk patients may be appropriate. ((C) 2013 by Elsevier Inc. All rights reserved.) C1 [Baxter, Sally L.; Kempen, John H.] Univ Penn, Perelman Sch Med, Scheie Eye Inst, Philadelphia, PA 19104 USA. [Pistilli, Maxwell; Kempen, John H.] Univ Penn, Perelman Sch Med, Ctr Prevent Ophthalmol & Biostat, Dept Ophthalmol, Philadelphia, PA 19104 USA. [Pujari, Siddharth S.; Foster, C. Stephen] Massachusetts Eye Res & Surg Inst, Cambridge, MA USA. [Pujari, Siddharth S.] Vasan Eye Care Hosp, Belgaum, Karnataka, India. [Liesegang, Teresa L.; Suhler, Eric B.; Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97201 USA. [Suhler, Eric B.; Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA. [Thorne, Jennifer E.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA. [Thorne, Jennifer E.; Jabs, Douglas A.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Foster, C. Stephen] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. [Jabs, Douglas A.] Icahn Sch Med Mt Sinai, Dept Ophthalmol, New York, NY USA. [Jabs, Douglas A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY USA. [Levy-Clarke, Grace A.; Nussenblatt, Robert B.] NEI, Immunol Lab, Bethesda, MD 20892 USA. [Levy-Clarke, Grace A.] Johnson & Johnson, New Brunswick, NJ USA. [Rosenbaum, James T.] Legacy Hlth Syst, Devers Eye Inst, Portland, OR USA. [Kempen, John H.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. RP Kempen, JH (reprint author), Univ Penn, Dept Ophthalmol, Ctr Prevent Ophthalmol & Biostat, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA. EM john.kempen@uphs.upenn.edu OI Pistilli, Maxwell/0000-0002-4266-4150 FU Research to Prevent Blindness, Inc, New York, New York; Paul and Evanina Mackall Foundation; National Eye Institute; Department of Veterans' Affairs FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST and the following were reported. Jennifer E. Thome serves a consultant for Allergan and XOMA. C. Stephen Foster serves as a lecturer for Alcon, Inspire, Ista, and Centocor; as a Consultant for Sirion; as a consultant and lecturer for Allergan and Bausch & Lomb; and as an equity owner for EyeGate. Douglas A. Jabs serves a consultant for Abbott Laboratories, Alcon Laboratories, Allergan Pharmaceutical Corporation, Corcept Therapeutics, Genentech, Genzyme Corporation, GlaxoSmith Kline, and Roche Pharmaceuticals and is a member of the Data and Safety Monitoring Board for Applied Genetic Technologies Corporation and Novartis Pharmaceutical Corporation. Grace A. Levy-Clarke is employed by Johnson & Johnson Vision Care. James T. Rosenbaum serves or has served as a consultant for Abbott Laboratories, Amgen, Allergan, Genentech, Novartis, and UCB and has been involved in clinical trials for Abbott Laboratories, Genentech, Lux Biosciences, and Eyegate Pharma. John H. Kempen serves or has served as a consultant for Alcon, Allergan, Can-Fite, Clearside, Lux Biosciences, Sanofi-Pasteur, and Xoma. Supported primarily by Grant EY014943 from the National Eye Institute, National Institutes of Health, Bethesda, Maryland (J.H.K.). Additional support was provided by Research to Prevent Blindness, Inc, New York, New York, and the Paul and Evanina Mackall Foundation. Dr Kempen was a Research to Prevent Blindness James S Adams Special Scholar Award recipient, Dr Thome was a Research to Prevent Blindness Harrington Special Scholar Award recipient, and Drs Jabs and Rosenbaum were Research to Prevent Blindness Senior Scientific Investigator Award recipients during the course of the study. Dr Levy-Clarke was previously supported by and Dr Nussenblatt continues to be supported by intramural funds from the National Eye Institute. Dr Suhler receives support from the Department of Veterans' Affairs. None of the sponsors had any role in the design and conduct of the report; collection, management, analysis, and interpretation of the data; or in the preparation, review, and approval of this manuscript. Involved in Design and conduct of study (S.L.B., M.P., J.H.K.); Collection, management, analysis, and interpretation of data (all authors); Preparation of manuscript (S.L.B., M.P., J.H.K.); and review and approval of manuscript (all authors). NR 28 TC 16 Z9 16 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9394 J9 AM J OPHTHALMOL JI Am. J. Ophthalmol. PD SEP PY 2013 VL 156 IS 3 BP 468 EP 477 DI 10.1016/j.ajo.2013.04.040 PG 10 WC Ophthalmology SC Ophthalmology GA 214RM UT WOS:000324153500009 PM 23795984 ER PT J AU Khazim, K Gorin, Y Cavaglieri, RC Abboud, HE Fanti, P AF Khazim, Khaled Gorin, Yves Cavaglieri, Rita Cassia Abboud, Hanna E. Fanti, Paolo TI The antioxidant silybin prevents high glucose-induced oxidative stress and podocyte injury in vitro and in vivo SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE albuminuria; apoptosis; diabetic nephropathy; NADPH oxidase; phytochemicals ID TYPE-2 DIABETIC-NEPHROPATHY; NADPH OXIDASE ACTIVITY; STAGE RENAL-DISEASE; INDUCED NEPHROTOXICITY; SUPEROXIDE-PRODUCTION; SIGNALING PATHWAYS; OVERT NEPHROPATHY; KIDNEY-DISEASE; SILIBININ; SILYMARIN AB Podocyte injury, a major contributor to the pathogenesis of diabetic nephropathy, is caused at least in part by the excessive generation of reactive oxygen species (ROS). Overproduction of superoxide by the NADPH oxidase isoform Nox4 plays an important role in podocyte injury. The plant extract silymarin is attributed antioxidant and antiproteinuric effects in humans and in animal models of diabetic nephropathy. We investigated the effect of silybin, the active constituent of silymarin, in cultures of mouse podocytes and in the OVE26 mouse, a model of type 1 diabetes mellitus and diabetic nephropathy. Exposure of podocytes to high glucose (HG) increased 60% the intracellular superoxide production, 90% the NADPH oxidase activity, 100% the Nox4 expression, and 150% the number of apoptotic cells, effects that were completely blocked by 10 mu M silybin. These in vitro observations were confirmed by similar in vivo findings. The kidney cortex of vehicle-treated control OVE26 mice displayed greater Nox4 expression and twice as much superoxide production than cortex of silybin-treated mice. The glomeruli of control OVE26 mice displayed 35% podocyte drop out that was not present in the silybin-treated mice. Finally, the OVE26 mice experienced 54% more pronounced albuminuria than the silybin-treated animals. In conclusion, this study demonstrates a protective effect of silybin against HG-induced podocyte injury and extends this finding to an animal model of diabetic nephropathy. C1 [Abboud, Hanna E.; Fanti, Paolo] Audie L Murphy Mem Hosp Div, South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Khazim, Khaled; Gorin, Yves; Cavaglieri, Rita Cassia; Abboud, Hanna E.; Fanti, Paolo] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Khazim, Khaled] Western Galilee Hosp, Nephrol & Hypertens Unit, Nahariyya, Israel. RP Fanti, P (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol, Dept Med, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM fanti@uthscsa.edu FU National Center for Complementary and Alternative Medicine [AT-004490]; Merit Review Grant [1I01CX000264]; Juvenile Diabetes Research Foundation Multiproject Grants; National Institute of Diabetes and Digestive and Kidney Diseases [RO1 DK 079996]; American Physicians Fellowship for Medicine in Israel FX This work was supported in part through National Center for Complementary and Alternative Medicine Grant AT-004490 (P. Fanti), Merit Review Grant 1I01CX000264 (P. Fanti), Juvenile Diabetes Research Foundation Multiproject Grants (Y. Gorin and H. E. Abboud), National Institute of Diabetes and Digestive and Kidney Diseases Grant RO1 DK 079996 (Y. Gorin), and American Physicians Fellowship for Medicine in Israel (K. Khazim). NR 63 TC 28 Z9 30 U1 1 U2 13 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD SEP PY 2013 VL 305 IS 5 BP F691 EP F700 DI 10.1152/ajprenal.00028.2013 PG 10 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 214AA UT WOS:000324101000011 PM 23804455 ER PT J AU Friedman, MJ AF Friedman, Matthew J. TI Toward Rational Pharmacotherapy for Posttraumatic Stress Disorder: Reprise SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Editorial Material C1 [Friedman, Matthew J.] Geisel Sch Med Dartmouth, US Dept Vet Affairs, Natl Ctr PTSD, Hanover, NH 03755 USA. [Friedman, Matthew J.] Geisel Sch Med Dartmouth, Dept Psychiat, Hanover, NH USA. [Friedman, Matthew J.] Geisel Sch Med Dartmouth, Dept Pharmacol, Hanover, NH USA. [Friedman, Matthew J.] Geisel Sch Med Dartmouth, Dept Toxicol, Hanover, NH USA. RP Friedman, MJ (reprint author), Geisel Sch Med Dartmouth, US Dept Vet Affairs, Natl Ctr PTSD, Hanover, NH 03755 USA. EM matthew.j.friedman@dartmouth.edu NR 10 TC 4 Z9 4 U1 0 U2 4 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD SEP PY 2013 VL 170 IS 9 BP 944 EP 946 DI 10.1176/appi.ajp.2013.13060768 PG 3 WC Psychiatry SC Psychiatry GA 212VK UT WOS:000324010700003 PM 24030605 ER PT J AU Wortzel, HS AF Wortzel, Hal S. TI Clinical Manual of Neuropsychiatry SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Book Review C1 [Wortzel, Hal S.] Denver VA Med Ctr, Educ & Clin Ctr, VISN Mental Illness Res 19, Denver, CO USA. [Wortzel, Hal S.] Univ Colorado, Sch Med, Denver, CO USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD SEP PY 2013 VL 170 IS 9 BP 1063 EP 1064 DI 10.1176/appi.ajp.2013.13020193 PG 2 WC Psychiatry SC Psychiatry GA 212VK UT WOS:000324010700023 ER PT J AU Weathington, NM Sznajder, JI Mallampalli, RK AF Weathington, Nathaniel M. Sznajder, Jacob I. Mallampalli, Rama K. TI The Emerging Role of the Ubiquitin Proteasome in Pulmonary Biology and Disease SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE ubiquitin; proteasome; pulmonary disease; drug development; E3 ligase ID SURFACTANT PROTEIN-C; TRANSMEMBRANE CONDUCTANCE REGULATOR; ACUTE LUNG INJURY; NF-KAPPA-B; F-BOX PROTEINS; ALLOSTERIC INHIBITOR; MITOTIC ARREST; BETA-TRCP; DEGRADATION; LIGASE AB Derangements in normal cellular homeostasis at the protein level can cause or be the consequence of initiation and progression of pulmonary diseases related to genotype, infection, injury, smoking, toxin exposure, or neoplasm. We discuss one of the fundamental mechanisms of protein homeostasis, the ubiquitin proteasome system (UPS), as it relates to lung disease. The UPS effects selective degradation of ubiquitinated target proteins via ubiquitin ligase activity. Important pathobiological mechanisms relating to the UPS and lung disease have been the focus of research, with inappropriate cellular proteolysis now a validated therapeutic target. We review the contributions of this system in various lung diseases, and discuss the exciting area of UPS-targeting drug development for pulmonary disease. C1 [Weathington, Nathaniel M.; Mallampalli, Rama K.] Univ Pittsburgh, Acute Lung Injury Ctr Excellence Pulm Allergy & C, Dept Med, Pittsburgh, PA 15213 USA. [Sznajder, Jacob I.] Northwestern Univ, Chicago, IL 60611 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Dept Cell Biol & Physiol, Pittsburgh, PA USA. RP Mallampalli, RK (reprint author), Univ Pittsburgh, UPMC Montefiore, Dept Med, NW 628, Pittsburgh, PA 15213 USA. EM mallampallirk@upmc.edu FU U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; U.S. Department of Veterans Affairs; National Institutes of Health [HL096376, HL097376, HL098174, HL-R37-48129, HL-PO1-71643]; Department of Veterans Affairs, Veterans Health Administration, VA Pittsburgh Healthcare System FX The authors thank Bill Chen and Yutong Zhao for careful review of this manuscript. This material is based on work supported, in part, by the U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. This work was supported by a Merit Review Award from the U.S. Department of Veterans Affairs and National Institutes of Health R01 grants HL096376, HL097376, and HL098174 (to R. K. M.) and HL-R37-48129 and HL-PO1-71643 (to J.I.S.). N.M.W. is supported by a research fellowship through the U.S. Department of Veterans Affairs, Veterans Health Administration, VA Pittsburgh Healthcare System. NR 72 TC 13 Z9 14 U1 0 U2 8 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD SEP 1 PY 2013 VL 188 IS 5 BP 530 EP 537 DI 10.1164/rccm.201304-0754PP PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 214BU UT WOS:000324106200007 PM 23713962 ER PT J AU Shah, FA Pike, F Alvarez, K Angus, D Newman, AB Lopez, O Tate, J Kapur, V Wilsdon, A Krishnan, JA Hansel, N Au, D Avdalovic, M Fan, VS Barr, G Yende, S AF Shah, Faraaz Ali Pike, Francis Alvarez, Karina Angus, Derek Newman, Anne B. Lopez, Oscar Tate, Judith Kapur, Vishesh Wilsdon, Anthony Krishnan, Jerry A. Hansel, Nadia Au, David Avdalovic, Mark Fan, Vincent S. Barr, Graham Yende, Sachin TI Bidirectional Relationship between Cognitive Function and Pneumonia SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE pneumonia; dementia; cognitive function ID RESPIRATORY-DISTRESS-SYNDROME; COMMUNITY-ACQUIRED PNEUMONIA; LONG-TERM MORTALITY; INFLAMMATORY MARKERS; CARDIOVASCULAR HEALTH; CRITICAL ILLNESS; GLOBAL BURDEN; UNITED-STATES; SEVERE SEPSIS; OLDER-PEOPLE AB Rationale: Relationships between chronic health conditions and acute infections remain poorly understood. Preclinical studies suggest crosstalk between nervous and immune systems. Objectives: To determine bidirectional relationships between cognition and pneumonia. Methods: We conducted longitudinal analyses of a population-based cohort over 10 years. We determined whether changes in cognition increase risk of pneumonia hospitalization by trajectory analyses and joint modeling. We then determined whether pneumonia hospitalization increased risk of subsequent dementia using a Cox model with pneumonia as a time-varying covariate. Measurements and Main Results: Of the 5,888 participants, 639 (10.9%) were hospitalized with pneumonia at least once. Most participants had normal cognition before pneumonia. Three cognition trajectories were identified: no, minimal, and severe rapid decline. A greater proportion of participants hospitalized with pneumonia were on trajectories of minimal or severe decline before occurrence of pneumonia compared with those never hospitalized with pneumonia( proportion with no, minimal, and severe decline were 67.1%, 22.8%, and 10.0% vs. 76.0%, 19.3%, and 4.6% for participants with [GRAPHICS] and without pneumonia, respectively; P<0.001). Small subclinical changes in cognition increased risk of pneumonia, even in those with normal cognition and physical function before pneumonia (beta = -0.02; P < 0.001). Participants with pneumonia were subsequently at an increased risk of dementia (hazard ratio, 2.24 [95% confidence interval, 1.62-3.11]; P = 0.01). Associations were independent of demographics, health behaviors, other chronic conditions, and physical function. Bidirectional relationship did not vary based on severity of disease, and similar associations were noted for those with severe sepsis and other infections. Conclusions: A bidirectional relationship exists between pneumonia and cognition and may explain how a single episode of infection in well-appearing older individuals accelerates decline in chronic health conditions and loss of functional independence. C1 [Shah, Faraaz Ali] Univ Pittsburgh, Med Ctr, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15261 USA. [Pike, Francis; Alvarez, Karina; Angus, Derek; Tate, Judith; Yende, Sachin] Univ Pittsburgh, Clin Res Invest & Syst Modeling Acute Illness Ctr, Pittsburgh, PA 15261 USA. [Angus, Derek; Yende, Sachin] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15261 USA. [Newman, Anne B.] Univ Pittsburgh, Div Geriatr, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Lopez, Oscar] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15261 USA. [Kapur, Vishesh; Wilsdon, Anthony; Au, David; Fan, Vincent S.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. [Krishnan, Jerry A.] Univ Illinois, Sect Pulm Crit Care Sleep & Allergy, Chicago, IL USA. [Krishnan, Jerry A.] Univ Illinois Hosp & Hlth Sci Syst, Chicago, IL USA. [Hansel, Nadia] Johns Hopkins Univ, Div Pulm & Crit Care Med, Baltimore, MD USA. [Au, David; Fan, Vincent S.] VA Puget Sound, HSR&D, Seattle, WA USA. [Avdalovic, Mark] Univ Calif Davis, Div Pulm & Crit Care Med, Davis, CA USA. [Barr, Graham] Columbia Univ, Dept Med, Med Ctr, New York, NY USA. [Barr, Graham] Columbia Univ, Dept Epidemiol, Med Ctr, New York, NY USA. RP Yende, S (reprint author), Univ Pittsburgh, 606D Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. EM yendes@upmc.edu RI Kapur, Vishesh/K-1054-2014; Tate, Judith/C-7447-2015; Newman, Anne/C-6408-2013; Angus, Derek/E-9671-2012 OI Kapur, Vishesh/0000-0002-5417-1097; Newman, Anne/0000-0002-0106-1150; FU NHLBI [HL080295]; National Institute on Aging [AG-023629, AG-15928, AG-20098, AG-027058]; Department of Veterans Affairs; [HHSN268201200036C]; [HHSN268200800007C]; [N01-HC-85079]; [N01-HC-85080]; [N01-HC-85081]; [N01-HC-85082]; [N01-HC-85083]; [N01-HC-85084]; [N01-HC-85085]; [N01-HC-85086]; [N01-HC-35129]; [N01-HC-15103]; [N01-HC-55222]; [N01-HC-75150]; [N01-HC-45133]; [K23 GM083215]; [R01GM097471] FX Supported by contracts HHSN268201200036C, HHSN268200800007C, N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01-HC-15103, N01-HC-55222, N01-HC-75150, N01-HC-45133, and grant HL080295 from the NHLBI, with additional contribution from the National Institute of Neurological Disorders and Stroke. Additional support was provided through AG-023629, AG-15928, AG-20098, and AG-027058 from the National Institute on Aging. Dr. Au is funded through the Department of Veterans Affairs. A full list of principal CHS investigators and institutions can be found at http://www.chs-nhlbi.org/pi.htm. Dr. Yende is supported by K23 GM083215 and R01GM097471. NR 43 TC 39 Z9 39 U1 1 U2 5 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD SEP 1 PY 2013 VL 188 IS 5 BP 586 EP 592 DI 10.1164/rccm.201212-2154OC PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 214BU UT WOS:000324106200014 PM 23848267 ER PT J AU Johannesmeyer, D Smith, V Cole, DJ Esnaola, NF Camp, ER AF Johannesmeyer, David Smith, Valerie Cole, David J. Esnaola, Nestor F. Camp, E. Ramsay TI The impact of lymph node disease in extremity soft-tissue sarcomas: a population-based analysis SO AMERICAN JOURNAL OF SURGERY LA English DT Article DE Lymph node; Sarcoma; Extremity; Prognosis ID METASTASIS; EPIDEMIOLOGY; SURVEILLANCE; SURVIVAL; DATABASE; REGISTRY; BIOPSY AB BACKGROUND: Because of the low incidence of regional lymph node metastasis, node-positive soft-tissue sarcoma patients remain poorly characterized. Our objective was to assess regional lymph node metastasis in extremity sarcoma patients using a large population database. METHODS: The Surveillance, Epidemiology, and End Results database was queried for extremity sarcoma patients. Clinicopathologic data and outcomes were examined to evaluate the significance of regional lymph node metastasis. RESULTS: Of 7,159 patients without distant metastasis, 64 patients had identified regional lymph node metastasis (.9%). Regional lymph node metastasis was associated with younger age, tumor grade, size, invasion, and tumor subtype. Excluding distant metastasis, lymph node status was the strongest prognostic factor (hazards ratio = 5.1, P < .001). CONCLUSIONS: Isolated regional lymph node metastasis is rare in extremity sarcoma patients. However, in the absence of distant metastasis, lymph node status is the most important prognostic factor. The management of positive lymph nodes remains uncertain although diagnosing lymph node metastasis may identify early biologically aggressive disease. Published by Elsevier Inc. C1 [Camp, E. Ramsay] Med Univ S Carolina, Dept Surg, Div Surg Oncol, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. RP Camp, ER (reprint author), Med Univ S Carolina, Dept Surg, Div Surg Oncol, 25 Courtenay Dr, Charleston, SC 29425 USA. EM campe@musc.edu NR 19 TC 2 Z9 2 U1 0 U2 0 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9610 J9 AM J SURG JI Am. J. Surg. PD SEP PY 2013 VL 206 IS 3 BP 289 EP 295 DI 10.1016/j.amjsurg.2012.10.043 PG 7 WC Surgery SC Surgery GA 213YK UT WOS:000324096400001 PM 23806824 ER PT J AU Baker, RR AF Baker, Rodney R. TI Robert Spurlin Waldrop (1912-2012) OBITUARY SO AMERICAN PSYCHOLOGIST LA English DT Biographical-Item C1 [Baker, Rodney R.] Dept Vet Affairs, San Antonio, TX USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0003-066X J9 AM PSYCHOL JI Am. Psychol. PD SEP PY 2013 VL 68 IS 6 BP 473 EP 473 DI 10.1037/a0033585 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 217FP UT WOS:000324342800010 PM 24016122 ER PT J AU Carlozzi, NE Fyffe, D Morin, KG Byrne, R Tulsky, DS Victorson, D Lai, JS Wecht, JM AF Carlozzi, Noelle E. Fyffe, Denise Morin, Kel G. Byrne, Rachel Tulsky, David S. Victorson, David Lai, Jin-Shei Wecht, Jill M. TI Impact of Blood Pressure Dysregulation on Health-Related Quality of Life in Persons With Spinal Cord Injury: Development of a Conceptual Model SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article; Proceedings Paper CT Meeting of the Academy-of-Spinal-Cord-Injury-Professionals CY SEP 03-05, 2012 CL Las Vegas, NV SP Acad Spinal Cord Injury Profess DE Blood pressure; Outcome assessment (health care); Quality of life; Rehabilitation; Spinal cord injuries ID PATIENT-REPORTED OUTCOMES; CARDIOVASCULAR-DISEASE RISK; ORTHOSTATIC HYPOTENSION; AUTONOMIC DYSREFLEXIA; COGNITIVE PERFORMANCE; NEUROLOGICAL LEVEL; FUNCTIONAL INDEX; TETRAPLEGIA; PARAPLEGIA; ASSOCIATION AB Objectives: To identify medically relevant aspects of blood pressure dysregulation (BPD) related to quality of life in individuals with spinal cord injury (SCI), and to propose an integrated conceptual framework based on input from both individuals with SCI and their clinical providers. This framework will serve as a guide for the development of a patient-reported outcome (PRO) measure specifically related to BPD. Design: Three focus groups with individuals with SCI and 3 groups with SCI providers were analyzed using grounded-theory based qualitative analysis to ascertain how blood pressure impacts health-related quality of life (HRQOL) in individuals with SCI. Setting: Focus groups were conducted at 2 Veterans Affairs medical centers and a research center. Participants: Individuals with SCI (n=27) in 3 focus groups and clinical providers (n=25) in 3 focus groups. Interventions: Not applicable. Main Outcome Measures: Not applicable. Results: Qualitative analysis indicated that all focus groups spent the highest percentage of time discussing symptoms of BPD (39%), followed by precipitators/causes of BPD (16%), preventative actions (15%), corrective actions (12%), and the impact that BPD has on social or emotional functioning (8%). While patient/consumer focus groups and provider focus groups raised similar issues, providers spent more time discussing precipitators/causes of BPD and preventative actions (38%) than patient/consumer groups (24%). Conclusions: These results suggest that BPD uniquely and adversely impacts HRQOL in persons with SCI. While both individuals with SCI and their providers highlighted the relevant symptoms of BPD, the SCI providers offered additional detailed information regarding the precipitators/causes and what can be done to prevent/treat BPD. Further, the results suggest that persons with SCI are aware of how BPD impacts their HRQOL and are able to distinguish between subtle signs and symptoms. These findings exemplify the need for a validated and sensitive clinical measurement tool that can assess the extent to which BPD impacts HRQOL in patients with SCI. (C) 2013 by the American Congress of Rehabilitation Medicine C1 [Carlozzi, Noelle E.; Tulsky, David S.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA. [Fyffe, Denise; Byrne, Rachel] Kessler Fdn Res Ctr, Spinal Cord Injury Outcomes & Assessment Lab, W Orange, NJ USA. [Fyffe, Denise] Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, Newark, NJ 07103 USA. [Morin, Kel G.; Wecht, Jill M.] James J Peters Vet Affairs Med Ctr, Rehabil Res & Dev Serv, Bronx, NY USA. [Victorson, David; Lai, Jin-Shei] Northwestern Univ, Dept Med & Social Sci, Chicago, IL 60611 USA. [Wecht, Jill M.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Wecht, Jill M.] Mt Sinai Sch Med, New York, NY USA. RP Carlozzi, NE (reprint author), Univ Michigan, Ctr Rehabil Outcomes & Assessment Res, Dept Phys Med & Rehabil, North Campus Res Complex,2800 Plymouth Rd,Bldg NC, Ann Arbor, MI 48109 USA. EM carlozzi@med.umich.edu FU RRD VA [I01 RX000405] NR 58 TC 7 Z9 7 U1 1 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD SEP PY 2013 VL 94 IS 9 BP 1721 EP 1730 DI 10.1016/j.apmr.2013.02.024 PG 10 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 214QZ UT WOS:000324151900011 PM 23499779 ER PT J AU Yuan, KY Sun, Y Zhou, T McDonald, J Chen, YB AF Yuan, Kaiyu Sun, Yong Zhou, Tong McDonald, Jay Chen, Yabing TI PARP-1 Regulates Resistance of Pancreatic Cancer to TRAIL Therapy SO CLINICAL CANCER RESEARCH LA English DT Article ID LIGAND-INDUCED APOPTOSIS; FAS-MEDIATED APOPTOSIS; NF-KAPPA-B; POLY(ADP-RIBOSE) POLYMERASE; IN-VITRO; MONOCLONAL-ANTIBODY; INHIBITORY PROTEIN; DNA-DAMAGE; CELL-LINES; MECHANISMS AB Purpose: Activating extrinsic apoptotic pathways targeting death receptors (DR) using agonistic antibodies or TNF-related apoptosis-inducing ligand (TRAIL) is promising for cancer therapy. However, most pancreatic cancers are resistant to TRAIL therapy. The present studies aimed to identify combination therapies that enhance the efficacy of TRAIL therapy and to investigate the underlying mechanisms. Experimental Design: A xenograft model in nude mice was used to determine pancreatic cancer tumorigenesis and therapeutic efficacy of TRA-8, a monoclonal agonistic antibody for DR5. Pancreatic cancer cells were used to characterize mechanisms underlying PARP-1 regulation of TRA-8-induced apoptosis in vitro. Results: PARP-1 was found highly expressed in the TRA-8-resistant PANC-1 and Suit-2 cells, compared with TRA-8-sensitive BxPc-3 and MiaPaca-2. Inhibition of PARP-1 with a pharmacologic inhibitor sensitized PANC-1 and Suit2 cells to TRA-8-induced apoptosis in a dose-dependent manner. Furthermore, siRNAs specifically knocking down PARP-1 markedly enhanced TRA-8-induced apoptosis in vitro and augmented the efficacy of TRA-8 therapy on tumorigenesis in vivo. PARP-1 knockdown increased TRA-8-induced activation of caspase-8 in the death-induced signaling complex (DISC). Immunoprecipitation with DR5 antibody identified the recruitment of PARP-1 and PARP-1-mediated protein poly-ADP-ribosylation (pADPr) modification in the DR5-associated DISC. Further characterization revealed that PARP-1-mediated pADPr modification of caspase-8 inhibited caspase-8 activation, which may contribute to its function in regulating TRA-8 resistance. Conclusions: Our studies provide molecular insights into a novel function of PARP-1 in regulating the extrinsic apoptosis machinery and also support interventions combining PARP-1 inhibitors with DR agonists for pancreatic cancer therapy. (C)2013 AACR. C1 [Yuan, Kaiyu; Sun, Yong; McDonald, Jay; Chen, Yabing] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Zhou, Tong] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [McDonald, Jay; Chen, Yabing] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Chen, YB (reprint author), Univ Alabama Birmingham, Dept Pathol, 614 Shelby Res Bldg,1825 Univ Blvd, Birmingham, AL 35294 USA. EM ybchen@uab.edu FU UAB Department of Pathology; VA Merit Review Award; NIH [P50CA101955] FX This work was supported in part by UAB Department of Pathology start-up funds (to Y. Chen) and a VA Merit Review Award (to J.M. McDonald). T. Zhou was support by a NIH grant P50CA101955. NR 49 TC 22 Z9 22 U1 2 U2 11 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD SEP 1 PY 2013 VL 19 IS 17 BP 4750 EP 4759 DI 10.1158/1078-0432.CCR-13-0516 PG 10 WC Oncology SC Oncology GA 213ZE UT WOS:000324098400023 PM 23833311 ER PT J AU Brooks-Worrell, B Narla, R Palmer, JP AF Brooks-Worrell, B. Narla, R. Palmer, J. P. TI Islet autoimmunity in phenotypic type 2 diabetes patients SO DIABETES OBESITY & METABOLISM LA English DT Review DE autoimmune disease; autoimmunity; inflammation; islet-reactive T cells; T cells; type 1 diabetes; type 2 diabetes ID GLUTAMIC-ACID DECARBOXYLASE; T-CELL RESPONSES; INSULIN-RESISTANCE; CHRONIC INFLAMMATION; CLINICAL PHENOTYPE; ADULTS LADA; OLDER AGE; LATENT; ANTIBODIES; PROTEINS AB Historically, type 2 diabetes (T2D) was considered a metabolic disease of ageing. However, recent discoveries have demonstrated the role of chronic systemic inflammation in the development of insulin resistance and subsequent progression to T2D. Over the years, investigations into the pathophysiology of T2D have identified the presence of islet-specific T cells and islet autoimmune disease in T2D patients. Moreover, the cell-mediated islet autoimmunity has also been correlated with the progressive loss of beta-cell function associated with T2D disease pathogenesis. In this manuscript, the involvement of cell-mediated islet autoimmune disease in the progression of T2D disease and the similarities in islet-specific T-cell reactivity between type 1 diabetes (T1D) and T2D are discussed. C1 [Brooks-Worrell, B.; Palmer, J. P.] Univ Washington, Dept Med, Seattle, WA USA. [Narla, R.; Palmer, J. P.] VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98108 USA. RP Brooks-Worrell, B (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM bbrooks@u.washington.edu FU NIDDK NIH HHS [R01 DK083471, P30 DK017047] NR 34 TC 14 Z9 15 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1462-8902 J9 DIABETES OBES METAB JI Diabetes Obes. Metab. PD SEP PY 2013 VL 15 SU 3 SI SI BP 137 EP 140 DI 10.1111/dom.12167 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 211DV UT WOS:000323885900016 PM 24003930 ER PT J AU McMillan, GP Reavis, KM Konrad-Martin, D Dille, MF AF McMillan, Garnett P. Reavis, Kelly M. Konrad-Martin, Dawn Dille, Marilyn F. TI The Statistical Basis for Serial Monitoring in Audiology SO EAR AND HEARING LA English DT Article ID PRODUCT OTOACOUSTIC EMISSIONS; TEST-RETEST RELIABILITY; SAMPLE-SIZE; SOUND-LEVEL; CALIBRATION AB Objectives: Audiologists regularly use serial monitoring to evaluate changes in a patient's auditory function over time. Observed changes are compared with reference standards to determine whether further clinical action is necessary. Reference standards are established in a control sample of otherwise healthy subjects to identify the range of auditory shifts that one might reasonably expect to occur in the absence of any pathological insult. Statistical approaches to this seemingly mundane problem typically invoke 1 of 3 approaches: percentiles of the cumulative distribution, the variance of observed shifts, and the standard error of measurement. In this article, the authors describe the statistical foundation for these approaches, along with a mixed model-based alternative, and identify several necessary, although typically unacknowledged assumptions. Regression to the mean, the phenomenon of an unusual measurement typically followed by a more common one, can seriously bias observed changes in auditory function and clinical expectations. An approach that adjusts for this important effect is also described. Design: Distortion product otoacoustic emissions (DPOAEs) elicited at a single primary frequency, f(2) of 3175 Hz, were collected from 32 healthy subjects at baseline and 19 to 29 days later. Ninety percent test-retest reference limits were computed from these data using each statistical approach. DPOAE shifts were also collected from a sample of 18 cisplatin patients tested after 120 to 200mg of cisplatin. Reference limits established according to each of the statistical approaches in the healthy sample were used to identify clinically alarming DPOAE shifts in the cisplatin patient sample. Results: Reference limits established with any of the parametric methods were similar. The percentile-based approach gave the widest and least precisely estimated intervals. The highest sensitivity for detecting clinically alarming DPOAE shifts was based on a mixed model approach that adjusts for regression to the mean. Conclusions: Parametric methods give similar serial monitoring criteria as long as certain critical assumptions are met by the data. The most flexible method for estimating test-retest limits is based on the linear mixed model. Clinical sensitivity may be further enhanced by adjusting for regression to the mean. C1 [McMillan, Garnett P.; Reavis, Kelly M.; Konrad-Martin, Dawn; Dille, Marilyn F.] Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Vet Affairs Rehabil Res & Dev Serv VA RR&D, Portland, OR USA. [McMillan, Garnett P.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. [Konrad-Martin, Dawn; Dille, Marilyn F.] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA. RP McMillan, GP (reprint author), Portland VA Med Ctr, NCRAR, 3710 US Vet Hosp Rd P5, Portland, OR USA. EM garnett.mcmillan@va.gov OI Reavis, Kelly/0000-0002-4906-1010 FU Department of Veterans Affairs Rehabilitation Research and Development Service [C4183R, C7113N]; VA RR&D National Center for Rehabilitative Auditory Research, Portland, Oregon FX This work was supported by the Department of Veterans Affairs Rehabilitation Research and Development Service (grants C4183R and C7113N) and the VA RR&D National Center for Rehabilitative Auditory Research, Portland, Oregon. NR 22 TC 7 Z9 7 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0196-0202 J9 EAR HEARING JI Ear Hear. PD SEP PY 2013 VL 34 IS 5 BP 610 EP 618 DI 10.1097/AUD.0b013e31828a21b3 PG 9 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 213JL UT WOS:000324052800010 PM 23563060 ER PT J AU Wasterlain, CG Naylor, DE Liu, H Niquet, J Baldwin, R AF Wasterlain, Claude G. Naylor, David E. Liu, Hantao Niquet, Jerome Baldwin, Roger TI Trafficking of NMDA receptors during status epilepticus: Therapeutic implications SO EPILEPSIA LA English DT Article DE NMDA receptor; Receptor trafficking; Status epilepticus; Acute seizures; Cholinergic seizures; Epilepsy; Monotherapy; Hippocampus ID SUSTAINING STATUS EPILEPTICUS; EPILEPTOGENESIS; ANTAGONISTS AB We used two models of status epilepticus (SE) to study trafficking of N-methyl-d-aspartate (NMDA) receptors. SE is associated with increased surface expression of NR1 subunits of NMDA receptors, and with an increase of NMDA synaptic and extrasynaptic currents suggesting an increase in number of functional NMDA receptors on dentate granule cells. The therapeutic implications of these results are discussed. C1 [Wasterlain, Claude G.; Naylor, David E.; Liu, Hantao; Niquet, Jerome; Baldwin, Roger] Vet Adm Greater Los Angeles Healthcare Syst, Dept Neurol, West Los Angeles, CA USA. [Wasterlain, Claude G.; Naylor, David E.; Liu, Hantao; Niquet, Jerome] UCLA Brain Res Inst, West Los Angeles, CA USA. [Wasterlain, Claude G.] Univ Calif Los Angeles, David Geffen Sch Med, West Los Angeles, CA USA. [Naylor, David E.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, West Los Angeles, CA USA. RP Wasterlain, CG (reprint author), West LA VA Med Ctr, Dept Neurol 127, 11301 Wilshire Blvd, West Los Angeles, CA 90073 USA. EM wasterla@ucla.edu FU Research Service of the Veterans Health Administration; NINDS [NS13515, NS074926]; James and Debbie Cho Foundation; VHA (Career Development Award); Los Angeles Biomedical Research Institute FX Supported by the Research Service of the Veterans Health Administration (Merit Review C.W.), by NINDS (NS13515 and NS074926 to C.W.), by the James and Debbie Cho Foundation and by the VHA (Career Development Award to D.N.) and the Los Angeles Biomedical Research Institute (to D.N.). NR 13 TC 18 Z9 18 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PD SEP PY 2013 VL 54 SU 6 SI SI BP 78 EP 80 DI 10.1111/epi.12285 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 210JA UT WOS:000323826600023 PM 24001081 ER PT J AU Leung, FW AF Leung, Felix W. TI Water-aided Colonoscopy SO GASTROENTEROLOGY CLINICS OF NORTH AMERICA LA English DT Article DE Colonoscopy; Water-aided method; Discomfort; Pain; Adenoma detection rate; Water immersion; Water exchange ID UNSEDATED COLONOSCOPY; WARM WATER; SEDATED COLONOSCOPY; AIR INSUFFLATION; PATIENT TOLERANCE; CECAL INTUBATION; MINIMAL SEDATION; CONTROLLED-TRIAL; US VETERANS; INFUSION AB Water-aided methods for colonoscopy include the established water immersion and the recent novel modification of water exchange. Water immersion entails the use of water as an adjunct to air insufflations to facilitate insertion. Water exchange evolved from water immersion to facilitate completion of colonoscopy without discomfort in unsedated patients. Infused water is removed predominantly during insertion rather than withdrawal. A higher adenoma detection rate has been reported with water exchange. Aggregate data of randomized controlled trials suggest that water exchange may be superior to water immersion in attenuating colonoscopy discomfort and optimizing adenoma detection, particularly in the proximal colon. C1 [Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, Dept Med, Div Gastroenterol, North Hills, CA 91343 USA. [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Leung, FW (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, Dept Med, Div Gastroenterol, 111G,16111 Plummer St, North Hills, CA 91343 USA. EM felix.leung@va.gov FU Veterans Affairs Medical Research Funds at Veterans Affairs Greater Los Angeles Healthcare System; American College of Gastroenterology Clinical Research Award FX The study is supported in part by Veterans Affairs Medical Research Funds at Veterans Affairs Greater Los Angeles Healthcare System and an American College of Gastroenterology Clinical Research Award (FWL). NR 50 TC 5 Z9 5 U1 1 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8553 J9 GASTROENTEROL CLIN N JI Gastroenterol. Clin. North Am. PD SEP PY 2013 VL 42 IS 3 BP 507 EP + DI 10.1016/j.gtc.2013.05.006 PG 14 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 215PA UT WOS:000324221500007 PM 23931857 ER PT J AU Jayadev, S Bird, TD AF Jayadev, Suman Bird, Thomas D. TI Hereditary ataxias: overview SO GENETICS IN MEDICINE LA English DT Review DE ataxia; cerebellum; neurogenetics ID ONSET SPINOCEREBELLAR ATAXIA; RECESSIVE CEREBELLAR-ATAXIA; GENETICALLY DEFINED SUBTYPES; MARINESCO-SJOGREN-SYNDROME; OCULAR MOTOR APRAXIA; ADULT-ONSET; COENZYME-Q10 DEFICIENCY; POLYGLUTAMINE EXPANSIONS; TREMOR/ATAXIA SYNDROME; MOLECULAR DIAGNOSIS AB The hereditary ataxias are a highly heterogeneous group of disorders phenotypically characterized by gait ataxia, incoordination of eye movements, speech, and hand movements, and usually associated with atrophy of the cerebellum. There are more than 35 autosomal dominant types frequently termed spinocerebellar ataxia and typically having adult onset. The most common subtypes are spinocerebellar ataxia 1, 2, 3, 6, and 7, all of which are nucleotide repeat expansion disorders. Autosomal recessive ataxias usually have onset in childhood; the most common subtypes are Friedreich, ataxia-telangiectasia, ataxia with oculomotor apraxia type 1, and ataxia with oculomotor apraxia type 2. Four autosomal recessive types have dietary or biochemical treatment modalities (ataxia with vitamin E deficiency, cerebrotendinous xanthomatosis, Refsum, and coenzyme Q10 deficiency), whereas there are no specific treatments for other ataxias. Diagnostic genetic testing is complicated because of the large number of relatively uncommon subtypes with extensive phenotypic overlap. However, the best testing strategy is based on assessing relative frequencies, ethnic predilections, and recognition of associated phenotypic features such as seizures, visual loss, or associated movement abnormalities. C1 [Jayadev, Suman; Bird, Thomas D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Bird, Thomas D.] Univ Washington, Dept Med Med Genet, Seattle, WA 98195 USA. [Bird, Thomas D.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. RP Bird, TD (reprint author), Univ Washington, Dept Neurol, Seattle, WA 98195 USA. EM tomnroz@uw.edu FU Veterans Affairs Research; National Center for Biotechnology Information FX This study was supported by funding from Veterans Affairs Research and the National Center for Biotechnology Information. This overview represents a revised and updated version of Thomas D. Bird's Hereditary Ataxia in GeneReviews at GeneTests: Medical Genetics Information Resource (online resource). Copyright University of Washington, Seattle, Washington, 1998-2012. http://www.genetests.org. NR 80 TC 25 Z9 26 U1 3 U2 22 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 J9 GENET MED JI Genet. Med. PD SEP PY 2013 VL 15 IS 9 BP 673 EP 683 DI 10.1038/gim.2013.28 PG 11 WC Genetics & Heredity SC Genetics & Heredity GA 214XN UT WOS:000324172000002 PM 23538602 ER PT J AU Makarov, DV Loeb, S Ulmert, D Drevin, L Lambe, M Stattin, P AF Makarov, Danil V. Loeb, Stacy Ulmert, David Drevin, Linda Lambe, Mats Stattin, Par TI Prostate Cancer Imaging Trends After a Nationwide Effort to Discourage Inappropriate Prostate Cancer Imaging SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID STAGING EVALUATION; BONE-SCAN; APPROPRIATE; ANTIGEN; RISK; PREVALENCE; GUIDELINES; PARAMETERS; SURVIVAL; OVERUSE AB Background Reducing inappropriate use of imaging to stage incident prostate cancer is a challenging problem highlighted recently as a Physician Quality Reporting System quality measure and by the American Society of Clinical Oncology and the American Urological Association in the Choosing Wisely campaign. Since 2000, the National Prostate Cancer Register (NPCR) of Sweden has led an effort to decrease national rates of inappropriate prostate cancer imaging by disseminating utilization data along with the latest imaging guidelines to urologists in Sweden. We sought to determine the temporal and regional effects of this effort on prostate cancer imaging rates. Methods We performed a retrospective cohort study among men diagnosed with prostate cancer from the NPCR from 1998 to 2009 (n = 99 879). We analyzed imaging use over time stratified by clinical risk category (low, intermediate, high) and geographic region. Generalized linear models with a logit link were used to test for time trend. Results Thirty-six percent of men underwent imaging within 6 months of prostate cancer diagnosis. Overall, imaging use decreased over time, particularly in the low-risk category, among whom the imaging rate decreased from 45% to 3% (P < .001), but also in the high-risk category, among whom the rate decreased from 63% to 47% (P < .001). Despite substantial regional variation, all regions experienced clinically and statistically (P < .001) significant decreases in prostate cancer imaging. Conclusions A Swedish effort to provide data on prostate cancer imaging use and imaging guidelines to clinicians was associated with a reduction in inappropriate imaging over a 10-year period, as well as slightly decreased appropriate imaging in high-risk patients. These results may inform current efforts to promote guideline-concordant imaging in the United States and internationally. C1 [Makarov, Danil V.; Loeb, Stacy] US Dept Vet Affairs, New York, NY USA. [Makarov, Danil V.; Loeb, Stacy] NYU, Dept Urol, New York, NY USA. [Makarov, Danil V.; Loeb, Stacy] NYU, Dept Populat Hlth, New York, NY USA. [Makarov, Danil V.; Loeb, Stacy] NYU, Inst Canc, New York, NY USA. [Drevin, Linda; Lambe, Mats] Univ Uppsala Hosp, Reg Canc Ctr, Uppsala, Sweden. [Ulmert, David; Stattin, Par] Mem Sloan Kettering Canc Ctr, Dept Surg, Urol Serv, New York, NY 10021 USA. [Stattin, Par] Umea Univ, Dept Surg & Perioperat Sci Urol & Androl, SE-90187 Umea, Sweden. [Lambe, Mats] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden. RP Stattin, P (reprint author), Umea Univ, Dept Surg & Perioperat Sci Urol & Androl, SE-90187 Umea, Sweden. EM par.stattin@urologi.umu.se OI Lambe, Mats/0000-0002-4624-3767; Makarov, Danil/0000-0002-0565-9272; Loeb, Stacy/0000-0003-3933-9207 FU Swedish Research Council [825-2012-5047]; Swedish Cancer Foundation [11 0471]; United States Department of Veterans Affairs, Health Services Research and Development Service; Louis Feil Charitable Lead Trust FX This work was supported by the Swedish Research Council (825-2012-5047) and The Swedish Cancer Foundation (11 0471). SL and DVM (VA HSR&D CDA & CDP 11-257) are supported by the United States Department of Veterans Affairs, Health Services Research and Development Service and the Louis Feil Charitable Lead Trust. NR 32 TC 14 Z9 14 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 J9 JNCI-J NATL CANCER I JI JNCI-. Natl. Cancer Inst. PD SEP PY 2013 VL 105 IS 17 BP 1306 EP 1313 DI 10.1093/jnci/djt175 PG 8 WC Oncology SC Oncology GA 213EW UT WOS:000324038500011 PM 23853055 ER PT J AU Yarar-Fisher, C Bickel, CS Windham, ST McLain, AB Bamman, MM AF Yarar-Fisher, Ceren Bickel, C. Scott Windham, Samuel T. McLain, Amie B. Bamman, Marcas M. TI Skeletal muscle signaling associated with impaired glucose tolerance in spinal cord-injured men and the effects of contractile activity SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE spinal cord injury; skeletal muscle; glucose uptake signaling; neuromuscular electrical stimulation; resistance exercise ID ACTIVATED PROTEIN-KINASE; RESISTANCE EXERCISE; INSULIN SENSITIVITY; LIPID-METABOLISM; OLDER-ADULTS; MOLECULAR RESPONSES; AKT SUBSTRATE; TIME-COURSE; AMPK; PHOSPHORYLATION AB The mechanisms underlying poor glucose tolerance in persons with spinal cord injury (SCI), along with its improvement after several weeks of neuromuscular electrical stimulation-induced resistance exercise (NMES-RE) training, remain unclear, but presumably involve the affected skeletal musculature. We, therefore, investigated skeletal muscle signaling pathways associated with glucose transporter 4 (GLUT-4) translocation at rest and shortly after a single bout of NMES-RE in SCI (n = 12) vs. able-bodied (AB, n = 12) men. Subjects completed an oral glucose tolerance test during visit 1 and approximate to 90 NMES-RE isometric contractions of the quadriceps during visit 2. Muscle biopsies were collected before, and 10 and 60 min after, NMES-RE. We assessed transcript levels of GLUT-4 by quantitative PCR and protein levels of GLUT-4 and phosphorylated-and total AMP-activated protein kinase (AMPK)-alpha, CaMKII, Akt, and AS160 by immunoblotting. Impaired glucose tolerance in SCI was confirmed by higher (P < 0.05) plasma glucose concentrations than AB at all time points after glucose ingestion, despite equivalent insulin responses to the glucose load. GLUT-4 protein content was lower (P < 0.05) in SCI vs. AB at baseline. Main group effects revealed higher phosphorylation in SCI of AMPK-alpha, CaMKII, and Akt (P < 0.05), and Akt phosphorylation increased robustly (P < 0.05) following NMES-RE in SCI only. In SCI, low skeletal muscle GLUT-4 protein concentration may, in part, explain poor glucose tolerance, whereas heightened phosphorylation of relevant signaling proteins (AMPK-alpha, CaMKII) suggests a compensatory effort. Finally, it is encouraging to find (based on Akt) that SCI muscle remains both sensitive and responsive to mechanical loading (NMES-RE) even approximate to 22 yr after injury. C1 [Yarar-Fisher, Ceren; Bamman, Marcas M.] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL 35294 USA. [Bickel, C. Scott] Univ Alabama Birmingham, Dept Phys Therapy, Birmingham, AL 35294 USA. [Windham, Samuel T.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA. [McLain, Amie B.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL 35294 USA. [Yarar-Fisher, Ceren; Bickel, C. Scott; Windham, Samuel T.; McLain, Amie B.; Bamman, Marcas M.] Univ Alabama Birmingham, UAB Ctr Exercise Med, Birmingham, AL 35294 USA. [Bamman, Marcas M.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Bamman, MM (reprint author), Univ Alabama Birmingham, UAB Ctr Exercise Med, 966 McCallum Basic Hlth Sci Bldg,1720 2nd Ave Sou, Birmingham, AL 35294 USA. EM mbamman@uab.edu FU VA Merit Award; University of Alabama Birmingham (UAB) Center for Exercise Medicine, Department of Physical Medicine and Rehabilitation [5T32 DK-62710]; UAB Center for Clinical and Translational Science [UL1 TR000165] FX This work was supported by VA Merit Award (M. M. Bamman), University of Alabama Birmingham (UAB) Center for Exercise Medicine, Department of Physical Medicine and Rehabilitation, 5T32 DK-62710, and the UAB Center for Clinical and Translational Science (UL1 TR000165). NR 52 TC 3 Z9 3 U1 0 U2 6 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD SEP PY 2013 VL 115 IS 5 BP 756 EP 764 DI 10.1152/japplphysiol.00122.2013 PG 9 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 212YZ UT WOS:000324020600023 PM 23766505 ER PT J AU Lin, AL Zheng, W Halloran, JJ Burbank, RR Hussong, SA Hart, MJ Javors, M Shih, YYI Muir, E Fonseca, RS Strong, R Richardson, AG Lechleiter, JD Fox, PT Galvan, V AF Lin, Ai-Ling Zheng, Wei Halloran, Jonathan J. Burbank, Raquel R. Hussong, Stacy A. Hart, Matthew J. Javors, Martin Shih, Yen-Yu Ian Muir, Eric Fonseca, Rene Solano Strong, Randy Richardson, Arlan G. Lechleiter, James D. Fox, Peter T. Galvan, Veronica TI Chronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer's disease SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE age-associated; Alzheimer's disease; cerebral amyloid angiopathy; nitric oxide synthase; rapamycin; target-of-rapamycin (TOR); vascular dysfunction ID CEREBRAL AMYLOID ANGIOPATHY; GENETICALLY HETEROGENEOUS MICE; SIROLIMUS-ELUTING STENTS; EXTENDS LIFE-SPAN; TRANSGENIC MICE; MAMMALIAN TARGET; COGNITIVE DEFICITS; PLAQUE-FORMATION; BETA CLEARANCE; MOUSE MODEL AB Vascular pathology is a major feature of Alzheimer's disease (AD) and other dementias. We recently showed that chronic administration of the target-of-rapamycin (TOR) inhibitor rapamycin, which extends lifespan and delays aging, halts the progression of AD-like disease in transgenic human (h) APP mice modeling AD when administered before disease onset. Here we demonstrate that chronic reduction of TOR activity by rapamycin treatment started after disease onset restored cerebral blood flow (CBF) and brain vascular density, reduced cerebral amyloid angiopathy and microhemorrhages, decreased amyloid burden, and improved cognitive function in symptomatic hAPP (AD) mice. Like acetylcholine (ACh), a potent vasodilator, acute rapamycin treatment induced the phosphorylation of endothelial nitric oxide (NO) synthase (eNOS) and NO release in brain endothelium. Administration of the NOS inhibitor L-NG-Nitroarginine methyl ester reversed vasodilation as well as the protective effects of rapamycin on CBF and vasculature integrity, indicating that rapamycin preserves vascular density and CBF in AD mouse brains through NOS activation. Taken together, our data suggest that chronic reduction of TOR activity by rapamycin blocked the progression of AD-like cognitive and histopathological deficits by preserving brain vascular integrity and function. Drugs that inhibit the TOR pathway may have promise as a therapy for AD and possibly for vascular dementias. C1 [Lin, Ai-Ling; Muir, Eric; Fox, Peter T.] Res Imaging Inst, San Antonio, TX USA. [Zheng, Wei; Richardson, Arlan G.; Lechleiter, James D.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78245 USA. [Halloran, Jonathan J.; Burbank, Raquel R.; Hussong, Stacy A.; Fonseca, Rene Solano; Galvan, Veronica] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78245 USA. [Halloran, Jonathan J.; Burbank, Raquel R.; Hussong, Stacy A.; Hart, Matthew J.; Fonseca, Rene Solano; Strong, Randy; Richardson, Arlan G.; Galvan, Veronica] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. [Hart, Matthew J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78245 USA. [Javors, Martin] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78245 USA. [Shih, Yen-Yu Ian] Univ N Carolina, Dept Neurol, Chapel Hill, NC USA. [Shih, Yen-Yu Ian] Univ N Carolina, Biomed Res Imaging Ctr, Chapel Hill, NC USA. [Strong, Randy; Richardson, Arlan G.] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. [Strong, Randy; Richardson, Arlan G.] South Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX USA. [Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78245 USA. RP Galvan, V (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, 15355 Lambda Dr, San Antonio, TX 78245 USA. EM galvanv@uthscsa.edu RI Fox, Peter/B-4725-2010 OI Fox, Peter/0000-0002-0465-2028; Shih, Yen-Yu Ian/0000-0001-6529-911X FU Ellison Medical Foundation; William & Ella Owens Medical Research Foundation; UTHSCSA University Research Council; UTHSCSA Institute for Integration of Medicine and Science; NIA Interventions Testing Center [U01AG022307]; NIH [RC2AG036613]; NIA [5T32AG021890]; UTHSCSA; CTRC at UTHSCSA [NIH-NCI P30 CA54174]; San Antonio Nathan Shock Aging Center [P30AG-13319]; Neurodegeneration Research Center (REAP) from the Research and Development Service of the Department of Veterans Affairs FX This work was supported by an Ellison Medical Foundation New Scholar Award in Aging, a William & Ella Owens Medical Research Foundation Grant and a UTHSCSA University Research Council Award to VG, an UTHSCSA Institute for Integration of Medicine and Science Award to ALL, the NIA Interventions Testing Center (U01AG022307) to RS, RC2AG036613 NIH Recovery Act Grand Opportunities "GO'' grant to AR, and by 5T32AG021890 NIA Biology of Aging Training Grant Fellowship to SH. Images were generated in the Core Optical Imaging Facility, which is supported by UTHSCSA and NIH-NCI P30 CA54174 (CTRC at UTHSCSA). We recognize the support of the San Antonio Nathan Shock Aging Center (P30AG-13319, AR) and the VA Neurodegeneration Research Center (REAP) from the Research and Development Service of the Department of Veterans Affairs to AR and RS. NR 68 TC 42 Z9 43 U1 1 U2 12 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0271-678X J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD SEP PY 2013 VL 33 IS 9 BP 1412 EP 1421 DI 10.1038/jcbfm.2013.82 PG 10 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA 214IQ UT WOS:000324126400013 PM 23801246 ER PT J AU Pu, HJ Guo, YL Zhang, WT Huang, LT Wang, GH Liou, AK Zhang, J Zhang, PY Leak, RK Wang, Y Chen, J Gao, YQ AF Pu, Hongjian Guo, Yanling Zhang, Wenting Huang, Lanting Wang, Guohua Liou, Anthony K. Zhang, Jia Zhang, Pengyue Leak, Rehana K. Wang, Yun Chen, Jun Gao, Yanqin TI Omega-3 polyunsaturated fatty acid supplementation improves neurologic recovery and attenuates white matter injury after experimental traumatic brain injury SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE behavior (rodent); brain trauma; inflammation; neurodegeneration; white matter/oligodendrocytes ID SPINAL-CORD-INJURY; DOCOSAHEXAENOIC ACID; PARKINSONS-DISEASE; MODEL; RAT; OMEGA-3-FATTY-ACIDS; EXCITOTOXICITY; MECHANISMS; GLUTAMATE; VULNERABILITY AB Dietary supplementation with omega-3 (omega-3) fatty acids is a safe, economical mean of preventive medicine that has shown protection against several neurologic disorders. The present study tested the hypothesis that this method is protective against controlled cortical impact (CCI). Indeed, mice fed with omega-3 polyunsaturated fatty acid (PUFA)-enriched diet for 2 months exhibited attenuated short and long-term behavioral deficits due to CCI. Although omega-3 PUFAs did not decrease cortical lesion volume, these fatty acids did protect against hippocampal neuronal loss after CCI and reduced pro-inflammatory response. Interestingly, omega-3 PUFAs prevented the loss of myelin basic protein (MPB), preserved the integrity of the myelin sheath, and maintained the nerve fiber conductivity in the CCI model. omega-3 PUFAs also directly protected oligodendrocyte cultures from excitotoxicity and blunted the microglial activation-induced death of oligodendrocytes in microglia/oligodendrocyte cocultures. In sum, omega-3 PUFAs elicit multifaceted protection against behavioral dysfunction, hippocampal neuronal loss, inflammation, and loss of myelination and impulse conductivity. The present report is the first demonstration that omega-3 PUFAs protect against white matter injury in vivo and in vitro. The protective impact of omega-3 PUFAs supports the clinical use of this dietary supplement as a prophylaxis against traumatic brain injury and other nervous system disorders. C1 [Pu, Hongjian; Guo, Yanling; Zhang, Wenting; Huang, Lanting; Wang, Guohua; Zhang, Jia; Zhang, Pengyue; Wang, Yun; Chen, Jun; Gao, Yanqin] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China. [Pu, Hongjian; Guo, Yanling; Zhang, Wenting; Huang, Lanting; Wang, Guohua; Zhang, Jia; Zhang, Pengyue; Wang, Yun; Chen, Jun; Gao, Yanqin] Fudan Univ, Inst Brain Sci, Shanghai 200032, Peoples R China. [Liou, Anthony K.; Chen, Jun; Gao, Yanqin] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Liou, Anthony K.; Chen, Jun; Gao, Yanqin] Univ Pittsburgh, Ctr Cerebrovasc Dis Res, Pittsburgh, PA USA. [Liou, Anthony K.; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Leak, Rehana K.] Duquesne Univ, Mylan Sch Pharm, Div Pharmaceut Sci, Pittsburgh, PA 15219 USA. RP Gao, YQ (reprint author), Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China. EM chenj2@upmc.edu; yqgao@shmu.edu.cn RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819; Leak, Rehana/0000-0003-2817-7417 FU Chinese Ministry of Science and Technology; National Institutes of Health/NINDS [NS36736, NS43802, NS45048, NS056118]; Chinese Natural Science Foundation [30870794, 81020108021, 81171149, 81150110494, 81000497]; VA Research Career Scientist Award; VA Merit Review grant; UPMC FX This research is supported in part by the Special Research Funds from Chinese Ministry of Science and Technology to State Key laboratories (to YG and JC), National Institutes of Health/NINDS grants NS36736, NS43802, NS45048 and NS056118 (to JC), and Chinese Natural Science Foundation grants No 30870794, No 81020108021, No 81171149, No 81150110494, and No 81000497 (to YG). JC is a recipient of the VA Research Career Scientist Award, VA Merit Review grant, and the RK Mellon Endowed Chair from UPMC. NR 40 TC 25 Z9 26 U1 2 U2 24 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0271-678X J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD SEP PY 2013 VL 33 IS 9 BP 1474 EP 1484 DI 10.1038/jcbfm.2013.108 PG 11 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA 214IQ UT WOS:000324126400020 PM 23801244 ER PT J AU Sacks, HS Fain, JN Bahouth, SW Ojha, S Frontini, A Budge, H Cinti, S Symonds, ME AF Sacks, Harold S. Fain, John N. Bahouth, Suleiman W. Ojha, Shalini Frontini, Andrea Budge, Helen Cinti, Saverio Symonds, Michael E. TI Adult Epicardial Fat Exhibits Beige Features SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID BROWN ADIPOSE-TISSUE; WHITE ADIPOCYTES; COLD-EXPOSURE; PPAR-GAMMA; OBESITY; EXPRESSION; DISTINCT; HUMANS; MOUSE; IDENTIFICATION AB Context: Human epicardial fat has been designated previously as brown-like fat. The supraclavicular fat depot in man has been defined as beige coexistent with classical brown based on its gene expression profile. Objective: The aim of the study was to establish the gene expression profile and morphology of human epicardial and visceral paracardial fat compared with sc fat. Setting: The study was conducted at a tertiary care hospital cardiac center. Patients: Epicardial, visceral paracardial, and sc fat samples had been taken from middle-aged patients with severe coronary atherosclerosis or valvular heart disease. Interventions: Gene expression was determined by reverse transcription-quantitative PCR and relative abundance of the mitochondrial uncoupling protein-1 (UCP-1) by Western blotting. Epicardial tissue sections from patients were examined by light microscopy, UCP-1 immunohistochemistry, and cell morphometry. Main Outcome Measures: We hypothesized that epicardial fat has a mixed phenotype with a gene expression profile similar to that described for beige cell lineage. Results: Immunoreactive UCP-1 was clearly measurable in each epicardial sample analyzed but was undetectable in each of the 4 other visceral and sc depots. Epicardial fat exhibited high expression of genes for UCP-1, PRDM16, PGC-1 alpha, PPAR gamma, and the beige adipocyte-specific marker CD137, which were also expressed in visceral paracardial fat but only weakly in sternal, upper abdominal, and lower extremity sc fat. Histology of epicardial fat showed small unilocular adipocytes without UCP-1 immunostaining. Conclusion: UCP-1 is relatively abundant in epicardial fat, and this depot possesses molecular features characteristic of those found in vitro in beige lineage adipocytes. C1 [Sacks, Harold S.] VA Greater Angeles Healthcare Syst, Endocrinol & Diabet Div, Los Angeles, CA 90073 USA. [Sacks, Harold S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Fain, John N.] Univ Tennessee, Hlth Sci Ctr, Coll Med, Dept Microbiol Immunol & Biochem, Memphis, TN 38163 USA. [Bahouth, Suleiman W.] Univ Tennessee, Hlth Sci Ctr, Coll Med, Dept Pharmacol, Memphis, TN 38163 USA. [Ojha, Shalini; Budge, Helen; Symonds, Michael E.] Univ Nottingham Hosp, Sch Clin Sci, Acad Div Child Hlth, Early Life Nutr Res Unit, Nottingham NG7 2UH, England. [Frontini, Andrea; Cinti, Saverio] Univ Ancona, United Hosp, Politecn Marche,Obes Ctr, Dept Expt & Clin Med, I-60020 Ancona, Italy. RP Sacks, HS (reprint author), VA Greater Angeles Healthcare Syst, Endocrinol & Diabet Div 111D,11310 Wilshire Blvd, Los Angeles, CA 90073 USA. EM hsacks@hotmail.com OI Ojha, Shalini/0000-0001-5668-4227; Symonds, Michael/0000-0001-9649-8963 FU European Union FP7 Project DIABAT [HEALTH F2-2011-278373]; Cardiometabolic Disease Research Foundation, Los Angeles, California FX This work was supported by European Union FP7 Project DIABAT (HEALTH F2-2011-278373) (to S.C.), and the Cardiometabolic Disease Research Foundation, Los Angeles, California (to H.S.). NR 41 TC 30 Z9 34 U1 2 U2 11 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD SEP PY 2013 VL 98 IS 9 BP E1448 EP E1455 DI 10.1210/jc.2013-1265 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 214YJ UT WOS:000324175200002 PM 23824424 ER PT J AU Del Rossi, G Rechtine, GR Conrad, BP Horodyski, M AF Del Rossi, Gianluca Rechtine, Glenn R. Conrad, Bryan P. Horodyski, MaryBeth TI IS SUB-OCCIPITAL PADDING NECESSARY TO MAINTAIN OPTIMAL ALIGNMENT OF THE UNSTABLE SPINE IN THE PREHOSPITAL SETTING? A PRELIMINARY REPORT SO JOURNAL OF EMERGENCY MEDICINE LA English DT Article DE prehospital care; spinal immobilization; cervical spine ID CERVICAL-SPINE; ANKYLOSING-SPONDYLITIS; IMMOBILIZATION; POSITION; INTACT; INJURY; MODEL AB Background: As prehospital emergency rescuers prepare cervical spine-injured adult patients for immobilization and transport to hospital, it is essential that patients be placed in a favorable position. Previously, it was recommended that patients with cervical spine injuries be immobilized in a slightly flexed position using pads placed beneath the head. However, it is unknown how neck flexion created with pad placement affects the unstable spine. Objective: To determine the effects of three different head positions on the alignment of unstable vertebral segments. Methods: Five cadavers with a complete segmental instability at the C5 and C6 level were included in the study. The head was either placed directly on the ground (or spine board) or on foam pads. Three conditions were tested: no pad; pads 2.84 cm thick; and pads 4.26 cm thick. Pads were positioned beneath the head to determine their effect on spinal alignment. Anterior-posterior translation, flexion-extension motion, and axial displacement across the unstable segment were compared between conditions. Results: Although statistical tests failed to identify any significant differences between pad conditions, some meaningful results were noted. In general, the "no pad" condition aligned the spine in a position that best replicated the intact spine. Conclusions: Because the goal of emergency rescuers is to conserve whatever physiologic or structural integrity of the spinal cord and spinal column that remains, the outcome of this study suggests that this goal may be best achieved using the "no pad" condition. However, it is recommended that more research be conducted to confirm these preliminary findings. (C) 2013 Elsevier Inc. C1 [Del Rossi, Gianluca] Univ S Florida, Dept Orthopaed & Sports Med, Tampa, FL 33612 USA. [Rechtine, Glenn R.] US Dept Vet Affairs, St Petersburg, FL USA. [Conrad, Bryan P.; Horodyski, MaryBeth] Univ Florida, Dept Orthopaed & Rehabil, Gainesville, FL USA. RP Del Rossi, G (reprint author), Univ S Florida, Dept Orthopaed & Sports Med, 13220 USF Laurel Dr,MDF 5111,Mail Code MDC106, Tampa, FL 33612 USA. NR 16 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0736-4679 J9 J EMERG MED JI J. Emerg. Med. PD SEP PY 2013 VL 45 IS 3 BP 366 EP 370 DI 10.1016/j.jemermed.2013.01.042 PG 5 WC Emergency Medicine SC Emergency Medicine GA 213IC UT WOS:000324048400022 PM 23849357 ER PT J AU Douglas, VC Hessler, CS Dhaliwal, G Betjemann, JP Fukuda, KA Alameddine, LR Lucatorto, R Johnston, SC Josephson, SA AF Douglas, Vanja C. Hessler, Christine S. Dhaliwal, Gurpreet Betjemann, John P. Fukuda, Keiko A. Alameddine, Lama R. Lucatorto, Rachael Johnston, S. Claiborne Josephson, S. Andrew TI The AWOL tool: Derivation and validation of a delirium prediction rule SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article ID INTENSIVE-CARE PATIENTS; OLDER PATIENTS; MEDICAL INPATIENTS; CLINICAL JUDGMENT; MINI-COG; OUTCOMES; MODEL; SURGERY; DEMENTIA; ILLNESS AB BACKGROUND: Risk factors for delirium are well-described, yet there is no widely used tool to predict the development of delirium upon admission in hospitalized medical patients. OBJECTIVE: To develop and validate a tool to predict the likelihood of developing delirium during hospitalization. DESIGN: Prospective cohort study with derivation (May 2010-November 2010) and validation (October 2011-March 2012) cohorts. SETTING: Two academic medical centers and 1 Veterans Affairs medical center. PATIENTS: Consecutive medical inpatients (209 in the derivation and 165 in the validation cohort) over age 50 years without delirium at the time of admission. MEASUREMENTS: Delirium assessed daily for up to 6 days using the Confusion Assessment Method. RESULTS: The AWOL prediction rule was derived by assigning 1 point to each of 4 items assessed upon enrollment that were independently associated with the development of delirium (Age80 years, failure to spell World backward, disOrientation to place, and higher nurse-rated iLlness severity). Higher scores were associated with higher rates of delirium in the derivation and validation cohorts (P for trend<0.001 and 0.025, respectively). Rates of delirium according to score in the combined population were: 0(1/50, 2%), 1(5/141, 4%), 2(15/107, 14%), 3(10/50, 20%), and 4(7/11, 64%) (P for trend<0.001). Area under the receiver operating characteristic curve for the derivation and validation cohorts was 0.81 (0.73-0.90) and 0.69 (0.54-0.83) respectively. CONCLUSIONS: The AWOL prediction rule characterizes medical patients' risk for delirium at the time of hospital admission and could be used for clinical stratification and in trials of delirium prevention. Journal of Hospital Medicine 2013;8:493-499. (c) 2013 Society of Hospital Medicine C1 [Douglas, Vanja C.; Hessler, Christine S.; Betjemann, John P.; Fukuda, Keiko A.; Alameddine, Lama R.; Johnston, S. Claiborne; Josephson, S. Andrew] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Dhaliwal, Gurpreet; Lucatorto, Rachael] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Dhaliwal, Gurpreet; Lucatorto, Rachael] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA. [Alameddine, Lama R.] San Francisco VA Med Ctr, Dept Psychol, San Francisco, CA USA. [Johnston, S. Claiborne] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Douglas, VC (reprint author), UCSF Dept Neurol, Parnassus Ave,M798,San Francisco, San Francisco, CA 94143 USA. EM Vanja.Douglas@ucsf.edu FU University of California, San Francisco FX The following University of California, San Francisco neurology residents provided follow-up of study subjects on weekends and were financially compensated: Amar Dhand, MD, DPhil; Tim West, MD; Sarah Shalev, MD; Karen DaSilva, MD; Mark Burish, MD, PhD; Maggie Waung, MD, PhD; Raquel Gardner, MD; Molly Burnett, MD; Adam Ziemann, MD, PhD; Kathryn Kvam, MD; Neel Singhal, MD, PhD; James Orengo, MD, PhD; Kelly Mills, MD; and Joanna Hellmuth, MD, MHS. The authors are grateful to Dr. Douglas Bauer for assisting with the study design. NR 41 TC 6 Z9 7 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 J9 J HOSP MED JI J. Hosp. Med. PD SEP PY 2013 VL 8 IS 9 BP 493 EP 499 DI 10.1002/jhm.2062 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 212ZL UT WOS:000324022200003 PM 23922253 ER PT J AU Reddy, AT Lakshmi, SP Dornadula, S Pinni, S Rampa, DR Reddy, RC AF Reddy, Aravind T. Lakshmi, Sowmya P. Dornadula, Sireesh Pinni, Sudheer Rampa, Dileep R. Reddy, Raju C. TI The Nitrated Fatty Acid 10-Nitro-Oleate Attenuates Allergic Airway Disease SO JOURNAL OF IMMUNOLOGY LA English DT Article ID ACTIVATED-RECEPTOR-GAMMA; KAPPA-B KINASE; PPAR-GAMMA; SEVERE ASTHMA; ALVEOLAR MACROPHAGES; MURINE MODEL; HUMAN NEUTROPHILS; INFLAMMATION; CORTICOSTEROIDS; INHIBITION AB Asthma is a serious, growing problem worldwide. Inhaled steroids, the current standard therapy, are not always effective in this chronic inflammatory disease and can cause adverse effects. We tested the hypothesis that nitrated fatty acids (NFAs) may provide an effective alternative treatment. NFAs are endogenously produced by nonenzymatic reaction of NO with unsaturated fatty acids and exert anti-inflammatory actions both by activating the nuclear hormone receptor peroxisome proliferator-activated receptor (PPAR)gamma and via PPAR-independent mechanisms, but whether they might ameliorate allergic airway disease was previously untested. We found that pulmonary delivery of the NFA 10-nitro-oleic acid (OA-NO2) reduced the severity of murine allergic airway disease, as assessed by various pathological and molecular markers. Fluticasone, an inhaled steroid commonly used to treat asthma, produced similar effects on most end points, but only OA-NO2 induced robust apoptosis of neutrophils and their phagocytosis by alveolar macrophages. This suggests that OA-NO2 may be particularly effective in neutrophil-rich, steroid-resistant severe asthma. In primary human bronchial epithelial cells, OA-NO2 blocked phosphorylation and degradation of I kappa B and enhanced inhibitory binding of PPAR gamma to NF-kappa B. Our results indicate that the NFA OA-NO2 is efficacious in preclinical models of allergic airway disease and may have potential for treating asthma patients. C1 Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Dept Med, Sch Med, Pittsburgh, PA 15213 USA. Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. RP Reddy, RC (reprint author), Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. EM reddyrc@upmc.edu FU National Institutes of Health [HL093196] FX This work was supported by National Institutes of Health Grant HL093196 (to R.C.R.). NR 46 TC 16 Z9 16 U1 0 U2 2 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD SEP 1 PY 2013 VL 191 IS 5 BP 2053 EP 2063 DI 10.4049/jimmunol.1300730 PG 11 WC Immunology SC Immunology GA 204TU UT WOS:000323393300005 PM 23913958 ER PT J AU McMahan, RD Knight, SJ Fried, TR Sudore, RL AF McMahan, Ryan D. Knight, Sara J. Fried, Terri R. Sudore, Rebecca L. TI Advance Care Planning Beyond Advance Directives: Perspectives From Patients and Surrogates SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Advance directives; decision making; aging; qualitative research ID LIFE DECISION-MAKING; OF-LIFE; MEDICAL-CARE; LIVING WILL; HEALTH; DEATH; PREFERENCES; DISAGREE; FAMILY; OTHERS AB Context. Advance care planning (ACP) has focused on documenting life-sustaining treatment preferences in advance directives (ADs). The ADs alone may be insufficient to prepare diverse patients and surrogates for complex medical decisions. Objectives. To understand what steps best prepare patients and surrogates for decision making. Methods. We conducted 13 English/Spanish focus groups with participants from a Veterans Affairs and county hospital and the community. Seven groups included patients (n = 38), aged >= 65 years, who reported making serious medical decisions. Six separate groups included surrogates (n = 31), aged >= 18 years, who made decisions for others. Semistructured focus groups asked what activities best prepared the participants for decision making. Two investigators independently coded data and performed thematic content analysis. Disputes were resolved by consensus. Results. The mean +/- SD patient age was 78 +/- 8 years, and 61% were nonwhite. The mean +/- SD surrogate age was 57 +/- 10 years, and 91% were nonwhite. Qualitative analysis identified four overarching themes about how to best prepare for decision making: 1) identify values based on past experiences and quality of life, 2) choose surrogates wisely and verify that they understand their role, 3) decide whether to grant leeway in surrogate decision making, and 4) inform other family and friends of one's wishes to prevent conflict. Conclusion. Beyond ADs, patients and surrogates recommend several additional steps to prepare for medical decision making including using past experiences to identify values, verifying that the surrogate understands their role, deciding whether to grant surrogates leeway, and informing other family and friends of one's wishes. Future ACP interventions should consider incorporating these additional ACP activities. Published by Elsevier Inc. on behalf of U. S. Cancer Pain Relief Committee. C1 [McMahan, Ryan D.; Knight, Sara J.; Sudore, Rebecca L.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [McMahan, Ryan D.; Sudore, Rebecca L.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94121 USA. [Knight, Sara J.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. [Knight, Sara J.] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94121 USA. [Knight, Sara J.] Vet Hlth Adm, Hlth Serv Res & Dev Serv, Washington, DC USA. [Fried, Terri R.] Vet Affairs Connecticut Healthcare Syst, New Haven, CT USA. [Fried, Terri R.] Yale Univ, Sch Med, New Haven, CT USA. RP Sudore, RL (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Div Geriatr, 4150 Clement St,151R, San Francisco, CA 94121 USA. EM rebecca.sudore@ucsf.edu FU U.S. Department of Veterans Affairs; National Palliative Care Research Center FX This study was supported by the U.S. Department of Veterans Affairs and the National Palliative Care Research Center. The funding sources had no role in the creation of study materials, data collection, analysis, or interpretation of the data. No authors report any conflict of interest. NR 46 TC 25 Z9 25 U1 2 U2 24 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD SEP PY 2013 VL 46 IS 3 BP 355 EP 365 DI 10.1016/j.jpainsymman.2012.09.006 PG 11 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 213BA UT WOS:000324026700005 PM 23200188 ER PT J AU Sanders, DS Lattin, DJ Read-Brown, S Tu, DC Wilson, DJ Hwang, TS Morrison, JC Yackel, TR Chiang, MF AF Sanders, David S. Lattin, Daniel J. Read-Brown, Sarah Tu, Daniel C. Wilson, David J. Hwang, Thomas S. Morrison, John C. Yackel, Thomas R. Chiang, Michael F. TI Electronic Health Record Systems in Ophthalmology Impact on Clinical Documentation SO OPHTHALMOLOGY LA English DT Article ID INTENSIVE-CARE-UNIT; INFORMATION-TECHNOLOGY; VENOUS THROMBOEMBOLISM; DIABETIC-RETINOPATHY; MEDICAL INFORMATICS; TIME UTILIZATION; DATA-COLLECTION; PHYSICIANS; ERRORS; REPRESENTATION AB Objective: To evaluate quantitative and qualitative differences in documentation of the ophthalmic examination between paper and electronic health record (EHR) systems. Design: Comparative case series. Participants: One hundred fifty consecutive pairs of matched paper and EHR notes, documented by 3 attending ophthalmologist providers. Methods: An academic ophthalmology department implemented an EHR system in 2006. Database queries were performed to identify cases in which the same problems were documented by the same provider on different dates, using paper versus EHR methods. This was done for 50 consecutive pairs of examinations in 3 different diseases: age-related macular degeneration (AMD), glaucoma, and pigmented choroidal lesions (PCLs). Quantitative measures were used to compare completeness of documenting the complete ophthalmologic examination, as well as disease-specific critical findings using paper versus an EHR system. Qualitative differences in paper versus EHR documentation were illustrated by selecting representative paired examples. Main Outcome Measures: (1) Documentation score, defined as the number of examination elements recorded for the slit-lamp examination, fundus examination, and complete ophthalmologic examination and for critical clinical findings for each disease. (2) Paired comparison of qualitative differences in paper versus EHR documentation. Results: For all 3 diseases (AMD, glaucoma, PCL), the number of complete examination findings recorded was significantly lower with paper than the EHR system (P < 0.004). Among the 3 individual examination sections (general, slit lamp, fundus) for the 3 diseases, 5 of the 9 possible combinations had significantly lower mean documentation scores with paper than EHR notes. For 2 of the 3 diseases, the number of critical clinical findings recorded was significantly lower using paper versus EHR notes (P <= 0.022). All (150/150) paper notes relied on graphical representations using annotated hand-drawn sketches, whereas no (0/150) EHR notes contained drawings. Instead, the EHR systems documented clinical findings using textual descriptions and interpretations. Conclusions: There were quantitative and qualitative differences in the nature of paper versus EHR documentation of ophthalmic findings in this study. The EHR notes included more complete documentation of examination elements using structured textual descriptions and interpretations, whereas paper notes used graphical representations of findings. C1 [Sanders, David S.; Lattin, Daniel J.; Read-Brown, Sarah; Tu, Daniel C.; Wilson, David J.; Hwang, Thomas S.; Morrison, John C.; Chiang, Michael F.] Oregon Hlth & Sci Univ, Casey Eye Inst, Dept Ophthalmol, Portland, OR 97239 USA. [Tu, Daniel C.] Portland VA Med Ctr, Ophthalmol Operat Care Div, Portland, OR USA. [Yackel, Thomas R.; Chiang, Michael F.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97239 USA. RP Chiang, MF (reprint author), Oregon Hlth & Sci Univ, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA. EM chiangm@ohsu.edu OI Read-Brown, Sarah/0000-0002-6526-2939 FU Research to Prevent Blindness, Inc, New York, New York FX Supported by unrestricted departmental funding from Research to Prevent Blindness, Inc, New York, New York (D.S.S., S.R.B., D.C.T., D.J.W., T.S.H., J.C.M., and M.F.C.). The funding organization had no role in the design or conduct of this research. NR 39 TC 8 Z9 8 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0161-6420 EI 1549-4713 J9 OPHTHALMOLOGY JI Ophthalmology PD SEP PY 2013 VL 120 IS 9 BP 1745 EP 1755 DI 10.1016/j.ophtha.2013.02.017 PG 11 WC Ophthalmology SC Ophthalmology GA 213HG UT WOS:000324045800025 PM 23683945 ER PT J AU Tucker, RP Wingate, LR O'Keefe, VM Mills, AC Rasmussen, K Davidson, CL Grant, DM AF Tucker, Raymond P. Wingate, LaRicka R. O'Keefe, Victoria M. Mills, Adam C. Rasmussen, Kathy Davidson, Collin L. Grant, DeMond M. TI Rumination and suicidal ideation: The moderating roles of hope and optimism SO PERSONALITY AND INDIVIDUAL DIFFERENCES LA English DT Article DE Rumination; Hope; Optimism; Suicide; Suicidal ideation; Brooding; Reflection ID COLLEGE-STUDENTS; DEPRESSED MOOD; RISK; HOPELESSNESS; REFLECTION; SYMPTOMS; HISTORY; LIFE AB The current study aimed to investigate whether the correlation between rumination and suicidal ideation is moderated by the presence of hope and optimism. It was hypothesized that both hope and optimism would moderate (weaken) the relationship between rumination and suicidal ideation. Two hundred and ninety-eight participants completed self-report measures of hope, optimism, rumination (brooding and reflection), and depression. Results demonstrated that both hope and optimism weakened the relationship between rumination and suicidal ideation, as well as the relationships between both subscales of rumination and suicidal thinking. These results were found when controlling for symptoms of depression. Results suggest that a ruminative thinking style may be most harmful when an absence of hope or optimism is also present. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Tucker, Raymond P.; Wingate, LaRicka R.; O'Keefe, Victoria M.; Mills, Adam C.; Rasmussen, Kathy; Grant, DeMond M.] Oklahoma State Univ, Dept Psychol, Stillwater, OK 74078 USA. [Davidson, Collin L.] Denver VA Med Ctr, VA VISN MIRECC 19, Denver, CO USA. RP Wingate, LR (reprint author), Oklahoma State Univ, Dept Psychol, 116 North Murray Hall, Stillwater, OK 74078 USA. EM laricka.wingate@okstate.edu OI Grant, DeMond/0000-0002-5231-6563 NR 38 TC 14 Z9 16 U1 0 U2 16 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0191-8869 J9 PERS INDIV DIFFER JI Pers. Individ. Differ. PD SEP PY 2013 VL 55 IS 5 BP 606 EP 611 DI 10.1016/j.paid.2013.05.013 PG 6 WC Psychology, Social SC Psychology GA 191JZ UT WOS:000322410500028 ER PT J AU Bentley, JP Brown, CJ McGwin, G Sawyer, P Allman, RM Roth, DL AF Bentley, John P. Brown, Cynthia J. McGwin, Gerald, Jr. Sawyer, Patricia Allman, Richard M. Roth, David L. TI Functional status, life-space mobility, and quality of life: a longitudinal mediation analysis SO QUALITY OF LIFE RESEARCH LA English DT Article DE Wilson-Cleary model; Activities of daily living; Mobility; SF-12; Longitudinal mediation; Autoregressive mediation modeling ID STRUCTURAL EQUATION MODEL; DWELLING OLDER-ADULTS; CONCEPTUAL-MODEL; PREDICTORS; DEPRESSION; VARIABLES; SURVIVORS; DECLINES; SURGERY; PANEL AB Using the Wilson-Cleary model of patient outcomes as a conceptual framework, the impact of functional status on health-related quality of life (HRQoL) among older adults was examined, including tests of the mediation provided by life-space mobility. Participants were enrollees in a population-based, longitudinal study of mobility among community-dwelling older adults. Data from four waves of the study equally spaced approximately 18 months apart (baseline, 18, 36, and 54 months) were used for participants who survived at least 1 year beyond the 54-month assessment (n = 677). Autoregressive mediation models using longitudinal data and cross-sectional mediation models using baseline data were evaluated and compared using structural equation modeling. The longitudinal autoregressive models supported the mediating role of life-space mobility and suggested that this effect is larger for the mental component summary score than the physical component summary score of the SF-12. Evidence for a reciprocal relationship over time between functional status, measured by ADL difficulty, and life-space mobility was suggested by modification indices; these model elaborations did not alter the substantive meaning of the mediation effects. Mediated effect estimates from longitudinal autoregressive models were generally larger than those from cross-sectional models, suggesting that mediating relationships would have been missed or were potentially underestimated in cross-sectional models. These results support a mediating role for life-space mobility in the relationship between functional status and HRQoL. Functional status limitations might cause diminished HRQoL in part by limiting mobility. Mobility limitations may precede functional status limitations in addition to being a consequence thereof. C1 [Bentley, John P.] Univ Mississippi, Sch Pharm, University, MS 38677 USA. [Brown, Cynthia J.] Univ Alabama Birmingham, Birmingham VA Med Ctr, Birmingham, AL 35294 USA. [Brown, Cynthia J.; Sawyer, Patricia] Univ Alabama Birmingham, Div Gerontol Geriatr & Palliat Care, Birmingham, AL 35294 USA. [McGwin, Gerald, Jr.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL 35294 USA. [Allman, Richard M.] Univ Alabama Birmingham, Atlanta VA Geriatr Res Educ & Clin Ctr, Ctr Aging, Birmingham, AL 35294 USA. [Allman, Richard M.] Univ Alabama Birmingham, Div Gerontol Geriatr & Palliat Care, Birmingham, AL 35294 USA. [Roth, David L.] Johns Hopkins Univ, Ctr Aging & Hlth, Baltimore, MD 21205 USA. RP Bentley, JP (reprint author), Univ Mississippi, Sch Pharm, Faser Hall 235, University, MS 38677 USA. EM phjpb@olemiss.edu FU National Institute on Aging [R01 AG015062] FX The UAB Study of Aging is funded through a grant from the National Institute on Aging (R01 AG015062). NR 59 TC 15 Z9 16 U1 6 U2 32 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0962-9343 J9 QUAL LIFE RES JI Qual. Life Res. PD SEP PY 2013 VL 22 IS 7 BP 1621 EP 1632 DI 10.1007/s11136-012-0315-3 PG 12 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 214BL UT WOS:000324105100011 PM 23161329 ER PT J AU Moyer, CE Delevich, KM Fish, KN Asafu-Adjei, JK Sampson, AR Dorph-Petersen, KA Lewis, DA Sweet, RA AF Moyer, Caitlin E. Delevich, Kristen M. Fish, Kenneth N. Asafu-Adjei, Josephine K. Sampson, Allan R. Dorph-Petersen, Karl-Anton Lewis, David A. Sweet, Robert A. TI Intracortical excitatory and thalamocortical boutons are intact in primary auditory cortex in schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Article DE VGluT1; VGluT2; Primary auditory cortex; Quantitative microscopy; Stereology; Postmortem human tissue ID VESICULAR GLUTAMATE TRANSPORTERS; MISMATCH NEGATIVITY GENERATION; MESSENGER-RNA EXPRESSION; DENDRITIC SPINE DENSITY; SUPERIOR TEMPORAL GYRUS; RAT HIPPOCAMPAL SLICES; PREFRONTAL CORTEX; PLANUM TEMPORALE; HESCHL GYRUS; IN-VIVO AB Schizophrenia is associated with auditory processing impairments that could arise as a result of primary auditory cortex excitatory circuit pathology. We have previously reported a deficit in dendritic spine density in deep layer 3 of primary auditory cortex in subjects with schizophrenia. As boutons and spines can be structurally and functionally co-regulated, we asked whether the densities of intracortical excitatory or thalamocortical presynaptic boutons are also reduced. We studied 2 cohorts of subjects with schizophrenia and matched controls, comprising 27 subject pairs, and assessed the density, number, and within-bouton vesicular glutamate transporter (VGluT) protein level of intracortical excitatory (VGluT1-immunoreactive) and thalamocortical (VGluT2-immunoreactive) boutons in deep layer 3 of primary auditory cortex using quantitative confocal microscopy and stereologic sampling methods. We found that VGluT1- and VGluT2-immunoreactive puncta densities and numbers were not altered in deep layer 3 of primary auditory cortex of subjects with schizophrenia. Our results indicate that reduced dendritic spine density in primary auditory cortex of subjects with schizophrenia is not matched by a corresponding reduction in excitatory bouton density. This suggests excitatory boutons in primary auditory cortex in schizophrenia may synapse with structures other than spines, such as dendritic shafts, with greater frequency. The discrepancy between dendritic spine reduction and excitatory bouton preservation may contribute to functional impairments of the primary auditory cortex in subjects with schizophrenia. (C) 2013 Elsevier B.V. All rights reserved. C1 [Moyer, Caitlin E.; Fish, Kenneth N.; Lewis, David A.; Sweet, Robert A.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA. [Moyer, Caitlin E.; Delevich, Kristen M.; Fish, Kenneth N.; Dorph-Petersen, Karl-Anton; Lewis, David A.; Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA. [Asafu-Adjei, Josephine K.; Sampson, Allan R.] Univ Pittsburgh, Dept Stat, Pittsburgh, PA 15213 USA. [Dorph-Petersen, Karl-Anton] Aarhus Univ Hosp, Ctr Psychiat Res, Risskov, Denmark. [Dorph-Petersen, Karl-Anton] Aarhus Univ, Ctr Stochast Geometry & Adv Bioimaging, Aarhus, Denmark. [Lewis, David A.] Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15213 USA. [Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA 15213 USA. RP Sweet, RA (reprint author), Biomed Sci Tower,Rm W1645,3811 OHara St, Pittsburgh, PA 15213 USA. EM SweetRA@upmc.edu RI Lewis, David/G-4053-2014; Dorph-Petersen, Karl-Anton/A-9039-2015 OI Lewis, David/0000-0002-3225-6778; Dorph-Petersen, Karl-Anton/0000-0002-6676-034X; Moyer, Caitlin/0000-0002-2571-2595; Delevich, Kristen/0000-0001-5698-0093 FU [MH071533]; [MH084053]; [MH085108] FX This work was supported by Grants MH071533 (RAS), MH084053 (DAL), and MH085108 (KNF). NR 57 TC 8 Z9 8 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD SEP PY 2013 VL 149 IS 1-3 BP 127 EP 134 DI 10.1016/j.schres.2013.06.024 PG 8 WC Psychiatry SC Psychiatry GA 211UQ UT WOS:000323937200020 PM 23830684 ER PT J AU Hiremath, SV Ding, D Farringdon, J Vyas, N Cooper, RA AF Hiremath, S. V. Ding, D. Farringdon, J. Vyas, N. Cooper, R. A. TI Physical activity classification utilizing SenseWear activity monitor in manual wheelchair users with spinal cord injury SO SPINAL CORD LA English DT Article DE spinal cord injury; physical activity; manual wheelchair users; machine learning; energy expenditure; multisensor activity monitor ID ENERGY-EXPENDITURE AB Study design: Validation. Objectives: The primary aim of this study was to develop and evaluate activity classification algorithms for a multisensor-based SenseWear (SW) activity monitor that can recognize wheelchair-related activities performed by manual wheelchair users (MWUs) with spinal cord injury (SCI). The secondary aim was to evaluate how the accuracy in activity classification affects the estimation of energy expenditure (EE) in MWUs with SCI. Setting: University-based laboratory. Methods: Forty-five MWUs with SCI wore a SW on their upper arm and participated in resting, wheelchair propulsion, arm-ergometery and deskwork activities. The investigators annotated the start and end of each activity trial while the SW collected multisensor data and a portable metabolic cart collected criterion EE. Three methods including linear discriminant analysis, quadratic discriminant analysis (QDA), and Naive Bayes (NB) were used to develop classification algorithms for four activities based on the training data set from 36 subjects. Results: The classification accuracy was 96.3% for QDA and 94.8% for NB when the classification algorithms were tested on the validation data set from nine subjects. The average EE estimation errors using the activity-specific EE prediction model were 5.3 +/- 21.5% and 4.6 +/- 22.8% when the QDA and NB classification algorithms were applied, respectively, as opposed to 4.9 +/- 20.7% when 100% classification accuracy was assumed. Conclusion: The high classification accuracy and low EE estimation errors suggest that the SW can be used by researchers and clinicians to classify and estimate the EE for the four activities tested in this study among MWUs with SCI. C1 [Hiremath, S. V.; Ding, D.; Cooper, R. A.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Dept Vet Affairs, Pittsburgh, PA 15206 USA. [Hiremath, S. V.; Ding, D.; Cooper, R. A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Ding, D.; Cooper, R. A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. [Farringdon, J.; Vyas, N.] BodyMedia Inc, Pittsburgh, PA USA. RP Ding, D (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Dept Vet Affairs, 6425 Penn Ave,Suite 400, Pittsburgh, PA 15206 USA. EM dad5@pitt.edu OI Farringdon, Jonathan/0000-0001-5977-3700 FU Rehabilitation Engineering Research Center on Interactive Exercise & Recreation Technologies & Exercise Physiology benefitting Persons with Disabilities [H133E120005]; National Institute on Disability and Rehabilitation Research (NIDRR); Switzer Research Fellowship [H133Fl10032]; NIDRR; VA Center of Excellence for Wheelchairs and Associated Rehabilitation Engineering [B3142C] FX The work is supported by the Rehabilitation Engineering Research Center on Interactive Exercise & Recreation Technologies & Exercise Physiology benefitting Persons with Disabilities (H133E120005) funded by the National Institute on Disability and Rehabilitation Research (NIDRR). Mr. Hiremath's work on this article was also funded through the Switzer Research Fellowship (H133Fl10032) awarded by the NIDRR. The work is also supported by the VA Center of Excellence for Wheelchairs and Associated Rehabilitation Engineering (B3142C). The contents do not represent the views of the Department of Veterans Affairs or the United States Government. NR 18 TC 7 Z9 7 U1 1 U2 8 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1362-4393 J9 SPINAL CORD JI Spinal Cord PD SEP PY 2013 VL 51 IS 9 BP 705 EP 709 DI 10.1038/sc.2013.39 PG 5 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 216UB UT WOS:000324309000011 PM 23689386 ER PT J AU Krautkramer, KA Linnemann, AK Fontaine, DA Whillock, AL Harris, TW Schleis, GJ Truchan, NA Marty-Santos, L Lavine, JA Cleaver, O Kimple, ME Davis, DB AF Krautkramer, Kimberly A. Linnemann, Amelia K. Fontaine, Danielle A. Whillock, Amy L. Harris, Ted W. Schleis, Gregory J. Truchan, Nathan A. Marty-Santos, Leilani Lavine, Jeremy A. Cleaver, Ondine Kimple, Michelle E. Davis, Dawn Belt TI Tcf19 is a novel islet factor necessary for proliferation and survival in the INS-1 beta-cell line SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE diabetes; beta-cell; islet; proliferation; apoptosis; transcription factor 19; transcription; endoplasmic reticulum stress ID ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; DIABETES-MELLITUS; ER STRESS; MISFOLDED GLYCOPROTEINS; DEVELOPING PANCREAS; FHA DOMAIN; EXPRESSION; APOPTOSIS; MASS AB Recently, a novel type 1 diabetes association locus was identified at human chromosome 6p31.3, and transcription factor 19 (TCF19) is a likely causal gene. Little is known about Tcf19, and we now show that it plays a role in both proliferation and apoptosis in insulinoma cells. Tcf19 is expressed in mouse and human islets, with increasing mRNA expression in nondiabetic obesity. The expression of Tcf19 is correlated with beta-cell mass expansion, suggesting that it may be a transcriptional regulator of beta-cell mass. Increasing proliferation and decreasing apoptotic cell death are two strategies to increase pancreatic beta-cell mass and prevent or delay diabetes. siRNA-mediated knockdown of Tcf19 in the INS-1 insulinoma cell line, a beta-cell model, results in a decrease in proliferation and an increase in apoptosis. There was a significant reduction in the expression of numerous cell cycle genes from the late G1 phase through the M phase, and cells were arrested at the G1/S checkpoint. We also observed increased apoptosis and susceptibility to endoplasmic reticulum (ER) stress after Tcf19 knockdown. There was a reduction in expression of genes important for the maintenance of ER homeostasis (Bip, p58(IPK), Edem1, and calreticulin) and an increase in proapoptotic genes (Bim, Bid, Nix, Gadd34, and Pdia2). Therefore, Tcf19 is necessary for both proliferation and survival and is a novel regulator of these pathways. C1 [Krautkramer, Kimberly A.; Linnemann, Amelia K.; Fontaine, Danielle A.; Whillock, Amy L.; Harris, Ted W.; Schleis, Gregory J.; Truchan, Nathan A.; Kimple, Michelle E.; Davis, Dawn Belt] Univ Wisconsin, Dept Med, Div Endocrinol Diabet & Metab, Madison, WI USA. [Lavine, Jeremy A.; Davis, Dawn Belt] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. [Marty-Santos, Leilani; Cleaver, Ondine] Univ Texas Southwestern, Dept Mol Biol, Dallas, TX USA. [Davis, Dawn Belt] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Davis, DB (reprint author), 4148 MFCB,MC 5148,1685 Highland Ave, Madison, WI 53705 USA. EM dbd@medicine.wisc.edu RI Davis, Dawn/B-1624-2013 OI Cleaver, Ondine/0000-0003-2454-6641 FU NIDDK [K08-DK-083442, 3R01-DK-079862-S1, F31-DK-092098, 5-R01-DK-079862]; William and Judith Busse Women in Research Foundation; University of Wisconsin School of Medicine and Public Health and Department of Medicine, Division of Endocrinology; Wisconsin Alumni Research Foundation; Central Society for Clinical Research; Pilot Award from the Integrated Islet Distribution Program; JDRF [17-2011-608]; Medical Scientist Training Program [T32GM08692]; National Center for Advancing Translational Sciences [UL1TR0000427] FX D. B. Davis acknowledges research support from the NIDDK (K08-DK-083442), the William and Judith Busse Women in Research Foundation, the University of Wisconsin School of Medicine and Public Health and Department of Medicine, Division of Endocrinology, the Wisconsin Alumni Research Foundation, and the Central Society for Clinical Research. D. B. Davis was also the recipient of a Pilot Award from the Integrated Islet Distribution Program that provided an allotment of human islets. M. E. Kimple has received research support from JDRF (17-2011-608). J. A. Lavine and K. A. Krautkramer have been supported by the Medical Scientist Training Program (T32GM08692). O. Cleaver and L. Marty-Santos have also been supported by the NIDDK [3R01-DK-079862-S1 (L. Marty-Santos), F31-DK-092098 (L. Marty-Santos), and 5-R01-DK-079862 (O. Cleaver)]. We also acknowledge statistical consultation through the Clinical and Translational Science Award program through National Center for Advancing Translational Sciences Grant UL1TR0000427. NR 55 TC 5 Z9 5 U1 3 U2 8 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD SEP PY 2013 VL 305 IS 5 BP E600 EP E610 DI 10.1152/ajpendo.00147.2013 PG 11 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 211WH UT WOS:000323941900004 PM 23860123 ER PT J AU Mitchell, T Johnson, MS Ouyang, XS Chacko, BK Mitra, K Lei, XY Gai, Y Moore, DR Barnes, S Zhang, JH Koizumi, A Ramanadham, S Darley-Usmar, VM AF Mitchell, Tanecia Johnson, Michelle S. Ouyang, Xiaosen Chacko, Balu K. Mitra, Kasturi Lei, Xiaoyong Gai, Ying Moore, D. Ray Barnes, Stephen Zhang, Jianhua Koizumi, Akio Ramanadham, Sasanka Darley-Usmar, Victor M. TI Dysfunctional mitochondrial bioenergetics and oxidative stress in Akita(+/Ins2)-derived beta-cells SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE diabetes mellitus; beta-cell; mitochondrial respiration; endoplasmic reticulum stress; mitochondrial quality control ID ENDOPLASMIC-RETICULUM STRESS; DIABETES-MELLITUS; INSULIN GENE; SUPEROXIDE-DISMUTASE; MUTANT MICE; AUTOPHAGY; MUTATIONS; EXPRESSION; MECHANISM; MOUSE AB Insulin release from pancreatic beta-cells plays a critical role in blood glucose homeostasis, and beta-cell dysfunction leads to the development of diabetes mellitus. In cases of monogenic type 1 diabetes mellitus (T1DM) that involve mutations in the insulin gene, we hypothesized that misfolding of insulin could result in endoplasmic reticulum (ER) stress, oxidant production, and mitochondrial damage. To address this, we used the Akita(+/Ins2) T1DM model in which misfolding of the insulin 2 gene leads to ER stress-mediated beta-cell death and thapsigargin to induce ER stress in two different beta-cell lines and in intact mouse islets. Using transformed pancreatic beta-cell lines generated from wild-type Ins2(-/-) (WT) and Akita(+/Ins2) mice, we evaluated cellular bioenergetics, oxidative stress, mitochondrial protein levels, and autophagic flux to determine whether changes in these processes contribute to beta-cell dysfunction. In addition, we induced ER stress pharmacologically using thapsigargin in WT beta-cells, INS-1 cells, and intact mouse islets to examine the effects of ER stress on mitochondrial function. Our data reveal that Akita(+/Ins2)-derived beta-cells have increased mitochondrial dysfunction, oxidant production, mtDNA damage, and alterations in mitochondrial protein levels that are not corrected by autophagy. Together, these findings suggest that deterioration in mitochondrial function due to an oxidative environment and ER stress contributes to beta-cell dysfunction and could contribute to T1DM in which mutations in insulin occur. C1 [Mitchell, Tanecia; Johnson, Michelle S.; Ouyang, Xiaosen; Chacko, Balu K.; Zhang, Jianhua; Darley-Usmar, Victor M.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Mitchell, Tanecia; Johnson, Michelle S.; Ouyang, Xiaosen; Chacko, Balu K.; Barnes, Stephen; Zhang, Jianhua; Darley-Usmar, Victor M.] Univ Alabama Birmingham, Ctr Free Radical Biol, Birmingham, AL 35294 USA. [Mitra, Kasturi] Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA. [Lei, Xiaoyong; Gai, Ying; Ramanadham, Sasanka] Univ Alabama Birmingham, Dept Cell, Birmingham, AL 35294 USA. [Barnes, Stephen] Univ Alabama Birmingham, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA. [Ouyang, Xiaosen; Zhang, Jianhua] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Moore, D. Ray; Barnes, Stephen] Univ Alabama Birmingham, Targeted Metabol & Prote Lab, Birmingham, AL 35294 USA. [Koizumi, Akio] Kyoto Grad Sch Med, Dept Hlth & Environm Sci, Kyoto, Japan. RP Darley-Usmar, VM (reprint author), Univ Alabama Birmingham, Dept Pathol, Biomed Res Bldg 2,901 19th St South, Birmingham, AL 35294 USA. EM darley@uab.edu FU Veterans Affairs Merit Award [AA-13395, DK-075865]; O'Brien Center [P30-DK-079337]; University of Alabama at Birmingham Health Services Foundation General Endowment Fund; [T32-DK-007545]; [DK-69455]; [NS-064090] FX We appreciate support from the following: T32-DK-007545 (T. Mitchell), DK-69455 (S. Ramanadham), NS-064090 and a Veterans Affairs Merit Award (J. Zhang), AA-13395 and DK-075865 (V. M. Darley-Usmar), and the O'Brien Center P30-DK-079337 (S. Barnes and V. M. Darley-Usmar). Funds for the mass spectrometer used in this study were provided by a grant from the University of Alabama at Birmingham Health Services Foundation General Endowment Fund. NR 62 TC 16 Z9 17 U1 0 U2 6 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD SEP PY 2013 VL 305 IS 5 BP E585 EP E599 DI 10.1152/ajpendo.00093.2013 PG 15 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 211WH UT WOS:000323941900003 PM 23820623 ER PT J AU Kornblit, B Maloney, DG Storb, R Storek, J Hari, P Vucinic, V Maziarz, RT Chauncey, TR Pulsipher, MA Bruno, B Petersen, FB Bethge, WA Hubel, K Bouvier, ME Fukuda, T Storer, BE Sandmaier, BM AF Kornblit, Brian Maloney, David G. Storb, Rainer Storek, Jan Hari, Parameswaran Vucinic, Vladan Maziarz, Richard T. Chauncey, Thomas R. Pulsipher, Michael A. Bruno, Benedetto Petersen, Finn B. Bethge, Wolfgang A. Huebel, Kai Bouvier, Michelle E. Fukuda, Takahiro Storer, Barry E. Sandmaier, Brenda M. TI Fludarabine and 2-Gy TBI is Superior to 2 Gy TBI as Conditioning for HLA-Matched Related Hematopoietic Cell Transplantation: A Phase III Randomized Trial SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE Nonmyeloablative conditioning; Fludarabine/low dose total body irradiation; HLA-matched related hematopoietic cell transplantation randomized trial ID TOTAL-BODY IRRADIATION; CHRONIC LYMPHOCYTIC-LEUKEMIA; HEMATOLOGIC MALIGNANCIES; MARROW TRANSPLANTATION; FOLLICULAR LYMPHOMA; RISK-ASSESSMENT; KILLER-CELLS; CHIMERISM; DONOR; INTENSITY AB The risks and benefits of adding fludarabine to a 2-Gy total body irradiation (TBI) nonmyeloablative regimen are unknown. For this reason, we conducted a prospective randomized trial comparing 2-Gy TBI alone, or in combination with 90 mg/m(2) fludarabine (FLU/TBI), before transplantation of peripheral blood stem cells from HLA-matched related donors. Eighty-five patients with hematological malignancies were randomized to be conditioned with TBI alone (n = 44) or FLU/TBI (n = 41). All patients had initial engraftment. Two graft rejections were observed, both in the TBI group. Infection rates, nonrelapse mortality, and graft-versus-host disease (GVHD) were similar between groups. Three-year overall survival was lower in the TBI group (54% versus 65%; hazard ratio [HR], .57; P = .09), with higher incidences of relapse/progression (55% versus 40%; HR, .55; P = .06), relapse-related mortality (37% versus 28%; HR, .53; P = .09), and a lower progression-free survival (36% versus 53%; HR, .56; P = .05). Median donor T cell chimerism levels were significantly lower in the TBI group at days 28 (61% versus 90%; P < .0001) and 84 (68% versus 92%; P < .0001), as was NK cell chimerism on day 28 (75% versus 96%; P = .0005). In conclusion, this randomized trial demonstrates the importance of fludarabine in augmenting the graft-versus-tumor effect by ensuring prompt and durable high-level donor engraftment early after transplantation. (C) 2013 American Society for Blood and Marrow Transplantation. C1 [Kornblit, Brian; Maloney, David G.; Storb, Rainer; Chauncey, Thomas R.; Bouvier, Michelle E.; Storer, Barry E.; Sandmaier, Brenda M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA. [Maloney, David G.; Storb, Rainer; Sandmaier, Brenda M.] Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195 USA. [Storek, Jan] Univ Calgary, Dept Med, Calgary, AB, Canada. [Storek, Jan] Univ Calgary, Dept Oncol & Microbiol, Calgary, AB, Canada. [Storek, Jan] Univ Calgary, Dept Immunol, Calgary, AB, Canada. [Storek, Jan] Univ Calgary, Dept Infect Dis, Calgary, AB, Canada. [Hari, Parameswaran] Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI 53226 USA. [Vucinic, Vladan] Univ Leipzig, Dept Hematol & Oncol, D-04109 Leipzig, Germany. [Maziarz, Richard T.] Oregon Hlth & Sci Univ, Ctr Hematol Malignancies, Portland, OR 97201 USA. [Chauncey, Thomas R.] VA Puget Sound Hlth Care Syst, Marrow Transplant Unit, Seattle, WA USA. [Pulsipher, Michael A.] Univ Utah, Sch Med, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA. [Bruno, Benedetto] Univ Turin, Sch Med, Div Hematol, Turin, Italy. [Petersen, Finn B.] LDS Hosp, Intermt Blood & Marrow Transplant Acutr Leukemia, Salt Lake City, UT USA. [Bethge, Wolfgang A.] Univ Tubingen, Med Ctr, Dept Med, Tubingen, Germany. [Huebel, Kai] Univ Cologne, Ctr Integrated Oncol Cologne Bonn, Dept Med 1, D-50931 Cologne, Germany. [Fukuda, Takahiro] Natl Canc Ctr, Stem Cell Transplantat Div, Tokyo, Japan. [Storer, Barry E.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. RP Sandmaier, BM (reprint author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,D1-100,POB 19024, Seattle, WA 98109 USA. EM bsandmai@fhcrc.org OI Hari, Parameswaran/0000-0002-8800-297X FU National Institutes of Health, Bethesda, MD [CA078902, HL036444, CA015704]; Danish Cancer Society [DP08135]; Froken Amalie Jorgensens Mindelegat; Anders Hasselbalchs Fond; Ricerca Sanitaria Finalizzata [RF-PIE-2008-1206999, RF-PIE-2009-1491359] FX Financial disclosure: Research funding was provided by the National Institutes of Health, Bethesda, MD, grants, CA078902, HL036444, and CA015704. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health nor its subsidiary Institutes and Centers. B.K. was supported by a fellowship from the Danish Cancer Society (DP08135), Froken Amalie Jorgensens Mindelegat and Anders Hasselbalchs Fond. B.B. was supported by Ricerca Sanitaria Finalizzata RF-PIE-2008-1206999 and RF-PIE-2009-1491359. NR 36 TC 10 Z9 10 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD SEP PY 2013 VL 19 IS 9 BP 1340 EP 1347 DI 10.1016/j.bbmt.2013.06.002 PG 8 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 212WT UT WOS:000324014200009 PM 23769990 ER PT J AU Cassaday, RD Guthrie, KA Budde, EL Thompson, L Till, BG Press, OW Chauncey, TR Pagel, JM Petersdorf, SH Palanca-Wessels, MC Philip, M Bensinger, WI Holmberg, LA Shustov, A Green, DJ Libby, EN Maloney, DG Gopal, AK AF Cassaday, Ryan D. Guthrie, Katherine A. Budde, Elizabeth L. Thompson, Leslie Till, Brian G. Press, Oliver W. Chauncey, Thomas R. Pagel, John M. Petersdorf, Stephen H. Palanca-Wessels, Maria Corinna Philip, Mary Bensinger, William I. Holmberg, Leona A. Shustov, Andrei Green, Damian J. Libby, Edward N. Maloney, David G. Gopal, Ajay K. TI Specific Features Identify Patients with Relapsed or Refractory Mantle Cell Lymphoma Benefitting from Autologous Hematopoietic Cell Transplantation SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE Mantle cell lymphoma; Autologous transplantation ID PROGRESSION-FREE SURVIVAL; PLUS RITUXIMAB; REMISSION; MULTICENTER; PHASE-2; REGIMEN; TRIAL; CHOP AB Outcomes with autologous hematopoietic cell transplantation (auto HCT) for relapsed and/or refractory mantle cell lymphoma (MCL) are typically poor. We hypothesized that certain factors could predict which patients experience a favorable outcome with this approach. We thus developed a predictive score from a cohort of 67 such patients using 3 factors independently associated with progression-free survival (PFS): (1) simplified Mantle Cell Lymphoma International Prognostic Index score before auto HCT (hazard ratio MR], 2.9; P = .002); (2) B symptoms at diagnosis (HR, 2.7; P = .005); and (3) remission quotient, calculated by dividing the time, in months, from diagnosis to auto HCT by the number of prior treatments (HR, 1.4; P = .02). The estimated 5-year PFS for favorable-risk patients (n = 23) and unfavorable-risk patients (n = 44) were 58% (95% confidence interval [CI], 34% to 75%) and 15% (95% Cl, 6% to 28%), respectively. These factors also independently predicted overall survival. In summary, we have defined 3 simple factors that can identify patients with relapsed/refractory MCL who derive a durable benefit from salvage auto HCT. (C) 2013 American Society for Blood and Marrow Transplantation. C1 [Cassaday, Ryan D.; Guthrie, Katherine A.; Budde, Elizabeth L.; Thompson, Leslie; Till, Brian G.; Press, Oliver W.; Chauncey, Thomas R.; Pagel, John M.; Petersdorf, Stephen H.; Palanca-Wessels, Maria Corinna; Philip, Mary; Bensinger, William I.; Holmberg, Leona A.; Shustov, Andrei; Green, Damian J.; Libby, Edward N.; Maloney, David G.; Gopal, Ajay K.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Cassaday, Ryan D.; Budde, Elizabeth L.; Thompson, Leslie; Till, Brian G.; Press, Oliver W.; Chauncey, Thomas R.; Pagel, John M.; Petersdorf, Stephen H.; Bensinger, William I.; Holmberg, Leona A.; Green, Damian J.; Libby, Edward N.; Maloney, David G.; Gopal, Ajay K.] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA USA. [Chauncey, Thomas R.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Palanca-Wessels, Maria Corinna; Philip, Mary; Shustov, Andrei] Univ Washington, Dept Med, Div Hematol, Seattle, WA 98195 USA. RP Gopal, AK (reprint author), 825 Eastlake Ave E,Mailstop G3-200, Seattle, WA 98109 USA. EM agopal@u.washington.edu FU Lymphoma Research Foundation MCL Initiative; Leukemia and Lymphoma Society; NIH [T32 CA009515-27, P01 CA044991]; NCI [K08 CA163603, K08 CA151682]; Mary Wright Memorial Fund FX This work was supported by The Lymphoma Research Foundation MCL Initiative, a Clinical Scholar Award by the Leukemia and Lymphoma Society (A.K.G.), NIH T32 CA009515-27 (R.D.C.), NCI K08 CA163603 (M.C.P.W.), NCI K08 CA151682 (N.G.), NIH P01 CA044991, the Mary Wright Memorial Fund, and gifts from David and Patricia Giuliani, Frank and Betty Vandermeer, and Don and Debbie Hunkins. NR 19 TC 8 Z9 9 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD SEP PY 2013 VL 19 IS 9 BP 1403 EP 1406 DI 10.1016/j.bbmt.2013.07.005 PG 4 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 212WT UT WOS:000324014200020 PM 23871782 ER PT J AU Pasinetti, GM Bilski, AE Zhao, W AF Pasinetti, Giulio Maria Bilski, Amanda E. Zhao, Wei TI Sirtuins as therapeutic targets of ALS SO CELL RESEARCH LA English DT Editorial Material ID AMYOTROPHIC-LATERAL-SCLEROSIS; SURVIVAL C1 [Pasinetti, Giulio Maria; Bilski, Amanda E.; Zhao, Wei] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Pasinetti, Giulio Maria; Zhao, Wei] James J Peters Vet Affairs Med Ctr, GRECC, Bronx, NY USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, 1468 Madison Ave,Annenberg Bldg,Room 20-02, New York, NY 10029 USA. EM Giulio.Pasinetti@mssm.edu NR 10 TC 5 Z9 5 U1 1 U2 10 PU INST BIOCHEMISTRY & CELL BIOLOGY PI SHANGHAI PA SIBS, CAS, 319 YUEYANG ROAD, SHANGHAI, 200031, PEOPLES R CHINA SN 1001-0602 J9 CELL RES JI Cell Res. PD SEP PY 2013 VL 23 IS 9 BP 1073 EP 1074 DI 10.1038/cr.2013.94 PG 2 WC Cell Biology SC Cell Biology GA 211SH UT WOS:000323930200006 PM 23856645 ER PT J AU Huynh, AK Kinsler, JJ Cunningham, WE Sayles, JN AF Huynh, Alexis K. Kinsler, Janni J. Cunningham, William E. Sayles, Jennifer N. TI The role of mental health in mediating the relationship between social support and optimal ART adherence SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE HIV; AIDS; ART adherence; social support; mental health; mediation analyses ID ACTIVE ANTIRETROVIRAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; HIV-POSITIVE MEN; MEDICATION ADHERENCE; DEPRESSION; WOMEN; INTERVENTION; ADULTS AB Optimal adherence to antiretroviral therapy (ART) is essential for reducing mortality and morbidity in persons living with HIV/AIDS (PLWHA), as well as for reducing the risk of further HIV transmission. While studies have identified psychosocial factors such as lack of social support and poor mental health status as important barriers to optimal ART adherence, few studies have explored the potential of a mediation effect of psychosocial factors on the relationship between social support and optimal ART adherence. This paper assessed whether mental health status mediated the relationship between social support and optimal ART adherence among a cross-sectional sample of 202 persons living with HIV who were recruited from HIV clinical care sites and community-based organizations in Los Angeles County (LAC). Participants completed a survey that included social support items from the Medical Outcome Study: Social Support Survey (MOS-SSS) Instrument, mental health measures from the Medical Outcomes Study Short Form (SF-12), and ART adherence based on self-report. Among those currently taking ART, 61.7% reported having optimal adherence. Social support was significantly associated with a high score on the mental health status scale (AOR =2.90; 95% CI=1.14-5.78) and optimal ART adherence (AOR=1.81; 95% CI=1.81; 95% CI=1.18-2.79). When mental health status was introduced into the model, the association between social support and optimal ART adherence was no longer significant. Our findings suggest the HIV interventions targeting social support to improve ART adherence will likely be most successful if the support bolsters the mental health of the participants. Clearly, better understanding the relationships among social support, mental health, and ART adherence will be critical for development and implementation of future ART adherence interventions. C1 [Huynh, Alexis K.; Cunningham, William E.; Sayles, Jennifer N.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Huynh, Alexis K.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Kinsler, Janni J.] Univ Calif Los Angeles, Dept Community Hlth Sci, Los Angeles, CA USA. [Cunningham, William E.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. RP Kinsler, JJ (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. EM jkinsler@ucla.edu FU NIA NIH HHS [P30 AG021684]; NIMH NIH HHS [K23 MH083535]; NIMHD NIH HHS [P20 MD000182] NR 17 TC 8 Z9 8 U1 0 U2 12 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PD SEP 1 PY 2013 VL 25 IS 9 BP 1179 EP 1184 DI 10.1080/09540121.2012.752787 PG 6 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA 207VQ UT WOS:000323633200016 PM 23320407 ER PT J AU Jonassaint, CR Haywood, C Korthuis, PT Cooper, LA Saha, S Sharp, V Cohn, J Moore, RD Beach, MC AF Jonassaint, Charles R. Haywood, Carlton, Jr. Korthuis, Philip Todd Cooper, Lisa A. Saha, Somnath Sharp, Victoria Cohn, Jonathon Moore, Richard D. Beach, Mary Catherine TI The impact of depressive symptoms on patient-provider communication in HIV care SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE depression; communication; quality of health care; patient satisfaction; HIV ID MEDICAL-CARE; PHYSICIAN; ADHERENCE; SATISFACTION; HEALTH; INDIVIDUALS; PREDICTORS; INFECTION; VETERANS; OUTCOMES AB Persons with HIV who develop depression have worse medical adherence and outcomes. Poor patient-provider communication may play a role in these outcomes. This cross-sectional study evaluated the influence of patient depression on the quality of patient-provider communication. Patient-provider visits (n=406) at four HIV care sites were audio-recorded and coded with the Roter Interaction Analysis System (RIAS). Negative binomial and linear regressions using generalized estimating equations tested the association of depressive symptoms, as measured by the Center for Epidemiology Studies Depression scale (CES-D), with RIAS measures and postvisit patient-rated quality of care and provider-reported regard for his or her patient. The patients, averaged 45 years of age (range =20-77), were predominately male (n=286, 68.5%), of black race (n=250, 60%), and on antiretroviral medications (n=334, 80%). Women had greater mean CES-D depression scores (12.0) than men (10.6; p=0.03). There were no age, race, or education differences in depression scores. Visits with patients reporting severe depressive symptoms compared to those reporting none/mild depressive symptoms were longer and speech speed was slower. Patients with severe depressive symptoms did more emotional rapport building but less social rapport building, and their providers did more data gathering/counseling (ps<0.05). In postvisit questionnaires, providers reported lower levels of positive regard for, and rated more negatively patients reporting more depressive symptoms (p<0.01). In turn, patients reporting more depressive symptoms felt less respected and were less likely to report that their provider knows them as a person than none/mild depressive symptoms patients (ps<0.05). Greater psychosocial needs of patients presenting with depressive symptoms and limited time/resources to address these needs may partially contribute to providers' negative attitudes regarding their patients with depressive symptoms. These negative attitudes may ultimately serve to adversely impact patient-provider communication and quality of HIV care. C1 [Jonassaint, Charles R.; Cooper, Lisa A.; Moore, Richard D.; Beach, Mary Catherine] Johns Hopkins Univ, Div Gen Internal Med, Baltimore, MD 21218 USA. [Haywood, Carlton, Jr.] Johns Hopkins Univ, Berman Inst Bioeth, Baltimore, MD USA. [Haywood, Carlton, Jr.; Cooper, Lisa A.; Beach, Mary Catherine] Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA. [Korthuis, Philip Todd; Saha, Somnath] Oregon Hlth & Sci Univ, Dept Med, Gen Internal Med Sect, Portland VA Med Ctr, Portland, OR 97201 USA. [Sharp, Victoria] St Lukes Roosevelt Hosp, Dept Med, New York, NY 10025 USA. [Cohn, Jonathon] Wayne State Univ, Sch Med, Detroit, MI USA. RP Jonassaint, CR (reprint author), Johns Hopkins Univ, Div Gen Internal Med, Baltimore, MD 21218 USA. EM charles.jonassaint@jhmi.edu RI Jonassaint, Charles/I-2772-2014 OI Jonassaint, Charles/0000-0002-5662-5806; Haywood Jr., Carlton/0000-0002-3574-7871 FU NHLBI NIH HHS [K24 HL083113]; NIAAA NIH HHS [R01 AA016893, R21 AA015032]; NIAID NIH HHS [P30 AI094189, U01 AI069918]; NIDA NIH HHS [R01 DA011602]; PHS HHS [AHRQ 290-01-0012] NR 32 TC 1 Z9 1 U1 4 U2 5 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PD SEP 1 PY 2013 VL 25 IS 9 BP 1185 EP 1192 DI 10.1080/09540121.2012.752788 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA 207VQ UT WOS:000323633200017 PM 23320529 ER PT J AU Froehlich, JC Hausauer, BJ Federoff, DL Fischer, SM Rasmussen, DD AF Froehlich, Janice C. Hausauer, Brett J. Federoff, David L. Fischer, Stephen M. Rasmussen, Dennis D. TI Prazosin Reduces Alcohol Drinking Throughout Prolonged Treatment and Blocks the Initiation of Drinking in Rats Selectively Bred for High Alcohol Intake SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Prazosin; Alcohol; Alcohol-Preferring (P) Rats; Noradrenergic System; Alcohol Relapse; Alcoholism Pharmacotherapies ID ALPHA(1)-ADRENERGIC RECEPTOR ANTAGONIST; PREFERRING P RATS; ANXIETY DISORDERS; BLOOD-PRESSURE; ETHANOL; STRESS; DEPENDENCE; NEOPHOBIA; BRAIN; RENIN AB Background This study examined whether prazosin reduces alcohol drinking over the course of prolonged treatment and whether it blocks the initiation of alcohol drinking in rats with a genetic predisposition toward high alcohol drinking, that is alcohol-preferring (P) rats. Methods In study one, alcohol-experienced P rats that had been drinking alcohol for 2 h/d for several months were treated daily with prazosin (0, 0.5, 1.0, or 2.0mg/kg body weight [BW]) for 7weeks. In study two, alcohol-naive P rats were treated daily with prazosin (0, 1.0, or 2.0mg/kg BW) for 2weeks prior to, or concomitantly with, the initiation of alcohol access and throughout 3weeks of alcohol availability. Prazosin treatment and alcohol access were then discontinued for 2weeks followed by reinstatement of alcohol access without prazosin treatment for 4weeks, followed by resumption of daily prazosin treatment (2.0mg/kg BW) for 3weeks. Results Prazosin reduced alcohol drinking throughout 7weeks of treatment in P rats accustomed to drinking alcohol. Following termination of prazosin treatment, alcohol drinking slowly returned to pretreatment baseline. Reduced alcohol intake was accompanied by increased water intake. In alcohol-naive P rats, prazosin administration prior to the first opportunity to drink alcohol and throughout 3weeks of alcohol access retarded acquisition of alcohol drinking and reduced the amount of alcohol consumed. When prazosin was administered concomitantly with the first opportunity to drink alcohol, it abolished acquisition of alcohol drinking. Discontinuation of prazosin treatment allowed expression of a genetic predisposition toward high alcohol drinking to gradually emerge. Prazosin retained the ability to reduce alcohol intake with repeated treatments. Conclusions Prazosin decreased alcohol drinking during prolonged treatment and may be useful for treating alcoholism and alcohol-use disorders. Prazosin may also be useful for deterring the initiation of drinking in individuals with a family history of alcoholism. C1 [Froehlich, Janice C.; Hausauer, Brett J.; Federoff, David L.; Fischer, Stephen M.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Rasmussen, Dennis D.] VA Puget Sound Hlth Care Syst, VISN Mental Illness Res Educ & Clin Ctr 20, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. RP Froehlich, JC (reprint author), Indiana Univ Sch Med, 975 West Walnut St IB 448, Indianapolis, IN 46202 USA. EM jcfroehl@iupui.edu FU NIH [AA018604, AA07611, AA13881] FX We thank Dr. Ting-Kai Li and the Indiana Alcohol Research Center for supplying the selectively bred rats used in this study. This work was supported by NIH grants AA018604 (JCF and DDR), AA07611 (JCF), and AA13881 (DDR). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Alcohol Abuse and Alcoholism or the National Institutes of Health. NR 56 TC 16 Z9 16 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD SEP PY 2013 VL 37 IS 9 BP 1552 EP 1560 DI 10.1111/acer.12116 PG 9 WC Substance Abuse SC Substance Abuse GA 208KE UT WOS:000323676600014 PM 23731093 ER PT J AU Saliminejad, M Bemanian, S Ho, A Spiegel, B Laine, L AF Saliminejad, M. Bemanian, S. Ho, A. Spiegel, B. Laine, L. TI The yield and cost of colonoscopy in patients with metastatic cancer of unknown primary SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID PRIMARY TUMORS; PRIMARY SITE; CARCINOMA; EPIDEMIOLOGY; PROFILE AB Background Although gastroenterologists are asked to perform colonoscopy in patients with metastatic cancer of unknown primary (MCUP), studies evaluating this practice are lacking. Aim To determine the yield and cost of colonoscopy in patients referred for colonoscopy with an indication of MCUP. Methods We prospectively and retrospectively assessed colonoscopies performed from 2000 to 2011 at a county, a university, and a Veterans Administration medical centre to identify patients referred for colonoscopy for the indication of MCUP. Exclusion criteria included overt or occult bleeding, iron-deficiency anaemia, familial-colon-cancer syndrome, prior colon cancer, imaging suggesting colorectal lesion, and palpable rectal mass. Outcomes were the number of primary colon cancers and costs based on 2012 Medicare reimbursements. Results Two (1%) of the 160 patients meeting enrollment criteria had a primary colon cancer identified, and both died within 1month after diagnosis without receiving therapy targeted at colon cancer. One patient without colon cancer had a perforation because of colonoscopy, which required surgery and colostomy. The cost of a strategy of routinely performing colonoscopy in patients referred with MCUP was $84736 per colon primary identified. Conclusions Primary colon cancer was rarely identified at colonoscopy in patients with MCUP and no standard indications for diagnostic colonoscopy. Furthermore, the cost to diagnose one additional colon primary was very high. Those with colon cancer had advanced disease and were unable to benefit from targeted therapy. Routine colonoscopy for MCUP cannot be recommended at present. C1 [Saliminejad, M.; Bemanian, S.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Ho, A.; Spiegel, B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Ho, A.; Spiegel, B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Laine, L.] Yale Univ, Sch Med, New Haven, CT 06520 USA. [Laine, L.] VA Connecticut Healthcare Syst, West Haven, CT USA. RP Laine, L (reprint author), Yale Univ, Sect Digest Dis, Sch Med, POB 208019, New Haven, CT 06520 USA. EM loren.laine@yale.edu NR 15 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-2813 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD SEP PY 2013 VL 38 IS 6 BP 628 EP 633 DI 10.1111/apt.12429 PG 6 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 204OC UT WOS:000323375800008 PM 23869398 ER PT J AU Sabodash, V Mendez, MF Fong, S Hsiao, JJ AF Sabodash, Valeriy Mendez, Mario F. Fong, Sylvia Hsiao, Julia J. TI Suicidal Behavior in Dementia: A Special Risk in Semantic Dementia SO AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS LA English DT Article DE dementia; semantic dementia; Alzheimer's disease; suicide; suicidal; depression; primary progressive aphasia ID ALZHEIMERS-DISEASE; FRONTOTEMPORAL DEMENTIA; DEGENERATION; DYSFUNCTION; CONSENSUS; IDEATION; FEATURES; PEOPLE; MILD; LIFE AB Background: Some studies report a low suicide risk in general dementia and in Alzheimer's disease (AD). Objective: To evaluate suicidal behavior among patients with semantic dementia (SD), a disorder that impairs semantic knowledge. Methods: We reviewed the presence of active suicidal behavior and related factors among 25 patients with SD compared to 111 age-matched patients with early-onset AD. Results: In all, 5 (20%) patients with SD had suicidal behavior (2 successfully killed themselves) compared to 1 (0.9%) with AD (P < .001). There was significantly more depression and greater premorbid history of suicidal behavior among the patients with SD compared to those with AD. Among the patients with SD, those with suicidal behavior, compared to those without, had more depression and greater insight into their deficits. Conclusions: Patients with SD are at special risk of committing suicide, particularly if they have depression and preserved insight. Possible mechanisms include an impaired sense of semantic competence with increased impulsivity. C1 [Sabodash, Valeriy; Mendez, Mario F.; Hsiao, Julia J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Sabodash, Valeriy; Mendez, Mario F.; Fong, Sylvia; Hsiao, Julia J.] VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit 691 116AF, Los Angeles, CA 90073 USA. [Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. RP Sabodash, V (reprint author), VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit 691 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@UCLA.edu FU National Institute on Aging [R01 AG034499] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: National Institute on Aging R01 AG034499 (MFM). NR 38 TC 7 Z9 8 U1 3 U2 20 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1533-3175 J9 AM J ALZHEIMERS DIS JI Am. J. Alzheimers Dis. Other Dement. PD SEP PY 2013 VL 28 IS 6 BP 592 EP 599 DI 10.1177/1533317513494447 PG 8 WC Geriatrics & Gerontology; Clinical Neurology SC Geriatrics & Gerontology; Neurosciences & Neurology GA 207YS UT WOS:000323641500007 PM 23821774 ER PT J AU Sher, L AF Sher, Leo TI Psychological autopsy studies: Past, present, and future SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY LA English DT Letter ID SUICIDE C1 [Sher, Leo] James J Peters Vet Adm Med Ctr, Bronx, NY 10468 USA. [Sher, Leo] Mt Sinai Sch Med, New York, NY USA. RP Sher, L (reprint author), James J Peters Vet Adm Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM Leo.Sher@mssm.edu NR 5 TC 4 Z9 4 U1 1 U2 11 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0004-8674 J9 AUST NZ J PSYCHIAT JI Aust. N. Z. J. Psych. PD SEP PY 2013 VL 47 IS 9 BP 884 EP 884 DI 10.1177/0004867413479071 PG 1 WC Psychiatry SC Psychiatry GA 208GS UT WOS:000323666500021 PM 23411093 ER PT J AU Turner, EH AF Turner, Erick H. TI Author's Reply to Shrier: "Publication Bias, With a Focus on Psychiatry: Causes and Solutions" SO CNS DRUGS LA English DT Letter ID TRIALS; PROTOCOLS; OUTCOMES C1 [Turner, Erick H.] Behav Hlth & Neurosci Div, Portland, ME USA. [Turner, Erick H.] Portland VA Med Ctr, Portland, OR 97239 USA. [Turner, Erick H.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Turner, Erick H.] Oregon Hlth & Sci Univ, Dept Pharmacol, Portland, OR 97201 USA. [Turner, Erick H.] Oregon Hlth & Sci Univ, Ctr Eth Hlth Care, Portland, OR 97201 USA. RP Turner, EH (reprint author), Behav Hlth & Neurosci Div, Portland, ME USA. EM turnere@ohsu.edu RI Turner, Erick/A-4848-2008 OI Turner, Erick/0000-0002-3522-3357 NR 7 TC 0 Z9 0 U1 0 U2 2 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 1172-7047 J9 CNS DRUGS JI CNS Drugs PD SEP PY 2013 VL 27 IS 9 BP 775 EP 776 DI 10.1007/s40263-013-0099-1 PG 2 WC Clinical Neurology; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 207RJ UT WOS:000323620900009 PM 23907702 ER PT J AU Sosenko, JM Skyler, JS Palmer, JP Krischer, JP Yu, LP Mahon, J Beam, CA Boulware, DC Rafkin, L Schatz, D Eisenbarth, G AF Sosenko, Jay M. Skyler, Jay S. Palmer, Jerry P. Krischer, Jeffrey P. Yu, Liping Mahon, Jeffrey Beam, Craig A. Boulware, David C. Rafkin, Lisa Schatz, Desmond Eisenbarth, George CA Type 1 Diabetes TrialNet Grp Diabet Prevention Trial-Type 1 Stu TI The Prediction of Type 1 Diabetes by Multiple Autoantibody Levels and Their Incorporation Into an Autoantibody Risk Score in Relatives of Type 1 Diabetic Patients SO DIABETES CARE LA English DT Article ID ANTIBODY-POSITIVE RELATIVES; PREVENTION TRIAL-TYPE-1; 1ST-DEGREE RELATIVES; METABOLIC MARKERS; GLUCOSE-TOLERANCE; INSULIN-SECRETION; NATURAL-HISTORY; CHILDREN; MELLITUS; VALIDATION AB OBJECTIVE We assessed whether a risk score that incorporates levels of multiple islet autoantibodies could enhance the prediction of type 1 diabetes (T1D).RESEARCH DESIGN AND METHODS TrialNet Natural History Study participants (n = 784) were tested for three autoantibodies (GADA, IA-2A, and mIAA) at their initial screening. Samples from those positive for at least one autoantibody were subsequently tested for ICA and ZnT8A. An autoantibody risk score (ABRS) was developed from a proportional hazards model that combined autoantibody levels from each autoantibody along with their designations of positivity and negativity.RESULTS The ABRS was strongly predictive of T1D (hazard ratio [with 95% CI] 2.72 [2.23-3.31], P < 0.001). Receiver operating characteristic curve areas (with 95% CI) for the ABRS revealed good predictability (0.84 [0.78-0.90] at 2 years, 0.81 [0.74-0.89] at 3 years, P < 0.001 for both). The composite of levels from the five autoantibodies was predictive of T1D before and after an adjustment for the positivity or negativity of autoantibodies (P < 0.001). The findings were almost identical when ICA was excluded from the risk score model. The combination of the ABRS and the previously validated Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) predicted T1D more accurately (0.93 [0.88-0.98] at 2 years, 0.91 [0.83-0.99] at 3 years) than either the DPTRS or the ABRS alone (P 0.01 for all comparisons).CONCLUSIONS These findings show the importance of considering autoantibody levels in assessing the risk of T1D. Moreover, levels of multiple autoantibodies can be incorporated into an ABRS that accurately predicts T1D. C1 [Sosenko, Jay M.; Skyler, Jay S.; Rafkin, Lisa] Univ Miami, Div Endocrinol, Miami, FL 33152 USA. [Palmer, Jerry P.] Univ Washington, Div Endocrinol Metab & Nutr, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Krischer, Jeffrey P.; Beam, Craig A.; Boulware, David C.] Univ S Florida, Div Informat & Biostat, Tampa, FL USA. [Yu, Liping; Eisenbarth, George] Univ Colorado, Hlth Sci Ctr, Barbara Davis Ctr Childhood Diabet, HLA DNA Lab, Denver, CO 80262 USA. [Mahon, Jeffrey] Univ Western Ontario, Dept Epidemiol & Biostat, London, ON, Canada. [Schatz, Desmond] Univ Florida, Div Endocrinol, Gainesville, FL USA. RP Sosenko, JM (reprint author), Univ Miami, Div Endocrinol, Miami, FL 33152 USA. EM jsosenko@med.miami.edu RI Moore, Daniel/A-4924-2008; Skyler, Jay/F-4211-2016 OI Moore, Daniel/0000-0002-6889-9345; FU National Institutes of Health (NIH) through the National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development [U01-DK-061010, U01-DK-061016, U01-DK-061034, U01-DK-061036, U01-DK-061040, U01-DK-061041, U01-DK-061042, U01-DK-061055, U01-DK-061058, U01-DK-084565, U01-DK-085453, U01-DK-085461, U01-DK-085463, U01-DK-085466, U01-DK-085499, U01-DK-085505, U01-DK-085509, HHSN267200800019C]; National Center for Research Resources through Clinical Translational Science Awards [UL1-RR-024131, UL1-RR-024139, UL1-RR-024153, UL1-RR-024975, UL1-RR-024982, UL1-RR-025744, UL1-RR-025761, UL1-RR-025780, UL1-RR-029890, UL1-RR-031986, P30-DK-017047]; General Clinical Research Center Award [M01-RR-00400]; JDRF; American Diabetes Association (ADA) FX The sponsor of the trial was the Type 1 Diabetes TrialNet Study Group. The Type 1 Diabetes TrialNet Study Group is a clinical trials network funded by the National Institutes of Health (NIH) through the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Allergy and Infectious Diseases, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development through cooperative agreements U01-DK-061010, U01-DK-061016, U01-DK-061034, U01-DK-061036, U01-DK-061040, U01-DK-061041, U01-DK-061042, U01-DK-061055, U01-DK-061058, U01-DK-084565, U01-DK-085453, U01-DK-085461, U01-DK-085463, U01-DK-085466, U01-DK-085499, U01-DK-085505, and U01-DK-085509 and contract HHSN267200800019C; the National Center for Research Resources through Clinical Translational Science Awards UL1-RR-024131, UL1-RR-024139, UL1-RR-024153, UL1-RR-024975, UL1-RR-024982, UL1-RR-025744, UL1-RR-025761, UL1-RR-025780, UL1-RR-029890, UL1-RR-031986, and P30-DK-017047 and General Clinical Research Center Award M01-RR-00400; the JDRF; and the American Diabetes Association (ADA). NR 30 TC 38 Z9 38 U1 4 U2 41 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD SEP PY 2013 VL 36 IS 9 BP 2615 EP 2620 DI 10.2337/dc13-0425 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 205CZ UT WOS:000323420200048 PM 23818528 ER PT J AU Meek, TH Matsen, ME Dorfman, MD Guyenet, SJ Damian, V Nguyen, HT Taborsky, GJ Morton, GJ AF Meek, Thomas H. Matsen, Miles E. Dorfman, Mauricio D. Guyenet, Stephan J. Damian, Vincent Nguyen, Hong T. Taborsky, Gerald J., Jr. Morton, Gregory J. TI Leptin Action in the Ventromedial Hypothalamic Nucleus Is Sufficient, But Not Necessary, to Normalize Diabetic Hyperglycemia SO ENDOCRINOLOGY LA English DT Article ID GLUCOSE-UPTAKE; CARDIOVASCULAR ACTIONS; PERIPHERAL-TISSUES; WEIGHT HOMEOSTASIS; INSULIN-RESISTANCE; NERVOUS-SYSTEM; FOOD-INTAKE; RATS; NEURONS; CNS AB In rodent models of type 1 diabetes, leptin administration into brain ventricles normalizes blood glucose at doses that have no effect when given peripherally. The ventromedial nucleus of the hypothalamus (VMN) is a potential target for leptin's antidiabetic effects because leptin-sensitive neurons in this brain area are implicated in glucose homeostasis. To test this hypothesis, we injected leptin directly into the bilateral VMN of rats with streptozotocin-induced uncontrolled diabetes mellitus. This intervention completely normalized both hyperglycemia and the elevated rates of hepatic glucose production and plasma glucagon levels but had no effect on tissue glucose uptake in the skeletal muscle or brown adipose tissue as measured using tracer dilution techniques during a basal clamp. To determine whether VMN leptin signaling is required for leptin-mediated normalization of diabetic hyperglycemia, we studied mice in which the leptin receptor gene was deleted in VMN steroidogenic factor 1 neurons using cre-loxP technology. Our findings indicate leptin action within these neurons is not required for the correction of diabetic hyperglycemia by central leptin infusion. We conclude that leptin signaling in the VMN is sufficient to mediate leptin's antidiabetic action but may not be necessary for this effect. Leptin action within a distributed neuronal network may mediate its effects on glucose homeostasis. C1 [Meek, Thomas H.; Matsen, Miles E.; Dorfman, Mauricio D.; Guyenet, Stephan J.; Damian, Vincent; Nguyen, Hong T.; Morton, Gregory J.] Univ Washington, Diabet & Obes Ctr Excellence, Dept Med, Seattle, WA 98109 USA. [Taborsky, Gerald J., Jr.] Vet Affairs Puget Sound Hlth Care Syst, Dept Vet Affairs Med Ctr, Seattle, WA 98108 USA. RP Morton, GJ (reprint author), Univ Washington South Lake Union, Dept Med, 850 Republican St,N334,Box 358055, Seattle, WA 98195 USA. EM gjmorton@u.washington.edu FU Novo Nordisk Proof-of-Principle Award; National Institutes of Health [DK089053, DK050154]; Nutrition Obesity Research Center [DK035816]; Diabetes and Metabolism Training Grants [F32 DK097859, T32 DK0007247] FX This work was supported by a Novo Nordisk Proof-of-Principle Award (to G.J.M.), National Institutes of Health Grants DK089053 (to G.J.M.), and DK050154 (to G.J.T.), the Nutrition Obesity Research Center Grant DK035816, and the Diabetes and Metabolism Training Grants F32 DK097859 and T32 DK0007247. NR 33 TC 14 Z9 14 U1 0 U2 2 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD SEP PY 2013 VL 154 IS 9 BP 3067 EP 3076 DI 10.1210/en.2013-1328 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 207RE UT WOS:000323620100012 PM 23782941 ER PT J AU Garcia, JM Scherer, T Chen, JA Guillory, B Nassif, A Papusha, V Smiechowska, J Asnicar, M Buettner, C Smith, RG AF Garcia, Jose M. Scherer, Thomas Chen, Ji-an Guillory, Bobby Nassif, Anriada Papusha, Victor Smiechowska, Joanna Asnicar, Mark Buettner, Christoph Smith, Roy G. TI Inhibition of Cisplatin-Induced Lipid Catabolism and Weight Loss by Ghrelin in Male Mice SO ENDOCRINOLOGY LA English DT Article ID HORMONE-SENSITIVE LIPASE; FATTY-ACID OXIDATION; SKELETAL-MUSCLE; ADIPOSE-TISSUE; CANCER CACHEXIA; METABOLISM; LIPOLYSIS; ANOREXIA; RATS; IDENTIFICATION AB Cachexia, defined as an involuntary weight loss >= 5%, is a serious and dose-limiting side effect of chemotherapy that decreases survival in cancer patients. Alterations in lipid metabolism are thought to cause the lipodystrophy commonly associated with cachexia. Ghrelin has been proposed to ameliorate the alterations in lipid metabolism due to its orexigenic and anabolic properties. However, the mechanisms of action through which ghrelin could potentially ameliorate chemotherapy-associated cachexia have not been elucidated. The objectives of this study were to identify mechanisms by which the chemotherapeutic agent cisplatin alters lipid metabolism and to establish the role of ghrelin in reversing cachexia. Cisplatin-induced weight and fat loss were prevented by ghrelin. Cisplatin increased markers of lipolysis in white adipose tissue (WAT) and of beta-oxidation in liver and WAT and suppressed lipogenesis in liver, WAT, and muscle. Ghrelin prevented the imbalance between lipolysis, beta-oxidation, and lipogenesis in WAT and muscle. Pair-feeding experiments demonstrated that the effects of cisplatin and ghrelin on lipogenesis, but not on lipolysis and beta-oxidation, were due to a reduction in food intake. Thus, ghrelin prevents cisplatin-induced weight and fat loss by restoring adipose tissue functionality. An increase in caloric intake further enhances the anabolic effects of ghrelin. C1 [Garcia, Jose M.; Chen, Ji-an; Guillory, Bobby; Papusha, Victor; Smiechowska, Joanna] Baylor Coll Med, Dept Med & Mol & Cell Biol, Ctr Translat Res Inflammatory Dis, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Garcia, Jose M.; Papusha, Victor; Smiechowska, Joanna; Asnicar, Mark; Smith, Roy G.] Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA. [Scherer, Thomas; Buettner, Christoph] Mt Sinai Sch Med, Dept Med & Neurosci, New York, NY 10029 USA. [Nassif, Anriada] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15261 USA. RP Garcia, JM (reprint author), Michael E DeBakey VA Med Ctr, Div Endocrinol Diabet & Metab, 2002 Holcombe Blvd,Bldg 109,Room 210, Houston, TX 77584 USA. EM jgarcia1@bcm.edu FU US Department of Veterans Affairs (MERIT) [I01-BX000507, I01 CX000174]; US Department of Veterans Affairs (MREP); US Department of Veterans Affairs (SHCNCDA); Caroline Wiess Law Fund for Molecular Medicine; NIH [AG040583, T32AG000183, DK083658, DK082724, DK059637, DK020593]; Irma T. Hirschl Scholar Award; University of Virginia [DK076037]; Baylor Diabetes and Endocrinology Research Center [P30 DK079638]; University of Pittsburgh School of Medicine Dean's Summer Research Program [DK 065521]; [U24 DK59637] FX This work was supported by the US Department of Veterans Affairs (MERIT grants I01-BX000507 and I01 CX000174, MREP, and a SHCNCDA); the Caroline Wiess Law Fund for Molecular Medicine (to J.M.G.) and NIH Grants AG040583 (to J.M.G.), T32AG000183 (to J.M.G. and B. G.), and DK083658 and DK082724 (to C. B.) C. B. is the recipient of an Irma T. Hirschl Scholar Award. The Vanderbilt MMPC was supported in part by U24 DK59637; Vanderbilt University Medical Center Hormone Assay and Analytical Services Core was supported by NIH Grants DK059637 and DK020593; University of Virginia and Baylor Diabetes and Endocrinology Research Center received grants (DK076037 and P30 DK079638, respectively). A.N. received support from the University of Pittsburgh School of Medicine Dean's Summer Research Program T35 Grant DK 065521. NR 41 TC 20 Z9 20 U1 0 U2 12 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD SEP PY 2013 VL 154 IS 9 BP 3118 EP 3129 DI 10.1210/en.2013-1179 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 207RE UT WOS:000323620100017 PM 23832960 ER PT J AU Dyer, CA AF Dyer, Christopher A. TI Safety and tolerability of paricalcitol in patients with chronic kidney disease SO EXPERT OPINION ON DRUG SAFETY LA English DT Review DE chronic kidney disease; hyperparathyroidism; paricalcitol; proteinuria; vitamin D ID RANDOMIZED CONTROLLED-TRIAL; DOSE VITAMIN-D; PATIENTS RECEIVING HEMODIALYSIS; SECONDARY HYPERPARATHYROIDISM; PARATHYROID-HORMONE; RENAL-FAILURE; CARDIOVASCULAR-DISEASE; DIALYSIS PATIENTS; 19-NOR-1-ALPHA,25-DIHYDROXYVITAMIN D-2; ORAL PARICALCITOL AB Introduction: Secondary hyperparathyroidism (SHPT) is a complication of chronic kidney disease (CKD). Beyond skeletal complications, uncontrolled SHPT is associated with cardiovascular mortality. Vitamin D receptor activators (VDRAs) are a mainstay of therapy for SHPT; however, use is limited by hypercalcemia, though less so with calcitriol analogs such as paricalcitol and there is emerging experience with oral formulations for non-SHPT indications. The role of VDRAs in the treatment of SHPT becomes a complex question as alternative strategies have developed. Areas covered: This review summarizes trials that established the safety and efficacy of paricalcitol for SHPT. Comparative experience with paricalcitol as against other VDRAs will be reviewed as will the experience with paricalcitol in non-dialysis CKD and comparative experience with non-VDRA-based therapy. Expert opinion: VDRA therapy is considered first-line therapy for treatment of SHPT. Paricalcitol has demonstrated superiority to calcitriol with respect to parathyroid hormone suppression and calcium-phosphorus balance. Oral formulations of paricalcitol appear to be similarly effective for SHPT. While there is evidence to suggest adjunctive antiproteinuria benefit with the use of VDRAs, efficacy of these agents to slow the progression of CKD or to reduce cardiovascular risk has not yet been demonstrated. C1 Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Dyer, CA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, 7703 Floyd Curl Dr,MC 7882, San Antonio, TX 78229 USA. EM DyerCA@uthscsa.edu NR 56 TC 4 Z9 4 U1 0 U2 7 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1474-0338 J9 EXPERT OPIN DRUG SAF JI Expert Opin. Drug Saf. PD SEP PY 2013 VL 12 IS 5 BP 717 EP 728 DI 10.1517/14740338.2013.791675 PG 12 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 206AW UT WOS:000323488900012 PM 23621417 ER PT J AU Husain, N Chen, TC Hou, JK AF Husain, Nisreen Chen, Tien-Chun Hou, Jason K. TI An Unusual Cause of Diarrhea in an Immunocompromised Patient Scedosporium apiospermum Colitis and Brain Abscess SO GASTROENTEROLOGY LA English DT Editorial Material C1 [Husain, Nisreen; Chen, Tien-Chun; Hou, Jason K.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Husain, Nisreen; Hou, Jason K.] Baylor Coll Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA. [Chen, Tien-Chun] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. RP Husain, N (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD SEP PY 2013 VL 145 IS 3 BP 519 EP + DI 10.1053/j.gastro.2013.06.006 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 207PG UT WOS:000323613700017 PM 23896373 ER PT J AU Ather, S Bavishi, C McCauley, MD Dhaliwal, A Deswal, A Johnson, S Chan, W Aguilar, D Pritchett, AM Ramasubbu, K Wehrens, XHT Bozkurt, B AF Ather, Sameer Bavishi, Chirag McCauley, Mark D. Dhaliwal, Amandeep Deswal, Anita Johnson, Sarah Chan, Wenyaw Aguilar, David Pritchett, Allison M. Ramasubbu, Kumudha Wehrens, Xander H. T. Bozkurt, Biykem TI Worsening renal function is not associated with response to treatment in acute heart failure SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Article DE BNP; Renal function; Heart failure ID BRAIN NATRIURETIC PEPTIDE; SERUM CREATININE; CARDIORENAL INTERACTIONS; HOSPITALIZED-PATIENTS; OUTCOMES; IMPACT; ADMISSION AB Background: About a fourth of acute decompensated heart failure (ADHF) patients develop renal dysfunction during their admission. To date, the association of ADHF treatment with the development of worsening renal function (WRF) remains contentious. Thus, we examined the association of WRF with changes in BNP levels and with mortality. Methods: We performed retrospective chart review of patients admitted with ADHF who had BNP, eGFR, creatinine and blood urea nitrogen (BUN) values measured both on admission and discharge. Survival analysis was conducted using Cox proportional hazards model and correlation was measured using Spearman's rank correlation test. Results: 358 patients admitted for ADHF were evaluated. WRF was defined as >20% reduction in eGFR from admission to discharge and response to treatment was assessed by Delta BNP. There was a statistically significant reduction in BNP and increase in BUN during the admission. Delta BNP did not correlate with either Delta GFR or Delta BUN. Patients who developed WRF and those who did not, had a similar reduction in BNP. On univariate survival analysis, Delta BUN, but not Delta eGFR, was associated with 1-year mortality. In multivariate Cox proportional hazards model, BUN at discharge was associated with 1-year mortality (HR: 1.02, p<0.001), but Delta eGFR and Delta BUN were not associated with the primary endpoint. Conclusion: During ADHF treatment, Delta BNP was not associated with changes in renal function. Development of WRF during ADHF treatment was not associated with mortality. Our study suggests that development of WRF should not preclude diuresis in ADHF patients in the absence of volume depletion. (C) 2012 Published by Elsevier Ireland Ltd. C1 [Ather, Sameer; McCauley, Mark D.; Deswal, Anita; Aguilar, David; Pritchett, Allison M.; Ramasubbu, Kumudha; Wehrens, Xander H. T.; Bozkurt, Biykem] Baylor Coll Med, Dept Med, Cardiol Sect, Houston, TX 77030 USA. [Bavishi, Chirag; Chan, Wenyaw] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA. [Dhaliwal, Amandeep] Univ Iowa, Dept Med, Cardiol Sect, Iowa City, IA 52242 USA. [Deswal, Anita; Johnson, Sarah; Bozkurt, Biykem] Baylor Coll Med, DeBakey VA Med Ctr, Winters Ctr Heart Failure Res, Houston, TX 77030 USA. RP Bozkurt, B (reprint author), Michael E DeBakey VA Med Ctr, Div Cardiol, Winters Ctr Heart Failure, 3C-310 F,2002 Holcombe Blvd, Houston, TX 77030 USA. EM bbozkurt@bcm.edu OI ather, sameer/0000-0002-5579-0658 FU American Heart Association SCA predoctoral fellowship; Alkek foundation fellowship FX S.A. is supported by American Heart Association SCA predoctoral fellowship (2010-2012) and Alkek foundation fellowship (2009-2012). NR 22 TC 8 Z9 8 U1 0 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-5273 J9 INT J CARDIOL JI Int. J. Cardiol. PD SEP 1 PY 2013 VL 167 IS 5 BP 1912 EP 1917 DI 10.1016/j.ijcard.2012.05.004 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 207AU UT WOS:000323569600048 PM 22633437 ER PT J AU Harbaugh, MP Manuck, SB Jennings, JR Conklin, SM Yao, JK Muldoon, MF AF Harbaugh, Matthew P. Manuck, Stephen B. Jennings, J. Richard Conklin, Sarah M. Yao, Jeffrey K. Muldoon, Matthew F. TI Long-chain, n-3 fatty acids and physical activity - Independent and interactive associations with cardiac autonomic control SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Article DE n-3 fatty acids; Exercise; HRV ID HEART-RATE-VARIABILITY; MYOCARDIAL-INFARCTION; FISH-OIL; HEALTHY-VOLUNTEERS; COLLEGE ALUMNI; EXERCISE; BLOOD; MORTALITY; RISK; OMEGA-3-FATTY-ACIDS AB Background/objectives: Intake of the marine-based, n-3 fatty acids and engagement in physical activity are inversely related to cardiac morbidity and mortality. Among putative mechanisms, both n-3 fatty acids and physical activity may act through modulation of autonomic control of the cardiovascular system. This investigation examined the independent and interactive associations of n-3 fatty acids (eicosapentaenoic and docosahexanenoic acid; EPA, DHA) and physical activity with heart rate variability (HRV). Methods: Subjects were 259 healthy 30-54 year-old adults. Serum phospholipid fatty acid composition was employed as a biomarker of dietary n-3 fatty acid exposure. Physical activity based on the Paffenbarger questionnaire was coded as < or >= 2000 kcal/week. Standard time-domain (standard deviation of normal-to-normal intervals and root-mean squared of successive differences; SDNN, RMSSD) and frequency domain (high frequency and low frequency power) measures of HRV were derived from resting electrocardiographic recordings. Results: In linear regression models with covariate adjustment for age, gender and race, greater n-3 fatty acid exposure was associated with greater SDNN and RMSSD, and high physical activity was associated with greater RMSSD. n-3 fatty acid exposure also predicted variation in SDNN, RMSSD, and high-frequency power in interaction with physical activity. Specifically, n-3 fatty acid exposure covaried positively with these three HRV indices only among participants expending 2000 kcal per week or more in physical activity. These latter findings were noted for DHA but not EPA. Conclusions: These results suggest that the cardiovascular benefits of n-3 fatty acid consumption may be mediated, in part, by effects on cardiac autonomic control and may be dependent upon concomitant habitual exercise. (C) 2012 Elsevier Ireland Ltd. All rights reserved. C1 [Harbaugh, Matthew P.] UPMC St Margarets, Pittsburgh, PA USA. [Manuck, Stephen B.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. [Jennings, J. Richard] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Conklin, Sarah M.] Allegheny Coll, Dept Psychol, Meadville, PA 16335 USA. [Yao, Jeffrey K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Muldoon, Matthew F.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. RP Muldoon, MF (reprint author), Univ Pittsburgh, Old Engn Hall,Room 506, Pittsburgh, PA 15260 USA. EM mfm10@pitt.edu FU US Public Health Service Awards [T32 HL07560, P01 HL40962, R21 HL081282] FX US Public Health Service Awards T32 HL07560, P01 HL40962, and R21 HL081282. NR 44 TC 1 Z9 1 U1 0 U2 11 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-5273 J9 INT J CARDIOL JI Int. J. Cardiol. PD SEP 1 PY 2013 VL 167 IS 5 BP 2102 EP 2107 DI 10.1016/j.ijcard.2012.05.110 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 207AU UT WOS:000323569600078 PM 22704872 ER PT J AU Suffoletto, B Akers, A McGinnis, KA Calabria, J Wiesenfeld, HC Clark, DB AF Suffoletto, Brian Akers, Aletha McGinnis, Kathleen A. Calabria, Jaclyn Wiesenfeld, Harold C. Clark, Duncan B. TI A Sex Risk Reduction Text-Message Program for Young Adult Females Discharged From the Emergency Department SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE Young adult; Health promotion; Sexual health; Text messaging ID RANDOMIZED CONTROLLED-TRIAL; SEXUALLY-TRANSMITTED-DISEASES; UNITED-STATES; HEALTH-CARE; BEHAVIOR; ADOLESCENTS; SERVICE; PEOPLE; SMS; INTERVENTIONS AB Purpose: To pilot test a text message (SMS) sex risk reduction program among at-risk young adult female patients discharged from an emergency department (ED). Methods: A convenience sample of 52 female patients with hazardous drinking behavior and recent risky sexual encounters were recruited from an urban ED and randomized to the SMS program (n = 23) or a control group (n = 29). All participants completed a web-based questionnaire in the ED and at 3-month follow-up. For 12 weeks, SMS participants were asked to report whether they had a risky sexual encounter in the past week, received theory-based feedback, and were asked if they were willing set a goal to refrain from having another risky encounter. Results: Thirty-nine percent of SMS participants completed all weeks of SMS reports, and non-completion increasing from 12% on week 1 to a 33% by week 12. Three-month follow-up was completed in 56% of participants. In the intervention group, there was an increase in the proportion with condom use with last vaginal sex from 20% (95% CI 4%-48%) to 53% (95% CI 27%-79%) and an increase in always condom use over the past 28 days from 0% (95% CI 0%-22%) to 33% (95% CI 12%-62%). These changes were not statistically different from control participants. Conclusions: SMS programs may be useful to reduce risk for sexually transmitted diseases among at-risk young adults being discharged from the ED. Future trials should examine ways to improve adherence to SMS dialog over time and measure objective outcomes in a larger sample. (C) 2013 Society for Adolescent Health and Medicine. All rights reserved. C1 [Suffoletto, Brian; Calabria, Jaclyn] Univ Pittsburgh, Sch Med, Dept Emergency Med, Pittsburgh, PA 15221 USA. [Akers, Aletha; Wiesenfeld, Harold C.] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15221 USA. [McGinnis, Kathleen A.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Clark, Duncan B.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15221 USA. RP Suffoletto, B (reprint author), Univ Pittsburgh, 3600 Forbes Ave,Iroquois Bldg,Suite 400A, Pittsburgh, PA 15221 USA. EM suffbp@upmc.edu FU EMF-Century Council; Robert Wood Johnson Foundation Harold Amos Medical Faculty Development Program; [R01AA016482]; [P50DA05605] FX The authors thank Jack Doman in the Office of Academic Computing at the Western Psychiatric Institute at the University of Pittsburgh for all computer programming support. B. S. is supported by an EMF-Century Council grant, A. A. is supported by the Robert Wood Johnson Foundation Harold Amos Medical Faculty Development Program, and D.B.C. is supported by R01AA016482 and P50DA05605. NR 38 TC 17 Z9 17 U1 3 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD SEP PY 2013 VL 53 IS 3 BP 387 EP 393 DI 10.1016/j.jadohealth.2013.04.006 PG 7 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 207MA UT WOS:000323602900014 PM 23707402 ER PT J AU Muldoon, MF Erickson, KI Goodpaster, BH Jakicic, JM Conklin, SM Sekikawa, A Yao, JK Manuck, SB AF Muldoon, Matthew F. Erickson, Kirk I. Goodpaster, Bret H. Jakicic, John M. Conklin, Sarah M. Sekikawa, Akira Yao, Jeffrey K. Manuck, Stephen B. TI Concurrent Physical Activity Modifies the Association between n3 Long-Chain Fatty Acids and Cardiometabolic Risk in Mid life Adults SO JOURNAL OF NUTRITION LA English DT Article ID EXERCISE-INDUCED ALTERATIONS; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; FISH-OIL; METABOLIC SYNDROME; WEIGHT-LOSS; YOUNG-ADULTS; N-3; FITNESS; GLUCOSE AB Greater consumption of n3 (omega 3) polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) can reduce risk for cardiovascular disease events, yet their effects on metabolic risk factors and diabetes remain unclear. This cross-sectional study used a community volunteer sample to test whether the associations between n3 fatty acids and cardiometabolic risk vary as a function of physical activity. Participants were 344 generally healthy adults, 30-54 y of age, not taking fish oil supplements or confounding medications. Serum phospholipid EPA and DHA were used together (EPA+DHA) as a biomarker of n3 fatty acid exposure. Cardiometabolic risk was calculated as a continuous measure based on standardized distributions of blood pressure, waist circumference, HDL cholesterol, triglycerides, glucose, and a simple count of risk factors. Insulin resistance was estimated from the homeostatic model assessment. Physical activity was found to predict cardiometabolic risk (P <= 0.02) and insulin resistance (P <= 0.02) and to moderate the association between EPA+DHA and both cardiometabolic risk (P-interaction <= 0.02) and insulin resistance (P-interaction <= 0.02). Specifically, higher EPA+DHA was associated with lower cardiometabolic risk and insulin resistance in persons engaged in regular physical activity but not in relatively inactive individuals. These findings were noted in several components of cardiometabolic risk, in men and women separately, and in models adjusted for overall diet quality. In midlife adults, habitual physical activity may be necessary to unmask the salutary effects of n3 fatty acids on cardiometabolic risk and insulin resistance. C1 [Muldoon, Matthew F.] Univ Pittsburgh, Sch Med, Heart & Vasc Inst, Pittsburgh, PA 15213 USA. [Erickson, Kirk I.; Manuck, Stephen B.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. [Goodpaster, Bret H.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Jakicic, John M.] Univ Pittsburgh, Sch Educ, Dept Hlth & Phys Act, Pittsburgh, PA 15260 USA. [Conklin, Sarah M.] Allegheny Coll, Dept Psychol & Neurosci, Meadville, PA 16335 USA. [Sekikawa, Akira] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Yao, Jeffrey K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Muldoon, MF (reprint author), Univ Pittsburgh, Sch Med, Heart & Vasc Inst, Pittsburgh, PA 15213 USA. EM mfm10@pitt.edu OI Sekikawa, Akira/0000-0002-7197-6321 FU U.S. Public Health Service Awards [P01 HL40962, R21 HL081282] FX Supported by U.S. Public Health Service Awards P01 HL40962 and R21 HL081282. NR 40 TC 2 Z9 2 U1 1 U2 22 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3166 J9 J NUTR JI J. Nutr. PD SEP PY 2013 VL 143 IS 9 BP 1414 EP 1420 DI 10.3945/jn.113.174078 PG 7 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 205SX UT WOS:000323466200008 PM 23884386 ER PT J AU Polack, PO Friedman, J Golshani, P AF Polack, Pierre-Olivier Friedman, Jonathan Golshani, Peyman TI Cellular mechanisms of brain state-dependent gain modulation in visual cortex SO NATURE NEUROSCIENCE LA English DT Article ID BARREL CORTEX; CORTICAL NETWORKS; IN-VIVO; GABAERGIC NEURONS; BEHAVIORAL STATE; BASAL FOREBRAIN; ACETYLCHOLINE; NOREPINEPHRINE; ACTIVATION; NEOCORTEX AB Visual cortical neurons fire at higher rates to visual stimuli during locomotion than during immobility, while maintaining orientation selectivity. The mechanisms underlying this change in gain are not understood. We performed whole-cell recordings from layer 2/3 and layer 4 visual cortical excitatory neurons and from parvalbumin-positive and somatostatin-positive inhibitory neurons in mice that were free to rest or run on a spherical treadmill. We found that the membrane potential of all cell types became more depolarized and (with the exception of somatostatin-positive interneurons) less variable during locomotion. Cholinergic input was essential for maintaining the unimodal membrane potential distribution during immobility, whereas noradrenergic input was necessary for the tonic depolarization associated with locomotion. Our results provide a mechanism for how neuromodulation controls the gain and signal-to-noise ratio of visual cortical neurons during changes in the state of vigilance. C1 [Polack, Pierre-Olivier; Friedman, Jonathan; Golshani, Peyman] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Polack, Pierre-Olivier; Golshani, Peyman] W Los Angeles Vet Affairs Med Ctr, Dept Neurol, Los Angeles, CA 90073 USA. RP Golshani, P (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. EM pgolshani@mednet.ucla.edu OI Polack, Pierre-Olivier/0000-0003-1716-6595 FU US National Institutes of Health [KO8 NS0562101]; Whitehall Foundation [2012-05-83]; Veterans Affairs Merit Review Award [1I01BX001524-01A1] FX We acknowledge R. Gruver for technical assistance on visual stimulation, Z. Peng and C. Houser for histology, and D. Contreras, M. Einstein, T. Indersmitten, M. Javaherian, C. Kaba, S. Mahon, A. Silva and S. Singh for their thoughtful comments on the manuscript. This work was supported by the US National Institutes of Health (KO8 NS0562101), the Whitehall Foundation (grant 2012-05-83) and a Veterans Affairs Merit Review Award (1I01BX001524-01A1). NR 53 TC 128 Z9 128 U1 0 U2 35 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1097-6256 J9 NAT NEUROSCI JI Nat. Neurosci. PD SEP PY 2013 VL 16 IS 9 BP 1331 EP U227 DI 10.1038/nn.3464 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 207KN UT WOS:000323597500026 PM 23872595 ER PT J AU Oursler, KK Tate, JP Gill, TM Crothers, K Brown, TT Crystal, S Womack, J Leaf, DA Sorkin, JD Justice, AC AF Oursler, Krisann K. Tate, Janet P. Gill, Thomas M. Crothers, Kristina Brown, Todd T. Crystal, Stephen Womack, Julie Leaf, David A. Sorkin, John D. Justice, Amy C. TI Association of the Veterans Aging Cohort Study Index with Exercise Capacity in HIV-Infected Adults SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; ADVANCED HEART-FAILURE; 6-MINUTE WALK TEST; PEAK OXYGEN-UPTAKE; ANTIRETROVIRAL THERAPY; FUNCTIONAL STATUS; PHYSICAL FUNCTION; AEROBIC CAPACITY; SKELETAL-MUSCLE; MORTALITY AB Physical disability is a major priority in aging, affecting morbidity, mortality, and quality of life. Despite the large number of adults aging with HIV, our understanding of the physiologic and clinical risk factors for disability is limited. Our goal is to determine whether the Veterans Aging Cohort Study (VACS) Index, based on routine clinical blood tests, could serve as a point of care screening tool to identify HIV-infected adults at high risk for physical disability. HIV-infected adults enrolled in the VACS participated in a cross-sectional exercise study with established measures of strength and endurance. The VACS Index was calculated using recent clinical laboratory values and age; a higher score reflects greater mortality risk. Statistical analyses included correlation and linear regression models adjusted for muscle mass. Fifty-five HIV-infected adults, predominantly African-American men, were included with age mean +/- SD of 52 +/- 7 years. Median (IQR) CD4 cell count was 356 cells/mm(3) (212-527). The VACS Index was inversely correlated with quadriceps strength (r = -0.45, p < 0.01), grip strength (r = -0.28, p = 0.04), and 6-min walk distance (r = -0.27, p = 0.05). A 20-point increase in VACS Index score was associated with a 10% lower leg strength (p < 0.01), which remained significant after adjustment for muscle cross-sectional area (p = 0.02). The VACS Index explained 31% of the variance in specific leg strength. In this group of middle-aged adults with well-controlled HIV infection the VACS Index was significantly associated with upper and lower extremity strength. The VACS Index may be valuable for identification of patients at high risk for disability due to muscle weakness. C1 [Oursler, Krisann K.; Sorkin, John D.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Oursler, Krisann K.; Sorkin, John D.] Baltimore VA Med Ctr, Geriatr Res Educ & Clin Ctr, Baltimore, MD 21201 USA. [Tate, Janet P.; Justice, Amy C.] Yale Univ, Sch Med & Publ Hlth, New Haven, CT USA. [Tate, Janet P.; Justice, Amy C.] VA Connecticut Healthcare Syst, New Haven, CT USA. [Gill, Thomas M.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. [Crothers, Kristina] Univ Washington, Seattle, WA 98195 USA. [Brown, Todd T.] Johns Hopkins Sch Med, Baltimore, MD USA. [Crystal, Stephen] Rutgers State Univ, Ctr Hlth Serv Res Pharmacotherapy Chron Dis Manag, Inst Hlth, New Brunswick, NJ 08903 USA. [Womack, Julie] Yale Univ, Sch Nursing, New Haven, CT 06536 USA. [Leaf, David A.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. [Leaf, David A.] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. RP Oursler, KK (reprint author), Baltimore VA Med Ctr, BT GRECC 18, 10 North Greene St, Baltimore, MD 21201 USA. EM koursler@grecc.umaryland.edu OI Crothers, Kristina/0000-0001-9702-0371 FU National Institute on Aging (NIA) [K23 AG024896]; NIA University of Maryland Claude D. Pepper Older Americans Independence Center [P60-AG12583]; Baltimore VA Geriatric Research, Clinical and Education Center; NIA [K24AG021507, P30AG021342]; NHLBI [R01 HL090342]; NINR [K01 NR013437]; CTSA NCRR [UL1 RR024139]; NIAAA [U10-AA13566, U24-AA020794]; U.S. Department of Veterans Affairs FX Disclosure of Funding: National Institute on Aging (NIA) K23 AG024896 (Dr. Oursler), NIA University of Maryland Claude D. Pepper Older Americans Independence Center P60-AG12583 (Drs. Oursler and Sorkin), Baltimore VA Geriatric Research, Clinical and Education Center (Drs. Oursler and Sorkin), NIA K24AG021507 and P30AG021342 (Dr. Gill), NHLBI R01 HL090342 (Dr. Crothers), NINR K01 NR013437 and CTSA NCRR UL1 RR024139 (Dr. Womack), and NIAAA U10-AA13566 and U24-AA020794 and in kind by the U.S. Department of Veterans Affairs (Dr. Justice). NR 44 TC 10 Z9 10 U1 0 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD SEP PY 2013 VL 29 IS 9 BP 1218 EP 1223 DI 10.1089/aid.2012.0388 PG 6 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 204NL UT WOS:000323372600007 PM 23705911 ER PT J AU Berger, D Williams, EC Bryson, CL Rubinsky, AD Bradley, KA AF Berger, Douglas Williams, Emily C. Bryson, Chris L. Rubinsky, Anna D. Bradley, Katharine A. TI Alcohol questionnaires and HDL: Screening scores as scaled markers of alcohol consumption SO ALCOHOL LA English DT Article DE HDL cholesterol; Alcohol; Alcohol screening questionnaire ID PRIMARY-CARE PATIENTS; IDENTIFICATION TEST AUDIT; USE DISORDERS; PROBLEM DRINKING; RISK-FACTORS; HEALTH; DEPRESSION; VALIDATION; DEPENDENCE; SEVERITY AB Improving the quality of alcohol-related care requires practical approaches to assessing alcohol consumption to guide management and monitor outcomes. Given the increasing use of alcohol screening questionnaires to identify alcohol misuse it would be ideal if scores on screening questionnaires were also indicators of average alcohol consumption. However, the questionnaires were not designed for this purpose and include dimensions of drinking that may not reflect average consumption (e.g. heavy episodic drinking, alcohol-related problems). In a general population sample, scores on the AUDIT-C screen correlated with reports of alcohol consumption in detailed interviews, but the relationship is unknown for clinical populations and other questionnaires. Serum high-density lipoprotein cholesterol (HDL) is a biomarker routinely obtained in clinical care and is known to rise with average alcohol consumption. This cross-sectional study of 11,175 male U.S. Veterans Affairs patients enrolled in a primary care study used HDL as an objective biomarker to evaluate whether average alcohol consumption increased as scores increased on 3 brief alcohol screens - the AUDIT-C, AUDIT Question #3 (a single-item screen), and the CAGE questionnaire. Mean HDL progressively increased as screening scores increased for the AUDIT-C and AUDIT Question #3: about 12 mg/dL from the lowest to the highest scores. The association was much weaker for the CAGE questionnaire. Results were minimally affected by adjustment for covariates (e.g. age, race, medical comorbidity, smoking, medication count, and depression) but the association was modified (p = 0.008) and mildly attenuated by adherent use of lipid-lowering medications. This study using HDL as a biomarker of average alcohol consumption adds to evidence that some alcohol screening scores may also serve as scaled markers of average alcohol consumption. Published by Elsevier Inc. C1 [Berger, Douglas; Bryson, Chris L.] Dept Vet Affairs VA Puget Sound Hlth Care Syst, Gen Med Serv, Seattle, WA USA. [Berger, Douglas; Bryson, Chris L.; Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA USA. [Williams, Emily C.; Bryson, Chris L.; Rubinsky, Anna D.; Bradley, Katharine A.] Dept Vet Affairs VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Northwest Ctr Excellence, Seattle, WA USA. [Williams, Emily C.; Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Rubinsky, Anna D.; Bradley, Katharine A.] Vet Affairs VA Puget Sound Hlth Care Syst, Ctr Excellence Substance Abuse Treatment & Educ, Seattle, WA USA. [Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA USA. RP Berger, D (reprint author), VA Puget Sound, Gen Internal Med Sect, 1660 S Columbian Way,S-123 PCC, Seattle, WA 98108 USA. EM douglas.berger@va.gov FU VA HSRD IAC [05-206] FX This project was funded by VA HSR&D IAC Grant 05-206. The funding organization had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. NR 45 TC 4 Z9 4 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-8329 J9 ALCOHOL JI Alcohol PD SEP PY 2013 VL 47 IS 6 BP 439 EP 445 DI 10.1016/j.alcohol.2013.07.001 PG 7 WC Substance Abuse; Pharmacology & Pharmacy; Toxicology SC Substance Abuse; Pharmacology & Pharmacy; Toxicology GA 204IY UT WOS:000323360200003 PM 23886863 ER PT J AU LaRowe, SD Kalivas, PW Nicholas, JS Randall, PK Mardikian, PN Malcolm, RJ AF LaRowe, Steven D. Kalivas, Peter W. Nicholas, Joyce S. Randall, Patrick K. Mardikian, Pascale N. Malcolm, Robert. J. TI A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID NUCLEUS-ACCUMBENS; RECEPTOR AGONIST; SEEKING BEHAVIOR; RELAPSE; REINSTATEMENT; INDIVIDUALS; VALIDITY; LY379268 AB Background: There remains no FDA approved medication for the treatment of cocaine dependence. Preclinical studies and early pilot clinical investigations have suggested that N-acetylcysteine (NAC) may be useful in the treatment of the disorder. Objective: The present report assessed the efficacy of NAC in the treatment of cocaine dependence. Methods: Cocaine-dependent volunteers (n = 111) were randomized to receive daily doses of 1,200 mg of NAC, 2,400 mg of NAC, or placebo. Participants were followed for 8 weeks (up to three visits weekly). At each of these visits, urine samples were collected, along with self-reports of cocaine use. Urine samples were assessed for quantitative levels of benzoylecognine (ie, cocaine metabolite). Results: Overall, the primary results for the clinical trial were negative. However, when considering only subjects who entered the trial having already achieved abstinence, results favored the 2,400 mg NAC group relative to placebo, with the 2,400 mg group having longer times to relapse and lower craving ratings. Conclusion: While the present trial failed to demonstrate that NAC reduces cocaine use in cocaine-dependent individuals actively using, there was some evidence it prevented return to cocaine use in individuals who had already achieved abstinence from cocaine. Scientific Significance: N-acetylcysteine may be useful as a relapse prevention agent in abstinent cocaine-dependent individuals. C1 [LaRowe, Steven D.] Ralph H Johnson VAMC, Charleston, SC USA. [LaRowe, Steven D.; Randall, Patrick K.; Mardikian, Pascale N.; Malcolm, Robert. J.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Kalivas, Peter W.; Nicholas, Joyce S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Nicholas, Joyce S.] Med Univ S Carolina, Dept Med, Div Biostat & Epidemiol, Charleston, SC 29425 USA. RP LaRowe, SD (reprint author), Med Univ S Carolina, Dept Psychiat, Ctr Drug & Alcohol Programs, Charleston, SC 29425 USA. EM larowe@musc.edu OI LaRowe, Steven/0000-0002-7664-2451 FU NIDA NIH HHS [DA0199903, P50 DA015369, R01 DA003906, R01 DA012513] NR 32 TC 32 Z9 34 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 J9 AM J ADDICTION JI Am. J. Addict. PD SEP PY 2013 VL 22 IS 5 BP 443 EP 452 DI 10.1111/j.1521-0391.2013.12034.x PG 10 WC Substance Abuse SC Substance Abuse GA 202DV UT WOS:000323194600004 PM 23952889 ER PT J AU Collins, E Gilkeson, G AF Collins, Erin Gilkeson, Gary TI Hematopoetic and mesenchymal stem cell transplantation in the treatment of refractory systemic lupus erythematosus - Where are we now? SO CLINICAL IMMUNOLOGY LA English DT Review DE Lupus; Stem cell transplantation ID VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; COLLAGEN-INDUCED ARTHRITIS; AUTOIMMUNE-DISEASES; T-CELLS; INDOLEAMINE 2,3-DIOXYGENASE; HEALTHY DONORS; IN-VITRO; MECHANISMS; MICE AB Cell based therapies are of increasing interest in the treatment of systemic lupus due to their potential for long term suppression or cure of disease. Two methods for stem cell transplantation are currently being investigated/performed for treatment of lupus. Autologous hematopoetic stem cell transplantation is used in patients refractory to standard therapy. The morbidity and mortality of the procedure limit its use to select patients. Results indicate 50% long term disease free survival. The technical difficulty of the procedure requires it to be performed only in experienced centers. Mesenchymal stem cell transplants are a new emerging therapy for the treatment of lupus. Studies in murine models of lupus provide evidence of efficacy with safety. Limited uncontrolled trials in humans provide evidence of efficacy as well. Controlled trials are needed to assess the efficacy of both these therapies compared to standard therapy. Published by Elsevier Inc. C1 Med Univ S Carolina, Div Rheumatol, Charleston, SC 29425 USA. Ralph H Johnson VAMC, Med Res Serv, Charleston, SC USA. RP Gilkeson, G (reprint author), 96 Jonathan Lucas St,Suite 912, Charleston, SC 29425 USA. EM Gilkeson@musc.edu NR 58 TC 6 Z9 7 U1 0 U2 17 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PD SEP PY 2013 VL 148 IS 3 BP 328 EP 334 DI 10.1016/j.clim.2013.01.009 PG 7 WC Immunology SC Immunology GA 202CX UT WOS:000323192200005 PM 23411031 ER PT J AU Arbizu, J Prieto, E Martinez-Lage, P Marti-Climent, JM Garcia-Granero, M Lamet, I Pastor, P Riverol, M Gomez-Isla, MT Penuelas, I Richter, JA Weiner, MW AF Arbizu, Javier Prieto, E. Martinez-Lage, P. Marti-Climent, J. M. Garcia-Granero, M. Lamet, I. Pastor, P. Riverol, M. Gomez-Isla, M. T. Penuelas, I. Richter, J. A. Weiner, M. W. CA Alzheimer's Dis Neuroimaging TI Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer's disease dementia SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING LA English DT Article DE FDG; PET; Alzheimer's disease; Mild cognitive impairment; Dementia; Prediction ID MILD COGNITIVE IMPAIRMENT; BRAIN GLUCOSE-METABOLISM; GRAY-MATTER VOLUME; F-18-FDG PET; APOE GENOTYPE; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; MRI; MCI AB To introduce, evaluate and validate a voxel-based analysis method of F-18-FDG PET imaging for determining the probability of Alzheimer's disease (AD) in a particular individual. The subject groups for model derivation comprised 80 healthy subjects (HS), 36 patients with mild cognitive impairment (MCI) who converted to AD dementia within 18 months, 85 non-converter MCI patients who did not convert within 24 months, and 67 AD dementia patients with baseline FDG PET scan were recruited from the AD Neuroimaging Initiative (ADNI) database. Additionally, baseline FDG PET scans from 20 HS, 27 MCI and 21 AD dementia patients from our institutional cohort were included for model validation. The analysis technique was designed on the basis of the AD-related hypometabolic convergence index adapted for our laboratory-specific context (AD-PET index), and combined in a multivariable model with age and gender for AD dementia detection (AD score). A logistic regression analysis of different cortical PET indexes and clinical variables was applied to search for relevant predictive factors to include in the multivariable model for the prediction of MCI conversion to AD dementia (AD-Conv score). The resultant scores were stratified into sixtiles for probabilistic diagnosis. The area under the receiver operating characteristic curve (AUC) for the AD score detecting AD dementia in the ADNI database was 0.879, and the observed probability of AD dementia in the six defined groups ranged from 8 % to 100 % in a monotonic trend. For predicting MCI conversion to AD dementia, only the posterior cingulate index, Mini-Mental State Examination (MMSE) score and apolipoprotein E4 genotype (ApoE4) exhibited significant independent effects in the univariable and multivariable models. When only the latter two clinical variables were included in the model, the AUC was 0.742 (95 % CI 0.646 - 0.838), but this increased to 0.804 (95 % CI 0.714 - 0.894, bootstrap p = 0.027) with the addition of the posterior cingulate index (AD-Conv score). Baseline clinical diagnosis of MCI showed 29.7 % of converters after 18 months. The observed probability of conversion in relation to baseline AD-Conv score was 75 % in the high probability group (sixtile 6), 34 % in the medium probability group (merged sixtiles 4 and 5), 20 % in the low probability group (sixtile 3) and 7.5 % in the very low probability group (merged sixtiles 1 and 2). In the validation population, the AD score reached an AUC of 0.948 (95 % CI 0.625 - 0.969) and the AD-Conv score reached 0.968 (95 % CI 0.908 - 1.000), with AD patients and MCI converters included in the highest probability categories. Posterior cingulate hypometabolism, when combined in a multivariable model with age and gender as well as MMSE score and ApoE4 data, improved the determination of the likelihood of patients with MCI converting to AD dementia compared with clinical variables alone. The probabilistic model described here provides a new tool that may aid in the clinical diagnosis of AD and MCI conversion. C1 [Arbizu, Javier; Prieto, E.; Marti-Climent, J. M.; Penuelas, I.; Richter, J. A.] Univ Navarra Clin, Dept Nucl Med, Pamplona 31008, Spain. [Martinez-Lage, P.; Lamet, I.; Pastor, P.; Riverol, M.; Gomez-Isla, M. T.] Univ Navarra Clin, Dept Neurol, Pamplona 31008, Spain. [Garcia-Granero, M.] Univ Navarra, Sch Sci, Dept Biochem & Genet, Pamplona 31008, Spain. [Weiner, M. W.] San Francisco VA Med Ctr, CIND, San Francisco, CA 94121 USA. RP Arbizu, J (reprint author), Univ Navarra Clin, Dept Nucl Med, Ave Pio 12 36, Pamplona 31008, Spain. EM jarbizu@unav.es RI Saykin, Andrew/A-1318-2007; Pastor, Pau/C-9834-2009; Prieto, Elena/N-2142-2014; Jack, Clifford/F-2508-2010 OI Saykin, Andrew/0000-0002-1376-8532; Pastor, Pau/0000-0002-7493-8777; Prieto, Elena/0000-0002-3609-1210; Jack, Clifford/0000-0001-7916-622X FU Government of Spain, Institute of Health Carlos III, the Ministry of Health [01/0809]; Ministry of Science and Innovation CIBERNED (Centro de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas) [ADE 10/00028, CB06/05/0077]; Alzheimer's Disease Neuroimaging Initiative (ADNI; National Institutes of Health) [U01 AG024904]; National Institute on Aging; National Institute of Biomedical Imaging and Bioengineering; Abbott; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Amorfix Life Sciences Ltd.; AstraZeneca; Bayer HealthCare; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck Co., Inc.; Meso Scale Diagnostics, LLC.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier; Synarc Inc.; Takeda Pharmaceutical Company; Canadian Institutes of Health Research; NIH [P30 AG010129, K01 AG030514] FX This work was supported in part by the Government of Spain, Institute of Health Carlos III, the Ministry of Health grant 01/0809, and the Ministry of Science and Innovation grant ADE 10/00028, and CB06/05/0077 CIBERNED (Centro de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas).; Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI; National Institutes of Health grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Amorfix Life Sciences Ltd.; AstraZeneca; Bayer HealthCare; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research provides funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study was coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuroimaging at the University of California, Los Angeles. This research was also supported by NIH grants P30 AG010129 and K01 AG030514. NR 40 TC 16 Z9 17 U1 0 U2 13 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1619-7070 J9 EUR J NUCL MED MOL I JI Eur. J. Nucl. Med. Mol. Imaging PD SEP PY 2013 VL 40 IS 9 BP 1394 EP 1405 DI 10.1007/s00259-013-2458-z PG 12 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 200GO UT WOS:000323056300014 PM 23715905 ER PT J AU Goldberger, JJ Schliamser, JE Kadish, AH Subacius, H Shalaby, A Schaechter, A Levine, J AF Goldberger, Jeffrey J. Schliamser, Jorge E. Kadish, Alan H. Subacius, Haris Shalaby, Alaa Schaechter, Andi Levine, Joseph TI Should an Improvement in Left Ventricular Systolic Function Preclude ICD Generator Replacement? Reply SO HEART RHYTHM LA English DT Letter ID CARDIOMYOPATHY C1 [Goldberger, Jeffrey J.; Schliamser, Jorge E.; Kadish, Alan H.; Subacius, Haris; Schaechter, Andi] Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, Chicago, IL 60611 USA. [Goldberger, Jeffrey J.; Schliamser, Jorge E.; Kadish, Alan H.; Subacius, Haris; Schaechter, Andi] Northwestern Univ, Feinberg Sch Med, Div Cardiol, Chicago, IL USA. [Kadish, Alan H.] Touro Coll, Brooklyn, NY USA. [Kadish, Alan H.] New York Med Coll, Valhalla, NY 10595 USA. [Shalaby, Alaa] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Levine, Joseph] St Francis Hosp, Ctr Heart, Roslyn, NY USA. RP Goldberger, JJ (reprint author), Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, Chicago, IL 60611 USA. EM j-goldberger@northwestern.edu NR 2 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1547-5271 J9 HEART RHYTHM JI Heart Rhythm PD SEP PY 2013 VL 10 IS 9 BP E77 EP E78 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 206CQ UT WOS:000323494600004 PM 23872694 ER PT J AU Krebs, CE Karkheiran, S Powell, JC Cao, M Makarov, V Darvish, H Di Paolo, G Walker, RH Shahidi, GA Buxbaum, JD De Camilli, P Yue, ZY Paisan-Ruiz, C AF Krebs, Catharine E. Karkheiran, Siamak Powell, James C. Cao, Mian Makarov, Vladimir Darvish, Hossein Di Paolo, Gilbert Walker, Ruth H. Shahidi, Gholam Ali Buxbaum, Joseph D. De Camilli, Pietro Yue, Zhenyu Paisan-Ruiz, Coro TI The Sac1 Domain of SYNJ1 Identified Mutated in a Family with Early-Onset Progressive Parkinsonism with Generalized Seizures SO HUMAN MUTATION LA English DT Article DE homozygosity mapping; whole-exome sequencing; SYNJ1; autosomal recessive Parkinsonism AB This study aimed to elucidate the genetic causes underlying early-onset Parkinsonism (EOP) in a consanguineous Iranian family. To attain this, homozygosity mapping and whole-exome sequencing were performed. As a result, a homozygous mutation (c.773G>A; p.Arg258Gln) lying within the NH2-terminal Sac1-like inositol phosphatase domain of polyphosphoinositide phosphatase synaptojanin 1 (SYNJ1), which has been implicated in the regulation of endocytic traffic at synapses, was identified as the disease-segregating mutation. This mutation impaired the phosphatase activity of SYNJ1 against its Sac1 domain substrates in vitro. We concluded that the SYNJ1 mutation identified here is responsible for the EOP phenotype seen in our patients probably due to deficiencies in its phosphatase activity and consequent impairment of its synaptic functions. Our finding not only opens new avenues of investigation in the synaptic dysfunction mechanisms associated with Parkinsonism, but also suggests phosphoinositide metabolism as a novel therapeutic target for Parkinsonism.(C) 2013 Wiley Periodicals, Inc. C1 [Krebs, Catharine E.; Powell, James C.; Walker, Ruth H.; Yue, Zhenyu; Paisan-Ruiz, Coro] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY USA. [Karkheiran, Siamak] Univ Tehran Med Sci, Hazrat Rasool Hosp, Movement Disorders Clin, Tehran, Iran. [Cao, Mian; De Camilli, Pietro] Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Cell Biol, New Haven, CT 06510 USA. [Cao, Mian; De Camilli, Pietro] Yale Univ, Sch Med, Program Cellular Neurosci Neurodegenerat & Repair, New Haven, CT USA. [Makarov, Vladimir] Columbia Univ, Dept Biostat, Mailman Sch Publ Hlth, New York, NY USA. [Darvish, Hossein] Shahid Beheshti Univ Med Sci, Dept Med Genet, Tehran, Iran. [Di Paolo, Gilbert] Columbia Univ, Taub Inst Res Alzheimers Dis & Aging Brain, Med Ctr, Dept Pathol & Cell Biol, New York, NY USA. [Walker, Ruth H.] James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY USA. [Shahidi, Gholam Ali] Univ Tehran Med Sci, Hazrat Rasool Hosp, Dept Neurol, Tehran, Iran. [Buxbaum, Joseph D.] Mt Sinai Schoool Med, Seaver Autism Ctr Res & Treatment, New York, NY USA. [Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY USA. [Buxbaum, Joseph D.; Yue, Zhenyu] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY USA. [Buxbaum, Joseph D.; Paisan-Ruiz, Coro] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY USA. [Buxbaum, Joseph D.; Paisan-Ruiz, Coro] Icahn Sch Med Mt Sinai, Mindich Child Hlth & Dev Inst, New York, NY USA. [Buxbaum, Joseph D.; Yue, Zhenyu; Paisan-Ruiz, Coro] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY USA. RP Paisan-Ruiz, C (reprint author), Icahn Sch Med Mt Sinai, Dept Neurol, 1 Gustave L Levy Pl, New York, NY USA. EM coro.paisan-ruiz@mssm.edu RI Paisan-Ruiz, Coro/C-2912-2009 OI Buxbaum, Joseph/0000-0001-8898-8313 FU Parkinson's Disease Foundation; Ellison Foundation; Michael J. Fox Foundation; NIH/NINDS [R01NS060809, R01NS072359, R37NS036251, R01NS079388]; NIMH [R01MH095797] FX Contract grant sponsors: The Parkinson's Disease Foundation; Ellison Foundation; Michael J. Fox Foundation; NIH/NINDS (R01NS060809, R01NS072359, R37NS036251, R01NS079388); NIMH (R01MH095797). NR 53 TC 74 Z9 76 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1059-7794 J9 HUM MUTAT JI Hum. Mutat. PD SEP PY 2013 VL 34 IS 9 BP 1200 EP 1207 DI 10.1002/humu.22372 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA 200YZ UT WOS:000323109200004 PM 23804563 ER PT J AU Smith, KJ Wateska, A Nowalk, MP Raymund, M Lee, BY Zimmerman, RK Fine, MJ AF Smith, Kenneth J. Wateska, Angela Nowalk, M. Patricia Raymund, Mahlon Lee, Bruce Y. Zimmerman, Richard K. Fine, Michael J. TI Cost-Effectiveness of Procalcitonin-Guided Antibiotic Use in Community Acquired Pneumonia SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE cost-effectiveness analysis; procalcitonin; community-acquired pneumonia ID RANDOMIZED-CONTROLLED-TRIAL; LOW-RISK PATIENTS; LENGTH-OF-STAY; CRITICAL PATHWAY; REDUCE DURATION; CARE; THERAPY; IMPLEMENTATION; METAANALYSIS; COHORT AB Although prior randomized trials have demonstrated that procalcitonin-guided antibiotic therapy effectively reduces antibiotic use in patients with community-acquired pneumonia (CAP), uncertainties remain regarding use of procalcitonin protocols in practice. To estimate the cost-effectiveness of procalcitonin protocols in CAP. Decision analysis using published observational and clinical trial data, with variation of all parameter values in sensitivity analyses. Hypothetical patient cohorts who were hospitalized for CAP. Procalcitonin protocols vs. usual care. Costs and cost per quality adjusted life year gained. When no differences in clinical outcomes were assumed, consistent with clinical trials and observational data, procalcitonin protocols cost $10-$54 more per patient than usual care in CAP patients. Under these assumptions, results were most sensitive to variations in: antibiotic cost, the likelihood that antibiotic therapy was initiated less frequently or over shorter durations, and the likelihood that physicians were nonadherent to procalcitonin protocols. Probabilistic sensitivity analyses, incorporating procalcitonin protocol-related changes in quality of life, found that protocol use was unlikely to be economically reasonable if physician protocol nonadherence was high, as observational study data suggest. However, procalcitonin protocols were favored if they decreased hospital length of stay. Procalcitonin protocol use in hospitalized CAP patients, although promising, lacks physician nonadherence and resource use data in routine care settings, which are needed to evaluate its potential role in patient care. (C) Society of General Internal Medicine 2013 C1 [Smith, Kenneth J.; Wateska, Angela; Lee, Bruce Y.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Nowalk, M. Patricia; Raymund, Mahlon; Zimmerman, Richard K.] Univ Pittsburgh, Sch Med, Dept Family Med, Pittsburgh, PA 15213 USA. [Fine, Michael J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ & Promot, Pittsburgh, PA USA. RP Smith, KJ (reprint author), Univ Pittsburgh, Sch Med, Dept Med, 200 Meyran Ave,Suite 200, Pittsburgh, PA 15213 USA. EM smithkj2@upmc.edu OI Smith, Kenneth J/0000-0001-8088-566X; Zimmerman, Richard/0000-0001-5941-6092 FU NIAID [R01AI 076256] FX Supported by the NIAID (R01AI 076256) NR 29 TC 13 Z9 13 U1 1 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD SEP PY 2013 VL 28 IS 9 BP 1157 EP 1164 DI 10.1007/s11606-013-2400-x PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 202XR UT WOS:000323254700015 PM 23463457 ER PT J AU Yoon, J Rose, DE Canelo, I Upadhyay, AS Schectman, G Stark, R Rubenstein, LV Yano, EM AF Yoon, Jean Rose, Danielle E. Canelo, Ismelda Upadhyay, Anjali S. Schectman, Gordon Stark, Richard Rubenstein, Lisa V. Yano, Elizabeth M. TI Medical Home Features of VHA Primary Care Clinics and Avoidable Hospitalizations SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE medical home; avoidable hospitalizations; access; care coordination ID HEALTH-CARE; SENSITIVE CONDITIONS; ILLNESS; ACCESS; RATES AB As the Veterans Health Administration (VHA) reorganizes providers into the patient-centered medical home, questions remain whether this model of care can demonstrate improved patient outcomes and cost savings. We measured adoption of medical home features by VHA primary care clinics prior to widespread implementation of the patient-centered medical home and examined if they were associated with lower risk and costs of potentially avoidable hospitalizations. Secondary patient data was linked to clinic administrative and survey data. Patient and clinic factors in the baseline year (FY2009) were used to predict patient outcomes in the follow-up year. 2,853,030 patients from 814 VHA primary care clinics Patient outcomes were measured by hospitalizations for an ambulatory care sensitive condition (ACSC) and their costs and identified through diagnosis and procedure codes from inpatient records. Clinic adoption of medical home features was obtained from the American College of Physicians Medical Home BuilderA (R). The overall mean home builder score in the study clinics was 88 (SD = 13) or 69 %. In adjusted analyses an increase of 10 points in the medical home adoption score in a clinic decreased the odds of an ACSC hospitalization for patients by 3 % (P = 0.032). By component, higher access and scheduling (P = 0.004) and care coordination and transitions (P = 0.020) component scores were related to lower risk of an ACSC hospitalization, and higher population management was related to higher risk (P = 0.023). Total medical home features was not related to ACSC hospitalization costs among patients with at least one (P = 0.074). Greater adoption of medical home features by VHA primary care clinics was found to be significantly associated with lower risk of avoidable hospitalizations with access and scheduling and care coordination/transitions in care as key factors. (C) Society of General Internal Medicine 2013 C1 [Yoon, Jean; Upadhyay, Anjali S.] VA Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, Menlo Pk, CA 94025 USA. [Yoon, Jean] VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA USA. [Rose, Danielle E.; Canelo, Ismelda; Rubenstein, Lisa V.; Yano, Elizabeth M.] VA Greater Los Angeles, Ctr Ctr Excellence Study Healthcare Provider Beha, Sepulveda, CA USA. [Rubenstein, Lisa V.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. [Rubenstein, Lisa V.] RAND Corp, Santa Monica, CA USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. [Schectman, Gordon; Stark, Richard] Vet Hlth Adm, Patient Care Serv, Washington, DC USA. RP Yoon, J (reprint author), VA Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, 795 Willow Rd 152 MPD, Menlo Pk, CA 94025 USA. EM jean.yoon@va.gov FU Department of Veterans Affairs, Veterans Health Administration Office of Research and Development, Health Services Research and Development [IIR 09-082]; VA HSR&D Senior Research Career Scientist Award [RCS 05-195] FX This work was supported by the Department of Veterans Affairs, Veterans Health Administration Office of Research and Development, Health Services Research and Development (grant #: IIR 09-082). Dr. Yano's effort was covered by a VA HSR&D Senior Research Career Scientist Award (Project #RCS 05-195). The authors wish to acknowledge Belinda Black MSPH, Office of Patient Care Services, Veterans Health Administration for administering the clinic survey and Michael Barr MD, MBA, FACP, American College of Physicians for providing valuable comments. Preliminary results from this study were presented at the Academy Health Annual Research Meeting, June 24-26, 2012, in Orlando, FL and the VA Health Services Research and Development Meeting, July 17-19, in Washington, DC. NR 21 TC 15 Z9 15 U1 0 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD SEP PY 2013 VL 28 IS 9 BP 1188 EP 1194 DI 10.1007/s11606-013-2405-5 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 202XR UT WOS:000323254700019 PM 23529710 ER PT J AU Cronholm, PF Shea, JA Werner, RM Miller-Day, M Tufano, J Crabtree, BF Gabbay, R AF Cronholm, Peter F. Shea, Judy A. Werner, Rachel M. Miller-Day, Michelle Tufano, Jim Crabtree, Benjamin F. Gabbay, Robert TI The Patient Centered Medical Home: Mental Models and Practice Culture Driving the Transformation Process SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE patient-centered care; primary health care; delivery of health care; workplace; program evaluation ID PRIMARY-CARE; HEALTH-CARE; IMPROVEMENT; QUALITY AB The Patient-Centered Medical Home (PCMH) has become a dominant model of primary care re-design. The PCMH model is a departure from more traditional models of healthcare delivery and requires significant transformation to be realized. To describe factors shaping mental models and practice culture driving the PCMH transformation process in a large multi-payer PCMH demonstration project. Individual interviews were conducted at 17 primary care practices in South Eastern Pennsylvania. A total of 118 individual interviews were conducted with clinicians (N = 47), patient educators (N = 4), office administrators (N = 12), medical assistants (N = 26), front office staff (N = 7), nurses (N = 4), care managers (N = 11), social workers (N = 4), and other stakeholders (N = 3). A multi-disciplinary research team used a grounded theory approach to develop the key constructs describing factors shaping successful practice transformation. Three central themes emerged from the data related to changes in practice culture and mental models necessary for PCMH practice transformation: 1) shifting practice perspectives towards proactive, population-oriented care based in practice-patient partnerships; 2) creating a culture of self-examination; and 3) challenges to developing new roles within the practice through distribution of responsibilities and team-based care. The most tension in shifting the required mental models was displayed between clinician and medical assistant participants, revealing significant barriers towards moving away from clinician-centric care. Key factors driving the PCMH transformation process require shifting mental models at the individual level and culture change at the practice level. Transformation is based upon structural and process changes that support orientation of practice mental models towards perceptions of population health, self-assessment, and the development of shared decision-making. Staff buy-in to the new roles and responsibilities driving PCMH transformation was described as central to making sustainable change at the practice level; however, key barriers related to clinician autonomy appeared to interfere with the formation of team-based care. (C) Society of General Internal Medicine 2013 C1 [Cronholm, Peter F.] Univ Penn, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA. [Cronholm, Peter F.] Univ Penn, Ctr Publ Hlth Initiat, Philadelphia, PA 19104 USA. [Cronholm, Peter F.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Shea, Judy A.; Werner, Rachel M.] Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Werner, Rachel M.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Miller-Day, Michelle] Chapman Univ, Dept Commun Studies, Orange, CA USA. [Tufano, Jim] Univ Washington, Sch Med, Dept Biomed Informat & Med Educ, Seattle, WA USA. [Crabtree, Benjamin F.] UMDNJ Robert Wood Johnson Med Sch, Dept Family Med & Community Hlth, New Brunswick, NJ USA. [Gabbay, Robert] Penn State Coll Med, Penn State Milton S Hershey Med Ctr, Penn State Hershey Diabet Inst, Diabet Program, Hershey, PA USA. RP Cronholm, PF (reprint author), Univ Penn, Dept Family Med & Community Hlth, 141 Anat & Chem Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA. EM peter.cronholm@uphs.upenn.edu FU Agency for Healthcare Research and Quality [5R18HS019150]; Aetna Foundation FX This project was supported by a grant from the Agency for Healthcare Research and Quality (5R18HS019150) and funds from Aetna Foundation. NR 30 TC 26 Z9 26 U1 5 U2 30 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD SEP PY 2013 VL 28 IS 9 BP 1195 EP 1201 DI 10.1007/s11606-013-2415-3 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 202XR UT WOS:000323254700020 PM 23539283 ER PT J AU Ganzini, L Denneson, LM Press, N Bair, MJ Helmer, DA Poat, J Dobscha, SK AF Ganzini, Linda Denneson, Lauren M. Press, Nancy Bair, Matthew J. Helmer, Drew A. Poat, Jennifer Dobscha, Steven K. TI Trust is the Basis for Effective Suicide Risk Screening and Assessment in Veterans SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE depression; post-traumatic stress disorder; qualitative methods; screening; suicide; veterans ID CARE AB To reduce suicides among Veterans, the Department of Veterans Affairs (VA) has designated suicide risk assessments for Veterans who screen positive for depression or post-traumatic stress disorder as a national performance goal. Many VA Medical Centers (VAMCs) are using brief suicidal ideation screens, administered in non-mental health ambulatory care settings, as the first step in the assessment process. To explore Veterans' perceptions of the suicide screening and risk assessment process, the barriers and facilitators to disclosing suicidal thoughts, and perceptions of possible consequences of revealing suicidal thoughts. Investigators recorded one semi-structured interview with each Veteran. Transcripts were analyzed using a modified grounded theory approach. Thirty-four Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) Veterans who screened positive for suicidal ideation in non-mental health ambulatory care settings in 2009 and 2010. Veterans accepted the need to assess suicide risk. They increasingly experienced attempts to suppress and avoid thoughts of suicide as burdensome and exhausting. Despite this, Veterans often failed to disclose severe and pervasive suicidal thoughts when screened because: (1) they considered suicidal thoughts as shameful and a sign of weakness; (2) they believed suicidal thoughts were private and not to be divulged to strangers; (3) they worried that disclosure would lead to unwanted hospitalization or medication recommendations; and (4) the templated computer reminder process was perceived as perfunctory and disrespectful. In contrast, admitting and discussing thoughts of suicide with a health provider who focused on building a relationship, demonstrated genuineness and empathy, offered information on the rationale for suicide risk assessment, and used straightforward and understandable language, all promoted trust that resulted in more honest disclosure of suicidal thoughts. In ambulatory care settings, both provider behaviors and system modifications may lead to more honest disclosure of suicidal thoughts. (C) Society of General Internal Medicine 2013 C1 [Ganzini, Linda; Denneson, Lauren M.; Dobscha, Steven K.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Phys & Mental D, Portland, OR 97207 USA. [Ganzini, Linda; Denneson, Lauren M.; Dobscha, Steven K.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Press, Nancy] Oregon Hlth & Sci Univ, Dept Publ Hlth, Portland, OR 97201 USA. [Press, Nancy; Poat, Jennifer] Oregon Hlth & Sci Univ, Dept Nursing, Portland, OR 97201 USA. [Bair, Matthew J.] Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN 46202 USA. [Helmer, Drew A.] W Haven Vet Affairs Med Ctr, West Haven, CT USA. [Helmer, Drew A.] VA New Jersey Hlth Care Syst, War Related Illness & Injury Study Ctr, E Orange, NJ USA. RP Ganzini, L (reprint author), Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Phys & Mental D, POB 1034 RD 66, Portland, OR 97207 USA. EM linda.ganzini@va.gov FU Department of Veterans Affairs, Veterans Health Administration, and Health Services Research and Development Service [DHI-08-096] FX We gratefully acknowledge the assistance of Michael Martin; Megan Crutchfield, MPH; and Monica Huffman, BS. This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, and Health Services Research and Development Service Project DHI-08-096. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 17 TC 21 Z9 21 U1 0 U2 12 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD SEP PY 2013 VL 28 IS 9 BP 1215 EP 1221 DI 10.1007/s11606-013-2412-6 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 202XR UT WOS:000323254700023 PM 23580131 ER PT J AU Cassese, T Kaplan, E Douglas, V Dhaliwal, G AF Cassese, Todd Kaplan, Elizabeth Douglas, Vanja Dhaliwal, Gurpreet TI Getting to the Right Question SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material DE diagnostic reasoning; clinical problem solving; history-taking; weakness ID PRIMARY SJOGRENS-SYNDROME; HYPOKALEMIC PERIODIC PARALYSIS; RESPIRATORY ARREST; PHYSICIANS; DIAGNOSIS; ACIDOSIS C1 [Cassese, Todd] Quinnipiac Univ, Dept Med Sci, Frank H Netter MD Sch Med, Hamden, CT 06518 USA. [Kaplan, Elizabeth] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Douglas, Vanja] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, San Francisco, CA USA. RP Cassese, T (reprint author), Quinnipiac Univ, Dept Med Sci, Frank H Netter MD Sch Med, 275 Mt Carmel Ave, Hamden, CT 06518 USA. EM todd.cassese@quinnipiac.edu NR 15 TC 1 Z9 1 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD SEP PY 2013 VL 28 IS 9 BP 1242 EP 1246 DI 10.1007/s11606-012-2254-7 PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 202XR UT WOS:000323254700030 PM 23184311 ER PT J AU Cahill, ME Remmers, C Jones, KA Xie, Z Sweet, RA Penzes, P AF Cahill, Michael E. Remmers, Christine Jones, Kelly A. Xie, Zhong Sweet, Robert A. Penzes, Peter TI Neuregulin1 signaling promotes dendritic spine growth through kalirin SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE environmental enrichment; ERBB4; NRG1; plasticity; schizophrenia; synapse ID CENTRAL-NERVOUS-SYSTEM; PARVALBUMIN-POSITIVE INTERNEURONS; GDP/GTP EXCHANGE FACTOR; LONG-TERM POTENTIATION; DEVELOPMENTAL PROFILE; BEHAVIORAL PHENOTYPES; SURFACE EXPRESSION; PREFRONTAL CORTEX; TYROSINE KINASE; RECEPTOR ERBB4 AB The biological functions of the neuregulin 1 (NRG1) and ERBB4 genes have received much recent attention due to several studies showing associations between these genes and schizophrenia. Moreover, reduced forebrain dendritic spine density is a consistent feature of schizophrenia. It is thus important to understand the mechanisms whereby NRG1 and erbB4 modulate spine morphogenesis. Here, we show that long-term incubation with NRG1 increases both spine size and density in cortical pyramidal neurons. NRG1 also enhances the content of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptors in spines. Knockdown of ERBB4 expression prevented the effects of NRG1 on spine size, but not on spine density. The effects of NRG1 and erbB4 on spines were mediated by the RacGEF kalirin, a well-characterized regulator of dendritic spines. Finally, we show that environmental enrichment, known to promote spine growth, robustly enhances the levels of erbB4 protein in the forebrain. These findings provide a mechanistic link between NRG1 signaling and spine morphogenesis. C1 [Cahill, Michael E.; Remmers, Christine; Jones, Kelly A.; Xie, Zhong; Penzes, Peter] Northwestern Univ, Feinberg Sch Med, Dept Physiol, Chicago, IL 60611 USA. [Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Psychiat, Translat Neurosci Program, Pittsburgh, PA USA. [Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, Educ & Clin Ctr, VISN Mental Illness Res 4, Pittsburgh, PA USA. [Penzes, Peter] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA. RP Penzes, P (reprint author), 303 E Chicago Ave, Chicago, IL 60611 USA. EM p-penzes@northwestern.edu RI Xie, Zhong/B-6829-2011; Penzes, Peter/L-3987-2016 OI Xie, Zhong/0000-0002-8348-4455; Penzes, Peter/0000-0001-5449-1640 FU NIH-NIMH [R01MH071316, R01MH097216]; National Alliance for Research on Schizophrenia and Depression (NARSAD); Ruth L. Kirschstein National Research Service Awards [1F31AG031621-01A2, 1F31MH085362]; NIH [R01 MH 071533, R01 AG027224]; VHA [I01 BX000452] FX This study was supported by grants from NIH-NIMH (R01MH071316, R01MH097216), National Alliance for Research on Schizophrenia and Depression (NARSAD) to P. P., Ruth L. Kirschstein National Research Service Awards 1F31AG031621-01A2 to M. E. C and 1F31MH085362 to K.A.J, and research grants from NIH (R01 MH 071533, R01 AG027224) and from the VHA (I01 BX000452) to RAS. All experiments involving animals were done according to the Institutional Animal Care and Use Committee of Northwestern University. M. E. C, C. R, K.A.J., Z.X. performed research and analyzed results. M. E. C., C. R., and P. P. wrote the manuscript, and P. P. and R. A. S. contributed resources necessary to complete this study. NR 54 TC 15 Z9 15 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD SEP PY 2013 VL 126 IS 5 BP 625 EP 635 DI 10.1111/jnc.12330 PG 11 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 204TV UT WOS:000323393400008 PM 23742124 ER PT J AU Cirnigliaro, CM Fountaine, MF Emmons, R Kirshblum, SC Asselin, P Spungen, AM Bauman, WA AF Cirnigliaro, Christopher M. La Fountaine, Michael F. Emmons, Racine Kirshblum, Steven C. Asselin, Pierre Spungen, Ann M. Bauman, William A. TI Prediction of limb lean tissue mass from bioimpedance spectroscopy in persons with chronic spinal cord injury SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE Spinal cord injury; Bioimpedance spectroscopy; Lean tissue mass; Extracellular volume; Intracellular volume; Dual-energy X-ray absorptiometry ID X-RAY ABSORPTIOMETRY; SKELETAL-MUSCLE MASS; FAT-FREE MASS; RESTING ENERGY-EXPENDITURE; BODY-COMPOSITION; BIOELECTRICAL-IMPEDANCE; HEMODIALYSIS-PATIENTS; MEN; WATER; MODEL AB Background: Bioimpedance spectroscopy (BIS) is a non-invasive, simple, and inexpensive modality that uses 256 frequencies to determine the extracellular volume impedance (ECVRe) and intracellular volume impedance (ICVRi) in the total body and regional compartments. As such, it may have utility as a surrogate measure to assess lean tissue mass (LTM). Objective: To compare the relationship between LTM from dual-energy X-ray absorptiometry (DXA) and BIS impedance values in spinal cord injury (SCI) and able-bodied (AB) control subjects using a cross-sectional research design. Methods: In 60 subjects (30 AB and 30 SCI), a total body DXA scan was used to obtain total body and leg LTM. BIS was performed to measure the impedance quotient of the ECVRe and ICVRi in the total body and limbs. Results: BIS-derived ECVRe yielded a model for LTM in paraplegia, tetraplegia, and control for the right leg (RL) (R-2 = 0.75, standard errors of estimation (SEE) = 1.02 kg, P < 0.0001; R-2 = 0.65, SEE = 0.91 kg, P = 0.0006; and R-2 = 0.54, SEE = 1.31 kg, P < 0.0001, respectively) and left leg (LL) (R-2 = 0.76, SEE = 1.06 kg, P < 0.0001; R-2 = 0.64, SEE = 0.83 kg, P = 0.0006; and R-2 = 0.54, SEE = 1.34 kg, P < 0.0001, respectively). The ICVRi was similarly predictive of LTM in paraplegia, tetraplegia, and AB controls for the RL (R-2 = 0.85, SEE = 1.31 kg, P < 0.0001; R-2 = 0.52, SEE = 0.95 kg, P = 0.003; and R-2 = 0.398, SEE = 1.46 kg, P = 0.0003, respectively) and LL (R-2 = 0.62, SEE = 1.32 kg, P = 0.0003; R-2 = 0.57, SEE = 0.91 kg, P = 0.002; and R-2 = 0.42, SEE = 1.31 kg, P = 0.0001, respectively). Conclusion: Findings demonstrate that the BIS-derived impedance quotients for ECVRe and ICVRi may be used as surrogate markers to track changes in leg LTM in persons with SCI. C1 [Cirnigliaro, Christopher M.; La Fountaine, Michael F.; Asselin, Pierre; Spungen, Ann M.; Bauman, William A.] James J Peters VA Med Ctr, Natl Ctr Excellence Med Consequences Spinal Cord, Bronx, NY USA. [La Fountaine, Michael F.; Spungen, Ann M.; Bauman, William A.] James J Peters VA Med Ctr, Med & Spinal Cord Injury Serv, Bronx, NY USA. [La Fountaine, Michael F.] Seton Hall Univ, S Orange, NJ 07079 USA. [La Fountaine, Michael F.; Spungen, Ann M.; Bauman, William A.] Icahn Sch Med Mt Sinai, New York, NY USA. [Emmons, Racine] William Paterson Univ, Wayne, NJ USA. [Kirshblum, Steven C.] Kessler Inst Rehabilitat, W Orange, NJ 07052 USA. [Kirshblum, Steven C.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA. RP Cirnigliaro, CM (reprint author), Kessler Inst Rehabilitat, Rm L052m,1199 Pleasant Valley Way, W Orange, NJ 07052 USA. EM christopher.cirnigliaro@va.gov FU James J. Peters VA Medical Center, Bronx, NY; Department of Veterans Affairs Rehabilitation Research & Development (RRD) Service; Kessler Institute for Rehabilitation, West Orange, NJ; RR&D National Center of Excellence for the Medical Consequences of Spinal Cord Injury [B2648C, B4162C] FX The authors thank the James J. Peters VA Medical Center, Bronx, NY, the Department of Veterans Affairs Rehabilitation Research & Development (RR&D) Service, and the Kessler Institute for Rehabilitation, West Orange, NJ for their support. This work was funded by a RR&D National Center of Excellence for the Medical Consequences of Spinal Cord Injury (#B2648C & B4162C). NR 45 TC 1 Z9 1 U1 1 U2 6 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD SEP PY 2013 VL 36 IS 5 SI SI BP 443 EP 453 DI 10.1179/2045772313Y.0000000108 PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA 203YL UT WOS:000323330700006 PM 23941792 ER PT J AU Wecht, JM Zhu, C Weir, JP Yen, C Renzi, C Galea, M AF Wecht, Jill M. Zhu, Carolyn Weir, Joseph P. Yen, Christina Renzi, Christopher Galea, Marinella TI A prospective report on the prevalence of heart rate and blood pressure abnormalities in veterans with spinal cord injuries SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE Spinal cord injuries; Bradycardia; Tachycardia; Hypotension; Hypertension; Tetraplegia; Paraplegia; Autonomic function; Cardiovascular disease; Veterans ID REMAINING AUTONOMIC FUNCTION; PULSE-WAVE VELOCITY; INTERNATIONAL STANDARDS; ARTERIAL STIFFNESS; CHRONIC HYPOTENSION; ORTHOSTATIC HYPOTENSION; CARDIOVASCULAR-DISEASE; COGNITIVE PERFORMANCE; NEUROLOGICAL LEVEL; PHYSICAL-ACTIVITY AB Objective: Decentralized autonomic cardiovascular regulation may lead to increased prevalence of heart rate (HR) and blood pressure (BP) abnormalities in veterans with SCI. In addition, comorbid medical conditions and prescription medication use may increase HR and BP abnormalities. These abnormalities include bradycardia, and tachycardia, hypotension, hypertension as well as autonomic dysreflexia and orthostatic hypotension; the prevalence of which is unknown. Design: HR and BP data were measured during a routine annual physical examination in 64 veterans with SCI. Measurements of HR and BP were recorded in the seated and supine positions to document the influence of body position and to document intra-subject variability in these assessments. Results: All subjects were chronically injured (20 +/- 14 years), 33 subjects were tetraplegic (T: C3-C8), nine had high paraplegia (HP: T1-T6), and 22 had low paraplegia (LP: T7-L2). Regardless of position, the prevalence of bradycardia was increased in the T group, whereas prevalence of tachycardia was increased in the HP and LP groups. Systolic hypotension was more common in the T and HP groups than the LP group and positional effects were most evident in the T group. Systolic hypertension was comparable in the T and HP groups but was twice as prevalent in the LP group. Increased prevalence of individuals with three or more medical conditions and prescribed three or more medications which might influence HR and BP was observed. Conclusion: Decentralized autonomic regulation, comorbid medical conditions, and prescription medication use in veterans with SCI result in HR and BP abnormalities; our data suggest that these abnormalities vary depending on the level of injury and orthostatic positioning. C1 [Wecht, Jill M.; Yen, Christina; Renzi, Christopher] James J Peters VAMC, Ctr Excellence, Bronx, NY USA. [Wecht, Jill M.; Galea, Marinella] James J Peters VAMC, Med Serv, Bronx, NY USA. Mt Sinai Sch Med, Dept Med, New York, NY USA. [Wecht, Jill M.; Galea, Marinella] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. [Zhu, Carolyn] Mt Sinai Sch Med, Dept Geriatr & Palliat Care, New York, NY USA. [Zhu, Carolyn; Weir, Joseph P.] Univ Kansas, Dept Hlth Sport & Exercise Sci, Lawrence, KS 66045 USA. RP Wecht, JM (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Rm 7A 13,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM JM.Wecht@va.gov FU Veterans Affairs Rehabilitation Research and Development Service [B6999R] FX This research was supported by the Veterans Affairs Rehabilitation Research and Development Service (Grant no. B6999R). NR 45 TC 5 Z9 5 U1 1 U2 10 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD SEP PY 2013 VL 36 IS 5 SI SI BP 454 EP 462 DI 10.1179/2045772313Y.0000000109 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 203YL UT WOS:000323330700007 PM 23941793 ER PT J AU Zhu, C Galea, M Livote, E Signor, D Wecht, JM AF Zhu, Carolyn Galea, Marinella Livote, Elayne Signor, Dan Wecht, Jill M. TI A retrospective chart review of heart rate and blood pressure abnormalities in veterans with spinal cord injury SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Review DE Spinal cord injuries; Cardiac arrhythmias; Hypotension; Hypertension; Orthostatic hypotension; Autonomic dysreflexia; Tetraplegia; Paraplegia ID CARDIOVASCULAR-DISEASE RISK; CONTINGENT NEGATIVE-VARIATION; INTERNATIONAL STANDARDS; DEPRESSIVE SYMPTOMS; ARTERIAL STIFFNESS; AUTONOMIC DYSREFLEXIA; COGNITIVE PERFORMANCE; HYPERTENSIVE SUBJECTS; NEUROLOGICAL LEVEL; FOLLOW-UP AB Objective: Autonomic impairment may lead to increased prevalence of heart rate (HR) and blood pressure (BP) abnormalities in veterans with spinal cord injury (SCI). In addition, comorbid medical conditions and prescription medication use may influence these abnormalities, including bradycardia, and tachycardia, hypotension, hypertension as well as autonomic dysreflexia (AD), and orthostatic hypotension (OH). Design: A retrospective review of clinical and administrative datasets in veterans with SCI and compared the prevalence rates between clinical values and ICD-9 diagnostic codes in individuals with tetraplegia (T: C1-C8), high paraplegia (HP: T1-T6), and low paraplegia (LP: T7 and below). Results: The prevalence of clinical values indicative of a HR >= 80 beats per minute was higher in the HP compared to the LP and T groups. A systolic BP (SBP) <= 110 mmHg was more common in the T compared to the HP and LP groups, whereas the prevalence of a SBP >= 140 mmHg was increased in the LP compared to the HP and T groups. Diagnosis of hypertension was 39-60% whereas the diagnosis of hypotension was less than 1%. Diagnosis of AD and OH was highest in the T group, but remained below 10%, regardless of categorical lesion level. Antihypertensive medications were commonly prescribed (55%), and patients on these medications were less likely to have high BP. The odds ratio of higher SBP and DBP increased with age and body mass index (BMI). Conclusion: In veterans with SCI, the prevalence of HR and BP abnormalities varied depending on level of lesion, age, BMI, and prescription medication use. C1 [Zhu, Carolyn; Livote, Elayne; Signor, Dan] James J Peters VAMC, Dept Geriatr & Palliat Med, Bronx, NY USA. [Galea, Marinella; Wecht, Jill M.] James J Peters VAMC, Med Serv, Bronx, NY USA. [Wecht, Jill M.] James J Peters VAMC, Ctr Excellence, Bronx, NY USA. [Wecht, Jill M.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Galea, Marinella; Wecht, Jill M.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. RP Wecht, JM (reprint author), James J Peters VA Med Ctr, Room 1E-02,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM JM.Wecht@va.gov FU Veterans Affairs Rehabilitation Research and Development Service [B6999R] FX This research was supported by the Veterans Affairs Rehabilitation Research and Development Service (Grant # B6999R). NR 59 TC 7 Z9 7 U1 2 U2 10 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD SEP PY 2013 VL 36 IS 5 SI SI BP 463 EP 475 DI 10.1179/2045772313Y.0000000145 PG 13 WC Clinical Neurology SC Neurosciences & Neurology GA 203YL UT WOS:000323330700008 PM 23941794 ER PT J AU Bauman, WA La Fountaine, MF Cirnigliaro, CM Kirshblum, SC Spungen, AM AF Bauman, William A. La Fountaine, Michael F. Cirnigliaro, Christopher M. Kirshblum, Steven C. Spungen, Ann M. TI Low-dose baclofen therapy raised plasma insulin-like growth factor-1 concentrations, but not into the normal range in a predictable and sustained manner in men with chronic spinal cord injury SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE Baclofen; Gamma-aminobutyric acid; Insulin-like growth factor-1; Testosterone; Spinal cord injuries; Paraplegia; Tetraplegia; Spasticity ID GAMMA-AMINOBUTYRIC-ACID; RESTING ENERGY-EXPENDITURE; HORMONE-SECRETION; BODY-COMPOSITION; TESTOSTERONE; STIMULATION; INDIVIDUALS; INVOLVEMENT; DISCORDANT; FAILURE AB Objective: To evaluate, whether once-daily oral baclofen administration increases and/or sustains plasma insulin-like growth factor-1 (IGF-1) concentration in 11 men with chronic spinal cord injury (SCI) and IGF-1 deficiency (i.e. <250 ng/ml). Design: Prospective, open-label, dose titration study. Baclofen was administered at 20 mg/day for 8 weeks; then increased to 40 mg/day for another 8 weeks. Plasma IGF-1 and self-reported side effects were measured at baseline and every other week for the duration of the study. Results: The subjects were 43 +/- 12 years old, had duration of injury of 20 +/- 12 years; eight subjects had a complete motor injury, and eight had paraplegia. Nine of 11 subjects completed the 20 mg/day treatment and 5 subjects completed the 40 mg/day treatment. Plasma IGF-1 levels improved with each baclofen dose; however, only one subject increased from baseline and remained above the targeted physiological range of 250 ng/ml throughout treatment. A significant increase in IGF-1concentration was observed between baseline and week 2 (154 +/- 63 vs. 217 +/- 69 ng/ml; P < 0.05), weeks 8 and 10 (188 +/- 95 vs. 228 +/- 93 ng/ml; P < 0.05), and weeks 8 and 16 (188 +/- 95 vs. 259 +/- 92 ng/ml; P < 0.05). No serious side effects were observed at 20 mg/day; the 40 mg/day dose was less well tolerated. Conclusion: Baclofen was not effective at sustaining plasma IGF-1 concentrations in the physiological range in men with chronic SCI. C1 [Bauman, William A.; La Fountaine, Michael F.; Cirnigliaro, Christopher M.; Spungen, Ann M.] James J Peters VA Med Ctr, VA RR&D Natl Ctr Excellence Med Consequences Spin, Bronx, NY 10468 USA. [Bauman, William A.; Spungen, Ann M.] James J Peters VA Med Ctr, Med Serv, Bronx, NY 10468 USA. [Bauman, William A.; Spungen, Ann M.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Bauman, William A.; Spungen, Ann M.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. [La Fountaine, Michael F.] Seton Hall Univ, Sch Hlth & Med Sci, Dept Phys Therapy, S Orange, NJ 07079 USA. [Kirshblum, Steven C.] Kessler Inst Rehabil, W Orange, NJ USA. [Kirshblum, Steven C.] Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, Newark, NJ 07103 USA. RP Bauman, WA (reprint author), James J Peters VA Med Ctr, Natl Ctr Excellence Med Consequences Spinal Cord, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM william.bauman@va.gov FU James J. Peters VA Medical Center, Bronx, NY; Department of Veterans Affairs Rehabilitation Research & Development Service; Kessler Institute for Rehabilitation, West Orange, NJ; Veteran Affairs Rehabilitation Research & Development National Center of Excellence for the Medical Consequences of Spinal Cord Injury [B4162-C, B9212-C] FX The authors thank the James J. Peters VA Medical Center, Bronx, NY, the Department of Veterans Affairs Rehabilitation Research & Development Service, and Kessler Institute for Rehabilitation, West Orange, NJ for their support. This work was funded by the Veteran Affairs Rehabilitation Research & Development National Center of Excellence for the Medical Consequences of Spinal Cord Injury (No.'s B4162-C & B9212-C). NR 37 TC 3 Z9 3 U1 0 U2 1 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD SEP PY 2013 VL 36 IS 5 SI SI BP 476 EP 482 DI 10.1179/2045772312Y.0000000061 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 203YL UT WOS:000323330700009 PM 23941795 ER PT J AU Evans, CT Rogers, TJ Chin, A Johnson, S Smith, B Weaver, FM Burns, SP AF Evans, Charlesnika T. Rogers, Thea J. Chin, Amy Johnson, Stuart Smith, Bridget Weaver, Frances M. Burns, Stephen P. TI Antibiotic prescribing trends in the emergency department for veterans with spinal cord injury and disorder 2002-2007 SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE Physician's practice patterns; Spinal cord injuries; Antibiotic prescribing patterns; Antibiotic resistance; Veterans; Clinical guidelines ID RESPIRATORY-TRACT INFECTIONS; UNITED-STATES; ADULTS; RESISTANCE; BRONCHITIS; PROVIDERS; SETTINGS AB Objective: Clinical guidelines exist to promote antibiotic stewardship, particularly in ambulatory care settings such as the emergency department (ED). However, there is limited evidence on prescribing practice for persons with spinal cord injury and disorder (SCI/D). The goal of this study was to assess trends in antibiotic prescribing in the ED setting for persons with SCI/D. Design: A retrospective dynamic cohort study design. Setting: ED visits that did not result in same day hospitalization over 6 years (fiscal year (FY) 2002-FY2007) in Department of Veterans Affairs (VA) facilities Participants: Veterans with SCI/D. Outcome measures: VA clinical and administrative databases were used to identify the cohort and to obtain demographics, diagnoses, and medications. The rate of antibiotic prescribing for ED visits was defined as the number of antibiotics/total ED visits. Results: Veterans with SCI/D had 21 934 ED visits and 5887 antibiotics prescribed over the study period (rate of 268.4 prescriptions/1000 visits). The antibiotic prescribing rate increased from 238.8/1000 visits in FY2002 to 310.8/1000 visits in FY2007 (P < 0.0001). This increase in the rate of prescribing was seen across all patient demographics and factors assessed. Conclusion: Although clinical guidelines for judicious use of antibiotics in persons with SCI/D have been disseminated to providers, antibiotic prescribing in an ED setting is high and continuing to rise in this population. C1 [Evans, Charlesnika T.; Rogers, Thea J.; Chin, Amy; Smith, Bridget; Weaver, Frances M.] Northwestern Univ, Feinberg Sch Med, Dept Vet Affairs VA, Ctr Management Complex Chron Care, Chicago, IL 60611 USA. [Evans, Charlesnika T.; Rogers, Thea J.; Chin, Amy; Smith, Bridget; Weaver, Frances M.; Burns, Stephen P.] Northwestern Univ, Feinberg Sch Med, Spinal Cord Injury Qual Enhancement Res Initiat S, Chicago, IL 60611 USA. [Evans, Charlesnika T.] Northwestern Univ, Feinberg Sch Med, Inst Healthcare Studies, Chicago, IL 60611 USA. [Johnson, Stuart; Smith, Bridget; Weaver, Frances M.] Loyola Univ, Med Ctr, Dept Med, Maywood, IL 60153 USA. [Burns, Stephen P.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Burns, Stephen P.] Univ Washington, Seattle, WA 98195 USA. RP Evans, CT (reprint author), Edward J Hines Jr VA Hosp 151H, 5th Ave & Roosevelt Rd,POB 5000,Room D302, Hines, IL 60141 USA. EM Charlesnika.Evans@va.gov NR 23 TC 3 Z9 3 U1 0 U2 8 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD SEP PY 2013 VL 36 IS 5 SI SI BP 492 EP 498 DI 10.1179/2045772312Y.0000000076 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 203YL UT WOS:000323330700011 PM 23941797 ER PT J AU Doran, KM Ragins, KT Iacomacci, AL Cunningham, A Jubanyik, KJ Jenq, GY AF Doran, Kelly M. Ragins, Kyle T. Iacomacci, Andrea L. Cunningham, Alison Jubanyik, Karen J. Jenq, Grace Y. TI The Revolving Hospital Door Hospital Readmissions Among Patients Who Are Homeless SO MEDICAL CARE LA English DT Article DE homelessness; readmissions; hospital quality ID CASE-MANAGEMENT PROGRAM; HEART-FAILURE; RESPITE CARE; HEALTH-CARE; COSTS; ADULTS AB Background: National attention is increasingly focused on hospital readmissions. Little prior research has examined readmissions among patients who are homeless.Objective: The aim of the study was to determine 30-day hospital readmission rates among patients who are homeless and examine factors associated with hospital readmissions in this population.Methods: We conducted a retrospective chart review of patients who were homeless and hospitalized at a single urban hospital from May-August 2012. Homelessness was identified by an electronic medical record flag and confirmed by manual chart review. The primary outcome was all-cause hospital readmission to the study hospital within 30 days of hospital discharge. Patient-level and hospitalization-level factors associated with risk for readmission were examined using generalized estimating equations.Results: There were 113 unique patients who were homeless and admitted to the hospital a total of 266 times during the study period. The mean age was 49 years, 27.4% of patients were women, and 75.2% had Medicaid. Half (50.8%) of all hospitalizations resulted in a 30-day hospital inpatient readmission and 70.3% resulted in either an inpatient readmission, observation status stay, or emergency department visit within 30 days of hospital discharge. Most readmissions occurred early after hospital discharge (53.9% within 1 week, 74.8% within 2 weeks). Discharge to the streets or shelter versus other living situations was associated with increased risk for readmission in multivariable analyses.Conclusions: Patients who were homeless had strikingly high 30-day hospital readmission rates. These findings suggest the urgent need for further research and interventions to improve postdischarge care for patients who are homeless. C1 [Doran, Kelly M.] Yale Univ, Sch Med, Robert Wood Johnson Fdn, Clin Scholars Program, New Haven, CT USA. [Doran, Kelly M.] US Dept Vet Affairs, New Haven, CT USA. [Doran, Kelly M.; Jubanyik, Karen J.] Yale Univ, Sch Med, Dept Emergency Med, New Haven, CT USA. [Ragins, Kyle T.] Yale Univ, Sch Med, New Haven, CT USA. [Iacomacci, Andrea L.] Yale New Haven Med Ctr, Dept Clin Effectiveness, New Haven, CT 06504 USA. [Cunningham, Alison] Columbus House Inc, New Haven, CT USA. [Jenq, Grace Y.] Yale Univ, Sch Med, Dept Med, Sect Geriatr, New Haven, CT 06510 USA. RP Doran, KM (reprint author), Bellevue Hosp Ctr, Dept Emergency Med, 1st Ave & 27th St,Room A345, New York, NY 10016 USA. EM kmdoran@gmail.com NR 24 TC 11 Z9 11 U1 2 U2 25 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD SEP PY 2013 VL 51 IS 9 BP 767 EP 773 DI 10.1097/MLR.0b013e31829fafbb PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 205AE UT WOS:000323411600004 PM 23929401 ER PT J AU Brent, GA Kogai, T AF Brent, Gregory A. Kogai, Takahiko TI CANCER Novel target to enhance radioiodine uptake in thyroid cancer SO NATURE REVIEWS ENDOCRINOLOGY LA English DT Editorial Material AB The sodium-iodide symporter mediates iodide uptake, but its activity is reduced by the overexpression of pituitary tumour-transforming gene 1 protein-binding factor (PBF) in thyroid tumours. A recent study shows that inhibiting PBF phosphorylation enhances radioiodine uptake in thyroid cancer models. C1 [Brent, Gregory A.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA. [Kogai, Takahiko] Dokkyo Med Univ, Dept Infect Control & Clin Lab Med, Mibu, Tochigi 3210293, Japan. RP Brent, GA (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM gbrent@ucla.edu FU NCI NIH HHS [R01 CA89364] NR 10 TC 3 Z9 4 U1 0 U2 8 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-5029 J9 NAT REV ENDOCRINOL JI Nat. Rev. Endocrinol. PD SEP PY 2013 VL 9 IS 9 BP 508 EP 509 DI 10.1038/nrendo.2013.132 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 202LQ UT WOS:000323218200003 PM 23817292 ER PT J AU Blomberg, BA Akers, SR Saboury, B Mehta, NN Cheng, G Torigian, DA Lim, E Del Bello, C Werner, TJ Alavi, A AF Blomberg, Bjoern A. Akers, Scott R. Saboury, Babak Mehta, Nehal N. Cheng, Gang Torigian, Drew A. Lim, Esther Del Bello, Catherine Werner, Thomas J. Alavi, Abass TI Delayed time-point F-18-FDG PET CT imaging enhances assessment of atherosclerotic plaque inflammation SO NUCLEAR MEDICINE COMMUNICATIONS LA English DT Article DE atherosclerosis; fluorine-18 fluorodeoxyglucose; multiple time-point imaging; positron emission tomography ID POSITRON-EMISSION-TOMOGRAPHY; VASCULAR INFLAMMATION; FLUORODEOXYGLUCOSE UPTAKE; LARGE ARTERIES; FDG-PET; RISK; RESOLUTION; WALL AB Objective The aim of this study was to determine the ideal circulation time of fluorine-18 fluorodeoxyglucose (F-18-FDG) in order to detect and quantify atherosclerotic plaque inflammation with PET computed tomography (CT) imaging.Methods Fifteen patients underwent multiple time-point imaging at approximate to 60, 120, and 180 min after F-18-FDG administration. For each time point, global assessment of aortic and carotid F-18-FDG uptake was determined qualitatively by visual assessment and semiquantitatively by calculation of the mean and maximum standardized uptake values (SUV) and the corresponding target-to-background ratio (TBR).Results Delayed imaging achieved significant improvement in visualization of atherosclerotic plaque inflammation [Friedman's (2) statistic (d.f.=2, n=15)=24.13, P<0.001, Kendall's W=0.80]. This observation was confirmed by semiquantitative image analysis. At 1 h, the aortic and carotid SUVmean-calculated TBR was 1.05 [95% confidence interval (CI)=0.98, 1.11] and 0.88 (95% CI=0.81, 0.96), respectively. At 3 h, the TBR significantly increased to 1.57 (95% CI=1.28, 1.86; P=0.001) for the aorta and to 1.61 (95% CI=1.36, 1.87; P<0.001) for the carotid arteries. SUVmax-calculated TBRs showed a similar increase over time.Conclusion One- and 2-h F-18-FDG PET CT imaging is suboptimal for global assessment of atherosclerotic plaque inflammation compared with imaging at 3 h. Our data support the utilization of 3-h delayed imaging to obtain optimal data for the detection and quantification of atherosclerotic plaque inflammation in human arteries. C1 [Blomberg, Bjoern A.; Saboury, Babak; Torigian, Drew A.; Alavi, Abass] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Blomberg, Bjoern A.; Saboury, Babak; Torigian, Drew A.; Werner, Thomas J.; Alavi, Abass] Hosp Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA. [Akers, Scott R.; Cheng, Gang; Lim, Esther; Del Bello, Catherine] Philadelphia VA Med Ctr, Dept Radiol, Philadelphia, PA USA. [Mehta, Nehal N.] NHLBI, Bethesda, MD 20892 USA. [Blomberg, Bjoern A.] Univ Utrecht, Sch Med, Univ Med Ctr Utrecht, Utrecht, Netherlands. RP Alavi, A (reprint author), 3400 Spruce St, Philadelphia, PA 19104 USA. EM abass.alavi@uphs.upenn.edu FU United States Department of Veterans Affairs (VISN 4 CPPF Grant) FX This study was supported in part by a grant from the United States Department of Veterans Affairs (VISN 4 CPPF Grant). NR 29 TC 11 Z9 12 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0143-3636 J9 NUCL MED COMMUN JI Nucl. Med. Commun. PD SEP PY 2013 VL 34 IS 9 BP 860 EP 867 DI 10.1097/MNM.0b013e3283637512 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 202QA UT WOS:000323232000004 PM 23799532 ER PT J AU Gandhi, NR Tate, JP Rodriguez-Barradas, MC Rimland, D Goetz, MB Gibert, C Brown, ST Mattocks, K Justice, AC AF Gandhi, Neel R. Tate, Janet P. Rodriguez-Barradas, Maria C. Rimland, David Goetz, Matthew Bidwell Gibert, Cynthia Brown, Sheldon T. Mattocks, Kristin Justice, Amy C. TI Validation of an algorithm to identify antiretroviral-naive status at time of entry into a large, observational cohort of HIV-infected patients SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Article DE HIV-1; antiretroviral therapy; cohort studies; HIV infections; epidemiology; HIV infections/drug therapy; pharmacoepidemiology ID IMMUNODEFICIENCY-VIRUS-INFECTION; FRENCH-HOSPITAL-DATABASE; MYOCARDIAL-INFARCTION; HIV-1-INFECTED PATIENTS; THERAPY; RISK; MORTALITY; AIDS; AGE; COLLABORATION AB Purpose Large, observational HIV cohorts play an important role in answering questions which are difficult to study in randomized trials; however, they often lack detailed information regarding previous antiretroviral treatment (ART). Knowledge of ART treatment history is important when ascertaining the long-term impact of medications, co-morbidities, or adverse reactions on HIV outcomes. Methods We performed a retrospective study to validate a prediction algorithm for identifying ART-naive patients using the Veterans Aging Cohort Study's Virtual Cohortan observational cohort of 40594 HIV-infected veterans nationwide. Medical records for 3070 HIV-infected patients were reviewed to determine history of combination ART treatment. An algorithm using Virtual Cohort laboratory data was used to predict ART treatment status and compared to medical record review. Results Among 3070 patients' medical records reviewed, 1223 were eligible for analysis. Of these, 990 (81%) were ART naive at cohort entry based on medical record review. The prediction algorithm's sensitivity was 86%, specificity 47%, positive predictive value (PPV) 87%, and negative predictive value 45%, using a viral load threshold of <400 copies/ml. Sensitivity analysis revealed that PPV would be maximized by increasing the viral load threshold, whereas sensitivity would be maximized by lowering the viral load threshold. Conclusions A prediction algorithm using available laboratory data can be used to accurately identify ART-naive patients in large, observational HIV cohorts. Use of this algorithm will allow investigators to accurately limit analyses to ART-naive patients when studying the contribution of ART to outcomes and adverse events. Copyright (c) 2013 John Wiley & Sons, Ltd. C1 [Gandhi, Neel R.] Albert Einstein Coll Med, Div Gen Internal Med, Bronx, NY 10467 USA. [Gandhi, Neel R.] Montefiore Med Ctr, Bronx, NY 10467 USA. [Gandhi, Neel R.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. [Gandhi, Neel R.] Emory Univ, Rollins Sch Publ Hlth, Dept Global Hlth, Atlanta, GA 30322 USA. [Gandhi, Neel R.] Emory Univ, Rollins Sch Publ Hlth, Dept Infect Dis, Atlanta, GA 30322 USA. [Tate, Janet P.; Justice, Amy C.] Yale Univ, Sch Med, Dept Med, Gen Internal Med Sect, New Haven, CT 06510 USA. [Tate, Janet P.; Justice, Amy C.] VA Connecticut Healthcare Syst, New Haven, CT USA. [Rodriguez-Barradas, Maria C.] Michael E DeBakey VA Med Ctr, Infect Dis Sect, Houston, TX USA. [Rodriguez-Barradas, Maria C.] Michael E DeBakey VA Med Ctr, Dept Med, Houston, TX USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Houston, TX 77030 USA. [Rimland, David] Emory Univ, Sch Med, Dept Med, Infect Dis Sect, Atlanta, GA 30322 USA. [Rimland, David] Atlanta VA Med Ctr, Atlanta, GA USA. [Goetz, Matthew Bidwell] VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, Los Angeles, CA USA. [Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Gibert, Cynthia] Washington DC VA Med Ctr, Infect Dis Sect, Washington, DC USA. [Gibert, Cynthia] George Washington Univ, Med Ctr, Washington, DC 20037 USA. [Brown, Sheldon T.] James J Peters VA Med Ctr, Dept Med, Infect Dis Sect, New York, NY USA. [Brown, Sheldon T.] Mt Sinai Sch Med, New York, NY USA. [Mattocks, Kristin] VA Cent Western Massachusetts Hlth Care Syst, Quantitat Hlth Sci & Psychiat, Leeds, MA USA. [Mattocks, Kristin] Univ Massachusetts, Med Ctr, Worcester, MA USA. RP Gandhi, NR (reprint author), Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, 1518 Clifton Rd NE,CNR 3031, Atlanta, GA 30322 USA. EM neelgandhi@alumni.williams.edu OI Goetz, Matthew/0000-0003-4542-992X FU National Institutes of Health: NIAAA [U10-AA13566]; NIA [R01-AG029154, K23 AG024896]; Doris Duke Charitable Foundation Clinical Scientist Development Award [2007070]; Training Program in Environmental Epidemiology [T32 ES07069]; Centers for AIDS Research at Albert Einstein/Montefiore [AI-51519]; Emory University [P30 AI050409] FX This work was financially supported by National Institutes of Health: NIAAA (U10-AA13566), and NIA (R01-AG029154; K23 AG024896). Dr. Gandhi is the recipient of the Doris Duke Charitable Foundation Clinical Scientist Development Award (2007070). Dr. Tate was supported by the Training Program in Environmental Epidemiology funded under grant no. T32 ES07069. This work was also facilitated by the Centers for AIDS Research at Albert Einstein/Montefiore (AI-51519) and at Emory University (P30 AI050409). NR 24 TC 6 Z9 6 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD SEP PY 2013 VL 22 IS 9 BP 1019 EP 1025 DI 10.1002/pds.3476 PG 7 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 202WF UT WOS:000323250600013 PM 23836591 ER PT J AU Davidson, TM Price, M McCauley, JL Ruggiero, KJ AF Davidson, Tatiana M. Price, Matthew McCauley, Jenna L. Ruggiero, Kenneth J. TI Disaster Impact Across Cultural Groups: Comparison of Whites, African Americans, and Latinos SO AMERICAN JOURNAL OF COMMUNITY PSYCHOLOGY LA English DT Article DE Disaster impact; Cultural groups; PTSD; Depression ID STRESSFUL LIFE EVENTS; HURRICANE-KATRINA; PSYCHOLOGICAL DISTRESS; PTSD; RACE; RESOURCES; ETHNICITY; COMMUNICATION; RESILIENCE; CHECKLIST AB The current study extends knowledge regarding the differential impact of natural disasters among White, African American, and Latino survivors of Hurricane Ike through its use of a large, regional sample recruited via representative sampling procedures to examine the associations between cultural identification and disaster impact, including loss, damage, and negative mental health outcomes. Consistent with previous research, results indicated disparities between cultural groups with regard to disaster exposure. Additionally, type of disaster impact was differentially associated with PTSD and depression status dependent on cultural group. Specifically, the extent of personal disaster exposure, property damage, and loss of services made significant contributions to PTSD status among White survivors. African-Americans were more likely than White and Latino Ike survivors to endorse post-disaster PTSD and depression and endorsement of depression was predicted by severity of property damage. With respect to Latino respondents, only the extent of personal disaster exposure significantly contributed to both PTSD and depression status. Implications of the current findings are discussed with regard to future disaster preparedness and response efforts and the implementation and evaluation of community-based disaster resources. C1 [Davidson, Tatiana M.; Price, Matthew; McCauley, Jenna L.] Med Univ S Carolina, Natl Crime Victims Res & Treatment Ctr, Charleston, SC 29425 USA. [Ruggiero, Kenneth J.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. RP Davidson, TM (reprint author), Med Univ S Carolina, Natl Crime Victims Res & Treatment Ctr, 67 President St IOP 2 South,MSC 861, Charleston, SC 29425 USA. EM davidst@musc.edu FU NIMH NIH HHS [R34 MH077149, R34 MH77149] NR 50 TC 6 Z9 6 U1 4 U2 28 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0091-0562 J9 AM J COMMUN PSYCHOL JI Am. J. Community Psychol. PD SEP PY 2013 VL 52 IS 1-2 BP 97 EP 105 DI 10.1007/s10464-013-9579-1 PG 9 WC Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Social Work SC Public, Environmental & Occupational Health; Psychology; Social Work GA 194QE UT WOS:000322647000008 PM 23709270 ER PT J AU Kazamel, M Cutter, G Claussen, G Alsharabati, M Oh, SJ Lu, L King, PH AF Kazamel, Mohamed Cutter, Gary Claussen, Gwendolyn Alsharabati, Mohammad Oh, Shin J. Lu, Liang King, Peter H. TI Epidemiological features of amyotrophic lateral sclerosis in a large clinic-based African American population SO AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION LA English DT Article DE Motor neuron disease; race; phenotype; gender effect ID MOTOR-NEURON DISEASE; PROGNOSIS; ALS AB Our objective was to identify the main clinical and epidemiological features of ALS in a large cohort of African American (AA) patients and compare them to Caucasian (CA) patients in a clinic-based population. We retrospectively identified 207 patients who were diagnosed with ALS based on the revised El Escorial criteria (60 AA and 147 CA subjects). Patients were seen in the Neuromuscular Division at the University Medical Center. We compared epidemiological and clinical features of these two groups, focusing on age of onset and diagnosis, clinical presentation and survival. Results showed that AA patients had a significantly younger age of disease onset (55 years vs. 61 years for CA, p = 0.011) and were diagnosed at an earlier age (56 years vs. 62 years, p = 0.012). In younger ALS patients (< 45 years of age), there was a significant difference in gender frequency, with females predominating in the AA population and males in the CA population (p = 0.025). In a multivariable Cox proportional hazard model, survival rates were not different between the groups. In both groups, survival significantly increased with younger age. In conclusion, AA patients presented at an earlier age, but there was no difference in survival compared to CA patients. A gender reversal occurred in younger ALS patients, with AA patients more likely to be female and CA patients more likely to be male. C1 [Kazamel, Mohamed; Claussen, Gwendolyn; Alsharabati, Mohammad; Oh, Shin J.; Lu, Liang; King, Peter H.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL USA. [Cutter, Gary] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL USA. [King, Peter H.] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL USA. [King, Peter H.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL USA. [Oh, Shin J.; Lu, Liang; King, Peter H.] Birmingham VA Med Ctr, Birmingham, AL USA. RP King, PH (reprint author), 1720 7th Ave S,SC 260, Birmingham, AL 35294 USA. EM pking@uab.edu FU National Institutes of Health; Department of Veterans Affairs FX Funding was provided by the National Institutes of Health (PHK and LL), and Department of Veterans Affairs (PHK). NR 16 TC 7 Z9 8 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 2167-8421 J9 AMYOTROPH LA SCL FR JI Amyotroph. Lateral Scher. Frontotemp. Degenerat. PD SEP PY 2013 VL 14 IS 5-6 BP 334 EP 337 DI 10.3109/21678421.2013.770030 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 196NR UT WOS:000322782800002 PM 23458155 ER PT J AU Liang, QL Benavides, GA Vassilopoulos, A Gius, D Darley-Usmar, V Zhang, JH AF Liang, Qiuli Benavides, Gloria A. Vassilopoulos, Athanassios Gius, David Darley-Usmar, Victor Zhang, Jianhua TI Bioenergetic and autophagic control by Sirt3 in response to nutrient deprivation in mouse embryonic fibroblasts SO BIOCHEMICAL JOURNAL LA English DT Article DE apoptosis; autophagy; c-Jun; c-Jun N-terminal kinase (JNK); sirtuin 3 ID OXIDATIVE STRESS; DEPENDENT DEACETYLASE; LYSINE ACETYLATION; CELLULAR BIOENERGETICS; MONITORING AUTOPHAGY; CALORIE RESTRICTION; SKELETAL-MUSCLE; SIRTUINS; LC3; PROTEIN AB Sirt3 (sirtuin 3) is an NAD-dependent deacetylase localized to mitochondria. Sirt3 expression is increased in mouse muscle and liver by starvation, which could protect against the starvation-dependent increase in oxidative stress and protein damage. Damaged proteins and organelles depend on autophagy for removal and this is critical for cell survival, but the role of Sirt3 is unclear. To examine this, we used Sirt3-KO (knockout) mouse embryonic fibroblast cells, and found that, under basal conditions, Sirt3-KO cells exhibited increased autophagy flux compared with WT (wild-type) cells. In response to nutrient deprivation, both WT and KO cells exhibited increased basal and ATP-linked mitochondrial respiration, indicating an increased energy demand. Both cells exhibited lower levels of phosphorylated mTOR (mammalian target of rapamycin) and higher autophagy flux, with KO cells exhibiting lower maximal mitochondrial respiration and reserve capacity, and higher levels of autophagy than WT cells. KO cells exhibit higher phospho-JNK (c-Jun N-terminal kinase) and phospho-c-Jun than WT cells under starvation conditions. However, inhibition of JNK activity in Sirt3-KO cells did not affect LC3-I (light chain 3-I) and LC3-II levels, indicating that Sirt3-regulated autophagy is independent of the JNK pathway. Caspase 3 activation and cell death are significantly higher in Sirt3-KO cells compared with WT cells in response to nutrient deprivation. Inhibition of autophagy by chloroquine exacerbated cell death in both WT and Sirt3-KO cells, and by 3-methyadenine exacerbated cell death in Sirt3-KO cells. These data suggest that nutrient deprivation-induced autophagy plays a protective role in cell survival, and Sirt3 decreases the requirement for enhanced autophagy and improves cellular bioenergetics. C1 [Liang, Qiuli; Benavides, Gloria A.; Darley-Usmar, Victor; Zhang, Jianhua] Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35294 USA. [Liang, Qiuli; Benavides, Gloria A.; Darley-Usmar, Victor; Zhang, Jianhua] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Liang, Qiuli; Zhang, Jianhua] Birmingham VA Med Ctr, Dept Vet Affairs, Birmingham, AL 35233 USA. [Vassilopoulos, Athanassios; Gius, David] Northwestern Univ, Feinberg Sch Med, Dept Radiat Oncol, Chicago, IL 60611 USA. RP Zhang, JH (reprint author), Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35294 USA. EM zhanja@uab.edu OI Zhang, Jianhua/0000-0002-2128-9574 FU National Institutes of Health [NIHR01-NS064090]; Veterans Affairs merit award FX This work was supported by the National Institutes of Health [grant number NIHR01-NS064090] and a Veterans Affairs merit award (to J.Z.). NR 52 TC 18 Z9 19 U1 0 U2 11 PU PORTLAND PRESS LTD PI LONDON PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND SN 0264-6021 J9 BIOCHEM J JI Biochem. J. PD SEP 1 PY 2013 VL 454 BP 249 EP 257 DI 10.1042/BJ20130414 PN 2 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 202CL UT WOS:000323191000009 PM 23767918 ER PT J AU Wheeler, S Moore, K Forsberg, CW Riley, K Floyd, JS Smith, NL Boyko, EJ AF Wheeler, S. Moore, K. Forsberg, C. W. Riley, K. Floyd, J. S. Smith, N. L. Boyko, E. J. TI Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy SO DIABETOLOGIA LA English DT Article DE Cohort study; Diabetes mellitus; Monotherapy; Mortality; Oral hypoglycaemic medication; Pharmacoepidemiology; Veterans ID ALL-CAUSE MORTALITY; ADVERSE CARDIOVASCULAR OUTCOMES; PROPENSITY SCORE METHODS; POPULATION-BASED COHORT; MYOCARDIAL-INFARCTION; PHARMACOLOGICAL-TREATMENT; CLINICAL-TRIALS; HEART-FAILURE; RISK; MELLITUS AB Despite oral hypoglycaemic medications being the most commonly used pharmacological treatments for type 2 diabetes, research is limited on their comparative safety, particularly their effects on overall mortality. We compared mortality risk with monotherapy initiation of four oral hypoglycaemic medications in a nationwide cohort of US veterans with type 2 diabetes. We identified new users of oral hypoglycaemic medication monotherapy between 2004 and 2009 who received care for at least 1 year from the Veterans Health Administration. Patients were followed until initial monotherapy discontinuation, addition of another diabetes pharmacotherapy, death or end of follow-up. Mortality HRs were estimated using Cox regression adjusted for potential confounding factors. Among new users of metformin, sulfonylureas and rosiglitazone (185,360 men, 7,812 women), 4,256 (2.2%) died during follow-up. Average duration of medication use ranged from 1.4 to 1.7 years. Significantly higher mortality risk was seen for glibenclamide (known as glyburide in the USA and Canada) (HR 1.38, 95% CI 1.27, 1.50) or glipizide (HR 1.55, 95% CI 1.43, 1.67) compared with metformin monotherapy, and for glipizide compared with rosiglitazone (HR 1.27, 95% CI 1.01, 1.59) or glibenclamide monotherapy (HR 1.12, 95% CI 1.02, 1.23). A significant sex-rosiglitazone interaction was seen (p = 0.034) compared with metformin monotherapy, with women having a higher HR (HR 4.36, 95% CI 1.34, 14.20) than men (HR 1.19, 95% CI 0.95, 1.49). Significantly higher mortality was associated with glibenclamide, glipizide and rosiglitazone use compared with metformin, and with glipizide use compared with rosiglitazone or glibenclamide. The potential for residual confounding by indication should be considered in interpreting these results. C1 [Wheeler, S.; Boyko, E. J.] VA Puget Sound Hlth Care Syst, Gen Med Serv, Seattle, WA 98108 USA. [Moore, K.; Forsberg, C. W.; Riley, K.; Smith, N. L.; Boyko, E. J.] VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. [Floyd, J. S.] Univ Washington, Dept Med, Seattle, WA USA. [Smith, N. L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Smith, N. L.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA. [Boyko, E. J.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Boyko, EJ (reprint author), VA Puget Sound Hlth Care Syst, 1660 South Columbian Way, Seattle, WA 98108 USA. EM eboyko@uw.edu RI Floyd, James/G-7563-2015 OI Boyko, Edward/0000-0002-3695-192X FU ERIC of VA Puget Sound in Seattle; National Heart, Lung and Blood Institute [T32 HL007902] FX This work was supported by the ERIC of VA Puget Sound in Seattle, and by facilities and services provided by the Diabetes Research Center (DK-17047) at the University of Washington. VA Puget Sound Health Care System provided support for the involvement of E. J. Boyko, N. L. Smith and S. Wheeler in this research. J. S. Floyd was supported by National Heart, Lung and Blood Institute training grant T32 HL007902. NR 42 TC 18 Z9 18 U1 0 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X J9 DIABETOLOGIA JI Diabetologia PD SEP PY 2013 VL 56 IS 9 BP 1934 EP 1943 DI 10.1007/s00125-013-2958-1 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 200HV UT WOS:000323059800011 PM 23797633 ER PT J AU Geng, T Hu, W Broadwater, MH Snider, JM Bielawski, J Russo, SB Schwacke, JH Ross, J Cowart, LA AF Geng, T. Hu, W. Broadwater, M. H. Snider, J. M. Bielawski, J. Russo, S. B. Schwacke, J. H. Ross, J. Cowart, L. A. TI Fatty acids differentially regulate insulin resistance through endoplasm reticulum stress-mediated induction of tribbles homologue 3: a potential link between dietary fat composition and the pathophysiological outcomes of obesity SO DIABETOLOGIA LA English DT Article DE Animal model; Diet-induced obesity; ER stress; Insulin resistance; NEFA; Trib3 ID COA DEHYDROGENASE-DEFICIENCY; PALMITATE-INDUCED APOPTOSIS; SKELETAL-MUSCLE CELLS; METABOLICALLY HEALTHY; GLUCOSE-HOMEOSTASIS; LIPID-METABOLISM; SATURATED-FAT; TRB3; ACTIVATION; CERAMIDE AB Previous studies have shown that saturated fatty acids cause insulin resistance (IR) that is prevented by unsaturated fatty acids. Tribbles homologue 3 (TRIB3) is a putative endogenous inhibitor of insulin signalling, but its role in insulin signalling is controversial. This study aimed to determine whether fatty acids regulate IR via TRIB3. We treated HepG2 cells with saturated and unsaturated fatty acids and evaluated TRIB3 expression. We then tested whether regulation of TRIB3 occurred through endoplasmic reticulum (ER) stress, and whether modulating TRIB3 and ER stress marker genes was necessary and/or sufficient for regulation of insulin signalling. To test the in vivo significance of this mechanism, we fed mice obesogenic diets with different fatty acid profiles and assessed physiological variables of diabetes, ER stress markers and Trib3 expression in the liver. Our data show that fatty acids differentially regulate IR through ER stress-mediated induction of TRIB3. Intriguingly, a standard and widely used obesogenic diet high in unsaturated fats failed to induce ER stress, TRIB3 or IR. However, an alternative obesogenic diet with lower unsaturated fat recapitulated the cell studies by causing ER stress, TRIB3 induction and IR. This study revealed a novel mechanism linking dietary fat composition to IR. Given the emerging roles for ER stress in non-alcoholic liver disease, we conclude that dietary fat composition rather than total amount may mediate hepatic pathology associated with obesity. C1 [Geng, T.; Hu, W.; Broadwater, M. H.; Snider, J. M.; Bielawski, J.; Russo, S. B.; Schwacke, J. H.; Ross, J.; Cowart, L. A.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Broadwater, M. H.] NOAA, Ctr Coastal Environm Hlth & Biomol Res, Charleston, SC 29412 USA. [Cowart, L. A.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29403 USA. RP Cowart, LA (reprint author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA. EM cowartl@musc.edu FU VA Merit award; COBRE in Lipidomics in Pathobiology FX This work was supported by a VA Merit award and the COBRE in Lipidomics in Pathobiology, both to L. A. Cowart NR 48 TC 13 Z9 15 U1 0 U2 23 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X J9 DIABETOLOGIA JI Diabetologia PD SEP PY 2013 VL 56 IS 9 BP 2078 EP 2087 DI 10.1007/s00125-013-2973-2 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 200HV UT WOS:000323059800027 PM 23820633 ER PT J AU Golden-Mason, L Rosen, HR AF Golden-Mason, Lucy Rosen, Hugo R. TI Natural killer cells: multifaceted players with key roles in hepatitis C immunity SO IMMUNOLOGICAL REVIEWS LA English DT Review DE innate immunity; liver; human; interferon ID HUMAN NK-CELLS; PLASMACYTOID-DENDRITIC-CELLS; ACTIVATED STELLATE CELLS; INHIBITORY RECEPTOR GENES; B-ASSOCIATED TRANSCRIPT-3; VIRUS ENVELOPE PROTEIN; INDUCED LIVER-INJURY; HLA-E EXPRESSION; COMPLEX CLASS-I; T-CELLS AB Natural killer cells (NKs) are involved in every stage of hepatitis C viral (HCV) infection, from protection against HCV acquisition and resolution in the acute phase to treatment-induced clearance. In addition to their direct antiviral actions, NKs are involved in the induction and priming of appropriate downstream T-cell responses. In the setting of chronic HCV, overall NK cell levels are decreased, subset distribution is altered, and changes in NK receptor (NKR) expression have been demonstrated, although the contribution of individual NKRs to viral clearance or persistence remains to be clarified. Enhanced NK cell cytotoxicity accompanied by insufficient interferon- production may promote liver damage in the setting of chronic infection. Treatment-induced clearance is associated with activation of NK cells, and it will be of interest to monitor NK cell responses to triple therapy. Activated NK cells also have anti-fibrotic properties, and the same hepatic NK cell populations that are actively involved in control of HCV may also be involved in control of HCV-associated liver damage. We still have much to learn, in particular: how do liver-derived NKs influence the outcome of HCV infection? Do NK receptors recognize HCV-specific components? And, are HCV-specific memory NK populations generated? C1 [Golden-Mason, Lucy; Rosen, Hugo R.] UCD, Dept Med, Hepatitis Ctr C, Div Gastroenterol & Hepatol, Aurora, CO USA. [Golden-Mason, Lucy; Rosen, Hugo R.] UCD, Integrated Program Immunol, Denver, CO USA. [Golden-Mason, Lucy; Rosen, Hugo R.] NJH, Denver, CO USA. [Rosen, Hugo R.] Denver VA Med Ctr, Denver, CO USA. RP Rosen, HR (reprint author), Div GI Hepatol B 158, Acad Off Bldg 1,12631 E 17th Ave,Rm 7614,POB 6511, Aurora, CO 80045 USA. EM hugo.rosen@ucdenver.edu FU HCV Center Grant [U19 AI 1066328]; VA Merit Review [RO1 DK60590, RO1 DK071560] FX This work was supported by the following grants to H. R. R.: U19 AI 1066328 (HCV Center Grant); VA Merit Review; RO1 DK60590 and RO1 DK071560. The authors declare no conflicts of interest. NR 187 TC 27 Z9 29 U1 2 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0105-2896 J9 IMMUNOL REV JI Immunol. Rev. PD SEP PY 2013 VL 255 IS 1 SI SI BP 68 EP 81 DI 10.1111/imr.12090 PG 14 WC Immunology SC Immunology GA 201OM UT WOS:000323150900006 PM 23947348 ER PT J AU Clark, RB Cervantes, JL Maciejewski, MW Farrokhi, V Nemati, R Yao, XD Anstadt, E Fujiwara, M Wright, KT Riddle, C La Vake, CJ Salazar, JC Finegold, S Nichols, FC AF Clark, Robert B. Cervantes, Jorge L. Maciejewski, Mark W. Farrokhi, Vahid Nemati, Reza Yao, Xudong Anstadt, Emily Fujiwara, Mai Wright, Kyle T. Riddle, Caroline La Vake, Carson J. Salazar, Juan C. Finegold, Sydney Nichols, Frank C. TI Serine Lipids of Porphyromonas gingivalis Are Human and Mouse Toll-Like Receptor 2 Ligands SO INFECTION AND IMMUNITY LA English DT Article ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; BIOLOGICAL-ACTIVITIES; MULTIPLE-SCLEROSIS; BONE LOSS; LIPOPOLYSACCHARIDE; ATHEROSCLEROSIS; RECOGNITION; ACTIVATION; FLAVOLIPIN; FIMBRIAE AB The total cellular lipids of Porphyromas gingivalis, a known periodontal pathogen, were previously shown to promote dendritic cell activation and inhibition of osteoblasts through engagement of Toll-like receptor 2 (TLR2). The purpose of the present investigation was to fractionate all lipids of P. gingivalis and define which lipid classes account for the TLR2 engagement, based on both in vitro human cell assays and in vivo studies in mice. Specific serine-containing lipids of P. gingivalis, called lipid 654 and lipid 430, were identified in specific high-performance liquid chromatography fractions as the TLR2-activating lipids. The structures of these lipids were defined using tandem mass spectrometry and nuclear magnetic resonance methods. In vitro, both lipid 654 and lipid 430 activated TLR2-expressing HEK cells, and this activation was inhibited by anti-TLR2 antibody. In contrast, TLR4-expressing HEK cells failed to be activated by either lipid 654 or lipid 430. Wild-type (WT) or TLR2-deficient (TLR2(-/-)) mice were injected with either lipid 654 or lipid 430, and the effects on serum levels of the chemokine CCL2 were measured 4 h later. Administration of either lipid 654 or lipid 430 to WT mice resulted in a significant increase in serum CCL2 levels; in contrast, the administration of lipid 654 or lipid 430 to TLR2(-/-) mice resulted in no increase in serum CCL2. These results thus identify a new class of TLR2 ligands that are produced by P. gingivalis that likely play a significant role in mediating inflammatory responses both at periodontal sites and, potentially, in other tissues where these lipids might accumulate. C1 [Clark, Robert B.; Cervantes, Jorge L.; Anstadt, Emily; Fujiwara, Mai; Wright, Kyle T.; Riddle, Caroline; La Vake, Carson J.; Salazar, Juan C.] Univ Connecticut, Sch Med, Dept Pediat, Dept Immunol, Farmington, CT 06032 USA. [Clark, Robert B.; Cervantes, Jorge L.; Anstadt, Emily; Fujiwara, Mai; Wright, Kyle T.; Riddle, Caroline; La Vake, Carson J.; Salazar, Juan C.] Univ Connecticut, Sch Med, Dept Med, Farmington, CT USA. [Maciejewski, Mark W.] Univ Connecticut, Ctr Hlth, Dept Mol Microbial & Struct Biol, Farmington, CT USA. [Farrokhi, Vahid; Nemati, Reza; Yao, Xudong] Univ Connecticut, Dept Chem, Storrs, CT USA. [Finegold, Sydney] VA Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA USA. [Nichols, Frank C.] Univ Connecticut, Sch Dent Med, Dept Oral Hlth & Diagnost Sci, Farmington, CT 06032 USA. RP Nichols, FC (reprint author), Univ Connecticut, Sch Dent Med, Dept Oral Hlth & Diagnost Sci, Farmington, CT 06032 USA. EM Nichols@nso.uchc.edu FU NIH [1 R01 DE021055-01A1]; National MS Society [RG4070-A-6]; NIAID [AI090166] FX This work was supported by NIH 1 R01 DE021055-01A1 (F.C.N.), National MS Society RG4070-A-6 (R.B.C.), and NIAID AI090166 (J.C.S.). NR 53 TC 11 Z9 12 U1 0 U2 8 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 J9 INFECT IMMUN JI Infect. Immun. PD SEP PY 2013 VL 81 IS 9 BP 3479 EP 3489 DI 10.1128/IAI.00803-13 PG 11 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 201NM UT WOS:000323148300042 PM 23836823 ER PT J AU Salgado, CD Sepkowitz, KA John, JF Cantey, JR Attaway, HH Freeman, KD Sharpe, PA Michels, HT Schmidt, MG AF Salgado, Cassandra D. Sepkowitz, Kent A. John, Joseph F. Cantey, J. Robert Attaway, Hubert H. Freeman, Katherine D. Sharpe, Peter A. Michels, Harold T. Schmidt, Michael G. TI The Environment and Healthcare-Acquired Infections: Why Accurate Reporting and Evaluation of Biological Plausibility Are Important Reply SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Letter ID COPPER; SURFACES; UNIT C1 [Salgado, Cassandra D.; Cantey, J. Robert] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Sepkowitz, Kent A.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA. [John, Joseph F.] Ralph H Johnson VA, Dept Med, Charleston, SC USA. [Attaway, Hubert H.; Schmidt, Michael G.] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. [Freeman, Katherine D.] Extrapolate, Delray Beach, FL USA. [Sharpe, Peter A.] Sharpe & Associates, W Orange, NJ USA. [Michels, Harold T.] Copper Dev Assoc, New York, NY USA. RP Salgado, CD (reprint author), Med Univ S Carolina, Div Infect Dis, 135 Rutledge Ave, Charleston, SC 29425 USA. EM salgado@musc.edu NR 8 TC 1 Z9 2 U1 0 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD SEP 1 PY 2013 VL 34 IS 9 BP 997 EP 999 DI 10.1086/671938 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 195LD UT WOS:000322702900020 PM 23917920 ER PT J AU Fitz-Gibbon, S Tomida, S Chiu, BH Nguyen, L Du, C Liu, MH Elashoff, D Erfe, MC Loncaric, A Kim, J Modlin, RL Miller, JF Sodergren, E Craft, N Weinstock, GM Li, HY AF Fitz-Gibbon, Sorel Tomida, Shuta Chiu, Bor-Han Lin Nguyen Du, Christine Liu, Minghsun Elashoff, David Erfe, Marie C. Loncaric, Anya Kim, Jenny Modlin, Robert L. Miller, Jeff F. Sodergren, Erica Craft, Noah Weinstock, George M. Li, Huiying TI Propionibacterium acnes Strain Populations in the Human Skin Microbiome Associated with Acne SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Article ID STREPTOLYSIN-S; STAPHYLOCOCCUS-AUREUS; ESCHERICHIA-COLI; BODY HABITATS; BACTERIA; SEQUENCE; STREPTOCOCCUS; RESISTANCE; DIVERSITY; GENES AB The human skin microbiome has important roles in skin health and disease. However, bacterial population structure and diversity at the strain level is poorly understood. We compared the skin microbiome at the strain level and genome level of Propionibacterium acnes, a dominant skin commensal, between 49 acne patients and 52 healthy individuals by sampling the pilosebaceous units on their noses. Metagenomic analysis demonstrated that although the relative abundances of P. acnes were similar, the strain population structures were significantly different in the two cohorts. Certain strains were highly associated with acne, and other strains were enriched in healthy skin. By sequencing 66 previously unreported P. acnes strains and comparing 71 P. acnes genomes, we identified potential genetic determinants of various P. acnes strains in association with acne or health. Our analysis suggests that acquired DNA sequences and bacterial immune elements may have roles in determining virulence properties of P. acnes strains, and some could be future targets for therapeutic interventions. This study demonstrates a previously unreported paradigm of commensal strain populations that could explain the pathogenesis of human diseases. It underscores the importance of strain-level analysis of the human microbiome to define the role of commensals in health and disease. C1 [Fitz-Gibbon, Sorel; Tomida, Shuta; Chiu, Bor-Han; Lin Nguyen; Du, Christine; Li, Huiying] Univ Calif Los Angeles, David Geffen Sch Med, Crump Inst Mol Imaging, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA. [Du, Christine; Elashoff, David; Loncaric, Anya; Kim, Jenny; Modlin, Robert L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Liu, Minghsun; Modlin, Robert L.; Miller, Jeff F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA. [Erfe, Marie C.; Craft, Noah] Univ Calif Los Angeles, David Geffen Sch Med, Harbor UCLA Med Ctr, Ctr Immunotherapeut Res,Los Angeles Biomed Res In, Los Angeles, CA 90095 USA. [Kim, Jenny; Sodergren, Erica; Weinstock, George M.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Dermatol, Los Angeles, CA USA. [Li, Huiying] Washington Univ, Genome Inst, St Louis, MO USA. [Fitz-Gibbon, Sorel; Tomida, Shuta] UCLA DOE Inst Genom & Prote, Los Angeles, CA USA. RP Li, HY (reprint author), Univ Calif Los Angeles, 4339 CNSI,570 Westwood Plaza,Bldg 114, Los Angeles, CA 90095 USA. EM huiying@mednet.ucla.edu OI Modlin, Robert/0000-0003-4720-031X FU NIH [U54HG004968]; NIH/NIAMS [UH2AR057503] FX We thank G Kasimatis, B Shi, EE Curd, R Yan, M Wong, and J Liu for comments and technical support. We thank C Lee for performing statistical analyses in the initial phase. We also thank Z Guo and CS Miller for critical reading of the manuscript. This research was funded as one of the Demonstration Projects by the NIH Human Microbiome Project (HMP). It was supported by grant UH2AR057503 from NIH/NIAMS and grant U54HG004968 from NIH. NR 43 TC 106 Z9 112 U1 5 U2 78 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD SEP PY 2013 VL 133 IS 9 BP 2152 EP 2160 DI 10.1038/jid.2013.21 PG 9 WC Dermatology SC Dermatology GA 202GY UT WOS:000323203300013 PM 23337890 ER PT J AU Park, SH Wang, DJJ Duong, TQ AF Park, Sung-Hong Wang, Danny J. J. Duong, Timothy Q. TI Balanced steady state free precession for arterial spin labeling MRI: Initial experience for blood flow mapping in human brain, retina, and kidney SO MAGNETIC RESONANCE IMAGING LA English DT Article DE Blood flow; Arterial spin labeling; Pseudo-continuous arterial spin labeling; Balanced steady state free precession; fMRI; Retina; Kidney ID SINGLE-SHOT RARE; RADIO-FREQUENCY; DYNAMIC MRI; MOUSE MODEL; SSFP FMRI; PERFUSION; RESOLUTION; INVERSION; QUANTIFICATION; QUANTITATION AB We implemented pseudo-continuous ASL (pCASL) with 2D and 3D balanced steady state free precession (bSSFP) readout for mapping blood flow in the human brain, retina, and kidney, free of distortion and signal dropout, which are typically observed in the most commonly used echo-planar imaging acquisition. High resolution functional brain imaging in the human visual cortex was feasible with 3D bSSFP pCASL. Blood flow of the human retina could be imaged with pCASL and bSSFP in conjunction with a phase cycling approach to suppress the banding artifacts associated with bSSFP. Furthermore, bSSFP based pCASL enabled us to map renal blood flow within a single breath hold. Control and test-retest experiments suggested that the measured blood flow values in retina and kidney were reliable. Because there is no specific imaging tool for mapping human retina blood flow and the standard contrast agent technique for mapping renal blood flow can cause problems for patients with kidney dysfunction, bSSFP based pCASL may provide a useful tool for the diagnosis of retinal and renal diseases and can complement existing imaging techniques. (c) 2013 Elsevier Inc. All rights reserved. C1 [Park, Sung-Hong] Korea Adv Inst Sci & Technol, Dept Bio & Brain Engn, Taejon 305701, South Korea. [Park, Sung-Hong; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Wang, Danny J. J.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA. [Duong, Timothy Q.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Park, SH (reprint author), Korea Adv Inst Sci & Technol, Dept Bio & Brain Engn, 291 Daehak Ro, Taejon 305701, South Korea. EM sunghongpark@kaist.ac.kr; duongt@uthscsa.edu RI Duong, Timothy/B-8525-2008; Park, Sung-Hong/B-3393-2012 OI Park, Sung-Hong/0000-0002-1731-0668 FU VA MERIT; KUSTAR-KAIST Institute; [R01 EY014211]; [R01 EY018855]; [R01 MH080892]; [R01-EB014922]; [R01 NS081077] FX This work is supported in part by R01 EY014211, R01 EY018855, and VA MERIT to TQD, by R01 MH080892, R01-EB014922 and R01 NS081077 to DJW, and by KUSTAR-KAIST Institute to SHP. NR 44 TC 15 Z9 15 U1 0 U2 18 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0730-725X J9 MAGN RESON IMAGING JI Magn. Reson. Imaging PD SEP PY 2013 VL 31 IS 7 BP 1044 EP 1050 DI 10.1016/j.mri.2013.03.024 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 198TG UT WOS:000322944600002 PM 23664680 ER PT J AU Wallace, GC Dixon-Mah, YN Vandergrift, WA Ray, SK Haar, CP Mittendorf, AM Patel, SJ Banik, NL Giglio, P Das, A AF Wallace, Gerald C. Dixon-Mah, Yaenette N. Vandergrift, W. Alex, III Ray, Swapan K. Haar, Catherine P. Mittendorf, Amber M. Patel, Sunil J. Banik, Naren L. Giglio, Pierre Das, Arabinda TI Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma SO METABOLIC BRAIN DISEASE LA English DT Review DE Glioblastoma; ALK; MET; AKT ID ANAPLASTIC LYMPHOMA KINASE; HEPATOCYTE GROWTH-FACTOR; C-MET; MALIGNANT GLIOMAS; TYROSINE KINASE; STEM-CELLS; RECURRENT GLIOBLASTOMA; FACTOR/SCATTER FACTOR; TRANSCRIPTION FACTOR; GENETIC PATHWAYS AB Glioblastoma is the most common aggressive, highly glycolytic, and lethal brain tumor. In fact, it is among the most commonly diagnosed lethal malignancies, with thousands of new cases reported in the United States each year. Glioblastoma's lethality is derived from a number of factors including highly active pro-mitotic and pro-metastatic pathways. Two factors increasingly associated with the intracellular signaling and transcriptional machinery required for such changes are anaplastic lymphoma kinase (ALK) and the hepatocyte growth factor receptor (HGFR or, more commonly MET). Both receptors are members of the receptor tyrosine kinase (RTK) family, which has itself gained much attention for its role in modulating mitosis, migration, and survival in cancer cells. ALK was first described as a vital oncogene in lymphoma studies, but it has since been connected to many carcinomas, including non-small cell lung cancer and glioblastoma. As the receptor for HGF, MET has also been highly characterized and regulates numerous developmental and wound healing events which, when upregulated in cancer, can promote tumor progression. The wealth of information gathered over the last 30 years regarding these RTKs suggests three downstream cascades that depend upon activation of STAT3, Ras, and AKT. This review outlines the significance of ALK and MET as they relate to glioblastoma, explores the significance of STAT3, Ras, and AKT downstream of ALK/MET, and touches on the potential for new chemotherapeutics targeting ALK and MET to improve glioblastoma patient prognosis. C1 [Wallace, Gerald C.; Dixon-Mah, Yaenette N.; Vandergrift, W. Alex, III; Haar, Catherine P.; Mittendorf, Amber M.; Patel, Sunil J.; Banik, Naren L.; Giglio, Pierre; Das, Arabinda] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Wallace, Gerald C.; Dixon-Mah, Yaenette N.; Vandergrift, W. Alex, III; Haar, Catherine P.; Mittendorf, Amber M.; Patel, Sunil J.; Banik, Naren L.; Giglio, Pierre; Das, Arabinda] Med Univ S Carolina, MUSC Brain & Spine Tumor Program, Charleston, SC 29425 USA. [Ray, Swapan K.] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA. [Banik, Naren L.] Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. RP Das, A (reprint author), Med Univ S Carolina, Dept Neurosci, 96 Jonathan Lucas St, Charleston, SC 29425 USA. EM dasa@musc.edu FU National Institutes of Health (NIH); National Institute of Neurological Disorders and Stroke (NINDS) [NS31622, NS-38146, NS-57811, NS-41088]; State of South Carolina Spinal Cord Injury Research Project (SCSCIRF); VA [1I01BX001262-01A2]; Pfizer, Inc.; Jerry Zucker Fund for Brain Tumor Research of the MUSC Foundation FX Completion of this project was made possible by funding from the National Institutes of Health (NIH) and National Institute of Neurological Disorders and Stroke (NINDS): (NS31622, NS-38146, NS-57811, and NS-41088), the State of South Carolina Spinal Cord Injury Research Project (SCSCIRF), VA (1I01BX001262-01A2), Pfizer, Inc., and the Jerry Zucker Fund for Brain Tumor Research of the MUSC Foundation. NR 92 TC 3 Z9 3 U1 1 U2 19 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0885-7490 J9 METAB BRAIN DIS JI Metab. Brain Dis. PD SEP PY 2013 VL 28 IS 3 BP 355 EP 366 DI 10.1007/s11011-013-9401-7 PG 12 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA 197XK UT WOS:000322885700003 PM 23543207 ER PT J AU Bodhankar, S Chen, YX Vandenbark, AA Murphy, SJ Offner, H AF Bodhankar, Sheetal Chen, Yingxin Vandenbark, Arthur A. Murphy, Stephanie J. Offner, Halina TI IL-10-producing B-cells limit CNS inflammation and infarct volume in experimental stroke SO METABOLIC BRAIN DISEASE LA English DT Article DE MCAO; Inflammatory cells; Regulatory B-cells; IL-10 ID REGULATORY T-CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; ACUTE ISCHEMIC-STROKE; MURINE EXPERIMENTAL STROKE; BRAIN-INJURY; B10 CELLS; NEUROLOGIC DEFICITS; RAT-BRAIN; IN-VIVO; IL-10 AB Clinical stroke induces inflammatory processes leading to cerebral injury. IL-10 expression is elevated during major CNS diseases and limits inflammation in the brain. Recent evidence demonstrated that absence of B-cells led to larger infarct volumes and increased numbers of activated T-cells, monocytes and microglial cells in the brain, thus implicating a regulatory role of B-cell subpopulations in limiting CNS damage from stroke. The aim of this study was to determine whether the IL-10-producing regulatory B-cell subset can limit CNS inflammation and reduce infarct volume following ischemic stroke in B-cell deficient (mu MT-/-) mice. Five million IL-10-producing B-cells were obtained from IL-10-GFP reporter mice and transferred i.v. to mu MT(-/-)mice. After 24 h following this transfer, recipients were subjected to 60 min of middle cerebral artery occlusion (MCAO) followed by 48 h of reperfusion. Compared to vehicle-treated controls, the IL-10(+) B-cell-replenished mu MT(-/-)mice had reduced infarct volume and fewer infiltrating activated T-cells and monocytes in the affected brain hemisphere. These effects in CNS were accompanied by significant increases in regulatory T-cells and expression of the co-inhibitory receptor, PD-1, with a significant reduction in the proinflammatory milieu in the periphery. These novel observations provide the first proof of both immunoregulatory and protective functions of IL-10-secreting B-cells in MCAO that potentially could impart significant benefit for stroke patients in the clinic. C1 [Bodhankar, Sheetal; Vandenbark, Arthur A.; Offner, Halina] Portland VA Med Ctr, VA Med Ctr, Portland, OR 97239 USA. [Bodhankar, Sheetal; Vandenbark, Arthur A.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. [Chen, Yingxin; Murphy, Stephanie J.; Offner, Halina] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Offner, H (reprint author), Portland VA Med Ctr, VA Med Ctr, R&D-31,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM offnerva@ohsu.edu FU NIH/NINDS [1RO1 NS075887]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development FX The authors wish to thank Melissa Barber for assistance with manuscript preparation. This work was supported by NIH/NINDS 1RO1 NS075887. This material is based upon work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. NR 63 TC 31 Z9 34 U1 0 U2 7 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0885-7490 J9 METAB BRAIN DIS JI Metab. Brain Dis. PD SEP PY 2013 VL 28 IS 3 BP 375 EP 386 DI 10.1007/s11011-013-9413-3 PG 12 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA 197XK UT WOS:000322885700005 PM 23640015 ER PT J AU Crist, RC Clarke, TK Ang, A Ambrose-Lanci, LM Lohoff, FW Saxon, AJ Ling, W Hillhouse, MP Bruce, RD Woody, G Berrettini, WH AF Crist, Richard C. Clarke, Toni-Kim Ang, Alfonso Ambrose-Lanci, Lisa M. Lohoff, Falk W. Saxon, Andrew J. Ling, Walter Hillhouse, Maureen P. Bruce, R. Douglas Woody, George Berrettini, Wade H. TI An Intronic Variant in OPRD1 Predicts Treatment Outcome for Opioid Dependence in African-Americans SO NEUROPSYCHOPHARMACOLOGY LA English DT Article DE pharmacogenetics; methadone; buprenorphine; treatment outcome ID METHADONE-MAINTENANCE; RANDOMIZED-TRIAL; RECEPTOR GENE; ALCOHOL DEPENDENCE; HEROIN-ADDICTION; DRUG-DEPENDENCE; RHESUS-MONKEYS; CLINICAL-TRIAL; DELTA; BUPRENORPHINE AB Although buprenorphine and methadone are both effective treatments for opioid dependence, their efficacy can vary significantly among patients. Genetic differences may explain some of the variability in treatment outcome. Understanding the interactions between genetic background and pharmacotherapy may result in more informed treatment decisions. This study is a pharmacogenetic analysis of the effects of genetic variants in OPRD1, the gene encoding the delta-opioid receptor, on the prevalence of opioid-positive urine tests in African-Americans (n = 77) or European-Americans (n = 566) undergoing treatment for opioid dependence. Patients were randomly assigned to treatment with either methadone or buprenorphine/naloxone (Suboxone) over a 24-week open-label clinical trial, in which illicit opioid use was measured by weekly urinalysis. In African-Americans, the intronic SNP rs678849 predicted treatment outcome for both medications. Methadone patients with the CC genotype were less likely to have opioid-positive urine tests than those in the combined CT and TT genotypes group (relative risk (RR) = 0.52, 95% confidence interval (CI) = 0.44-0.60, p = 0.001). In the buprenorphine treatment group, however, individuals with the CC genotype were more likely to have positive opioid drug screens than individuals in the combined CT and TT genotypes group (RR = 2.17, 95% CI = 1.95-2.68, p = 0.008). These findings indicate that the genotype at rs678849 predicts African-American patient response to two common treatments for opioid dependence, suggesting that matching patients to treatment type based on the genotype at this locus may improve overall treatment efficacy. This observation requires confirmation in an independent population. C1 [Crist, Richard C.; Clarke, Toni-Kim; Ambrose-Lanci, Lisa M.; Lohoff, Falk W.; Berrettini, Wade H.] Univ Penn, Sch Med, Ctr Neurobiol & Behav, Dept Psychiat, Philadelphia, PA 19104 USA. [Ang, Alfonso; Ling, Walter; Hillhouse, Maureen P.] Univ Calif Los Angeles, Integrated Subst Abuse Programs, Los Angeles, CA USA. [Saxon, Andrew J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Bruce, R. Douglas] Yale Univ, Sch Med, New Haven, CT USA. [Woody, George] Univ Penn, Perelman Sch Med, Treatment Res Inst, Philadelphia, PA 19104 USA. RP Crist, RC (reprint author), Univ Penn, Sch Med, Ctr Neurobiol & Behav, Translat Res Labs,Dept Psychiat, 125 South 31st St,Room 2109, Philadelphia, PA 19104 USA. EM crist@mail.med.upenn.edu RI Lohoff, Falk/M-7951-2016 OI Clarke, Toni-Kim/0000-0002-7745-6351 FU Pfizer; Pamlab; Guidepoint Global LLC; Genome Canada; Genome Quebec; Reckitt Benckiser Pharmaceuticals; Gilead Sciences; Merck Co.; Bristol Myers Squibb; Boehringer Ingelheim; Abbott Laboratories; Pfizer, Inc. FX Falk Lohoff received research grant support from Pfizer. Issued to University of Pennsylvania and also scientific advisor or paid consultant to Pamlab. Guidepoint Global LLC, Genome Canada, and Genome Quebec. Andrew Saxon is a paid consultant to Reckitt Benckiser Pharmaceuticals; Walter Ling is a paid consultant to Reckitt Benckiser Pharmaceuticals; R Douglas Bruce received research grant support from Gilead Sciences, Merck & Co., Bristol Myers Squibb, Boehringer Ingelheim, Reckitt Benckiser Pharmaceuticals, Abbott Laboratories, Pfizer, Inc., and honorarium from Reckitt Benckiser Pharmaceuticals; the remaining authors declare no conflict of interest. NR 54 TC 14 Z9 14 U1 0 U2 7 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD SEP PY 2013 VL 38 IS 10 BP 2003 EP 2010 DI 10.1038/npp.2013.99 PG 8 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 201TI UT WOS:000323165500019 PM 23612435 ER PT J AU Ovrutsky, AR Merkel, PA Schonteich, E Bai, XY Kinney, W Iseman, MD Kartalija, M Knight, V Chan, ED AF Ovrutsky, Alida R. Merkel, Patricia A. Schonteich, Eric Bai, Xiyuan Kinney, William Iseman, Michael D. Kartalija, Marinka Knight, Vijaya Chan, Edward D. TI Patients with non-tuberculous mycobacterial lung disease have elevated transforming growth factor-beta following ex vivo stimulation of blood with live Mycobacterium intracellulare SO SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Non-tuberculous mycobacteria; Mycobacterium avium complex; Marfan syndrome; interferon-gamma; fibrillin-1 ID INTERFERON-GAMMA; MARFANS-SYNDROME; CYTOKINE PRODUCTION; AVIUM INFECTION; TGF-BETA; EXPRESSION; COMPLEX; ALPHA AB We previously found that a subset of patients with pulmonary non-tuberculous mycobacterial (pNTM) disease were taller, leaner, and had a higher prevalence of pectus excavatum and scoliosis than uninfected controls. Additionally, whole blood of pNTM patients stimulated ex vivo with live Mycobacterium intracellulare produced significantly less interferon-gamma (IFN gamma) compared to that of uninfected controls. Since IFN. production can be suppressed by transforming growth factor-beta (TGF beta), an immunosuppressive cytokine, we measured basal and M. intracellulare-stimulated blood levels of TGF beta in a group of 20 pNTM patients and 20 uninfected controls. In contrast to the IFN. findings, we found that stimulated blood from pNTM patients produced significantly higher levels of TGF beta compared to controls. Since pNTM patients frequently possess body features that overlap with Marfan syndrome (MFS), and increased TGF beta expression is important in the pathogenesis of MFS, we posit that a yet-to-be-identified syndrome related to MFS predisposes certain individuals to develop pNTM disease. C1 [Ovrutsky, Alida R.; Bai, Xiyuan; Kinney, William; Kartalija, Marinka; Chan, Edward D.] Denver Vet Affairs Med Ctr, Aurora, CO USA. [Ovrutsky, Alida R.; Merkel, Patricia A.; Bai, Xiyuan; Kinney, William; Iseman, Michael D.; Knight, Vijaya; Chan, Edward D.] Natl Jewish Hlth, Dept Med, Aurora, CO USA. [Ovrutsky, Alida R.; Merkel, Patricia A.; Bai, Xiyuan; Kinney, William; Iseman, Michael D.; Knight, Vijaya; Chan, Edward D.] Natl Jewish Hlth, Dept Acad Affairs, Aurora, CO USA. [Schonteich, Eric] Natl Jewish Hlth, Complement Lab, Aurora, CO USA. [Iseman, Michael D.; Chan, Edward D.] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Aurora, CO USA. RP Chan, ED (reprint author), Natl Jewish Hlth, D509,Neustadt Bldg,1400 Jackson St, Denver, CO 80206 USA. EM chane@njhealth.org FU NCRR NIH HHS [UL1 RR025780] NR 29 TC 4 Z9 4 U1 0 U2 3 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0036-5548 EI 1651-1980 J9 SCAND J INFECT DIS JI Scand. J. Infect. Dis. PD SEP PY 2013 VL 45 IS 9 BP 711 EP 714 DI 10.3109/00365548.2013.800947 PG 4 WC Infectious Diseases SC Infectious Diseases GA 202TP UT WOS:000323242800009 PM 23808720 ER PT J AU Lai, A Tran, T Nguyen, HM Fleischmann, J Beenhouwer, DO Graber, CJ AF Lai, Andrew Thuong Tran Nguyen, Hien M. Fleischmann, Jacob Beenhouwer, David O. Graber, Christopher J. TI Outpatient Parenteral Antimicrobial Therapy at Large Veterans Administration Medical Center SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article AB Objectives: To evaluate our outpatient parenteral antimicrobial therapy (OPAT) program to determine its impact on infection management in a facility notable for high patient comorbidity and a large catchment area that includes most of Southern California. Study Design: Retrospective chart review. Methods: We reviewed all episodes of patients receiving OPAT from our institution from 2006 through 2009 for patient utilization characteristics and assessment of complications. Results: A total of 333 patients received 393 courses of OPAT for a mean of 21.1 days. Diabetes mellitus (53.5%), psychiatric disease (39%), and chronic kidney disease (31%) were common; more than half the patients lived more than 20 miles from our medical center. Osteomyelitis (39.7%) and bacteremia (19.3%) accounted for the majority of OPAT indications. Staphylococcus aureus (36.4%) was the most frequent infecting organism, and vancomycin (37.4%) was the most frequently prescribed medication. Complications including hospital readmission, adverse drug reactions, or line- related complications were noted in 96 of 393 (24.4%) episodes, but most were minor, reversible, or not directly related to the OPAT given. Serious line- related complications that required hospital readmission were noted in only 6 (1.5%) episodes. OPAT was completed as planned in 313 (79.6%) episodes; end-stage renal disease was associated with OPAT noncompletion in multivariable analysis (odds ratio = 2.20, P = .047). We estimated that OPAT saved our medical center $4 million per year. Conclusions: Despite our patients' high level of comorbidity and our facility's large catchment area, we were able to deliver OPAT successfully and safely with significant cost savings. C1 [Lai, Andrew] Huntington Hosp, Dept Med, Pasadena, CA USA. [Thuong Tran; Fleischmann, Jacob; Beenhouwer, David O.; Graber, Christopher J.] VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, 11301 Wilshire Blvd,111-F, Los Angeles, CA 90073 USA. [Thuong Tran] VA Greater Los Angeles Healthcare Syst, Serv Pharm, Los Angeles, CA 90073 USA. [Nguyen, Hien M.] Kaiser Permanente Northwest, Portland, OR USA. [Fleischmann, Jacob; Beenhouwer, David O.; Graber, Christopher J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Graber, CJ (reprint author), VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, 11301 Wilshire Blvd,111-F, Los Angeles, CA 90073 USA. EM christopher.graber@va.gov NR 14 TC 0 Z9 0 U1 0 U2 0 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD SEP PY 2013 VL 19 IS 9 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V44PB UT WOS:000209759800003 ER PT J AU Selby, VN Teerlink, JR AF Selby, Van N. Teerlink, John R. TI What's New in the Treatment of Acute Heart Failure? SO CURRENT CARDIOLOGY REPORTS LA English DT Article DE Acute heart failure; Drug therapy; Clinical trials; Vasodilators; Inotropes; Ultrafiltration; Diuretics; Nitroglycerin; Sodium nitroprusside; Nesiritide; Dobutamine; Milrinone; Levosimendan; Omecamtiv mecarbil; Serelaxin; Istaroxime; Ularitide; Cenderitide; Aliskiren; Rolofylline; Tezosentan; Cinaciguat ID ACUTE MYOCARDIAL-INFARCTION; NATIONAL REGISTRY ADHERE; RANDOMIZED CONTROLLED-TRIALS; CARDIAC MYOSIN ACTIVATOR; SODIUM-NITROPRUSSIDE; NATRIURETIC PEPTIDE; INTRAVENOUS NESIRITIDE; OMECAMTIV MECARBIL; RENAL IMPAIRMENT; DOUBLE-BLIND AB Acute heart failure is associated with substantial morbidity and mortality. Goals of treatment are decongestion, correction of hemodynamic abnormalities, symptom relief, and reducing long-term morbidity and mortality. Loop diuretics are a first-line agent for treatment of volume overload, with ultrafiltration reserved for those who do not respond to pharmacologic therapy. In patients with normal or elevated blood pressure, vasodilators are used to correct hemodynamics and reverse central volume redistribution, although no currently available agent has been shown to improve outcomes. Intravenous inotropes and inodilators are associated with frequent adverse effects and are reserved for patients with hypotension and evidence of inadequate perfusion. Novel drugs designed to maximize hemodynamic benefits while minimizing adverse effects are under investigation, with several agents showing promise in clinical studies. C1 [Selby, Van N.] Univ Calif San Francisco, Div Cardiol, San Francisco, CA 94143 USA. [Teerlink, John R.] San Francisco VA Med Ctr, Cardiol Sect, San Francisco, CA 94121 USA. RP Teerlink, JR (reprint author), San Francisco VA Med Ctr, Cardiol Sect, 4150 Clement St,Cardiol 111C, San Francisco, CA 94121 USA. EM john.teerlink@ucsf.edu FU Amgen; Cytokinetics; Corthera; Novartis FX John R. Teerlink has been consultant for Amgen, Cytokinetics, Corthera, Novartis, and St. Jude, and has received grant support from Amgen, Cytokinetics, Corthera, and Novartis. NR 56 TC 5 Z9 5 U1 4 U2 10 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3782 EI 1534-3170 J9 CURR CARDIOL REP JI Curr. Cardiol. Rep. PD SEP PY 2013 VL 15 IS 9 AR 393 DI 10.1007/s11886-013-0393-z PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AT6YQ UT WOS:000345083400002 PM 23881577 ER PT J AU Arnardottir, ES Janson, C Bjornsdottir, E Benediktsdottir, B Juliusson, S Kuna, SK Pack, AI Gislason, T AF Arnardottir, Erna Sif Janson, Christer Bjornsdottir, Erla Benediktsdottir, Bryndis Juliusson, Sigurdur Kuna, Sam K. Pack, Allan I. Gislason, Thorarinn TI Is frequent nocturnal sweating a symptom of obstructive sleep apnea? SO EUROPEAN RESPIRATORY JOURNAL LA English DT Meeting Abstract DE Sleep disorders; Sleep studies; Apnoea / Hypopnea C1 [Arnardottir, Erna Sif; Bjornsdottir, Erla; Benediktsdottir, Bryndis; Gislason, Thorarinn] Landspitali, Dept Resp Med & Sleep, Reykjavik, Iceland. [Arnardottir, Erna Sif; Bjornsdottir, Erla; Benediktsdottir, Bryndis; Gislason, Thorarinn] Univ Iceland, Fac Med, Reykjavik, Iceland. [Arnardottir, Erna Sif; Kuna, Sam K.; Pack, Allan I.] Univ Penn, Sch Med, Dept Med, Div Sleep Med, Philadelphia, PA 19104 USA. [Janson, Christer] Uppsala Univ, Dept Med Sci Resp Med & Allergol, Uppsala, Sweden. [Juliusson, Sigurdur] Landspitali, Dept Otolaryngol, Reykjavik, Iceland. [Kuna, Sam K.] Philadelphia Vet Affairs Med Ctr, Pulm Crit Care & Sleep Sect, Philadelphia, PA USA. EM ernasif@landspitali.is; christer.janson@medsci.uu.se; erlabjo@gmail.com; brynben@hi.is; sjul@landspitali.is; Samuel.Kuna@va.gov; Allan.Pack@uphs.upenn.edu; thorarig@landspitali.is NR 0 TC 0 Z9 0 U1 0 U2 0 PU EUROPEAN RESPIRATORY SOC JOURNALS LTD PI SHEFFIELD PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND SN 0903-1936 EI 1399-3003 J9 EUR RESPIR J JI Eur. Resp. J. PD SEP 1 PY 2013 VL 42 SU 57 MA 4672 PG 1 WC Respiratory System SC Respiratory System GA V38VH UT WOS:000209370403316 ER PT J AU Riaz, H Riaz, I Abir, T Badshah, M Milton, A AF Riaz, Hans Riaz, Irbaz Abir, Tanvir Badshah, Maaz Milton, Abul TI Vitamin D as a supplementary agent in the treatment of pulmonary tuberculosis: A systematic review and meta-analysis of randomized controlled trials SO EUROPEAN RESPIRATORY JOURNAL LA English DT Meeting Abstract DE Tuberculosis - management C1 [Riaz, Hans] Dow Univ Hlth Sci, Internal Med, Karachi, Sindh, Pakistan. [Riaz, Irbaz] Univ Arizona, Internal Med, Tucson, AZ USA. [Abir, Tanvir] Univ Western Sydney, Sch Med, Sydney, NSW, Australia. [Badshah, Maaz] Mt Sinai Sch Med, James J Peters VA Med Ctr, Internal Med, New York, NY USA. [Milton, Abul] Univ Newcastle, Ctr Clin Epidemiol & Biostat, Newcastle, NJ USA. EM harisriaz73@yahoo.com; sipra.irbaz@gmail.com; abir_tanvir100@yahoo.com.au; maazbadshah501@hotmail.com; milton.hasnat@newcastle.edu.au NR 0 TC 0 Z9 0 U1 0 U2 0 PU EUROPEAN RESPIRATORY SOC JOURNALS LTD PI SHEFFIELD PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND SN 0903-1936 EI 1399-3003 J9 EUR RESPIR J JI Eur. Resp. J. PD SEP 1 PY 2013 VL 42 SU 57 MA 567 PG 1 WC Respiratory System SC Respiratory System GA V38VH UT WOS:000209370400438 ER PT J AU Akopians, AL Rosales, M Janzen, D Memarzadeh, S AF Akopians, A. L. Rosales, M. Janzen, D. Memarzadeh, S. TI DISTRIBUTION OF CD44 (CLUSTER OF DIFFERENTIATION-44) POSITIVE ENDOMETRIAL EPITHELIAL PROGENITORS IN HUMAN ENDOMETRIOSIS SO FERTILITY AND STERILITY LA English DT Meeting Abstract CT International-Federation-of-Fertility-Societies 21st World Congress on Fertility and Sterility / 69th Annual Meeting of the American-Society-for-Reproductive-Medicine CY OCT 12-17, 2013 CL Boston, MA SP Int Federat Fertil Soc, Amer Soc Reprod Med C1 [Akopians, A. L.; Rosales, M.; Janzen, D.; Memarzadeh, S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA. [Memarzadeh, S.] Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Los Angeles, CA USA. [Memarzadeh, S.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD SEP PY 2013 VL 100 IS 3 SU S MA P-745 BP S363 EP S364 PG 2 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA AQ1PY UT WOS:000342554501520 ER PT J AU Orellana, G Alvarado, L Munoz-Neira, C Avila, R Mendez, MF Slachevsky, A AF Orellana, Gricel Alvarado, Luis Munoz-Neira, Carlos Avila, Rodrigo Mendez, Mario F. Slachevsky, Andrea TI Psychosis-Related Matricide Associated With a Lesion of the Ventromedial Prefrontal Cortex SO JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW LA English DT Article ID LATE-ONSET SCHIZOPHRENIA; PSYCHOPATHY; DELUSIONS; BRAIN; NEUROPSYCHIATRY; CONFABULATION; VIOLATIONS; RETRIEVAL; JUDGMENT; INJURY AB Matricide, the killing of a mother by her biological child, is a rare event. We report a case of matricide associated with a woman who sustained a right ventromedial prefrontal lesion during surgery for nasal polyposis that was performed when she was 40 years old. After her surgery, she developed psychotic symptoms associated with the emergence of antisocial behavior. She committed matricide 22 years later. Neuropsychological evaluation showed decreased frontal-executive deficits, and magnetic resonance imaging revealed a lesion in the right gyrus rectus area of the ventromedial prefrontal region. This case suggests that a secondary psychotic syndrome associated with a lesion in the frontal neural network, which is disturbed in psychopathy, could facilitate homicidal behavior. Furthermore, this case has legal implications for the prosecution of murder associated with a brain lesion. C1 [Orellana, Gricel] Univ Chile, Fac Med, Dept Psiquiatria Oriente, Santiago, Chile. [Alvarado, Luis] Univ Chile, Fac Ciencias Sociales, Dept Psicol, Santiago, Chile. [Alvarado, Luis] Univ Chile, Fac Med, Dept Psiquiatria Oriente, Santiago, Chile. [Munoz-Neira, Carlos; Slachevsky, Andrea] Hosp Salvador, Unidad Neurol Cognit & Demencias, Serv Neurol, Santiago, Chile. [Avila, Rodrigo] Hosp Salvador, Serv Psiquiatria, Santiago, Chile. [Mendez, Mario F.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Mendez, Mario F.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Mendez, Mario F.] VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA USA. [Slachevsky, Andrea] Univ Chile, Dept Neurol Oriente, Santiago, Chile. [Slachevsky, Andrea] Univ Chile, Programa Farmacol Mol & Clin, ICBM, Fac Med, Santiago, Chile. [Slachevsky, Andrea] Clin Alemana, Santiago, Chile. RP Slachevsky, A (reprint author), Univ Chile, Ctr Invest Avanzada Educ, Periodista Jose Carrasco Tapia 75, Santiago, Chile. EM aslachevsky@me.com RI Alvarado, L./F-7134-2014 OI Alvarado, L./0000-0002-8219-9476 FU NIA NIH HHS [R01AG034499-03] NR 42 TC 1 Z9 1 U1 4 U2 11 PU AMER ACAD PSYCHIATRY & LAW PI BLOOMFIELD PA ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA SN 1093-6793 EI 1943-3662 J9 J AM ACAD PSYCHIATRY JI J. Am. Acad. Psychiatry Law PD SEP 1 PY 2013 VL 41 IS 3 BP 401 EP 406 PG 6 WC Law; Psychiatry SC Government & Law; Psychiatry GA AN8LT UT WOS:000340856400010 PM 24051593 ER PT J AU Greysen, SR Horwitz, LI Covinsky, KE Gordon, K Ohl, ME Justice, AC AF Greysen, S. Ryan Horwitz, Leora I. Covinsky, Kenneth E. Gordon, Kirsha Ohl, Michael E. Justice, Amy C. TI Does Social Isolation Predict Hospitalization and Mortality Among HIV+ and Uninfected Older Veterans? SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE social isolation; outcomes of care; mortality; aging; hospitalization; HIV/AIDS ID LONG-TERM-CARE; ALCOHOL-CONSUMPTION; AFRICAN-AMERICANS; FOLLOW-UP; ADULTS; SUPPORT; HEALTH; COHORT; WOMEN; RISK AB Objectives To compare levels of social isolation in aging veterans with and without the human immunodeficiency virus (HIV) and determine associations with hospital admission and mortality. Design Longitudinal data analysis. Setting The Veterans Aging Cohort Study (VACS), at eight VA Medical Centers nationally. Participants Veterans aged 55 and older enrolled in VACS from 2002 to 2008 (N = 1,836). Measurements A Social Isolation Score (SIS) was created using baseline survey responses about relationship status; number of friends and family and frequency of visits; and involvement in volunteer work, religious or self-help groups, and other community activities. Scores were compared according to age and HIV status, and multivariable regression was used to assess effects of SIS on hospital admission and all-cause mortality. Results Mean SIS was higher for HIV-positive (HIV+) individuals, with increasing difference according to age (P = .01 for trend). Social isolation was also more prevalent for HIV+ (59%) than uninfected participants (51%, P < .001). In multivariable regression analysis of HIV+ and uninfected groups combined, adjusted for demographic and clinical features, isolation was independently associated with greater risk of incident hospitalization (hazard rate (HR) = 1.25, 95% confidence interval (CI) = 1.09-1.42) and risk of all-cause mortality (HR=1.28, 95% CI = 1.06-1.54). Risk estimates calculated for HIV+ and uninfected groups separately were not significantly different. Conclusion Social isolation is associated with greater risk of hospitalization and death in HIV+ and uninfected older veterans. Despite similar effects in both groups, the population-level effect of social isolation may be greater in those who are HIV+ because of the higher prevalence of social isolation, particularly in the oldest individuals. C1 [Greysen, S. Ryan] Univ Calif San Francisco, Div Hosp Med, San Francisco, CA 94113 USA. [Horwitz, Leora I.; Justice, Amy C.] Yale Univ, Sch Med, Div Gen Internal Med, New Haven, CT USA. [Covinsky, Kenneth E.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94113 USA. [Covinsky, Kenneth E.] San Francisco VA Med Ctr, San Francisco, CA USA. [Gordon, Kirsha; Justice, Amy C.] W Haven Vet Affairs Med Ctr, West Haven, CT USA. [Ohl, Michael E.] Univ Iowa, Sch Med, Div Infect Dis, Iowa City, IA 52242 USA. RP Greysen, SR (reprint author), Univ Calif San Francisco, Div Hosp Med, 533 Parnassus Ave,Box 0131, San Francisco, CA 94113 USA. EM Ryan.Greysen@ucsf.edu OI Horwitz, Leora/0000-0003-1800-6040 FU Robert Wood Johnson Foundation; U.S. Department of Veterans Affairs; National Institute on Aging [K08 AG038336]; American Federation for Aging FX The authors would like to thank the Robert Wood Johnson Foundation Clinical Scholars program and U.S. Department of Veterans Affairs for funding support. Dr. Horwitz is supported by the National Institute on Aging (K08 AG038336) and the American Federation for Aging Research through the Paul B. Beeson Career Development Award Program. NR 57 TC 10 Z9 11 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD SEP PY 2013 VL 61 IS 9 BP 1456 EP 1463 DI 10.1111/jgs.12410 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 216TL UT WOS:000324307200003 PM 23927911 ER PT J AU Bouchard, R Chong, T Pugazhenthi, S AF Bouchard, Ron Chong, Thomas Pugazhenthi, Subbiah TI Laser Capture Microdissection of Neurons from Differentiated Human Neuroprogenitor Cells in Culture SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS LA English DT Article DE Neuroscience; Issue 79; Neurobiology; Cellular Biology; Cells; Cultured; Neurons; Central Nervous System; Neurodegenerative Diseases; Human neuroprogenitor cells; neuronal differentiation; neuronal markers; astrocytes; laser capture microdissection; PEN membrane slides; cell culture AB Neuroprogenitor cells (NPCs) isolated from the human fetal brain were expanded under proliferative conditions in the presence of epidermal growth factor (EGF) and fibroblast growth factor (FGF) to provide an abundant supply of cells. NPCs were differentiated in the presence of a new combination of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), dibutyryl cAMP (DBC) and retinoic acid on dishes coated with poly-L-lysine and mouse laminin to obtain neuron-rich cultures. NPCs were also differentiated in the absence of neurotrophins, DBC and retinoic acid and in the presence of ciliary neurotrophic factor (CNTF) to yield astrocyte-rich cultures. Differentiated NPCs were characterized by immunofluorescence staining for a panel of neuronal markers including NeuN, synapsin, acetylcholinesterase, synaptophysin and GAP43. Glial fibrillary acidic protein (GFAP) and STAT3, astrocyte markers, were detected in 10-15% of differentiated NPCs. To facilitate cell-type specific molecular characterization, laser capture microdissection was performed to isolate neurons cultured on polyethylene naphthalate (PEN) membrane slides. The methods described in this study provide valuable tools to advance our understanding of the molecular mechanism of neurodegeneration. C1 [Bouchard, Ron; Chong, Thomas; Pugazhenthi, Subbiah] Denver VA Med Ctr, Endocrinol Sect, Denver, CO 80220 USA. [Bouchard, Ron; Chong, Thomas; Pugazhenthi, Subbiah] Univ Colorado Denver Sch Med, Dept Med, Denver, CO 80204 USA. RP Pugazhenthi, S (reprint author), Denver VA Med Ctr, Endocrinol Sect, Denver, CO 80220 USA. EM Subbiah.Pugazhenthi@ucdenver.edu FU Merit Review grant from the Veterans Administration [NEUD-004-07F] FX This work was supported by Merit Review grant (NEUD-004-07F) from the Veterans Administration (to S.P). NR 15 TC 0 Z9 0 U1 0 U2 1 PU JOURNAL OF VISUALIZED EXPERIMENTS PI CAMBRIDGE PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA SN 1940-087X J9 JOVE-J VIS EXP JI J. Vis. Exp. PD SEP PY 2013 IS 79 AR UNSP e50487 DI 10.3791/50487 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA V36RI UT WOS:000209228100011 PM 24084642 ER PT J AU Kalapatapu, RK Delucchi, KL Lasher, BA Vinogradov, S Batki, SL AF Kalapatapu, Raj K. Delucchi, Kevin L. Lasher, Brooke A. Vinogradov, Sophia Batki, Steven L. TI Alcohol Use Biomarkers Predicting Cognitive Performance: A Secondary Analysis in Veterans With Alcohol Dependence and Posttraumatic Stress Disorder SO MILITARY MEDICINE LA English DT Article ID SUBSTANCE USE DISORDERS; GAMMA-GLUTAMYL-TRANSFERASE; LIVER-FUNCTION; NEUROPSYCHOLOGICAL IMPAIRMENT; ABUSING PATIENTS; TREATMENT ENTRY; DEPRESSION; ABUSERS; DICHOTOMIZATION; ABILITIES AB Objective: We conducted a secondary analysis of baseline data from a recently completed pharmacological pilot clinical trial among 30 veterans with alcohol dependence and posttraumatic stress disorder (PTSD). This trial included baseline measures of alcohol use biomarkers, both indirect (carbohydrate-deficient transferrin, GGT [gamma-glutamyltransferase], mean corpuscular volume, AST [aspartate aminotransferase], alanine aminotransferase) and direct (ethyl glucuronide, ethyl sulfate), as well as neurocognitive measures (Trail Making Test parts A and B, Hopkins Verbal Learning Test-Revised, Balloon Analogue Risk Task, Delay Discounting Task). Methods: Two regression models were estimated and tested for each neurocognitive measure (dependent measure). The first model included the alcohol use biomarker alone as the predictor. The second model included the alcohol use biomarker along with the following 3 additional predictors: Beck Depression Inventory, Clinician-Administered PTSD Scale, and receiving medications. Results: In both models, the indirect biomarkers, such as GGT and AST, significantly predicted performance on the Hopkins Verbal Learning Test-Revised %Retention. GGT alone significantly predicted performance on the Trail Making Test part A. Conclusions: Indirect alcohol use biomarkers may have a specific role in identifying those veterans with alcohol dependence and PTSD who have impaired cognitive performance. However, direct alcohol use biomarkers may not share such a role. C1 [Kalapatapu, Raj K.; Delucchi, Kevin L.; Vinogradov, Sophia; Batki, Steven L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Kalapatapu, Raj K.; Lasher, Brooke A.; Vinogradov, Sophia; Batki, Steven L.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Lasher, Brooke A.; Vinogradov, Sophia; Batki, Steven L.] Northern Calif Inst Res & Educ, San Francisco, CA 94121 USA. RP Kalapatapu, RK (reprint author), Univ Calif San Francisco, Dept Psychiat, 401 Parnassus Ave, San Francisco, CA 94143 USA. FU Department of Defense [W81XWH-05-2-0094]; National Center for Research Resources; National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI [UL1 RR024131]; [K23DA034883] FX This study was supported by the Department of Defense Grant Number W81XWH-05-2-0094 (PI: Batki), which was given by the Northern California Institute for Research and Education, and with resources of the Veterans Affairs Medical Center, San Francisco, California. Dr. Kalapatapu is currently funded by K23DA034883. This project was also supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1 RR024131. NR 62 TC 2 Z9 2 U1 4 U2 10 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD SEP PY 2013 VL 178 IS 9 BP 974 EP 980 DI 10.7205/MILMED-D-13-00097 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA AN7UC UT WOS:000340805500013 PM 24005546 ER EF